"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04106817","Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus",,"Completed","Has Results","Influenza","Biological: Live, wild-type A/California/H1N1 2009 influenza virus","Viral Shedding|Seroconversion|Number and Severity of AEs","WCCT Global|Stanford University|National Institutes of Health (NIH)","All","18 Years to 45 Years   (Adult)","Phase 1","35","Industry|Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","WCCTG 14-01","January 19, 2015","August 10, 2015","August 10, 2015","September 27, 2019","November 19, 2019","January 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04106817"
2,"NCT04069221","Absolute BA and OZ439 PK Effect of Different OZ439 Dose Volumes and Cobicistat Co-administration Study",,"Completed","Has Results","Malaria","Drug: Single oral dose of 800 mg OZ439|Drug: Single oral dose of 400 mg OZ439|Drug: Single oral dose of cobicistat|Drug: iv infusion of [14C]-OZ439","OZ439 Fpo|OZ439 Cmax|OZ439 C168h|OZ439 AUC0-168h|OZ439 AUC0-inf","Medicines for Malaria Venture","All","18 Years to 55 Years   (Adult)","Phase 1","26","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MMV_OZ439_16_01","February 28, 2017","May 30, 2017","May 30, 2017","August 28, 2019","November 26, 2019","November 26, 2019","PRA Health Sciences (PRA) - Early Development Services (EDS), Groningen, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT04069221/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT04069221/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04069221"
3,"NCT04032652","Use of Rectal Dialysis Technique to Measure Rectal 5-ASA Levels in Healthy Volunteers Receiving Asacol",,"Terminated","Has Results","Ulcerative Colitis","Procedure: Rectal dialysis|Drug: Rectal dialysis","Detection of 5-ASA|Change in Detected 5-ASA With Change in Ingested Asacol Dose","NorthShore University HealthSystem","All","18 Years to 45 Years   (Adult)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","EH 11-364","December 2012","November 2014","December 5, 2014","July 25, 2019","October 15, 2019","October 15, 2019",,,"https://ClinicalTrials.gov/show/NCT04032652"
4,"NCT04027218","Clinical Trial to Assess the Effectiveness of Applying Dry Local Heat and/ or High Tourniquet Pressure for Venipuncture.","ECYPVEN-H/17","Completed","Has Results","Venipuncture|Healthy Adult","Device: Dry heat|Device: High pressure|Device: Combination of dry heat and high pressure","Number of Participants With Successful Venous Catheterization at the First Attempt|Number of the Grade of Venous International Assessment (VIA) Scale After Application of Intervention|Number of the Grade in Visual Analogue Scale (VAS) for Pain After Intervention|Number of Participants in Each Type of Skin Standardized According to Fitzpatrick Scale|Level of Hemolysis in Absorbance Units|Number of Participants With Adverse Events","Universidad Complutense de Madrid|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","All","18 Years to 55 Years   (Adult)","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","3113","July 9, 2017","July 23, 2017","April 3, 2018","July 19, 2019","October 30, 2019","November 13, 2019","Leticia Carmen Simón López, Madrid, Spain","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT04027218/Prot_SAP_ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04027218"
5,"NCT04015232","Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.",,"Completed","Has Results","Immunogenicity|Healthy Volunteers","Combination Product: INTP5|Combination Product: US Neulasta","Immunogenicity Screening Incidence to Detect the Presence of Anti-PegG-CSF Antibodies.|PK Endpoints: Pegfilgrastim C[Max]|PK Endpoints: Pegfilgrastim AUC[0-t]|PK Endpoints: Pegfilgrastim AUC[0-∞]|PK Endpoints: Pegfilgrastim T[Max]|PK Endpoints: Pegfilgrastim λz (Lambda-z)|PK Endpoints: Pegfilgrastim R^2 Adjusted|PK Endpoints: Pegfilgrastim AUC[_%Extrap_Obs]|PK Endpoints: Pegfilgrastim t[1/2]|PD Endpoints for Baseline Non-adjusted ANC: E[Max]|PD Endpoints for Baseline Non-adjusted ANC: T[Max]|PD Endpoints for Baseline Non-adjusted ANC: AUEC[0-t]|PD Endpoints for Baseline Adjusted ANC: E[Max]|PD Endpoints for Baseline Adjusted ANC: AUEC[0-t]|PD Endpoints for Baseline Adjusted ANC: T[Max]|PD Endpoints for Baseline Adjusted ANC: λz (Lambda-z)|PD Endpoints for Baseline Adjusted ANC: t[1/2]","Intas Pharmaceuticals, Ltd.|Lambda Therapeutic Research Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","0554-17","February 26, 2018","June 5, 2018","June 5, 2018","July 10, 2019","October 4, 2019","October 4, 2019","Lambda Therapeutic Research Ltd., Ahmedabad, Gota, India","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT04015232/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT04015232/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04015232"
6,"NCT04014062","Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.",,"Completed","Has Results","Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers","Combination Product: INTP5|Combination Product: US Neulasta","Pharmacokinetic (PK) Endpoints: Pegfilgrastim C[Max]|Pharmacokinetic (PK) Endpoints: Pegfilgrastim AUC[0-infinity]|Pharmacodynamic (PD) Endpoints: E[Max] for Baseline Non-adjusted ANC|Pharmacodynamic (PD) Endpoints: AUEC[0-t] for Baseline Non-adjusted ANC|PK Endpoint: Pegfilgrastim AUC[0-t]|PK Endpoint: Pegfilgrastim T[Max]|PK Endpoint: Pegfilgrastim λz(Lambda-z)|PK Endpoint: Pegfilgrastim R^2 Adjusted|PK Endpoint: Pegfilgrastim t[1/2]|PK Endpoint: Pegfilgrastim AUC[_Percent_Extrap_Obs]|PD Endpoint: T[Max] for Baseline Non-adjusted ANC|PD Endpoint: E[Max], Baseline-adjusted ANC|PD Endpoint: AUEC[0-t], Baseline-adjusted ANC|PD Endpoint: T[Max], Baseline-adjusted ANC|PD Endpoint: λz(Lamda-z) and Baseline-adjusted ANC|PD Endpoint: t[1/2] for Baseline-adjusted ANC","Intas Pharmaceuticals, Ltd.|Lambda Therapeutic Research Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","144","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","0553-17","February 12, 2018","May 1, 2018","May 1, 2018","July 10, 2019","October 4, 2019","October 4, 2019","Lambda Therapeutic Research Ltd., Ahmedabad, Gota, India","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT04014062/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT04014062/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04014062"
7,"NCT03966365","Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®","PRO-122/I","Completed","Has Results","Glaucoma","Drug: PRO-122|Drug: Krytantek Ofteno®","Number of Adverse Events|Eye Comfort Index|Number of Eyes With Epithelial Defects by Grade|Visual Ability|Participants With Conjunctival Hyperemia (CH) by Grade|Participants With Chemosis","Laboratorios Sophia S.A de C.V.","All","18 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SOPH122-0518/I","May 2, 2019","August 30, 2019","August 30, 2019","May 29, 2019","December 13, 2019","December 13, 2019","Unidad Clínica de Bioequivalencia, S. de R.L. de C.V., Guadalajara, Jalisco, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03966365/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03966365"
8,"NCT03965052","Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®","PRO-179/I","Completed","Has Results","Glaucoma","Drug: PRO 179|Drug: Travatan 0.004 % Ophthalmic Solution","Number of Participants With Adverse Events|Eye Comfort Index|Number of Eyes With Epithelial Defects by Grade|Visual Ability|Percentage of Eyes With Conjunctival Hyperemia (CH) by Grade|Number of Eyes of Chemosis","Laboratorios Sophia S.A de C.V.","All","18 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SOPH179-0818/I","April 24, 2019","July 2, 2019","August 29, 2019","May 28, 2019","December 12, 2019","December 12, 2019","Jose Navarro Partida, Guadalajara, Jalisco, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03965052/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03965052"
9,"NCT03902392","Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis","Grapolyphen","Completed","Has Results","Allergic Contact Dermatitis","Dietary Supplement: NaturOx Group (A)|Other: Placebo Group (B)","Evaluation of Serum Biomarker Concentrations at the Time of Enrollment (T0)|Evaluation of Serum Biomarker Concentrations at the End of the Treatment (T1)","University of Bari","Female","25 Years to 60 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","5480","April 16, 2018","September 10, 2018","October 31, 2018","April 4, 2019","January 2, 2020","January 2, 2020","Thea Magrone, Bari, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT03902392/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT03902392/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03902392"
10,"NCT03894449","Probing the Synergistic Effect of Pre-Biotics & Iron Fortificants in Anemic Subjects",,"Completed","Has Results","Iron-deficiency","Combination Product: Prebiotic + Iron Forificant","Change in Hemoglobin Concentration From Baseline to 90 Days|Change in Hematocrit in Concentration From Baseline to 90 Days|Change in Mean Corpuscular Volume From Baseline to 90 Days|Change in Mean Corpuscular Hemoglobin From Baseline to 90 Days|Change in Mean Corpuscular Hemoglobin Concentration From Baseline to 90 Days|Change in Serum Iron Levels From Baseline to 90 Days|Change in Serum Folate Levels From Baseline to 90 Days|Change in Serum Ferritin Levels From Baseline to 90 Days|Change in Serum Transferrin Levels From Baseline to 90 Days|Change in Transferrin Saturation Factor Levels From Baseline to 90 Days|Change in Total Iron Binding Capacity Levels From Baseline to 90 Days|Change in Liver Functions Tests (ALT) From Baseline to 90 Days|Change in Liver Functions Tests (AST) From Baseline to 90 Days|Change in Liver Functions Tests (ALP) From Baseline to 90 Days|Change in Liver Functions Tests (Total Bilirubin) From Baseline to 90 Days|Change in Renal Functions Tests (Serum Urea) From Baseline to 90 Days|Change in Renal Functions Tests (Serum Creatinine) From Baseline to 90 Days|Change in Immunoglobulins (IgA) From Baseline to 90 Days|Change in Immunoglobulins (IgE) From Baseline to 90 Days|Change in Immunoglobulins (IgG) From Baseline to 90 Days|Change in Immunoglobulins (IgM) From Baseline to 90 Days","University of Veterinary and Animal Sciences, Lahore - Pakistan","Female","18 Years to 25 Years   (Adult)","Phase 1|Phase 2","75","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2015-VA-04","April 6, 2019","July 6, 2019","July 6, 2019","March 28, 2019","August 22, 2019","August 22, 2019","University of Veterinary and Animal Sciences, Lahore, Punjab, Pakistan","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03894449/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03894449/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03894449"
11,"NCT03857230","The Safety and Pharmacokinetics of Primapur and Gonal-f",,"Completed","Has Results","Area Under Curve|Pharmacokinetics|Absorption","Drug: Follitropin alfa (Primapur)|Drug: Follitropin alfa (Gonal-F)","Area Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192))|Maximum Serum Concentration of Follicle Stimulating Hormone (FSH) (Cmax)|Time to Reach a Maximum Follicle Stimulating Hormone (FSH) Serum Concentration (Tmax)|Follicle Stimulating Hormone (FSH) Apparent Terminal Half-life (T1/2)","IVFarma LLC|NADIM LLC","Female","18 Years to 40 Years   (Adult)","Phase 1","28","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","FSG-01-01","October 29, 2015","May 10, 2016","May 10, 2016","February 27, 2019","August 5, 2019","August 13, 2019","O.M. Filatov Municipal Clinical Hospital N 15, Moscow, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03857230/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03857230"
12,"NCT03850093","Preoperative Gabapentin Versus Bisoprolol for Hemodynamic Optimization During Sinus Surgery",,"Completed","Has Results","Blood Pressure","Drug: Gabapentin1200 mg|Drug: bisoprolol 2.5mg|Drug: placebo","Changes in Surgical Field Visibility|Blood Loss|Heart Rate Change|Mean Arterial Blood Pressure Change","Zagazig University","All","18 Years to 50 Years   (Adult)","Phase 4","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","ZU-IRB 2139-24-5-2015","August 2015","October 2016","December 2016","February 21, 2019","August 12, 2019","December 20, 2019",,"""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03850093/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03850093"
13,"NCT03828149","Evaluation of Safety and Pharmacodynamics of OP0201 Compared to Placebo in Healthy Adults",,"Completed","Has Results","Healthy Adults","Combination Product: Drug:OP0201|Combination Product: Drug: Placebo","Safety (Evaluation of Adverse Events)","Novus Therapeutics, Inc","All","18 Years to 50 Years   (Adult)","Phase 1","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","OP0201-C-001","February 8, 2019","March 7, 2019","March 7, 2019","February 4, 2019","December 30, 2019","December 30, 2019","Cologne University Hospital, Cologne, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03828149/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03828149/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03828149"
14,"NCT03783780","Desaturation Validation of INVSENSOR00031",,"Completed","Has Results","Healthy","Device: INVSENSOR00031","Oxygen Saturation (SpO2) Accuracy of Sensor by Arms Calculation During Non-motion|Oxygen Saturation (SpO2) Accuracy of Sensor by Arms Calculation During Motion","Masimo Corporation","All","18 Years to 50 Years   (Adult)","Not Applicable","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TP-19564","December 11, 2018","December 18, 2018","December 18, 2018","December 21, 2018","July 2, 2019","December 17, 2019","Masimo Corporation, Irvine, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03783780/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03783780"
15,"NCT03765138","Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression",,"Terminated","Has Results","PTSD|MDD","Combination Product: PE/Pramipexole","Change in PTSD Symptoms as Measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)|Change in Depressive Symptoms as Measured by the Hamilton Rating Scale for Depression (HRSD).|Changes in Functional Connectivity of Fear and Reward Pathways as Measured by Functional Magentic Resonance Imaging (fMRI) Resting State Functional Connectivity (Rs-FC).","Research Foundation for Mental Hygiene, Inc.","All","18 Years to 60 Years   (Adult)","Phase 3","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Research Foundation for Mental","February 19, 2019","August 26, 2019","August 26, 2019","December 5, 2018","November 26, 2019","November 26, 2019","New York State Psychiatric Institute, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03765138/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03765138"
16,"NCT03758365","Evaluation of the Vasoconstriction Properties of MC2-01 Cream",,"Completed","Has Results","Vasoconstriction","Drug: MC2-01 Cream|Drug: Clobetasol Propionate 0.05% Lotion|Drug: Betamethasone Dipropionate 0.05% Cream|Drug: Triamcinolone Acetonide 0.1% Cream|Drug: Hydrocortisone Butyrate 0.1% Cream|Drug: Desonide 0.05% Cream|Drug: Vehicle","Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and Vehicle|Compare Local Tolerability of the MC2-01 Cream With Active Comparators and Vehicle","MC2 Therapeutics","All","18 Years to 50 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MC2-01-C4","November 5, 2018","November 23, 2018","November 23, 2018","November 29, 2018","January 9, 2020","January 9, 2020","CPCAD, Nice, France","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03758365/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03758365/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03758365"
17,"NCT03755882","Clinical Comparison of Two Marketed Reusable Cosmetic Contact Lenses",,"Completed","Has Results","Visual Acuity","Device: ACUVUE® DEFINE™ Vivid Style|Device: LACELLE™ Sparkling Brown","Visual Performance","Johnson & Johnson Vision Care, Inc.","Female","18 Years to 29 Years   (Adult)","Not Applicable","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-6286","November 5, 2018","December 26, 2018","December 26, 2018","November 28, 2018","January 10, 2020","January 10, 2020","Sun Yat-Sen University Zhongshan Ophthalmic Center, Guanzhou, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03755882/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03755882"
18,"NCT03738020","Clinical Study to Evaluate the Correction of Wrinkles and Folds and Safety of YVOIRE Classic Versus Restylane in Nasolabial Fold Intradermal Injection",,"Completed","Has Results","Temporary Correction of Wrinkles","Device: HA IDF (YVOIRE classic)|Device: Restylane","Average of Wrinkle Severity Rating Scale (WSRS) Score Evaluated by the Evaluating Investigator at Week 26 (Visit 7) After the Final Treatment With the Investigational Medical Device","LG Life Sciences","All","30 Years to 55 Years   (Adult)","Not Applicable","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","LG-HACL008","January 2009","October 2009","October 2009","November 13, 2018","December 18, 2019","December 18, 2019",,,"https://ClinicalTrials.gov/show/NCT03738020"
19,"NCT03733470","Hypoxic Pulmonary Vasoconstriction Pilot Study",,"Completed","Has Results","Emphysema","Drug: Sildenafil study group","Perfused Blood Volume Assessed for a Change in Lung Inflammation Pre and Post Dose Sildenafil Administration","Eric A. Hoffman|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|University of Iowa","All","30 Years to 60 Years   (Adult)","Phase 4","22","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","201101707|5R01HL112986","June 29, 2011","January 13, 2014","January 13, 2014","November 7, 2018","October 1, 2019","October 1, 2019","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT03733470"
20,"NCT03723980","Role of Propolis Paste in Preventing Pain After Root Canal Treatment.",,"Completed","Has Results","Pain, Postoperative","Drug: Propolis|Drug: Calcium Hydroxide","Pain Intensity Measure: Visual Analogue Pain Scale|Acute Increase in Pain Score (Acute Exacerbation of Pain)|Difference of Pain Score Between Different Time Intervals","Juzer Shabbir Saifee|Dow University of Health Sciences","All","20 Years to 40 Years   (Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","MDSJUZER|ISRCTN66816132","November 16, 2017","April 24, 2018","October 15, 2018","October 30, 2018","June 6, 2019","June 6, 2019","Dow International Dental College, Karachi, Sindh, Pakistan","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03723980/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03723980"
21,"NCT03720847","Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality",,"Completed","Has Results","Suicidal Ideation","Drug: Estradiol Transdermal Patch 0.1 mg/24 hrs|Drug: Oral Micronized Progesterone|Drug: Inactive Clear Patch|Drug: Placebo capsule","Perimenstrual Change in Self-Injurious Thoughts and Behaviors Interview (SITBI) Suicidal Ideation Score|Perimenstrual Change in Self-Injurious Thoughts and Behaviors Interview (SITBI) Suicidal Planning Score|Perimenstrual Change in Beck Hopelessness Scale (BHS) Score|Perimenstrual Change in Center for Epidemiological Studies Depression Scale (CES-D) Score|Perimenstrual Change in Lack of Premeditation Subscale Score of the ""Urgency, Premeditation, Perseverance, Sensation Seeking, and Positive Urgency (UPPSP) Impulsivity Scale""|Perimenstrual Changes in Patient-Reported Outcomes Measurement Information Systems (PROMIS) Anxiety Scale Score|Perimenstrual Change in State Self-Esteem Scale Social Evaluation Subscale (SSES-SE) Score","University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)","Female","18 Years to 45 Years   (Adult)","Phase 4","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","16-2078|K99MH109667","December 31, 2016","November 2017","November 2017","October 25, 2018","February 4, 2019","February 4, 2019","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT03720847/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03720847"
22,"NCT03717064","A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers",,"Completed","Has Results","Healthy Volunteers","Drug: RO7049389|Drug: Pitavastatin","Period 1: Maximum Plasma Concentration (Cmax) of Pitavastatin|Period 1: Plasma Concentration Versus Time (Area Under the Curve, AUC0-inf) of Pitavastatin|Period 1: Time to Maximum Concentration (Tmax) of Pitavastatin|Period 1: Apparent Total Clearance (CL/F) of Pitavastatin|Period 1: Volume of Distribution (V/F) of Pitavastatin|Period 1: Elimination Half-Life (T1/2) of Pitavastatin|Period 2: Maximum Plasma Concentration (Cmax) of Pitavastatin|Period 2: Plasma Concentration Versus Time (Area Under the Curve, AUC0-inf) of Pitavastatin|Period 2: Time to Maximum Concentration (Tmax) of Pitavastatin|Period 2: Apparent Total Clearance (CL/F) of Pitavastatin|Period 2: Volume of Distribution (V/F) of Pitavastatin|Period 2: Elimination Half-Life (T1/2) of Pitavastatin|Percentage of Participants With Adverse Events (AEs)|Period 2: Cmax of RO7049389|Period 2: AUC-tau of RO7049389|Period 1: Cmax of Pitavastatin Lactone|Period 1: AUC0-inf of Pitavastatin Lactone|Period 1: AUC Ratio of Pitavastatin Lactone to Pitavastatin|Period 2: Cmax of Pitavastatin Lactone|Period 2: AUC0-inf of Pitavastatin Lactone|Period 2: AUC Ratio of Pitavastatin Lactone to Pitavastatin","Hoffmann-La Roche","All","18 Years to 60 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","YP40218","November 7, 2018","December 17, 2018","December 17, 2018","October 24, 2018","January 10, 2020","January 10, 2020","Covance Research Unit - Daytona, Daytona Beach, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03717064/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03717064"
23,"NCT03715530","Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women","PAMG-1","Terminated","Has Results","Preterm Labor|Preterm Birth","Device: PAMG-1 immunoassay","Number of Participants With PAMG-1 Test Results That Matched the Results of Gold Standard Testing","Mark Santillan|AmniSure International LLC|University of Iowa","Female","18 Years to 50 Years   (Adult)","Not Applicable","162","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","200706757","September 2007","July 2011","July 2011","October 23, 2018","October 3, 2019","October 3, 2019","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT03715530"
24,"NCT03714672","Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar Extraction",,"Completed","Has Results","Acute Pain","Drug: Tramadol/Diclofenac 50/50|Drug: Tramadol/Diclofenac 25/25|Drug: Tramadol 50|Drug: Diclofenac 50","Pain Relief Expressed as Total Pain Relief (TOTPAR) Over the 4 Hours Post-dose Period (TOTPAR4)|Total Pain Relief at 6 Hours Post-dose (TOTPAR6)|Total Pain Relief at 8 Hours Post-dose (TOTPAR8)|Summed Pain Intensity Difference (SPID) at 4, 6, 8, and 24 Hours Post-dose|Time to Achieve a 50 Percent Reduction in Baseline Pain (Pain at Least Half Gone)|Time to Onset of First Perceptible Pain Relief|Time to Onset of Meaningful Pain Relief|Time to Intake of First Rescue Medication Dose|Subject's Global Evaluation of the Treatment|Incidence and Type of Adverse Events","Grünenthal GmbH|Grünenthal, S.A.","All","18 Years to 60 Years   (Adult)","Phase 3","1151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KF8001-01|U1111-1179-2333","August 26, 2017","March 9, 2018","March 22, 2018","October 22, 2018","July 24, 2019","July 24, 2019","Private Clinic, Zapopan, Jalisco, Mexico|Private Clinic, Monterrey, Nuevo León, Mexico|Private Clinic, Monterrey, Nuevo León, Mexico|Private Clinic, Aguascalientes, Mexico|Private Clinic, Chihuahua, Mexico|Private Clinic, Leon Guanajuato, Mexico|Private Clinic, Puebla, Mexico|University, San Luis Potosí, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT03714672/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT03714672/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03714672"
25,"NCT03708744","A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers",,"Completed","Has Results","Migraine","Drug: A: M207 3.8mg, 30 min, upper arm|Drug: B: M207 3.8 mg, 30 min, thigh|Drug: C: M207 3.8 mg, 1 hr, upper arm|Drug: D:zolmitriptan nasal spray","Cmax|Adverse Events|t(1/2)","Zosano Pharma Corporation","All","18 Years to 50 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CP-2018-002","November 1, 2018","November 20, 2018","November 20, 2018","October 17, 2018","December 23, 2019","December 23, 2019","Hill Top Research, Inc., Neptune, New Jersey, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03708744/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03708744/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03708744"
26,"NCT03707821","Design Validation of Senofilcon A With New UV-blocking Additive",,"Completed","Has Results","Visual Acuity","Device: senofilcon A TEST Lens|Device: senofilcon A CONTROL Lens","Overall Comfort Score|Vision Satisfaction in Bright Lighting|Distance Visual Acuity|Contact Lens Fitting Acceptance Rate|Number of Grade 3 or Higher Slit Lamp Findings|Overall Handling Score|Overall Quality of Vision Score","Johnson & Johnson Vision Care, Inc.","All","18 Years to 49 Years   (Adult)","Not Applicable","253","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-6305","October 1, 2018","November 1, 2018","November 1, 2018","October 16, 2018","December 5, 2019","December 5, 2019","James T. Fujimoto, OD, Cupertino, California, United States|Maitland Vision Center, Maitland, Florida, United States|Tallahassee Eye Center, Tallahassee, Florida, United States|Eyecare Associates LLP, Bloomington, Illinois, United States|Kannarr Eye Care, Pittsburg, Kansas, United States|ProCare Vision Centers, Granville, Ohio, United States|Professional Vision Care, Inc, Westerville, Ohio, United States|Bradley Hines, OD, Memphis, Tennessee, United States|Frazier Vision, Inc, Tyler, Texas, United States|Ziegler Leffingwell Eyecare, New Berlin, Wisconsin, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03707821/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03707821/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03707821"
27,"NCT03706469","A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants",,"Completed","Has Results","Healthy Volunteers","Drug: TAK-831 T2|Drug: TAK-831 T3","AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-831|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831|Cmax: Maximum Observed Plasma Concentration for TAK-831|Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)","Millennium Pharmaceuticals, Inc.|Takeda","All","19 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-831-1006|U1111-1217-5483","October 18, 2018","December 11, 2018","December 22, 2018","October 16, 2018","December 23, 2019","December 23, 2019","Celerion, Lincoln, Nebraska, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03706469/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03706469/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03706469"
28,"NCT03698591","Testing a Neurocognitive Model of Distancing Using Transcranial Magnetic Stimulation.",,"Completed","Has Results","Emotion Regulation|Real Versus Sham Transcranial Magnetic Stimulation (TMS)","Device: Transcranial magnetic stimulation task|Device: Sham transcranial magnetic stimulation task","Change in Self-reported Valence (Distancing) From Baseline to 30 Minutes Post Stimulation.|Change in Self-reported Effort (Distancing) From Baseline to 30 Minutes Post Stimulation.","Duke University","All","18 Years to 39 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Pro00100171","October 31, 2018","May 24, 2019","May 24, 2019","October 9, 2018","December 10, 2019","December 17, 2019","LaBar Lab, Duke University, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT03698591/Prot_SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT03698591/ICF_003.pdf","https://ClinicalTrials.gov/show/NCT03698591"
29,"NCT03693950","The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers",,"Completed","Has Results","Healthy","Biological: BCD-066|Biological: Aranesp","AUC(0-72)|Cmax|T½|AUC(0-∞)|Tmax|Kel|CL","Biocad","Male","18 Years to 45 Years   (Adult)","Phase 1","57","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","BCD-066-3","March 28, 2017","July 3, 2017","July 3, 2017","October 3, 2018","July 1, 2019","July 1, 2019","BIOCAD, Saint Petersburg, Strelna, Russian Federation","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03693950/ICF_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03693950/SAP_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03693950/Prot_003.pdf","https://ClinicalTrials.gov/show/NCT03693950"
30,"NCT03685396","Patient Morbidity After Palatal Free Gingival Grafts With or Without PRF Membranes Coverage",,"Completed","Has Results","Postoperative Pain|Postoperative Complications|Gingival Recession","Biological: Platelet rich fibrin ( PRF)|Drug: hemostatic agents with oxidized and regenerated cellulosa","Post-operative Pain: VAS|Post-operative Discomfort|Post-operative Stress|Post-operative Inability to Chew","Azienda Ospedaliera San Paolo","All","18 Years to 60 Years   (Adult)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRF","November 27, 2017","July 23, 2018","September 9, 2018","September 26, 2018","August 5, 2019","August 5, 2019","Azienda Ospedaliera San Paolo - Polo Universitario - Università degli Studi di Milano, Milan, Milano, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT03685396/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT03685396/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT03685396"
31,"NCT03684265","A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets",,"Completed","Has Results","Healthy","Drug: Meloxicam Capsule (Test)|Drug: Meloxicam Tablet (Reference)","Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-t)|Maximum Measured Concentration of the Analyte in Plasma (Cmax)|Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)","Boehringer Ingelheim","All","18 Years to 45 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0107-0277","October 5, 2018","October 30, 2018","November 6, 2018","September 25, 2018","November 22, 2019","November 22, 2019","City Clinical Hospital named after V.P. Demikhova Department of Health of Moscow, Moscow, Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03684265/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03684265/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03684265"
32,"NCT03683758","Effects of the FIFA11+ Warm-up Program on Speed, Agility, and Vertical Jump Performance in Adult Female Amateur Soccer Players","FIFA","Completed","Has Results","Soccer|Exercise|Athletic Performance","Other: FIFA11+|Other: 'Usual' Soccer Warm-up","Percentage Change From Baseline in 10m Sprint Times After an 8 Week Intervention|Percentage Change From Baseline in Agility T-Test Times After an 8 Week Intervention|Percentage Change From Baseline in Squat Jump Height After an 8 Week Intervention|Warm-up Attendance","University of British Columbia|North Shore Girls Soccer Club","Female","18 Years to 45 Years   (Adult)","Not Applicable","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","H18-00383","September 6, 2018","November 11, 2018","November 11, 2018","September 25, 2018","September 6, 2019","September 6, 2019","Windsor Bubble, North Vancouver, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03683758/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03683758"
33,"NCT03679741","Initial Evaluation of Investigational Lenses Manufactured on a New Production Line",,"Completed","Has Results","Visual Acuity","Device: CONTROL Lens|Device: TEST Lens","Overall Comfort Score|Vision Satisfaction in Bright Lighting|Distance Monocular LogMAR Visual Acuity|Contact Lens Fitting Acceptance Rate|Number of Grade 3 or Higher Slit Lamp Findings|Overall Quality of Vision Score|Overall Handling Scores|Overall Quality of Vision Indoors","Johnson & Johnson Vision Care, Inc.","All","18 Years to 49 Years   (Adult)","Not Applicable","126","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-6283","August 29, 2018","October 31, 2018","October 31, 2018","September 20, 2018","December 26, 2019","December 26, 2019","Randall Go, OD, San Francisco, California, United States|VRC-East, Jacksonville, Florida, United States|Sacco Eye Group, Vestal, New York, United States|Pickens Eye Care, Pickens, South Carolina, United States|William J. Bogus, OD, FAAO, Salt Lake City, Utah, United States|Botetourt Eyecare, LLC, Roanoke, Virginia, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03679741/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03679741/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03679741"
34,"NCT03677375","Hemodilution Validation of INVSENSOR00026",,"Completed","Has Results","Healthy","Device: INVSENSOR00026","Accuracy of Noninvasive Hemoglobin Sensor by Arms Calculation","Masimo Corporation","All","18 Years to 50 Years   (Adult)","Not Applicable","173","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TP-19466","September 4, 2018","February 4, 2019","February 4, 2019","September 19, 2018","May 20, 2019","May 20, 2019","Masimo Corporation, Irvine, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03677375/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03677375"
35,"NCT03667547","Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)",,"Completed","Has Results","Human Immunodeficiency Virus (HIV) Infection","Drug: Raltegravir","Number of Participants With an Adverse Event (AE)|Number of Participants Discontinued From the Study Due to an AE|Number of Participants With a Serious Adverse Event (SAE)|Number of Participants With a Drug-related AE|Area Under the Concentration-Time Curve Up to Infinity (AUC0-∞) of Plasma Raltegravir|Maximum Plasma Concentration (Cmax) of Raltegravir|Plasma Concentration of Raltegravir at 24 Hours After Dosing (C24)|Time of Maximum Plasma Concentration (Tmax) of Raltegravir|Apparent Plasma Half-life (t1/2) of Raltegravir|Apparent Total Plasma Clearance (CL/F) of Raltegravir|Apparent Volume of Distribution (Vz/F) of Raltegravir","Merck Sharp & Dohme Corp.","Male","20 Years to 45 Years   (Adult)","Phase 4","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0518-851|MK-0518-851","September 27, 2018","October 23, 2018","October 23, 2018","September 12, 2018","October 2, 2019","October 2, 2019","Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic ( Site 0001), Tokyo, Japan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT03667547/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03667547"
36,"NCT03660787","Efficacy and Dose Ranging Study of Seroguard",,"Completed","Has Results","Adhesion","Drug: Seroguard|Drug: Placebo","Number of Participants With Reduction of Adhesions Number by 3 or More|Change in Thickness of Pelvic Adhesions|Number of Participants With Detection of Pelvic Organs Limited Mobility|Number of Participants With Detection of Hyperechoic Linear Lesions Post Surgery|Change in Number of Participants in Detecting Pelvic Organs Limited Mobility|Change Number of Participants in Detecting Hyperechoic Linear Lesions|Number of Participants With Detection of no Ultrasound Signs of Pelvic Adhesive Disease Post Surgery","Pharmasyntez|Cromos Pharma, LLC","Female","18 Years to 45 Years   (Adult)","Phase 2","114","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","SG-2/1215","May 4, 2017","January 23, 2018","January 23, 2018","September 7, 2018","June 19, 2019","June 19, 2019","Krai Government-Owned State Funded Healthcare Institution ""Krai Clinical Hospital"", Krasnoyarsk, Krasnoyarsk Krai, Russian Federation|State Educational Government-Financed Institution of Higher Professional Education ""Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky"" of the Ministry of Healthcare of the Russian Federation at the clinical site Publicly Funded, Krasnoyarsk, Krasnoyarsk Krai, Russian Federation|State Funded Healthcare Institution of Moscow of City Health Department ""V.M. Buyanov Municipal Clinical Hospital"", Moscow, Moscow Region, Russian Federation|Federal State Institution ""V.I. Kulakov Research Center for Obstetrics, Gynecology, and Perinatology"" of the Ministry of Healthcare and Social Development of the Russian Federation., Moscow, Moscow Region, Russian Federation|State Educational Government-Financed Institution of Higher Professional Education ""Kazan State Medical University"" of the Ministry of Health of the Russian at the clinical site of Kazan Maternity Hospital No. 3 named after V.S. Gruzdev, Kazan, Republic Of Tatarstan, Russian Federation|State Funded Health Care Institution ""Bryansk Municipal Hospital No 1, Bryansk, The Bryansk Region, Russian Federation|Federal State Educational Government-Financed Institution of Higher Education ""Kemerovo State Medical University"" of the Ministry of Healthcare of the Russian Federation at the clinical site of Kemerovo Oblast Publicly Funded Healthcare Institution ""L.A., Kemerovo, The Kemerovo Region, Russian Federation|Federal State Funded Healthcare Institution ""L.G. Sokolov Federal Biomedical Agency Clinical Hospital No 122""., Saint Petersburg, The Leningrad Region, Russian Federation|Federal State Funded Scientific Institution ""Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott"" of the Ministry of Healthcare of the Russian Federation, Saint Petersburg, The Leningrad Region, Russian Federation|Moscow Oblast State Funded Healthcare Institution ""Moscow Oblast Research Institute of Obstetrics and Gynecology"", Moscow, The Moscow Region, Russian Federation|State Funded Healthcare Institution of Moscow of City Health Department ""Moscow Municipal Clinical Hospital No 31"", Moscow, The Moscow Region, Russian Federation|State Educational Government-Financed Institution of Higher Professional Education ""Rostov State Medical University"" of the Ministry of Healthcare of the Russian Federation at the clinical site of Obstetrics and Pediatrics Research Institute, Rostov-on-Don, The Rostov Region, Russian Federation|Federal State Educational Government-Financed Institution of Higher Education ""I.P. Pavlov Ryazan State Medical University"" of the Ministry of Healthcare of the Russian Federation at the clinical site of State Funded Healthcare Institution ""Municipal Clin, Ryazan', The Ryazan Region, Russian Federation|Federal State Funded Healthcare Institution ""Ural Research Institute of Maternal and Infant Care"" of the Ministry of Healthcare of the Russian Federation, Yekaterinburg, The Sverdlovsk Region, Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03660787/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03660787/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03660787"
37,"NCT03657264","Cardiac Safety Evaluation of P03277",,"Completed","Has Results","Healthy Volunteers","Drug: P03277 0.1 mmol/kg|Drug: Moxifloxacin 400mg|Drug: NaCl 0.9%|Drug: P03277 0.3 mmol/kg","Change-from-baseline Mean Effect of P03277 on QT Interval Expressed as QTc According to Fridericia's Formula (∆QTcF)|Change-from-baseline Mean Effect of Moxifloxacin on QT Interval Expressed as QTc According to Fridericia's Formula (∆QTcF)|Predicted Value of ∆∆QTc at Cmax","Guerbet","All","18 Years to 59 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","GDX-44-006","August 21, 2017","June 7, 2018","June 7, 2018","September 5, 2018","August 22, 2019","August 22, 2019","Clinical Pharmacology unit, SGS-Life Science Service, Antwerpen, Belgium","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03657264/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03657264/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03657264"
38,"NCT03655301","Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics",,"Completed","Has Results","Healthy Volunteers","Drug: Copanlisib (Aliqopa, BAY80-6946)|Drug: Metformin","Maximum Drug Concentration of Metformin in Plasma After Single Dose Administration (Cmax)|Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours of Metformin After Single Dose Administration (AUC[0-24])|Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity of Metformin After Single Dose Administration (AUC)|Number of Participants With Treatment-Emergent Adverse Events|Number of Participants With Treatment-Emergent Adverse Events by Severity|Plasma Lactate Levels|Maximum Change From Baseline in Plasma Lactate Levels","Bayer","All","18 Years to 45 Years   (Adult)","Phase 1","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19951","September 11, 2018","November 12, 2018","February 12, 2019","August 31, 2018","December 23, 2019","December 23, 2019","Pharmaceutical Product Development (PPD), LLC, Austin, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03655301/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03655301/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03655301"
39,"NCT03649750","Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted",,"Completed","Has Results","Healthy Subjects","Drug: Mucinex®","Maximum Observed Plasma Concentration (Cmax) of Guaifenesin|Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Plasma Concentration (AUCt) of Guaifenesin|Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin|Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of Guaifenesin|Terminal Elimination Rate Constant (Kel) of Guaifenesin|Terminal Elimination Half-life (T½) of Guaifenesin|Relative Bioavailability (RF) of Guaifenesin|Number of Adverse Events(AEs) Experienced by Participants","Reckitt Benckiser LLC","All","18 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2013-MUC-01","May 29, 2013","August 7, 2013","August 7, 2013","August 28, 2018","February 22, 2019","March 27, 2019",,,"https://ClinicalTrials.gov/show/NCT03649750"
40,"NCT03644108","Study to Evaluate the Pharmacokinetics of Mucinex 600 mg Extended-release Bi-layer Tablet in Healthy Volunteers",,"Completed","Has Results","Healthy Subjects","Drug: Mucinex® ER 600 mg","Maximum Observed Plasma Concentration (Cmax) of Guaifenesin|Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC(0-t)) of Guaifenesin|Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC(0-inf)) of Guaifenesin|Time to Maximum Observed Concentration (Tmax) of Guaifenesin|Area Under Plasma Concentration Curve Ratio (AUCR) of Guaifenesin|Apparent Terminal Elimination Rate Constant (Kel) of Guaifenesin|Apparent Terminal Elimination Half-life (t1/2) of Guaifenesin|Number of Subjects With Treatment Emergent Adverse Events (TEAEs)","Reckitt Benckiser Inc.|Reckitt Benckiser LLC","All","19 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2009-GGE-04","June 4, 2009","June 15, 2009","June 15, 2009","August 23, 2018","February 28, 2019","February 28, 2019",,,"https://ClinicalTrials.gov/show/NCT03644108"
41,"NCT03644095","Bioequivalence Study Comparing Mucinex Extended-release 600 mg Tablets to Immediate-release Guaifenesin 600 mg in Healthy Volunteers",,"Completed","Has Results","Healthy Subjects","Drug: Mucinex® SE|Drug: Vicks Cough Syrup for Chesty Coughs","Maximum Observed Plasma Concentration (Cmax) of Guaifenesin|Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC(0-t)) of Guaifenesin|Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUC(0-inf)) of Guaifenesin|Time to Maximum Observed Concentration (Tmax) of Guaifenesin|Area Under Plasma Concentration Curve Ratio (AUCR) of Guaifenesin|Apparent Terminal Elimination Rate Constant (Kel) of Guaifenesin|Apparent Terminal Elimination Half-life (t1/2) of Guaifenesin|Number of Adverse Events (AE) of Participants","Reckitt Benckiser Inc.|Reckitt Benckiser LLC","All","19 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2009-GGE-02","January 16, 2009","February 1, 2009","February 1, 2009","August 23, 2018","June 19, 2019","June 19, 2019",,,"https://ClinicalTrials.gov/show/NCT03644095"
42,"NCT03643575","Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers.",,"Completed","Has Results","Healthy Subjects","Drug: Vicks Cough Syrup for Chesty Coughs|Drug: Robitussin Extra Strength Chest Congestion|Drug: Organ-I- NR tablet","Maximum Observed Plasma Concentration (Cmax) of Guaifenesin|Maximum Measured Plasma Concentration at Steady State (Cmax,ss) of Guaifenesin Following the Third Dose|Observed Plasma Concentration at the End of Dosing Interval at Steady State (Cmin,ss) of Guaifenesin Following the Third Dose|Average Plasma Concentration (Cav) of Guaifenesin Following the Third Dose|Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin|Time to Maximum Observed Plasma Concentration at Steady State (Tmax,ss) of Guaifenesin Following the Third Dose|Apparent First-order Terminal Elimination Half-life (T1/2) of Guaifenesin|Apparent First-order Terminal Elimination Rate Constant (Kel) of Guaifenesin|Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration [AUC(0-t)] of Guaifenesin|Area Under Plasma Concentration Versus Time Curve From Time 0 to Infinity [AUC(0-inf)] of Guaifenesin|Area Under Plasma Concentration Versus Time Curve From 0 to 4 Hours [AUC(0-4)] of Guaifenesin|Area Under Plasma Concentration Versus Time Curve From Time 8 to 12 Hours [AUC(8-12)] of Guaifenesin|Area Under Plasma Concentration Curve Ratio (AUCR) of Guaifenesin|Accumulation Index (AI) of Guaifenesin|Degree of Fluctuation (DF) of Guaifenesin|Peak Plasma Concentrations at Steady State (Swing) of Guaifenesin|Number of Participants With Adverse Events (AEs)","Reckitt Benckiser Inc.|Reckitt Benckiser LLC","All","19 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2009-GGE-05","June 30, 2009","July 16, 2009","July 16, 2009","August 23, 2018","February 22, 2019","March 27, 2019",,,"https://ClinicalTrials.gov/show/NCT03643575"
43,"NCT03643159","A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder",,"Terminated","Has Results","Schizophrenia|Bipolar 1 Disorder|Major Depressive Disorder","Combination Product: Abilify MyCite - Digital Medicine System|Drug: Aripiprazole or other oral antipsychotics","Difference In The Number Of Participants With All-cause Hospitalizations For Participants Using Abilify MyCite Versus Virtual Matched Controls From Baseline To Day 180|Difference In The Number Of Participants With At Least 80% Proportion Of Days Covered (PDC) (With Antipsychotic Medication) For Participants Using Abilify MyCite Versus Virtual Matched Controls From Baseline To Day 180","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 63 Years   (Adult)","Phase 4","2","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","316-13-217","June 28, 2018","October 17, 2018","October 17, 2018","August 22, 2018","November 8, 2019","November 8, 2019","Siyan Clinical Research, Santa Rosa, California, United States|Psychiatric Addiction Curative/PACT Atlanta LLC, Decatur, Georgia, United States|Georgia Psychiatry and Sleep, Smyrna, Georgia, United States|Kolade Research Institute, Las Vegas, Nevada, United States|Signature Research Associates, Inc., Fairlawn, Ohio, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03643159/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03643159/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03643159"
44,"NCT03642873","Study to Evaluate Drug-drug Interactions of Guaifenesin and Hydrocodone Bitartrate",,"Completed","Has Results","Healthy Subjects","Drug: Humibid®|Drug: Hydrocodone Bitartrate|Drug: Humibid® and Hydrocodone Bitartrate tablet","Maximum Observed Plasma Concentration (Cmax) of Guaifenesin|Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC(0-t)) of Guaifenesin|Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUC(0-inf)) of Guaifenesin|Apparent Terminal Elimination Rate Constant (Kel) of Guaifenesin|Time to Maximum Observed Concentration (Tmax) of Guaifenesin|Apparent Terminal Elimination Half-life (T1/2) of Guaifenesin|Number of Adverse Events(AEs) Experienced by Participants","Reckitt Benckiser LLC","All","19 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2006-HYDRO-04","May 5, 2007","May 21, 2007","May 21, 2007","August 22, 2018","June 20, 2019","June 20, 2019",,,"https://ClinicalTrials.gov/show/NCT03642873"
45,"NCT03642262","Mucinex® ER 600 mg Bi-layer Tablet Versus Guaifenesin Immediate Release (IR) 200 mg q4h",,"Completed","Has Results","Healthy Subjects","Drug: Mucinex®","Maximum Observed Plasma Concentration (Cmax) of Guaifenesin|Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUCt) of Guaifenesin|Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin|Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of Guaifenesin|Terminal Elimination Rate Constant (Kel) of Guaifenesin|Terminal Elimination Half-life (T½) of Guaifenesin|Relative Bioavailability (RF) of Guaifenesin|Number of Adverse Events(AEs) Experienced by Participants","Reckitt Benckiser Inc.|Reckitt Benckiser LLC","All","18 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2013-MUC-02","June 2, 2013","August 9, 2013","August 9, 2013","August 22, 2018","June 17, 2019","June 17, 2019",,,"https://ClinicalTrials.gov/show/NCT03642262"
46,"NCT03633487","Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet",,"Completed","Has Results","Healthy Subjects","Drug: Mucinex®","Maximum Observed Plasma Concentration (Cmax)|Time of the Maximum Observed Plasma Concentration (Tmax)|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t)|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf)|Percentage of AUC0-inf Extrapolated Area Under Plasma Concentration Curve Ratio (AUCR) of Guaifenesin|Apparent First-order Terminal Elimination Rate Constant (Kel)|Terminal Elimination Half Life (t1/2)|Time at Which the Percentage of Subjects Achieved a Target Concentration of at Least 65 ng/mL (T65)|Number of Subjects With Treatment-Emergent Adverse Events (TEAEs)","Reckitt Benckiser LLC","All","19 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2011-MUC-05","October 11, 2011","October 15, 2011","October 15, 2011","August 16, 2018","February 28, 2019","February 28, 2019",,,"https://ClinicalTrials.gov/show/NCT03633487"
47,"NCT03633344","Efficacy of the Administration of Colloidal Silicon Dioxide in Tablet Dosage Form in Patients With Acute Diarrhea",,"Completed","Has Results","Diarrhoea;Acute","Drug: Carbowhite|Drug: Carbowhite placebo","Reduction in Frequency of Defecation to 3 Times Per Day|Compliance Rate|Duration of Treatment|Quantity of Used Medication","Omnifarma Kiev LLC","All","18 Years to 55 Years   (Adult)","Phase 2","145","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CRID CODE-7-180","March 29, 2016","October 7, 2016","October 7, 2016","August 16, 2018","June 6, 2019","June 6, 2019",,"""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03633344/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03633344"
48,"NCT03630016","SpO2 Accuracy Comparison of Smart Sock V. 2 SpO2 to Arterial Blood CO-Oximetry",,"Completed","Has Results","Hypoxia","Diagnostic Test: Pulse oximetry with Owlet BabySat v1.0 sensor","It Was Expected That the Accuracy Root Mean Square (ARMS) Between Measured SpO2 of Owlet Smart Sock V2 v1.1 and Reference SpO2 Would Meet the Required Specification of ARMS 3% or Lower in Non-motion Conditions for the Range of 70 - 100%","Owlet Baby Care, Inc.|Clinimark, LLC","All","18 Years to 50 Years   (Adult)","Not Applicable","11","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PR2017-263","December 13, 2017","December 17, 2017","December 17, 2017","August 14, 2018","July 23, 2019","July 23, 2019","Owlet Baby Care, Inc., Lehi, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03630016/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03630016"
49,"NCT03628456","Effect of HFCWO Vests on Spirometry Measurements",,"Completed","Has Results","Cystic Fibrosis|Bronchiectasis","Device: International Biophysics AffloVest|Device: Hill-Rom Monarch","Tidal Volume (TV) Assessed in Participants at Baseline and With Both Devices|Peak Expiratory Flow (PEF) Assessed in Participants at Baseline and With Both Devices|Forced Vital Capacity (FVC) Assessed in Participants at Baseline and With Both Devices|Forced Expiratory Volume (1 Second) Assessed in Participants at Baseline and With Both Devices|Forced Expiratory Flow (FEF25-75%) Assessed in Participants at Baseline and With Both Devices","International Biophysics Corporation","All","18 Years to 50 Years   (Adult)","Not Applicable","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-01","September 13, 2018","September 21, 2018","July 2, 2019","August 14, 2018","November 13, 2019","November 22, 2019","PDS Research, Kissimmee, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03628456/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03628456"
50,"NCT03626714","Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study",,"Completed","Has Results","Organ Transplant Rejection|Psoriasis","Drug: Sustained Release Injectable Tacrolimus","Number of Subjects That Experienced Treatment-related Adverse Events [Safety and Tolerability]|Drug Concentrations in Blood Samples at Individual Time-points|Mean Blood Concentration-time Curve - Cmax|Mean Blood Concentration-time Curve - Tmax|Blood Concentration-time Curve [AUC]|Terminal Elimination Half-life [t1/2]","Auritec Pharmaceuticals|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Early Phase 1","8","Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RTB-010|U44AI069674","October 16, 2018","January 5, 2019","January 5, 2019","August 13, 2018","June 11, 2019","August 13, 2019","Worldwide Clinical Trials, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03626714/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03626714"
51,"NCT03621878","Effect of Neural Mobilization on Lumbosacral Radiculopathy Patients With Peripheral Sensitization",,"Completed","Has Results","Radiculopathy","Other: Neural mobilization exercises -Tensioner technique|Other: Neural mobilization exercises -Slider technique|Other: Transcutaneous Electrical Nerve Stimulation (TENS)","Visual Analog Scale|Hip Flexion Range of Motion (Symptomatic Side)|Knee Flexion Range of Motion (Symptomatic Side)|Hip Flexion Range of Motion (Asymptomatic Side)|Knee Flexion Range of Motion (Asymptomatic Side)","Mohammed Al-Ghamdi|Imam Abdulrahman Bin Faisal University","Male","18 Years to 60 Years   (Adult)","Not Applicable","51","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB-2014-04-321","July 1, 2015","November 28, 2017","March 30, 2018","August 9, 2018","July 22, 2019","July 22, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03621878/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03621878"
52,"NCT03619135","Effectiveness of External Vibration for Pain Relief During Intravenous Access in Adult Patients",,"Completed","Has Results","Pain Management|Anxiety","Device: Buzzy|Other: Placebo","Change in Pain|Change in Anxiety","Kyle Stein|University of Iowa","All","18 Years to 40 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201601806","October 17, 2016","August 24, 2017","August 24, 2017","August 7, 2018","February 5, 2019","February 5, 2019","University of Iowa College of Dentistry, Iowa City, Iowa, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03619135/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03619135"
53,"NCT03616171","A Sleep Intervention (SLEEP-Extend) for Young Adults At-Risk for Type 2 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 2","Behavioral: SLEEP-Extend intervention|Other: Control","Number of Enrollments in the Study Over One Year|Number of Participants Enrolled in the Intervention Arm Who Complete the Study|Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Scores|Hours of Sleep|Number of Participants Extending Sleep","Emory University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 25 Years   (Adult)","Not Applicable","6","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00105390|5P30DK111024-02","August 30, 2017","April 2, 2018","April 2, 2018","August 6, 2018","December 30, 2019","December 30, 2019","Georgia State University, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03616171/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03616171/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03616171"
54,"NCT03615534","Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females",,"Completed","Has Results","Atherogenic Dyslipidemia|Obesity Associated Disorder","Other: Therapeutic Lifestyle Changes|Other: Placebo|Drug: Fenofibrate|Dietary Supplement: Wax Matrix Extended Release Niacin (WMER Niacin)","Changes Serum Triglyceride Levels|Changes in Serum Lipoprotein Cholesterol Levels|Changes in Serum Apolipoprotein Levels|Changes in Serum Fasting Glucose Levels.|Changes in Estimated Glomerular Filtration Rate (eGFR)|Changes in Serum Uric Acid Levels|Changes in Serum Enzymes Levels|Changes in Systolic and Diastolic Blood Pressure|Adverse Events","Lewai Sharki Abdulaziz, MSc PhD|Al-Kindy College of Medicine","Female","20 Years to 60 Years   (Adult)","Phase 4","161","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","1Al-KindyCM","October 1, 2014","June 30, 2015","October 30, 2015","August 6, 2018","October 12, 2018","September 4, 2019","Al Kindy College of Medicine, University of Baghdad, Baghdad, Iraq|Lewai S Abdulaziz, Baghdad, Iraq",,"https://ClinicalTrials.gov/show/NCT03615534"
55,"NCT03610633","Oxytocin and Stress Response in Alcohol Use Disorder",,"Completed","Has Results","Alcohol Use Disorder","Drug: Oxytocin|Drug: Placebo","Corticolimbic Functional Connectivity Based on fMRI Blood Oxygenation Level Dependent (BOLD) Response During the Stress Versus Neutral Conditions of the Montreal Imaging Stress Test Task Averaged Over the Second and Third Functional Runs","Medical University of South Carolina","All","21 Years to 40 Years   (Adult)","Phase 2","11","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO 50913","March 2016","September 2018","September 2018","August 1, 2018","October 23, 2019","October 23, 2019","Addiction Sciences Division-Medical University of South Carolina, Charleston, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03610633/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03610633"
56,"NCT03601715","Analysis of Human Tissue Temperature After Application of Therapeutic Modalities.",,"Completed","Has Results","Humans|Young Adult|Health","Other: Coplanar|Other: Contraplanar|Other: Longitudinal","The Most Effective Capacitance Shortwave Technique in Relation to Temperature Increase and Heat Conservation Measured by Infrared Thermography|Temperature Increase|Heat Conservation","Alessandro Haupenthal|Santa Catarina Federal University|Universidade Federal de Santa Catarina","Male","19 Years to 40 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","1.771.454","September 3, 2018","December 10, 2018","December 10, 2018","July 26, 2018","January 2, 2020","January 2, 2020","Santa Catarina Federal University, Araranguá, SC, Brazil","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03601715/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03601715"
57,"NCT03599349","Evaluation of the Ulthera® System and Efficacy Correlation to Morphological Differences",,"Completed","Has Results","Facial and Neck Skin Laxity","Device: Microfocused ultrasound w/ visualization","Determine if There is a Correlation Between D90 Quantitative Efficacy Results of the Eyebrow and Lower Face Region With Where the TCPs Produced During Ultherapy Treatment Make Contact With Anatomical Layers of the Skin and Underlying Tissues.|Comparison of CGAIS Ratings to Average SMAS and Average Dermal Thickness of the Treated Areas to Determine if There is or is Not a Correlation.|The Subject Will Complete a SGAIS Assessing Overall Aesthetic Improvement at Day 90 and 180 Post-treatment Which Will be Compared to Average SMAS and Average Dermal Thickness of the Treated Areas to Determine if There is or is Not a Correlation|Qualitative Assessment of Overall Aesthetic Improvement Will be Compared to the Average SMAS and Average Dermal Thickness of the Treated Areas to Determine if There is or is Not a Correlation|The Subject Will Complete a Patient Satisfaction Questionnaire at the 90 and 180 Day Follow-up Visits Which Will be Compared to Average SMAS and Average Dermal Thickness of the Treated Areas to Determine if There is or is Not a Correlation|The Depth of Frontal Region Tissue Layers Will be Compared to the Quantitative Measurements of Lift in the Eyebrow Region to Determine if There is or is Not a Correlation.|The Depth of the Temple Region Tissue Layers Will be Compared to the Quantitative Measurement of Lift the Eyebrow Region to Determine if There is or is Not a Correlation.|The Depth of Cheek Tissue Layers Will be Compared to the Quantitative Measurement of Lift in the Lower Face Regions to Determine if There is or is Not a Correlation.|The Depth of Submental Tissue Layers Will be Compared to the Quantitative Measurement of Lift in the Lower Face Regions to Determine if There is or is Not a Correlation","Ulthera, Inc|Merz North America, Inc.","All","30 Years to 55 Years   (Adult)","Not Applicable","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ULT-145","August 20, 2015","July 13, 2016","July 13, 2016","July 26, 2018","June 11, 2019","June 11, 2019","Clinical Testing of Beverly Hills, Beverly Hills, California, United States",,"https://ClinicalTrials.gov/show/NCT03599349"
58,"NCT03591458","Amitriptyline in Treating Hypoglycemia",,"Terminated","Has Results","Type1 Diabetes Mellitus|Hypoglycemia Unawareness","Drug: Amitriptyline|Drug: Placebo","Glucose Area Under the Curve (AUC): Values < 70 mg/dL|Glucose Area Under the Curve (AUC): Values < 54 mg/dL|Ratio of Self-Reported Hypoglycemic Episodes to Total Hypoglycemic Episodes|Total Count of Severe Hypoglycemic Episodes|Hypoglycemia Episode Count With Blood Glucose < 70 mg/dL|Hypoglycemia Episode Count With Blood Glucose < 54 mg/dL|Average Hypoglycemia Duration With Blood Glucose < 70 mg/dL|Average Hypoglycemia Duration With Blood Glucose < 54 mg/dL|Hypoglycemia Awareness Score by Gold Questionnaire|Hypoglycemia Awareness Score by Clarke Questionnaire|Hypoglycemia Awareness Score by Pedersen-Bjergaard Questionnaire|Hypoglycemia Fear Survey Score","University of Utah","All","21 Years to 60 Years   (Adult)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB_00110853","August 1, 2018","June 3, 2019","June 3, 2019","July 19, 2018","July 22, 2019","July 22, 2019","University of Utah, Salt Lake City, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03591458/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03591458/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03591458"
59,"NCT03590613","Phase I Study of GSK2982772 in Japanese Healthy Male Participants",,"Completed","Has Results","Autoimmune Diseases","Drug: GSK2982772|Drug: Placebo","Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change From Baseline in Clinical Chemistry Parameters|Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein|Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatinine Kinase (CK), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrognase (LDH)|Change From Baseline in Clinical Chemistry Parameter: Amylase|Change From Baseline in Clinical Chemistry Parameters: Direct Bilirubin, Bilirubin, Creatinine and Urate (Uric Acid)|Change From Baseline in Clinical Chemistry Parameter: C-reactive Protein (CRP) of TID Doses for One Day of GSK2982772|Change From Baseline in Hematology Parameter: Hematocrit|Change From Baseline in Hematology Parameter: Hemoglobin|Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Hemoglobin (MCH)|Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume (MCV)|Change From Baseline in Hematology Parameter: Erythrocytes|Change From Baseline in Hematology Parameter: Reticulocytes/Erythrocytes|Change From Baseline in Hematology Parameters: Platelets and Leukocytes of TID Doses for One Day of GSK2982772|Change From Baseline in Hematology Parameters of TID Doses for One Day of GSK2982772|Change From Baseline in Urine Potential of Hydrogen (pH)|Change From Baseline in Urine Specific Gravity|Number of Participants With Abnormal Urinalysis Results by Dipstick Method|Change From Baseline in Electrocardiogram (ECG) Finding: Mean Heart Rate|Change From Baseline in ECG Findings of TID Doses for One Day of GSK2982772|Number of Participants With Abnormal Not Clinically Significant Cardiac Telemetry|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Pulse Rate of TID Doses for One Day of GSK2982772|Change From Baseline in Body Temperature of TID Doses for One Day of GSK2982772|Number of Participants With Abnormal Neurological Examinations of TID Doses for One Day of GSK2982772|Area Under the Plasma Drug Concentration Versus Time Curve Over 24 Hours (AUC[0-24]) and AUC Over Each Dose Interval of TID Doses for One Day of GSK2982772|Maximum Observed Plasma Concentration (Cmax) and Observed Trough Drug Plasma Concentrations Following Each TID Doses for One Day of GSK2982772|Terminal Half Life (t1/2) After the Third TID Dose for One Day of GSK2982772|Time to Maximum Observed Plasma Drug Concentration (Tmax) of Each TID Doses for One Day of GSK2982772","GlaxoSmithKline","Male","20 Years to 64 Years   (Adult)","Phase 1","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","205037","July 19, 2018","September 21, 2018","September 26, 2018","July 18, 2018","September 17, 2019","September 17, 2019","GSK Investigational Site, Fukuoka, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT03590613/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT03590613/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03590613"
60,"NCT03585790","The Impact of Soft Contact Lens Attributes on Symptoms Associated With Digital Eye Strain in Symptomatic Soft Contact Lens Wearers",,"Completed","Has Results","Asthenopia|Myopia","Device: Contact lens with Multifocal Optics|Device: Contact lens with Single Vision Optics","Subject Reported Eye Fatigue","Pete Kollbaum, OD, PhD|Alcon Research|Indiana University","All","18 Years to 35 Years   (Adult)","Not Applicable","45","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Kollbaum001","September 13, 2018","November 2, 2018","November 2, 2018","July 13, 2018","January 7, 2020","January 7, 2020","Indiana University Clinical Optics Research Lab, Bloomington, Indiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT03585790/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03585790"
61,"NCT03583385","Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study",,"Completed","Has Results","Healthy","Drug: Glucophage XR (Test drug)|Drug: Glucophage XR (Comparator drug)","Maximum Observed Plasma Concentration (Cmax) of Metformin|Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Metformin|Area Under Plasma Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Metformin|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metformin|Terminal Elimination Half-life in Plasma (t½) of Metformin|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs","Merck KGaA, Darmstadt, Germany","All","18 Years to 55 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","MS200084_0015","August 16, 2018","October 5, 2018","October 5, 2018","July 11, 2018","November 25, 2019","November 25, 2019","PT Equilab International, Jakarta, Indonesia","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03583385/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03583385/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03583385"
62,"NCT03579940","A Study of Lasmiditan in Healthy Japanese and Caucasian Participants",,"Completed","Has Results","Healthy","Drug: Lasmiditan|Drug: Placebo","Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Lasmiditan in Each Period|PK: Maximum Observed Concentration (Cmax) of Lasmiditan in Each Period","Eli Lilly and Company","All","20 Years to 64 Years   (Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","17010|H8H-JE-LAIE","June 27, 2018","August 9, 2018","August 9, 2018","July 9, 2018","November 29, 2019","November 29, 2019","Covance, Dallas, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03579940/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03579940/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03579940"
63,"NCT03578926","Performance of Two Toric Silicone Hydrogel Contact Lenses",,"Completed","Has Results","Astigmatism","Device: fanfilcon A toric lens|Device: senofilcon A toric lens","Lens Centration|Corneal Coverage|Post Blink Movement|Wearing Time|Comfortable Wearing Time","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EX-MKTG-93","June 18, 2018","October 8, 2018","October 8, 2018","July 6, 2018","December 10, 2019","December 10, 2019","Optometry Clinic, National Autonomous University, Mexico City, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT03578926/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03578926"
64,"NCT03578146","Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)",,"Completed","Has Results","Healthy Volunteers","Combination Product: PRT064445/Rivaroxaban|Combination Product: Placebo/Rivaroxaban|Drug: Placebo","Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration|Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration|Efficacy: Percent Change From Baseline in Unbound Rivaroaxaban Plasma Concentration at 2 Mins Following Andexanet/Placebo Administration|Andexanet Maximum Observed Plasma Concentration (Cmax)|Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )|Andexanet Time of Maximum Observed Plasma Concentration (Tmax)|Andexanet Apparent Terminal Elimination Half-life (t1/2)|Andexanet Total Systemic Clearance (CL)|Andexanet Total Volume of Distribution (Vss)","Portola Pharmaceuticals","All","18 Years to 45 Years   (Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-502 Module 2","December 2012","September 2015","September 2015","July 6, 2018","September 5, 2018","October 2, 2018",,,"https://ClinicalTrials.gov/show/NCT03578146"
65,"NCT03577275","A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval",,"Completed","Has Results","Dyslipidemias","Drug: NST-4016 600mg|Drug: Placebo oral capsule|Drug: Moxifloxacin 400mg|Drug: NST-4016 2000mg","Change From Baseline in Fridericia's Correction for QT Interval (QTcF)|Change From Baseline in Heart Rate (HR)|Change From Baseline in PR Interval (PR)|Change From Baseline in QRS Interval (QRS)","NorthSea Therapeutics B.V.","All","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NST-01","June 15, 2018","September 15, 2018","September 24, 2018","July 5, 2018","November 4, 2019","November 4, 2019","Covance Clinical Research Unit (CRU) Ltd, Leeds, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03577275/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03577275/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03577275"
66,"NCT03575962","A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254",,"Completed","Has Results","HIV Infections","Drug: GSK3640254 bis-hydrochloride salt capsule|Drug: GSK3640254 Mesylate Salt Capsule","Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-infinity]) of GSK3640254 Following Single Oral Dose in Healthy Participants|Area Under the Concentration-time Curve From Zero to Time of Last Sample Taken (AUC[0-t]) of GSK3640254 Following Single Oral Dose in Healthy Participants|Maximum Observed Concentration (Cmax) of GSK3640254 Following Single Oral Dose in Healthy Participants|Time to Reach Maximum Observed Concentration (Tmax) of GSK3640254 Following Single Oral Dose in Healthy Participants|Concentration at 24 Hours Post-dose (C24h) of GSK3640254 Following Single Oral Dose in Healthy Participants|Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)|Change From Baseline in Clinical Chemistry Parameters; Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)|Change From Baseline in Clinical Chemistry Parameters; Bicarbonate, Calcium, Chloride, Glucose (Fasting), Potassium, Sodium and Urea|Change From Baseline in Clinical Chemistry Parameters; Bilirubin, Creatinine and Direct Bilirubin|Change From Baseline in Clinical Chemistry Parameter; Protein|Number of Participants With Worst Case Hematology Results by Potential Clinical Importance (PCI) Criteria|Number of Participants With Urinalysis Results by Dipstick Method by Visit|Number of Participants With Clinically Significant Abnormal Findings for Electrocardiogram (ECG) Parameters|Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) at Indicated Time-points|Pulse Rate (PR) at Indicated Time-points|Respiratory Rate (RR) at Indicated Time-points|Temperature at Indicated Time-points|Number of Participants With the Indicated Assessment Events of Suicidal Behavior (SB) and Suicidal Ideation (SI) Via the Columbia Suicide Severity Rating Scale (C-SSRS)","ViiV Healthcare","All","18 Years to 55 Years   (Adult)","Phase 1","14","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","208131|2018-001175-21","June 18, 2018","August 6, 2018","August 6, 2018","July 3, 2018","September 6, 2019","September 6, 2019","GSK Investigational Site, Nottingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03575962/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03575962/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03575962"
67,"NCT03569033","Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)",,"Terminated","Has Results","Acute Cough","Drug: Gefapixant|Drug: Placebo","Awake Coughs Per Hour on Day 3|Change From Baseline in the Cough Severity Visual Analog Scale (VAS) Score on Day 3|Change From Baseline in the Mean Total Daily Cough Severity Diary (CSD) Score on Day 3|Change From Baseline in the Leicester Cough Questionnaire (LCQ)-Acute Score on Day 3|Percentage of Participants Who Experienced One or More Adverse Events (AEs)|Percentage of Participants Who Discontinued Treatment Due to an Adverse Event (AE)","Merck Sharp & Dohme Corp.","All","18 Years to 55 Years   (Adult)","Phase 2","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","7264-013|MK-7264-013|2017-000472-28","July 4, 2018","October 31, 2018","November 19, 2018","June 26, 2018","December 10, 2019","December 10, 2019","Hvivo Service Limited. Queen Mary BioEnterprises ( Site 0003), London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03569033/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03569033"
68,"NCT03567005","Clinical Validation of DACP Digital Design",,"Completed","Has Results","Refractive Errors","Device: Nelfilcon A digital contact lenses|Device: Nelfilcon A contact lenses","Distance Visual Acuity (VA) (logMAR, OU)|Overall Vision","Alcon Research","All","18 Years to 35 Years   (Adult)","Not Applicable","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLD523-C001","June 25, 2018","August 26, 2018","August 26, 2018","June 25, 2018","June 18, 2019","June 18, 2019","Alcon Investigative Site, Bloomington, Illinois, United States|Alcon Investigative Site, Powell, Ohio, United States|Alcon Investigative Site, Brentwood, Tennessee, United States|Alcon Investigative Site, Memphis, Tennessee, United States|Alcon Investigative Site, Memphis, Tennessee, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03567005/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03567005/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03567005"
69,"NCT03566810","Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt)",,"Completed","Has Results","Healthy","Drug: Test GXR|Drug: Reference GXR","Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin|Maximum Observed Plasma Concentration (Cmax) of Metformin|Time to Reach Maximum Plasma Concentration of Metformin|Apparent Terminal Half-Life (t1/2) of Metformin|Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Metformin|Area Under the Plasma Concentration-Time Curve From Time Tlast Extrapolated to Infinity (AUCextra) of Metformin|Elimination Rate Constant (Lambda z) of Metformin|Total Body Clearance (CL/f) of Metformin|Apparent Volume of Distribution at After Extravascular Administration (Vz/f) of Metformin|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs|Number of Participants With Clinically Significant Abnormalities in Vital Signs|Number of Participants With Clinically Significant Abnormalities in Laboratory Values|Number of Participants With Clinically Significant Abnormalities in Physical Examination Findings|Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings","Merck KGaA, Darmstadt, Germany","All","18 Years to 55 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","MS200084_0013","October 11, 2018","November 28, 2018","November 28, 2018","June 25, 2018","January 9, 2020","January 9, 2020","Xuanwu Hospital Capital Medical University, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03566810/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03566810/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03566810"
70,"NCT03565679","SpO2 Accuracy Comparison of Medline ReNewal Sensors to Arterial Blood CO-Oximetry",,"Completed","Has Results","Arterial Oxygen Saturation|Healthy","Device: MEDLINE RENEWAL PULSE OXIMETRY SENSORS|Device: CO-OXIMETRY SENSORS","SpO2 Percentage Specification","Medline Industries|Clinimark, LLC","All","18 Years to 50 Years   (Adult)","Not Applicable","10","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","PR 2018-268","May 9, 2018","May 10, 2018","May 10, 2018","June 21, 2018","June 10, 2019","June 18, 2019","Clinimark Desaturation Laboratory, Site ID# 001, Louisville, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03565679/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03565679"
71,"NCT03564444","D2560C00015 FluMist Annual Safety Study 2018",,"Completed","Has Results","Influenza|Healthy","Biological: Bivalent influenza vaccine|Other: Placebo","Percentage of Participants Reporting Fever (Oral Temperature >= 101 Degrees Fahrenheit) Through Day 8|Number of Participants With Solicited Symptoms Through Day 8|Number of Participants With Solicited Symptoms Through Day 15|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through Day 8 and Day 15|Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs) Through Day 29 and Day 181|Number of Participants With New Onset Chronic Diseases (NOCDs) Through Day 29 and Day 181","MedImmune LLC","All","18 Years to 49 Years   (Adult)","Phase 4","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D2560C00015","June 6, 2018","December 27, 2018","December 27, 2018","June 20, 2018","December 26, 2019","December 26, 2019","Research Site, Stockbridge, Georgia, United States|Research Site, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03564444/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03564444"
72,"NCT03557801","Promotora Navigator - Culturally Appropriate Patient Navigator",,"Completed","Has Results","Breast Cancer|Screening Mammography|Community Health Worker","Behavioral: Mammography with Community Health Worker (individual)|Behavioral: Mammography with Community Health Worker (group)|Other: Standard of Care Mammography","Patient Reported Measures From Interpersonal Processes of Care Survey|Patient Reported Measures From the Distrust in the Healthcare System Scale. Reported at Baseline and Post Intervention. Also Reported as the Change Between Baseline and Intervention.|Patient Reported Measures From the Satisfaction With Cancer Related Care Scale.","Vanderbilt University Medical Center","Female","40 Years to 64 Years   (Adult)","Not Applicable","101","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","180276","June 7, 2018","October 15, 2018","October 15, 2018","June 15, 2018","July 31, 2019","August 14, 2019","Matthew Walker Comprehensive Health Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03557801/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03557801"
73,"NCT03555890","Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT)",,"Completed","Has Results","Rhinitis","Drug: Levocetirizine IRT 5 mg|Drug: Levocetirizine ODT 5 mg","Part 1: Area Under the Concentration-time Curve (AUC) From Time Zero Time (Pre-dose) to the Time of Last Quantifiable Concentration (AUC[0-t]) of Levocetirizine|Part 2: AUC(0-t) of Levocetirizine|Part 1: Maximum Observed Concentration (Cmax) of Levocetirizine|Part 2: Cmax of Levocetirizine|Part 1: Area Under the Concentration-time Curve From Zero Time (Pre-dose) Extrapolated to Infinite Time AUC(0-inf) of Levocetirizine|Part 2: AUC(0-inf) of Levocetirizine|Part 1: Time to First Occurrence of Cmax (Tmax) of Levocetirizine|Part 2: Tmax of Levocetirizine|Part 1: Apparent Terminal Phase Half-life (t1/2) of Levocetirizine|Part 2: t1/2 of Levocetirizine|Part 1: Percentage of AUC(0-inf) Obtained by Extrapolation (%AUCex) of Levocetirizine|Part 2: %AUCex of Levocetirizine|Part 1: Apparent Clearance Following Oral Dosing (CL/F) of Levocetirizine|Part 2: CL/F of Levocetirizine|Part 1: Apparent Volume of Distribution Following Oral Dosing (Vz/F) of Levocetirizine|Part 2: Vz/F of Levocetirizine|Part 1: Elimination Rate Constant (Kel) (lambda_z) of Levocetirizine|Part 2: Kel (lambda_z) of Levocetirizine|Part 1: Mean Residence Time (MRT) of Levocetirizine|Part 2: MRT of Levocetirizine|Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part 2: Number of Participants With AEs and SAEs|Part 1: Change From Baseline in Albumin and Total Protein Levels|Part 2: Change From Baseline in Albumin and Total Protein Levels|Part 1: Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase Levels|Part 2: Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase Levels|Part 1: Change From Baseline in Amylase Levels|Part 2: Change From Baseline in Amylase Levels|Part 1: Change From Baseline in Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid Levels|Part 2: Change From Baseline in Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid Levels|Part 1: Change From Baseline in Calcium, Cholesterol, Chloride, Glucose, High Density Lipids Cholesterol, Potassium, Low Density Lipids Cholesterol, Sodium, Phosphorus Inorganic, Triglycerides and Urea/Blood Urea Nitrogen (BUN) Levels|Part 2: Change From Baseline in Calcium, Cholesterol, Chloride, Glucose, High Density Lipids Cholesterol, Potassium, Low Density Lipids Cholesterol, Sodium, Phosphorus Inorganic, Triglycerides and Urea/BUN Levels|Part 1: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes and Total Neutrophils Count|Part 2: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes and Total Neutrophils Count|Part 1: Change From Baseline in Platelet Count and White Blood Cell Count|Part 2: Change From Baseline in Platelet Count and White Blood Cell Count|Part 1: Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration|Part 2: Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration|Part 1: Change Form Baseline in Hematocrit|Part 2: Change Form Baseline in Hematocrit|Part 1: Change From Baseline in Mean Corpuscle Hemoglobin|Part 2: Change From Baseline in Mean Corpuscle Hemoglobin|Part 1: Change From Baseline in Mean Corpuscle Volume|Part 2: Change From Baseline in Mean Corpuscle Volume|Part 1: Change From Baseline in Red Blood Cell Count|Part 2: Change From Baseline in Red Blood Cell Count|Part 1: Change From Baseline in Reticulocytes|Part 2: Change From Baseline in Reticulocytes|Part 1: Number of Participants With Urinalysis Results by Dipstick Method|Part 2: Number of Participants With Urinalysis Results by Dipstick Method|Part 1: Urine Potential of Hydrogen (pH)|Part 2: Urine Potential of Hydrogen (pH)|Part 1: Urine Specific Gravity|Part 2: Urine Specific Gravity|Part 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Part 2: Change From Baseline in SBP and DBP|Part 1: Change From Baseline in Heart Rate|Part 2: Change From Baseline in Heart Rate|Part 1: Change From Baseline in Body Temperature|Part 2: Change From Baseline in Body Temperature|Part 1: Change From Baseline in Heart Rate (12-Lead Electrocardiogram [ECG])|Part 2: Change From Baseline in Heart Rate (ECG)|Part 1: Change From Baseline in PR Interval, QRS Interval, QT Interval and QTcF Interval|Part 2: Change From Baseline in PR Interval, QRS Interval, QT Interval and QTcF Interval","GlaxoSmithKline|Zensei Pharmaceutical Co., Ltd.","Male","20 Years to 55 Years   (Adult)","Phase 1","72","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","204706","May 18, 2018","September 17, 2018","September 17, 2018","June 14, 2018","September 12, 2019","September 12, 2019","GSK Investigational Site, Fukuoka, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT03555890/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT03555890/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03555890"
74,"NCT03551743","Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)",,"Completed","Has Results","Healthy Volunteers","Combination Product: PRT064445/Edoxaban|Combination Product: Placebo/Edoxaban|Drug: Placebo","Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration|Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration|Efficacy: Percent Change From Baseline in Unbound Edoxaban Plasma Concentration at 2 Mins Following Andexanet/Placebo Administration|Andexanet Maximum Observed Plasma Concentration (Cmax)|Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )|Andexanet Time of Maximum Observed Plasma Concentration (Tmax)|Andexanet Apparent Terminal Elimination Half-life (t1/2)|Andexanet Total Systemic Clearance (CL)|Andexanet Total Volume of Distribution (Vss)","Portola Pharmaceuticals","All","18 Years to 45 Years   (Adult)","Phase 2","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-502 Module 4","December 2012","September 2015","September 2015","June 11, 2018","August 31, 2018","September 28, 2018",,,"https://ClinicalTrials.gov/show/NCT03551743"
75,"NCT03551730","Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)",,"Completed","Has Results","Healthy Volunteers","Combination Product: PRT064445/Enoxaparin|Combination Product: Placebo/Enoxaparin|Drug: Placebo","Efficacy:Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration Activity|Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration|Andexanet Maximum Observed Plasma Concentration (Cmax)|Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )|Andexanet Time of Maximum Observed Plasma Concentration (Tmax)|Andexanet Apparent Terminal Elimination Half-life (t1/2)|Andexanet Total Systemic Clearance (CL)|Andexanet Total Volume of Distribution (Vss)","Portola Pharmaceuticals","All","18 Years to 45 Years   (Adult)","Phase 2","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-502 Module 3","December 2012","September 2015","September 2015","June 11, 2018","August 13, 2018","September 26, 2018","Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03551730"
76,"NCT03544216","Accommodative Relief for Uncomfortable Non-Presbyopes",,"Completed","Has Results","Asthenopia","Device: Multifocal Contact Lens|Device: Single Vision Contact Lens","Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Score","Ohio State University|Bausch & Lomb Incorporated","All","30 Years to 40 Years   (Adult)","Not Applicable","84","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2016H0382-60058303","February 2, 2017","May 6, 2018","May 6, 2018","June 1, 2018","February 15, 2019","February 15, 2019","The Ohio State University College of Optometry, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03544216/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03544216"
77,"NCT03543137","To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers",,"Completed","Has Results","Tobacco Use Disorder","Drug: Nicotine Prototype Mini lozenge|Drug: Nicorette Mini Lozenge","Assessment of Bioequivalence of Prototype Mini Lozenges With Nicorette Mini Lozenge by Measuring Area Under the Plasma Concentration Versus Time Curve From Time Zero to Time t (AUC [0-t])|Assessment of Bioequivalence of Prototype Mini Lozenges With Nicorette Mini Lozenge by Measuring Area Under the Plasma Concentration Versus Time Curve Calculated From Time Zero to Infinity (AUC [(0-inf])|Assessment of Bioequivalence of Prototype Mini Lozenges With Nicorette Mini Lozenge by Measuring Maximum Observed Plasma Nicotine Concentration (Cmax)|Comparison of Prototype Mini Lozenges With Nicorette Mini Lozenge by Measuring Time of Maximum Plasma Nicotine Concentration (Tmax)|Comparison of Prototype Mini Lozenges With Nicorette Mini Lozenge by Measuring Apparent Elimination Half-Life (t1/2)|Comparison of Prototype Mini Lozenges With Nicorette Mini Lozenge by Measuring Apparent Elimination Rate Constant for Plasma Nicotine (Kel)|Number of Participants With Clinically Significant Change in Laboratory Test Values","GlaxoSmithKline","All","19 Years to 55 Years   (Adult)","Phase 1","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","207790","June 18, 2018","November 12, 2018","November 12, 2018","June 1, 2018","December 4, 2019","December 4, 2019","GSK Investigational Site, Lincoln, Nebraska, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03543137/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03543137/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03543137"
78,"NCT03537404","A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs",,"Completed","Has Results","Healthy","Drug: Narlaprevir|Drug: Ritonavir|Drug: Tenofovir Disoproxil Fumarate|Drug: Raltegravir","Cmax of Narlaprevir|AUCtau of Narlaprevir|Cmax of Tenofovir|AUCtau of Tenofovir|Cmax of Raltegravir|AUCtau of Raltegravir|Number of Patients With Adverse Events|Number of Patients With Changes in Vital Signs|Number of Patients With Abnormal Laboratory Values|Number of Patients With Abnormal ECG Changes","R-Pharm|Almedis","All","21 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CJ05013019","April 24, 2017","June 24, 2017","June 30, 2017","May 25, 2018","February 19, 2019","February 19, 2019","Clinic ""Bessalar"" JSC, Moscow, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT03537404/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03537404"
79,"NCT03537092","A Study of the Safety and Acceptability of a Placebo Vaginal Film: FAME101","FAME101","Completed","Has Results","Safety of Vaginal Film Use","Device: Vaginal Film","Grade 2 or Higher Urogenital System Adverse Event Related to Film Use|Correct Insertion of Vaginal Film|Difficulty of Vaginal Film Insertion|Acceptability of Vaginal Film Use","Katherine Bunge|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)|University of Pittsburgh","Female","18 Years to 45 Years   (Adult)","Not Applicable","64","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","PRO17090024|ES-38322|U19AI120249","May 22, 2018","December 4, 2018","December 4, 2018","May 25, 2018","January 13, 2020","January 13, 2020","Magee womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT03537092/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03537092"
80,"NCT03535571","A Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females",,"Completed","Has Results","Healthy","Dietary Supplement: Salmon Protein Hydrolysate","The Change From Baseline (Day 0) to End-of-study (Day 128) in Energy Level After a 128-day Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)|Change From Baseline to Day 128 in Red Blood Cell (RBC) Count After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)|Change From Baseline to Day 128 in Mean Corpuscular Volume (MCV) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)|Change From Baseline to Day 128 in Mean Corpuscular Hemoglobin (MCH) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)|Change From Baseline to Day 128 in Mean Corpuscular Hemoglobin Concentration (MCHC) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)|Change From Baseline to Day 128 in Hematocrit After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)|Change From Baseline to Day 128 in Red Cell Distribution Width (RDW) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)|Change From Baseline to Day 128 in Hemoglobin (Hb) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)|Change From Baseline to Day 128 in Relative Expression of 84 Stress Genes After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)|Change From Baseline to Day 128 in Total Reactive Oxygen Species/Reactive Nitrogen Species Free Radical Activity After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)|Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-1 Alpha After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).|Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-4 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).|Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-6 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).|Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-10 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).|Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-11 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).|Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-13 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).|Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine TGF-Beta After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)|Change From Baseline to Day 128 in Glycated Hemoglobin (HbA1c) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)|Change From Baseline to Day 128 in Fasting Glucose After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)|Change in Score of the Hair, Nails, and Skin Self-Assessment Questionnaire After 128-day Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)","Hofseth Biocare ASA|KGK Science Inc.","All","30 Years to 60 Years   (Adult)","Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18PEHH","June 5, 2018","October 23, 2018","October 23, 2018","May 24, 2018","August 19, 2019","August 19, 2019","KGK Science Inc., London, Ontario, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03535571/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03535571"
81,"NCT03534986","Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements",,"Completed","Has Results","Cystic Fibrosis|Bronchiectasis","Device: International Biophysics AffloVest|Device: Hill-Rom The Vest|Device: Respirtech inCourage|Device: Electromed SmartVest","TV|PEF|FVC|FEV1|FEF25-75%","International Biophysics Corporation","All","18 Years to 50 Years   (Adult)","Not Applicable","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-02","February 20, 2018","March 16, 2018","March 16, 2018","May 23, 2018","September 6, 2018","October 3, 2018","PDS Research, Kissimmee, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03534986/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03534986"
82,"NCT03530631","Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance",,"Completed","Has Results","Expectancy Versus Pharmacotherapy Effect of Adderall","Drug: Adderall|Drug: Placebo","Number of Participants Consistently Attending and Completing Four Neuroimaging Sessions","University of Alabama at Birmingham","All","18 Years to 24 Years   (Adult)","Phase 4","4","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research","IRB-300000343","November 10, 2018","December 18, 2018","December 18, 2018","May 21, 2018","October 14, 2019","December 16, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03530631/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03530631"
83,"NCT03524157","Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects","PRO-087/I","Completed","Has Results","Dry Eye Syndromes|Lubricant Allergy|Tear Disorder","Drug: PRO-087|Drug: Systane Ultra|Drug: Xyel Ofteno","Goblet Cell Density (GCD)|Presence of Adverse Events (AEs)|Intraocular Pressure (IOP)|Epithelial Defects (ED)|Breakup Time (BUT)|Conjunctival Hyperemia (CH)|Chemosis|Ocular Burning (OB)|Foreign Body Sensation (FBS)|Ocular Pruritus (P)","Laboratorios Sophia S.A de C.V.","All","18 Years to 40 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SOPH087-0616/I","July 17, 2017","February 12, 2018","March 27, 2018","May 14, 2018","July 19, 2019","July 19, 2019","Private Ophthalmological Office, Zapopan, Jalisco, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03524157/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03524157"
84,"NCT03522506","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults",,"Completed","Has Results","Healthy Volunteers","Drug: TAK-925|Drug: TAK-925 Placebo|Drug: Modafinil|Drug: Modafinil Placebo","Latency to Sleep Onset on Maintenance of Wakefulness Test (MWT) at 2 Hours Post-infusion Start|Latency to Sleep Onset on MWT at 4 Hours Post-infusion Start|Latency to Sleep Onset on MWT at 6 Hours Post-infusion Start|Latency to Sleep Onset on MWT at 8 Hours Post-infusion Start|Latency to Sleep Onset on MWT at 1 Hour Post-end of Infusion|AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-925 and Its Metabolites M-I and M-II|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-925 and Its Metabolites M-I and M-II|Cmax: Maximum Observed Plasma Concentration for TAK-925 and Its Metabolites M-I and M-II|Ceoi: Plasma Concentration Observed at the End of Infusion for TAK-925 and Its Metabolites M-I and M-II|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-925 and Its Metabolites M-I and M-II|T1/2z: Terminal Disposition Phase Half-life for TAK-925 and Its Metabolites M-I and M-II|CL: Total Clearance After Intravenous Administration for TAK-925|Vz: Volume of Distribution During the Terminal Disposition Phase After Intravenous Administration for TAK-925|Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-925|Sleepiness on KSS","Takeda","Male","18 Years to 40 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","TAK-925-1002|U1111-1211-2133","May 9, 2018","November 7, 2018","November 7, 2018","May 11, 2018","November 26, 2019","November 26, 2019","PRA Health Sciences, Salt Lake City, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03522506/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03522506/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03522506"
85,"NCT03520348","Safety and Tolerability of the Ophthalmic Gel PRO-167 Versus Corneregel® on Healthy Subjects.","PRO-167/I","Completed","Has Results","Dry Eye|Dry Eye Syndrome of Unspecified Lacrimal Gland","Drug: PRO-167|Drug: Corneregel","Goblet Cell Density (GCD)|Presence of Adverse Events (EAS)|Intraocular Pressure (IOP)|Breakup Time (BUT)|Chemosis|Ocular Burning (OB)|Epithelial Defects (ED)|Conjunctival Hyperemia (CH)|Foreign Body Sensation (FBS)|Ocular Pruritus (P)","Laboratorios Sophia S.A de C.V.","All","18 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SOPH167-0816/I","October 4, 2017","May 22, 2018","July 16, 2018","May 9, 2018","July 19, 2019","July 19, 2019","Centro Oftalmológico San Angel, Guadalajara, Jalisco, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03520348/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03520348"
86,"NCT03519854","Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).",,"Completed","Has Results","Neuromuscular Blockade","Drug: Placebo|Drug: Sugammadex|Drug: Esmeron®","Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.9|Mean Heart Rate at Baseline|Mean Heart Rate at 2 Minutes Following Administration of Study Treatment|Mean Heart Rate at 30 Minutes Following Administration of Study Treatment|Mean Corrected QT Interval (QTc) at Baseline|Mean Corrected QT Interval (QTc) at 2 Minutes Following Administration of Study Treatment|Mean Corrected QT Interval (QTc) at 30 Minutes Following Administration of Study Treatment|Number of Participants Experiencing an Adverse Event","Merck Sharp & Dohme Corp.","Male","18 Years to 64 Years   (Adult)","Phase 2","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","P05940|MK-8616-020|19.4.202","December 1, 2002","June 1, 2003","June 1, 2003","May 9, 2018","February 1, 2019","April 2, 2019",,,"https://ClinicalTrials.gov/show/NCT03519854"
87,"NCT03519516","Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects","PRO-174/I","Completed","Has Results","Conjunctivitis|Conjunctivitis, Bacterial","Drug: PRO-174|Drug: Sophixín Ofteno®","Number of Adverse Events (EAS)|Ocular Burning (OB)|Intraocular Pressure (IOP)|Breakup Time (BUT)|Number of Eyes With Epithelial Defects (ED) by Grade|Percentage of Eyes With Conjunctival Hyperemia (CH) by Grade|Number of Eyes With Foreign Body Sensation (FBS) by Grade|Number of Eyes With Ocular Pruritus (P) by Grade|Number of Eyes of Chemosis|Visual Capacity","Laboratorios Sophia S.A de C.V.","All","18 Years to 45 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SOPH174-0816/I","January 25, 2018","May 25, 2018","June 10, 2018","May 9, 2018","October 25, 2019","October 25, 2019","Private Medical Offices, Guadalajara, Jalisco, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03519516/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03519516"
88,"NCT03512041","Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement","RLICC","Completed","Has Results","Healthy, Young Adults","Behavioral: RLIC - 5 cycles|Behavioral: RLIC - 4 Cycles|Behavioral: RLIC - 3 Cycles|Behavioral: Sham conditioning|Behavioral: Balance training|Behavioral: Arm training|Behavioral: Sequence production training","Balance Score|Cup Stacking Score|Discrete Sequence Production Task Score","Washington University School of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","18 Years to 40 Years   (Adult)","Phase 1","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NIHR01HD085930-Aim2|R01HD085930","December 13, 2016","February 13, 2018","February 13, 2018","April 30, 2018","August 26, 2019","August 26, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03512041/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03512041"
89,"NCT03509948","A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation",,"Completed","Has Results","Smoking Cessation","Drug: cytisine","Maximum Concentration (Cmax)|Area Under the Concentration Versus Time Curve (AUC) Extrapolated to Infinity (AUC0-∞)|Total Cytisine Excreted in Urine Over 48 Hours (Ae0-48h)|Percent of Total Cytisine Excreted in Urine Over 48 Hours (Ae0-48h%)|Time to Cmax (Tmax)|Terminal Elimination Half-Life (T1/2)|AUC From Time of Dosing to Last Measurable Concentration (AUC0-t)|Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Withdrawal of Study Drug|Number of Participants With Clinically Significant Biochemistry, Hematology, Urinalysis, and/or 12-lead Electrocardiogram (ECG) Values","Achieve Life Sciences","All","18 Years to 55 Years   (Adult)","Phase 1","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACH-CYT-07","April 27, 2018","June 10, 2018","June 12, 2018","April 27, 2018","September 12, 2019","September 24, 2019","Simbec Research Ltd, Cardiff, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03509948/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03509948/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03509948"
90,"NCT03507569","Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513",,"Completed","Has Results","Autism Spectrum Disorder","Drug: RO7017773|Other: [11C] Ro15-4513","Percentage of Brain Alpha5-Containing GABA-A Receptors Occupied by RO7017773|Plasma Concentrations of RO7017773|Number of Participants With Adverse Events (AEs)","Hoffmann-La Roche","All","23 Years to 55 Years   (Adult)","Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BP40257","April 24, 2018","June 22, 2018","June 22, 2018","April 25, 2018","September 30, 2019","September 30, 2019","Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03507569/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03507569"
91,"NCT03503578","EEG Studies of Sevoflurane-Induced General Anesthesia",,"Completed","Has Results","Anesthesia","Drug: Sevoflurane|Drug: Ketamine","Frequencies At Which Changes in Alpha, Theta, and Slow-Delta Wave Power Were Observed From Baseline During Sevoflurane-induced General Anesthesia","Massachusetts General Hospital","All","18 Years to 50 Years   (Adult)","Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2014P000111","May 1, 2018","August 1, 2018","August 1, 2018","April 20, 2018","October 24, 2019","October 24, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03503578/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03503578"
92,"NCT03501277","A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants",,"Completed","Has Results","Healthy Volunteers","Drug: Alogliptin|Drug: Pioglitazone|Drug: SYR-322-4833 BL","Cmax: Maximum Observed Plasma Concentration for Alogliptin and Pioglitazone|AUC(0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Postdose for Alogliptin and Pioglitazone","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","Alogliptin-1002|U1111-1196-9223","May 26, 2018","July 11, 2018","July 11, 2018","April 18, 2018","August 8, 2019","August 8, 2019","Non-governmental healthcare Institution Road Clinical Hospital at the station Yaroslavl JSC Russian Railways, Yaroslavl, Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03501277/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03501277/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03501277"
93,"NCT03500224","A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male Participants",,"Completed","Has Results","Healthy Volunteers","Drug: [14C]-TAK-954","Cumulative Percentage of Administered Radioactivity Recovered in Urine|Cumulative Percentage of Administered Radioactivity Recovered in Feces|Cumulative Percentage of Radioactivity in Urine and Feces Combined|Normalized Recovery as Percentage of Dose for TAK-954 and TAK-954 Metabolites in Urine and Feces Combined|Normalized Recovery as Percentage of Dose for TAK-954 and TAK-954 Metabolites in Urine|Normalized Recovery as Percentage of Dose for TAK-954 and TAK-954 Metabolites in Feces|Mean Percent of Total Radioactivity in Plasma for TAK-954 and TAK-954 Metabolites|Cumulative Percentage of Dose Excreted in Urine for TAK-954|Cumulative Percentage of Dose Excreted in Feces for TAK-954|Mean Concentration of Total Radioactivity in Whole Blood and Plasma [14C]-TAK-954|Cmax: Maximum Observed Plasma and Whole Blood Concentrations of Radioactivity for [14C]-TAK-954|Cmax: Maximum Observed Plasma Concentration for TAK-954 and TAK-954 Metabolites|AUClast: Area Under the Plasma and Whole Blood Radioactivity-time Curve From Time 0 to the Time of the Last Quantifiable Radioactivity for [14C]-TAK-954|AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954 and TAK-954 Metabolites|AUC∞: Area Under the Plasma and Whole Blood Radioactivity-time Curve From Time 0 to Infinity for [14C]-TAK-954|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 and TAK-954 Metabolites|Tmax: Time to Reach the Maximum Plasma and Whole Blood Radioactivity for [14C]-TAK-954|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-954 and TAK-954 Metabolites|t1/2z: Terminal Disposition Phase Half-life of Radioactivity in Plasma and Whole Blood for [14C]-TAK-954|t1/2z: Terminal Disposition Phase Half-life in Plasma for TAK-954 and TAK-954 Metabolites|CL: Total Clearance After Intravenous Administration for [14C]-TAK-954|CL: Total Clearance of TAK-954 After Intravenous Administration of [14C]-TAK-954|Vz: Volume of Distribution During the Terminal Disposition Phase After Intravenous Administration for [14C]-TAK-954|Vz: Volume of Distribution During the Terminal Disposition Phase After Intravenous Administration for TAK-954|Aet Urine: Amount of Total Radioactivity Excreted in Urine From Time 0 to Time t for [14C]-TAK-954|Aet Urine: Amount of Drug Excreted in Urine From Time 0 to Time t for TAK-954|Aet Feces: Amount of Total Radioactivity Excreted in Feces From Time 0 to Time t for [14C]-TAK-954|Fet Urine: Fraction of Drug Excreted in Urine From Time 0 to Time t for TAK-954|Fet Urine: Fraction of Total Radioactivity Excreted in Urine From Time 0 to Time t for [14C]-TAK-954|Fet Feces: Fraction of Radioactivity Excreted in Feces From Time 0 to Time t for [14C]-TAK-954|Ratio of Total Radioactivity in Whole Blood to Plasma|Ratio of AUC∞: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 to Total Radioactivity in Plasma TAK-954|Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE)|Percentage of Participants With Adverse Events (AEs) Leading to Discontinuation of [14C]-TAK-954","Millennium Pharmaceuticals, Inc.|Takeda","Male","18 Years to 55 Years   (Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-954-1005|U1111-1202-5762|NL65503.056.18|2018-001181-42","April 30, 2018","June 1, 2018","June 1, 2018","April 18, 2018","July 29, 2019","July 29, 2019","PRAHS, Groningen, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03500224/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03500224/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03500224"
94,"NCT03496324","Ibuprofen 4% (w/v) Pivotal Bioequivalence Study",,"Completed","Has Results","Bioequivalence of the Test Formulation","Drug: Nurofen for Children®|Drug: Algifor® Junior","Maximum Plasma Concentration (Cmax) of Ibuprofen|Area Under Plasma Concentration-time Curve From Administration to the Last Quantifiable Concentration at Time t (AUC0-t) of Ibuprofen|Elimination Rate Constant (Kel) of Ibuprofen|Area Under Plasma Concentration-time Curve From Administration to Infinity (AUC0-inf) of Ibuprofen|Ratio of AUC0-t/AUC0-inf (AUCR)|Time to Maximum Plasma Concentration (Tmax) of Ibuprofen|Plasma Concentration Half-life (T1/2) of Ibuprofen|Number of Subjects With Treatment Emergent Adverse Events (TEAEs)","Reckitt Benckiser Healthcare (UK) Limited","All","18 Years to 50 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RB7-UK-1509|2015-003894-13","February 29, 2016","May 6, 2016","May 6, 2016","April 12, 2018","June 5, 2019","June 5, 2019",,,"https://ClinicalTrials.gov/show/NCT03496324"
95,"NCT03493386","Daprodustat Bioequivalence and Food Effect Study",,"Completed","Has Results","Anaemia","Drug: Daprodustat 2 mg tablet|Drug: Daprodustat 4 mg tablet","Part 1:Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Last Measurable Concentration (AUC[0-t]) and AUC From Zero Hours Extrapolated to Infinity AUC [0-inf] of Daprodustat|Part 1:Maximum Observed Drug Concentration (Cmax) of Daprodustat|Part 1:Terminal Phase Half-life (T1/2) of Daprodustat and Mean Residence Time (MRT)|Part 1: Time of Occurrence of Cmax (Tmax) of Daprodustat|Part 1: Percentage of AUC (0-inf) Obtained by Extrapolation (Percentage AUCex)|Part 1:Apparent Clearance (CL/F) of Daprodustat|Part 1:Apparent Oral Volume of Distribution (Vz/F) of Daprodustat|Part 1: Elimination Rate Constant (Kel) of Daprodustat|Part 2:AUC[0-t] andAUC [0-inf] of Daprodustat|Part 2: Cmax of Daprodustat|Part 2: T1/2 and MRT of Daprodustat|Part 2: Tmax of Daprodustat|Part 2: Percentage AUCex of Dapordustat|Part 2: CL/F of Daprodustat|Part 2: Vz/F of Daprodustat|Part 2: Kel of Daprodustat|Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part 1: Change From Baseline Chemistry Paramters: Glucose, Calcium, Cholesterol, Chloride, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Potassium, Phosphate, Sodium, Triglycerides, and Urea.|Part 1: Change From Baseline in Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase, Lactate Dehydrogenase and Gamma Glutamyl Transferase (GGT).|Part 1: Change From Baseline in Chemistry Parameters; Albumin, Protein.|Part 1: Change From Baseline in Chemistry Parameters; Direct Bilirubin, Bilirubin, Creatinine, Urate|Part 1:Change From Baseline in Hematology Parameter; Hematocrit|Part 1:Change From Baseline in Hematology Parameter; Reticulocytes|Part 1: Change From Baseline in Hematology Parameters; Hemoglobin (Hb), Erythrocyte Mean Corpuscular Hb Concentration (MCHC)|Part 1: Change From Baseline in Hematology Parameters; Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils|Part 1: Change From Baseline in Hematology Parameter Erythrocyte MCHC|Part 1: Change From Baseline in Hematology Parameter Erythrocyte Mean Corpuscular Volume (EMCV)|Part 1: Change From Baseline in Hematology Parameters Platelets, Leukocytes|Part 1: Change From Baseline in Hematology Parameter: Erythrocytes|Part 1: Change From Baseline in Urinalysis Parameter; Potential of Hydrogen (pH)|Part 1: Change From Baseline in Urinalysis Parameter; Specific Gravity|Part 1: Change From Baseline in Vital Signs; Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)|Part 1: Change From Baseline in Pulse Rate|Part 1: Change From Baseline in Temperature|Part 1: Change From Baseline in Electrocardiogram (ECG) Parameter; Mean Heart Rate (HR)|Part 1: Change From Baseline in ECG Parameter; PR Interval, QRS Interval, QT Interval, QT Duration Corrected for Heart Rate by Friderician Formula (QTcF) Interval|Part 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part 2: Change From Baseline Chemistry Parameters; Glucose, Calcium, Cholesterol, Chloride, HDL Cholesterol, LDL Cholesterol, Potassium, Phosphate, Sodium, Triglycerides, and Urea|Part 2: Change From Baseline in Chemistry Paremeters; ALP, ALT, AST, Creatine Kinase, Lactate Dehydrogenase, GGT|Part 2: Change From Baseline in Chemistry Parameters; Albumin, Protein|Part 2: Change From Baseline in Chemistry Parameters; Direct Bilirubin, Bilirubin, Creatinine, Urate|Part 2: Change From Baseline in Hematology Parameters; Hematocrit|Part 2: Change From Baseline in Hematology Parameters; Reticulocytes|Part 2: Change From Baseline in Hematology Parameters; Hb, Erythrocyte MCHC|Part 2: Change From Baseline in Hematology Parameters; Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils|Part 2: Change From Baseline in Hematology Parameter: EMCH|Part 2: Change From Baseline in Hematology Parameter EMCV|Part 2: Change From Baseline in Hematology Parameters Platelets, Leukocytes|Part 2: Change From Baseline in Hematology Parameter Erythrocytes|Part 2: Change From Baseline in Urinalysis Parameter; Potential of Hydrogen (pH)|Part 2: Change From Baseline in Urinalysis Parameter; Specific Gravity|Part 2: Change From Baseline in Vital Signs; Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)|Part 2: Change From Baseline in Pulse Rate|Part 2: Change From Baseline in Temperature|Part 2: Change From Baseline in ECG Parameter; Mean Heart Rate (HR)|Part 2: Change From Baseline in ECG Parameter; PR Interval, QRS Interval, QT Interval, QTcF Interval","GlaxoSmithKline","Male","20 Years to 55 Years   (Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","207727","April 24, 2018","June 9, 2018","June 9, 2018","April 10, 2018","August 6, 2019","August 6, 2019","GSK Investigational Site, Fukuoka, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03493386/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03493386/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03493386"
96,"NCT03481309","Modulation of Motor Cortex Excitability by TMS and tDCS (MAGS1)",,"Completed","Has Results","Motor Activity|Motor Neuroplasticity","Device: anodal tDCS|Device: cathodal tDCS|Device: sham tDCS","Changes in Motor-evoked Potentials Ratios (Unit: uV)|Changes in TMS-evoked Potentials Ratios (Unit: uV)|Changes in Resting-state EEG Dynamics Ratios (Unit: uV)","University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)","Male","18 Years to 35 Years   (Adult)","Not Applicable","19","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","17-0149|R01MH101547","August 24, 2018","January 31, 2019","February 1, 2019","March 29, 2018","October 23, 2019","October 23, 2019","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03481309/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03481309"
97,"NCT03478891","Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults",,"Completed","Has Results","Healthy Adult Immune Responses to Vaccine","Biological: VRC-EBOMAB092-00-AB (MAb114)","Number of Subjects Experiencing Infusion Reaction During Product Administration|Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Product Administration|Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration|Number of Subjects Reporting 1 or More Unsolicited Non-Serious Adverse Events|Number of Subjects Reporting Serious Adverse Events|Maximum Observed Serum Concentration (Cmax) of MAb114|Time to Reach Maximum Observed Serum Concentration (Tmax) of MAb114|Mean Serum Concentration of MAb114|Overall IV Half-life (T1/2) of MAb114|Area Under the Curve (AUC0-28D)|Volume of Distribution (Vd) at Steady-state|MAb114 Clearance Rate|Number of Subjects Who Produced Anti-drug Antibodies to MAb114","National Institute of Allergy and Infectious Diseases (NIAID)|The Emmes Company, LLC|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","Phase 1","19","NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","180069|18-I-0069","May 16, 2018","March 20, 2019","March 20, 2019","March 27, 2018","October 11, 2018","July 15, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT03478891/Prot_SAP_ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03478891"
98,"NCT03478371","In-use Study of Four Different Tampons",,"Completed","Has Results","Menstruation","Device: tampon D|Device: tampon M|Device: tampon T|Device: tampon V","Tolerance of Tampon Wear Via Physician Assessment of Vaginal Health|Vaginal pH|Subject Comfort Diary|Subject Comfort Questionnaire","Procter and Gamble","Female","18 Years to 55 Years   (Adult)","Not Applicable","94","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","CSD 2017-164","January 16, 2018","July 18, 2018","July 18, 2018","March 27, 2018","August 26, 2019","August 26, 2019","Synexus-US, Cincinnati, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03478371/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03478371"
99,"NCT03468543","Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects",,"Terminated","Has Results","Gastric Retention|Healthy","Drug: Memantine Hydrochloride MR Prototype Capsule Formulation A|Drug: Memantine Hydrochloride MR Prototype Capsule Formulation B|Drug: Memantine Hydrochloride MR Prototype Capsule Formulation C|Drug: Memantine Hydrochloride MR Prototype Capsule Formulation D|Drug: Memantine Hydrochloride MR Prototype Capsule Formulation E|Procedure: Magnetic Resonance Imaging","Gastric Retention by Magnetic Resonance Imaging (MRI)","Lyndra Inc.","All","18 Years to 60 Years   (Adult)","Early Phase 1","3","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","QCL117924|2017-000982-61","July 26, 2017","September 18, 2017","September 18, 2017","March 16, 2018","June 5, 2019","June 5, 2019","Quotient Sciences (formerly Quotient Clinical), Ruddington, Nottingham, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03468543/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03468543"
100,"NCT03467971","A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy Participants",,"Completed","Has Results","Healthy","Drug: Metformin/Gliclazide Fixed Combination","Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Metformin and Gliclazide|Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Metformin and Gliclazide|Maximum Observed Plasma Concentration (Cmax) of Metformin and Gliclazide|Time to Reach Maximum Plasma Concentration (Tmax) of Metformin and Gliclazide|Elimination Half Life (t1/2) of Metformin and Gliclazide|Apparent Volume of Distribution (Vz/f) of Metformin and Gliclazide|Apparent Total Body Clearance (CL/f) of Metformin and Gliclazide From Plasma|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","Merck KGaA, Darmstadt, Germany","All","18 Years to 55 Years   (Adult)","Phase 1","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","EMR200763_004","March 6, 2018","April 22, 2018","April 22, 2018","March 16, 2018","July 8, 2019","July 8, 2019","CECYPE, Mexico City, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03467971/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03467971/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03467971"
101,"NCT03467945","Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants",,"Completed","Has Results","Healthy","Drug: Metformin/Gliclazide Fixed Combination|Drug: Metformin|Drug: Gliclazide","Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Metformin|Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Gliclazide|Maximum Observed Plasma Concentration (Cmax) of Metformin|Maximum Observed Plasma Concentration (Cmax) of Gliclazide|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Metformin|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Gliclazide|Apparent Volume of Distribution (Vz/f) of Metformin|Apparent Volume of Distribution (Vz/f) of Gliclazide|Elimination Half Life (t1/2) of Metformin|Elimination Half Life (t1/2) of Gliclazide|Apparent Total Body Clearance (CL/f) of Metformin|Apparent Total Body Clearance (CL/f) of Gliclazide|Median Residence Time (MRT) for Metformin|Median Residence Time (MRT) for Gliclazide|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","Merck KGaA, Darmstadt, Germany","All","18 Years to 55 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","EMR200763_003","February 16, 2018","April 29, 2018","April 29, 2018","March 16, 2018","July 16, 2019","July 16, 2019","Please Contact the Merck KGaA Communication Center, Darmstadt, Germany","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03467945/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03467945/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03467945"
102,"NCT03460899","Impact of Hypoglycaemia in Patients With Diabetes Mellitus Type 2 on Platelet Activation","Diaplate","Completed","Has Results","Diabetes Mellitus With Hypoglycemia|Diabetes Mellitus, Type 2|Hypoglycemia|Hypoglycemic Episode","Other: Euglycaemic Clamp|Other: Hyperinsulinaemic/Hypoglycaemic Clamp","Changes in Platelet Activation Marker Adenosin Diphosphate (%)|Quantification of Platelet Function and Activation PAC1CD62PCD63POS (%)|Markers of Coagulation Plasminogen Activator Inhibitor-1 (ng/mL)|Changes in Coagulation Marker Fibrinogen (g/L)","Medical University of Graz|Merck Sharp & Dohme Corp.","All","18 Years to 64 Years   (Adult)","Not Applicable","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HS-2017-04","February 12, 2018","June 11, 2018","June 11, 2018","March 9, 2018","November 18, 2019","November 18, 2019","Medical University of Graz, Department for Internal Medicine, Graz, Austria","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03460899/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03460899"
103,"NCT03459612","A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants",,"Completed","Has Results","Healthy","Drug: Lasmiditan|Drug: Placebo|Drug: Diphenhydramine","Simulated Driving Performance in Healthy Participants as Measured by Standard Deviation of Lateral Position (SDLP) Using the Cognitive Research Corporation Driving Simulator-MiniSim (CRCDS-MiniSim)|Karolinska Sleepiness Scale (KSS) Score|Number of Correct Responses in Driving Performance Using CogScreen Symbol Digit Coding (SDC) Test|Total Number of Collisions|Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan|PK: Area Under the Concentration Versus Time Curve (AUC) of Lasmiditan to the Last Timepoint (0-tlast)","Eli Lilly and Company","All","21 Years to 50 Years   (Adult)","Phase 1","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","17048|H8H-MC-LAIF","March 26, 2018","June 23, 2018","June 23, 2018","March 9, 2018","January 13, 2020","January 13, 2020","Covance Clinical Research Inc, Daytona Beach, Florida, United States|Covance, Dallas, Texas, United States|Covance Clinical Research Inc, Madison, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03459612/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03459612/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03459612"
104,"NCT03459131","Clinical Evaluation of Two Monthly Contact Lenses",,"Completed","Has Results","Refractive Errors","Device: Comfilcon A with Digital Zone Optics™ contact lenses|Device: Comfilcon A contact lenses","Subjective Rating of Overall Vision|Over-refraction","Alcon Research","All","18 Years to 35 Years   (Adult)","Not Applicable","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLD523-E001","March 7, 2018","March 26, 2018","March 26, 2018","March 8, 2018","March 5, 2019","March 5, 2019","Alcon Investigative Site, Maitland, Florida, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03459131/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03459131/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03459131"
105,"NCT03458702","The Effects of Emotional Exposure on State Anxiety",,"Completed","Has Results","Generalized Anxiety Disorder","Behavioral: YogaFit|Behavioral: Quiet Rest","STAI-Y1 Score Assessed at Baseline, Post-Condition and Post-Exposure|Heart Rate Assessed at Baseline, During Condition, Post-Condition and Post-Exposure|Root Mean Square of Successive Differences (RMSSD) Assessed at Baseline, Post-Condition and Post-Exposure|Low-frequency Band (LFNU) Assessed at Baseline, Post-Condition and Post-Exposure|High-frequency Band (HFNU) Assessed at Baseline, Post-Condition and Post-Exposure|RPE Assessed Post-Condition","Texas Tech University","Female","18 Years to 25 Years   (Adult)","Not Applicable","56","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","504055","September 12, 2013","March 15, 2014","May 2014","March 8, 2018","November 25, 2019","November 25, 2019","Texas Tech University, Lubbock, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03458702"
106,"NCT03456960","A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA Tablet",,"Completed","Has Results","Healthy Volunteers","Drug: TAK-438ASA|Drug: TAK-438|Drug: Aspirin","Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Free Base of TAK-438 (TAK-438F)|Study 1, Cmax: Maximum Observed Plasma Concentration for TAK-438F|Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin|Study 1, Cmax: Maximum Observed Plasma Concentration for Unchanged Aspirin|Study 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F|Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F|Study 1, MRT (Infinity,ev): Mean Residence Time From Time 0 to Infinity for TAK-438F|Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for TAK-438F|Study 1, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Unchanged Aspirin|Study 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Unchanged Aspirin|Study 1, MRT (Infinity,ev): Mean Residence Time From Time 0 to Infinity for Unchanged Aspirin|Study 1, Lambda (z): Terminal Disposition Phase Rate Constant for Unchanged Aspirin|Study 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and Its Metabolites (M) (M-I, M-II, M-III and M-IV-Sul)|Study 2, AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to Time 48 Hours Over the Dosing Interval for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)|Study 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)|Study 2, Cmax: Maximum Observed Plasma Concentration for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)|Study 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)|Study 2, T1/2z: Terminal Disposition Phase Half-life for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)|Study 2, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Unchanged Aspirin and Its Metabolite (Salicylic Acid)|Study 2, AUC(0-24): Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours Over the Dosing Interval for Unchanged Aspirin and Its Metabolite (Salicylic Acid)|Study 2, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Unchanged Aspirin and Its Metabolite (Salicylic Acid)|Study 2, Cmax: Maximum Observed Plasma Concentration for Unchanged Aspirin and Its Metabolite (Salicylic Acid)|Study 2, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Unchanged Aspirin and Its Metabolite (Salicylic Acid)|Study 2, T1/2z: Terminal Disposition Phase Half-life for Unchanged Aspirin and Its Metabolite (Salicylic Acid)|Study 2, Ae(0-48): Amount of Drug Excreted in Urine From Time 0 to 48 Hours for TAK-438F and Its Metabolites (M-I, M-II, M-III, and M-IV-Sul)|Study 2, Fe(0-48): Fraction of Administered Dose Excreted Into Urine From Time 0 to Time 48 Hours for TAK-438F and Its Metabolites (M-I, M-II, M-III and M-IV-Sul)|Study 2, CLR: Renal Clearance for TAK-438F and Its Metabolites (M-I, M-II, M-III, and M-IV-Sul)|Study 2, Ae(0-24): Amount of Drug Excreted in Urine From Time 0 to 24 Hours for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)|Study 2, Fe(0-24): Fraction of Administered Dose Excreted Into Urine From Time 0 to Time 24 Hours for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)|Study 2, CLR: Renal Clearance for Unchanged Aspirin and Its Metabolites (Salicylic Acid and Salicyluric Acid)","Takeda","Male","20 Years to 60 Years   (Adult)","Phase 1","276","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-438ASA-1001|U1111-1208-7631|JapicCTI-183885","March 8, 2018","October 10, 2018","October 12, 2018","March 7, 2018","November 4, 2019","November 19, 2019","Fukuoka Mirai Hospital, Fukuoka, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03456960/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03456960/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03456960"
107,"NCT03455491","Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections",,"Completed","Has Results","Acute Respiratory Viral Infections|Influenza","Drug: XC221 100 mg|Drug: XC221 200 mg|Drug: Placebo","Time to Sustained Improvement in Clinical Symptoms Based on Modified Jackson Scale for ARVI|Time to Body Temperature Normalization|Percentage of Patients With Complications|The Area Under the Curve ""Modified Jackson Scale Score"" During 3-day Therapy","PHARMENTERPRISES LLC","All","18 Years to 45 Years   (Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ARI-XC221-02","February 12, 2018","June 28, 2018","June 28, 2018","March 6, 2018","November 4, 2019","November 4, 2019","City Clinical Hospital №9, Izhevsk, Russian Federation|Kuban State Medical University, Krasnodar, Russian Federation|City Clinical Hospital №1 n.a. Semashko, Rostov-on-Don, Russian Federation|Ryazan State Medical University n.a. Pavlov, Ryazan', Russian Federation|The Center for Prevention and Fight about AIDS and Infectious Diseases, Saint Petersburg, Russian Federation|The Consulting and Diagnostic Center with out-patient help of the Administration of the President of the Russian Federation, Saint Petersburg, Russian Federation|Research Institute of Influenza, Saint Petersburg, Russian Federation|City Clinical Hospital №40 of Kurortny District, Saint Petersburg, Russian Federation|Mordovia State Medical University n.a. N.P.Ogarev, Clinical site - Republic Infectious Clinical Hospital, Saransk, Russian Federation|Volgograd State Medical University, Clinical site - Infectious Regional Clinical Hospital № 1, Volgograd, Russian Federation|Сlinical Hospital №3, Yaroslavl, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT03455491/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03455491"
108,"NCT03453060","Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects",,"Completed","Has Results","Thrombosis","Drug: E-WE Thrombin- Dose 1|Drug: E-WE Thrombin- Dose 2|Drug: E-WE Thrombin- Dose 3|Drug: E-WE Thrombin- Dose 4|Other: Placebo","The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Will be Summarized Using Frequency Counts.|The Number of Subjects With Clinically Significant Changes in Body Temperature, Frequency, and Relation to Treatment Will be Assessed.|The Number of Subjects With Clinically Significant Changes in Respiratory Rate, Frequency, and Relation to Treatment Will be Assessed.|The Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic), Frequency, and Relation to Treatment Will be Assessed.|The Number of Subjects With Clinically Significant Changes in Heart Rate, Frequency, and Relation to Treatment Will be Assessed.|The Number of Subjects With Abnormal Electrocardiogram and Frequency and/ or Adverse Events That Are Related to Treatment.|The Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT), Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.|The Number of Subjects With Clinically Significant Changes in Prothrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.|The Number of Subjects With Clinically Significant Changes in Thrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.|The Number of Subjects With Clinically Significant Changes in Plasma Fibrinogen, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.|The Number of Subjects With Injection Site Reaction and/ or Adverse Events That Are Related to Treatment.|The Number of Subjects That Develop Treatment-related Immunogenicity.|The Number of Subjects With Clinically Significant Changes in Blood Urea Nitrogen Levels (BUN) as Part of a Standard Serum Chemistry Panel, Frequency, and Relation to Treatment Will be Assessed.|The Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.|The Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.|The Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.|The Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.|The Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.|The Number of Subjects With Clinically Significant Changes in Albumin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.|The Number of Subjects With Clinically Significant Changes in Sodium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.|The Number of Subjects With Clinically Significant Changes in Potassium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.|The Number of Subjects With Clinically Significant Changes in Chloride Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.|The Number of Subjects With Clinically Significant Changes in Bicarbonate Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.|The Number of Subjects With Clinically Significant Changes in Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.|The Number of Subjects With Clinically Significant Changes in Creatinine Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.|The Number of Subjects With Clinically Significant Changes in Hemoglobin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.|The Number of Subjects With Clinically Significant Changes in Hematocrit Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.|The Number of Subjects With Clinically Significant Changes in Total Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.|The Number of Subjects With Clinically Significant Changes in Differential Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.|The Number of Subjects With Clinically Significant Changes in Red Blood Cell Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.|The Number of Subjects With Clinically Significant Changes in Platelet Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.|The Number of Subjects With Clinically Significant Changes in Urine pH, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.|The Number of Subjects With Clinically Significant Changes in Urine Specific Gravity, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.|The Number of Subjects With Clinically Significant Changes in Urine Protein Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.|The Number of Subjects With Clinically Significant Changes in Urine Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.|The Number of Subjects With Clinically Significant Changes in Urine Ketone Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.|The Number of Subjects With Clinically Significant Changes in Urine Bilirubin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.|The Number of Subjects With Clinically Significant Changes in Urine Blood Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.|The Number of Subjects With Clinically Significant Changes in Urine Nitrite Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.|The Number of Subjects With Clinically Significant Changes in Urine Urobilinogen Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.|The Number of Subjects With Clinically Significant Changes in Urine Leukocyte Esterase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.|The Effect of a Single Intravenous Dose of E-WE Thrombin on Generation of Activated Protein C- Protein C Inhibitor Complexes (APC-PCI).","Aronora, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EWE-17-01","May 30, 2018","November 25, 2018","November 25, 2018","March 5, 2018","October 29, 2019","October 29, 2019","Celerion, Tempe, Arizona, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03453060/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03453060/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03453060"
109,"NCT03447353","Opiates and Benzodiazepines on Driving",,"Completed","Has Results","Driving Behavior","Drug: Xanax 1Mg Tablet|Drug: Norco 10Mg-325Mg Tablet|Drug: Placebo Oral Tablet","SDLP|Lane Departures","Timothy L. Brown|University of Iowa","All","18 Years to 40 Years   (Adult)","Phase 4","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","201604731","June 14, 2016","October 25, 2016","October 25, 2016","February 27, 2018","September 27, 2018","September 27, 2018","National Advanced Driving Simulator, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT03447353"
110,"NCT03447015","Effects of Ambulation During First Stage of Labour on Maternal and Neonatal Outcomes",,"Completed","Has Results","Labor Pain","Other: ambulation","Duration of the First Stage of Labour|Labour Pain Intensity|Use of Analgesics|Mode of Birth|Woman's Satisfaction With the Birth Experience|Newborn Health Status","Mutah University","Female","18 Years to 50 Years   (Adult)","Not Applicable","290","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","112018","March 1, 2018","February 20, 2019","February 20, 2019","February 27, 2018","October 11, 2019","October 11, 2019","Ministry Of Health, Karak, Jordan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03447015/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03447015"
111,"NCT03445156","Effect of Violent First-Person Shooter (FPS) Video Games on Shooting Accuracy",,"Completed","Has Results","Gun Shot Wound","Behavioral: Video game|Behavioral: Controller","Hits to Head and Face|Other Hits","Ohio State University","All","18 Years to 46 Years   (Adult)","Not Applicable","327","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2010B0261","February 1, 2016","April 25, 2016","April 25, 2016","February 26, 2018","August 5, 2019","August 5, 2019",,,"https://ClinicalTrials.gov/show/NCT03445156"
112,"NCT03442933","Assessment of the Acute Effect of Cycling Practice in Lumbar and Thigh Muscles",,"Completed","Has Results","Physical Endurance|Muscle Fatigue|Musculoskeletal Pain|Muscle Tightness","Other: 3 hours Road Cycling Time Trial|Other: 3 hours Mountain Biking Time Trial","Low Back Pain Perception (LBPP)|Maximal Radial Displacement (Dm)|Pressure Pain Threshold (PPT)|Roland-Morris Questionnaire (RMQ)","Universidad Europea de Madrid","Male","18 Years to 55 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2016/UEM18","December 14, 2017","May 5, 2018","June 13, 2018","February 22, 2018","August 12, 2019","August 12, 2019","Universidad Europea de Madrid, Villaviciosa De Odón, Madrid, Spain","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03442933/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03442933"
113,"NCT03437564","A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets",,"Completed","Has Results","Healthy Adult Participants","Drug: Vortioxetine","AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004|Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004|AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004|Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004|MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004|MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004|λz: Apparent Elimination Rate Constant of Unchanged Lu AA21004|T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004|Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)|Number of Participants With TEAE Related to Vital Sign|Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased)|Number of Participants With TEAE Related to 12-lead Electrocardiograms","Takeda","All","20 Years to 45 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","Vortioxetine-1001|U1111-1208-2715|JapicCTI-183863","February 16, 2018","April 13, 2018","April 13, 2018","February 19, 2018","June 26, 2019","June 27, 2019","Nishi Kumamoto Hospital, Kumamoto, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03437564/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03437564/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03437564"
114,"NCT03437447","Praziquantel Bioequivalence Study",,"Completed","Has Results","Healthy","Drug: Cisticid|Drug: Biltricide","Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ)|Maximum Observed Plasma Concentration (Cmax) of L-Praziquantel (L-PZQ)|Time to Reach Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)|Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)|Extrapolated Area Under the Plasma Concentration Curve From Time Tlast to Infinity (AUCextra) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)|Terminal Elimination Half-Life (t1/2) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)|Terminal Elimination Rate Constant (Lambda Z) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)|Apparent Clearance (CL/f) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)|Apparent Volume of Distribution During Terminal Phase (Vd/f) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)|Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Racemate PZQ (Rac-PZQ)|Maximum Observed Plasma Concentration (Cmax) of Racemate PZQ (Rac-PZQ)|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs|Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters|Number of Participants With Clinically Significant Abnormalities in Vital Signs|Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings","Merck KGaA, Darmstadt, Germany","Male","18 Years to 55 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","MS200585_0002","June 18, 2018","July 6, 2018","July 6, 2018","February 19, 2018","September 18, 2019","September 18, 2019","Clínica de Enfermedades Crónicas y de Procedimientos Especiales, Sociedad Civil (SC), México, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT03437447/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT03437447/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03437447"
115,"NCT03434977","A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation",,"Completed","Has Results","Healthy Volunteers","Drug: TAK-536","Cmax: Maximum Observed Plasma Concentration for TAK-536|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536|AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-536|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-536|T1/2z: Terminal Disposition Phase Half-life for TAK-536|MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration for TAK-536|MRT∞, ev: Mean Residence Time From Time 0 to Infinity for TAK-536|λz: Terminal Disposition Phase Rate Constant for TAK-536|CL/F: Apparent Clearance for TAK-536|Vz/F: Apparent Volume of Distribution for TAK-536|Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)|Number of Participants With TEAE Related to Vital Sign|Number of Participants With TEAE Related to Body Weight|Number of Participants With TEAE Related to Clinical Laboratory Tests (Eosinophil Count Increased)|Number of Participants With TEAE Related to 12-lead Electrocardiograms (ECGs)","Takeda","Male","20 Years to 35 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Azilsartan-1005|U1111-1206-5973|JapicCTI-183856","February 14, 2018","March 11, 2018","March 11, 2018","February 15, 2018","June 7, 2019","June 10, 2019","Fukuoka Mirai Hospital, Fukuoka, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03434977/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03434977/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03434977"
116,"NCT03431441","Clinical Evaluation of 2-Week Reusable ACUVUE 2 Vivid Style",,"Completed","Has Results","Visual Acuity","Device: JJVC Marketed Contact Lens","LogMAR Objective Vision (High Illumination/High Contrast)","Johnson & Johnson Vision Care, Inc.","Female","18 Years to 39 Years   (Adult)","Not Applicable","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-6180","January 16, 2018","February 14, 2018","February 14, 2018","February 13, 2018","March 5, 2019","March 5, 2019","VRC East, Jacksonville, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03431441/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03431441"
117,"NCT03430245","VelaShape III & UltraShape Power for Thigh Circumference Reduction",,"Completed","Has Results","Circumference Reduction","Device: VelaShape III|Device: UltraShape Power","Circumference Change in the Thighs at the 12-week Follow-up Compared to Baseline Measurements|Change in the Thighs Circumference at Each Treatment Visit Post Baseline and at The 4 and 8 Week Follow-up Visits|Investigator Satisfaction|Subject Satisfaction","Syneron Medical","All","18 Years to 60 Years   (Adult)","Not Applicable","16","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DHF24451","February 19, 2018","May 30, 2019","July 3, 2019","February 12, 2018","December 26, 2019","January 9, 2020","Skin Laser & Surgery Specialist of NY/NJ, Hackensack, New Jersey, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03430245/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03430245"
118,"NCT03430050","Progesterone for Cannabis Withdrawal",,"Completed","Has Results","Cannabis Use Disorder|Cannabis Withdrawal","Drug: Progesterone|Drug: Placebo","Change in Salivary Progesterone Level|Change in Cannabis Withdrawal Scale Score.","Medical University of South Carolina|National Institute on Drug Abuse (NIDA)|National Institutes of Health (NIH)","Female","18 Years to 45 Years   (Adult)","Early Phase 1","8","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","65954|5K24DA038240-03","October 16, 2017","April 4, 2018","April 4, 2018","February 12, 2018","May 22, 2019","May 22, 2019","Medical University of South Carolina, Charleston, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03430050/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03430050"
119,"NCT03429556","Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty",,"Terminated","Has Results","Abdominoplasty","Biological: Botulinum Neurotoxin Serotype E|Drug: Placebo","Area Under the Curve (AUC) of Participant's Assessment of Pain Using the Numerical Pain Rating Scale (NPRS) at Rest Between 12 and 96 Hours Postsurgery (AUC12-96)|AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 96 Hours Postsurgery|AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 72 Hours Postsurgery (AUC0-72)|AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 48 Hours Postsurgery (AUC0-48)|AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 24 Hours Postsurgery (AUC0-24)|AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 12 and 24 Hours Postsurgery (AUC12-24)|Participants Overall Assessment of Pain Using the NPRS After Discharge|Participant's Overall Assessment of Pain Using the NPRS-Activity (NPRS-A)|Number of Participants by Patient Global Assessment (PGA) of Pain Control Score Categories|Number of Doses of Rescue Medications Used","Allergan","All","23 Years to 55 Years   (Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EB001-ABD201","May 8, 2018","July 10, 2018","July 10, 2018","February 12, 2018","August 5, 2019","August 5, 2019","Huntington Ambulatory Surgery Center, Pasadena, California, United States|Lotus Clinical Research, LLC, Pasadena, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03429556/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03429556/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03429556"
120,"NCT03428997","Human Comedogenicity Test",,"Completed","Has Results","Comedogenicity","Device: Lotion|Other: Negative Control","Microcomedone Score of Follicular Biopsies","Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide","All","18 Years to 45 Years   (Adult)","Not Applicable","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","CO-171106085430-SACT","November 20, 2017","February 5, 2018","February 5, 2018","February 12, 2018","August 2, 2019","August 2, 2019","Stephens and Associates, Richardson, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT03428997/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03428997"
121,"NCT03420625","Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices",,"Completed","Has Results","Venous Stasis|Deep Vein Thrombosis","Device: Foot IPC|Device: Rapid calf IPC|Device: Slow calf IPC|Device: Calf NMES","Blood Flow - Peak Systolic Velocity (cm/Sec)|Blood Flow - Time-averaged Mean Velocity (cm/Sec)|Blood Flow - Volume Flow (ml/Min)|Blood Flow - Ejected Volume Per Individual Stimulus (ml)|Tolerability to IPC and NMES According to Visual Analogue Scale 0-10","Karolinska University Hospital","All","18 Years to 60 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SW2016-17-HEMOD","September 2016","January 2017","February 2017","February 5, 2018","February 12, 2019","February 12, 2019",,,"https://ClinicalTrials.gov/show/NCT03420625"
122,"NCT03418064","Performance of Toric Silicone Hydrogel Contact Lenses Following One Month of Daily Wear",,"Completed","Has Results","Astigmatism","Device: Fanfilcon A toric lens|Device: Lotrafilcon B toric lens","Lens Centration|Corneal Coverage|Post-blink Movement|Overall Fit Acceptance|Average Hours of Wear Per Day|Average Comfortable Wearing Time","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EX-MKTG-90","February 10, 2018","May 16, 2018","May 16, 2018","February 1, 2018","November 13, 2019","November 13, 2019","Optometry Clinic, National Autonomous University, Mexico City, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03418064/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03418064"
123,"NCT03415243","To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers",,"Completed","Has Results","Common Cold","Drug: Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg|Drug: Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg","Mean Time to Onset of Gastric Emptying|Mean Time to Complete Gastric Emptying|Mean Time for Gastric Emptying by Measuring 25 Percent Values|Mean Time for Gastric Emptying by Measuring 50 Percent Values|Mean Time for Gastric Emptying by Measuring 90 Percent Values|Percentage of Radiolabeled Drug Remaining in the Stomach After 15 Minutes of Administration|Percentage of Radiolabeled Drug Remaining in the Stomach After 30 Minutes of Administration|Percentage of Radiolabeled Drug Remaining in the Stomach After 45 Minutes of Administration|Percentage of Radiolabeled Drug Remaining in the Stomach After 60 Minutes of Administration|Percentage of Radiolabeled Drug Remaining in the Stomach After 75 Minutes of Administration|Percentage of Radiolabeled Drug Remaining in the Stomach After 90 Minutes of Administration|Percentage of Radiolabeled Drug Remaining in the Stomach After 105 Minutes of Administration|Percentage of Radiolabeled Drug Remaining in the Stomach After 120 Minutes of Administration|Percentage of Radiolabeled Drug Remaining in the Stomach After 180 Minutes of Administration|Percentage of Radiolabeled Drug Remaining in the Stomach After 240 Minutes of Administration|Area Under the Gastric Emptying Curve From Time 0 to 15 Minutes|Area Under the Gastric Emptying Curve From Time 0 to 30 Minutes|Area Under the Gastric Emptying Curve From Time 0 to 45 Minutes|Area Under the Gastric Emptying Curve From Time 0 to 60 Minutes|Area Under the Gastric Emptying Curve From Time 0 to 75 Minutes|Area Under the Gastric Emptying Curve From Time 0 to 90 Minutes|Area Under the Gastric Emptying Curve From Time 0 to 105 Minutes|Area Under the Gastric Emptying Curve From Time 0 to 120 Minutes|Area Under the Gastric Emptying Curve From Time 0 to 180 Minutes|Area Under the Gastric Emptying Curve From Time 0 to 240 Minutes|Total Area Under the Gastric Emptying Curve|Gastric Emptying Half-Life|Small Intestine Transit Time|Number of Participants With Clinically Significant Change in Laboratory Test Values","GlaxoSmithKline","Male","21 Years to 45 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","208821","March 1, 2018","March 29, 2018","March 29, 2018","January 30, 2018","June 24, 2019","June 24, 2019","GSK Investigational Site, Lexington, Kentucky, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03415243/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03415243/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03415243"
124,"NCT03410628","Non-invasive Neurostimulation for the Relief of Migraine",,"Terminated","Has Results","Migraine","Device: gammaCore","Safety - Number of Participants With Adverse Events|Change in Headache Pain Severity From Baseline to 120 Minutes for First Treated Migraine Attack","ElectroCore INC","All","18 Years to 55 Years   (Adult)","Not Applicable","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M-SA-01","July 2011","August 2011","December 2011","January 25, 2018","July 26, 2018","July 26, 2018",,,"https://ClinicalTrials.gov/show/NCT03410628"
125,"NCT03404167","A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers",,"Completed","Has Results","Gonorrhoea","Drug: AZD0914","Maximum Observed Concentration (Cmax) of Zoliflodacin|Time of Maximum Observed Concentration (Tmax) of Zoliflodacin|Area Under the Concentration Time-curve From Time Zero to Infinity (AUC(0-infinity)) for Zoliflodacin|Area Under the Concentration Time-curve From Time Zero to the Last Concentration Above the Lower Limit of Quantitation (AUC(0-last)) for Zoliflodacin|Apparent Volume of Distribution (Vz/F) of Zoliflodacin|Apparent Oral Clearance (CL/F) of Zoliflodacin|Elimination Rate Constant (Ke) of Zoliflodacin|Terminal Elimination Half-life (t1/2) of Zoliflodacin|Changes From Baseline for White Blood Cells With Differentials and Platelets|Changes From Baseline Hematocrit|Changes From Baseline Hemoglobin|Changes From Baseline Red Blood Cell Count|Changes From Baseline for Albumin and Total Protein|Change From Baseline for Alkaline Phosphatase (AP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)|Change From Baseline for Blood Urea Nitrogen (BUN), Serum Creatinine, Glucose (Fasting at Least 4h), Magnesium, Total and Direct Bilirubin|Changes From Baseline for Sodium, Potassium, Chloride and Bicarbonate|Changes From Baseline for Blood Pressure - Systolic|Changes From Baseline for Blood Pressure - Diastolic|Changes From Baseline in Oral Temperature|Changes From Baseline in Pulse Rate|Changes From Baseline for Respiratory Rate|Changes From Baseline in ECG: PR Interval (Interval From Onset of P-wave to the Onset of the QRS Complex)|Changes From Baseline in ECG: QRS Duration (Time From the Start of the Q-wave to the End of the S-wave)|Changes From Baseline in ECG: QTcF Interval (QT Interval Corrected by Fridericia's Formula)|Changes From Baseline in ECG: QT Interval (Interval From Onset of the Q-wave to the End of the T-wave)|Changes From Baseline in ECG: RR Interval (Interval From the Peak of the R Wave of a QRS Complex to the Peak of the R Wave of the Next QRS Complex)|Changes From Baseline in ECG: Ventricular Rate|Changes From Baseline for Occult Blood Via Dipstick|Changes From Baseline for Glucose Via Dipstick|Changes From Baseline for Protein Via Dipstick|Occurrence of Unsolicited Treatment-emergent Adverse Events|Occurrence of Treatment-emergent Serious Adverse Events","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Phase 1","8","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-0118|HHSN272201500005I","February 2, 2018","March 2, 2018","March 2, 2018","January 19, 2018","March 18, 2019","March 18, 2019","Quintiles Phase I Services - Overland Park, Overland Park, Kansas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03404167/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03404167/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03404167"
126,"NCT03403504","OTR Tablet 10 mg Fasted-state Bioequivalence Study",,"Completed","Has Results","Chronic Pain","Drug: Oxycodone Tamper Resistant|Drug: OXYCONTIN®","Cmax of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg in a Fasted State|AUCt of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg in a Fasted State|AUCINF of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg in a Fasted State|Adverse Events of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg, When Given to Chinese Subjects With Chronic Pain in a Fasted State|Number of AEs Related to Vital Signs|Number of AEs Related to ECGs|Number of Lab Tests With Clinical Significance|Number of AEs Related to Physical Examination","Mundipharma (China) Pharmaceutical Co. Ltd","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","ONF16-CN-101","February 1, 2017","July 24, 2017","September 7, 2017","January 18, 2018","October 31, 2019","November 26, 2019","The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT03403504/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT03403504/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03403504"
127,"NCT03401671","Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects",,"Completed","Has Results","Healthy Volunteers","Drug: Lanadelumab","Maximum Observed Plasma Concentration (Cmax) of Lanadelumab|Time to Reach Maximum Observed Drug Concentration in Plasma (Tmax) of Lanadelumab|Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) in Plasma of Lanadelumab|Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Lanadelumab|Terminal Elimination Rate Constant (Lambda z) for Lanadelumab|Terminal Half-life (t12) of Lanadelumab|Apparent Clearance (CL/F) of Lanadelumab|Apparent Volume of Distribution (Vz/F) of Lanadelumab|Body-weight Adjusted Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) in Plasma of Lanadelumab|Body-weight Adjusted Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) in Plasma of Lanadelumab|Body-weight Adjusted Maximum Observed Plasma Concentration (Cmax) of Lanadelumab|Body-weight Adjusted Apparent Clearance (CL/F) of Lanadelumab|Body-weight Adjusted Apparent Volume of Distribution (Vz/F) of Lanadelumab|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Based on Severity, Seriousness and Causality|Number of Participants With Clinically Significant Change in Clinical Laboratory Results Reported as an Adverse Event|Number of Participants With Clinically Significant Change in Vital Signs Reported as an Adverse Event|Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Reported as an Adverse Event|Number of Participants Who Developed Antidrug Antibodies to Lanadelumab at Specified Time Points","Shire","All","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHP643-101","January 15, 2018","May 30, 2018","May 30, 2018","January 17, 2018","July 29, 2019","July 29, 2019","WCCT Global, Inc., Cypress, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03401671/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03401671/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03401671"
128,"NCT03398330","OTR Tablet 40 mg Fed-state Bioequivalence Study",,"Completed","Has Results","Chronic Pain","Drug: Oxycodone Tamper Resistant|Drug: OxyContin®","Cmax of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State|AUCt of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State|AUCINF of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State|Adverse Events of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg, When Given to Chinese Subjects With Chronic Pain in a Fed State|Number of Lab Tests With Clinical Significance|Number of AEs Related to Vital Signs|Number of AEs Related to ECGs|Number of AEs Related to Physical Examination","Mundipharma (China) Pharmaceutical Co. Ltd","All","18 Years to 55 Years   (Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","ONF16-CN-103","March 16, 2017","September 5, 2017","November 6, 2017","January 12, 2018","November 15, 2019","November 15, 2019","Xiangya Hospital of Central South University, Changsha, Hunan, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03398330/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03398330/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03398330"
129,"NCT03398278","OTR Tablet 40 mg Fasted-state Bioequivalence Study",,"Completed","Has Results","Chronic Pain","Drug: Oxycodone Tamper Resistant|Drug: OXYCONTIN®","Cmax of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fasted State|AUCt of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fasted State|AUCINF of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fasted State|Adverse Event of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg, When Given to Chinese Subjects With Chronic Pain in a Fasted State|Number of Lab Tests With Clinical Significance|Number of AEs Related to Vital Sign|Number of AEs Related to ECGs|Number of AEs Related to Physical Examination","Mundipharma (China) Pharmaceutical Co. Ltd","All","18 Years to 55 Years   (Adult)","Phase 1","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","ONF16-CN-102","June 30, 2017","October 15, 2017","March 20, 2018","January 12, 2018","October 31, 2019","November 26, 2019","West Hospital, Sichuan University, Chengdu, Sichuan, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03398278/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03398278/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03398278"
130,"NCT03396835","Desaturation Validation of INVSENSOR00009",,"Completed","Has Results","Healthy","Device: INVSENSOR00009","Trending Regional Oxygen Saturation Accuracy of the INVSENSOR00009 Relative to the Control Sensor by Arms Calculation","Masimo Corporation","All","18 Years to 50 Years   (Adult)","Not Applicable","16","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TP-19029","December 18, 2017","January 16, 2018","January 16, 2018","January 11, 2018","August 28, 2019","August 28, 2019","Masimo Clinical Lab, Irvine, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03396835/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03396835"
131,"NCT03393208","Glucophage Immediate Release (GIR) China Bioequivalence Study",,"Completed","Has Results","Healthy","Drug: Test GIR|Drug: Reference GIR","Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin (GIR Tablet Active Ingredient)|Maximum Observed Plasma Concentration (Cmax) of Metformin (GIR Tablet Active Ingredient)|Time to Reach Maximum Plasma Concentration of Metformin (GIR Tablet Active Ingredient)|Apparent Terminal Half-Life (t1/2) of Metformin (GIR Tablet Active Ingredient)|Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Metformin (GIR Tablet Active Ingredient)|Area Under the Plasma Concentration-Time Curve From Time Tlast Extrapolated to Infinity (AUCextra) of Metformin (GIR Tablet Active Ingredient)|Elimination Rate Constant (λz) of Metformin (GIR Tablet Active Ingredient)|Total Body Clearance (CL/f) of Metformin (GIR Tablet Active Ingredient)|Apparent Volume of Distribution at After Extravascular Administration (Vz/f) of Metformin (GIR Tablet Active Ingredient)|Apparent Volume of Distribution at Steady-State After Extravascular Administration (Vss/f) of Metformin|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs|Number of Participants With Clinically Significant Abnormalities in Vital Signs, Laboratory Parameters, Physical Examination Findings and 12-lead Electrocardiogram (ECG) Findings","Merck KGaA, Darmstadt, Germany","All","18 Years to 55 Years   (Adult)","Phase 1","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","MS200084_0009","January 10, 2018","January 29, 2018","January 29, 2018","January 8, 2018","July 15, 2019","July 15, 2019","Xuanwu Hospital, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03393208/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03393208/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03393208"
132,"NCT03391986","Acupuncture for Pain Management During Uterine Aspiration",,"Completed","Has Results","Pain Acute|Acupuncture","Device: SEIRIN® Pyonex™ Acupuncture Needles|Procedure: 12 mm Plasters","Visual Analog Scale for Pain (VAS Pain) Score - Acupuncture Versus Routine Care|Change in Visual Analog Scale for Pain (VAS Pain) Score - Placebo Versus Routine Care|Percentage of Patients Rated Good or Very Good on Satisfaction Survey in Overall Care - Acupuncture Versus Routine Care","Columbia University|Society of Family Planning","Female","18 Years to 55 Years   (Adult)","Not Applicable","153","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","AAAR2610","September 9, 2017","April 30, 2018","July 1, 2018","January 5, 2018","September 3, 2019","September 3, 2019","Columbia University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03391986/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03391986"
133,"NCT03386435","The Effect of Remote Ischemic Preconditioning in Living Donor Hepatectomy",,"Completed","Has Results","Tissue Donors|Liver Transplantation|Ischemia Reperfusion Injury","Procedure: remote ischemic preconditioning","Postopera The Maximal Aspartate Aminotransferase Level Within 7 Postoperative Days|The Maximal Alanine Aminotransferase Level Within 7 Postoperative Days|Number of Participants With Delayed Recovery of Liver Function|Postoperative Liver Regeneration","Asan Medical Center","All","18 Years to 60 Years   (Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","RIPC_donor","August 22, 2016","August 31, 2017","October 30, 2017","December 29, 2017","August 19, 2019","August 19, 2019","Asan medical center, Seoul, Songpa-gu, Korea, Republic of","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03386435/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03386435"
134,"NCT03380780","A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers",,"Completed","Has Results","Healthy Volunteers|Hemophilia A","Drug: Emicizumab","Maximum Observed Plasma Concentration (Cmax) of Emicizumab|Area Under the Plasma Concentration Versus Time Curve (AUC) Between Time Zero Extrapolated to Infinity (AUC0-inf) of Emicizumab|AUC Between Time Zero and the Time of Last Quantifiable Concentration (AUC0-last) of Emicizumab|Time to Cmax (Tmax) of Emicizumab|Apparent Terminal Half-Life (t1/2) of Emicizumab|Apparent Clearance (CL/F) of Emicizumab|Apparent Volume of Distribution (Vz/F) of Emicizumab|Mean Residence Time (MRT) of Emicizumab|Number of Participants With Adverse Events by Highest World Health Organization (WHO) Toxicity Grade|Number of Participants Testing Negative or Positive for the Presence of Anti-Drug Antibodies (ADA) Against Emicizumab by Timepoint and for the Overall Study|Number of Participants With Laboratory Test Abnormalities|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Albumin Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Alkaline Phosphatase Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Bilirubin Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Fasting Blood Glucose Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Blood Urea Nitrogen Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: C-Reactive Protein Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Chloride Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Cholesterol Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Creatine Kinase Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Creatinine Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Direct Bilirubin Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Gamma Glutamyl Transferase Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Lactate Dehydrogenase Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Potassium Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Total Protein Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: SGOT/AST Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: SGPT/ALT Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Sodium Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Fasting Triglycerides Concentration|Change From Baseline in Clinical Chemistry Laboratory Test Results by Timepoint: Uric Acid Concentration|Change From Baseline in Coagulation Laboratory Test Results by Timepoint: Activated Partial Thromboplastin Time|Change From Baseline in Coagulation Laboratory Test Results by Timepoint: Fibrinogen Concentration|Change From Baseline in Coagulation Laboratory Test Results by Timepoint: Prothrombin Time|Change From Baseline in Coagulation Laboratory Test Results by Timepoint: Prothrombin Time/International Normalized Ratio (INR)|Change From Baseline in Hematology Laboratory Test Results by Timepoint: Basophils, Absolute Count|Change From Baseline in Hematology Laboratory Test Results by Timepoint: Eosinophils, Absolute Count|Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Mean Corpuscular Hemoglobin|Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Mean Corpuscular Volume|Change From Baseline in Hematology Laboratory Test Results by Timepoint: Erythrocyte Mean Corpuscular Hemoglobin Concentration|Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hematocrit (as a Fraction of 1)|Change From Baseline in Hematology Laboratory Test Results by Timepoint: Hemoglobin Concentration|Change From Baseline in Hematology Laboratory Test Results by Timepoint: Lymphocytes, Absolute Count|Change From Baseline in Hematology Laboratory Test Results by Timepoint: Monocytes, Absolute Count|Change From Baseline in Hematology Laboratory Test Results by Timepoint: Total Neutrophils, Absolute Count|Change From Baseline in Hematology Laboratory Test Results by Timepoint: Platelet Count|Change From Baseline in Hematology Laboratory Test Results by Timepoint: Red Blood Cell Count|Change From Baseline in Hematology Laboratory Test Results by Timepoint: White Blood Cell Count|Number of Participants by Test Results for Blood in Urine by Timepoint|Number of Participants by Test Results for Glucose in Urine by Timepoint|Number of Participants by Test Results for Protein in Urine by Timepoint|Change From Baseline in Vital Signs by Timepoint: Diastolic Blood Pressure|Change From Baseline in Vital Signs by Timepoint: Pulse Rate|Change From Baseline in Vital Signs by Timepoint: Respiratory Rate|Change From Baseline in Vital Signs by Timepoint: Systolic Blood Pressure|Change From Baseline in Vital Signs by Timepoint: Temperature (Axillary)|Change From Baseline in Electrocardiogram (ECG) Results by Timepoint: Heart Rate|Change From Baseline in ECG Results by Timepoint: PR Duration|Change From Baseline in ECG Results by Timepoint: QRS Duration|Change From Baseline in ECG Results by Timepoint: QT Duration|Change From Baseline in ECG Results by Timepoint: QTcB Duration (Bazett's Correction Formula)|Change From Baseline in ECG Results by Timepoint: QTcF Duration (Fridericia's Correction Formula)|Change From Baseline in ECG Results by Timepoint: RR Duration|Number of Participants With Concomitant Medications","Hoffmann-La Roche","Male","20 Years to 45 Years   (Adult)","Phase 1","16","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","YP39308","March 12, 2018","September 18, 2018","September 18, 2018","December 21, 2017","September 30, 2019","September 30, 2019","Peking University Third Hospital, Beijing, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03380780/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03380780"
135,"NCT03373162","Functional Effects of Botox on the Brain Using MRS and fMRI",,"Completed","Has Results","Healthy","Drug: onabotulinumtoxinA","Glutamate + Glutamine (Glx)/Creatine Ratio as Measured by MRS in the Brainstem Pre and Post-Botox|Change From Baseline in Functional MRI Mean Blood Oxygen Level Dependent (BOLD) Response in the Amygdala|Number of Participants With Structural Brain Volume Change Following Botox Injections","University of California, Irvine|Allergan","Female","30 Years to 40 Years   (Adult)","Phase 4","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2017-3377","September 30, 2017","November 1, 2017","November 1, 2017","December 14, 2017","April 26, 2019","April 26, 2019","University of California, Irvine, Irvine, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03373162/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03373162/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03373162"
136,"NCT03372382","Ibuprofen and Acetaminophen Versus Ibuprofen and Acetaminophen Plus Hydrocodone for Analgesia After Cesarean Section","IVY","Completed","Has Results","Opioid Use|Pain, Postoperative","Drug: Ibuprofen|Drug: Acetaminophen|Drug: Norco","Pain Level|Patient Satisfaction","The University of Texas Health Science Center, Houston","Female","18 Years to 50 Years   (Adult)","Phase 4","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-17-0777","December 13, 2017","April 10, 2018","April 10, 2018","December 13, 2017","July 2, 2019","July 2, 2019","The University of Texas Health Science Center at Houston, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03372382/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03372382"
137,"NCT03372369","Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk",,"Completed","Has Results","Contraception|Knowledge, Attitudes, Practice","Other: View CDC Poster|Other: View Patient-Centered Poster","Change in Contraceptive Knowledge Assessment (CKA) Score|Change in Effective Contraception Preference Score|Change in Perceived Pregnancy Risk Score","University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute","Female","18 Years to 44 Years   (Adult)","Not Applicable","990","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","17-2955|UL1TR001111","January 26, 2018","February 13, 2018","February 13, 2018","December 13, 2017","June 7, 2019","August 20, 2019","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03372369/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03372369"
138,"NCT03371459","Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma",,"Completed","Has Results","Asthma","Drug: AS MDI|Drug: Proventil","Baseline-adjusted FEV1 30 Minutes After Each Cumulative Dose|Baseline-adjusted FEV1 AUC0-6 After the Last Cumulative Dose","AstraZeneca","All","18 Years to 45 Years   (Adult)","Phase 2","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D6930C00002","December 29, 2017","March 26, 2018","March 26, 2018","December 13, 2017","July 23, 2019","July 23, 2019","Research Site, Winter Park, Florida, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Medford, Oregon, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03371459/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03371459/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03371459"
139,"NCT03370289","A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects",,"Completed","Has Results","Pandemic Influenza Prevention","Biological: BLB-750 Vaccine (Qinghai RG strain)","Seroprotection Rate as Measured by Single Radial Hemolysis (SRH) Antibody Titer for the Vaccine Strain at 21 Days After the Second Vaccination|Seroconversion Rate as Measured by SRH Antibody Titer for the Vaccine Strain at 21 Days After the Second Vaccination|Geometric Mean Fold Increase (GMFI) in SRH Antibody Titer From Baseline for the Vaccine Strain at 21 Days After the Second Vaccination|Seroprotection Rate as Measured by SRH Antibody Titer for the Vaccine Strain at 21 Days After the First Vaccination|Seroconversion Rate as Measured by SRH Antibody Titer for the Vaccine Strain at 21 Days After the First Vaccination|GMFI in SRH Antibody Titer From Baseline for the Vaccine Strain at 21 Days After the First Vaccination|Geometric Mean Titer (GMT) of SRH Antibody Titer for the Vaccine Strain at 21 Days After Each Vaccination|Number of Participants Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE)|Number of Participants With Adverse Events Related to Solicited Local and Systemic Adverse Events to be Recorded in the Participant Diary|Change From Baseline in Mean Systolic Blood Pressure at Specific Time Points After Vaccination|Change From Baseline in Mean Diastolic Blood Pressure at Specific Time Points After Vaccination|Change From Baseline in Mean Pulse Rate at Specific Time Points After Vaccination|Change From Baseline in Mean Respiratory Rate at 30 Minutes After Vaccination|Mean Body Temperature at Specific Time Points After Vaccination","Takeda","All","20 Years to 49 Years   (Adult)","Phase 4","55","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BLB-750/CCT-901|U1111-1198-2695|JapicCTI-173797","January 12, 2018","February 28, 2018","February 28, 2018","December 12, 2017","July 29, 2019","July 29, 2019","Sekino Rinsho Yakuri Clinic, Toshima-ku, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03370289/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03370289/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03370289"
140,"NCT03365934","Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds",,"Completed","Has Results","Healthy Volunteers","Device: ADHESIVE BANDAGE #1|Device: ADHESIVE BANDAGE #2|Device: ADHESIVE BANDAGE #3|Device: Antibacterial Bandage with 0.8% BZK|Other: Intact and No Bandage|Other: Wounded and No Bandage","Microbial Community Richness - Baseline (Day 0)|Microbial Community Richness - (Day 1)|Microbial Community Richness - (Day 2)|Microbial Community Richness - (Day 3)|Microbial Community Richness - (Day 4)|Microbial Community Richness - (Day 5)|Microbial Community Richness - (Day 6)|Microbial Community Richness - (Day 7)|Microbial Community Richness - (Day 14)|Microbial Community Diversity - Baseline (Day 0)|Microbial Community Diversity - Day 1|Microbial Community Diversity - Day 2|Microbial Community Diversity - Day 3|Microbial Community Diversity - Day 4|Microbial Community Diversity - Day 5|Microbial Community Diversity - Day 6|Microbial Community Diversity - Day 7|Microbial Community Diversity - Day 14|Microbial Community Evenness - Baseline (Day 0)|Microbial Community Evenness - Day 1|Microbial Community Evenness - Day 2|Microbial Community Evenness - Day 3|Microbial Community Evenness - Day 4|Microbial Community Evenness - Day 5|Microbial Community Evenness - Day 6|Microbial Community Evenness - Day 7|Microbial Community Evenness - Day 14|Skin Barrier Function -Baseline (Day 0)|Skin Barrier Function - Day 1|Skin Barrier Function - Day 2|Skin Barrier Function - Day 3|Skin Barrier Function - Day 4|Skin Barrier Function - Day 5|Skin Barrier Function - Day 6|Skin Barrier Function - Day 7|Skin Barrier Function - Day 14|Redness: Wound Area Oxyhemoglobin Level- Baseline (Day 0)|Redness: Wound Area Oxyhemoglobin Level - Day 1|Redness: Wound Area Oxyhemoglobin Level - Day 2|Redness: Wound Area Oxyhemoglobin Level - Day 3|Redness: Wound Area Oxyhemoglobin Level - Day 4|Redness: Wound Area Oxyhemoglobin Level - Day 5|Redness: Wound Area Oxyhemoglobin Level - Day 6|Redness: Wound Area Oxyhemoglobin Level - Day 7|Redness: Wound Area Oxyhemoglobin Level - Day 14","Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide","All","18 Years to 55 Years   (Adult)","Not Applicable","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CO-170726100607-SACT","November 20, 2017","February 12, 2018","February 12, 2018","December 8, 2017","June 4, 2019","June 4, 2019","TKL Research Inc., Fair Lawn, New Jersey, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03365934/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03365934/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03365934"
141,"NCT03362944","Active and Passive Music Therapy Interventions",,"Completed","Has Results","Autonomic Nervous System Imbalance|Hypothalamic Pituitary Adrenal Axis Suppression","Behavioral: Active Music Therapy|Behavioral: Passive Music Therapy","Change From Baseline to Post Intervention High Frequency (HF) and Low Frequency Divided by High Frequency (LF/HF) Power Amplitude|Change From Baseline to Post Intervention Cortisol|Change From Baseline to Post Intervention Alpha-amylase (A-amylase)|Active and Passive Music Therapy Post Intervention HF and LF/HF Power Amplitude|Active and Passive Music Therapy Post Intervention Cortisol|Active and Passive Music Therapy Post Intervention A-amylase","University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute","All","18 Years to 34 Years   (Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-2508|2KR961706","November 20, 2017","December 18, 2017","December 18, 2017","December 5, 2017","June 5, 2019","June 5, 2019","UNC Chapel Hill Medical School Wing C, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03362944/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03362944"
142,"NCT03360903","A Study to Determine if Caffeine Accelerates Emergence From Propofol Anesthesia",,"Completed","Has Results","Anesthesia","Drug: Placebo|Drug: Caffeine","Waking Time - Time Between Terminating Anesthesia and Subject Opening Eyes.|Cognitive Test1 - Visual Analog Scale|Cognitive Test2 - Sternberg Test of Memory|Cognitive Test3 - Divided Attention Task|Bispectral Index|Mean Arterial Blood Pressure|Heart Rate","University of Chicago|National Institutes of Health (NIH)|National Institute of General Medical Sciences (NIGMS)","Male","25 Years to 40 Years   (Adult)","Phase 4","8","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB17-1174|1R01GM116119","January 2, 2018","December 31, 2018","June 1, 2019","December 4, 2017","November 18, 2019","November 18, 2019","The University of Chicago, Chicago, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03360903/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03360903"
143,"NCT03352713","Using Mobile Technology to Better Understand and Measure Self-Regulation",,"Completed","Has Results","Self-regulation|Binge Eating|Smoking","Behavioral: Laddr","12-item Momentary Self-regulation Questionnaire|Binge Eating Episodes [Binge Eating Sample Only]|Smoking Episodes [Smoking Sample Only]","Dartmouth-Hitchcock Medical Center|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA)|University of Memphis|Ohio State University","All","21 Years to 50 Years   (Adult)","Not Applicable","185","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","5UH2DA041713-03 D18029|UH2DA041713","January 11, 2018","November 29, 2018","December 3, 2018","November 24, 2017","January 10, 2020","January 10, 2020","Center for Technology and Behavioral Health, Dartmouth College, Lebanon, New Hampshire, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT03352713/Prot_SAP_002.pdf","https://ClinicalTrials.gov/show/NCT03352713"
144,"NCT03351699","Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)",,"Completed","Has Results","HIV-1 Infection","Drug: MK-4250","Change From Baseline in Plasma HIV-1 RNA Copies Per mL at 168 Hours|Percentage of Participants Experiencing ≥1 Adverse Events (AE)|Percentage of Participants Who Discontinued Study Due to an Adverse Event (AE)|Area Under the Concentration-Time Curve From 0 to Last Measurable Concentration (AUC0-last) for MK-4250|Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) for MK-4250|Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) for MK-4250|Maximum Concentration (Cmax) of MK-4250 Reached in Plasma|Concentration of MK-4250 at 168 Hours (C168hr)|Apparent Terminal Half-life (t1/2) of MK-4250|Apparent Clearance (CL/F) of MK-4250|Apparent Volume of Distribution (Vz/F) of MK-4250|Time to Maximum Concentration (Tmax) of MK-4250 Reached in Plasma","Merck Sharp & Dohme Corp.","All","18 Years to 60 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4250-002|2017-001784-21","January 18, 2018","November 2, 2018","November 2, 2018","November 24, 2017","October 30, 2019","October 30, 2019","Charite Research Organisation GmbH ( Site 0001), Berlin, Germany","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03351699/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03351699"
145,"NCT03348683","Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients",,"Completed","Has Results","Induction of Labor Affected Fetus / Newborn","Drug: Propranolol|Drug: Placebo","Time From Beginning of Induction to Delivery|Number of Participants With Various Mode of Delivery|Duration of Latent|Number of Participants With Maternal Morbidity Composite Score = 1|Number of Participants With Postpartum Hemorrhage|Number of Fetus With Heart Rate Decelerations|Number of Fetus With Fetal Bradycardia|Number of Neonates With Neonatal Outcome Composite Score = 1|Number of Neonates With Hypoglycemia","Icahn School of Medicine at Mount Sinai","Female","18 Years to 50 Years   (Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GCO 17-1441","December 11, 2017","December 11, 2018","December 11, 2018","November 21, 2017","December 26, 2019","January 7, 2020","Icahn School of Medicine at Mount Sinai, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03348683/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03348683"
146,"NCT03343067","A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain",,"Terminated","Has Results","Endometriosis","Drug: elagolix|Drug: estradiol/norethindrone acetate (E2/NETA)","Proportion of Responders at Month 6 Based on DYS Pain Scale|Proportion of Responders at Month 6 Based on NMPP Pain Scale|Change From Baseline in DYS at Month 6|Change From Baseline in NMPP at Month 6|Change From Baseline in Dyspareunia at Month 6|Change From Baseline in Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS) at Month 6|Change From Baseline in Rescue Analgesic Use Across Both Classes of Rescue Analgesics (NSAIDs/Opioids) at Month 6|Percentage of Participants With 30% or More Reduction From Baseline Based on the 35 Day Mean of the Daily Diary Endometriosis-Associated Pain Score Via NRS at Month 6|Proportion of Responders Over Time|Proportion of Responders Over Time (Not Taking Into Consideration of Analgesic Use)|Change From Baseline Over Time in Monthly Average DYS Pain Score|Change From Baseline Over Time in Monthly Average NMPP Pain Score|Change From Baseline Over Time in Monthly Average Dyspareunia Pain Score|Change From Baseline Over Time in Monthly Average Daily Diary Endometriosis-Associated Pain Score Via NRS|Percent Change From Baseline to Each Month During the Treatment Period for DYS|Percent Change From Baseline to Each Month During the Treatment Period for NMPP|Percent Change From Baseline to Each Month During the Treatment Period for Dyspareunia|Percent Change From Baseline to Each Month During the Treatment Period for Daily Diary Endometriosis-Associated Pain Score Via NRS|Change From Baseline Over Time in Daily Rescue Analgesic Use Across Both Classes of Rescue Analgesics|Number of Analgesic Use Responders and Non-Responders Over Time|Patient Global Impression of Change (PGIC) Scores Over Time|Overall Endometriosis-Associated Pain Via NRS (7-Day Recall) Scores Over Time|Endometriosis Health Profile-30 (EHP-30) Scores Over Time: Pain|EHP-30 Scores Over Time: Control and Powerlessness|EHP-30 Scores Over Time: Emotional Well-Being|EHP-30 Scores Over Time: Social Support|EHP-30 Scores Over Time: Self-Image|EHP-30 Scores Over Time: Sexual Intercourse|EuroQol-5D 5 Level (EQ-5D-5L) Scores Over Time: Mobility|EQ-5D-5L Scores Over Time: Self-Care|EQ-5D-5L Scores Over Time: Usual Activities|EQ-5D-5L Scores Over Time: Pain/Discomfort|EQ-5D-5L Scores Over Time: Anxiety/Depression|EQ-5D-5L VAS Scores Over Time: Health Today|Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) Scores Over Time: Percent Work Missed Due to Problem|WPAI:SHP Scores Over Time: Percent Impairment While Working Due to Problem|WPAI:SHP Scores Over Time: Percent Overall Work Impairment Due to Problem|WPAI:SHP Scores Over Time: Percent Activity Impairment Due to Problem|Health Endometriosis Treatment Satisfaction Questionnaire (ETSQ) Scores Over Time|PROMIS Fatigue Short Form 6a Scores Over Time","AbbVie","Female","18 Years to 49 Years   (Adult)","Phase 3","11","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-383","December 27, 2017","October 23, 2018","October 23, 2018","November 17, 2017","November 27, 2019","November 27, 2019","Pinnacle Research Group /ID# 202016, Anniston, Alabama, United States|Noble Clinical Research /ID# 170628, Tucson, Arizona, United States|Lynn Institute of the Ozarks /ID# 165052, Little Rock, Arkansas, United States|SC Clinical Research /ID# 165049, Garden Grove, California, United States|Marvel Clinical Research /ID# 169633, Huntington Beach, California, United States|Health care Affiliates Medical Group /ID# 165048, Santa Ana, California, United States|Western States Clinical Res /ID# 169809, Wheat Ridge, Colorado, United States|Nova Clinical Research, LLC /ID# 202227, Bradenton, Florida, United States|Midland Florida Clinical Research Center /ID# 201327, DeLand, Florida, United States|Southeastern Integrated Med /ID# 203109, Gainesville, Florida, United States|Care Partners Clinical Researc /ID# 168395, Jacksonville, Florida, United States|LCC Medical Research Institute /ID# 168888, Miami, Florida, United States|A Premier Clinical Research of Florida, LLC /ID# 201887, Orange City, Florida, United States|GCP Clinical Research, LLC /ID# 169774, Tampa, Florida, United States|Triple O Research Institute /ID# 201128, West Palm Beach, Florida, United States|Bingham Memorial Hospital /ID# 170110, Blackfoot, Idaho, United States|Leavitt Womens Healthcare /ID# 169495, Idaho Falls, Idaho, United States|Quad Clinical Research, LLC /ID# 168294, Chicago, Illinois, United States|Quad Clinical Research, LLC /ID# 170629, Chicago, Illinois, United States|Women's Health Care, PC /ID# 165033, Newburgh, Indiana, United States|Delricht Research /ID# 200219, New Orleans, Louisiana, United States|Quad Clinical Research, LLC /ID# 200180, Saint Louis, Missouri, United States|Montana Health Research Inst /ID# 170624, Billings, Montana, United States|Excel Clinical Research /ID# 170620, Las Vegas, Nevada, United States|Northwell health system /ID# 200162, Manhasset, New York, United States|Radiant Research, Inc /ID# 200045, Akron, Ohio, United States|Central Ohio Clinical Research /ID# 170750, Columbus, Ohio, United States|Optimed Research /ID# 167642, Columbus, Ohio, United States|VitaLink Research /ID# 168401, Greenville, South Carolina, United States|VitaLink Research /ID# 170625, Greenville, South Carolina, United States|Fusion Clinical Research of Spartanburg /ID# 200010, Spartanburg, South Carolina, United States|Centex Studies, Inc /ID# 169897, Houston, Texas, United States|America's Adv. Wellness Center /ID# 170005, Houston, Texas, United States|ClinRx Research, LLC /ID# 201189, Plano, Texas, United States|Progressive Clinical Research /ID# 205565, San Antonio, Texas, United States|Eastern Virginia Med School /ID# 165016, Norfolk, Virginia, United States|Seattle Reproductive Medicine /ID# 171079, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03343067/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03343067"
147,"NCT03339453","A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus",,"Completed","Has Results","Hypoglycemia|Diabetes Mellitus, Type 1","Drug: Nasal Glucagon|Drug: Intramuscular Glucagon","Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia|Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax)|PD: Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Tlast (AUC[0-tlast]) of Baseline Adjusted Glucagon|PK: Maximum Change From Baseline Concentration (Cmax) of Glucagon|PK: Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon","Eli Lilly and Company","All","18 Years to 64 Years   (Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16547|I8R-MC-IGBI|2017-000249-33","November 10, 2017","December 17, 2017","January 13, 2018","November 13, 2017","September 23, 2019","September 23, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03339453/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03339453/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03339453"
148,"NCT03338556","A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16",,"Completed","Has Results","Viral Upper Respiratory Tract Infection","Drug: PrEP-001|Other: Placebo","Total Symptom Scores|Area Under Curve of Symptom Scores|Incidence(s) of Laboratory Confirmed Illness","Prep Biopharm Limited|Hvivo",,"18 Years to 55 Years   (Adult)","Phase 2","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PrEP-CS-003","April 6, 2016","September 30, 2016","September 30, 2016","November 9, 2017","June 27, 2018","November 9, 2018","hVIVO Services Limited, QMB Innovation Centre, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03338556"
149,"NCT03336853","A New Approach for Controlling Hemostasis During Canal Treatment",,"Completed","Has Results","Blood Contamination of Root Canal During Endodontic Therapy","Device: HybenX|Other: Placebo control","Change From Baseline in Root Canal Bleeding","Dr Riccardo Pace|Azienda Ospedaliero-Universitaria Careggi","All","20 Years to 60 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","endo 2-2017","April 1, 2017","July 21, 2017","December 22, 2017","November 8, 2017","March 13, 2019","March 26, 2019","AOUCareggi, Firenze, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03336853/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03336853"
150,"NCT03330275","Evaluating the Impact of JJVC Senofilcon A - Based Contact Lens With New UV-blocker on Day and Night Driving Performance",,"Completed","Has Results","Visual Performance","Device: Investigational Contact Lens|Device: Commercial ACUVUE OASYS|Device: Commercial ACUVUE OASYS and Spectacles","Overall Nighttime Driving Score|Binocular Visual Acuity|Binocular Contrast Threshold Without Glare|Percentage of Road Signs Correctly Identified During Night Driving|Average Distance to Correctly Identify Road Signs During Night Driving|Percentage of Hazards Avoided During Night Driving|Average Pedestrian Recognition Distance","Johnson & Johnson Vision Care, Inc.","All","20 Years to 49 Years   (Adult)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-5830","September 27, 2017","December 11, 2017","December 11, 2017","November 6, 2017","August 7, 2018","August 7, 2018","Queensland University of Technology, School of Optometry and Vision Science, Brisbane, Queensland, Australia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03330275/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03330275/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03330275"
151,"NCT03329573","Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects",,"Completed","Has Results","Anxiety Disorders","Drug: Paroxetine IR tablets A|Drug: Paroxetine IR tablets B","Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fed Condition|AUC(0-infinity) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fasting Condition|Area Under the Concentration-time Curve From Administration Extrapolated to the Last Time of Quantifiable Concentration (AUC[0-t]) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fed Condition|AUC(0-t) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fasting Condition|Maximum Observed Concentration (Cmax) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fed Condition|Cmax of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fasting Condition|Time to Reach Maximum Observed Concentration (Tmax) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fed Condition|Tmax of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fasting Condition|Terminal Elimination Rate Constant (Lambda z) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fed Condition|Lambda z of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fasting Condition|Terminal Elimination Half-life (t1/2) of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fed Condition|t1/2 of Paroxetine Following Single Oral Dose in Healthy Chinese Participants Under Fasting Condition|Number of Participants With Non-serious Adverse Events and Serious Adverse Events (SAEs) Under Fed Condition|Number of Participants With Non-SAE and SAEs Under Fasting Condition|Number of Participants With Chemistry Laboratory Values Relative to Potential Clinical Importance (PCI) Criteria on Day 16 Under Fed Condition|Number of Participants With Chemistry Laboratory Values Relative to PCI Criteria on Day 16 Under Fasting Condition|Number of Participants With Hematology Laboratory Values Relative to PCI Criteria on Day 16 Under Fed Condition|Number of Participants With Hematology Laboratory Values Relative to PCI Criteria on Day 16 Under Fasting Condition|Number of Participants With Urinalysis Results by Dipstick Method Under Fed Condition|Number of Participants With Urinalysis Results by Dipstick Method Under Fasting Condition|Number of Participants With Clinically Significant Abnormal Findings for Electrocardiogram (ECG) Parameters Under Fed Condition|Number of Participants With Clinically Significant Abnormal Findings for ECG Parameters Under Fasting Condition|Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) at Indicated Time-points Under Fed Condition|DBP and SBP at Indicated Time-points Under Fasting Condition|Pulse Rate (PR) at Indicated Time-points Under Fed Condition|Pulse Rate (PR) at Indicated Time-points Under Fasting Condition|Respiratory Rate (RR) at Indicated Time-point Under Fed Condition|RR at Indicated Time-point Under Fasting Condition|Temperature at Indicated Time-point Under Fed Condition|Temperature at Indicated Time-point Under Fasting Condition","GlaxoSmithKline","All","18 Years to 45 Years   (Adult)","Phase 1","85","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","207652","May 30, 2018","August 3, 2018","August 3, 2018","November 6, 2017","August 19, 2019","August 19, 2019","GSK Investigational Site, Shanghai, China","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03329573/SAP_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03329573/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT03329573"
152,"NCT03329209","A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants",,"Completed","Has Results","Colitis, Ulcerative|Crohn Disease","Drug: Vedolizumab","Cmax: Maximum Observed Serum Concentration for Vedolizumab|AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab|AUC∞: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for Vedolizumab|Percentage of Participants With Positive Anti-vedolizumab Antibody (AVA)|Percentage of Participants With Positive Neutralizing AVA","Takeda","All","18 Years to 45 Years   (Adult)","Phase 1","16","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Vedolizumab-1014|U1111-1197-3577","March 5, 2018","July 26, 2018","September 5, 2018","November 1, 2017","September 6, 2019","September 6, 2019","Peking University First Hospital, Beijing, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03329209/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03329209/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03329209"
153,"NCT03326986","Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)",,"Completed","Has Results","Pharmacokinetics|Cancer","Drug: MK-7252|Drug: Placebo","Number of Participants Who Experienced at Least One Adverse Event (AE)|Number of Participants Who Discontinued Study Treatment Due to an AE|MK-7252 Area Under the Concentration-Time Curve From Zero to Infinity (AUC0-∞)|MK-7252 Area Under the Concentration-Time Curve From Zero to 24 Hours Postdose (AUC0-24hr)|MK-7252 Area Under the Concentration-Time Curve From Zero to 12 Hours Postdose (AUC0-12hr)|MK-7252 Area Under the Concentration-Time Curve From Zero to Last Measurable Concentration (AUClast)|MK-7252 Maximal Plasma Concentration (Cmax)|MK-7252 Plasma Concentration at 12 Hours Postdose (C12hr)|MK-7252 Plasma Concentration at 24 Hours Postdose (C24hr)|MK-7252 Time to Reach Maximal Concentration (Tmax)|MK-7252 Apparent Terminal Half-life (t½)|Change From Baseline in Systolic Blood Pressure (SBP) at 4 Hours|Change From Baseline in Systolic Blood Pressure (SBP) at 24 Hours|Change From Baseline in Diastolic Blood Pressure (DBP) at 4 Hours|Change From Baseline in Diastolic Blood Pressure (DBP) at 24 Hours|Change From Baseline in Heart Rate (HR) at 4 Hours|Change From Baseline in Heart Rate (HR) at 24 Hours","Merck Sharp & Dohme Corp.","All","18 Years to 50 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","7252-001|2017-003407-22|MK-7252-001","November 10, 2017","December 17, 2018","December 17, 2018","October 31, 2017","January 9, 2020","January 9, 2020","Universitair Ziekenhuis Gent ( Site 0001), Gent, Belgium","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03326986/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03326986"
154,"NCT03323086","Women SHARE Study: Reducing Sexual Risk","HIV","Completed","Has Results","Alcohol and Substance-Related Mental Disorders|Sexually Transmitted Diseases","Behavioral: Brief Intervention (BI) with Technology Extender|Other: Brochure","Feasibility of Providing Intervention|Session Evaluation Questionnaire|Number of Sexual Partners|Condomless Sex|Alcohol Use Quantity|Alcohol Use Binge Frequency","The Miriam Hospital|Planned Parenthood of Southern New England|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","Female","18 Years to 29 Years   (Adult)","Not Applicable","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","775844-4|R34AA023158","October 18, 2017","June 30, 2019","November 1, 2019","October 26, 2017","January 2, 2020","January 7, 2020","Planned Parenthood of Southern New England, Providence, Rhode Island, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03323086/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03323086/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03323086/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03323086"
155,"NCT03319212","Clinical Characterization of Symptomatic Populations",,"Completed","Has Results","Ametropia","Device: senofilcon A contact lenses","Meibomian Gland Imaging|Meibomian Gland Expressibility|Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings|Lid Wiper Epitheliopathy|Conjunctival Folds|Conjunctival Redness|Conjunctival Staining|Corneal Staining|Tear Film Lipid Layer Thickness|Tear Film Stability|Tear Film Lipid Pattern","Johnson & Johnson Vision Care, Inc.","All","18 Years to 55 Years   (Adult)","Not Applicable","105","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-5969","September 29, 2017","August 15, 2018","August 15, 2018","October 24, 2017","October 15, 2019","October 15, 2019","VRC-East, Jacksonville, Florida, United States|University of Waterloo Center for Contact Lens Research, Waterloo, Ontario, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03319212/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03319212"
156,"NCT03316976","A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) and 60 mg Delayed-release Capsules in Healthy Chinese Participants",,"Completed","Has Results","Healthy Volunteers","Drug: Dexlansoprazole","Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole|AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Dexlansoprazole|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Dexlansoprazole","Takeda","All","18 Years to 45 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-390MR_106|U1111-1192-7711|CTR20160792","November 22, 2017","February 8, 2018","February 8, 2018","October 23, 2017","May 10, 2019","May 10, 2019","Phase I Clinical Trial Department, Beijing, Beijing, China","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03316976/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03316976/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03316976"
157,"NCT03315559","Absorption & Elimination of Radiolabelled GSK2269557",,"Completed","Has Results","Pulmonary Disease, Chronic Obstructive","Drug: [14C]-GSK2269557 IV infusion|Drug: GSK2269557 via DPI|Drug: [14C]-GSK2269557 oral solution","Area Under Concentration-time Curve (AUC) From Time 0 (Pre-dose) to Infinite Time (0 to Inf) and AUC From Time 0 (Pre-dose) to Last Time of Quantifiable Concentration (0 to t) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1|AUC From Time Zero (Pre-dose) Extrapolated to Infinite Time (0 to Inf) and AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (0 to t) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2|Maximum Observed Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1|Cmax of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2|Time of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1|Tmax of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2|Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 1|Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma for Treatment Period 2|Urinary and Faecal Cumulative Excretion as a Percentage of the Total Radioactive Dose Administered Over Time for Treatment Period 1|Urinary and Fecal Cumulative Excretion as a Percentage of the Total Radioactive Dose Administered Over Time for Treatment Period 2|AUC (0 to Inf) and AUC (0 to t) of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1|AUC (0 to Inf) and AUC (0 to t) of [14C]-GSK2269557 in Plasma for Treatment Period 2|Cmax of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1|Cmax of [14C]-GSK2269557 in Plasma for Treatment Period 2|Tmax of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1|Tmax of [14C]-GSK2269557 in Plasma for Treatment Period 2|t1/2 of Parent GSK2269557 and [14C]-GSK2269557 in Plasma for Treatment Period 1|t1/2 of [14C]-GSK2269557 in Plasma for Treatment Period 2|Volume of Distribution of Parent [14C]-GSK2269557 After IV Dose Only in Plasma|Clearance of Parent [14C]-GSK2269557 After IV Dose Only in Plasma|Inhaled Absolute Bioavailability (F) for Treatment Period 1|Oral Absolute Bioavailability (F) for Treatment Period 2|Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)|Number of Participants With Hematology Parameters of Potential Clinical Concern|Number of Participants With Clinical Chemistry Parameters of Potential Clinical Concern|Number of Participants With Clinically Significant Urinalysis Findings|Number of Participants With Electrocardiogram Findings of Clinical Significance|Number of Participants With Vital Signs of Potential Clinical Concern","GlaxoSmithKline","Male","30 Years to 55 Years   (Adult)","Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","206764|2017-002347-16","November 14, 2017","December 22, 2017","December 22, 2017","October 20, 2017","March 20, 2019","March 20, 2019","GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03315559/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03315559/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03315559"
158,"NCT03313037","Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age",,"Completed","Has Results","Pneumococcal Infections","Biological: Multivalent|Biological: Prevnar 13|Biological: PPSV23|Other: Saline","Percentage of Participants With Local Reactions Within 10 Days After Vaccination 1|Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1|Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination 1|Percentage of Participants With Serious Adverse Events (SAEs) or Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination 1|Percentage of Participants With Serious Adverse Events (SAEs) or Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 12 Months After Vaccination 1|Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titres (GMTs) 1 Month After Vaccination 1: 13 Common Serotypes in 13vPnC|Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titres (GMTs) 1 Month After Any Vaccination: 7 Additional Serotypes in 20vPnC|Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From Pre-Vaccination 1 to 1 Month Post-Vaccination 1: 13 Common Serotypes in 13vPnC|Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From Pre-Vaccination 1 to 1 Month Post Any Vaccination: 7 Additional Serotypes in 20vPnC","Pfizer","All","60 Years to 64 Years   (Adult)","Phase 2","444","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","B7471002","October 10, 2017","December 10, 2018","December 10, 2018","October 18, 2017","December 26, 2019","December 26, 2019","Anaheim Clinical Trials, LLC, Anaheim, California, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Qps-Mra, Llc, South Miami, Florida, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Medical Research South, LLC, Charleston, South Carolina, United States|Benchmark Research, Austin, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|J. Lewis Research Inc. / Foothill Family Clinic Draper, Draper, Utah, United States|J. Lewis Research, Inc. - Jordan River Family Medicine, South Jordan, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03313037/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03313037/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03313037"
159,"NCT03312517","Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs",,"Completed","Has Results","Insomnia","Drug: Suvorexant 10 mg|Drug: Suvorexant 20 mg|Drug: Placebo oral capsule","Auditory Awakening Threshold","Henry Ford Health System","All","18 Years to 64 Years   (Adult)","Phase 4","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MISP 57338","April 15, 2018","October 25, 2018","October 25, 2018","October 17, 2017","November 1, 2019","November 1, 2019","Henry Ford Medical Center - Columbus, Novi, Michigan, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT03312517/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT03312517/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03312517"
160,"NCT03307252","This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men",,"Completed","Has Results","Healthy","Drug: Digoxin|Drug: Furosemide|Drug: Metformin|Drug: Rosuvastatin|Drug: Verapamil|Drug: Rifampin|Drug: Cimetidine|Drug: Probenecid","Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Verapamil + R1 (T1) vs. R1)|Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Rifampin + R1 (T2) vs. R1)|Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Cimetidine + R1 (T3) vs. R1)|Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Probenecid + R1 (T4) vs. R1)|Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T1 vs. R1)|Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T2 vs. R1)|Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T3 vs. R1)|Maximum Measured Concentration of the Analytes: Digoxin, Furosemide, Metformin, and Rosuvastatin (Cmax) (T4 vs. R1)|Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T1 vs. R1)|Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T2 vs. R1)|Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T3 vs. R1)|Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) (T4 vs. R1)","Boehringer Ingelheim","Male","18 Years to 55 Years   (Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","0352-2100|2017-001549-29","October 25, 2017","May 2, 2018","May 2, 2018","October 11, 2017","July 12, 2019","July 12, 2019","CTC North GmbH & Co. KG, Hamburg, Hamburg, Germany","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03307252/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03307252/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03307252"
161,"NCT03306589","Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects",,"Completed","Has Results","Arthritis, Rheumatoid","Biological: Cantharidin|Biological: Lipopolysaccharide|Biological: Granulocyte-Macrophage Colony-Stimulating Factor|Drug: Saline Solution","Part 1: Change From Baseline Primary Soluble Inflammatory Mediators in Blood: Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL) 6 for LPS Arm|Part 1: Change From Baseline in Primary Soluble Inflammatory Mediators : Urinary Tetranor Prostaglandin D Metabolite (PGDM) LPS Arm|Part 2: Change From Baseline Primary Soluble Inflammatory Mediators in Blood: TNF Alpha and IL 6: LPS Arm|Part 2: Change From Baseline Primary Soluble Inflammatory Mediators : Urinary Tetranor PGDM: LPS Arm|Part 1: Change From Baseline in White Blood Cell Numbers in Blood: GM-CSF|Part 2: Change From Baseline in White Blood Cell Numbers in Blood: GM-CSF|Part 1: Change From Baseline Soluble Inflammatory Biomarkers in Skin Blister|Part 2: Change From Baseline Soluble Inflammatory Biomarkers in Skin Blister|Part 1: Absolute Values of Blister Volume|Part 2: Absolute Values of Blister Volume|Part 1: Change From Baseline in Cell Numbers in Blister|Part 2: Change From Baseline in Cell Numbers in Blister|Part 1:Change From Baseline in Cell Activation Markers by Flow Cytometry on Monocytes in Blister|Part 2:Change From Baseline in Cell Activation Markers by Flow Cytometry on Monocytes in Blister|Part 1:Change From Baseline of CD40+/CD80+ by Flow Cytometry on Monocytes in Blister|Part 2:Change From Baseline of CD40+/CD80+ by Flow Cytometry on Monocytes in Blister|Part 1:Change From Baseline in Cell Activation Markers by Flow Cytometry on Dendritic Cells in Blister|Part 2:Change From Baseline in Cell Activation Markers by Flow Cytometry on Dendritic Cells in Blister|Part 1:Change From Baseline of CD40+/CD80+ by Flow Cytometry on Dendritic Cells in Blister|Part 2:Change From Baseline of CD40+/CD80+ by Flow Cytometry on Dendritic Cells in Blister|Part 1:Change From Baseline in Cell Activation Markers by Flow Cytometry on Macrophages in Blister|Part 2:Change From Baseline in Cell Activation Markers by Flow Cytometry on Macrophages in Blister|Part 1:Change From Baseline of CD40+/CD80+ by Flow Cytometry on Macrophages in Blister|Part 2:Change From Baseline of CD40+/CD80+ by Flow Cytometry on Macrophages in Blister|Part 1:Change From Baseline in Soluble Inflammatory Mediators in Blood|Part 2:Change From Baseline in Soluble Inflammatory Mediators in Blood|Part 1: Change From Baseline in Soluble Inflammatory Mediators in Blood: TNF-alpha, IL-6 and GM-CSF: GM-CSF Arm|Part 2: Change From Baseline in Soluble Inflammatory Mediators in Blood: TNF-alpha, IL-6 and GM-CSF for GM-CSF Arm|Part 1: Change From Baseline in Soluble Inflammatory Mediators in Blood: C-reactive Protein (CRP)|Part 2: Change From Baseline in Soluble Inflammatory Mediators in Blood: CRP|Part 1: Change From Baseline in Cell Activation Markers by Flow Cytometry on Monocytes in Blood|Part 2: Change From Baseline in Cell Activation Markers by Flow Cytometry on Monocytes in Blood|Part 1: Change From Baseline in Cell Activation Markers by Flow Cytometry on Dendritic Cells in Blood|Part 2: Change From Baseline in Cell Activation Markers by Flow Cytometry on Dendritic Cells in Blood|Part 1: Change From Baseline in Circulating Leukocyte Numbers in Blood: LPS Arm|Part 2: Change From Baseline in Circulating Leukocyte Numbers in Blood: LPS Arm","GlaxoSmithKline","Male","18 Years to 45 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","207654","August 11, 2017","January 3, 2018","June 20, 2018","October 11, 2017","August 8, 2019","August 8, 2019","GSK Investigational Site, Cambridge, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03306589/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03306589/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03306589"
162,"NCT03301298","Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: SXC-2023|Drug: Placebo oral capsule","Number of Subjects Experiencing TEAEs.|Pharmacokinetic Assessments: Cmax|Pharmacokinetics Assessments: Tmax|Pharmacokinetic Assessments: AUC|Pharmacokinetic: Food Effect, AUC|Pharmacokinetic: Food Effect, CMax","Promentis Pharmaceuticals, Inc.|Celerion","All","18 Years to 55 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRO-101","September 11, 2017","February 13, 2018","February 13, 2018","October 4, 2017","September 26, 2019","September 26, 2019","Celerion, Tempe, Arizona, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT03301298/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT03301298/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03301298"
163,"NCT03292692","Empirically-Based Couple Interventions on the Web: Serving the Underserved",,"Completed","Has Results","Relationship, Marital|Marital Conflict","Behavioral: OurRelationship","Relationship Satisfaction|Relationship Confidence|Depressive Symptoms|Anxiety Symptoms","University of Miami|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of California, Los Angeles|University of Washington","All","21 Years to 64 Years   (Adult)","Not Applicable","600","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120378|R01HD059802","August 13, 2013","October 18, 2014","October 18, 2014","September 25, 2017","February 12, 2018","February 12, 2018",,,"https://ClinicalTrials.gov/show/NCT03292692"
164,"NCT03286218","A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users",,"Completed","Has Results","Recreational Drug Use|Prescription Drug Abuse (Not Dependent)","Drug: Lasmiditan|Drug: Alprazolam|Drug: Placebo","Pharmacodynamics (PD): Maximal Effect Score (Emax) of Bipolar Drug Liking Visual Analog Scale (VAS) Scores|Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan|PK: Area Under the Curve of Lasmiditan From Zero to Infinity (AUC[0-∞])|PD: Maximal Drug Effects (Emax) Visual Analog Scale (VAS)|PD: Maximal Drug Effects (Emax) VAS (Hallucinations)|PD: Minimum Drug Effects (Emin) Visual Analog Scale (VAS)|PD: Mean Scores on Drug Similarity VAS Measures","Eli Lilly and Company","All","18 Years to 55 Years   (Adult)","Phase 1","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","16853|H8H-MC-LAHB","September 15, 2017","November 20, 2017","November 20, 2017","September 18, 2017","January 10, 2020","January 10, 2020","Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03286218/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03286218/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03286218"
165,"NCT03283319","Panblok H7 Vaccine Adjuvanted With AS03 or MF59",,"Completed","Has Results","Influenza, Human","Biological: 3.75 ug Panblok H7|Biological: 7.5 ug Panblok H7|Biological: 15 ug Panblok H7|Biological: MF59|Biological: AS03","Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant AS03|Solicited Systemic Reactogenicity Symptoms for Participants Given Adjuvant AS03|Solicited Local Reactogenicity Symptoms for Participants Given Adjuvant MF59|Solicited Systemic Reactogenicity Symptoms for Participants Given Adjuvant MF59|Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03|Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59|Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03|Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59|Treatment-emergent Serious Adverse Events (SAEs) for Participants Given Adjuvant AS03|Treatment-emergent Serious Adverse Events (SAEs) for Participants Given Adjuvant MF59|Treatment-emergent Medically Attended Adverse Events (MAAEs) for Participants Given Adjuvant AS03|Treatment-emergent Medically Attended Adverse Events (MAAEs) for Participants Given Adjuvant MF59|Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs) for Participants Given Adjuvant AS03|Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs) for Participants Given Adjuvant MF59|Treatment-emergent Unsolicited Adverse Events for Participants Given Adjuvant AS03|Treatment-emergent Unsolicited Adverse Events for Participants Given Adjuvant MF59|Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03|Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03|Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59|Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03|Serum Hemagglutination-inhibition (HAI) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59|Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03|Seroprotection Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59|Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant AS03|Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59|Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03|Seroconversion Based on Serum Hemagglutination-inhibition (HAI) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59|Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Guangdong Strain for Participants Given Adjuvant MF59|Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant AS03|Seroconversion Based on Serum Microneutralization (MN) Antibody Titers Against Hong Kong Strain for Participants Given Adjuvant MF59|Serum Microneutralization (MN) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant AS03|Serum Microneutralization (MN) Antibody Titers Against the Guangdong Strain for Participants Given Adjuvant MF59|Serum Microneutralization (MN) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant AS03|Serum Microneutralization (MN) Antibody Titers Against the Hong Kong Strain for Participants Given Adjuvant MF59","Biomedical Advanced Research and Development Authority|Rho, Inc.","All","18 Years to 49 Years   (Adult)","Phase 2","366","U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","BP-I-17-002|HHSO100201400004I|TO# HHSO10033001T","September 20, 2017","December 15, 2017","November 9, 2018","September 14, 2017","September 25, 2019","December 5, 2019","Johnson County Clin-Trials, Lenexa, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Central Kentucky Research Associates, Inc., Lexington, Kentucky, United States|Rochester Clinical Research, Inc, Rochester, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03283319/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03283319/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03283319"
166,"NCT03271424","Innovations in HIV Testing (TI)",,"Completed","Has Results","Human Immunodeficiency Virus","Diagnostic Test: Oraquick HIV Self Test - Choice|Diagnostic Test: Atomo HIV Self Test - Choice|Diagnostic Test: Oraquick HIV Self Test and Atomo HIV Self Test - Both","Qualitative Summaries of Participant Experience in Focus Group Discussions|Quantitative Summaries of Participants Experience in Observation Sessions","University of North Carolina, Chapel Hill|University of Witwatersrand, South Africa|University of California, San Francisco|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","18 Years to 24 Years   (Adult)","Not Applicable","95","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","15-1361a|5R01HD083033","October 1, 2015","June 1, 2016","June 1, 2016","September 5, 2017","January 19, 2018","January 19, 2018","Medical Research Council/Wits University Rural Public Health and Health Transitions Research Unit, Agincourt, Mpumalanga, South Africa",,"https://ClinicalTrials.gov/show/NCT03271424"
167,"NCT03268590","Neuroimaging During Pure Oxygen Breathing",,"Completed","Has Results","Hyperoxia|Hypoxia, Brain|Neurobehavioral Manifestations","Drug: Oxygen","Cerebral Blood Flow|Cortical Network Activity|Cognitive Performance","Case Western Reserve University","All","18 Years to 60 Years   (Adult)","Phase 4","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CON215044|FA8650-12-D6280 TO0052","October 2, 2017","May 2, 2018","May 9, 2018","August 31, 2017","November 13, 2019","November 13, 2019","Case Western Reserve University, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT03268590/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03268590"
168,"NCT03268343","A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine",,"Completed","Has Results","Smoking Cessation","Drug: Cytisine","Plasma Cytisine Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax)|Plasma Cytisine PK: Total Area Under the Curve From Time Zero to Infinity (AUC0-∞)|Plasma Cytisine PK: Time of Occurrence of Cmax (Tmax)|Plasma Cytisine PK: AUC From Time Zero to the Last Sampling Time (AUC0-t)|Plasma Cytisine PK: Residual Area, or Percentage of Extrapolated Part for the Calculation of AUC0-∞ (AUC%)|Plasma Cytisine PK: Apparent Terminal Elimination Rate Constant (Lambda z)|Plasma Cytisine PK: Apparent Terminal Elimination Half-Life (t1/2)|Urine Cytisine PK: Amount Excreted in Urine Over Time (Ae)|Urine Cytisine PK: Percentage of Drug Excreted in Urine (Ae%)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuation of Study Drug Due to AEs, by Severity and Relationship","Achieve Life Sciences","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACH-CYT-01|2017-001562-19","August 8, 2017","August 26, 2017","September 1, 2017","August 31, 2017","February 7, 2019","February 26, 2019","Simbec Research Ltd, Merthyr Tydfil, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03268343/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03268343/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03268343"
169,"NCT03267576","An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin","COMETA","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Canagliflozin 300 mg|Drug: Sitagliptin 100 mg|Drug: Metformin","Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 1|Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 2|Change From Baseline in Glycemic Standard Deviation (SD) for 24-hour Glucose Profile|Change From Baseline in Mean 24-hour Glucose Profile|Change From Baseline in Fasting Plasma Glucose Levels|Change From Baseline in 2-hour Post-prandial Glucose (PPG) Levels|Percent Change From Baseline in Time During 24 Hours With Glucose 70 to 139 mg/dL|Percent Change From Baseline in Time During 24 Hours With Glucose Greater Than (>) 140 mg/dL|Percent Change From Baseline in Time During 24 Hours With Glucose Level > 180 mg/dL|Percent Change From Baseline in Time During 24 Hours With Glucose Level Less Than (<) 70 mg/dL|Change From Baseline in Time Spent With Glucose Level 70 to 139 mg/dL|Change From Baseline in Time Spent With Glucose Level > 140 mg/dL|Change From Baseline in Time Spent With Glucose Level > 180 mg/dL|Change From Baseline in Time Spent With Glucose Level < 70 mg/dL|Change From Baseline in Percentage of 2 Consecutive Glucose Readings With < 70 mg/dL","Janssen Research & Development, LLC","All","19 Years to 54 Years   (Adult)","Phase 4","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108346|28431754DIA4026","October 27, 2017","October 1, 2018","October 1, 2018","August 30, 2017","November 29, 2019","November 29, 2019","Consultorio Privado, Guadalajara, Mexico|Investigación Clínica Especializada, Guadalajara, Mexico|Consultorio Privado en Unidad de Patología Clínica, Guadalajara, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico|Hospital Universitario 'Dr. Jose Eleuterio Gonzalez', Monterrey, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03267576/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03267576/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03267576"
170,"NCT03262233","Stress Neuroadaptation in Tobacco Dependence",,"Completed","Has Results","Nicotine Dependence","Combination Product: nicotine|Other: placebo","Overall Stressor Reactivity|Relative Unpredictable Stressor Reactivity|Change in Overall Stressor Reactivity|Change in Relative Unpredictable Stressor Reactivity","University of Wisconsin, Madison","All","18 Years to 60 Years   (Adult)","Phase 4","226","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","2017-0433","April 1, 2015","February 20, 2018","February 20, 2018","August 25, 2017","April 23, 2019","April 23, 2019","University of Wisconsin, Madison, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03262233/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03262233"
171,"NCT03260595","A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis",,"Completed","Has Results","Healthy|Atopic Dermatitis","Drug: Crisaborole ointment 2%|Drug: Vehicle","Cohort 1: Skin Irritation Index|Cohort 2: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)|Cohort 2: Number of Participants With Clinically Significant Vital Signs Abnormalities|Cohort 2: Number of Participants With Laboratory Tests Abnormalities|Cohort 2: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities|Cohort 1: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)|Cohort 2: Maximum Observed Plasma Concentration (Cmax) of Crisaborole and Its Identified Main Oxidative Metabolites|Cohort 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crisaborole and Its Metabolites|Cohort 2: Area Under the Plasma Concentration-Time Curve From Time Zero Until the Last Measurable Concentration (AUClast) of Crisaborole and Its Identified Main Oxidative Metabolites|Cohort 2: Area Under the Plasma Concentration-Time Curve From Time Zero to the 24 Hours Post-Dose (AUC24) of Crisaborole and Its Identified Main Oxidative Metabolites (AN7602 and AN8323)|Cohort 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Tau (12 Hours Dosing Interval) (AUCtau) of Crisaborole and Its Identified Main Oxidative Metabolites|Cohort 2: Accumulation Ratio for Cmax (Rac [Cmax]) of Crisaborole and Its Identified Main Oxidative Metabolites|Cohort 2: Accumulation Ratio for AUCtau (Rac [AUCtau]) of Crisaborole and Its Identified Main Oxidative Metabolites","Pfizer","All","20 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","C3291029","September 13, 2017","November 27, 2017","November 27, 2017","August 24, 2017","March 1, 2019","March 1, 2019","Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT03260595/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT03260595/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03260595"
172,"NCT03258762","Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects",,"Completed","Has Results","Toxoplasmosis","Drug: Pyrimethamine|Drug: Calcium folinate","Maximum Observed Concentration (Cmax) of Pyrimethamine in Healthy Japanese Male Participants|Area Under the Concentration-time Curve From Time 0 to t (AUC[0-t]) of Pyrimethamine in Healthy Japanese Male Participants|Area Under the Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) of Pyrimethamine in Healthy Japanese Male Participants|Area Under the Concentration-time Curve From Time 0 to 24 (AUC[0-24]) of Pyrimethamine in Healthy Japanese Male Participants|Terminal Half-life (t1/2) of Pyrimethamine in Healthy Japanese Male Participants|Time to Maximum Observed Concentration (Tmax) of Pyrimethamine in Healthy Japanese Male Participants|Apparent Clearance Following Oral Dosing (CL/F) of Pyrimethamine in Healthy Japanese Male Participants|Apparent Volume of Distribution Following Oral Dosing (Vd/F) of Pyrimethamine in Healthy Japanese Male Participants|Cmax of Pyrimethamine in Healthy Caucasian Male Participants|AUC (0-t) of Pyrimethamine in Healthy Caucasian Male Participants|AUC (0-inf) of Pyrimethamine in Healthy Caucasian Male Participants|AUC (0-24) of Pyrimethamine in Healthy Caucasian Male Participants|Tmax of Pyrimethamine in Healthy Caucasian Male Participants|T1/2 of Pyrimethamine in Healthy Caucasian Male Participants|CL/F of Pyrimethamine in Healthy Caucasian Male Participants|Vd/F of Pyrimethamine in Healthy Caucasian Male Participants|Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)|Change From Baseline of Clinical Chemistry Parameters: Glucose, Sodium, Calcium, Potassium, and Urea.|Change From Baseline of Clinical Chemistry Parameters: Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)|Change From Baseline of Clinical Chemistry Parameters: Direct Bilirubin, Bilirubin, Creatinine.|Change From Baseline of Clinical Chemistry Parameters: Protein|Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet and Leukocytes|Change From Baseline in Hematology Parameter: Reticulocytes|Change From Baseline in Hematology Parameter: Hematocrit|Change From Baseline in Hematology Parameter: Hemoglobin|Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin|Change From Baseline in Hematology Parameter: Mean Corpuscular Volume|Change From Baseline in Hematology Parameter: Erythrocytes|Number of Participants With Abnormal Urinalysis Parameter|Specific Gravity at Indicated Time Points|Urine Potential of Hydrogen (pH) at Indicated Time Points|Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)|Change From Baseline in Pulse Rate|Change From Baseline in Temperature|Change From Baseline of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, and QT Interval Corrected for Heart Rate by Fredericia's Formula (QTcF) Interval|Change From Baseline of ECG Parameter: ECG Mean Heart Rate","GlaxoSmithKline","Male","20 Years to 64 Years   (Adult)","Phase 1","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","204678","September 25, 2017","November 19, 2017","November 19, 2017","August 23, 2017","March 27, 2019","March 27, 2019","GSK Investigational Site, Melbourne, Victoria, Australia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03258762/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03258762/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03258762"
173,"NCT03247673","To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin",,"Completed","Has Results","Healthy","Drug: CT-P16|Drug: EU-approved Avastin|Drug: US-licensed Avastin","AUC0-inf|Cmax|AUC0-last|Additional Pharmacokinetics (Time to Cmax)|Number of Participants With Anti-Drug Antibody Positive","Celltrion","Male","19 Years to 55 Years   (Adult)","Phase 1","141","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","CT-P16 1.1","August 7, 2017","December 22, 2017","January 17, 2018","August 14, 2017","July 25, 2019","July 25, 2019","Inje University Busan Paik Hospital, Busan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul St.Mary's hospital, Seoul, Korea, Republic of","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03247673/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03247673/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03247673"
174,"NCT03245619","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults",,"Terminated","Has Results","Pancreatitis, Acute Necrotizing","Drug: GSK3335065|Drug: Placebo","Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part A|Number of Participants With AEs and SAEs-Part B|Number of Participants With AEs and SAEs-Part C|Number of Participants With Hematological Parameters of Potential Clinical Importance-Part A|Number of Participants With Hematological Parameters of Potential Clinical Importance-Part B|Number of Participants With Hematological Parameters of Potential Clinical Importance-Part C|Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part A|Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part B|Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part C|Number of Participants With Abnormal Urine Parameters-Part A|Number of Participants With Abnormal Urine Parameters-Part B|Number of Participants With Abnormal Urine Parameters-Part C|Number of Participants With Abnormal Electrocardiogram (ECG) Findings-Part A|Number of Participants With Abnormal ECG Findings-Part B|Number of Participants With Abnormal ECG Findings-Part C|Number of Participants With Abnormal Vital Signs-Part A|Number of Participants With Abnormal Vital Signs-Part B|Number of Participants With Abnormal Vital Signs-Part C|Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration (AUC[0-t]) for GSK3335065-Part A (Cohorts 1 and 2)|AUC(0-t) for GSK3335065-Part A (Cohorts 3 to 8)|AUC(0-t) for GSK3335065-Part B|AUC(0-t) for GSK3335065-Part C (Cohort 13)|AUC(0-t) for GSK3335065-Part C (Cohort 14)|Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-Inf]) for GSK3335065-Part A (Cohorts 1 and 2)|AUC(0-Inf) for GSK3335065-Part A (Cohorts 3 to 8)|AUC(0-Inf) for GSK3335065-Part B|AUC(0-Inf) for GSK3335065-Part C (Cohort 13)|AUC(0-Inf) for GSK3335065-Part C (Cohort 14)|Time of the Last Measurable Concentration (Tlast) of GSK3335065-Part A (Cohorts 1 and 2)|Tlast of GSK3335065-Part A (Cohorts 3 to 8)|Tlast of GSK3335065-Part B|Tlast of GSK3335065-Part C (Cohort 13)|Tlast of GSK3335065-Part C (Cohort 14)|Maximum Observed Concentration (Cmax) of GSK3335065-Part A (Cohorts 1 and 2)|Cmax of GSK3335065-Part A (Cohorts 3 to 8)|Cmax of GSK3335065-Part B|Cmax of GSK3335065-Part C (Cohort 13)|Cmax of GSK3335065-Part C (Cohort 14)|Time to Reach Maximum Concentration (Tmax) for GSK3335065-Part A (Cohorts 1 and 2)|Tmax of GSK3335065-Part A (Cohorts 3 to 8)|Tmax of GSK3335065-Part B|Tmax of GSK3335065-Part C (Cohort 13)|Tmax of GSK3335065-Part C (Cohort 14)|Clearance for GSK3335065-Part A (Cohorts 1 and 2)|Clearance for GSK3335065-Part A (Cohorts 3 to 8)|Clearance for GSK3335065-Part B|Clearance for GSK3335065-Part C (Cohort 13)|Clearance for GSK3335065-Part C (Cohort 14)|Volume of Distribution for GSK3335065-Part A (Cohorts 1 and 2)|Volume of Distribution for GSK3335065-Part A (Cohorts 3 to 8)|Volume of Distribution for GSK3335065-Part B|Volume of Distribution for GSK3335065-Part C (Cohort 13)|Volume of Distribution for GSK3335065-Part C (Cohort 14)|Apparent Terminal Half Life (T1/2) for GSK3335065-Part A (Cohorts 1 and 2)|T1/2 for GSK3335065-Part A (Cohorts 3 to 8)|T1/2 for GSK3335065-Part B|T1/2 for GSK3335065-Part C (Cohort 13)|T1/2 for GSK3335065-Part C (Cohort 14)|Change From Baseline in Levels of Tryptophan Metabolites-Part A (Cohort 1 and 2)|Change From Baseline in Levels of Tryptophan Metabolites-Part A (Cohorts 3 to 8)|Change From Baseline in Levels of Tryptophan Metabolites-Part B|Change From Baseline in Levels of Tryptophan Metabolites-Part C","GlaxoSmithKline","All","18 Years to 60 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201570|2016-001303-22","August 22, 2017","May 19, 2018","May 19, 2018","August 10, 2017","September 20, 2019","September 20, 2019","GSK Investigational Site, Cambridge, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03245619/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03245619/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03245619"
175,"NCT03239522","Absorption and Elimination of Radiolabeled Daprodustat",,"Completed","Has Results","Anaemia","Drug: [14C]-GSK1278863 solution for IV infusion|Drug: [14C]-GSK1278863 oral solution|Drug: Daprodustat 6 mg oral tablet","Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-Inf]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863|AUC (0-Inf) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863|AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863|AUC (0-t) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863|Maximum Observed Plasma Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863|Cmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863|Time of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863|Tmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863|Apparent Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863|T1/2 of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863|Volume of Distribution at Steady State (Vss) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863|Vss of Total Drug-related Material (Radioactivity) in Blood Following IV Dose of GSK1278863|Total Systemic Clearance (CL) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863|CL of Total Drug-related Material (Radioactivity) in Blood Following IV Dose of GSK1278863|Percentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863|Percentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863|Percentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time|AUC (0-Inf) of GSK1278863 in Plasma Following Administration IV and Both Oral Doses|AUC(0-t) of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses|Cmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses|Tmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses|T1/2 of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses|AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses|AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses|Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses|Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses|T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses|Vss of GSK1278863 in Plasma Following IV Dose Administration|Vss of GSK1278863 Metabolites in Plasma Following IV Dose Administration|CL of GSK1278863 in Plasma Following IV Dose Administration|CL of GSK1278863 Metabolites in Plasma Following IV Dose Administration|Absolute Bioavailability of GSK1278863 Following Oral Dosing|Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg|Percent Radioactivity Recovered for Each Metabolite in Urine Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg|Percent Radioactivity Recovered for Each Metabolite in Feces Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg|Percent Radioactivity Recovered for Each Metabolite in Duodenal Bile Following a Single Dose of [14C]-GSK1278863 50 µg IV Infusion|Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)|Number of Participants With AEs at a Particular Severity|Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range|Number of Participants With Worst Case Hematology Results Relative to Normal Range|Number of Participants With Abnormal Urinalysis Findings|Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Change From Baseline in Blood Pressure|Change From Baseline in Heart Rate|Change From Baseline in Respiratory Rate|Change From Baseline in Body Temperature","GlaxoSmithKline","Male","30 Years to 55 Years   (Adult)","Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200232|2017-001729-42","October 10, 2017","November 28, 2017","November 28, 2017","August 4, 2017","March 18, 2019","December 3, 2019","GSK Investigational Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03239522/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03239522/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03239522"
176,"NCT03239483","Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults",,"Completed","Has Results","HIV Infections","Drug: Dapivirine gel|Drug: Placebo gel","Frequency of Grade 2 or Higher Adverse Events (AEs)|Measurement of Dapivirine Concentrations in Plasma|Measurement of Dapivirine Concentrations in Rectal Fluid|Measurement of Dapivirine Concentrations in Rectal Mucosal Tissue Homogenates|Terminal Half-life of Dapivirine Concentrations in Plasma|Acceptability: Ease of Use|Acceptability: Comfort","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Phase 1","28","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MTN-026|12021","October 26, 2017","September 20, 2018","September 20, 2018","August 4, 2017","November 7, 2019","November 7, 2019","Alabama CRS, Birmingham, Alabama, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|Silom Community Clinic CRS, Nonthaburi, Bangkok, Thailand","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03239483/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03239483/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03239483"
177,"NCT03237871","The EMERGE Project: Feasibility of Assessing Economic and Sexual Risk Behaviors Using Text Messages in Young Adults",,"Completed","Has Results","Feasibility","Behavioral: Text-message survey and informational text messages","Number of Participants Who Respond to the Survey in Week 1|Mean Number of Questions to Which Participant Respond in Each Survey in Week 1|Mean Number of Hours From Sending a Survey to Participants to Receiving Their Response in Week 1","Johns Hopkins Bloomberg School of Public Health|National Institute of Mental Health (NIMH)","All","18 Years to 24 Years   (Adult)","Not Applicable","17","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB0007563|K01MH107310","July 7, 2017","September 19, 2017","September 19, 2017","August 3, 2017","April 12, 2019","April 12, 2019","Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03237871/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03237871"
178,"NCT03237156","Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants",,"Completed","Has Results","Japanese Healthy Adult Male Participants","Drug: TAK-906|Drug: TAK-906 Placebo","Number of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE)|Number of Participants With Markedly Abnormal Values of Vital Signs|Number of Participants With Markedly Abnormal Values of Clinical Laboratory Test Results|Number of Participants With Markedly Abnormal Values of 12-lead Electrocardiogram (ECG)|Number of Participants With TEAEs Related to Physical Examinations|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-906 and Its Metabolite M23 on Day 1 of Single Dose Period|Cmax: Maximum Observed Plasma Concentration for TAK-906 and Its Metabolite M23 on Day 1 of Single Dose Period|AUCtau: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-906 and Its Metabolite M23 on Day 1 of Single Dose Period|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 and Its Metabolite M23 on Day 1 of Single Dose Period|t1/2z: Terminal Disposition Phase Half-life for TAK-906 and Its Metabolite M23 on Day 1 of Single Dose Period|Ae(0-24): Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose for TAK-906 and Its Metabolite M23 on Day 1 of Single Dose Period|Fe24: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to 24 Hours for TAK-906 and Its Metabolite M23 on Day 1 of Single Dose|CLR: Renal Clearance for TAK-906 and Its Metabolite M23 on Day 1 of Single Dose Period|AUC(τ,ss): Area Under the Plasma Concentration-time Curve From Time 0 During Dosing Interval at Steady State for TAK-906 and Its Metabolite M23 on Day 7 of Multiple Dose Period|Cmax,ss: Maximum Observed Plasma Concentration During Dosing Interval at Steady State for TAK-906 and Its Metabolite M23 on Day 7 of Multiple Dose Period|Tmax,ss: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State for TAK-906 and Its Metabolite M23 on Day 7 of Multiple Dose Period|t1/2z: Terminal Disposition Phase Half-life for TAK-906 and Its Metabolite M23 on Day 7 of Multiple Dose Period|Aetau: Amount of Drug Excreted in Urine During a Dosing Interval for TAK-906 and Its Metabolite M23 on Day 7 of Multiple Dose Period|Fetau: Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time Tau Over the Dosing Interval for TAK-906 and Its Metabolite M23 on Day 7 of Multiple Dose Period|CLR: Renal Clearance for TAK-906 and Its Metabolite M23 on Day 7 of Multiple Dose Period|AUCtau: Area Under the Serum Concentration-time Curve During a Dosing Interval for Serum Prolactin on Day 1 of Single Dose Period|Cmax: Maximum Observed Serum Concentration for Serum Prolactin on Day 1 of Single Dose Period|AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Serum Prolactin on Day 1 of Single Dose Period|AUC(t,ss): Area Under the Serum Concentration-time Curve From Time 0 During Dosing Interval at Steady State for Serum Prolactin on Day 7 of Multiple Dose Period|Cmax,ss: Maximum Observed Serum Concentration During Dosing Interval at Steady State for Serum Prolactin on Day 7 of Multiple Dose Period","Takeda","Male","20 Years to 60 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","TAK-906-1004|U1111-1197-9663|JapicCTI-173661","August 7, 2017","October 7, 2017","October 7, 2017","August 2, 2017","February 18, 2019","March 19, 2019","Sekino Clinical Pharmacology Clinic, Toshima, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03237156/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03237156/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03237156"
179,"NCT03235115","Fitting Evaluation of Hydrogel and Silicone Hydrogel Spherical Contact Lenses",,"Completed","Has Results","Myopia","Device: Methafilcon A IV|Device: Ocufilcon B|Device: Omafilcon A","Visual Acuity Using logMAR|Lens Fit - Horizontal Centration|Lens Fit - Vertical Centration|Lens Fit - Corneal Coverage of Lens|Lens Fit - Movement of Lens","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EX-MKTG-85","June 23, 2017","September 22, 2017","September 22, 2017","August 1, 2017","November 14, 2018","September 12, 2019","Eurolens Research - The University of Manchester, Manchester, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03235115/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03235115"
180,"NCT03234036","A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir",,"Completed","Has Results","Infection, Human Immunodeficiency Virus","Drug: GSK2838232 100 mg tablet|Drug: GSK2838232 50 mg capsule|Drug: Ritonavir 100 mg tablets|Drug: Placebo for GSK2838232 tablets","Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State|Part 1: Maximum Observed Concentration (Cmax) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State|Part 1: AUC (0-infinity) Following Administration of GSK2838232 Tablet in Fasted and Fed State|Part 1: Cmax Following Administration of GSK2838232 Tablet in Fasted and Fed State|Part 1: Time of Occurrence of Cmax (Tmax) Following Administration of GSK2838232 Tablet in Fasted and Fed State|Part 2: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs|Part 2: Number of Participants With Worst Case Hematology Results to Potential Clinical Importance (PCI) Criteria|Part 2: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria|Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria|Part 2: Blood Pressure at Indicated Time Points|Part 2: Change From Baseline in Blood Pressure|Part 2: Pulse Rate at Indicated Time Points|Part 2: Change From Baseline in Pulse Rate|Part 2: Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Part 2: Change From Baseline in Mean Heart Rate Values as ECG Parameter|Part 2: Change From Baseline in PR Interval, QRS, QT Interval, and QTcF Interval as ECG Parameters|Part 2: Area Under the Plasma Drug Concentration Time Curve From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State|Part 2: Cmax Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State|Part 2: Observed Concentration at the End of the Dosing Interval (Ctau) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State|Part 2: Tmax Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State|Part 2: Lag-time (Tlag) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 1|Part 2: AUC(0-infinity) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11|Part 2: Apparent Terminal Phase Half-life (T1/2) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11|Part 2: Time of Last Quantifiable Concentration (Tlast) Following Administration of Non-boosted Once-daily Doses of GSK2838232 Tablet in Fed State on Day 11|Part 1: Number of Participants With SAEs and Non-SAEs|Part 1: Number of Participants With Worst Case Hematology Results to PCI Criteria|Part 1: Number of Participants With Worst Case Clinical Chemistry Results to PCI Criteria|Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range Criteria|Part 1: Blood Pressure at Indicated Time Points|Part 1: Change From Baseline in Blood Pressure|Part 1: Pulse Rate at Indicated Time Points|Part 1: Change From Baseline in Pulse Rate|Part 1: Number of Participants With Abnormal ECG Findings|Part 1: Change From Baseline in Mean Heart Rate Values as ECG Parameter|Part 1: Change From Baseline in PR Interval, QRS, QT Interval, and QTcF Interval as ECG Parameters|Part 1: Tlag Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State|Part 1: Tmax Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State|Part 1: T1/2 Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State|Part 1: Tlast Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State|Part 1: Plasma Drug Concentration at 24 Hours (C24) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State|Part 1: AUC(0-t) Following Administration of GSK2838232 Tablet and Capsule Formulation in Fed State and Tablet Formulation in Fasted State|Part 2: Slope of Pre-dose Concentration of GSK2838232 Administered as Non-boosted Once-daily Doses of a Tablet Formulation to Assess Achievement of Steady State|Part 2: Accumulation Ratio Calculated From AUC(0-tau) Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation|Part 2: Accumulation Ratio Calculated From Cmax Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation|Part 2: Accumulation Ratio Calculated From Ctau Following Administration of GSK2838232 as Non-boosted Once-daily Doses of a Tablet Formulation","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","205820","August 2, 2017","November 10, 2017","November 10, 2017","July 31, 2017","March 7, 2019","March 7, 2019","GSK Investigational Site, Baltimore, Maryland, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03234036/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03234036/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03234036"
181,"NCT03232827","The Impact of Waterpipe Tobacco Flavors on Waterpipe Smoking Intentions, Perceptions, Patterns, and Toxicant Exposure",,"Completed","Has Results","Smoking, Hookah|Waterpipe Smoking","Behavioral: Flavored-Sweetened Waterpipe Tobacco|Behavioral: Unflavored-sweetened waterpipe tobacco|Behavioral: Unflavored-very low sweetened waterpipe tobacco|Behavioral: Flavored-very low sweetened waterpipe","Level of Smoke Inhalation Measured by Topography Device|Levels of Smoke Inhalation Between High vs. Low Dependent WP","University of Oklahoma|Virginia Commonwealth University|American University of Beirut Medical Center|National Institute on Drug Abuse (NIDA)","All","18 Years to 50 Years   (Adult)","Not Applicable","91","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","1R03DA041928-01A1","June 1, 2017","March 12, 2018","March 12, 2018","July 28, 2017","June 24, 2019","June 24, 2019","University of Oklahoma Health Sciences Center Tobacco Research Center, Oklahoma City, Oklahoma, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03232827/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03232827/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03232827"
182,"NCT03232567","Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX",,"Completed","Has Results","Influenza","Biological: NasoVAX","Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability]|Number of Treatment-Emergent Reactogenicity Events in Participants [Safety and Tolerability]|HAI Immune Response|Microneutralization Immune Response","Altimmune, Inc.","All","18 Years to 49 Years   (Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","ALT103-201","September 18, 2017","March 7, 2018","June 15, 2018","July 28, 2017","April 11, 2019","April 11, 2019","Optimal Health Research, Rockville, Maryland, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03232567/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03232567/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03232567"
183,"NCT03231943","GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers",,"Completed","Has Results","Infection, Human Immunodeficiency Virus|HIV Infections","Drug: GSK3640254|Drug: Placebo","Part 1:Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)|Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets.|Part 1: Change From Baseline in Hematology Parameters: Erythrocytes.|Part 1: Change From Baseline in Hematology Parameters: Erythrocytes Mean Corpuscular Volume (Erythrocyte MCV).|Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin (Erythrocyte MCH)|Part 1: Change From Baseline in Hematology Parameter: Hematocrit|Part 1: Change From Baseline in Hematology Parameter: Percentage of Reticulocytes|Part 1: Change From Baseline in Hematology Parameter: Hemoglobin (Hb)|Part 1: Change From Baseline in Clinical Chemistry Parameter: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphate (ALP)|Part 1: Change From Baseline in Clinical Chemistry Parameters : Bicarbonate, Calcium, Chloride, Magnesium, Phosphate, Potassium, Sodium, Urea|Part 1: Change From Baseline in Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Cholesterol (LDL) Cholesterol, Triglycerides|Part 1: Change From Baseline in Chemistry Parameter: Glucose|Part 1: Change From Baseline in Clinical Chemistry Parameter: Bilirubin, Creatinine, Direct Bilirubin|Part 1: Change From Baseline in Clinical Chemistry Parameter: Protein|Part 1: Number of Participants With Abnormal Urinalysis|Part 1: Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)|Part 1: Change From Baseline in Vital Signs: Pulse Rate|Part 1: Change From Baseline in Vital Signs: Temperature|Part 1: Change From Baseline in Vital Sign: Respiratory Rate|Part 1: Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Part 2: Number of Participants AEs and SAEs|Part 2: Change From Baseline in Abnormal Hematology Findings: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets.|Part 2: Change From Baseline in Hematology Parameter: Erythrocytes|Part 2: Change From Baseline in Hematology Parameter: Erythrocytes MCV|Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin (Erythrocyte MCH)|Part 2: Change From Baseline in Hematology Parameter: Hematocrit|Part 2: Change From Baseline in Hematology Parameter: Percentage of Reticulocytes|Part 2: Change From Baseline in Hematology Parameter: Hb|Part 2: Change From Baseline in Chemistry Parameter: ALT, AST,ALP|Part 1: Change From Baseline in Bicarbonate, Calcium, Chloride, Cholesterol, Magnesium, Phosphate, Potassium, Sodium, Urea|Part 2: Change From Baseline in Cholesterol, HDL Cholesterol, LDL Cholesterol, Triglycerides|Part 2: Change From Baseline in Chemistry Parameter: Glucose|Part 2: Change From Baseline in Chemistry Parameter: Bilirubin, Creatinine, Direct Bilirubin|Part 2: Change From Baseline in Chemistry Parameter: Protein|Part 2: Number of Participants With Abnormal Urinalysis|Part 2: Change From Baseline in Vital Signs: SBP and DBP|Part 2: Change From Baseline in Vital Sign: Pulse Rate|Part 2: Change From Baseline in Vital Sign: Temperature|Part 2: Change From Baseline in Vital Sign: Respiratory Rate|Part 2: Number of Participants With Abnormal ECG Findings|Part 1: Area Under the Plasma Concentration Time Curve (AUC) From Zero to 24 Hour (AUC[0-24]) of GSK3640254|Part 1: AUC From Zero to Time of Last Sample Taken (AUC[0-Tlast]) of GSK3640254|Part 1: AUC From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK3640254|Part 1: Apparent Terminal Phase Half-life (T1/2) of GSK3640254|Part 1: Apparent Oral Clearance (CL/F) of GSK3640254|Part 1: Maximum Observed Concentration (Cmax), Concentration of GSK3640254 at 24 Hours (C24) and Last Quantifiable Concentration (Clast) of GSK3640254|Part 1: Time of Occurrence of Cmax (Tmax), Lag Time (Tlag), and Time to Reach Clast (Tlast) of GSK3640254|Part 2: AUC(0-24) of GSK3640254: Day 1|Part 2: Cmax, C24 of GSK3640254 on Day 1|Part 2: Tmax, Tlag of GSK3640254 on Day 1|Part 2: Tmax GSK3640254 on Day 14|Part 2: Cmax of GSK3640254 on Day 14|Part 2: AUC From Pre-dose to the End of the Dosing Interval at Steady State (AUC[0-tau]): Day 14|Part 2: Plasma Trough Concentration (Ctau) of GSK3640254: Day 14|Part 2: T1/2 of GSK3640254: Day 14|Part 2: CL/F of GSK3640254: Day 14|Part 1: Dose Proportionality (AUC[0-inf]) Following Single Dose of GSK3640254 on Day 1|Part 1: Dose Proportionality (AUC0-24) Following Single Dose of GSK3640254 on Day 1|Part 1: Dose Proportionality for Cmax Following Single Dose of GSK3640254 on Day 1|Part 2: Dose Proportionality (AUC0-tau) Following Repeated Dose of GSK3640254 on Day 14|Part 2: Dose Proportionality (Ctrough) Following Repeated Dose of GSK3640254 on Day 14|Part 2: Dose Proportionality (Cmax) Following Repeated Dose of GSK3640254 on Day 14|Part 2: Accumulation Ratio of AUC(0-tau) (R [AUC{0-TAU}]) From Day 1 to Day 14|Part 2: Accumulation Ratio of Cmax (R [CMAX]) From Day 1 to Day 14|Part 2: Accumulation Ratio of C(Tau) (R[CTAU]) From Day 2 to Day 15|Part 2: Pre-dose Concentration of GSK3640254 on Day 2 to Day 14|Part 2: Dose Proportionality (Cmax) Following Repeated Dose of GSK3640254 at Day 1|Part 2: Dose Proportionality (AUC0-24) Following Repeated Dose of GSK3640254 at Day 1","ViiV Healthcare|GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","207187|2017-001367-21","September 19, 2017","September 9, 2018","September 9, 2018","July 27, 2017","October 18, 2019","October 18, 2019","GSK Investigational Site, Cambridge, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03231943/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03231943/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03231943"
184,"NCT03229252","An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis","(HOPE-1)","Completed","Has Results","Cystic Fibrosis","Drug: Placebo Inhalation Solution|Drug: SPX-101","Change in Percent Predicted FEV1|Number of Participants With Adverse Events|Change From Baseline Through Day 28 in Clinical Laboratory Tests","Spyryx Biosciences, Inc.","All","18 Years to 50 Years   (Adult)","Phase 2","91","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPX-101-CF-201","August 1, 2017","June 20, 2019","June 20, 2019","July 25, 2017","December 30, 2019","December 30, 2019","University of Calgary Heritage Medical Research Center, Calgary, Alberta, Canada|Ottawa Hospital Research Institute/Institut de Recherche de l'Hospital d'Ottawa, Ottawa, Ontario, Canada|Saint Michael's Hospital, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Brest, Roscoff, Bretagne, France|CHU de Rouen, Rouen, Haute-Normandie, France|CHU de Montpellier, Montpellier, Languedoc-Roussillon, France|CHU de Angers, Angers, Pays De La Loire, France|Hopital Pasteur, Nice, Provence Alpes Cote D'azur, France|Hospices Civils de Lyon (HCL), Pierre Bénite, Rhone-Alpes, France|Assistance Publique-Hôpitaux de Paris Hôpital Cochin, Paris, France|Istituto Giannina Gaslini Ospedale Pediatrico, Genoa, Italy|Hospital de Santa Maria, Lisbon, Portugal|Belfast Health and Social Care Trust, Belfast, United Kingdom|Heart of England NHS Foundation Trust, Birmingham, United Kingdom|University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom|Western General Hospital - NHS Lothian, Edinburgh, United Kingdom|Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, United Kingdom|The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, United Kingdom|Barts Health NHS Trust Saint Bartholomews Hospital, London, United Kingdom|Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom|University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom|Newcastle Upon Tyne Hospitals, Newcastle-upon-Tyne, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03229252/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03229252/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03229252"
185,"NCT03229109","Analysis of Sweat Secretion and Body Dehydration Monitoring",,"Completed","Has Results","Dehydration","Device: Spectrophon dehydration body monitor","Number of Measurements Grouped by Level or Error","Tirat Carmel Mental Health Center|Ariel University","All","18 Years to 50 Years   (Adult)","Not Applicable","201","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","04/17","May 3, 2017","July 27, 2017","July 27, 2017","July 25, 2017","October 31, 2019","October 31, 2019","Mental Health Center, Tirat Karmel, Haifa, Israel|Tirat Carmel Mental Health Center, Tirat Karmel, Haifa, Israel","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03229109/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03229109"
186,"NCT03228433","A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants",,"Completed","Has Results","Healthy Participants","Drug: TAK-418|Drug: TAK-418 Placebo","Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)|Number of Participants Who Discontinued Due to an Adverse Event (AE)|Number of Participants Who Meet the Markedly Abnormal Criteria for Neurological Assessment Measurements at Least Once Post Dose|Number of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose|Number of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose|Number of Participants Who Meet the Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose|AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration of TAK-418F (TAK-418 Free Base)|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-418F|Cmax: Maximum Observed Plasma Concentration for TAK-418F|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-418F","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","TAK-418-1001|U1111-1195-7777","July 21, 2017","May 12, 2018","May 12, 2018","July 24, 2017","September 9, 2019","September 9, 2019","PAREXEL International, Glendale, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03228433/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03228433/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03228433"
187,"NCT03228212","Evaluation of Approved and Investigational Contact Lenses",,"Completed","Has Results","Visual Acuity","Device: CONTROL|Device: TEST","Overall Comfort|Distance Monocular LogMAR Visual Acuity|Contact Lens Fitting Acceptance Rate|Number of Grade 3 or Higher Slit Lamp Findings|Overall Quality of Vision|Overall Handling","Johnson & Johnson Vision Care, Inc.","All","18 Years to 49 Years   (Adult)","Not Applicable","133","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-5960","July 14, 2017","September 18, 2017","September 18, 2017","July 24, 2017","December 13, 2018","December 13, 2018","Dr. James Weber & Associates, PA, Jacksonville, Florida, United States|Vue Optical Boutique, Jacksonville, Florida, United States|VisionCare Associates, East Lansing, Michigan, United States|Pickens Family Eye Care, Pickens, South Carolina, United States|William J. Bogus, OD, Salt Lake City, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03228212/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03228212"
188,"NCT03226275","Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants",,"Completed","Has Results","Healthy","Drug: Bisoprolol-Amlodipine FDC|Drug: Bisoprolol|Drug: Amlodipine","Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Bisoprolol and Amlodipine|Maximum Observed Plasma Concentration (Cmax) of Bisoprolol and Amlodipine|Time to Reach Maximum Plasma Concentration (Tmax) of Bisoprolol and Amlodipine|Apparent Terminal Half-life (t1/2) of Bisoprolol and Amlodipine|Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC 0-inf) of Bisoprolol and Amlodipine|Extrapolated Part of Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUCextra%) of Bisoprolol and Amlodipine|Apparent Terminal Elimination Rate Constant (λz) of Bisoprolol and Amlodipine|Apparent Total Body Clearance From Plasma (CL/f) of Bisoprolol and Amlodipine|Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/f) of Bisoprolol and Amlodipine|Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, AEs Leading to Death, and AEs Leading to Discontinuation","Merck KGaA, Darmstadt, Germany","All","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","EMR200006-001","August 9, 2017","September 9, 2017","September 9, 2017","July 21, 2017","February 20, 2019","February 20, 2019","Xuanwu Hospital, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03226275/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03226275/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03226275"
189,"NCT03225313","Comparison Between Ultra Sound Guided Rectus Sheath Block and Field Block for Midline Hernia Repair",,"Completed","Has Results","Ultrasound Guided Rectus Sheath Block|Pain, Postoperative","Drug: Bupivacaine Hydrochloride 0.5% Injection Solution_#4|Drug: Normal Saline Flush, 0.9% Injectable Solution_#5","Immediate Postoperative Pain|Postoperative Pain at 2 Hours After Procedure.|Postoperative Pain at 6 Hours After Procedure.|Change in the Level of Serum Cortisol.|Measurement of Serum Adrenaline Levels (ng/ml) Using ELISA Technique.|Measurement of Serum Noradrenaline Levels (ng/ml) Using ELISA Technique.|Measurement of Serum Cortisol Level (Nmol/ Liter) Using ELISA Technique.|Measurement of Serum Adrenaline Level (ng/ml) Using ELISA Technique.","Theodor Bilharz Research Institute","All","18 Years to 60 Years   (Adult)","Not Applicable","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","722014","August 20, 2016","October 20, 2016","March 20, 2017","July 21, 2017","July 11, 2019","August 6, 2019","Theodor Bilharz Research Institute, Giza, Egypt",,"https://ClinicalTrials.gov/show/NCT03225313"
190,"NCT03224390","A Pilot Study to Estimate the Impact of a Screening and Referral Service on Contraceptive Use",,"Completed","Has Results","Contraception Behavior","Other: digital family planning screening and referral service","Number of Participants Who Report Starting Any Modern Method of Contraception Since the Start of the Study|Uptake of Long-acting Contraception","Duke University|Moi University","Female","18 Years to 35 Years   (Adult)","Not Applicable","112","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Health Services Research","E0108","July 12, 2017","March 13, 2018","March 13, 2018","July 21, 2017","July 19, 2019","October 22, 2019","Bungoma County, Bungoma, Kenya","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT03224390/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03224390"
191,"NCT03224325","A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants",,"Completed","Has Results","Healthy","Drug: TAK-831 Tablet T2|Drug: Placebo|Drug: TAK-831 Suspension","Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event (TEAE)|Percentage of Participants Who Met the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose|Percentage of Participants Who Met the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose|Percentage of Participants Who Met the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Postdose|Cmax: Maximum Observed Plasma Concentration for TAK-831|Cmax ss: Maximum Observed Steady-state Plasma Concentration During a Dosing Interval for TAK-831|Tmax: Time of First Occurrence of Cmax for TAK-831|AUC0-24: Area Under the Plasma Concentration-time Curve During a Dosing Interval for TAK-831","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TAK-831-1005","July 21, 2017","September 9, 2018","September 9, 2018","July 21, 2017","November 19, 2019","November 19, 2019","California Clinical Trials Medical Group/PAREXEL, Glendale, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT03224325/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT03224325/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03224325"
192,"NCT03222037","Evaluation of Electronic LogMar Visual Acuity and Contrast Sensitivity in a Population of Contact Lens Wearers",,"Completed","Has Results","Visual Acuity","Device: senofilcon A|Device: Control","Visual Acuity (logMAR)|Area Under Contrast Sensitivity Function Curve","Johnson & Johnson Vision Care, Inc.","All","18 Years to 35 Years   (Adult)","Phase 4","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-5968","June 27, 2017","August 4, 2017","August 4, 2017","July 19, 2017","August 24, 2018","September 10, 2019","VRC East, Jacksonville, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03222037/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03222037"
193,"NCT03220048","Study Examining PrEP-001 in Healthy Subjects",,"Completed","Has Results","Influenza A H3N2","Drug: PrEP-001|Other: Placebo Comparator","Primary Efficacy Endpoint: The Area Under the Curve (AUC) of Total Symptom Score From Day 1 (Post Viral Challenge) to Day 8 (Quarantine Discharge).|Secondary Efficacy Endpoint: Symptom Scores: Peak Symptoms Score|Secondary Efficacy Endpoint: Incidence(s) of Illness and Infection: Viral Shedding|Secondary Efficacy Endpoint: Incidence(s) of Illness and Infection: Seroconversion|Secondary Efficacy Endpoint: Viral Load Parameters: Area Under the Curve (AUC) of Viral Load, as Measured by Nasopharyngeal Swab RT-qPCR.|Secondary Efficacy Endpoint: Total Weight of Nasal Discharge Produced Post Viral Challenge to Quarantine Discharge","Hvivo|Prep Biopharm Limited","All","18 Years to 55 Years   (Adult)","Phase 2","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PrEP-CS-001","September 16, 2015","February 2016","February 2016","July 18, 2017","November 12, 2019","November 12, 2019","hVIVO Services Ltd, QMB Bioenterprise building, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03220048"
194,"NCT03214588","Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia",,"Completed","Has Results","Friedreich Ataxia","Drug: TAK-831|Drug: TAK-831 Placebo","Change From Baseline in the Inverse Time to Complete the 9-Hole Peg Test (9-HPT-1)|Change From Baseline in the Activities of Daily Living (ADL) Component Score of the Friedreich Ataxia Rating Scale (FARS)|Change From Baseline in the Inverse Time to Complete the 9-HPT-1|Change From Baseline in the ADL Component Individual Item Scores|Change From Baseline in the Modified Friedreich Ataxia Rating Scale Neurological Examination (mFARS-neuro) Total Score|Change From Baseline in the mFARS-neuro Subscales Scores|Change From Baseline in the mFARS-neuro Individual Item Scores|Change From Baseline in the Timed 25-Foot Walk (T25FW)|Change From Baseline in the 9-HPT and T25FW Composite Score|Change From Baseline in Low-Contrast Letter Acuity (LCLA) Test Score|Number of Participants by Clinical Global Impression-Improvement (CGI-I) (Global Change) Score Categories|Number of Participants by Patient Global Impression-Improvement (PGI-I) (Global Change) Score Categories|Number of Participants by CGI-I (Upper Extremity Functional Change) Score Categories|Number of Participants by PGI-I (Upper Extremity Functional Change) Score Categories|Number of Participants by Clinical Global Impression-Severity (CGI-S) (Global Severity) Score Categories Relative to Baseline|Number of Participants by Patient Global Impression-Severity (PGI-S) (Global Severity) Score Categories Relative to Baseline|Number of Participants by CGI-S (Upper Extremity Functional Severity) Score Categories Relative to Baseline|Number of Participants by PGI-S (Upper Extremity Functional Severity) Score Categories|Change From Baseline in the ADL Component Score for Upper Limb Function Items of the FARS|Number of Participants With at Least a 15 Percent (%) or at Least a 20% Reduction in 9-HPT Completion Time From Baseline","Takeda","All","18 Years to 55 Years   (Adult)","Phase 2","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-831-1501|U1111-1189-7951","November 8, 2017","December 27, 2018","December 27, 2018","July 11, 2017","December 19, 2019","December 19, 2019","UCLA Ataxia Center, Los Angeles, California, United States|University of Florida Center for Movement Disorders, Gainesville, Florida, United States|USF College of Medicine, Tampa, Florida, United States|University of Iowa Children's Hospital, Iowa City, Iowa, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT03214588/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT03214588/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03214588"
195,"NCT03213366","Social Media Based Peer-Led Intervention for HIV Prevention",,"Completed","Has Results","HIV Prevention|PrEP Uptake","Behavioral: E-PrEP- Peer-Led Intervention about PrEP|Behavioral: BxNow - General Health Campaign","Number of Participants Intending to Start Using PrEP Over Time|Number of Participants Using PrEP Over Time|Change in PrEP Knowledge|PrEP Awareness|PrEP Stigma|Communication About PrEP|PrEP Barriers|Self-efficacy About Using PrEP","Montefiore Medical Center|National Institutes of Health (NIH)|Albert Einstein College of Medicine|National Institute of Mental Health (NIMH)","All","18 Years to 29 Years   (Adult)","Not Applicable","152","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","2016-7263|5K23MH102118-04","June 16, 2017","November 1, 2017","November 1, 2017","July 11, 2017","September 6, 2019","November 6, 2019","Albert Einstein College of Medicine, Bronx, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03213366/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03213366"
196,"NCT03212261","Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma",,"Completed","Has Results","Lymphoma","Behavioral: 3RP-Lymphoma","Program Feasibility: Number of Participants Who Completed at Least 75% of the Treatment Sessions|Number of Participants Who Found the 3RP Program Acceptable|Number of Participants Who Were Eligible to Provide and Provided Hair Cortisol Samples","Massachusetts General Hospital|American Cancer Society, Inc.","All","18 Years to 64 Years   (Adult)","Not Applicable","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","17-063","August 3, 2017","June 30, 2018","September 24, 2018","July 11, 2017","October 2, 2019","October 22, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03212261/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03212261"
197,"NCT03197883","Assessment of the Cosmetic Benefit of a Skin Cream in Healthy Females With Mild to Advanced Photo-damaged Facial Skin Who Have Undergone a Glycolic Acid Facial Peel Procedure",,"Completed","Has Results","Skin Care","Other: Test Product|Other: Cleanser|Other: Sunscreen","Number of Participants Reporting Product Tolerability Based on Evaluator Global Assessment Scores|Change From Baseline in Total Score of Dermatologist Assessments|Number of Participants Reporting no/Mild/Moderate/Severe Change From Baseline in Individual Dermatologist Scores for Erythema, Edema, Desquamation and Dryness|Change From Baseline in Sum of Participant Self-assessment Scores for Redness, Pain, Stinging/Burning, Itching, Tightness and Dryness|Change From Baseline in Participant Self-assessment Scores for Redness|Change From Baseline in Participant Self-assessment Scores for Pain|Change From Baseline in Participant Self-assessment Scores for Itching|Change From Baseline in Participant Self-assessment Scores for Stinging/Burning|Change From Baseline in Participant Self-assessment Scores for Tightness|Change From Baseline in Participant Self-assessment Scores for Dryness|Change From Baseline in Instrumental Measurement of Barrier Function Using Tewameter|Change From Baseline in Instrumental Measurement of Moisturisation Using Corneometer|Global Self-assessment of Participants","GlaxoSmithKline","Female","30 Years to 60 Years   (Adult)","Not Applicable","123","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","206827","July 17, 2017","October 31, 2017","October 31, 2017","June 23, 2017","July 31, 2019","July 31, 2019","GSK Investigational Site, Campinas, São Paulo, Brazil","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03197883/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03197883/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03197883"
198,"NCT03194490","Benefit of Adding Stretching to Standard Intervention For Patients With Nonspecific Mechanical Neck Pain",,"Completed","Has Results","Neck Pain","Other: combined intervention group|Other: The standard intervention","Cervical Range of Motion|Numeric Pain Rating Scale|Neck Disability Index|Global Rating of Change|Pressure Pain Threshold","Loma Linda University","All","18 Years to 60 Years   (Adult)","Not Applicable","43","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","5160230","August 24, 2016","January 8, 2018","January 8, 2018","June 21, 2017","October 31, 2019","October 31, 2019","Loma Linda U, Loma Linda, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT03194490/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03194490"
199,"NCT03193593","Study to Evaluate EB-001 in Reducing Musculoskeletal Pain",,"Completed","Has Results","Musculoskeletal Pain","Drug: Placebo|Drug: EB-001","Subject's Assessment of Pain Using the Numeric Pain Rating Scale (AUC16h-96h)","Bonti, Inc.","Female","18 Years to 55 Years   (Adult)","Phase 2","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EB001-MA201","August 29, 2017","April 26, 2018","August 7, 2018","June 21, 2017","January 25, 2019","January 25, 2019","Lotus Clinical Research, Pasadena, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03193593/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03193593"
200,"NCT03188523","Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)",,"Completed","Has Results","HIV-1 Infection","Drug: MK-8504","Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) at 168 Hours Post-Dose|Number of Participants Who Experienced At Least One Adverse Event (AE)|Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)|Area Under the Concentration-Time Curve of MK-8504 in Plasma From Time 0 to Last Measurable Concentration (AUC0-last)|Area Under the Concentration-Time Curve of MK-8504 in Plasma From Time 0 to Infinity (AUC0-inf)|Area Under the Concentration-Time Curve of MK-8504 in Plasma From Time 0 to 168 Hours (AUC0-168hr)|Time to Maximum Concentration of MK-8504 in Plasma (Tmax)|Maximum Concentration of MK-8504 in Plasma (Cmax)|Apparent Terminal Half Life of MK-8504 in Plasma (t½)|Apparent Total Clearance of MK-8504 in Plasma (CL/F)|Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-8504 in Plasma|Intracellular Area Under the Concentration-Time Curve of Tenofovir-Diphosphate (TFV-DP) From Time 0 to 168 Hours (Intracellular AUC0-168hr) In Peripheral Blood Mononuclear Cells (PBMCs)|Intracellular Area Under the Concentration-Time Curve of Tenofovir-Diphosphate (TFV-DP) From Time 0 to Infinity (Intracellular AUC0-inf) In Peripheral Blood Mononuclear Cells (PBMCs)|Intracellular Time to Maximum Concentration (Intracellular Tmax) of Tenofovir-Diphosphate (TFV-DP) In Peripheral Blood Mononuclear Cells (PBMCs)|Intracellular Maximum Concentration (Intracellular Cmax) of Tenofovir-Diphosphate (TFV-DP) In Peripheral Blood Mononuclear Cells (PBMCs)|Intracellular Apparent Terminal Half Life (Intracellular t½) of Tenofovir-Diphosphate (TFV-DP) In Peripheral Blood Mononuclear Cells (PBMCs)|Intracellular Concentration of Tenofovir-Diphosphate (TFV-DP) at 168 Hours (Intracellular C168hr) In Peripheral Blood Mononuclear Cells (PBMCs)|Area Under the Concentration-Time Curve of Tenofovir in Plasma From Time 0 to Last Measurable Concentration (AUC0-last)|Area Under the Concentration-Time Curve of Tenofovir in Plasma From Time 0 to Infinity (AUC0-inf)|Area Under the Concentration-Time Curve of Tenofovir in Plasma From Time 0 to 168 Hours (AUC0-168hr)|Time to Maximum Concentration of Tenofovir in Plasma (Tmax)|Maximum Concentration of Tenofovir in Plasma (Cmax)|Apparent Terminal Half Life of Tenofovir in Plasma (t½)","Merck Sharp & Dohme Corp.","All","18 Years to 60 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8504-002|2017-000998-37|MK-8504-002","September 8, 2017","May 21, 2018","June 4, 2018","June 15, 2017","July 15, 2019","July 15, 2019","Charite Research Organisation GmbH. ( Site 0002), Berlin, Germany|St Stephen's Clinical Research ( Site 0001), London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03188523/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03188523"
201,"NCT03184077","Rapidly Absorbing Polyglactin 910 Versus Poliglecaprone 25 for Laceration Repair",,"Completed","Has Results","Dyspareunia|Perineal Tear|Sutured Laceration","Procedure: Laceration Repair with Polyglactin 910|Procedure: Laceration Repair with poliglecaprone 25","Rates of Dyspareunia|Postpartum Pain|Overall Sexual Function","Virginia Commonwealth University","Female","18 Years to 50 Years   (Adult)","Not Applicable","318","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HM20000992","September 2, 2014","August 27, 2017","August 27, 2017","June 12, 2017","August 8, 2018","August 28, 2019","Virginia Commonwealth University, Richmond, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03184077/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03184077"
202,"NCT03180801","Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model",,"Completed","Has Results","Influenza","Biological: adjuvanted FLU-v|Biological: adjuvanted placebo|Other: Influenza challenge","Number of Participants With Mild to Moderate Influenza Disease (MMID)|Number of Treatment Emergent Adverse Events (TEAEs) Per Subject.|Number of Subjects With Treatment Emergent Adverse Event Classified by Relatedness and Severity.|Number of Subjects With Detectable Viral Shedding and Number of Subjects With Recorded Influenza Symptoms During the Quarantine Period.|Viral Shedding Duration|Total Viral Shedding (Area Under the Curve)|Peak Viral Load|Duration of Influenza Symptoms|Number of Symptoms Experienced Per Subject Per Day.|Peak Number of Symptoms Experienced Per Subject in a Single Day.|Assessment of Self-reported Influenza Symptoms by FLU-PRO Questionnaire.","PepTcell Limited|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 55 Years   (Adult)","Phase 2","153","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","FLU-v-004|2016-002134-74|2015-25472","August 18, 2016","March 31, 2017","May 25, 2017","June 8, 2017","May 1, 2019","November 6, 2019","hVIVO Services Limited, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03180801/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03180801/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03180801/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03180801"
203,"NCT03176654","The Effect of Manipulation of the Cervical Spine on Pain Biomarkers","HVLAT","Completed","Has Results","Neck Pain, Posterior","Procedure: HVLAT manipulation|Procedure: Sham HVLAT manipulation","Plasma Concentration of Oxytocin|Plasma Concentration of Neurotensin|Plasma Concentration of Orexin A|Plasma Concentration of Cortisol","Loma Linda University","Female","20 Years to 45 Years   (Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","5160076","August 15, 2016","September 20, 2016","September 20, 2016","June 5, 2017","August 1, 2019","August 1, 2019","Loma Linda University, Loma Linda, California, United States",,"https://ClinicalTrials.gov/show/NCT03176654"
204,"NCT03173170","A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants",,"Completed","Has Results","Healthy Participants","Drug: TAK-954|Drug: Itraconazole","Cmax: Maximum Observed Plasma Concentration for TAK-954|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-954-1004|2017-000713-22|U1111-1195-7682","May 31, 2017","July 24, 2017","July 24, 2017","June 1, 2017","January 15, 2019","January 15, 2019","Pharmaceutical Research Associates, Inc., Lenexa, Kansas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03173170/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03173170/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03173170"
205,"NCT03171415","Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers",,"Completed","Has Results","Obesity|Weight Loss|Overweight and Obesity","Drug: RZL-012|Drug: Placebo","Safety: The Incidence of Treatment-related Adverse Events [AEs]|Efficacy: A Significant Thermogenesis at the Injected Site.|Duration of the Thermogenic Effect From Day 28.|Local Reduction in Fat Mass as Measured by MRI. Local Reduction in Fat Will be Measured by Periodically MRI Scans of the Abdomen.|Changes in Fasting Blood Glucose From Baseline.|Changes in Blood Lipid Profile From Baseline.|Pharmacokinetics: Establishing Pharmacokinetic Profile of RZL-012.|Changes in Body Weight|Changes in Waist to Hip Ratio [WHR]|Elucidation of the Histological Changes Account for the Thermogenic Effect.|Change From Baseline in Inflammatory Markers and Cytokines. Testing of Inflammatory Markers and Cytokines Will be Conducted by Blood Sampling.","Raziel Therapeutics Ltd.|Spaulding Clinical Research LLC","Male","20 Years to 60 Years   (Adult)","Phase 2","32","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RZL-012-P2aUS-001","July 25, 2017","December 28, 2018","December 28, 2018","May 31, 2017","August 21, 2019","August 21, 2019","Spaulding Clinical, West Bend, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03171415/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03171415/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03171415"
206,"NCT03170609","A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age",,"Completed","Has Results","Group B Streptococcal Infections","Biological: Multivalent group B streptococcus vaccine|Biological: Placebo","Percentage of Participants With Clinical Laboratory Abnormalities at 1-Week After Vaccination as Measured by Food and Drug Administration (FDA) Grade|Percentage of Participants With Local Reactions by Maximum Severity Within 14 Days After Vaccination|Percentage of Participants With Systemic Events by Maximum Severity Within 14 Days After Vaccination|Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination|Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Month After Vaccination|Percentage of Participants With Medically Attended Adverse Events (MAEs) Within 6 Months After Vaccination|GBS6 Serotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 1 Month After Vaccination","Pfizer","All","18 Years to 49 Years   (Adult)","Phase 2","365","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","C1091001","June 5, 2017","June 25, 2018","June 25, 2018","May 31, 2017","July 2, 2019","July 2, 2019","Clinical Research Atlanta, Stockbridge, Georgia, United States|Kentucky Pediatric / Adult Research, Bardstown, Kentucky, United States|J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City, Utah, United States|J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03170609/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03170609/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03170609"
207,"NCT03170544","Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)",,"Completed","Has Results","Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus","Drug: MK-1092, 4.0 nmol/kg|Drug: MK-1092, 8.0 nmol/kg|Drug: MK-1092, 16 nmol/kg|Drug: MK-1092, 32 nmol/kg|Drug: MK-1092, 64 nmol/kg|Drug: Glargine 3.0 nmol/kg|Drug: Lispro 1.2 nmol/kg|Drug: Placebo to glargine|Drug: Placebo to MK-1092|Other: Dextrose|Biological: Insulin","Number of Participants Who Experienced an Adverse Event (AE)|Number of Participants Who Discontinued the Study Due to an AE|GIRmax After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Adult Participants With Type 1 Diabetes Mellitus (T1DM) (Part 3)|GIRmax After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Healthy Adult Participants (Part 1)|GIRmax After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Adult Participants With Type 2 Diabetes Mellitus (T2DM) (Part 4)|Time-Weighted Average GIR (TWA[GIR]) After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Healthy Adult Participants (Part 1)|Time-Weighted Average GIR (TWA[GIR]) After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Adult Participants With T1DM (Part 3)|Time-Weighted Average GIR (TWA[GIR]) After a Single Dose Administration of Subcutaneous MK-1092 or Glargine to Adult Participants With T2DM (Part 4)|Maximal Plasma MK-1092 Concentration (Cmax) Parts 1 and 3|Area Under the Plasma Drug Curve From 0 to Infinity (AUC0-inf) MK-1092 Parts 1 and 3|Rate of Plasma Drug Removal (CL/F) MK-1092 Parts 1 and 3|Time to Reach Maximum Plasma MK-1092 Concentration (Tmax) Parts 1 and 3|Time to Reach a 50% Decrease In Plasma MK-1092 Concentration (t1/2) Parts 1 and 3|Maximal Plasma MK-1092 Concentration (Cmax) Part 4|Area Under the Plasma Drug Curve From 0 to Infinity (AUC0-inf) MK-1092 Part 4|Rate of Plasma Drug Removal (CL/F) MK-1092 Part 4|Time to Reach Maximum Plasma MK-1092 Concentration (Tmax) Part 4|Time to Reach a 50% Decrease In Plasma MK-1092 Concentration (t1/2) Part 4|Maximal Plasma Insulin Glargine Concentration (Cmax) Parts 1 and 3|Area Under the Plasma Drug Curve From 0 to Infinity (AUC0-inf) Insulin Glargine Parts 1 and 3|Time to Reach Maximum Plasma Insulin Glargine Concentration (Tmax) Parts 1 and 3|Time to Reach a 50% Decrease In Plasma Insulin Glargine Concentration (t1/2) Parts 1 and 3|Maximal Plasma Insulin Glargine Concentration (Cmax) Part 4|Area Under the Plasma Drug Curve From 0 to Infinity (AUC0-inf) Insulin Glargine Part 4|Time to Reach Maximum Plasma Insulin Glargine Concentration (Tmax) Part 4|Time to Reach a 50% Decrease In Plasma Insulin Glargine Concentration (t1/2) Part 4","Merck Sharp & Dohme Corp.","All","18 Years to 60 Years   (Adult)","Phase 1","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1092-001|MK-1092-001","August 16, 2017","November 8, 2018","November 8, 2018","May 31, 2017","November 15, 2019","November 15, 2019","ProSciento Inc. ( Site 0001), Chula Vista, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03170544/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03170544"
208,"NCT03170193","AMG 529 First in Human Study",,"Completed","Has Results","Cardiovascular","Drug: AMG 529|Drug: Placebo","Number of Participants With Adverse Events (AEs)|Maximum Observed Concentration (Cmax) of AMG 529|Time to Maximum Observed Concentration (Tmax) of AMG 529|Area Under the Curve From Time 0 to the Last Quantifiable Concentration (AUClast) for AMG 529|Change From Baseline in Blood Alkaline Phosphatase Concentration Over Time|Change From Baseline in Total Cholesterol Concentration Over Time|Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Concentration Over Time|Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) Concentration Over Time|Change From Baseline in Triglycerides Concentration Over Time","Amgen","All","18 Years to 55 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20160338","May 15, 2017","November 17, 2017","November 17, 2017","May 30, 2017","July 5, 2019","July 5, 2019","Research Site, Overland Park, Kansas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03170193/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03170193/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03170193"
209,"NCT03168425","Opioid Prescribing After Cesarean Delivery",,"Completed","Has Results","Surgery|Opioid Use","Other: Tailored prescription|Other: Control","Unused Opioids|Pain: Frequency That Participants Reported Uncontrolled Pain","Vanderbilt University Medical Center","Female","18 Years to 50 Years   (Adult)","Not Applicable","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSMUNDSS04192017181235","June 14, 2017","September 21, 2017","September 21, 2017","May 30, 2017","June 3, 2019","June 3, 2019","Sarah Osmundson, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT03168425/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03168425"
210,"NCT03167541","Naproxen Sodium (2 x 220 mg) Fasted Comparative Bioavailability Study",,"Completed","Has Results","Healthy","Drug: Test|Drug: Reference","Area Under Plasma Concentration-time at Time t (AUC0-t)|Maximum Plasma Concentration (Cmax)|Elimination Rate Constant (Kel)|Area Under the Plasma Concentration Curve From Administration to Infinity (AUC0-inf)|Residual Area (AUC%Extrap)|Time Until Cmax is First Achieved (Tmax)|Plasma Concentration (Elimination) Half-life (T1/2)|Plasma Concentration at Each Planned Nominal Time-point (Cn)|Occurrence of Adverse Events (AEs)","Reckitt Benckiser Healthcare (UK) Limited|Simbec Research","All","18 Years to 50 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","RB9-UK-1514","October 12, 2016","December 2, 2016","December 2, 2016","May 30, 2017","February 28, 2019","February 28, 2019",,,"https://ClinicalTrials.gov/show/NCT03167541"
211,"NCT03165175","Mobile Application for Prescription Drug-Abuse Education (MAPDE)","MAPDE","Completed","Has Results","Prescription Drug Abuse (Not Dependent)","Behavioral: prescription drug-abuse education smartphone application","Current Opioid Misuse Measure (COMM)|Pain Medication Questionnaire (PMQ) Shortened Scale|Prescription Drug Misuse-related Attitudes|Prescription Drug Misuse-related Knowledge|Preparedness to Talk About Misuse","Naval Health Research Center|Intelligent Automation, Inc.","All","18 Years to 55 Years   (Adult)","Not Applicable","80","U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","HHSN271201500071C","May 22, 2017","June 11, 2018","October 17, 2018","May 24, 2017","August 5, 2019","August 5, 2019","Naval Health Research Center, San Diego, California, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03165175/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03165175"
212,"NCT03163342","Immune Response Following Seasonal Influenza Vaccination",,"Completed","Has Results","Influenza","Biological: Licensed seasonal influenza vaccine","HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain|Antibody Response to Divergent Influenza Strains|Cellular Immune Response|Mucosal Influenza Antibody Response","Altimmune, Inc.|Optimal Health Research","All","18 Years to 50 Years   (Adult)","Phase 4","20","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ALT-FLZ-401","May 8, 2017","November 21, 2017","June 15, 2018","May 23, 2017","April 26, 2019","April 26, 2019","Optimal Health Research, Rockville, Maryland, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT03163342/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT03163342/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03163342"
213,"NCT03162614","Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults",,"Completed","Has Results","Malaria","Biological: RTS,S/AS01E|Biological: RTS,S/AS01B|Procedure: Sporozoite-infected mosquitoes challenge.","Number of Subjects With at Least One Occurrence of Plasmodium Falciparum (P. Falciparum) Parasitemia for Each Vaccination Schedule Versus Infectivity Controls|Time to Onset of P. Falciparum Parasitemia After Sporozoite Challenge for Each Vaccination Schedule|Anti-Circumsporozoite (Anti-CS) Repeat Region Antibody Concentrations|Anti-Hepatitis B (Anti-HBs) Immunoglobulin G (IgG) Antibody Concentrations|Number of Subjects With Any Solicited Local Symptoms|Number of Subjects With Any Solicited General Symptoms|Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination|Number of Subjects With Any Unsolicited AEs After Challenge|Number of Subjects With Any, Fatal or Related Serious Adverse Events (SAEs) After Each Vaccination|Number of Subjects With Any, Fatal or Related SAEs During the Whole Study Period|Number of Subjects With Any AE and SAE Leading to Withdrawal From Further Vaccination|Number of Subjects With Potential Immune Mediated Diseases (pIMDs)|Number of Subjects With Meningitis|Number of Subjects With Abnormal Laboratory Values Gradings|Number of Subjects With Any, Fatal or Related SAE, After Challenge","GlaxoSmithKline|The PATH Malaria Vaccine Initiative (MVI)","All","18 Years to 55 Years   (Adult)","Phase 2","154","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","205081","May 24, 2017","July 9, 2018","September 24, 2018","May 22, 2017","July 24, 2019","November 14, 2019","GSK Investigational Site, Silver Spring, Maryland, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03162614/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03162614/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT03162614"
214,"NCT03162328","A Study of the Effectiveness and Efficacy of the PowerSleep Device",,"Completed","Has Results","Sleep Deprivation|Insufficient Sleep Syndrome|Healthy","Device: PowerSleep Stim|Device: PowerSleep Sham","Average Amount of Slow Wave Activity Delivered by the Powersleep Device With and Without Stimulation|Cumulative Amount of Slow Wave Activity Delivered by the Powersleep Device With and Without Stimulation|Changes in Multiple Sleep Latency Test (MSLT)|Paired Associates Learning (PAL)|Changes in Cognitive Testing - Verbal Fluency|Average Subjective Sleepiness Scales.|Average Subjective Sleepiness Scale- Karolinska Sleepiness Scale|Average of Subjective Sleepiness Scale- Samn Perelli|Psychomotor Vigilance Test - Reaction Times|Psychomotor Vigilance Test - Number of Anticipation and Number of Lapses.|Psychomotor Vigilance Test - Average Speed","Philips Respironics","All","21 Years to 50 Years   (Adult)","Not Applicable","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AI-16128-PSPIV-LO","April 25, 2017","November 10, 2017","November 10, 2017","May 22, 2017","January 29, 2019","January 29, 2019","Sleep Disorders Center of Alabama, Birmingham, Alabama, United States|Arkansas Center for Sleep Medicine, Little Rock, Arkansas, United States|Florida Lung & Sleep Associates, Lehigh Acres, Florida, United States|NeuroTrials Research Inc., Atlanta, Georgia, United States|Center for Sleep and Wake Disorders, Chevy Chase, Maryland, United States|Clayton Sleep Institute, Saint Louis, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT03162328/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03162328"
215,"NCT03161405","A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants",,"Completed","Has Results","Healthy Participants","Drug: TAK-906 Maleate|Drug: Itraconazole","Cmax: Maximum Observed Plasma Concentration for TAK-906|AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-906|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-906","Millennium Pharmaceuticals, Inc.|Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-906-1003|U1111-1192-7802","June 5, 2017","July 2, 2017","July 10, 2017","May 19, 2017","January 11, 2019","January 11, 2019","Takeda Investigational Site, Lenexa, Kansas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03161405/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03161405/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03161405"
216,"NCT03159468","Emotion Regulation Interventions for Alcohol-Related Sexual Aggression",,"Completed","Has Results","Sexual Aggression|Heavy Drinking","Behavioral: Cognitive Restructuring|Behavioral: Mindfulness|Other: Alcohol consumption","Sexual Aggression Intentions","University of Washington|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Arizona State University","Male","21 Years to 30 Years   (Adult)","Not Applicable","209","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","STUDY00002103|1R21AA023811-01A1","December 31, 2016","June 29, 2018","June 29, 2018","May 18, 2017","July 26, 2019","July 26, 2019","University of Washington, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT03159468/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03159468"
217,"NCT03158038","Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season","FluMist","Completed","Has Results","Influenza|Healthy","Biological: Monovalent Influenza Vaccine|Other: Placebo","Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F)|Percentage of Participants With Solicited Symptoms|Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) and New Onset Chronic Diseases (NOCDs)|Percentage of Participants Who Require Antipyretic and/or Analgesic Medication","MedImmune LLC|AstraZeneca","All","18 Years to 49 Years   (Adult)","Phase 4","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D2560C00014","May 30, 2017","December 14, 2017","December 14, 2017","May 17, 2017","January 4, 2019","January 4, 2019","Research Site, Stockbridge, Georgia, United States|Research Site, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03158038/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03158038"
218,"NCT03158012","Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients",,"Completed","Has Results","Atopic Dermatitis Eczema","Biological: Autologous Microbial Transplant","Relative Abundance of Staphylococcus Aureus Compared to Baseline","University of California, San Diego","All","18 Years to 60 Years   (Adult)","Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UCSD 131244.4","April 2016","December 2017","August 2018","May 17, 2017","November 7, 2019","November 7, 2019","University of California San Diego Dermatology Clinic, San Diego, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03158012/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03158012"
219,"NCT03157232","Rainbow DCI vs. R1-25 Sensor SpHb Sub-Range Performance Equivalence",,"Completed","Has Results","Healthy","Device: Rainbow DCI and R1-25 sensor","Sub-Range Performance Equivalence of Rainbow DCI and R1-25 Sensors by ARMS Calculation","Masimo Corporation","All","18 Years to 40 Years   (Adult)","Not Applicable","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TR18695-TP14480","June 19, 2009","June 29, 2009","June 29, 2009","May 17, 2017","July 27, 2017","July 27, 2017","Masimo, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT03157232"
220,"NCT03155269","To Investigate the Impact of a Nutritional Supplement on Bone Turnover Markers in Indian Healthy Premenopausal Women (25- 45 Years) After 6 Months of Intervention",,"Completed","Has Results","Growth and Development","Dietary Supplement: Fortified Beverage Powder|Dietary Supplement: Non fortified beverage Powder","Change From Baseline in Serum Cross Linking C-telopeptide of Type 1 Collagen (s-CTX-1) at 6 Months|Change From Baseline in the Ratio of Carboxylated (c-OC) to Under-carboxylated Osteocalcin (Uc-OC) at 6 Months|Change From Baseline in Serum Cross Linking C-telopeptide of Type 1 Collagen (s-CTX-1) at 3 Months|Change From Baseline in the Ratio of Carboxylated (c-OC) to Under-carboxylated Osteocalcin (Uc-OC) at 3 Months|Change From Baseline in Urinary Cross Linking C-telopeptide of Type 1 Collagen at 3 Months and 6 Months|Change From Baseline in Serum N-terminal Telopeptide of Type 1 Collagen (s-NTX-1) at 3 Months and 6 Months|Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (s-P1NP) at 3 Months and 6 Months|Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) at 3 Months and 6 Months|Change From Baseline in Serum Parathyroid Hormone (s-PTH) at 3 Months and 6 Months|Change From Baseline in Urinary Calcium at 3 Months and 6 Months|Change From Baseline in Serum Calcium at 3 Months and 6 Months|Change From Baseline in Serum Phosphorus at 3 Months and 6 Months|Change From Baseline in Total Alkaline Phosphatase (ALP) at 3 Months and 6 Months|Change From Baseline in Serum Vitamin D3 Using 25-hydroxycholecalciferol (25 OH D3) at 3 Months and 6 Months|Change From Baseline in Serum Selenium (Se) at 3 Months and 6 Months|Change From Baseline in Plasma Zinc (Zn) at 3 Months and 6 Months|Change From Baseline in Serum Folic Acid (Folate) at 3 Months and 6 Months|Change From Baseline in Plasma Vitamin-B6 at 3 Months and 6 Months|Change From Baseline in Serum Vitamin-B12 at 3 Months and 6 Months","GlaxoSmithKline","Female","25 Years to 45 Years   (Adult)","Not Applicable","114","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","207192","May 25, 2017","January 16, 2018","January 16, 2018","May 16, 2017","April 12, 2019","April 12, 2019","GSK Investigational Site, Pune, India","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03155269/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03155269/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03155269"
221,"NCT03154086","A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers",,"Completed","Has Results","Irritable Bowel Syndrome","Drug: GSK3352589|Drug: Matching Placebo","Part A: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs in Cohort 1|Part A: Number of Participants With SAEs and Non-SAEs in Cohort 2|Part A: Number of Participants With SAEs and Non-SAEs in Cohort 3|Part B: Number of Participants With SAEs and Non-SAEs|Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 1|Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 2|Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 3|Part B: Number of Participants With Abnormal Findings After Physical Examination|Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings in Cohort 1 and Cohort 3|Part A: Number of Participants With Abnormal ECG Findings in Cohort 2|Part B: Number of Participants With Abnormal ECG Findings|Part A: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in Cohort 1 and Cohort 3|Part A: Change From Baseline in SBP and DBP in Cohort 2|Part B: Change From Baseline in SBP and DBP|Part A: Change From Baseline in Pulse Rate in Cohort 1 and Cohort 3|Part A: Change From Baseline in Pulse Rate in Cohort 2|Part B: Change From Baseline in Pulse Rate|Part A: Change From Baseline in Body Temperature in Cohort 1 and Cohort 3|Part A: Change From Baseline in Body Temperature in Cohort 2|Part B: Change From Baseline in Body Temperature|Part A: Number of Participants With Different Stool Types Assessed Using Bristol Stool Form Scale (BSFS) in Cohort 1|Part A: Number of Participants With Different Stool Types Assessed Using BSFS in Cohort 2|Part A: Number of Participants With Different Stool Types Assessed Using BSFS in Cohort 3|Part B: Average BSFS at Indicated Time Points|Part A: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes in Cohort 1 and Cohort 3|Part A: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes in Cohort 2|Part B: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes|Part A: Change From Baseline in Erythrocytes in Cohort 1 and 3|Part A: Change From Baseline in Erythrocytes in Cohort 2|Part B: Change From Baseline in Erythrocytes|Part A: Change From Baseline in Hemoglobin in Cohort 1 and 3|Part A: Change From Baseline in Hemoglobin in Cohort 2|Part B: Change From Baseline in Hemoglobin|Part A: Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) in Cohort 1 and Cohort 3|Part A: Change From Baseline in Erythrocyte MCV in Cohort 2|Part B: Change From Baseline in Erythrocyte MCV|Part A: Change From Baseline in Erythorocyte Mean Corpuscular Hemoglobin (MCH) in Cohort 1 and 3|Part A: Change From Baseline in Erythrocyte MCH in Cohort 2|Part B: Change From Baseline in Erythrocyte MCH|Part A: Change From Baseline in Hematocrit in Cohort 1 and 3|Part A: Change From Baseline in Hematocrit in Cohort 2|Part B: Change From Baseline in Hematocrit|Part A: Change From Baseline in Alanine Aminotransferase (ALT),Aspartate Aminotransferase (AST), Alkaline Phosphatase (Alk Phos) in Cohort 1 and 3|Part A: Change From Baseline in ALT, AST and Alk Phos in Cohort 2|Part B: Change From Baseline in ALT, AST and Alk Phos|Part A: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin in Cohort 1 and 3|Part A: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin in Cohort 2|Part B: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin|Part A: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea in Cohort 1 and 3|Part A: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea in Cohort 2|Part B: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea|Part A: Change From Baseline in Albumin and Total Protein in Cohort 1 and 3|Part A: Change From Baseline in Albumin and Total Protein in Cohort 2|Part B: Change From Baseline in Albumin, Total Protein|Part A: Number of Participants With Abnormal Findings for Urine Parameters in Cohort 1 and Cohort 3|Part A: Number of Participants With Abnormal Findings for Urine Parameters in Cohort 2|Part B: Number of Participants With Abnormal Findings for Urine Parameters|Part A: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Non-zero Concentration (AUC [0-t]) Following Single Dose Administration of GSK3352589|Part A: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) Following Single Dose Administration of GSK3352589|Part A: Maximum Observed Plasma Concentration (Cmax) Following Single Dose Administration of GSK3352589|Part A: Time to Reach Cmax (Tmax) Following Single Dose Administration of GSK3352589|Part A: Terminal Elimination Half-life (t1/2) Following Single Dose Administration of GSK3352589|Part A: Cmax Following Single Dose Administration of GSK3352589-Food Effect|Part A: AUC (0-t) Following Single Dose Administration of GSK3352589- Food Effect|Part A: AUC (0-infinity) Following Single Dose Administration of GSK3352589- Food Effect|Part B: AUC (0-t) Following Repeat Dose Administration of GSK3352589|Part B: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours Post-dose (AUC [0-24]) Following Repeat Dose Administration of GSK3352589|Part B: Area Under the Concentration-time Curve Over the Dosing Interval (AUC [0-tau]) Following Repeat Dose Administration of GSK3352589|Part B: Cmax Following Repeat Dose Administration of GSK3352589|Part B: Tmax Following Repeat Dose Administration of GSK3352589","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","207440","May 17, 2017","March 5, 2018","March 5, 2018","May 15, 2017","August 9, 2019","August 9, 2019","GSK Investigational Site, Adelaide, South Australia, Australia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03154086/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03154086/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03154086"
222,"NCT03152591","Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome","PCOS","Completed","Has Results","Polycystic Ovary Syndrome","Drug: LIK066|Drug: Placebo","Change in Average Morning Fasting Free Testosterone Blood Concentrations From Baseline|Change From Baseline in Luteinizing Hormone (LH) at Day 15|Change From Baseline in Follicle Stimulating Hormone (FSH) at Day 15|Change From Baseline in Sex Hormone Binding Globulin (SHBG) at Day 15|Change From Baseline in Androstenedione at Day 15|Change From Baseline in Dehydroepiandrostenedione (DHEA) at Day 15|Change From Baseline in Dehydroepiandrostenedione Sulfate (DHEAS) at Day 15|Change From Baseline in Total Testosterone, at Day 15|Change From Baseline in Free Androgen Index (FAI), at Day 15","Novartis Pharmaceuticals|Novartis","Female","18 Years to 40 Years   (Adult)","Phase 2","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","CLIK066X2205|2017-001373-16","July 24, 2017","June 25, 2018","June 25, 2018","May 15, 2017","May 9, 2019","May 9, 2019","Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Freiburg, Germany","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT03152591/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT03152591/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03152591"
223,"NCT03151265","A Prospective Pilot Study Investigating the Impact of ThermaCare on Flexibility, Muscle Relaxation & Low Back Pain",,"Completed","Has Results","Low Back Pain","Device: ThermaCare Low Back Heat Wrap","Change in Movement Data Over Time|Change in Erector Spinae Muscle Activity Over Time|A Change Over Time in Range of Motion in Any One Plane of Movement Compared to Pre-intervention Range of Motion.|In Group 1 (LBP Patients), a Change in Maximum Pain During Movement Score, for Any One Plane of Movement.|A Change in Muscle Activity From Baseline in Subjects Where Abnormal EMG Activity During Baseline is Detected.|Change in Pain From Baseline|Observation of Self-reported Changes in Functional Status Pre- and Post- ThermaCare Application as Measured by the Oswestry Disability Index (ODI) if Subjects Scored >3 on the NRS|Impression of Change From Subjects Post Intervention and/or Assessment Period Using the Patient Global Impression of Change Scale (PGIC).|Observation of Self-reported Changes in Functional Status Pre- and Post- ThermaCare Application as Measured by the Roland Morris Disability Questionnaire (RMDQ) if Subjects Scored >3 on the NRS","dorsaVi Ltd|Monash University","All","21 Years to 54 Years   (Adult)","Not Applicable","40","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017THERMA","July 3, 2017","December 21, 2017","December 21, 2017","May 12, 2017","May 10, 2019","May 10, 2019","Clifton Hill Physiotherapy, Clifton Hill, Victoria, Australia|Peak MSK Physiotherapy, Hampton, Victoria, Australia|Hoppers Physio, Hoppers Crossing, Victoria, Australia","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03151265/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03151265/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03151265"
224,"NCT03151226","OSA Screen Negative With Spinal Duramorph",,"Terminated","Has Results","Respiratory Depression","Device: Capnography monitoring","Respiratory Depression/Suppression","Wake Forest University Health Sciences","Female","18 Years to 50 Years   (Adult)","Not Applicable","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB00033095","August 3, 2015","October 1, 2015","October 1, 2015","May 12, 2017","March 8, 2018","September 7, 2018","Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03151226"
225,"NCT03150082","Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Subjects",,"Completed","Has Results","Infections, Bacterial","Drug: GR37547 tablet|Drug: Ciprofloxacin reference tablet","Area Under the Plasma Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC[0-t]) for Ciprofloxacin|Maximum Observed Plasma Concentration (Cmax) of Ciprofloxacin|Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-infinity]) for Ciprofloxacin|Time of Occurrence of Cmax (Tmax) for Ciprofloxacin|Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) for Ciprofloxacin|Terminal Phase Half-life (t1/2) for Ciprofloxacin|Number of Participants With Serious Adverse Events (SAEs) and Non-serious AEs (Non-SAEs)|Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk Phos), Aspartate Aminotransferase (AST) and Lactate Dehydrogenase (LD) at Indicated Time-points|Blood Urea Nitrogen (BUN) at Indicated Time-points|Calcium, Chloride, Glucose, Magnesium, Potassium and Sodium at Indicated Time-points|Total Bilirubin (Total Bil), Direct Bilirubin (Direct Bil) and Creatinine (Creat) at Indicated Time-points|Total Protein at Indicated Time-points|Platelets, Neutrophils, Monocytes, Lymphocytes, Leucocyte, Eosinophils and Basophils at Indicated Time-points|Mean Corpuscular Volume (MCV) at Indicated Time-points|Mean Corpuscular Hemoglobin (MCH) at Indicated Time-points|Mean Corpuscular Hemoglobin Concentration (MCHC) and Hemoglobin (Hb) at Indicated Time-points|Percent Reticulocytes at Indicated Time-points|Hematocrit at Indicated Time-points|Erythrocyte Count at Indicated Time-points|Number of Participants With Clinically Significant Abnormal Findings for Urinalysis|Number of Participants With Clinically Significant Abnormal Findings for Electrocardiogram (ECG) Parameters|Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Indicated Time-points|Respiratory Rate at Indicated Time-points|Pulse Rate at Indicated Time-points|Body Temperature at Indicated Time-points","GlaxoSmithKline|Parexel","All","18 Years to 60 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","205730","August 1, 2017","August 28, 2017","August 28, 2017","May 11, 2017","December 19, 2018","December 19, 2018","GSK Investigational Site, Bloemfontein,, South Africa","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03150082/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03150082"
226,"NCT03143166","Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan",,"Completed","Has Results","Non-alcoholic Fatty Liver Disease","Drug: Dabigatran Etexilate|Drug: Rabeprazol sodium","Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Total Dabigatran (AUC0-tz).|Maximum Concentration of Total Dabigatran in Plasma (Cmax).|Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Free Dabigatran (AUC0-tz).|Maximum Concentration of Free Dabigatran in Plasma (Cmax).|Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).|Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).","Boehringer Ingelheim","Male","20 Years to 40 Years   (Adult)","Phase 1","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1160-0270","May 22, 2017","July 27, 2017","August 2, 2017","May 8, 2017","January 16, 2019","January 16, 2019","Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03143166/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03143166/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03143166"
227,"NCT03139578","Short-Term Clinical Comparison of Two Silicone Hydrogel Daily Disposable Contact Lenses",,"Completed","Has Results","Visual Acuity","Device: Test 8.5BC|Device: Test 9.0BC|Device: Control 8.5BC|Device: Control 9.0BC","Overall Fit Acceptance|Lens Power Requirement|Subjective Comfort at Lens Insertion|Subjective Comfort After Lens Settling|Subjective Vision Quality|Subjective Handling|Monocular High Contrast Visual Acuity (VA)","Johnson & Johnson Vision Care, Inc.","All","18 Years to 55 Years   (Adult)","Not Applicable","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR-5932","April 28, 2017","October 22, 2017","October 22, 2017","May 4, 2017","December 11, 2018","February 1, 2019","Aston University Optometry and Vision Science, Birmingham, United Kingdom|Visioncare Research, Farnham, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03139578/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03139578"
228,"NCT03139240","Opioid Analgesia for MAB",,"Completed","Has Results","MAB|Pain","Drug: Oxycodone 10mg oral|Other: Placebo","Overall Maximum Self-reported Pain Score|<7 Weeks of Gestation - Maximum Self-reported Pain Score|7-10 Weeks Gestation - Maximum Self-reported Pain Score","Oregon Health and Science University|Society of Family Planning","Female","18 Years to 50 Years   (Adult)","Phase 4","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16845","May 1, 2017","May 31, 2018","May 31, 2018","May 3, 2017","August 13, 2019","August 28, 2019","Site 1, Beaverton, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03139240/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03139240"
229,"NCT03138798","Dental Support Device in the Second Stage of Labor",,"Completed","Has Results","Labor","Device: Laboraide TM dental support device","Dilation Duration of Second Stage of Labor Time|Delivery Time|Dental Support Device Comfort and Patient Satisfaction|Mode of Delivery|Estimated Blood Loss|Number of Participants With Post-partum Hemorrhage|Number of Participants With Chorioamnionitis|Neonatal Birth Weight|Neonatal Sex|Number of NICU Admission","Angela Bianco|Icahn School of Medicine at Mount Sinai","Female","18 Years to 64 Years   (Adult)","Not Applicable","348","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 16-2121","January 6, 2017","November 7, 2017","November 7, 2017","May 3, 2017","December 11, 2018","December 11, 2018","Icahn School of Medicine at Mount Sinai, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT03138798/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03138798"
230,"NCT03135899","BI 443651 Methacholine Challenge",,"Completed","Has Results","Asthma","Drug: BI 443651|Drug: Placebo","Absolute Change From Baseline in Maximum Forced Expiratory Volume Within 1 Second (FEV1) Reduction Following Bolus Methacholine Challenge in Part 1|Absolute Change From Baseline in Maximum Forced Expiratory Volume Within 1 Second (FEV1) Reduction Following Bolus Methacholine Challenge in Part 2.|Relative Change From Baseline in FEV1 Area Under the Curve Over the Time Interval From 0 to Timepoint tz (FEV1 AUC0-tz) Following Bolus Methacholine Challenge in Part 1|Relative Change From Baseline in FEV1 Area Under the Curve Over the Time Interval From 0 to Timepoint tz (FEV1 AUC0-tz) Following Bolus Methacholine Challenge in Part 2|Time to Recovery of FEV1 to Within 95% of Post-diluent Value in Part 1|Time to Recovery of FEV1 to Within 95% of Post-diluent Value in Part 2","Boehringer Ingelheim","All","18 Years to 60 Years   (Adult)","Phase 1","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1363.7|2016-001506-42","May 18, 2017","February 7, 2018","February 21, 2018","May 2, 2017","November 27, 2019","November 27, 2019","The Medicines Evaluation Unit, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03135899/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03135899/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03135899"
231,"NCT03134183","24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E",,"Completed","Has Results","Abortion, Second Trimester","Drug: Vaginal Misoprostol|Drug: Buccal Misoprostol","Procedure Time|Cervical Dilation","Virginia Commonwealth University","Female","18 Years to 50 Years   (Adult)","Phase 4","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HM20005740","November 19, 2016","August 1, 2017","August 1, 2017","April 28, 2017","July 18, 2018","July 18, 2018","Virginia Commonwealth University, Richmond, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03134183/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03134183"
232,"NCT03131895","Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants",,"Completed","Has Results","Healthy Volunteers","Drug: 30 mg dexlansoprazole capsules manufactured at TOB|Drug: 30 mg dexlansoprazole capsules manufactured at TPC|Drug: 60 mg dexlansoprazole capsules manufactured at TOB|Drug: 60 mg dexlansoprazole capsules manufactured at TPC","Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole|AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Dexlansoprazole|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Dexlansoprazole","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","116","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-390MR-1001|U1111-1184-2186","April 25, 2017","July 3, 2017","July 31, 2017","April 27, 2017","June 14, 2019","June 14, 2019","PRAHS Phase 1 unit, Salt Lake City, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT03131895/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT03131895/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03131895"
233,"NCT03131596","Postoperative Intermittent Intrauterine Balloon Dilatation Therapy.",,"Completed","Has Results","Intrauterine Adhesion","Procedure: IUB dilatation therapy","Number of Participants With Adhesion Reformation (American Fertility Society Score of Greater Than 0) 8 Weeks Later After the Index Surgery|The American Fertility Society Score 8 Weeks After Operation|Pictorial Blood Loss Assessment Chart Score 8 Weeks After Operation|Pregnancy Outcome Within 12 Months Follow-up After Third Look Hysteroscopy","Fu Xing Hospital, Capital Medical University","Female","18 Years to 40 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","2016FXHEC—KY036","May 15, 2017","November 15, 2017","November 15, 2018","April 27, 2017","September 13, 2019","September 13, 2019","Fu Xing Hospital, Beijing, Beijing, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT03131596/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03131596"
234,"NCT03128372","Validation of Next Generation Cerebral and Tissue Oximeter",,"Completed","Has Results","Oxygen Deficiency","Device: Desaturation","Validated the Next Generation Oximeter","Medtronic - MITG","All","18 Years to 46 Years   (Adult)","Not Applicable","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MDT16010MAVJB3","May 22, 2017","July 19, 2017","July 19, 2017","April 25, 2017","November 9, 2018","November 9, 2018","Duke University Hospital, HPPL, Durham, North Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT03128372/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT03128372/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03128372"
235,"NCT03127943","Clinical Outcomes Mandible: Buffered 1% vs. Non-Buffered 1% Lidocaine",,"Completed","Has Results","Anesthesia, Local","Drug: Lidocaine","Mean Time to Pulpal Response After Mandibular Molar Anesthesia|Mean Time to Pulpal Response After Mandibular Canine Anesthesia","University of North Carolina, Chapel Hill","All","18 Years to 30 Years   (Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","16-0068","May 1, 2017","April 1, 2018","April 1, 2018","April 25, 2017","February 6, 2019","February 6, 2019","UNC School of Dentistry, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03127943/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03127943"
236,"NCT03127384","Performance and Safety of Restylane Lidocaine for Treatment of Depressed Facial Acne Scars",,"Completed","Has Results","Healthy Volunteers","Device: Restylane Lidocaine|Other: No-treatment control","Percentage of Participants With Lower Scar Severity in the Treated Cheek Compared to the Untreated Cheek|Percentage of Participants Improved on the Global Aesthetic Improvement Scale (GAIS)","Q-Med AB","All","25 Years to 55 Years   (Adult)","Phase 4","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","05DF1605","April 20, 2017","February 15, 2018","November 8, 2018","April 25, 2017","October 3, 2019","October 3, 2019","Darmstadt, Darmstadt, Germany|Munich, Munich, Germany","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03127384/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03127384"
237,"NCT03125031","Comparison of Noninvasive Hemoglobin Disposable Sensors",,"Completed","Has Results","Healthy","Device: Rainbow adhesive adult/pediatric sensor|Device: Rainbow adhesive adult/neonatal sensor","Accuracy of Noninvasive Sensors by Arms Calculation","Masimo Corporation","All","18 Years to 40 Years   (Adult)","Not Applicable","44","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TR26947-TP16847A","July 10, 2014","July 25, 2014","July 25, 2014","April 24, 2017","June 6, 2017","July 27, 2017","Masimo Clinical Lab, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT03125031"
238,"NCT03125018","Accuracy of SpO2 for Noninvasive Pulse Oximeter Sensor (LNCS ADTX)",,"Completed","Has Results","Healthy","Device: LNCS ADTX Sensor","Accuracy of Sensor by Arms Calculation","Masimo Corporation","All","18 Years to 40 Years   (Adult)","Not Applicable","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TR27479-TP16850A","September 30, 2014","October 9, 2014","October 9, 2014","April 24, 2017","July 28, 2017","July 28, 2017","Masimo Corporation, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT03125018"
239,"NCT03125005","Accuracy of Methemoglobin Measurement for Rainbow Universal Pulse Oximeter Sensor",,"Completed","Has Results","Healthy","Device: Rainbow Universal Pulse Oximeter Sensor","Accuracy of Sensor by Arms Calculation","Masimo Corporation","All","18 Years to 50 Years   (Adult)","Not Applicable","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TR22640-BICK0001","April 12, 2012","June 21, 2012","June 21, 2012","April 24, 2017","June 6, 2017","July 27, 2017","Masimo Clinical Lab, Irvine, California, United States|University of San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03125005"
240,"NCT03124979","Accuracy of Noninvasive Pulse Oximeter Sensor (LNCS DBI)",,"Completed","Has Results","Healthy","Device: LNCS DBI Sensor","Accuracy of Sensor by Arms Calculation","Masimo Corporation","All","18 Years to 40 Years   (Adult)","Not Applicable","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TR22194-TP16113","January 18, 2012","April 10, 2012","April 10, 2012","April 24, 2017","July 28, 2017","July 28, 2017","Masimo, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT03124979"
241,"NCT03124927","Accuracy of Methemoglobin Measurement for Rainbow DCI Sensors",,"Completed","Has Results","Healthy","Device: DCI pulse oximeter sensor","Accuracy of Sensor by Arms Calculation","Masimo Corporation","All","18 Years to 40 Years   (Adult)","Not Applicable","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TR-17413-REDF0003","April 23, 2008","August 8, 2008","August 8, 2008","April 24, 2017","June 12, 2017","June 12, 2017","University of Arizona, Tucson, Arizona, United States|University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03124927"
242,"NCT03124836","Accuracy of Methemoglobin Measurement of Various Rainbow Pulse Oximeter Sensors",,"Completed","Has Results","Healthy","Device: Pulse Oximeter Sensor","Accuracy of Methemoglobin Measurement by Arms Calculation","Masimo Corporation","All","18 Years to 50 Years   (Adult)","Not Applicable","28","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TR19427-BICK0001","November 18, 2009","December 17, 2009","December 17, 2009","April 24, 2017","July 27, 2017","July 27, 2017","University of San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03124836"
243,"NCT03124823","Accuracy of Noninvasive Pulse Oximeter Sensor (Rainbow DCI)",,"Completed","Has Results","Healthy","Device: Rainbow DCI Sensor","Accuracy of Sensor by Arms Calculation","Masimo Corporation","All","18 Years to 45 Years   (Adult)","Not Applicable","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TR29866-TP17699A","August 28, 2015","September 8, 2015","September 8, 2015","April 24, 2017","July 28, 2017","July 28, 2017","Masimo Corporation, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT03124823"
244,"NCT03124797","Accuracy of SpO2 for Noninvasive Pulse Oximeter Sensor (RD DCI)",,"Completed","Has Results","Healthy","Device: RD DCI Sensor","Accuracy of Sensor by Arms Calculation","Masimo Corporation","All","18 Years to 45 Years   (Adult)","Not Applicable","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TR30835-123A-123B-127A","March 2, 2016","April 5, 2016","April 5, 2016","April 24, 2017","July 28, 2017","July 28, 2017","Masimo Corporation, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT03124797"
245,"NCT03124784","Accuracy of Oxygen Saturation (SpO2) Noninvasive Pulse Oximeter Sensor (RD Disposable) Under Motion Conditions",,"Completed","Has Results","Healthy","Device: RD Disposable Sensors","SpO2 ARMS of Sensor Under Motion Conditions","Masimo Corporation","All","18 Years to 45 Years   (Adult)","Not Applicable","27","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TR33143-000190A","January 3, 2017","January 20, 2017","January 20, 2017","April 24, 2017","March 23, 2018","March 23, 2018","Masimo Corporation, Irvine, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03124784/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03124784"
246,"NCT03124771","Accuracy of Noninvasive Hemoglobin Pulse Oximeter (Rainbow Resposable Adhesive Sensors)",,"Completed","Has Results","Healthy","Device: Rainbow Resposable Adhesive Sensors","Accuracy of Sensor by Arms Calculation","Masimo Corporation","All","18 Years to 40 Years   (Adult)","Not Applicable","132","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TR23394-TP16171","December 27, 2011","April 3, 2012","April 3, 2012","April 24, 2017","June 6, 2017","July 27, 2017","Masimo, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT03124771"
247,"NCT03124602","SpO2 Validation of Noninvasive Red Diamond Disposable Pulse Oximeter Sensor",,"Completed","Has Results","Healthy","Device: Red Diamond Disposable Pulse Oximeter Sensor","Accuracy of Red Diamond Disposable Pulse Oximeter Sensor by Arms Calculation","Masimo Corporation","All","18 Years to 50 Years   (Adult)","Not Applicable","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TP18604A_195","March 7, 2017","May 11, 2017","May 11, 2017","April 24, 2017","August 22, 2019","August 22, 2019","Masimo Corporation, Irvine, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03124602/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03124602/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03124602"
248,"NCT03123848","A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants",,"Completed","Has Results","Healthy","Drug: Darunavir/Cobicistat","Maximum Observed Plasma Concentration (Cmax)|Concentration at Last Quantifiable Time Point (Clast)|Time to Reach the Maximum Plasma Concentration (Tmax)|Area Under the Plasma Concentration-Time Curve From Time Zero to Time the Last Quantifiable Time (AUC[0-last])|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC0-infinity)|Elimination Rate Constant (Lambda[z])|Terminal Elimination Half-Life (t1/2)|Apparent Volume of Distribution (Vz/F)|Apparent Total Body Clearance of Drug at the Terminal Phase After Extravascular Administration (CL/F)|Number of Participants With Adverse Events (AEs)","Janssen Pharmaceutical K.K.","All","20 Years to 55 Years   (Adult)","Phase 4","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CR108319|TMC114FD1HTX4002","April 14, 2017","May 19, 2017","May 19, 2017","April 21, 2017","June 12, 2018","June 12, 2018","Souseikai Hakata Clinic, Fukuoka, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03123848/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03123848/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03123848"
249,"NCT03121820","Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects",,"Completed","Has Results","Bioequivalence, AUC, Cmax, Pharmacokinetics","Drug: Memantinol tablets, 20 mg|Drug: Akatinol Memantine® tablets, 20 mg","Pharmacokinetics of Memantinol by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))|Pharmacokinetics of Memantinol by Assessment of Observed Maximum Plasma Concentration (Cmax)","Geropharm","All","18 Years to 45 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BIOMEM-20","October 11, 2016","November 19, 2016","November 19, 2016","April 20, 2017","October 29, 2018","October 29, 2018","City Clinical Hospital № 15 named. O.M.filatova, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03121820"
250,"NCT03119181","Study to Compare Active Tymbion Iontophoresis to Sham Tymbion Iontophoresis for Anesthesia of the Tympanic Membrane","ADEPT","Completed","Has Results","Healthy Volunteer","Drug: Tymbion Lidocaine/epinephrine solution|Combination Product: Device: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution","Subject-reported Visual Analog Scale (VAS) Pain Score Following Tympanic Membrane Tap for Subjects Treated With Active Tymbion Iontophoresis Compared to VAS Score for Subjects Treated With Sham Tymbion Iontophoresis.","Tusker Medical","All","18 Years to 50 Years   (Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","CPR007003 - Group A","April 27, 2017","May 11, 2017","May 11, 2017","April 18, 2017","January 6, 2020","January 6, 2020","Camino ENT, San Jose, California, United States|Specialty Physician Associates, Bethlehem, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03119181/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03119181/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03119181"
251,"NCT03118297","Intervention to End Recurrent Unscheduled Bleeding Trial","INTERRUPT","Completed","Has Results","Contraception|Bleeding","Drug: Ulipristal Acetate|Drug: Placebo oral capsule","Number of Bleeding/Spotting Days With Use of Ulipristal Acetate as Measured by Daily Bleeding Diaries|Number of Participants With Bleeding Cessation by Day 10|Participant Satisfaction With Bleeding Pattern at 30 Days|Number of Participants With Medication Side Effects by 30 Days|Ovulation Status Measured by Weekly Serum Progesterone Levels","Washington University School of Medicine","Female","18 Years to 45 Years   (Adult)","Phase 3","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201612002","May 1, 2017","January 31, 2018","January 31, 2018","April 18, 2017","August 31, 2018","August 31, 2018","Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT03118297/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03118297"
252,"NCT03111316","Foley Catheter Compared to the Foley Catheter Alone for Cervical Ripening",,"Active, not recruiting","Has Results","Cervical Ripening|Induction of Labor","Drug: Cervidil 10 MG Vaginal Insert|Device: Foley Catheter","The Median Times From Placement of Foley Catheter to Vaginal Delivery|To Evaluate the Proportion of Patients That Delivered by 12 Hours and Proportion of Patients Delivered by 24 Hours","University of Oklahoma|Ferring Pharmaceuticals","Female","18 Years to 50 Years   (Adult)","Not Applicable","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ferring","April 9, 2017","January 5, 2018","September 30, 2020","April 12, 2017","May 3, 2019","December 3, 2019","The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03111316/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03111316"
253,"NCT03110003","Bupivacaine With Epidural Volume Extension",,"Completed","Has Results","Spinal Anesthesia|Epidural; Anesthesia","Drug: 10 mg Bupivacaine|Drug: 5 mg Bupivacaine","Time Until PACU Discharge in Minutes|Peak Block Height|Degree of Peak Motor Blockade by Modified Bromage Scale|Time Elapsed Until Motor Block Regresses to Modified Bromage Score = 0|Quality of Block as Determined by Subjective Pain Assessment|Patient Satisfaction as Determined by a Likert-type Scale","University of Alabama at Birmingham","Female","18 Years to 60 Years   (Adult)","Phase 3","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","F1605020005","June 27, 2016","December 1, 2017","September 30, 2018","April 12, 2017","September 13, 2018","December 19, 2018","UAB Department of Anesthesiology and Perioperative Medicine, Birmingham, Alabama, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03110003/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03110003"
254,"NCT03108157","Endometrial Scratch Effect on Pregnancy Rates in Patients Undergoing Egg-donation IVF",,"Active, not recruiting","Has Results","EMBRYO IMPLANTATION","Procedure: Endometrial scratch","Positive Pregnancy Test","Procreatec|Hospital Universitario 12 de Octubre","Female","18 Years to 50 Years   (Adult)","Not Applicable","352","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENDOSCRATCH","January 12, 2017","November 30, 2018","December 31, 2019","April 11, 2017","December 4, 2019","December 4, 2019","Procreatec, Madrid, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03108157/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03108157/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03108157"
255,"NCT03106870","Adding Metformin to Insulin in Controlling Pregestational and Gestational Diabetes Mellitus",,"Completed","Has Results","Gestational Diabetes Mellitus in Pregnancy","Drug: Insulin Mixtard|Drug: Metformin","Number of Participants With Glycemic Control Over Period From 20 Weeks to 36 Weeks Gestation|Number of Participants With a Macrosomic Baby|Number of Participants With Neonates Who Were Hypoglycemic","Ain Shams University","Female","20 Years to 35 Years   (Adult)","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Metformin","June 2016","December 2016","December 2016","April 11, 2017","June 14, 2017","June 14, 2017",,,"https://ClinicalTrials.gov/show/NCT03106870"
256,"NCT03105518","Predictors of Postoperative Pain Following Oocyte Retrieval for Assisted Reproduction",,"Completed","Has Results","Oocyte Retrieval|Postoperative Pain","Drug: Fentanyl|Drug: Acetaminophen|Drug: Oxycodone","Amount of Discomfort|Amount of Discomfort Following Discharge Until Embryo Transfer","Brigham and Women's Hospital","Female","18 Years to 50 Years   (Adult)","Phase 4","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-P-002310/1","March 1, 2011","October 30, 2011","October 30, 2011","April 10, 2017","December 5, 2017","December 5, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03105518"
257,"NCT03103906","Evaluation of the Cosmetic Benefit of a Skin Cream in Healthy Females With Mild to Advanced Photo-damaged Facial Skin Who Have Undergone a Glycolic Acid Facial Peel Procedure",,"Completed","Has Results","Skin Care","Other: Cream (Test product)|Other: Cleanser (Reference Product)|Other: Sunscreen (Reference Product)","Number of Participants With Evaluator (Dermatologist) Global Assessment (EGA) Score for Well Tolerance of Product 14 Days Post-Procedure|Change From Baseline in Total Score of Dermatologist Assessment Score|Change From Baseline in Individual Dermatologist Assessment Scores of Erythema, Dryness, Desquamation and Edema|Change From Baseline in Total Score of Participant Self-Assessment Scores|Change From Baseline in Individual Participant Self-Assessment Scores for Pain, Stinging/Burning, Itching, Tightness, Redness and Dryness|Change From Baseline in Trans-epidermal Water Loss (TEWL)|Change From Baseline in Corneometer Measurements","GlaxoSmithKline","Female","30 Years to 60 Years   (Adult)","Not Applicable","106","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","207213","May 10, 2017","July 19, 2017","July 19, 2017","April 6, 2017","February 20, 2019","February 20, 2019","GSK Investigational Site, Campinas, São Paulo, Brazil|GSK Investigational Site, Campinas, São Paulo, Brazil","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03103906/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03103906/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03103906"
258,"NCT03101462","Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years",,"Completed","Has Results","Influenza","Biological: Inactivated Influenza Vaccine|Biological: Live Attenuated Influenza Vaccine","Serum Antibody Responses|T-cell Responses|Cluster of Differentiation 4 (CD4+) T Cells That Proliferate and Produce Interferon (IFN)-Gamma After Antigen Activation|Secretory Immunoglobulin A (IgA) Responses|Hemagglutinin Immunoglobulin A (IgA) Responses","St. Louis University|MedImmune LLC","All","18 Years to 49 Years   (Adult)","Phase 4","38","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16354","February 24, 2011","May 13, 2011","November 9, 2011","April 5, 2017","March 6, 2019","March 6, 2019",,,"https://ClinicalTrials.gov/show/NCT03101462"
259,"NCT03101293","A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation",,"Completed","Has Results","Healthy Volunteers","Drug: TAK-831","Cmax: Maximum Observed Plasma Concentration for TAK-831|AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-831|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831|Percentage of Participants Who Experience at Least 1 Treatment-emergent Adverse Event (TEAE)","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-831-1004|U1111-1189-8001","April 4, 2017","May 19, 2017","May 26, 2017","April 5, 2017","March 18, 2019","March 18, 2019","PRA Health Sciences, Lenexa, Kansas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03101293/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03101293/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03101293"
260,"NCT03101150","Effect of Vitamin D3 Supplementation in Pregnancy on Risk of Pre-eclampsia",,"Completed","Has Results","Vitamin D Deficiency|Pre-Eclampsia","Drug: 400 IU Vitamin D3|Drug: 4000 IU Vitamin D3","Number of Participants With Pre-eclampsia in Both Arms|Change in Vitamin D Level|Number of Patients With Intrauterine Growth Retardation","King Fahad Medical City","Female","20 Years to 40 Years   (Adult)","Phase 1|Phase 2","179","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00008644","October 1, 2012","October 31, 2014","December 31, 2015","April 4, 2017","November 2, 2018","November 2, 2018",,,"https://ClinicalTrials.gov/show/NCT03101150"
261,"NCT03100968","Utility of Ultrasound in Identification of Midline and Placement of Epidural in Severely Obese Parturients",,"Active, not recruiting","Has Results","Epidural Anesthesia|Spinal Ultrasound|Obesity","Procedure: Palpation|Device: Ultrasound","Time for Epidural Placement|Number of Needle Passes|Total Time|Time to Identify Midline|Epidural Failure Rate|Number of Topoffs Required","University of Alabama at Birmingham","Female","19 Years to 45 Years   (Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F150402002","June 22, 2015","October 1, 2018","June 2020","April 4, 2017","September 17, 2019","December 11, 2019","UAB Department of Anesthesiology and Perioperative Medicine, Birmingham, Alabama, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT03100968/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03100968"
262,"NCT03100838","Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets",,"Completed","Has Results","Healthy Volunteers","Drug: Nifedipine 60 MG Extended Release Oral Tablet|Drug: omeprazole/sodium bicarbonate|Device: SmartPill (TM)","Maximum Plasma Concentration (Cmax)|Time at Maximum Plasma Concentration (Tmax)|Area Under the Concentration (AUC 0-t)|Half-life|Adverse Events","Food and Drug Administration (FDA)|BioPharma Services, Inc","All","18 Years to 55 Years   (Adult)","Phase 1","64","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","RIHSC 16-070D","March 20, 2017","December 23, 2017","April 6, 2018","April 4, 2017","July 22, 2019","August 16, 2019","BioPharma Services Inc., Columbia, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03100838/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03100838"
263,"NCT03098745","Fitting Evaluation of Hydrogel and Silicone Hydrogel Sphere Design Contact Lenses",,"Completed","Has Results","Myopia","Device: Omafilcon A|Device: Somofilcon A|Device: Omafilcon A - Proclear (PC)","Visual Acuity|Comfort|Lens Centration|Post-blink Lens Movement|Lens Fit Acceptance|Lens Fit Preference|Limbal Redness|Bulbar Redness","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EX-MKTG-79","February 1, 2017","March 1, 2017","April 11, 2017","April 4, 2017","April 9, 2019","April 9, 2019","Optometry Clinic, National Autonomous University, Mexico City, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03098745/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03098745"
264,"NCT03097341","Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects",,"Completed","Has Results","Thrombosis","Drug: xisomab 3G3- Dose 1|Drug: xisomab 3G3-Dose 2|Drug: xisomab 3G3-Dose 3|Drug: xisomab 3G3- Dose 4|Other: Placebo","The Number of Subjects With Treatment-related Adverse Events (TEAEs) Will be Summarized Using Frequency Counts.|The Number of Subjects With Abnormal Vital Signs That Are Related to Treatment Will be Summarized Using Frequency Counts..|The Number of Subjects With Abnormal Electrocardiogram That is Related to Treatment Will be Summarized Using Frequency Counts..|The Number of Subjects With Abnormal Injection Site Reaction That Are Related to Treatment Will be Summarized Using Frequency Counts..|The Number of Subjects With Abnormal Laboratory Values and/ or Adverse Events That Are Related to Treatment Will be Summarized Using Frequency Counts..|The Number of Subjects That Develop Treatment-related Immunogenicity Will be Summarized Using Frequency Counts.|The Maximum Plasma Concentration (Cmax) of Xisomab 3G3 After a Single Injection Will be Measured in Each Subject.|The Time to Reach Maximum Plasma Concentrations of Xisomab 3G3 (Tmax) After a Single Injection Will be Measured in Each Subject.|The Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Non-zero Concentration (AUC0-t), as Calculated by the Linear Trapezoidal Method, After a Single Injection of Xisomab 3G3 Will be Calculated for Each Subject.|The Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Subject.|The Percent of AUC0-inf Extrapolated (AUC%Extrap) After a Single Injection of Xisomab 3G3 Will be Calculated for Each Subject.|The Apparent First Order Terminal Elimination Rate Constant (Kel) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject.|The Apparent First Order Terminal Elimination Half-life (T1/2) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject.|The Apparent Total Plasma Clearance (CL) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject.|The Total Apparent Volume of Distribution (Vss) of Xisomab 3G3 After a Single Intravenous Injection Will be Calculated for Each Subject.|The Effect of a Single Intravenous Dose of Xisomab 3G3 on the Activated Partial Thromboplastin Time (aPTT) in Healthy Adult Subjects Will be Measured.","Aronora, Inc.","All","18 Years to 48 Years   (Adult)","Phase 1","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","3G3-15-01","June 5, 2017","January 16, 2018","January 16, 2018","March 31, 2017","May 20, 2019","June 5, 2019","Celerion, Tempe, Arizona, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03097341/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03097341/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03097341"
265,"NCT03096444","Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine",,"Terminated","Has Results","Pruritus","Drug: Ketamine Hydrochloride|Drug: Amitriptyline Hydrochloride|Drug: Lidocaine Hydrochloride|Combination Product: Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride|Drug: Lipoderm Cream","Peak Itch Intensity Between the Vehicle and Active Treatments (Individual and KeAmLi-combo).|Thermal Threshold Detection (Warmth and Heat Pain)|Mechanical Thresholds (Mechanical Detection and Pain).","Gil Yosipovitch|University of Miami","All","18 Years to 50 Years   (Adult)","Phase 2","13","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20170087","May 23, 2017","July 19, 2017","July 21, 2017","March 30, 2017","July 2, 2019","July 2, 2019","University of Miami, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03096444/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03096444"
266,"NCT03095599","Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3","IVACFLUS-0203","Completed","Has Results","Influenza, Human","Biological: IVACFLU-S|Other: Placebo","Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE)|Number and Percentage of Subjects Experiencing Solicited Systemic Adverse Events (AE)|Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE), by Severity|Number and Percentage of Subjects Experiencing Solicited Systemic Adverse Events (AE), by Severity|Number and Percentage of Subjects Experiencing Fever|Number and Percentage of Subjects Experiencing Unsolicited Adverse Events (AE)|Number and Percentage of Subjects Experiencing Unsolicited Serious Adverse Events (SAE)|Number and Percentage of Subjects With Seroconversion of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens, Overall and by Age Group|Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22, Overall and by Age Group|Geometric Mean Fold Change of Serum Hemagglutination Inhibition (HAI) Antibody Titer, Overall and by Age Group|Number and Percentage of Subjects With at Least a 4-fold Increase in HAI Antibody Titer, by Strain, Age Group, and Baseline Titer|Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22: All Subjects|Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22: Subjects Aged 18-45|Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22: Subjects Aged 46-60|Geometric Mean Fold Change in HAI Antibody Titer, by Strain, Age Group, and Baseline Titer","Institute of Vaccines and Medical Biologicals, Vietnam|Pasteur Institute, Ho Chi Minh City|PATH|Quintiles, Inc.|World Health Organization","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","889","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IVACFLU-S 0203|CVIA 051","March 20, 2017","October 5, 2017","October 5, 2017","March 29, 2017","July 22, 2019","July 22, 2019","Pasteur Institute, Ho Chi Minh City, Ho Chi Minh City, Vietnam","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03095599/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03095599"
267,"NCT03095521","A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore Throat",,"Completed","Has Results","Sore Throat","Drug: Angal, lozenges [menthol],|Drug: ANTI-ANGIN® FORMULA","Percentage of Participants Without Sore Throat According to TSS Score|50% Reduction Tss SCORE|Change From Baseline in TSS Total Score|Days to Recovery, Defined by the Patient's Diary (Subjective Evaluation by the Patient)|Number of Participants Who Fully Recovered up to Day 5|Change From Baseline in Sore Throat Intensity by 100 mm in Visual Analogue Scale Filled in by the Patient (VAS) .","Sandoz","All","18 Years to 45 Years   (Adult)","Phase 3","228","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TE_004_ANG_LOZ","February 22, 2017","May 7, 2017","May 7, 2017","March 29, 2017","March 22, 2019","March 22, 2019","Sandoz Investigational Site, Arkhangel'sk, Russian Federation|Sandoz Investigational Site, Moscow, Russian Federation|Sandoz Investigational Site, Moscow, Russian Federation|Sandoz Investigational Site, Moscow, Russian Federation|Sandoz Investigational Site, Moscow, Russian Federation|Sandoz Investigational Site, Moscow, Russian Federation|Sandoz Investigational Site, Saint Petersburg, Russian Federation|Sandoz Investigational Site, Saint Petersburg, Russian Federation|Sandoz Investigational Site, Saint Petersburg, Russian Federation|Sandoz Investigational Site, Saint Petersburg, Russian Federation|Sandoz Investigational Site, Saint Petersburg, Russian Federation|Sandoz Investigational Site, Saint Petersburg, Russian Federation|Sandoz Investigational Site, Saint Petersburg, Russian Federation|Sandoz Investigational Site, Stavropol', Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03095521/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03095521/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03095521"
268,"NCT03095508","Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat",,"Completed","Has Results","Sore Throat","Drug: Angal S, topical spray [Menthol]|Drug: ANTI-ANGIN® FORMULA, topical metered spray","Percentage of Patients Without Sore Throat According to the Tonsillopharyngitis Severity Score (TSS)|Percentage of Participants With a ≥50% TSS Total Score Reduction|Change From Baseline in TSS Total Score|Number of Participants Who Fully Recovered|Change in the Sore Throat Intensity by 100 mm VAS|Period of Time Required for Disappearance of the Disease Symptoms","Sandoz","All","18 Years to 45 Years   (Adult)","Phase 3","229","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TE_003_ANG_LSP","February 22, 2017","May 8, 2017","May 8, 2017","March 29, 2017","March 21, 2019","March 21, 2019","Sandoz Investigational Site, Arkhangel'sk, Russian Federation|Sandoz Investigational Site, Moscow, Russian Federation|Sandoz Investigational Site, Moscow, Russian Federation|Sandoz Investigational Site, Moscow, Russian Federation|Sandoz Investigational Site, Moscow, Russian Federation|Sandoz Investigational Site, Moscow, Russian Federation|Sandoz Investigational Site, Saint Petersburg, Russian Federation|Sandoz Investigational Site, Saint Petersburg, Russian Federation|Sandoz Investigational Site, Saint Petersburg, Russian Federation|Sandoz Investigational Site, Saint Petersburg, Russian Federation|Sandoz Investigational Site, Saint Petersburg, Russian Federation|Sandoz Investigational Site, Saint Petersburg, Russian Federation|Sandoz Investigational Site, Saint Petersburg, Russian Federation|Sandoz Investigational Site, Stavropol', Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03095508/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03095508/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03095508"
269,"NCT03095053","PGT-A Versus Blastocyst Morphology Selection",,"Completed","Has Results","Pregnancy","Procedure: comprehensive chromosome screening","The Percentage of Patients With a Live Birth|The Percentage of Patients With a Clinical Pregnancy|The Percentage of Pregnancies That Miscarried","Antalya IVF","Female","18 Years to 35 Years   (Adult)","Not Applicable","302","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","euploid versus morphology|Optimizing implantation in FET","March 23, 2017","February 21, 2018","February 21, 2018","March 29, 2017","June 17, 2019","June 17, 2019","Antalya IVF, Antalya, Turkey","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03095053/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03095053"
270,"NCT03089879","A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study",,"Completed","Has Results","Dysentery, Bacillary","Biological: GVGH Shigella sonnei 1790GAHB vaccine","Concentrations of Immunoglobulin (IgG) Against Lipopolysaccharide (LPS) S. Sonnei O-antigen|Number of Subjects With Abnormal Haematological Test Values|Number of Subjects With Solicited Local Adverse Events|Number of Subjects With Solicited Systemic Adverse Events|Number of Subjects With Unsolicited Adverse Events|Number of Subjects With Serious Adverse Events (SAEs)|Concentrations of IgG Against LPS S. Sonnei O-antigen|Anti-LPS S. Sonnei IgG Geometric Mean Ratios|Percentage of Subjects With Seroresponse for Anti-LPS S. Sonnei|Percentage of Subjects With Anti-LPS S. Sonnei Concentrations Equal to or Above (≥) 121 EU/mL","GlaxoSmithKline","All","22 Years to 50 Years   (Adult)","Phase 1","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","205905|2016-004178-16","March 16, 2017","August 31, 2017","August 31, 2017","March 24, 2017","March 7, 2019","June 28, 2019","GSK Investigational Site, Paris, France","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03089879/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03089879/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03089879"
271,"NCT03089216","Combined Bleaching Technique: Efficacy and Tooth Sensitivity",,"Completed","Has Results","Tooth Bleaching|Tooth Sensitivity","Procedure: Combined Bleaching(2x20)|Procedure: Combined Bleaching(2x20) with arginine|Procedure: Combined Bleaching (1x20)|Procedure: Combined Bleaching(1x20) with arginine|Drug: 8% arginine and calcium carbonate","Tooth Sensitivity (TS)|Color Evaluation","Terezinha de Jesus Esteves Barata|Universidade Federal de Goias","All","18 Years to 35 Years   (Adult)","Phase 4","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","043178","April 1, 2016","November 30, 2016","December 31, 2018","March 24, 2017","August 5, 2019","August 5, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03089216/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03089216"
272,"NCT03088137","Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment",,"Completed","Has Results","Infertility, Female","Drug: Follitropin alfa (Gonal-f)|Drug: Follitropin alfa (Primapur)","Oocytes (Intention-to-Treat, ITT)|Number of Follicles With Size ≥ 16 mm|Mature Oocytes|Fertilised Oocytes|Percentage of Patients With Embryo Transfer|Total Dose of Follitropin Alfa|Number of Days of Follitropin Alfa Treatment|Number of Patients With Follitropin Alfa Dose Correction|Number of Patients With Cycle Cancellation|Number of No-responders|Percentage of Patients With Serum hCG More Than 25 IU/l|Percentage of Patients With the Evidence for Clinical Pregnancy","IVFarma LLC|BridgePharm LLC|GlobalPharma LLC","Female","20 Years to 35 Years   (Adult)","Phase 3","118","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","FSG-03-01","February 8, 2017","August 17, 2018","August 17, 2018","March 23, 2017","June 6, 2019","August 21, 2019","Clinical Hospital Lapino, Moscow Oblast, Russian Federation|AltraVita IVF clinic, Moscow, Russian Federation|Perinatal Medical Center, Moscow, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03088137/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03088137"
273,"NCT03086447","Evaluation of Astigmatic Contact Lenses",,"Completed","Has Results","Visual Acuity","Device: Investigational Contact Lens|Device: Marketed Contact Lens","Monocular Distance Visual Acuity (VA)|Lens Fit Acceptance|Lens Stability With Blink|Absolute Lens Rotation|Corneal Staining|Overall Comfort|Overall Handling","Johnson & Johnson Vision Care, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","267","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR-5871","March 1, 2017","May 4, 2017","May 4, 2017","March 22, 2017","July 10, 2018","July 10, 2018","Golden Optometric Group, Whittier, California, United States|Edward S. Wygonik, OD, Jacksonville Beach, Florida, United States|Dr. James Weber & Associates, PA, Jacksonville, Florida, United States|Sabal Eye Care, Longwood, Florida, United States|Maitland Vision Center, Maitland, Florida, United States|Indiana University School of Optometry, Bloomington, Indiana, United States|Kannarr Eye Care, Pittsburg, Kansas, United States|ABQ Eye Care, Albuquerque, New Mexico, United States|Sacco Eye Group, Vestal, New York, United States|ProCare Vision Centers, Granville, Ohio, United States|EyeCare Professionals of Powell, Powell, Ohio, United States|Professional Vision Care, Inc, Westerville, Ohio, United States|West Bay Eye Associates, Warwick, Rhode Island, United States|Total Eye Care, PA, Memphis, Tennessee, United States|Premier Vision, Amarillo, Texas, United States|William J Bogus, OD, FAAO, Salt Lake City, Utah, United States|Botetourt Eyecare, LLC, Salem, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT03086447/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT03086447/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03086447"
274,"NCT03086356","Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State",,"Completed","Has Results","Healthy Volunteers","Drug: Dabigatran etexilate|Drug: Idarucizumab","Maximum Measured Concentration of Idarucizumab in Plasma (Cmax)|For Diluted Thrombin Time: Area After Subtraction of Baseline Area From Area Under the Effect Curve Over the Time Interval From 2 - 12 Hours (AUEC Above,2-12) on Day 4 and Day 11|Area Under the Concentration-time Curve of Idarucizumab in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)|Amount of Idarucizumab Eliminated in Urine Over the Time Interval From 0 to 72 Hours (h) (Ae0-72)|For Sum Dabigatran: Amount of the Analyte Excreted in Urine at Steady State Over the Time Interval 0-74 Hours (Ae0-74,ss ) on Day 4 and Day 11|For Unbound Sum Dabigatran: Area Under the Concentration-time Curve of the Dabigatran in Plasma at Steady State Over the Time Interval 2 Hours-12 Hours","Boehringer Ingelheim","All","18 Years to 45 Years   (Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1321.6","May 10, 2017","September 12, 2017","September 12, 2017","March 22, 2017","March 8, 2019","March 8, 2019","Peking University First Hospital, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03086356/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03086356/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03086356"
275,"NCT03085836","A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants",,"Completed","Has Results","Healthy Participants","Drug: TAK-438","Cmax: Maximum Observed Plasma Concentration for Free Base of TAK-438 (TAK-438F) and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1|AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Tau Over the Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1|T1/2z: Terminal Disposition Half-life for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1|Cmax,ss: Maximum Observed Plasma Concentration, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9|Tmax, ss: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9|AUCτ,ss: Area Under the Plasma Concentration-time Curve During a Dosing Interval, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9|Aet: Total Amount of Drug Excreted in Urine From Time 0 to Time T for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1|Fe,t: Fraction of Drug Excreted in Urine From Time 0 to Time t for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1|CLr: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1|Aeτ: Amount of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9|Fe,τ: Fraction of Administered Dose of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9|CLR: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9","Takeda","All","18 Years to 45 Years   (Adult)","Phase 1","33","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-438_114|U1111-1191-6949|CTR20170137","April 19, 2017","August 17, 2017","August 17, 2017","March 21, 2017","January 30, 2019","January 30, 2019","Zhongshan Hospital Fudan University, Shanghai, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03085836/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03085836/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03085836"
276,"NCT03083639","A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants",,"Completed","Has Results","Healthy Participants","Drug: Esomeprazole Capsule|Drug: Esomeprazole Tablet","AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Esomeprazole|AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for Esomeprazole|Cmax: Maximum Observed Plasma Concentration for Esomeprazole","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","Esomeprazole-1001|U1111-1189-8028|03083639","March 27, 2017","May 13, 2017","May 13, 2017","March 20, 2017","June 14, 2019","June 14, 2019","Pharmaceutical Research Associates, Inc., Lenexa, Kansas, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT03083639/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT03083639/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03083639"
277,"NCT03078647","Profound Dermal and SubQ Cartridges for the Treatment of Cellulite",,"Completed","Has Results","Cellulite","Device: Profound","Improvement in Global Aesthetic Appearance of Cellulite in Treated Areas, as Assessed by Study Investigator Evaluations|Improvement in Skin Tightening/Laxity in Treated Areas, as Assessed by Study Investigator Evaluations|Investigator Satisfaction - by Questionnaire|Subject Satisfaction and Improvement - by Questionnaire","Syneron Medical","Female","18 Years to 60 Years   (Adult)","Not Applicable","31","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DHF21711","September 13, 2017","November 2, 2018","January 31, 2019","March 13, 2017","June 18, 2019","June 25, 2019","Macrene Alexiades, New York, New York, United States|Girish Munavalli, Charlotte, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT03078647/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03078647"
278,"NCT03078556","Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine",,"Completed","Has Results","Infection, Human Immunodeficiency Virus","Drug: Dolutegravir|Drug: Lamivudine|Drug: Dolutegravir + Lamivudine FDC Formulation 1|Drug: Dolutegravir + Lamivudine FDC Formulation 2","Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity [AUC (0-Inf)] of Plasma DTG and 3TC in the Fasted State: Part 1|AUC (0-Inf) of Plasma DTG and 3TC in the Fasted State: Part 2|Area Under the Concentration-time Curve From Time 0 to the Last Quantifiable Time Point (AUC[0-t]) of Plasma DTG and 3TC in the Fasted State: Part 1|AUC(0-t) of Plasma DTG and 3TC in the Fasted State: Part 2|Maximum Observed Concentration (Cmax) of Plasma DTG and 3TC in the Fasted State: Part 1|Cmax of Plasma DTG and 3TC in the Fasted State: Part 2|Absorption Lag Time (Tlag) of DTG and 3TC in Fasted State: Part 1|Tlag of DTG and 3TC in Fasted State: Part 2|Time to Reach Maximum Plasma Concentration (Tmax) of DTG and 3TC in the Fasted State: Part 1|Tmax of DTG and 3TC in the Fasted State: Part 2|Time of the Last Quantifiable Concentration (Tlast) of DTG and 3TC in the Fasted State: Part 1|Tlast of DTG and 3TC in the Fasted State: Part 2|Time to Reach Half the Maximum Plasma Concentration (t1/2) of DTG and 3TC in the Fasted State: Part 1|t1/2 of DTG and 3TC in the Fasted State: Part 2|Apparent Elimination Rate Constant (Lambda z) of DTG and 3TC in the Fasted State: Part 1|Lambda z of DTG and 3TC in in the Fasted State: Part 2|Percentage of Extrapolated AUC (0 to Inf) of DTG and 3TC in the Fasted State: Part 1|Percentage of Extrapolated AUC(0 to Inf) of DTG and 3TC in the Fasted State: Part 2|AUC of 0 to 24 Hours (AUC[0-24]) of DTG and 3TC in the Fasted State: Part 1|AUC(0-24) of DTG and 3TC in the Fasted State: Part 2|Apparent Oral Clearance (CL/F) of DTG and 3TC in the Fasted State: Part 1|CL/F of DTG and 3TC in the Fasted State: Part 2|Apparent Oral Volume of Distribution (Vz/F) of DTG and 3TC in the Fasted State: Part 1|Vz/F of DTG and 3TC in the Fasted State: Part 2|Concentration at 24 Hours Post-dose (C24) of DTG and 3TC in the Fasted State: Part 1|C24 of DTG and 3TC in the Fasted State: Part 2|Last Quantifiable Concentration (Clast) of DTG and 3TC in the Fasted State: Part 1|Clast of DTG and 3TC in the Fasted State: Part 2|AUC (0-Inf) of Plasma DTG and 3TC in the Fed State: Part 1|AUC (0-Inf) of Plasma DTG and 3TC in the Fed State: Part 2|AUC (0-t) of Plasma DTG and 3TC in the Fed State: Part 1|AUC (0-t) of Plasma DTG and 3TC in the Fed State: Part 2|Cmax of Plasma DTG and 3TC in the Fed State: Part 1|Cmax of Plasma DTG and 3TC in the Fed State: Part 2|Tlag of DTG and 3TC in Fed State: Part 1|Tlag of DTG and 3TC in Fed State: Part 2|Tmax of DTG and 3TC in the Fed State: Part 1|Tmax of DTG and 3TC in the Fed State: Part 2|T1/2 of DTG and 3TC in the Fed State: Part 1|T1/2 of DTG and 3TC in the Fed State: Part 2|Lambda z of DTG and 3TC in in the Fed State: Part 1|Lambda z of DTG and 3TC in in the Fed State: Part 2|Clast of DTG and 3TC in in the Fed State: Part 1|Clast of DTG and 3TC in in the Fed State: Part 2|Percentage of Extrapolated AUC (0-inf) in the Fed State: Part 1|Percentage of Extrapolated AUC (0-inf) in the Fed State: Part 2|AUC(0-24) of DTG and 3TC in the Fed State: Part 1|AUC(0-24) of DTG and 3TC in the Fed State: Part 2|CL/F of DTG and 3TC in the Fed State: Part 1|CL/F of DTG and 3TC in the Fed State: Part 2|Tlast of DTG and 3TC in the Fed State: Part 1|Tlast of DTG and 3TC in the Fed State: Part 2|Vz/F of DTG and 3TC in the Fed State: Part 1|Vz/F of DTG and 3TC in the Fed State: Part 2|C24 of DTG and 3TC in the Fed State: Part 1|C24 of DTG and 3TC in the Fed State: Part 2|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Part 1 and 2|Change From Baseline in Heart Rate (HR): Part 1 and 2|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 and 2","ViiV Healthcare|GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","154","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","204994","March 27, 2017","August 18, 2017","August 18, 2017","March 13, 2017","February 21, 2019","February 21, 2019","GSK Investigational Site, Overland Park, Kansas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03078556/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03078556/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03078556"
279,"NCT03077724","Fish Oil to Reduce Tobacco Use iN Expectant Mothers Study","FORTUNE","Completed","Has Results","Tobacco Use in Childbirth|Smoking Cessation|Pregnancy Related","Drug: Fish oil|Drug: Placebos","Change in Cigarettes Per Day From Baseline to 4-weeks|Change in Fagerström Scores From Baseline to 4-weeks|Point Prevalence Abstinence","Vanderbilt University Medical Center","Female","18 Years to 45 Years   (Adult)","Phase 2","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","161820","March 2, 2017","January 23, 2018","September 5, 2018","March 13, 2017","January 9, 2019","January 9, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03077724/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03077724"
280,"NCT03076970","Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants",,"Completed","Has Results","Migraine","Drug: lasmiditan 200 mg|Drug: Sumatriptan|Drug: matching placebo","Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Systolic Blood Pressure|Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Diastolic Blood Pressure|Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Pulse Rate|Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Temperature|Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Respiratory Rate|Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Heart Rate|Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) PR Duration|Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) QRS Duration|Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: QTcB - Bazett's Correction Formula|Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: QTcF - Fridericia's Correction Formula|Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) QT Duration|Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) RR Duration|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Pharmacokinetics - Cmax|Pharmacokinetics - AUC0-t|Pharmacokinetics - Tmax","Eli Lilly and Company|SNBL Clinical Pharmacology Center, Inc.|CoLucid Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","16885|COL MIG-118|H8H-CD-LAHI","March 21, 2017","April 13, 2017","April 13, 2017","March 10, 2017","December 2, 2019","December 2, 2019","SNBL Clinical Pharmacology Unit, Baltimore, Maryland, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03076970/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03076970/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03076970"
281,"NCT03075410","First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects",,"Completed","Has Results","Tuberculosis","Drug: GSK3036656|Drug: Placebo","Number of Participants With Non-serious Adverse Events (nSAE) and Serious Adverse Events (SAEs) for Part A|Number of Participants With nSAE and SAEs for Part B|Number of Participants With Abnormal Electrocardiogram (ECG) Findings for Part A|Number of Subjects With Clinically Relevant Changes in ECG in Part B|Number of Participants With Abnormal Cardiac Telemetry Findings for Part A|Number of Participants With Abnormal Cardiac Telemetry Findings for Part B|Number of Participants With Vital Sign Parameters Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) of Potential Clinical Importance (PCI) for Part A|Number of Participants With Vital Sign Parameters SBP and DBP of PCI for Part B|Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part A|Number of Participants With Vital Sign Parameter Heart Rate of PCI for Part B|Number of Participants With Vital Sign Parameter Temperature of PCI for Part A|Number of Participants With Vital Sign Parameter Temperature of PCI for Part B|Number of Participants With Clinical Chemistry Parameters of PCI for Part A|Number of Participants With Clinical Chemistry Parameters of PCI for Part B|Number of Participants With Hematology Parameters of PCI for Part A|Number of Participants With Hematology Parameters of PCI for Part B|Number of Participants With Abnormal Urinalysis Parameters for Part A|Urine Potential of Hydrogen (pH) Analysis by Dipstick Method for Part A|Number of Participants With Abnormal Urinalysis Parameters for Part B|Urine pH Analysis by Dipstick Method for Part B|Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) Following Single Dose Administration of GSK3036656 for Part A|AUC From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK3036656 Following Single Dose Administration for Part A|Maximum Observed Plasma Drug Concentration (Cmax) of GSK3036656 Following Single Dose Administration for Part A|Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK3036656 Following Single Dose Administration for Part A|Apparent Terminal Half-life (t1/2) of GSK3036656 Following Single Dose Administration for Part A|AUC[0-t] Following Repeated Dose Administration of GSK3036656 for Part B|AUC From Time Zero During a Dosing Interval of Duration Tau (AUC[0-tau]) of GSK3036656 Following Repeated Dose Administration for Part B|Cmax of GSK3036656 Following Repeated Dose Administration for Part B|Tmax of GSK3036656 Following Repeat Dose Administration for Part B|t1/2 of GSK3036656 Following Repeated Dose Administration for Part B|AUC (0-t) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A|AUC (0-infinity) of GSK3036656 Following Single Dose Administration in Fed Condition in Part A|Cmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A|t1/2 of GSK3036656 Following Single Dose Administration in Fed Condition in Part A|Tmax of GSK3036656 Following Single Dose Administration in Fed Condition in Part A|Observed Accumulation Ratio Based on AUC (AUC [Ro]) of GSK3036656 in Part B|Observed Accumulation Ratio Based on Cmax (RCmax) of GSK3036656 in Part B|Steady State Ratio (Rss) of GSK3036656 in Part B|Trough Plasma Concentrations at the End of the Dosing Interval (Ctau) of GSK3036656 Following Repeat Dose Administrations in Part B|AUC (0-infinity) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A|AUC (0-t) as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A|Cmax as a Measure of Dose Proportionality of GSK3036656 Following Single Dose Administrations for Part A|AUC (0-tau) as a Measure of Dose Proportionality of GSK3036656 Following Repeat Dose Administrations for Part B|Cmax as a Measure of Dose Proportionality of GSK3036656 Following Repeat Dose Administrations for Part B","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201040|2015-003654-41","April 2, 2017","August 4, 2017","August 4, 2017","March 9, 2017","April 19, 2019","April 19, 2019","GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03075410/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03075410/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03075410"
282,"NCT03074500","Kinesiotaping in Lateral Epicondylitis",,"Completed","Has Results","Lateral Epicondylitis","Device: Kinesiotaping|Other: Sham taping|Other: Exercise","Patient Rated Tennis Elbow Evaluation (PRTEE)|The Disabilities of the Arm, Shoulder and Hand Score (QuickDash)|Visual Analogue Scale (VAS) at Rest|Visual Analogue Scale (VAS) at Daily Activity|Visual Analogue Scale (VAS) at Night|Painless Grip Strength|Grip Strength","Marmara University","All","18 Years to 60 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","09.2017.004","March 10, 2017","April 1, 2018","April 30, 2018","March 8, 2017","October 3, 2019","October 3, 2019","Marmara University School of Medicine Department of Physical Medicine and Rehabilitation, Istanbul, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03074500/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03074500/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03074500"
283,"NCT03074409","The Modulatory Effect of Oxytocin on Interoception",,"Completed","Has Results","Interoception","Drug: oxytocin|Drug: placebo","Heartbeat Detection (Interoception) Accuracy|Interoceptive Network Activity","University of Electronic Science and Technology of China","Male","18 Years to 35 Years   (Adult)","Not Applicable","83","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","UESTC-neuSCAN-34","March 2, 2017","September 6, 2017","September 12, 2017","March 8, 2017","October 18, 2019","October 18, 2019","University of Electronic Science and Technology of China, Chengdu, Sichuan, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03074409/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03074409"
284,"NCT03074162","Comparison of the Bioavailability of Diclofenac in a Combination Product (Diclofenac 2% + Capsaicin 0.075% Topical Gel) With Two Diclofenac Only Products, Diclofenac Mono Gel 2% and Voltarol® 12 Hour Emulgel 2.32% Gel, in Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: Diclofenac Sodium|Drug: Diclofenac & Capsaicin|Drug: Diclofenac Sodium Topical Gel","Area Under the Plasma Concentration-time Curve (AUC) Over One Dosing Interval for Diclofenac at Steady State (AUC0-τ,ss) (τ = 12 Hours) (Day 7)|Maximum Plasma Concentration During a Dosage Interval (Cmax,ss) Obtained Directly From the Concentration-time Data for Diclofenac at Steady State (Day 7)|Time to Maximum Observed Plasma Concentration at Steady State for Diclofenac at Steady State (Tmax,ss) (Day 7)|Average Plasma Concentration (Cav,ss) for Diclofenac at Steady State|Percentage Peak-trough Fluctuation (%PTF), Calculated as [100*(Cmax,ss - Cpre,ss)/Cav,ss]","Boehringer Ingelheim","All","18 Years to 50 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1358.2","April 20, 2017","June 29, 2017","June 29, 2017","March 8, 2017","March 1, 2019","March 1, 2019","Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, South Africa","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03074162/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03074162/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03074162"
285,"NCT03070730","Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist",,"Terminated","Has Results","Postural Orthostatic Tachycardia Syndrome|Orthostatic Intolerance","Drug: Droxidopa|Drug: Atenolol|Drug: Placebos","Change in Maximal Postural Tachycardia During Tilt|Change Maximal Postural Tachycardia During Tilt|Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline|Change in Blood Pressure From Baseline|Change in Heart Rate From Baseline|Change in Vascular Resistance From Baseline|Change in Muscle Sympathetic Nerve Activity From Baseline|Change in Physical Functioning-SF-36 Q From Baseline|Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline|Change in Physical Functioning- HADS From Baseline|Change in Physical Functioning-CIS From Baseline|Change in Physical Functioning-MFI From Baseline|Change in Physical Functioning-FSS From Baseline|Change in Physical Functioning-EuroQOL From Baseline|Change in Physical Functioning-OI From Baseline","Beth Israel Deaconess Medical Center|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","8","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2011P000246|R01HL059459","August 15, 2011","December 18, 2012","July 28, 2014","March 6, 2017","May 18, 2017","May 18, 2017","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Center for Autonomic and Peripheral Nerve Disorders - Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03070730"
286,"NCT03070171","Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects",,"Completed","Has Results","Healthy","Drug: dabigatran etexilate","AUC0-tz of Free Dabigatran|Cmax of Free Dabigatran|AUC0-tz of Total Dabigatran|Cmax of Total Dabigatran|AUC0-∞ of Total Dabigatran|AUC0-∞ of Free Dabigatran","Boehringer Ingelheim","Male","20 Years to 40 Years   (Adult)","Phase 1","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1160-0271","March 21, 2017","June 16, 2017","June 20, 2017","March 3, 2017","January 9, 2019","January 9, 2019","SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03070171/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03070171/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03070171"
287,"NCT03066193","Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome",,"Completed","Has Results","Tourette Syndrome","Drug: Dronabinol and Palmitoylethanolamide","Improvement in Tic Severity","Yale University|Therapix Biosciences Ltd.","All","18 Years to 60 Years   (Adult)","Phase 2","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1610018525","February 1, 2017","June 28, 2018","June 28, 2018","February 28, 2017","December 19, 2019","December 19, 2019","Yale Child Study Center, New Haven, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03066193/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03066193"
288,"NCT03066102","Muscle Fatigue and Scapular Sensorimotor System",,"Completed","Has Results","Muscle; Fatigue","Other: muscle fatigue","Change From Baseline in Scapular Proprioception|Change From Baseline in Muscle Activation During Scapular Proprioception|Change From Baseline in Scapular Muscle Strength|Change From Baseline in Shoulder Kinematics Data During Shoulder Elevation in the Scapular Plane|Change From Baseline in Scapular Muscle Activity During Shoulder Elevation in the Scapular Plane|Change From Baseline in Scapular Muscle Recruitment Timing During Arm Elevation in Scapular Plane","National Yang Ming University","All","20 Years to 40 Years   (Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","YM105067E","July 1, 2017","August 11, 2017","March 27, 2018","February 28, 2017","July 15, 2019","July 29, 2019","National Yang Ming University, Taipei, Taiwan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03066102/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03066102"
289,"NCT03065933","An Extended-Release Form of Clonidine as an Anti-Manic Agent: An Add-on, Open-Label Study",,"Terminated","Has Results","Bipolar Disorder, Mania","Drug: extended-release clonidine","Score on a Mania Rating Scale","Mclean Hospital","All","18 Years to 60 Years   (Adult)","Phase 4","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-P-002018/1; McLean","January 2012","January 2013","January 2013","February 28, 2017","April 26, 2017","April 26, 2017",,,"https://ClinicalTrials.gov/show/NCT03065933"
290,"NCT03065530","Intravenous Dexmedetomidine for Cesarean Section",,"Completed","Has Results","Breast Feeding|Analgesia Obstetrical|Postoperative Pain","Drug: Normal Saline|Drug: Dexmedetomidine 0.03ug/kg/h|Drug: Dexmedetomidine 0.05ug/kg/h|Drug: Dexmedetomidine 0.08ug/kg/h","Postoperative Pain Score (Visual Analogue Scale, VAS) at Rest|Relative Infant Dose (RID) of Dexmedetomidine|Ramsay Sedation Score(RSS)|The Degree of Satisfaction|Number of Participants That Experienced Nausea or Vomiting|Postoperative Pain Score (Visual Analogue Scale, VAS)|Postoperative Pain Score (Visual Analogue Scale, VAS) on Movement|Postoperative Pain Score (Visual Analogue Scale, VAS) on Uterine Cramping","The First Affiliated Hospital with Nanjing Medical University","Female","24 Years to 45 Years   (Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2015-SR-203","February 7, 2017","September 30, 2017","October 5, 2017","February 28, 2017","January 13, 2020","January 13, 2020","The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03065530/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03065530"
291,"NCT03063476","The Effect of Acute Lysine Administration on α-aminoadipic Acid (Sub-study)",,"Completed","Has Results","Healthy","Drug: C-13 labeled Lysine|Drug: Normal saline","Peak Plasma 2-AAA Concentration Percentage Change From Baseline|Peak Urinary 2-AAA Concentration Percentage Change From Baseline","Vanderbilt University Medical Center","All","18 Years to 45 Years   (Adult)","Phase 1","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","160520-1","March 1, 2017","May 18, 2017","May 18, 2017","February 24, 2017","November 30, 2018","December 19, 2018","Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03063476/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03063476"
292,"NCT03060486","A New Approach for Controlling Hemostasis During Canal Treatment: a Pilot Study",,"Completed","Has Results","Blood Contamination of Root Canal During Endodontic Therapy","Device: HYBENX®","Change From Baseline in Root Canal Bleeding Score","Dr Riccardo Pace|Azienda Ospedaliero-Universitaria Careggi","All","20 Years to 60 Years   (Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","endo1-2016","December 1, 2016","January 10, 2017","January 17, 2017","February 23, 2017","October 17, 2018","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT03060486"
293,"NCT03059901","Caminamos: A Smartphone App to Connect With Walking Partners",,"Completed","Has Results","Physical Activity","Other: Caminamos App","System Usability Questionnaire","Klein Buendel, Inc.|Stanford University|National Institute on Minority Health and Health Disparities (NIMHD)","Female","18 Years to 45 Years   (Adult)","Not Applicable","60","Industry|Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","R43MD009652|R43MD009652-01|303","August 4, 2015","December 31, 2016","December 31, 2016","February 23, 2017","September 20, 2018","September 20, 2018","Stanford University, School of Medicine, The Stanford Prevention Research Center, Palo Alto, California, United States|Klein Buendel, Inc., Golden, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03059901"
294,"NCT03055806","IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)",,"Completed","Has Results","Premature Ejaculation","Drug: IX-01 400 mg|Drug: Placebo|Drug: IX-01 800 mg|Drug: IX-01 1200 mg","Change From Baseline in Geometric Mean (GM) Intravaginal Ejaculatory Latency Time (IELT) Over the Treatment Assessment Period|Fold Change From Baseline in Geometric Mean (GM) IELT Over the Treatment Assessment Period Compared With Baseline|Proportion of Patients With ≥2.5-fold Increase in Geometric Mean (GM) Intravaginal Ejaculatory Latency Time (IELT) Over the Treatment Assessment Period Compared With Baseline|Proportion of Patients Rating Their Premature Ejaculation (PE) as Improved Per the Clinical Global Impression of Change (CGIC) Questionnaire|Proportion of Patients Achieving Mean Change in Category of ≥1 or ≥2 on Control of Timing of Ejaculation on the Premature Ejaculation Profile (PEP) Questionnaire.|Proportion of Patients Achieving Mean Change in Category of ≥1 or ≥2 in Ejaculation-related Personal Distress on the Premature Ejaculation Profile (PEP) Questionnaire|Proportion of Patients Achieving Change in Category of ≥2 on Control of Timing of Ejaculation and Achieving Change in Category of ≥1 in Ejaculation-related Personal Distress at End of Treatment|Mean Change From Baseline in Score on Control of Ejaculation|Mean Change From Baseline in Score on Ejaculation-related Personal Distress","Ixchelsis Limited","Male","18 Years to 60 Years   (Adult)","Phase 2","239","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IX-0105","February 28, 2017","November 17, 2017","December 6, 2017","February 16, 2017","October 7, 2019","October 7, 2019","Coastal Clinical Research Inc, Mobile, Alabama, United States|Radiant Research, Inc. - Phoenix SE, Chandler, Arizona, United States|Desert Clinical Research, LLC - Radiant, Mesa, Arizona, United States|Family Practice Specialists - Radiant, Phoenix, Arizona, United States|San Diego Sexual Medicine, San Diego, California, United States|Columbine Family Practice - Radiant, Littleton, Colorado, United States|South Florida Medical Research Inc., Aventura, Florida, United States|A G A Clinical Trials, Hialeah, Florida, United States|Clinical Research Center of Florida, Pompano Beach, Florida, United States|Center for Marital and Sexual Health of South Florida, West Palm Beach, Florida, United States|Northwest Behavioral Research Center, Roswell, Georgia, United States|Boston Clinical Trials Inc, Boston, Massachusetts, United States|Mens Health Boston, Chestnut Hill, Massachusetts, United States|Center For Pharmaceutical Research, Kansas City, Missouri, United States|Clifford J Molin MD LTD - Radiant, Las Vegas, Nevada, United States|Accumed Research Associates, Garden City, New York, United States|Drug Trials America, Hartsdale, New York, United States|Manhattan Medical Research, New York, New York, United States|Radiant Research, Inc. - Akron, Akron, Ohio, United States|Radiant Research, Inc. - Cincinnati, Cincinnati, Ohio, United States|Radiant Research, Inc. - Columbus, Columbus, Ohio, United States|Urologic Consultants of Southeastern Pennsylvania, Bala-Cynwyd, Pennsylvania, United States|Miriam Hospital / The Men's Health Center, Providence, Rhode Island, United States|Radiant Research, Inc. - Anderson, Anderson, South Carolina, United States|Radiant Research, Inc. - Greer, Greer, South Carolina, United States|Radiant Research, Inc. - Dallas, Dallas, Texas, United States|Clinical Trials of Texas Incorporated, San Antonio, Texas, United States|Radiant Research Inc - San Antonio, San Antonio, Texas, United States|Radiant Research, Inc. - Salt Lake City, Murray, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03055806/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03055806"
295,"NCT03055338","An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)",,"Completed","Has Results","Schizophrenia, Acute Episode","Drug: MK-8189|Drug: Risperidone|Drug: Placebo matching MK-8189|Drug: Placebo matching risperidone","Least Squares Mean (LSM) Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4|Percentage of Participants Experiencing an Adverse Event (AE)|Percentage of Participants Discontinuing Study Treatment Due to an Adverse Event|Least Squares Mean (LSM) Change From Baseline in the Clinical Global Impression-Severity of Illness (CGI-S) Score at Week 4","Merck Sharp & Dohme Corp.","All","18 Years to 50 Years   (Adult)","Phase 2","224","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","8189-005|MK-8189-005","March 8, 2017","January 9, 2018","January 9, 2018","February 16, 2017","December 26, 2018","December 26, 2018","Woodland International Research Group, LLC ( Site 0001), Little Rock, Arkansas, United States|Woodland Research Northwest, LLC ( Site 0014), Rogers, Arkansas, United States|CITRIALS ( Site 0013), Bellflower, California, United States|Comprehensive Clinical Development ( Site 0049), Cerritos, California, United States|Collaborative Neuroscience Network, LLC ( Site 0057), Garden Grove, California, United States|Behavioral Research Specialists, LLC ( Site 0006), Glendale, California, United States|Synergy East ( Site 0003), Lemon Grove, California, United States|NRC Research Institute ( Site 0043), Orange, California, United States|CNRI - Los Angeles, LLC ( Site 0026), Pico Rivera, California, United States|Artemis Institute for Clinical Research ( Site 0027), San Diego, California, United States|Schuster Medical Research Institute ( Site 0032), Sherman Oaks, California, United States|Collaborative Neuroscience Network, LLC ( Site 0046), Torrance, California, United States|Larkin Community Hospital Behavioral Health Services ( Site 0020), Hollywood, Florida, United States|Clinical Research Centers of America, LLC ( Site 0038), Oakland Park, Florida, United States|Aspire Health Partners ( Site 0016), Orlando, Florida, United States|Radiant Research - Atlanta ( Site 0008), Atlanta, Georgia, United States|Atlanta Center For Medical Research ( Site 0056), Atlanta, Georgia, United States|Alexian Center for Psychiatric Research ( Site 0015), Hoffman Estates, Illinois, United States|Lake Charles Clinical Trials, LLC ( Site 0040), Lake Charles, Louisiana, United States|CBH Health, LLC ( Site 0022), Gaithersburg, Maryland, United States|Precise Research Centers ( Site 0018), Flowood, Mississippi, United States|Psych Care Consultants Research ( Site 0025), Saint Louis, Missouri, United States|St. Louis Clinical Trials, LLC ( Site 0012), Saint Louis, Missouri, United States|Altea Research Institute ( Site 0017), Las Vegas, Nevada, United States|Radiant Research -CliniLabs ( Site 0037), New York, New York, United States|Midwest Clinical Research Unit ( Site 0041), Dayton, Ohio, United States|InSite Clinical Research ( Site 0033), DeSoto, Texas, United States|Pillar Clinical Research, LLC ( Site 0004), Richardson, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03055338/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03055338"
296,"NCT03051646","Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis",,"Completed","Has Results","Fatigue|Overheating","Drug: Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit|Drug: Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit","Change in Time to Exhaustion|Exercise-induced Body Temperature Increase","Columbia University|National Multiple Sclerosis Society","All","18 Years to 60 Years   (Adult)","Early Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AAAQ1758","January 13, 2017","May 10, 2017","May 10, 2017","February 14, 2017","November 20, 2018","November 20, 2018","Columbia University Medical Center, MS Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03051646/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03051646/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03051646"
297,"NCT03050541","Effects of MDMA on Emotional and Social Memories",,"Completed","Has Results","Healthy","Drug: MDMA|Drug: Placebo","Probability of Accurately Recalling Visual Stimuli|Probability of Accurately Recognizing Visual Stimuli","University of Chicago","All","18 Years to 40 Years   (Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","14-1485","December 2014","September 2016","September 2016","February 13, 2017","June 29, 2018","June 29, 2018",,,"https://ClinicalTrials.gov/show/NCT03050541"
298,"NCT03045926","Chronic Administration of Diosmectite (SMECTA®) in Subjects With Chronic Diarrhoea",,"Completed","Has Results","Chronic Functional Diarrhea of Unknown Origin","Drug: Diosmectite (Smecta®)","Mean Change From Baseline in Blood Lead Levels During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Blood Aluminium Concentrations During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Blood Arsenic Concentrations During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Blood Barium Concentrations During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Blood Cadmium Concentrations During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Blood Cobalt Concentrations During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Blood Mercury Concentrations During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Blood Nickel Concentrations During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Urine Lead Levels During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Urine Aluminium Levels During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Urine Arsenic Levels During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Urine Barium Levels During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Urine Cadmium Levels During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Urine Cobalt Levels During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Urine Mercury Levels During the Treatment Period and Post-treatment Follow-up Period|Mean Change From Baseline in Urine Nickel Levels During the Treatment Period and Post-treatment Follow-up Period","Ipsen","All","18 Years to 60 Years   (Adult)","Phase 1","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","D-FR-00250-108|2016-002111-18","August 2016","May 9, 2017","May 9, 2017","February 8, 2017","March 11, 2019","April 5, 2019","PRA Health Sciences, Groningen, Netherlands|MAC Clinical Research Limited, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT03045926/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT03045926/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03045926"
299,"NCT03045887","Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes",,"Completed","Has Results","Asthma","Drug: GSK2292767 50 μg|Drug: GSK2292767 500 μg|Drug: Placebo","Part A: Number of Participants With Any Non-serious Adverse Event (nSAE) and Any Serious Adverse Event (SAE)|Part B: Number of Participants With Any AE and Any SAE|Part A: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Part B: Change From Baseline in SBP and DBP|Part A: Change From Baseline in Heart Rate|Part B: Change From Baseline in Heart Rate|Part A: Change From Baseline in Respiratory Rate|Part B: Change From Baseline in Respiratory Rate|Part A: Change From Baseline in Tympanic Temperature|Part B: Change From Baseline in Tympanic Temperature|Part A: Maximal Amount of Air Forcefully Exhaled in 1 Second (FEV1)|Part B: Maximal Amount of Air Forcefully Exhaled in 1 Second (FEV1)|Part A: Forced Vital Capacity (FVC)|Part B: Forced Vital Capacity (FVC)|Part A: Number of Participants With Electrocardiogram (ECG) Abnormalities|Part B: Number of Participants With ECG Abnormalities|Part A: Number of Participants With Clinical Chemistry Values of Potential Clinical Importance Criteria (PCC)|Part B: Number of Participants With Clinical Chemistry Values of PCC|Part A: Number of Participants With Hematology Values of PCC|Part B: Number of Participants With Hematology Values of PCC|Part A: Area Under the Plasma Drug Concentration Versus Time Curve (AUC) From Zero to Time t (AUC [0 to t]), AUC From Zero to 24 Hours (AUC [0 to 24]) and AUC From Zero to Infinity (AUC [0 to Inf]) of GSK2292767|Part B: AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK2292767|Part A: Maximum Observed Plasma Drug Concentration (Cmax) of GSK2292767|Part B: Cmax of GSK2292767|Part A: Time to Maximum Observed Plasma Drug Concentration (Tmax) of GSK2292767|Part B: Tmax of GSK2292767|Part A: Terminal Half-life (T1/2) of GSK2292767|Part B: T1/2 of GSK2292767|Part A: Trough Concentrations (Ctau) of GSK2292767|Part B: Ctau of GSK2292767|Part B: Concentration of GSK2292767 in Bronchoalveolar Lavage (BAL)|Part B: Concentration of GSK2292767 in Lung Epithelial Lining Fluid (ELF)","GlaxoSmithKline","All","18 Years to 50 Years   (Adult)","Phase 1","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","202062|2016-003188-21","February 6, 2017","August 11, 2017","August 16, 2017","February 8, 2017","May 28, 2019","July 24, 2019","GSK Investigational Site, Cambridge, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03045887/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03045887/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03045887"
300,"NCT03045861","Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults",,"Completed","Has Results","Infection, Human Immunodeficiency Virus|HIV Infections","Drug: GSK2838232|Drug: Cobicistat","Maximum Decline From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA)|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinical Chemistry Abnormalities of Potential Clinical Importance|Number of Participants With Hematology Parameter Abnormalities of Potential Clinical Importance|Number of Participants With Liver Function Laboratory Abnormalities of Potential Clinical Importance|Number of Participants With Abnormal Urine Parameters|Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Number of Participants With Vital Signs Data Outside Clinical Concern Range|Number of Participants Who Were Administered Concomitant Medications|Area Under the Plasma Concentration Time Curve From Zero (Pre-dose) to 24 Hours (AUC[0 to 24]) for GSK2838232 on Day 1|Maximum Observed Concentration (Cmax) for GSK2838232 on Day 1|Time to Maximum Observed Concentration (Tmax) for GSK2838232 on Day 1|Absorption Lag Time (Tlag) for GSK2838232 on Day 1|Concentration of GSK2838232 at 24 Hours Post-dose on Day 1|Area Under the Concentration-time Curve Over the Dosing Interval (AUC [0 to Tau]) for GSK2838232 on Day 10|Pre-dose Concentration (C0) of GSK2838232 on Day 10|Concentration at End of Dosing Interval (Ctau) for GSK2838232 on Day 10|Cmax for GSK2838232 on Day 10|Apparent Oral Clearance of GSK2838232 Following Administration on Day 10|Terminal Elimination Half-life (T1/2) of GSK2838232 Following Administration on Day 10|Tmax for GSK2838232 Following Administration on Day 10|Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 AUC (0 to Tau)|Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 Cmax|Change From Baseline to Day 11 in log10 Plasma HIV-1 RNA Relative to Day 10 Ctau|Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Count to Day 11|Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 AUC (0 to Tau)|Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 Cmax|Change From Baseline to Day 11 in CD4+ Count Relative to Day 10 Ctau|Number of Participants With Emergent Drug Resistance Mutations|Accumulation Ratio for GSK2838232|Dose Proportionality of GSK2838232|Pre-morning Dose Concentrations (C0) on Day 2 Through 11|Steady State Assessment of Plasma Pre-dose Concentrations by Treatment","GlaxoSmithKline","Male","18 Years to 55 Years   (Adult)","Phase 2","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200911","March 17, 2017","April 23, 2018","April 23, 2018","February 8, 2017","May 29, 2019","May 29, 2019","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Bakersfield, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Fort Pierce, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Springfield, Massachusetts, United States|GSK Investigational Site, Berkley, Michigan, United States|GSK Investigational Site, Newark, New Jersey, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Longview, Texas, United States|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03045861/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03045861/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03045861"
301,"NCT03044106","Cranial Laser Reflex Technique for Hamstring Function","CLRTHam","Completed","Has Results","Hamstring Injury|Muscle Tone Increased|Muscle Pain|Muscle Weakness","Device: CLRT","90-90 Knee Extension Angle Test|Handheld Dynamometry|Pain Pressure Threshold|Mean Difference Pre/Post KEA, Stratified by History of Prior Hamstring Strain","University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute|National Institutes of Health (NIH)","All","18 Years to 35 Years   (Adult)","Not Applicable","44","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","16-0898","March 4, 2017","July 31, 2017","July 31, 2017","February 6, 2017","January 29, 2019","February 12, 2019","UNC- Chapel Hill, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03044106/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03044106"
302,"NCT03043534","Pre-Shave Gel and Brush in Pseudofolliculitis Barbae",,"Completed","Has Results","Pseudofolliculitis Barbae","Other: shave gel|Other: Brush","Patient Global Severity Assessment- Mechanics of Shaving|Patient Global Severity Assessment (Degree of Itching, Burning and Stinging)|Quality of Life Survey|Lesions|Investigator Global Assessment (IGA)","Wake Forest University Health Sciences","Male","20 Years to 60 Years   (Adult)","Not Applicable","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","IRB00034479","November 12, 2015","October 12, 2016","October 12, 2016","February 6, 2017","July 2, 2017","December 19, 2018","Wake Forest University Health Sciences Dept of Dermatology, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03043534"
303,"NCT03042559","Protonics Knee Brace Versus Hamstring Resisted Exercise (HRE) on Individuals With Patellofemoral Pain Syndrome","HRE","Completed","Has Results","Patellofemoral Pain Syndrome","Device: Protonics Knee brace|Device: Sports Cords","Anterior Pelvic Tilt|Numeric Pain Rating Scale (NPRS)|Global Rating of Change (GROC)|Kujala Score|Lateral Step-Down Test|Iliotibial Band Flexibility|Hip Internal Rotation ROM|Hip External Rotation ROM","Loma Linda University","All","18 Years to 45 Years   (Adult)","Not Applicable","43","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5160417","February 14, 2017","January 8, 2018","January 8, 2018","February 3, 2017","November 22, 2019","November 22, 2019","Loma Linda University Health, Loma Linda, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03042559/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03042559"
304,"NCT03042299","A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation",,"Completed","Has Results","Japanese Healthy Adult Male Participants","Drug: TAK-536","AUC(0-48): Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours Postdose for TAK-536|Cmax: Maximum Observed Plasma Concentration for TAK-536|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-536|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-536|MRT∞,ev: Mean Residence Time After Extravascular Administration From Time 0 to Infinity for TAK-536|Terminal Disposition Phase Rate Constant (λz) for TAK-536|Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)|Number of Participants With TEAEs Related to Vital Signs|Number of Participants With TEAEs Related to Body Weight|Number of Participants With TEAEs Related to Electrocardiograms (ECGs)|Number of Participants With TEAEs Related to Clinical Laboratory Tests","Takeda","Male","20 Years to 35 Years   (Adult)","Phase 1","14","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Azilsartan-1004|U1111-1190-0845|JapicCTI-173503","February 10, 2017","March 11, 2017","March 11, 2017","February 3, 2017","October 9, 2018","November 14, 2018","Nishi Kumamoto Hospital, Kumamoto, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03042299/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03042299/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03042299"
305,"NCT03041909","An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001",,"Completed","Has Results","Sickle Cell Disease","Drug: GBT440","Number of Participants With Treatment-Emergent Adverse Events During Dosing of GBT440 for up to 6 Months.|To Assess the Efficacy of GBT440 as Measured by Improvements in Anemia|To Observed Pharmacokinetics in Plasma and Whole Blood.|To Characterize the Effect of GBT440 on Hemolysis.","Global Blood Therapeutics","All","18 Years to 60 Years   (Adult)","Phase 2","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","GBT440-024","August 2016","June 2017","August 2017","February 3, 2017","January 2, 2019","January 2, 2019","The BRC Research Facility, Floor 15 The Tower Wing, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03041909/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03041909"
306,"NCT03040687","Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge",,"Completed","Has Results","Healthy Volunteer","Biological: Anti CS6 BSIgG product (Lot PD1601105CS)|Biological: Anti B7A BSIgG product (Lot PD1601132ET)|Biological: Bovine Immunoglobin Negative Control (Lot PD161071NC)|Biological: B7A- CS6-expressing ETEC challenge strain","Safety of Serum Derived Bovine Immunoglobulins (BSIgG)|Efficacy of B7A and CS6- Hyperimmune Bovine Serum Immunoglobin to Protect Against Moderate to Severe Diarrhea After Challenge With the CS6 Expressing ETEC Strain B7A","Johns Hopkins Bloomberg School of Public Health|Naval Medical Research Center|United States Department of Defense","All","18 Years to 50 Years   (Adult)","Phase 1","60","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CIR 315 BSIgG","January 2017","April 2017","August 2017","February 2, 2017","June 14, 2019","June 14, 2019","Johns Hopkins Center for Immunization Research, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03040687/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03040687"
307,"NCT03040362","Absorption, Metabolism and Excretion of [14C]-Lasmiditan - Single Oral Dose Administration",,"Completed","Has Results","Healthy","Drug: [14C]-lasmiditan","Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)|Pharmacokinetics: Time of Maximum Observed Plasma Concentration (Tmax)|Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Tlast (AUC[0-tlast])|AUC Time Zero to Infinity (AUC0-∞) Blood/Plasma Ratio|AUC Time Zero to Infinity (AUC0-∞) Plasma Lasmiditan/Total Radioactivity Ratio|Pharmacokinetics - Cumulative Amount of Lasmiditan and Its Metabolites Excreted in Urine|Percentage of Lasmiditan Recovered in Urine, Relative to Dose Administered|Renal Clearance (CLR)|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","Eli Lilly and Company|CoLucid Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 1","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16884|H8H-CD-LAHH|COL MIG-110","April 20, 2017","May 6, 2017","May 6, 2017","February 2, 2017","January 10, 2020","January 10, 2020","Covance Clinical Research Unit, Madison, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03040362/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03040362/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03040362"
308,"NCT03038815","The Influence of Stability Boots on Gait Pattern in Healthy Adults",,"Completed","Has Results","Rehabilitation After Ankle Injuries","Device: VACOped|Device: Ortho Tri","ROM Ankle Joint|Symmetrie Index","Institute for Biomechanics, ETH Zürich","All","18 Years to 45 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Stability Boots","February 1, 2017","June 30, 2017","December 31, 2017","February 1, 2017","November 1, 2019","November 18, 2019","Institute for Biomechanics ETH Zürich, Zurich, ZH, Switzerland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03038815/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03038815"
309,"NCT03035929","Diagnosing Natriuretic Peptide Deficiency",,"Completed","Has Results","Healthy|Lean","Drug: Dexamethasone","Changes in NT-proANP From Baseline to 8 Hours|Changes in NT-proBNP From Baseline to 8 Hours|Changes in NT-proANP|Changes in NT-proBNP|BNP (B-type Natriuretic Peptide)|ANP (Atrial Natriuretic Peptide)","Vanderbilt University Medical Center","All","18 Years to 50 Years   (Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","161482","January 1, 2017","June 8, 2017","January 1, 2018","January 30, 2017","June 20, 2019","June 20, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT03035929/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03035929"
310,"NCT03035760","Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers",,"Completed","Has Results","Helminthic Infection","Drug: Oxfendazole","Number of Subjects Reporting Adverse Events (AEs) Related to Oxfendazole for Arms 1, 2, and 3|Number of Subjects Reporting Adverse Events (AEs) Related to Oxfendazole for Arm 4|Area Under the Concentration Time-curve for a Single Dosing Interval (AUCtau) of Oxfendazole for Arm 1, 2 and 3|Area Under the Concentration Time-curve to the Time of Last Measured Concentration (AUClast) of Oxfendazole for Arm 4|Maximum Observed Concentration (Cmax) of Oxfendazole in Plasma for Arms 1, 2, and 3|Maximum Observed Concentration (Cmax) of Oxfendazole in Plasma for Arm 4|Terminal Elimination Half-life (t1/2) of Oxfendazole for Arms 1, 2, and 3|Terminal Elimination Half-life (t1/2) of Oxfendazole for Arm 4|Time of Maximum Observed Concentration (Tmax) of Oxfendazole for Arms 1, 2, and 3|Time of Maximum Observed Concentration (Tmax) of Oxfendazole for Arm 4","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Phase 1","36","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-0005|HHSN272201300020I","May 12, 2017","April 23, 2018","April 23, 2019","January 30, 2017","December 17, 2019","December 17, 2019","University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03035760/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03035760/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03035760"
311,"NCT03034057","Sayana Press UK Self-Injection Study",,"Completed","Has Results","Contraception","Drug: Sayana Press","Percentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Full Analysis Set)|Percentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Sensitivity Analysis)|Continuation Rate for the Method (Self-injection With Sayana Press) at 1 Year","Pfizer","Female","18 Years to 45 Years   (Adult)","Phase 4","169","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","A6791040|2017-000051-13","August 23, 2017","December 7, 2018","December 7, 2018","January 27, 2017","October 18, 2019","October 18, 2019","Fowey Clinical Research Office, Fowey, Cornwall, United Kingdom|Fowey River Practice, Fowey, Cornwall, United Kingdom|Brannel Surgery, Saint Austell, Cornwall, United Kingdom|Rame Medical Ltd, Penntorr Health, Torpoint, Cornwall, United Kingdom|Rame Medical Ltd, Torpoint, Cornwall, United Kingdom|Knowle House Surgery, Plymouth, Devon, United Kingdom|NHS Ayrshire & Arran, University Hospital Crosshouse, Kilmarnock, EAST Ayrshire, United Kingdom|Trafalgar Medical Group Practice, Southsea, Hampshire, United Kingdom|NHS Highland Clinical Research Facility, Inverness, Highland, United Kingdom|Kent Community Health NHS Foundation Trust, Canterbury, Kent, United Kingdom|Kent Community Health NHS Foundation Trust, Chatham, Kent, United Kingdom|Southport & Ormskirk Hospital NHS Trust, The May Logan Healthy Living Centre, Liverpool, Merseyside, United Kingdom|Southport & Ormskirk Hospital NHS Trust, Liverpool, Merseyside, United Kingdom|NHS Lothian, Chalmers Sexual Health Centre, Edinburgh, Midlothian, United Kingdom|NHS Ayrshire & Arran, Ayrshire Central Hospital, Irvine, North Ayrshire, United Kingdom|Pickering Medical Practice, Pickering, North Yorkshire, United Kingdom|St Chad's Surgery, Radstock, Somerset, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne and Wear, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne and Wear, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, WEST Midlands, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, WEST Midlands, United Kingdom|Eve Hill Medical Practice, Dudley, WEST Midlands, United Kingdom|Bradford on Avon Health Centre, Bradford on Avon, Wiltshire, United Kingdom|Hathaway Medical Centre, Chippenham, Wiltshire, United Kingdom|Trowbridge Health Centre, Trowbridge, Wiltshire, United Kingdom|Westbury Group Practice, Westbury, Wiltshire, United Kingdom|CPS Research, Glasgow, United Kingdom|Homerton University Hospital NHS Foundation Trust, Homerton, London, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03034057/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03034057/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03034057"
312,"NCT03029000","Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants","GRANIX","Terminated","Has Results","Healthy Participants","Drug: Tbo-filgrastim","Percentage of Participants With at Least 2*10^6 Cluster of Differentiation 34+ (CD34+) Cells Per Kilogram (Cells/kg) of Recipient Body Weight Collected in the First Apheresis on Day 5|Percentage of Participants With at Least 2*10^6 CD34+ Cells/kg of Donor Baseline Body Weight Collected After the First Apheresis on Day 5|Percentage of Participants With at Least 5*10^6 CD34+ Cells/kg of Recipient Body Weight Collected After the First Apheresis on Day 5|Number of Aphereses Necessary to Collect at Least 5*10^6 CD34+ Cells/kg of Recipient Body Weight|Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Anti-Drug Antibodies (ADA)|Maximum Observed Serum Recombinant Methionyl Human Granulocyte Colony-Stimulating Factor (r-metHuG-CSF) Concentration (Cmax)|Maximum Observed Peripheral CD34+ Cell Count (CD34+Cmax)","Teva Pharmaceutical Industries, Ltd.|Teva Pharmaceutical Industries","All","18 Years to 60 Years   (Adult)","Phase 3","1","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TV44688-ONC-30054","August 2, 2017","October 30, 2017","October 30, 2017","January 23, 2017","December 14, 2018","December 14, 2018","Teva Investigational Site 14029, Duarte, California, United States|Teva Investigational Site 14025, La Jolla, California, United States|Teva Investigational Site 14023, Beech Grove, Indiana, United States|Teva Investigational Site 14026, Detroit, Michigan, United States|Teva Investigational Site 14027, Chapel Hill, North Carolina, United States|Teva Investigational Site 14030, Cincinnati, Ohio, United States|Teva Investigational Site 14033, Greenville, South Carolina, United States|Teva Investigational Site 14035, Memphis, Tennessee, United States|Teva Investigational Site 14024, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03029000/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03029000"
313,"NCT03028987","Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)",,"Terminated","Has Results","Influenza","Biological: Fluzone®|Biological: FluMist®","Number of Participants Who Received Influenza Vaccine|Number of Participants With Related Adverse Events","Stanford University|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 49 Years   (Adult)","Phase 4","10","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SU-31434-2014-2019|2U19AI057229-11","November 19, 2014","November 18, 2015","November 18, 2015","January 23, 2017","September 12, 2017","September 12, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03028987"
314,"NCT03028129","Prevention of Tuberculosis in Prisons",,"Terminated","Has Results","Tuberculosis, Pulmonary|Antibiotic Prophylaxis","Drug: Isoniazid 900 milligrams|Drug: Placebo","Quantiferon TB Gold Plus (QIAGEN®) Conversion at the Premature Exclusion Visit.","Federal University of Mato Grosso do Sul|Oswaldo Cruz Foundation","Male","18 Years to 45 Years   (Adult)","Phase 4","467","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","U1111-1189-0829","September 4, 2017","August 10, 2019","August 10, 2019","January 23, 2017","October 25, 2019","October 25, 2019","Roberto Oliveira, Dourados, Mato Grosso Do Sul, Brazil","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT03028129/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT03028129/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03028129"
315,"NCT03027661","Para-cervical Block Prior to Laparoscopic Hysterectomy as an Adjuvant Treatment to Reduce Postoperative Pain.",,"Completed","Has Results","Pain, Postoperative","Drug: Bupivacaine|Drug: 0.9% Sodium Chloride","Pain Reported on the Visual Analogue Scale (VAS) at 30 Minutes Postoperative|Pain Reported on the Visual Analogue Scale (VAS) at 60 Minutes Postoperative","University of Tennessee","Female","18 Years to 60 Years   (Adult)","Phase 3","41","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16-130","August 1, 2017","June 30, 2018","June 30, 2018","January 23, 2017","November 15, 2018","November 15, 2018","Erlanger Medical Center, Chattanooga, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03027661/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03027661"
316,"NCT03024606","Smoking Cessation Intervention in Pregnant Women",,"Completed","Has Results","Smoking Cessation","Behavioral: text messages focused on smoking cessation and pregnancy","Exhaled Carbon Monoxide Levels","St. Louis University","Female","18 Years to 55 Years   (Adult)","Not Applicable","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","23943","March 2014","June 14, 2017","June 14, 2017","January 19, 2017","October 24, 2018","October 24, 2018",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03024606/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03024606"
317,"NCT03023891","Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids",,"Active, not recruiting","Has Results","Glucocorticoids Toxicity|Glucose Intolerance","Drug: Prednisone","White Blood Cell Counts|Glucose Tolerance Test: Area Under the Curve (AUC) for Plasma Glucose|Glucose Tolerance Test: Area Under the Curve (AUC) for Insulin Levels|Glucose Tolerance Test: Area Under the Curve (AUC) for C-peptide Levels","Vanderbilt University Medical Center|National Institute of General Medical Sciences (NIGMS)","All","18 Years to 45 Years   (Adult)","Phase 1","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","161942|5K23GM117395-03","February 15, 2017","January 10, 2019","December 31, 2019","January 18, 2017","January 6, 2020","January 6, 2020","Vanderbilt University Medical Center -CRC, Nashville, Tennessee, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT03023891/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT03023891/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03023891"
318,"NCT03023709","Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)",,"Terminated","Has Results","Influenza","Biological: Fluzone®|Biological: FluMist®","Number of Participants Who Received Influenza Vaccine|Number of Participants With Related Adverse Events","Stanford University|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 49 Years   (Adult)","Phase 4","3","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SU-33722|2U19AI057229-11","September 2015","December 2015","December 2015","January 18, 2017","May 10, 2017","May 10, 2017",,,"https://ClinicalTrials.gov/show/NCT03023709"
319,"NCT03023553","The Human Mucosal Immune Responses to Influenza Virus (SLVP026)",,"Completed","Has Results","Influenza","Biological: Fluzone®|Biological: FluMist®","Number of Participants From Each Arm Who Received Influenza Vaccine|Number of Participants With Related Adverse Events","Stanford University|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 30 Years   (Adult)","Phase 4","13","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SU-25537|U19AI090019","December 2012","February 2013","February 2013","January 18, 2017","March 9, 2017","April 21, 2017",,,"https://ClinicalTrials.gov/show/NCT03023553"
320,"NCT03023137","Walking and Dietary Modification for Recurrent Early Miscarriages","W&D","Completed","Has Results","Recurrent Miscarriage","Behavioral: Walking & dietary modification","Take-home Baby Rate|Gestational Diabetes Mellitus|Preeclampsia|Mothers Who Used Heparin for Nephrotic Range Proteinuria or Placental Insufficiency|Excessive Weight Gain|First-trimester Losses|Second and Third-trimester Losses|Live-born Children|Babies Born at Term|Appropriate-for-gestational Age Babies|Neonates With Hypoglycemia","Hospital dos Servidores do Estado do Rio de Janeiro","Female","18 Years to 40 Years   (Adult)","Not Applicable","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","HospitalSERJ","May 2011","August 2016","February 2017","January 18, 2017","April 6, 2017","April 10, 2017","Hospital Federal dos Servidores do Estado, Ministry of Health, Rio de Janeiro, RJ, Brazil",,"https://ClinicalTrials.gov/show/NCT03023137"
321,"NCT03021642","Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: Tepotinib test (Treatment Period 1)|Drug: Tepotinib reference (Treatment Period 2)|Drug: Tepotinib reference (Treatment Period 1)|Drug: Tepotinib test (Treatment Period 2)","Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) at Concentration at or Above Lower Limit of Quantitation (LLOQ) of Tepotinib|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tepotinib|Maximum Plasma Concentration Observed (Cmax) of Tepotinib|Time to Reach the Maximum Plasma Concentration (Tmax) of Tepotinib|Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) of Tepotinib Metabolites (MSC2571109A and MSC2571107A)|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tepotinib Metabolites (MSC2571109A and MSC2571107A)|Maximum Plasma Concentration Observed (Cmax) of Tepotinib Metabolites (MSC2571109A and MSC2571107A)|Time to Reach the Maximum Plasma Concentration (Tmax) of Tepotinib Metabolites (MSC2571109A and MSC2571107A)|Apparent Terminal Half-Life (t1/2) of Tepotinib and Metabolites (MSC2571109A and MSC2571107A) in Plasma|Apparent Terminal Rate Constant (λz) of Tepotinib and Metabolites (MSC2571109A and MSC2571107A) in Plasma|Total Body Clearance of Drug From Plasma (CL/f) for Tepotinib|Apparent Volume of Distribution (Vz/f) for Tepotinib|Extrapolated Area Under the Plasma Concentration-Time Curve From Time t to Infinity (%AUCextra) of Tepotinib and Metabolites (MSC2571109A and MSC2571107A)|Ratio of Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Metabolite (MSC2571109A or MSC2571107A) to AUC0-inf of Tepotinib|Ratio of Maximum Plasma Concentration Observed (Cmax) of Metabolite (MSC2571109A or MSC2571107A) to Cmax of Tepotinib|Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death, TEAEs Leading to Discontinuation|Number of Subjects With Clinically Significant Change From Baseline in Vital Signs, Electrocardiogram (ECG) and Laboratory Parameters","Merck KGaA, Darmstadt, Germany","All","18 Years to 60 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MS200095-0012|2015-004369-95","January 31, 2016","March 31, 2016","March 31, 2016","January 16, 2017","January 25, 2019","January 25, 2019","For Recruiting Locations outside US, please Contact Merck KGaA Communication Center, Darmstadt, Germany",,"https://ClinicalTrials.gov/show/NCT03021642"
322,"NCT03015181","VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults",,"Completed","Has Results","HIV Prevention","Biological: VRC-HIVMAB075-00-AB","Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration|Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Any Product Administration|Number of Subjects Reporting 1 or More Unsolicited Non-Serious Adverse Events|Number of Subjects Reporting Serious Adverse Events|Maximum Observed Serum Concentration (Cmax) of VRC07-523LS: Single Dose Groups|Maximum Observed Serum Concentration (Cmax) of VRC07-523LS: Multiple Dose Groups|Time to Reach Maximum Observed Serum Concentration (Tmax) of VRC07-523LS|4 Week Mean Serum Concentration of VRC07-523LS|12 Week Mean Serum Concentration of VRC07-523LS: Single Dose Groups|12 Week Mean Serum Concentration of VRC07-523LS: Multiple Dose Groups|Area Under the Curve (AUC(0-inf)): Single Dose Groups|Area Under the Curve (AUC0-84D): Multiple Dose Groups|VRC07-523LS Clearance Rate|Overall IV Half-life (T1/2) of VRC07-523LS|Number of Single Dose Subjects Who Produced Anti-Drug Antibodies to VRC07-523LS|Number of Multiple Dose Subjects Who Produced Anti-Drug Antibodies to VRC07-523LS","National Institute of Allergy and Infectious Diseases (NIAID)|The Emmes Company, LLC|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","Phase 1","26","NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","170030|17-I-0030","February 21, 2017","July 10, 2018","July 10, 2018","January 9, 2017","July 11, 2019","September 24, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03015181/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03015181"
323,"NCT03012828","Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers",,"Completed","Has Results","QT Effects in Healthy Volunteers","Drug: Moxidectin|Other: Placebo","Mean Change From Baseline in QTc Interval (Corrected by Friderica's Formula, dQTcF) Associated With Plasma Moxidectin Concentrations After a Single Dose|Concentrations of Moxidectin in Plasma","Medicines Development Limited","Male","18 Years to 50 Years   (Adult)","Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MDGH-MOX-1008","January 2017","March 2017","May 2017","January 6, 2017","March 14, 2019","March 14, 2019","Spaulding Clinical, West Bend, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT03012828/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT03012828/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03012828"
324,"NCT03012334","The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants",,"Completed","Has Results","Migraine","Drug: Lasmiditan|Drug: Alprazolam|Other: Placebo","Simulated Driving Performance in Healthy Participants as Measured by Standard Deviation of Lateral Position (SDLP) Using the Cognitive Research Corporation Driving Simulator-MiniSim (CRCDS-MiniSim)|Karolinska Sleepiness Scale (KSS) Score|Percentage of Participants With Self-Reported Readiness to Drive|Motivational and Self-Appraisal Visual Analog Scale (VAS)|Number of Correct Responses in Driving Performance Using CogScreen Symbol Digit Coding (SDC) Test|Driving Performance Using the CRCDS-MiniSim - Lane Exceedance|Driving Performance Using the CRCDS-MiniSim - Speed Deviation","Eli Lilly and Company|Algorithme Pharma Inc|Cognitive Research Corporation|CoLucid Pharmaceuticals","All","21 Years to 50 Years   (Adult)","Phase 1","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","16883|COL MIG-106|H8H-CD-LAHG","January 16, 2017","June 8, 2017","June 8, 2017","January 6, 2017","January 10, 2020","January 10, 2020","Algorithme Pharma, Mount Royal, Quebec, Canada","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03012334/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03012334/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03012334"
325,"NCT03004911","Development of a Mobile Application to Promote Self-care in Patients With Fibromyalgia",,"Completed","Has Results","Fibromyalgia","Device: ProFibro (Mobile application)|Device: Paper booklet","Health-related Quality of Life Assessed With the Revised Fibromyalgia Impact Questionnaire|Number of Painful Areas Assessed With the Widespread Pain Index|Pain Assessed With the Visual Analogue Scale|Severity of Symptoms Assessed With the Symptom Severity Scale|Self-care Agency Assessed With the Appraisal of Self-Care Agency Scale - Revised|Adherence to Mobile Application Assessed by Number of Clicks on the App Functions","University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo","All","19 Years to 59 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","274/14","February 14, 2017","December 12, 2017","December 12, 2017","December 29, 2016","June 17, 2019","June 17, 2019","Department of Physical Therapy, Speech Therapy and Occupational Therapy of the School of Medicine of the University of Sao Paulo, Sao Paulo, Brazil","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03004911/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03004911"
326,"NCT03004469","Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia",,"Completed","Has Results","Alopecia, Androgenetic","Drug: P-3074|Drug: Finasteride|Drug: P-3074 Vehicle|Drug: Finasteride Placebo","Adjusted Mean Change From Baseline in Hair Growth Assessed by Target Area Hair Count (TAHC) in the Vertex at Week 24|Adjusted Mean Change From Baseline in Hair Growth Assessed by TAHC in the Vertex at Week 12|Adjusted Mean Change From Baseline in Target Area Hair Width (TAHW) in the Vertex at Weeks 12 and 24|Adjusted Mean Overall Male Hair Growth Questionnaire (MHGQ) Score as Assessed by the Participant at Weeks 12 and 24|Adjusted Mean Change From Baseline in Participants Hair Growth/Loss Assessed for the Vertex by Investigator at Weeks 12 and 24|Adjusted Mean Change From Baseline in Participants Hair Growth/Loss at Weeks 12 and 24, Assessed for the Vertex by Blind Assessor|Adjusted Mean International Index of Erectile Function (IIEF-2) Scores at Weeks 4, 8, 12 and 24|Local Tolerability as Assessed by Incidence Rate of Skin Irritation Event Via Severity Score for Skin Irritation Scale|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs","Polichem S.A.","Male","18 Years to 40 Years   (Adult)","Phase 3","458","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PM1541","August 2, 2016","March 5, 2018","March 5, 2018","December 28, 2016","April 19, 2019","June 20, 2019","Site #103, Brussels, Belgium|Site #104, Brussels, Belgium|Site #102, Brussel, Belgium|Site #101, Gent, Belgium|Site #211, Augsburg, Germany|Site #202, Berlin, Germany|Site #212, Berlin, Germany|Site #216, Bochum, Germany|Site #210, Dresden, Germany|Site #217, Dresden, Germany|Site #221, Dresden, Germany|Site #203, Dusseldorf, Germany|Site #204, Freiburg, Germany|Site #206, Hamburg, Germany|Site #214, Hamburg, Germany|Site #218, Hamburg, Germany|Site #213, Hannover, Germany|Site #215, Karlsruhe, Germany|Site #220, Lübeck, Germany|Site #208, Münster, Germany|Site #219, Potsdam, Germany|Site #209, Schwerin, Germany|Site #201, Wuppertal, Germany|Site #303, Budapest, Hungary|Site #309, Budapest, Hungary|Site #302, Debrecen, Hungary|Site #308, Satoraljaujhely, Hungary|Site #301, Szolnok, Hungary|Site #307, Szombathely, Hungary|Site #401, Chelyabinsk, Russian Federation|Site #402, Moscow, Russian Federation|Site #407, Moscow, Russian Federation|Site #411, Moscow, Russian Federation|Site #409, Rostov, Russian Federation|Site #403, Ryazan, Russian Federation|Site #406, Saint-Petersburg, Russian Federation|Site #408, Saint-Petersburg, Russian Federation|Site #410, Yaroslavl, Russian Federation|Site #503, Alicante, Spain|Site #505, Barakaldo, Spain|Site #502, Barcelona, Spain|Site #507, Cordoba, Spain|Site #501, Madrid, Spain|Site #504, Madrid, Spain|Site #508, Madrid, Spain|Site #506, Pamplona, Spain","""Study Protocol: Protocol Version 4 dated 8 Mar 2017"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03004469/Prot_000.pdf|""Study Protocol: Non-substantial amendment 1 dated 8 Mar 17"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03004469/Prot_001.pdf|""Statistical Analysis Plan: Statistical Analysis Plan dated 22 Jan 2018"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03004469/SAP_002.pdf|""Statistical Analysis Plan: Statistical Analysis Plan Amendment 1 dated 23 Mar 2018"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03004469/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT03004469"
327,"NCT03000686","Study of GSK2586881 on Acute Hypoxia and Exercise",,"Terminated","Has Results","Healthy Volunteers","Biological: GSK2586881|Other: Placebo","Change From Baseline of Pulmonary Artery Systolic Pressure (PASP) Measured Via Echocardiography-Part 1|Change From Baseline of PASP Measured Via Echocardiography-Part 2|Change From Baseline in Renin-angiotensin System (RAS) Peptides-Part 1|Change From Baseline in RAS Peptides-Part 2|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)-Part 1|Change From Baseline in SBP and DBP-Part 2|Change From Baseline in Heart Rate-Part 1|Change From Baseline in Heart Rate-Part 2|Change From Baseline in Oxygen Saturation-Part 1|Change From Baseline in Oxygen Saturation-Part 2|Number of Participants With Abnormal Electrocardiogram (ECG) Findings-Part 1|Number of Participants With Abnormal ECG Findings-Part 2|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1|Number of Participants With AEs and SAEs-Part 2|Number of Participants With Positive Immunogenicity Results-Part 1|Number of Participants With Positive Immunogenicity Results-Part 2|Number of Participants With Abnormal Hematology Parameters-Part 1|Number of Participants With Abnormal Hematology Parameters-Part 2|Number of Participants With Abnormal Clinical Chemistry Parameters-Part 1|Number of Participants With Abnormal Clinical Chemistry Parameters-Part 2|Number of Participants With Abnormal Urine Parameters-Part 1|Number of Participants With Abnormal Urine Parameters-Part 2|Plasma Concentrations of GSK2586881-Part 1|Plasma Concentrations of GSK2586881-Part 2|Area Under the Concentration-time Curve Over the Study Period (Pre-dose to 30 Minutes Rest Post Chamber Exit) (AUC[0-2.5 Hours])-Part 1|Area Under the Concentration-time Curve Over the Study Period (Pre-dose to 30 Minutes Rest Post Chamber Exit) (AUC[0-2.5 Hours])-Part 2|Area Under the Concentration-time Curve Over the Time Period for the Hypoxia Challenge (Immediately Prior to Chamber Entry to Chamber Exit) (AUC [0.5-2 Hours])-Part 1|Area Under the Concentration-time Curve Over the Time Period for the Hypoxia Challenge (Immediately Prior to Chamber Entry to Chamber Exit) (AUC [0.5-2 Hours])-Part 2|Maximum Observed Concentration (Cmax) of GSK2586881-Part 1|Cmax of GSK2586881-Part 2|Time to Reach Cmax (Tmax) of GSK2586881-Part 1|Tmax of GSK2586881-Part 2|Apparent Terminal Half-life (T1/2) of GSK2586881-Part 1|T1/2 of GSK2586881-Part 2|Clearance for GSK2586881-Part 1|Clearance for GSK2586881-Part 2|Volume of Distribution for GSK2586881-Part 1|Volume of Distribution for GSK2586881-Part 2","GlaxoSmithKline","All","18 Years to 40 Years   (Adult)","Phase 1","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","204987|2016-002465-55","May 17, 2017","January 4, 2019","January 4, 2019","December 22, 2016","December 23, 2019","December 23, 2019","GSK Investigational Site, Hannover, Niedersachsen, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03000686/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03000686/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03000686"
328,"NCT02999763","SlimShape Device for Abdominal Fat and Circumference Reduction",,"Completed","Has Results","Fat Disorder","Device: SlimShape","Change in Fat Thickness at Final Follow-up Compared to Baseline|Change in Fat Thickness After Treatments Compared to Baseline|Change in Abdominal Circumference After Treatments Compared to Baseline","Syneron Medical","All","18 Years to 60 Years   (Adult)","Not Applicable","70","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DHF22621","January 13, 2017","May 3, 2018","August 7, 2018","December 21, 2016","April 4, 2019","April 18, 2019","Laser & Skin Surgery Medical Group, Inc, Sacramento, California, United States|Syneron Candela Institute for Education Clinic, Wayland, Massachusetts, United States|Union Square Laser Dermatology, New York, New York, United States|Laser & Skin Surgery Center of New York, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02999763/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02999763"
329,"NCT02998996","Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU",,"Completed","Has Results","Influenza, Human","Biological: 15 µg HA/strain and 1% Endocine™|Biological: 15 µg HA/strain and 2% Endocine™|Biological: 15 µg HA/strain|Biological: intramuscular comparator|Biological: intranasal comparator|Biological: Placebo, Saline","Local Tolerability - First Dose|Local Tolerability - Second Dose (Group 1-4 Only)","Eurocine Vaccines AB","All","18 Years to 39 Years   (Adult)","Phase 1|Phase 2","162","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","EURO 15-11","September 2016","June 1, 2017","June 1, 2017","December 21, 2016","February 21, 2019","February 21, 2019","Site 2, Linkoping, Sweden|Site 1, Uppsala, Sweden","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02998996/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02998996"
330,"NCT02998671","Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne",,"Terminated","Has Results","Acne Vulgaris","Biological: CJM112|Other: Placebo","Total Inflammatory Facial Lesion Count at Day 85|Number and Severity of Adverse Events in Period 1|Number and Severity of Adverse Events in Period 2|Pharmacokinetics (PK): Serum Trough Concentrations of CJM112 in Period 1|Pharmacokinetics (PK): Serum Trough Concentrations of CJM112 in Period 2|Number of Patients With Clinically Significant Abnormal Hematology Laboratory Parameters|Number of Patients With Clinically Significant Abnormal Clinical Chemistry Laboratory Parameters Parameters|Number of Patients With Clinically Significant Abnormal Urinalysis Laboratory Parameters","Novartis Pharmaceuticals|Novartis","All","18 Years to 45 Years   (Adult)","Phase 2","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CCJM112X2203","December 22, 2016","August 1, 2018","August 1, 2018","December 20, 2016","October 10, 2019","October 10, 2019","Novartis Investigative Site, Culver City, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Pommelsbrunn, Germany|Novartis Investigative Site, Bergen op Zoom, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Leiden, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02998671/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02998671/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02998671"
331,"NCT02992236","Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers",,"Completed","Has Results","Renal Function Impairment in Healthy Volunteers","Drug: VAS203|Drug: Saline","Renal Plasma Flow|Glomerular Filtration Rate|Serum Creatinine Concentration","Vasopharm GmbH|Winicker Norimed GmbH","Male","18 Years to 45 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","VAS203/I/3/05","August 2015","May 2016","November 2016","December 14, 2016","August 9, 2019","August 9, 2019","Universitätsklinik Erlangen, Erlangen, Germany",,"https://ClinicalTrials.gov/show/NCT02992236"
332,"NCT02992119","Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults","RTSS","Completed","Has Results","Malaria Vaccine","Biological: RTS,S/AS01B Fractional dose|Biological: Double RTS,S/AS01E Fractional dose|Biological: RTS,S/AS01E Standard dose|Biological: RTS,S/AS01E + DHA-PIP+PQ Standard dose|Biological: RTS,S/AS01E Fractional dose|Biological: RTS,S/AS01E + DHA-PIP+PQ Fractional dose|Biological: RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose","Number of Participants Who Experience a Serious Adverse Events (SAEs) 29 Days After the Last Vaccination|Number of Participants Who Experience a Serious Adverse Events (SAEs) During a 6 Month Follow up Period From the Receipt of First Vaccination|Number of Participants Who Seroconverted One Month After First Dose.|Number of Participants Who Seroconverted One Month After the Second Dose.|Number of Participants Who Seroconverted One Month After the Third Dose.|Number of Participants Who Seroconverted at Month Six After First Dose.|Number of Participants Who Received RTS,S/AS01E + DHA-PIP+PQ Fractional Two-dose (Group 7) That Seroconverted at Month Two After First Dose.","University of Oxford","All","18 Years to 55 Years   (Adult)","Phase 2","193","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BAKMAL1605","June 4, 2017","February 20, 2018","February 20, 2018","December 14, 2016","July 29, 2019","July 29, 2019","Hospital of Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT02992119/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT02992119/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02992119"
333,"NCT02991729","Use of a Novel Computerized Decision Aid for Prenatal Aneuploidy Screening","DAAS","Completed","Has Results","Aneuploidy|Pregnancy Complications","Other: iPad-based decision aid|Other: Genetic counseling appointment","Knowledge Score|Decisional Conflict Score|Test Chosen|Supplementary Tests Performed","University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute","Female","18 Years to 50 Years   (Adult)","Not Applicable","197","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","15-1745","January 20, 2017","January 5, 2018","January 12, 2018","December 13, 2016","November 12, 2019","November 12, 2019","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT02991729/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02991729"
334,"NCT02987374","Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization","SLVP023","Completed","Has Results","Influenza","Biological: 2011-2012 Fluzone IIV3 (IM)","Number of Participants Who Received Influenza Vaccine|Number of Participants With Related Adverse Events","Stanford University|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 30 Years   (Adult)","Phase 4","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SU-24167|U19AI057229-06","May 2012","December 2012","December 2012","December 8, 2016","December 26, 2016","April 21, 2017",,,"https://ClinicalTrials.gov/show/NCT02987374"
335,"NCT02985996","Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities",,"Completed","Has Results","HIV Infections","Drug: Truvada|Drug: Genvoya","Changes in Intracellular Emtricitabine Triphosphate (FTC-TP)|Changes in Intracellular Tenofovir Diphosphate (TFV-DP)|Change in Plasma Emtricitabine (FTC) Concentration|Change in Plasma Tenofovir Disoproxil Fumarate (TDF) Concentration|Change in Plasma Tenofovir Alafenamide (TAF) Concentration|Change in Plasma Elvitegravir (EVG) Concentration|Change in Rectal Emtricitabine (FTC) Concentration|Change in Rectal Tenofovir Disoproxil Fumarate (TDF) Concentration|Change in Rectal Tenofovir Alafenamide (TAF) Concentration|Change in Rectal Elvitegravir (EVG) Concentration|Change in Intracellular Tenofovir Alafenamide (TAF) Concentration in Peripheral Blood Mononuclear Cells (PBMCs)|Change in Intracellular Elvitegravir (EVG) Concentration in Peripheral Blood Mononuclear Cells (PBMCs)|Change in Intracellular Emtricitabine (FTC) Concentration in Rectal Tissue|Change in Intracellular Tenofovir (TFV) Concentration in Rectal Tissue|Change in Tenofovir Alafenamide (TAF) Concentration in Rectal Tissue|Change in Elvitegravir (EVG) Concentration in Rectal Tissue|Change in Emtricitabine (FTC) Concentration in Penile Secretions|Change in Tenofovir Disoproxil Fumarate (TDF) Concentration in Penile Secretions|Change in Tenofovir Alafenamide (TAF) Concentration in Penile Secretions|Change in Elvitegravir (EVG) Concentration in Penile Secretions|PrEP Efficacy as Measured by Inhibition of in Vitro Infection of Rectal Biopsies to HIV","Emory University|Centers for Disease Control and Prevention","Male","18 Years to 49 Years   (Adult)","Phase 1","48","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00092488","February 6, 2017","November 29, 2017","November 29, 2017","December 7, 2016","September 17, 2019","September 17, 2019","Emory University, Atlanta, Georgia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02985996/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02985996/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02985996"
336,"NCT02976519","BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects",,"Completed","Has Results","Cystic Fibrosis","Drug: BI 443651|Drug: Placebo","Percentage of Participants With Treatment-emergent Adverse Events (TEAE) Over the Treatment Period in Part 1 and Part 2|Maximum Measured Concentration of the BI 443651 in Plasma After the Administration of the First Dose (Cmax) on Day 1 and Over the Time Interval From 0 to 12 h After the 13th Dose (Cmax,13) on Day 7, in Part 1|Area Under the Concentration-time Curve of the BI 443651 in Plasma Over the Time Interval From 0 to 12 Hours After the Administration of the First Dose (AUC0-12) on Day 1 and After the 13th Dose (AUC0-12,13) on Day 7 in Part 1","Boehringer Ingelheim","All","18 Years to 55 Years   (Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1363.2|2016-001504-31","February 15, 2017","August 29, 2018","August 29, 2018","November 29, 2016","November 27, 2019","November 27, 2019","Charité - Universitätsmedizin Berlin, Berlin, Germany|IKF Pneumologie GmbH & Co. KG, Frankfurt, Germany|Lungenärztliche Praxis, München-Pasing, Germany|Celerion Inc, Belfast, United Kingdom|The Medicines Evaluation Unit, Manchester, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT02976519/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT02976519/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02976519"
337,"NCT02974855","PF-06741086 Multiple Dose Study in Severe Hemophilia",,"Completed","Has Results","Hemophilia A or B","Biological: PF-06741086","Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Number of Participants Discontinued From Study Due to TEAEs|Number of Participants With Abnormal Laboratory Findings-Hematology|Number of Participants With Abnormal Laboratory Findings-Clinical Chemistry|Number of Participants With Abnormal Laboratory Findings-Urinalysis|Change From Baseline for Globulin by Dose Cohort|Change From Baseline for Prothrombin International Normalized Ratio (PT/INR) by Dose Cohort|Change From Baseline for Activated Partial Thromboplastin Time (aPTT) by Dose Cohort|Change From Baseline for Fibrinogen by Dose Cohort|Change From Baseline for Antithrombin III by Dose Cohort|Change From Baseline for Troponin I by Dose Cohort|Number of Participants With Vital Signs Data Meeting Pre-specified Criteria|Number of Participants With Electrocardiogram (ECG) Change Meeting Pre-specified Criteria|Number of Participants With Clinically Significant Changes in Physical Examination Findings|Number of Participants With Infusion and Injection Site Reactions|Annualized Bleeding Rate (ABR)|Plasma PF-06741086 Concentrations|Area Under the Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-06741086|Maximum Plasma Concentration (Cmax) of PF-06741086|Lowest Concentration Observed During the Dosing Interval (Cmin) of PF-06741086|Time to Reach Maximum Plasma Concentration (Tmax) of PF-06741086|Area Under the Serum Concentration-time Curve Over the Dosing Interval Tau (AUCtau) of PF-06741086|Apparent Clearance After Oral Dose (CL/F) of PF-06741086|Change From Baseline in Total Tissue Factor Pathway Inhibitor (TFPI)|Change From Baseline in Thrombin Generation (TGA) Lag Time|Change From Baseline in Thrombin Generation (TGA) Peak|Change From Baseline in Endogenous Thrombin Generation (TGA) Potential|Change From Baseline in Prothrombin Fragments 1 + 2|Change From Baseline in D-Dimer|Change From Baseline in Dilute Prothrombin Time|Number of Participants Who Tested Positive for Anti-PF-06741086 Antibody (ADA)|Number of Participants Who Tested Positive for Neutralizing Antibody (NAb)","Pfizer","Male","18 Years to 64 Years   (Adult)","Phase 2","27","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","B7841002|2016-001885-27","March 8, 2017","December 3, 2018","December 3, 2018","November 29, 2016","December 4, 2019","December 4, 2019","UC Denver Hemophilia and Thrombosis Center - Pharmacy, Aurora, Colorado, United States|UC Denver Hemophilia and Thrombosis Center, Aurora, Colorado, United States|Pharmacy, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Hospital Dr. Sotero del Rio, Santiago, Chile|Klinicki bolnicki centar Zagreb, Zagreb, Croatia|Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Phoenix Pharma (Pty) Ltd, Port Elizabeth, Eastern CAPE, South Africa|Haemophilia Comprehensive Care Centre, Johannesburg, Gauteng, South Africa|UniversitatsSpital Zurich, Klinik fur Hamatologie, Zurich, Switzerland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02974855/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02974855/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02974855"
338,"NCT02972554","Does Propranolol Attenuate Inflammatory Responses to a Psychological Stressor?",,"Completed","Has Results","Stress, Psychological|Inflammation|Cortisol|Sympathetic Nervous System","Drug: Propanolol hydrochloride|Other: Placebo","Change in Interleukin-6 (IL-6)|Change in Salivary Cortisol|Change in Salivary Alpha Amylase|Change in Pre-Ejection Period|Change in Respiratory Sinus Arrhythmia|Change in Negative, High Arousal Emotion","University of North Carolina, Chapel Hill","All","18 Years to 25 Years   (Adult)","Phase 4","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","16-2498","January 26, 2016","October 10, 2017","October 10, 2017","November 23, 2016","December 19, 2018","December 19, 2018","Howell Hall, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02972554/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02972554"
339,"NCT02971670","Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial",,"Completed","Has Results","Toxic-Shock Syndrome|Sepsis","Biological: rTSST-1 Variant Candidate Vaccine","Number of Participants With Adverse Events as a Measure of Safety|Persistence of TSST-1 Antibodies|Boosterability of BioMed rTSST-1 Variant Vaccine","Biomedizinische Forschungs gmbH|Medical University of Vienna","All","18 Years to 64 Years   (Adult)","Phase 1","23","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","BioMed0713 B","October 2015","March 2016","May 2016","November 23, 2016","May 8, 2017","June 9, 2017",,,"https://ClinicalTrials.gov/show/NCT02971670"
340,"NCT02971605","Persisting Effects of Psilocybin",,"Completed","Has Results","Healthy","Drug: Psilocybin","Amygdala Response to Stimuli in the Emotion Recognition Test|Change in Longitudinal Emotion and Mood Questionnaire Scores|Change in Emotional Functioning Task Accuracy|Change in Emotional Functioning Tasks Response Time (Milliseconds)","Johns Hopkins University|National Institute on Drug Abuse (NIDA)","All","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","13","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00102081|R03DA042336","July 1, 2017","August 21, 2018","August 21, 2018","November 23, 2016","September 10, 2019","September 10, 2019","Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02971605/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02971605"
341,"NCT02969590","Regulation of Cervical Mucus Secretion",,"Completed","Has Results","Fertility|Contraception","Drug: Leuprolide acetate|Drug: Estrogen and Progesterone Replacement|Drug: Progestin","Median Cervical Mucus Score - Baseline|Sperm Penetration Scores|Median Cervical Mucus Score - 2 Hour|Median Cervical Mucus Score - 6 Hour|Median Cervical Mucus Score - 24 Hour|Change in PGRMC1 During Menstrual Cycle","Oregon Health and Science University|Society of Family Planning","Female","21 Years to 40 Years   (Adult)","Phase 4","5","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","OHSU IRB 11532","March 29, 2015","August 23, 2017","August 23, 2017","November 21, 2016","October 18, 2019","October 18, 2019","Oregon Health & Science University, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02969590/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02969590"
342,"NCT02969421","Pain Perception With Tenaculum Placement",,"Completed","Has Results","Pain","Other: Cough method for placement of tenaculum|Other: Slow Tenaculum Placement of tenaculum","Pain With Tenaculum Placement|Overall Pain With Intrauterine Device Insertion|Provider Satisfaction With Tenaculum Placement","Duke University","Female","18 Years to 55 Years   (Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00078232","January 10, 2016","February 23, 2017","February 23, 2017","November 21, 2016","March 18, 2019","March 18, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02969421/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02969421"
343,"NCT02968914","Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers",,"Completed","Has Results","Asthma|Chronic Obstructive Pulmonary Disease","Biological: Benralizumab","Area Under the Concentration-time Curve From Zero to Infinity (AUCinf)|Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)|Maximum Observed Concentration (Cmax)|Time When Maximum Concentration is Observed (Tmax)|Terminal Half-life (t½)|Apparent Extravascular Clearance (CL/F)|Apparent Volume of Distribution Based on the Terminal Phase (Vz/F)|Number of Participants With Adverse Events|Antidrug Antibody (ADA) Status","AstraZeneca|Parexel","All","18 Years to 55 Years   (Adult)","Phase 1","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D3250C00030","January 4, 2017","July 13, 2017","July 13, 2017","November 21, 2016","July 5, 2019","July 5, 2019","Research Site, Berlin, Germany|Research Site, Harrow, Germany","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02968914/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02968914/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02968914"
344,"NCT02968576","Bioequivalence of Tenofovir and Emtricitabine Following Overencapsulation","A-TEAM","Completed","Has Results","Healthy Volunteers|Pharmacokinetics","Drug: TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA]|Device: Proteus Sensor System","Peak Plasma Concentration (Cmax)|Area Under the Concentration-time Curve (AUC)","University of Colorado, Denver","All","18 Years to 45 Years   (Adult)","Not Applicable","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16-1478","December 2016","April 2017","June 2017","November 18, 2016","May 14, 2019","May 14, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02968576/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02968576"
345,"NCT02966340","Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment",,"Completed","Has Results","Alcoholism","Drug: Prazosin|Drug: Placebo","Startle Potentiation During Stress Reactivity Task.|Self-reported Anxiety Potentiation During Stress Reactivity Task.","University of Wisconsin, Madison|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Screening","2014-0966|F31AA022845-01|Kaye2","November 1, 2016","March 12, 2018","March 12, 2018","November 17, 2016","May 28, 2019","May 28, 2019","University of Wisconsin, Madison, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02966340/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02966340"
346,"NCT02965534","Evaluation of a Night Spectacle Correction Concerning an Improvement of Mesopic Vision Quality",,"Completed","Has Results","Myopia-Night Blindness","Device: Spectacle/Glasses","Night Myopia|Mesopic Visual Acuity Improvement|Subjective Vision Comfort in Dark Light Conditions|Subjective Vision Sharpness in Dark Light Conditions|Subjective Glare Sensitivity in Dark Light Conditions|Subjective Driving Safety in Dark Light Conditions","University of Applied Sciences Jena|IGA OPTIC EG","All","18 Years to 40 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IGAMYO","October 2015","February 2016","March 2016","November 16, 2016","February 28, 2019","February 28, 2019","Degle Optometry, Augsburg, Bavaria, Germany|Hessler Optometry, Klingenberg am Main, Bavaria, Germany|University of Applied Sciences, Jena, TH, Germany",,"https://ClinicalTrials.gov/show/NCT02965534"
347,"NCT02963701","Bioequivalence of a Fixed Dose Combination Tablet Containing 400 mg Ibuprofen and 60 mg Pseudoephedrine-HCl Compared to Two Film Coated Fixed Dose Combination Tablets RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) Administered in Healthy Subjects",,"Completed","Has Results","Healthy Volunteers","Drug: Ibuprofen|Drug: Pseudoephedrine-HCl","Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Ibuprofen. (AUC0-tz)|Maximum Concentration of Ibuprofen in Plasma (Cmax).|Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Pseudoephedrine (AUC0-tz).|Maximum Concentration of Pseudoephedrine in Plasma (Cmax).|Area Under the Concentration-time Curve of Ibuprofen in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).|Area Under the Concentration-time Curve of Pseudoephedrine in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).|AUC0-tz of R-Ibuprofen|AUC0-∞ of R-Ibuprofen|Cmax of R-Ibuprofen|AUC0-tz of S-Ibuprofen|AUC0-∞ of S-Ibuprofen|Cmax of S-Ibuprofen|S/R-ibuprofen Ratio for AUC0-tz","Boehringer Ingelheim","All","21 Years to 50 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1024.9","December 20, 2016","January 31, 2017","February 8, 2017","November 15, 2016","September 27, 2018","September 27, 2018","Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, South Africa","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02963701/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02963701/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02963701"
348,"NCT02962908","A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine",,"Completed","Has Results","Influenza","Biological: FLU-v|Biological: adjuvanted FLU-v|Biological: Saline|Biological: Adjuvanted placebo","Percentage of CD4+ TH1 Cytokine Responders|Percentage of Responders on Day 42 and Day 180 for IFNgamma Secretion by PBMCs|Solicited AEs|Th2 Cytokine Responses (IL-4)|Antibody Responses to FLU-v","PepTcell Limited|Seventh Framework Programme|University of Groningen|University Medical Center Groningen|Robert Koch Institut|Norwegian Institute of Public Health","All","18 Years to 60 Years   (Adult)","Phase 2","175","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","FLU-v 003|2015-001932-38","August 2016","July 18, 2017","July 18, 2017","November 15, 2016","April 8, 2019","April 8, 2019","Isala, Zwolle, Netherlands","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02962908/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02962908/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02962908/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02962908"
349,"NCT02960295","The Virtual Visit for Women With Gestational Diabetes",,"Completed","Has Results","Diabetes, Gestational","Device: 1-Self-monitoring of blood glucose|Device: 2-Self-weighing|Device: 3-Self-checking of blood pressure|Device: 4-Checking fetal heart rate|Procedure: 5-Visits with caregivers","Compliance With Requirements for Frequency of Glucose Measures|Compliance With Self-weighing Requirements|Compliance With Blood Pressure Checking Requirements|Glucose Concentrations","Kaiser Permanente","Female","18 Years to 45 Years   (Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10539","September 2014","September 2016","September 2016","November 9, 2016","February 26, 2019","February 26, 2019","Kaiser Permanente Southern California, Pasadena, California, United States",,"https://ClinicalTrials.gov/show/NCT02960295"
350,"NCT02959892","A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)",,"Completed","Has Results","Healthy Volunteers","Drug: Amphetamine|Drug: TAK -041|Drug: [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)","Change in Non-displaceable Binding Potential (BP-ND) in the TAK-041+AMPH Condition Compared to AMPH Alone|Change in BP-ND in the TAK-041+AMPH Condition Compared to AMPH Alone as a Function of the Dose of TAK-041 Administered","Takeda","Male","20 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-041-1002|U1111-1184-1947|2016-002346-23","December 5, 2016","May 30, 2017","August 23, 2017","November 9, 2016","December 23, 2019","December 23, 2019","Hammersmith Medicines Research, London, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02959892/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02959892/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02959892"
351,"NCT02959840","Acupuncture Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean",,"Completed","Has Results","Nausea|Vomiting|Satisfaction","Device: Acupressure Point P6 stimulator|Drug: Metoclopramide|Drug: Ondansetron","Nausea|Vomiting|Nausea During Stage I (After the Administration of CSE and Until Eversion of the Uterus)|Nausea During Stage II (After Eversion of the Uterus and Until Replacement of the Uterus)|Nausea During Stage III (After Replacement of the Uterus and to the Next 15 Minutes)|Nausea During Stage IV (the Rest of the Time Until Arrival at PACU)|Vomiting During Stage I (After the Administration of CSE and Until Eversion of the Uterus)|Vomiting During Stage II (After Eversion of the Uterus and Until Replacement of the Uterus)|Vomiting During Stage III (After Replacement of the Uterus and to the Next 15 Minutes)|Vomiting During Stage IV (the Rest of the Time Until Arrival at PACU)|Satisfaction of Anti-emetic Treatment|Overall Anesthetic Care Satisfaction","Rutgers, The State University of New Jersey","Female","18 Years to 45 Years   (Adult)","Phase 4","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro20140000517","July 2015","March 2016","August 23, 2017","November 9, 2016","July 25, 2017","September 25, 2017","Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02959840"
352,"NCT02956837","A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women",,"Completed","Has Results","Respiratory Syncytial Virus Infections","Biological: RSV Vaccine (GSK3003891A) formulation 1|Biological: RSV Vaccine (GSK3003891A) formulation 2|Biological: RSV Vaccine (GSK3003891A) formulation 3|Drug: Placebo (Formulation buffer S9b)","Number of Subjects With Any Grade 2 and Grade 3 General Adverse Events (AEs) - Solicited and Unsolicited|Number of Subjects With Grade 2 and Grade 3 Fever|Number of Subjects With Related Serious Adverse Events (SAEs)|Neutralizing Antibody Titers Against RSV-A Subtype|Palivizumab Competing Antibody (PCA) Concentrations|Pavilizumab Competing Antibody (PCA) Concentrations|Number of Subjects With Any, Grade 2, Grade 3 and Medically Attended Solicited Local AEs|Number of Subjects With Any, Grade 2, Grade 3, Related and Medically Attended Solicited General AEs|Number of Subjects With Any Unsolicited AEs|Number of Subjects With Any SAEs|Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities|Number of Subjects With Any Biochemical and Hematological Laboratory Abnormalities, by Maximum Grading|Neutralizing Antibody Titers Against RSV-B Subtype|Antibody Concentrations Against Neogenin (NEO) Residual Host Cell Protein|Number of Subjects With Any Medically Attended (MA) Respiratory Tract Infections (RTIs) Associated With RSV","GlaxoSmithKline","Female","18 Years to 45 Years   (Adult)","Phase 2","406","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","204812|2016-001135-12","November 10, 2016","August 30, 2017","February 5, 2018","November 6, 2016","November 20, 2018","July 2, 2019","GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Clermont-Ferrand, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Goch, Nordrhein-Westfalen, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02956837/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02956837/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02956837"
353,"NCT02956746","A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines","RabiesMab","Completed","Has Results","Human Rabies","Biological: SYN023|Biological: Imovax|Biological: RabAvert|Biological: HyperRAB ST (human rabies immune globulin)","Percentage of Participants With Serum Rabies Virus Neutralizing Activity|Percentage of Participants With Adverse Event Incidence of SYN023 Compared to HRIG in RabAvert and Imovax Reciptients|Percentage of Participants With Immunogenicity: Anti-CTB012 Antibodies Positive|Percentage of Participants With Immunogenicity: Anti-CTB011 Antibodies Positive|SYN023 Monoclonal Antibody Areas Under the Curve (AUC0-last, AUC0-inf) for CTB011 and CTB012)|Time to Maximum Concentration Tmax of CTB011 and CTB012|Maximum Serum Concentration Cmax|Serum Clearance Rate (Clp) of CTB011 and CTB012|Serum Half Lives of CTB011 and CTB012","Synermore Biologics Co., Ltd.|inVentiv Health Clinical","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","164","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","SYN023-002","August 2016","December 2017","January 2018","November 6, 2016","February 27, 2019","February 27, 2019","inVentiv Clinical Research Facility, 1951 NW 7th Ave. Suit 450, Miami, Florida, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02956746/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02956746/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02956746"
354,"NCT02956460","Performance Comparison Between Fanfilcon A and Senofilcon A Sphere Lenses",,"Completed","Has Results","Myopia","Device: fanfilcon A|Device: senofilcon A","Overall Comfort|Overall Dryness|Vision Quality|Lens Handling|Vision Satisfaction|Lens Centration|Conjunctival Staining|Smoothness|Clean Feeling|Lens Hydrated|Lens Wettability","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EX-MKTG-73","October 27, 2016","December 14, 2016","December 14, 2016","November 6, 2016","December 8, 2017","April 2, 2018","Eric M. White O. D., Inc, San Diego, California, United States|Golden Vision, Sarasota, Florida, United States|Kannarr Eye Care, Pittsburg, Kansas, United States|Nittany Eye Associates, State College, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02956460"
355,"NCT02951780","A Study of LY3185643 and rGlucagon in Healthy Participants",,"Completed","Has Results","Healthy","Drug: LY3185643|Drug: rGlucagon","Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3185643 and rGlucagon|Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3185643 and rGlucagon|Pharmacodynamics (PD): Change From Baseline in Maximum Concentration (Cmax) of Blood Glucose of LY3185643 and rGlucagon|Pharmacodynamics (PD): Change From Baseline in Maximum Concentration (Cmax) of C-peptide of LY3185643 and rGlucagon|Pharmacodynamics (PD): Change From Baseline in Area Under the Concentration Time Curve (AUC) of Blood Glucose of LY3185643 and rGlucagon|Pharmacodynamics (PD): Change From Baseline in Area Under the Concentration Time Curve (AUC) of C-Peptide of LY3185643 and rGlucagon","Eli Lilly and Company","All","21 Years to 60 Years   (Adult)","Phase 1","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","16502|I8Z-MC-APCA","November 1, 2016","January 24, 2017","March 1, 2017","November 1, 2016","September 30, 2019","September 30, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02951780/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02951780/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02951780"
356,"NCT02950753","Does Intravenous Lactated Ringer Solution Raise Measured Serum Lactate?",,"Completed","Has Results","Hyperlactatemia","Drug: Lactated Ringer Solution|Drug: Normal Saline","Change in Mean Lactate Level of the LR Group Compared to the NS Group.|Decrease in Bicarbonate Level of the LR Group Compared to the NS Group|Final Chloride Level Minus Initial Chloride Level of the LR Group Compared to the NS Group","University Medical Center of Southern Nevada","All","18 Years to 64 Years   (Adult)","Early Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","EM 2016.10","January 4, 2017","May 5, 2017","June 1, 2017","November 1, 2016","April 12, 2019","April 12, 2019","University Medical Center of Southern Nevada, Las Vegas, Nevada, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02950753/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02950753"
357,"NCT02945410","Effect of Caloric Restriction and Protein Intake on Metabolism and Anabolic Sensitivity",,"Completed","Has Results","Weight Loss|Starvation","Other: Caloric Restriction|Other: Protein|Other: Exercise|Dietary Supplement: Calcium and Vitamin D|Other: Maltodextrin","Change in Resting Metabolic Rate|Change in Circulating IGF-1|Change in Marker of Bone Formation (P1NP)|Change in Marker of Bone Resorption (CTx)|Change in Body Weight|Change in Body Fat Percentage|Change in Aerobic Fitness (VO2peak)|Change in Perceived Hunger","University of Nebraska Lincoln","Male","19 Years to 30 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","15895","September 2016","February 2019","February 2019","October 26, 2016","December 19, 2019","December 19, 2019","Sports and Exercise Nutrition Laboratory, Department of Nutrition and Health Sciences, Ruth Leverton Hall, Lincoln, Nebraska, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02945410/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02945410"
358,"NCT02945254","Effect of Background Noise on Sleep Quality","Noise","Completed","Has Results","Sleep Onset Insomnia","Device: NIghtingale (R) device for filtered white noise (Cambridge Sound Management, Waltham, MA)","Sleep Onset Latency (Mins)|Subjective Sleep Quality (VAS)","Brigham and Women's Hospital","All","21 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2016P000982","August 2016","February 2017","February 2017","October 26, 2016","May 25, 2018","May 25, 2018","Sleep Disorders Research Program Brigham and Women's Hospital, Boston, Massachusetts, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02945254/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02945254"
359,"NCT02942017","A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)",,"Completed","Has Results","Postpartum Depression","Drug: Placebo|Drug: SAGE-547 90 μg/kg/h","Change From Baseline at 60 Hours in 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score|Change From Baseline in HAM-D Total Score at Day 30|Change From Baseline in HAM-D Total Score|Percentage of Participants With HAM-D Response|Percentage of Participants With HAM-D Remission|Change From Baseline in HAM-D Bech 6 Subscale|Change From Baseline in HAM-D Individual Item Scores|Change From Baseline at Key Time Points in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score|Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response|Change From Baseline in the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score|Percentage of Participants With Treatment Emergent Adverse Event (TEAE)|Time to Change in Antidepressant Medication","Sage Therapeutics","Female","18 Years to 45 Years   (Adult)","Phase 3","108","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","547-PPD-202 C","July 2016","September 17, 2017","October 11, 2017","October 21, 2016","June 13, 2019","June 13, 2019","Sage Investigational Site, Chandler, Arizona, United States|Sage Investigational Site, Rogers, Arkansas, United States|Sage Investigational Site, Lemon Grove, California, United States|Sage Investigational Site, Orange, California, United States|Sage Investigational Site, Ventura, California, United States|Sage Investigational Site, Gainesville, Florida, United States|Sage Investigational Site, Miami, Florida, United States|Sage Investigational Site, Miramar, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Pensacola, Florida, United States|Sage Investigational Site, Pinellas Park, Florida, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Hoffman Estates, Illinois, United States|Sage Investigational Site, Wichita, Kansas, United States|Sage Investigational Site, Edgewood, Kentucky, United States|Sage Investigational Site, Owensboro, Kentucky, United States|Sage Investigational Site, Boston, Massachusetts, United States|Sage Investigational Site, Flowood, Mississippi, United States|Sage Investigational Site, Marlton, New Jersey, United States|Sage Investigational Site, Glen Oaks, New York, United States|Sage Investigational Site, Chapel Hill, North Carolina, United States|Sage Investigational Site, Charlotte, North Carolina, United States|Sage Investigational Site, Raleigh, North Carolina, United States|Sage Investigational Site, Columbus, Ohio, United States|Sage Investigational Site, Dayton, Ohio, United States|Sage Investigational Site, Philadelphia, Pennsylvania, United States|Sage Investigational Site, Baytown, Texas, United States|Sage Investigational Site, Houston, Texas, United States|Sage Investigational Site, Houston, Texas, United States|Sage Investigational Site, Richardson, Texas, United States|Sage Investigational Site, San Antonio, Texas, United States|Sage Investigational Site, Orem, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02942017/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02942017/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02942017"
360,"NCT02942004","A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)",,"Completed","Has Results","Postpartum Depression","Drug: Placebo|Drug: SAGE-547 60 μg/kg/h|Drug: SAGE-547 90 μg/kg/h","Change From Baseline at 60 Hours in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score|Change From Baseline in HAM-D Total Score at Day 30|Change From Baseline in HAM-D Total Score|Percentage of Participants With HAM-D Response|Percentage of Participants With HAM-D Remission|Change From Baseline in HAM-D Bech 6 Subscale|Change From Baseline in HAM-D Individual Item Scores|Change From Baseline at Key Time Points in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score|Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response|Change From Baseline in the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score|Percentage of Participants With Treatment-Emergent Adverse Events|Time to Change in Antidepressant Medication","Sage Therapeutics","Female","18 Years to 45 Years   (Adult)","Phase 3","138","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","547-PPD-202 B","August 1, 2016","September 24, 2017","October 19, 2017","October 21, 2016","June 13, 2019","June 13, 2019","Sage Investigational Site, Chandler, Arizona, United States|Sage Investigational Site, Rogers, Arkansas, United States|Sage Investigational Site, Lemon Grove, California, United States|Sage Investigational Site, Orange, California, United States|Sage Investigational Site, Ventura, California, United States|Sage Investigational Site, Gainesville, Florida, United States|Sage Investigational Site, Miami, Florida, United States|Sage Investigational Site, Miramar, Florida, United States|Sage Investigational Site, Orlando, Florida, United States|Sage Investigational Site, Pensacola, Florida, United States|Sage Investigational Site, Pinellas Park, Florida, United States|Sage Investigational Site, Atlanta, Georgia, United States|Sage Investigational Site, Hoffman Estates, Illinois, United States|Sage Investigational Site, Wichita, Kansas, United States|Sage Investigational Site, Edgewood, Kentucky, United States|Sage Investigational Site, Owensboro, Kentucky, United States|Sage Investigational Site, Boston, Massachusetts, United States|Sage Investigational Site, Boston, Massachusetts, United States|Sage Investigational Site, Flowood, Mississippi, United States|Sage Investigational Site, Marlton, New Jersey, United States|Sage Investigational Site, Glen Oaks, New York, United States|Sage Investigational Site, Chapel Hill, North Carolina, United States|Sage Investigational Site, Charlotte, North Carolina, United States|Sage Investigational Site, Raleigh, North Carolina, United States|Sage Investigational Site, Columbus, Ohio, United States|Sage Investigational Site, Dayton, Ohio, United States|Sage Investigational Site, Philadelphia, Pennsylvania, United States|Sage Investigational Site, Houston, Texas, United States|Sage Investigational Site, Houston, Texas, United States|Sage Investigational Site, Richardson, Texas, United States|Sage Investigational Site, San Antonio, Texas, United States|Sage Investigational Site, Orem, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02942004/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02942004/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02942004"
361,"NCT02939950","Silicone Hydrogel Soft Contact Lens 7-Day Extended Wear Basis",,"Completed","Has Results","Myopia","Device: Bausch + Lomb Samfilcon A Soft Contact Lens|Device: Bausch + Lomb Pure Vision Soft Contact Lens","High Contrast Visual Acuity|Number of Participants With Adverse Events","Bausch Health Americas, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","816","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","818","April 30, 2015","August 3, 2016","August 3, 2016","October 20, 2016","December 10, 2019","December 23, 2019","Cicero Family Eye Care, Cicero, New York, United States",,"https://ClinicalTrials.gov/show/NCT02939950"
362,"NCT02939937","Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis",,"Completed","Has Results","Optic Neuritis","Drug: Phenytoin|Drug: placebo","Retinal Ganglion Cell Inner Plexiform Layer Thickness|Macular Layer Thickness|Best Corrected Visual Acuity|Visual Field Mean Deviation in Decibel|Retinal Nerve Fibre Layer Thickness in Micrometer","Tehran University of Medical Sciences","All","18 Years to 60 Years   (Adult)","Phase 2","71","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","9411257013","March 9, 2017","November 11, 2018","January 2, 2019","October 20, 2016","August 12, 2019","August 12, 2019","Eye Research Center Farabi Hosoital, Tehran, Iran, Islamic Republic of","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02939937/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02939937/ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02939937/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02939937"
363,"NCT02939326","Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines",,"Completed","Has Results","Glabellar Frown Lines (GL)","Drug: EB-001 injection|Drug: Placebo injection","Investigator's Assessment of GL Severity at Maximum Frown Using the Facial Wrinkle Scale (FWS).","Bonti, Inc.","All","18 Years to 60 Years   (Adult)","Phase 2","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EB001-GL201","December 2016","July 12, 2017","July 12, 2017","October 20, 2016","February 15, 2019","February 15, 2019","Center For Dermatology Clinical Research, Inc., Fremont, California, United States|Steve Yoelin, MD Medical Associates, INC., Newport Beach, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02939326/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02939326"
364,"NCT02939079","Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients",,"Completed","Has Results","Multiple Sclerosis","Drug: Fingolimod|Dietary Supplement: Fish Oil|Drug: Placebo (for Fish Oil)","Serum Level of TNF-α|Serum Level of IL1b|Serum Level of IL6|Serum Level of IFN-gamma","Isfahan University of Medical Sciences|Shiraz University of Medical Sciences","All","18 Years to 45 Years   (Adult)","Phase 2|Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","293396","April 2015","September 2016","October 2016","October 19, 2016","May 14, 2019","May 14, 2019",,,"https://ClinicalTrials.gov/show/NCT02939079"
365,"NCT02937168","An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation","DEAR","Terminated","Has Results","Asthma","Drug: Reslizumab|Drug: Fludeoxyglucose F 18 (FDG)|Drug: Placebo","Part 1: Average Global Lung Glycolysis (GLG) at Baseline (Day 1)|Part 1: Average Global Lung Glycolysis (GLG) at Day 8|Part 2: Change From Baseline to Week 4 in GLG|Part 2: Change From Baseline to Week 4 in Lung Parenchyma (LP) SUV Mean|Part 2: Change From Baseline to Week 4 in Blood Eosinophil Counts|Change From Baseline to Week 4 in Forced Expiratory Volume in 1 Second (FEV1)|Change From Baseline to Week 4 in Fractional Exhaled Nitric Oxide (FeNO)|Change From Baseline to Week 4 in Asthma Quality of Life Questionnaire (AQLQ) Score|Number of Participants With Adverse Events (AEs)","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","All","18 Years to 50 Years   (Adult)","Phase 4","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C38072-AS-40105","May 8, 2017","May 24, 2017","May 24, 2017","October 18, 2016","August 6, 2019","August 6, 2019","Teva Investigational Site 13808, New Brunswick, New Jersey, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02937168/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02937168/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02937168"
366,"NCT02936076","Exercise as a Buffer Against Stress-induced Overeating",,"Completed","Has Results","Obesity","Other: Exercise intervention|Other: Delayed exercise intervention","Stress-induced Overeating Measured Via Smartphone Surveys|Change in Body Weight (% Initial Weight)|Stress as Measured Via Questionnaire|Percentage of Overeating Episodes Characterized as 'Overeating'","The Miriam Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Female","18 Years to 60 Years   (Adult)","Not Applicable","49","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","592916-14|K01DK100498","January 16, 2017","November 1, 2018","May 21, 2019","October 18, 2016","October 23, 2019","November 21, 2019","Weight Control and Diabetes Research Center, Providence, Rhode Island, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02936076/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02936076/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02936076"
367,"NCT02935894","Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat",,"Completed","Has Results","Stability & Variability of Lipid-derived Molecules in Sweat","Drug: Ibuprofen|Other: Physiological induction of sweating|Drug: Pilocarpine","Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise|Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration|Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration|Change in Plasma Ibuprofen Concentrations|Change in Sweat Ibuprofen Concentrations","USDA, Western Human Nutrition Research Center|University of California, Davis","Male","20 Years to 40 Years   (Adult)","Not Applicable","14","U.S. Fed|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","929370","November 28, 2016","June 8, 2017","June 8, 2017","October 18, 2016","June 1, 2018","June 1, 2018","Western Human Nutrition Research Center, Davis, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02935894"
368,"NCT02935179","The Effect of White Sweet Potato Meal Replacement on Weight Control of the Obesity",,"Completed","Has Results","Overweight","Dietary Supplement: White sweet potato diet","Body Weight After Intervention|Body Fat After Intervention","Taipei Medical University","All","20 Years to 50 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","N201604045","July 2016","December 2016","May 2017","October 17, 2016","April 17, 2019","April 30, 2019",,,"https://ClinicalTrials.gov/show/NCT02935179"
369,"NCT02932904","Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers",,"Completed","Has Results","Healthy Volunteers","Drug: Vortioxetine|Drug: Paroxetine|Drug: Placebo","Change From Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Full Analysis Set (FAS)|Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 1 (mFAS1)|Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 2 (mFAS2)|Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Weeks 1, 2, 3 and 4|Change From Baseline in CSFQ-14 Total Score Difference for Paroxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5|Change From Baseline in CSFQ-14 Total Score Difference for Vortioxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5|Percentage of Participants Meeting Criteria for Sexual Dysfunction at Weeks 1, 2, 3, 4 and 5|Change From Baseline in CSFQ-14 Subscales 5 Dimensions at Weeks 1, 2, 3, 4 and 5|Change From Baseline in CSFQ-14 3 Phases of the Sexual Response Cycle (Desire, Arousal, and Orgasm/Completion) at Weeks 1, 2, 3, 4 and 5","Takeda","All","18 Years to 40 Years   (Adult)","Phase 4","361","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Vortioxetine-4001|U1111-1174-1779","November 21, 2016","May 31, 2017","June 9, 2017","October 13, 2016","September 14, 2018","September 14, 2018","Encino, California, United States|Long Beach, California, United States|Torrance, California, United States|Jacksonville, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Portland, Oregon, United States|Austin, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02932904/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02932904/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02932904"
370,"NCT02930005","Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders",,"Completed","Has Results","Psychotic Disorders|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder","Drug: Meclofenamic acid|Drug: Pentosan polysulfate sodium","Change in Cognitive Function as Assessed by the NIH Toolbox Cognitive Test Battery (NCTB) Composite Score|Change in Severity of Psychotic Symptoms as Assessed by Positive and Negative Syndrome Scale (PANSS)","The University of Texas Health Science Center, Houston","All","18 Years to 60 Years   (Adult)","Phase 2","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-15-0329","August 7, 2015","October 6, 2016","October 6, 2016","October 11, 2016","March 26, 2019","March 26, 2019","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02930005"
371,"NCT02925403","A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant",,"Completed","Has Results","Malaria","Biological: R21/Matrix-M1|Other: Saline","Safety and Tolerability of Administration of R21/Matrix-M1 Assessed by the Occurrence of Solicited Local and Systemic Adverse Events.|Safety and Tolerability of R21/Matrix-M1 Assessed by the Occurrence of Unsolicited Adverse Events.|Safety and Tolerability of R21/Matrix-M1 Assessed by the Occurrence of Serious Adverse Events.|Safety and Tolerability of R21/Matrix-M1 Assessed by the Occurrence of Laboratory Adverse Events.","University of Oxford","All","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","VAC060","August 26, 2016","February 15, 2017","February 15, 2017","October 5, 2016","November 6, 2019","November 6, 2019","Centre National de Recherche et de Formatation sur le Paludisme (CNRFP)/Unite de Recherche Clinique de Banfora (URC-B), Ouagadougou, Burkina Faso","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02925403/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02925403"
372,"NCT02922985","Multimodal Pain Management for Cesarean Delivery",,"Completed","Has Results","Pain","Drug: Intravenous acetominophen|Drug: Ketorolac, intramuscular|Drug: Bupivacaine, subcutaneous|Drug: Normal saline","Total Opioid Intake in Morphine Milligram Equivalents in the First 48 Hours After Cesarean Delivery (CD)|Time to First Administration of Opioid Pain Medication Post Operatively|Pain Score at 6-12 Hours Post Operatively|Number of Opioid Pain Tablets Remaining on Post-operative Day #7 From the Discharge Prescription.|Hospital Length of Stay|Pain Score at 24 Hours Post-operatively|Pain Score at 48 Hours Post-operatively|Apgar Score at 5 Minutes|NICU Admission|Need for Respiratory Support","The University of Texas Medical Branch, Galveston","Female","18 Years to 45 Years   (Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB 16-0121","October 2016","June 2017","July 2017","October 4, 2016","July 24, 2018","March 14, 2019","University of Texas Medical Branch, Galveston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02922985/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02922985"
373,"NCT02921412","Performance of Fanfilcon A Toric Lenses After at Least One Month Wearing Enfilcon A Toric Lenses",,"Completed","Has Results","Astigmatism","Device: fanfilcon A","Visual Acuity|Centration|Corneal Coverage|Post-blink Movement|Fit Acceptability","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","37","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","EX-MKTG-67","October 1, 2016","February 1, 2017","March 21, 2017","October 3, 2016","March 13, 2018","April 10, 2018","Hospital Contact Lens Service, Miami, Florida, United States|Debbie Kim, Closter, New Jersey, United States|West Village Eyecare, New York, New York, United States|Spokane Eye Clinic, Spokane, Washington, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02921412/ICF_001.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02921412/Prot_SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02921412"
374,"NCT02921087","Connecting Contact Lenses and Digital Technology",,"Completed","Has Results","Asthenopia|Contact Lenses|Ocular Accommodation|Convergence, Excess","Device: Test Daily Disposable Soft Contact Lenses|Device: Control Daily Disposable Soft Contact Lenses","Subjective Symptom Improvement|Lens Preference|Lag of Accommodation in Study Lenses|Convergence Insufficiency Symptom Survey (CISS)|Contact Lens Dry Eye Questionnaire- 8 Survey (CLDEQ-8)|Near Phoria at 40cm in Multifocal Contact Lens vs Single Vision Contact Lens","State University of New York College of Optometry|Johnson & Johnson Vision Care, Inc.","All","18 Years to 35 Years   (Adult)","Not Applicable","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","923606","January 2017","November 20, 2017","November 20, 2017","September 30, 2016","September 11, 2019","September 11, 2019","SUNY College of Optometry, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02921087/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02921087/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02921087"
375,"NCT02920957","Performance Comparison Between Comfilcon A and Senofilcon C Lenses",,"Completed","Has Results","Myopia","Device: comfilcon A|Device: senofilcon C","Overall Lens Fit Acceptance|Corneal Coverage|Lens Centration|Post-blink Movement|Lens Lag at Primary Gaze|Tightness on Push up|Lens Wettability|Deposit Grading","Coopervision, Inc.","All","18 Years to 34 Years   (Adult)","Not Applicable","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EX-MKTG-70","September 2016","November 23, 2016","November 23, 2016","September 30, 2016","January 9, 2018","January 9, 2018","Golden Optometric Group, Whittier, California, United States|Coan Eye Care & Optical Boutique, Ocoee, Florida, United States|Cornea & Contact Lens Institute of Minnesota, Edina, Minnesota, United States|Sacco Eye Group, Vestal, New York, United States|Vision Professionals, New Albany, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02920957"
376,"NCT02919813","M-gCBT for Women With Provoked Localized Vulvodynia",,"Completed","Has Results","Provoked Localized Vulvodynia","Behavioral: Mindfulness Based Group Cognitive BehaviorTherapy|Behavioral: Educational Seminars","Tampon Test|Sexual Distress Survey Response|Sexual Function Questionnaire Response|Depression Questionnaire Response|Anxiety Questionnaire Response|Pain Catastrophizing Scale Response|Quality of Life Questionnaire Response","Oregon Health and Science University|Medical Research Foundation, Oregon","Female","18 Years to 55 Years   (Adult)","Not Applicable","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","OHSU IRB 15221","December 16, 2015","September 30, 2017","September 30, 2017","September 29, 2016","December 30, 2019","December 30, 2019","Oregon Health and Science University, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT02919813/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02919813"
377,"NCT02919657","Absorption Comparison on Equivalency Value of Genepro Gen2",,"Completed","Has Results","Analysis, Event History|Absorption; Disorder, Protein","Dietary Supplement: Genepro Protein|Dietary Supplement: Whey Protein","Weekly Blood Draws to Measure Blood Protein Levels","Musclegen Research, Inc.","All","30 Years to 46 Years   (Adult)","Phase 4","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Genepro Gen 2","June 2016","September 2016","September 2016","September 29, 2016","December 1, 2016","April 24, 2017",,,"https://ClinicalTrials.gov/show/NCT02919657"
378,"NCT02919423","TMS Modulation of Insula-related Brain Networks.02","TMSINS02","Completed","Has Results","Healthy Subjects","Device: transcranial magnetic stimulation","Change in Functional Connectivity Strength Measured With Functional Magnetic Resonance Imaging","Duke University","All","18 Years to 55 Years   (Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","Pro00077293","December 2016","January 25, 2018","January 25, 2018","September 29, 2016","February 15, 2019","February 15, 2019","Duke University, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02919423/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02919423"
379,"NCT02918266","TAK-071 Scopolamine-Induced Cognitive Impairment Study",,"Terminated","Has Results","Healthy Volunteers","Drug: Scopolamine|Drug: TAK-071|Drug: Donepezil|Drug: Scopolamine Placebo|Drug: TAK-071 Placebo|Drug: Donepezil Placebo","Part 2: Change From Baseline in Total Number of Errors on the Groton Maze Learning Test (GMLT) at 2 Hours Post-Scopolamine Dose on Day 2|Part 2: Change From Baseline in Total Number of Errors on the GMLT|Part 2: AUECt: GMLT Area Under the Effect Curve From Time 0 Hours to Time t (AUECt) (Net Area) for TAK-071|Part 2: Emax: GMLT Maximum Observed Effect (Emax) for TAK-071|Part 2: TEmax: Time to Reach GMLT Emax for TAK-071|Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)|Percentage of Participants Who Meet the Takeda Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Postdose|Percentage of Participants Who Meet the Takeda Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose|Percentage of Participants Who Meet the Takeda Markedly Abnormal Criteria for Electrocardiogram (ECG) at Least Once Postdose|Cmax: Maximum Observed Plasma Concentration for TAK-071|Tmax: Time to Reach the Maximum Observed Plasma Concentration(Cmax) for TAK-071|AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-071|AUC24: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Postdose for TAK-071|AUCt1-t2: Area Under the Plasma Concentration-Time Curve From Time t1 to Time t2 for TAK-071|AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for TAK-071|T1/2z: Terminal Disposition Phase Elimination Half-Life in Plasma for TAK-071","Takeda","Male","18 Years to 55 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","TAK-071-1002|U1111-1184-2278","November 21, 2016","August 2, 2017","August 8, 2017","September 28, 2016","June 14, 2019","June 14, 2019","Glendale, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02918266/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02918266/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02918266"
380,"NCT02912650","A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain","SDDP","Completed","Has Results","Post-surgical Pain Following Extraction of Molar Teeth","Drug: Ibuprofen 250 mg / Acetaminophen 500 mg|Drug: Ibuprofen 250 mg|Drug: Acetaminophen 650 mg|Drug: Placebo","Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 0 to 8 Hours Post-dose (SPID11 [0-8])|Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 6 to 8 Hours Post-dose (SPID11 [6-8])|Time-weighted Sum of Pain Relief Rating (TOTPAR) From 0 to 8 Hours and 6 to 8 Hours Post-dose|Time to Treatment Failure|Cumulative Percentage of Participants With Treatment Failure at 6 and 8 Hours|Time to Onset of Meaningful Pain Relief","Pfizer","All","18 Years to 40 Years   (Adult)","Phase 3","568","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B5061003|GEMINI SDDP","September 2015","June 2016","June 2016","September 23, 2016","August 30, 2017","August 30, 2017","Jean Brown Research, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02912650"
381,"NCT02912364","Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults",,"Completed","Has Results","Epilepsy","Drug: Eslicarbazepine|Drug: Carbamazepine","Overall Composite Z Score of Neuropsychological Battery as a Measure of Direct Comparison of the 2 Antiepileptic Drugs.|Overall Z-score for Executive Function.|MCG Paragraph Recall Scores.|Dual Task Percent of Time in Box.|Profile of Mood States (POMS) Score.","Stanford University|Sunovion","All","18 Years to 55 Years   (Adult)","Phase 4","46","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","34098","July 2016","April 20, 2018","April 20, 2018","September 23, 2016","June 4, 2019","June 4, 2019","Stanford University, Palo Alto, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02912364/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02912364"
382,"NCT02911753","Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults",,"Completed","Has Results","Obesity|Hypercholesterolemia|Hyperglycemia|Hypertriglyceridemia","Other: Mediterranean Lemonade|Other: Green Tea|Other: Flavored Water","Study Recruitment: Interest in Participation|Study Recruitment: Screened for Eligibility|Study Recruitment: Eligibility|Study Recruitment: Ineligibility|Enrollment|Retention|Treatment Satisfaction|Change in Total Cholesterol (Baseline and Week 6)|Change in Fasting Glucose (Baseline and Week 6)|Change in Hemoglobin A1C (Baseline and Week 6)|Change in Body Weight (Baseline and Week 6)","University of Arizona","All","18 Years to 64 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1606621176","June 2016","August 2017","August 2017","September 22, 2016","October 25, 2019","October 25, 2019","University of Arizona Collaboratory for Metabolic Disease Prevention and Treatment, Tucson, Arizona, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02911753/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02911753"
383,"NCT02909101","Project IMPACT: Improving Memory Performance by Applying Cognitive Training",,"Completed","Has Results","Cocaine Use Disorders|HIV","Device: Active Cognitive Training (ACT)|Device: Control Training (CON)","Working Memory Assessed by Domain Deficit Score|Delay Discounting, Measured by the Monetary Choice Questionnaire (MCQ)|Acceptability as Measured by Participant Ratings|Acceptability as Measured by Participant Perception of Benefits and Barriers to Completing Sessions|Percent Medication Adherence Across All Antiretroviral Medications|Sexual Risk Behavior as Measured by the Risk Assessment Battery (RAB)|Number of Days of Cocaine Use as Measured by Timeline Followback Interview Methodology","Duke University","All","18 Years to 60 Years   (Adult)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Pro00053630_1","March 1, 2017","February 23, 2019","February 23, 2019","September 21, 2016","October 30, 2019","October 30, 2019","Duke University Medical Center, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02909101/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02909101"
384,"NCT02907489","Effect of Triple Antibiotic Paste as an Intracanal Medication With an Anti-Inflammatory Drug on Post-operative Pain.",,"Completed","Has Results","Asymptomatic Necrotic Teeth","Other: triple antibiotic paste with an anti-inflammatory drug","Post Operative Pain|Intracanal Bacterial Count","Cairo University","All","18 Years to 50 Years   (Adult)","Phase 1","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CEBD-CU-2016-09-194","October 2016","April 2018","July 2018","September 20, 2016","September 24, 2019","September 24, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02907489/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02907489"
385,"NCT02906813","A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants",,"Completed","Has Results","Healthy Volunteers","Drug: TAK-935 Tablets|Drug: TAK-935 Oral Solution","Cmax: Maximum Observed Plasma Concentration for TAK-935|AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-935|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-935|Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose.|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post Dose","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-935-1005|U1111-1177-8044","September 12, 2016","October 12, 2016","November 9, 2016","September 20, 2016","September 19, 2018","September 19, 2018","Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT02906813"
386,"NCT02904915","Paracervical Block Versus No Paracervical Block During IUD Insertion",,"Completed","Has Results","Analgesia|IUD Insertion","Drug: Lidocaine|Other: No analgesia|Device: Intrauterine device (IUD)","Pain Score as Assessed by a Visual Analogue Scale (VAS)|Pain Score as Assessed by a Visual Analogue Scale","The University of Texas Health Science Center, Houston","Female","18 Years to 52 Years   (Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-16-0664","January 12, 2017","October 9, 2017","October 9, 2017","September 19, 2016","November 7, 2018","November 7, 2018","The University of Texas Health Science Center at Houston, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02904915/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02904915"
387,"NCT02903394","Coherence Imaging of the Cervical Epithelium",,"Completed","Has Results","Cervical Epithelia","Device: mLCI Device","Number of Patients With Interferometric Data Acquired From Cervical Epithelium|Number of Patients With Automated Classification of Cervical Epithelium|Number and Frequency of Adverse Events","Duke University|National Cancer Institute (NCI)|Jacobi Medical Center","Female","18 Years to 36 Years   (Adult)","Not Applicable","55","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pro00070555|R01CA167421","October 27, 2016","October 24, 2017","October 24, 2017","September 16, 2016","November 14, 2018","November 14, 2018","Jacobi Medical Center, Bronx, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02903394/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02903394"
388,"NCT02902913","Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity",,"Completed","Has Results","Cardiovascular Diseases","Other: D2i2|Other: D2i0.5|Other: D2i0|Drug: Ibuprofen","Optical Platelet Aggregometry|Activated Platelet Oxylipin Production","University of California, Davis|USDA, Western Human Nutrition Research Center","Male","20 Years to 50 Years   (Adult)","Not Applicable","9","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","617247","January 2015","September 2015","September 2015","September 16, 2016","November 7, 2019","November 7, 2019",,,"https://ClinicalTrials.gov/show/NCT02902913"
389,"NCT02902081","Cannabidiol and Emotional Stimuli","CAS","Completed","Has Results","Drug Addiction","Drug: Cannabidiol|Drug: Placebo","Positivity Ratings of Social Images","University of Chicago|INSYS Therapeutics Inc","All","18 Years to 35 Years   (Adult)","Not Applicable","38","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","IRB13-0215","February 2013","March 2017","March 2017","September 15, 2016","August 28, 2019","August 28, 2019","University of Chicago, Chicago, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT02902081/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02902081"
390,"NCT02901951","Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B",,"Completed","Has Results","Hepatitis B Vaccine","Biological: Engerix-B","Percentage of Subjects With an Anamnestic Response to the HBV Challenge Dose, Based on the Last Available Time Point Before the Challenge Dose|Percentage of Subjects With Anti-HBs Antibody Concentrations Equal to or Above Cut-off Values|Anti-HBs Antibody Concentrations|Number of Subjects With Any Solicited Local Adverse Events (AEs)|Number of Subjects With Any Solicited General AEs|Number of Subjects With Any Unsolicited AEs|Number of Subjects With Any Serious Adverse Events (SAEs)","GlaxoSmithKline","All","40 Years to 60 Years   (Adult)","Phase 4","106","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","116811|2015-004099-31","October 11, 2016","May 1, 2017","May 1, 2017","September 15, 2016","August 3, 2018","January 2, 2020","GSK Investigational Site, Ghent, Belgium|GSK Investigational Site, Wilrijk, Belgium|GSK Investigational Site, Québec City, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02901951/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02901951/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02901951"
391,"NCT02894840","Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults",,"Completed","Has Results","Influenza","Biological: an inactivated influenza vaccine|Other: Placebo","Number of Participants With Adverse Events|Number (Percentage) of Participants With Achieving Seroconversions or Significant Increase in Antihemagglutinin Antibody Titer.|Geometric Mean of Immune Response at Every Time of Assessment|Geometric Mean of Immune Response Increase > 2.5 From Baseline of H1N1,H3N2 and B/Brisbane/60/2008 Antibody Titer","Mahidol University|The Government Pharmaceutical Organization|World Health Organization","All","18 Years to 49 Years   (Adult)","Phase 1|Phase 2","340","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","GPO Tri Fluvac Vaccine","November 2015","July 2016","November 2016","September 9, 2016","September 19, 2018","September 19, 2018",,,"https://ClinicalTrials.gov/show/NCT02894840"
392,"NCT02892409","TAK-438 Bismuth Drug Interaction Study",,"Completed","Has Results","Helicobacter Pylori","Drug: Clarithromycin|Drug: Amoxicillin|Drug: Tripotassium bismuth dicitrate|Drug: Lansoprazole|Drug: TAK-438","Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)|Percentage of Participants Who Discontinue Due to an Adverse Event (AE)|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post-dose|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post-dose|Cmax: Maximum Observed Plasma Concentration for Bismuth|AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Bismuth|Aeτ: Amount of Drug Excreted in Urine During a Dosing Interval for Bismuth","Takeda","All","19 Years to 60 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-438_115|U1111-1179-5816|02892409","September 5, 2016","April 17, 2017","May 11, 2017","September 8, 2016","January 3, 2019","January 3, 2019","Seoul, Korea, Republic of","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02892409/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02892409/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02892409"
393,"NCT02891174","The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy",,"Completed","Has Results","Hypertension, Pregnancy-Induced|Pre-eclampsia","Drug: Ibuprofen|Drug: Acetaminophen","Difference in Systolic Blood Pressure (SBP)|Change in Self-reported Pain Score 2 Hours After First Intervention|Mean Pain Score by Nursing Assessment|Satisfaction With Pain Control During 24 Hours of Exposure Each to Ibuprofen and Acetaminophen","University of Michigan","Female","18 Years to 45 Years   (Adult)","Phase 4","74","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HUM00117154","December 1, 2016","March 31, 2018","June 20, 2018","September 7, 2016","May 23, 2019","May 23, 2019","University of Michigan, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02891174/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02891174"
394,"NCT02886923","Evaluation of Vision Effects of a Cosmetic Tinted Hydrogel Contact Lens",,"Completed","Has Results","Refractive Error","Device: Hioxifilcon A Test|Device: Hioxifilcon A With Cosmetic Ring Control","The Binocular Functional Visual Performance Under Distance Day Time Conditions (250 cd/m2) for Centrally Presented High Contrasts (HC) Time Controlled Visual Acuity (TCVA) Targets.|The Binocular Functional Visual Performance Under Distance Night Time Conditions (2.5 cd/m2) for Centrally Presented HC TCVA Targets.|The Binocular Functional Visual Performance Under Intermediate Vision Indoor Conditions (50 cd/m2) for Centrally Presented HC TCVA Targets.","Johnson & Johnson Vision Care, Inc.","All","35 Years to 42 Years   (Adult)","Not Applicable","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-5856","August 1, 2016","January 23, 2017","January 23, 2017","September 1, 2016","December 20, 2019","December 20, 2019","Optometry Technology Group, Ltd., London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02886923/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02886923"
395,"NCT02885506","A FIH Study to Investigate the Safety, Tolerability and PK of P218",,"Completed","Has Results","Malaria","Drug: Oral administration of P218 capsules|Drug: Oral administration of P218 matching placebo","Safety and Tolerability of P218: Incidence, Severity and Relationship to the Investigational Product of Observed and Self-reported Adverse Events|Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUClast)|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf)|Maximum Plasma Drug Concentration (Cmax)|Time to Reach Maximum (Peak) Plasma Concentration Following Drug Administration (Tmax)|Elimination Half-life (t1/2)|Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F) (for Parent Only)|Apparent Volume of Distribution During Terminal Phase After Oral Administration (Vz/F) (for Parent Only).","Medicines for Malaria Venture|Richmond Pharmacology Limited","All","18 Years to 45 Years   (Adult)","Phase 1","64","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MMV_P218_15_01|2016-001933-29","August 24, 2016","December 4, 2017","December 4, 2017","August 31, 2016","August 1, 2019","August 1, 2019","Richmond Pharmacology Ltd, Croydon, Surrey, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02885506/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02885506/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02885506"
396,"NCT02881567","Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab","SUSTAIN","Terminated","Has Results","Relapsing-Remitting Multiple Sclerosis (RRMS)","Drug: Daclizumab","Percentage of Participants Relapse-free at Month 6|Percentage of Participants Relapse-free at Month 12|Percentage of Participants Experiencing Relapse Requiring Hospitalization and/or Steroid Treatment at Month 12|Annualized Relapse Rate (ARR) at Month 12|Number of Participants With New Gadolinium-Enhanced (Gd+) and T1 Hypointense Lesions at Months 6 and 12|Number of Participants With New and Newly Enlarged T2 Hypointense Lesions at Months 6 and 12|Permanent Discontinuation Rate of Daclizumab at Month 12|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Relevant Shifts in Laboratory Assessments","Biogen|AbbVie","All","18 Years to 55 Years   (Adult)","Phase 3","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","205MS305|2016-002820-10","April 18, 2017","September 12, 2018","September 12, 2018","August 29, 2016","September 24, 2019","September 27, 2019","Research Site, Tampa, Florida, United States|Research Site, Des Moines, Iowa, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Edmonton, Alberta, Canada|Research Site, Muenchen, Bayern, Germany|Research Site, Potsdam, Brandenburg, Germany|Research Site, Dresden, Sachsen, Germany|Research Site, Hamburg, Germany|Research Site, Pozzilli, Isernia, Italy|Research Site, Napoli, Italy|Research Site, Guaynabo, Puerto Rico","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02881567/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02881567/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02881567"
397,"NCT02877732","EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 2","ETA-TV","Terminated","Has Results","Eye-tracking","Device: EYE-SYNC eye-tracking|Other: SCAT-3 subtests|Other: DEM|Other: Simple Reaction Time subtest of ANAM-SRT|Other: Level of Alertnesss","Changes in the Measurement of EYE-SYNC Data Immediately After Concussive Event, 2 Days, 7 Days and 14 Days Post Concussive Event.|Reliability of EYE-SYNC Data|Integrity of EYE-SYNC Data|Compare Sport Concussion Assessment Tool (SCAT-3) Test and EYE-SYNC Score|Compare ANAM-SRT Test and EYE-SYNC Score|Compare DEM Test and EYE-SYNC Score","Stanford University|Brain Trauma Foundation|United States Department of Defense|Food and Drug Administration (FDA)|U.S. Army Medical Research and Development Command|Department of Health and Human Services","All","18 Years to 25 Years   (Adult)","Not Applicable","12","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","20160727","July 2016","April 2017","April 2017","August 24, 2016","April 30, 2018","May 30, 2018","University of Southern California, Los Angeles, California, United States|University of California Santa Barbara, Santa Barbara, California, United States|Oregon State University, Corvallis, Oregon, United States|University of Utah, Salt Lake City, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02877732/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02877732"
398,"NCT02876159","The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination","FLU1","Completed","Has Results","Influenza","Biological: 2016-2017 Influenza Vaccine","Change in Geometric Mean Serum Hemagglutination Inhibition (HAI) Antibody Titer|Change in Mean Level of Circulating Follicular Helper T (TFH) Cells|Change in Mean Levels of Plasmablasts|Change in Mean Levels of Memory B Cells From Baseline (Day 1) to Day 29|Change in Mean Levels of Antigen-specific IL-2 Producing CD4+ T Cells|Change in Mean Levels of Antigen-specific Cluster of Differentiation 8 (CD8) + T Cells","Emory University","All","20 Years to 30 Years   (Adult)","Phase 4","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00090196","July 2016","October 18, 2016","December 1, 2016","August 23, 2016","December 12, 2018","December 12, 2018","The Hope Clinic of the Emory Vaccine Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02876159"
399,"NCT02873481","Centering Pregnancy Care + Yoga for Diverse Pregnant Women","CPC+Y","Completed","Has Results","Pregnancy","Behavioral: Centering Pregnancy Care plus Yoga (CPC+Y)","Feasibility of Retention/ Adherence|Self-efficacy for Physical Activity|Salivary Biomarkers (α-amylase)|Depressive Symptoms|Stress|Number of Subjects Participating in Focus Group|Recruitment Feasibility","Virginia Commonwealth University|Sigma Theta Tau International Honor Society of Nursing|Southern Nursing Research Society","Female","18 Years to 55 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HM20005136","July 2015","December 2016","December 2016","August 19, 2016","June 6, 2018","June 6, 2018","Virginia Commonwealth University School of Nursing, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02873481"
400,"NCT02873104","Pivotal Study of the truSculpt Radiofrequency Device for Circumferential Reduction",,"Completed","Has Results","Abdominal Fat","Device: truSculpt rf device","Difference in Circumferential Measurement Related to Sham and Therapeutic Group at 12 Weeks Post-treatment|Subject Assessment of Improvement for Both Sham Group and Therapeutic Group at 12 Weeks Post-treatment.|Subject Satisfaction Level for Both Sham Group and Therapeutic Group at 12 Weeks Post-treatment.|Subject Discomfort and Pain Levels During Treatment","Cutera Inc.","All","24 Years to 60 Years   (Adult)","Not Applicable","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","C-16-TS11","March 2016","September 2016","September 2016","August 19, 2016","February 28, 2018","February 28, 2018","Cutera Research Center, Brisbane, California, United States",,"https://ClinicalTrials.gov/show/NCT02873104"
401,"NCT02867202","Adjuvant Therapy for Intrauterine Adhesions Between Two Groups",,"Completed","Has Results","Asherman Syndrome","Device: Intrauterine balloon|Device: Intrauterine Contraceptive Device Plus Foley Catheter","the AFS Score at Second-look Hysteroscopy","Wenzhou Medical University","Female","18 Years to 45 Years   (Adult)","Not Applicable","171","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Wenzhou MC","June 2015","December 2017","December 2017","August 15, 2016","January 2, 2020","January 2, 2020","the 1st Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02867202/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02867202/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02867202"
402,"NCT02864732","Stabilization Exercises Alone vs Stabilization Exercises Plus Neuromuscular Electrical Stimulation in People With Chronic Low Back Pain",,"Completed","Has Results","Low Back Pain","Other: Rehabilitation exercises|Device: Electrical Stimulation","Tolerability of Electrical Stimulation (NMES)|Modified Oswestry Disability Questionnaire (MODQ)|Numeric Pain Rating Scale (NPRS)|Fear-avoidance Behavior Questionnaire|Paraspinal Muscle Strength|Patient Satisfaction Survey","University of Pittsburgh|Saudi Arabian Cultural Mission|King Fahad Specialist Hospital Dammam",,"18 Years to 60 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","PRO12100651","January 2014","February 2015","February 2015","August 12, 2016","November 6, 2017","November 6, 2017",,,"https://ClinicalTrials.gov/show/NCT02864732"
403,"NCT02863198","Endometrial Injury for Unexplained Infertility",,"Completed","Has Results","Infertility","Device: endometrial injury","Measurement of Uterine Artery Pulsatility Index|Measurement of Uterine Artery Resistance Index|Appearance of Sub Endometrial Blood Flow in All Patients|Spiral Artery Pulsatility Indices in All Patients|Spiral Artery Doppler Resistance Indices in All Patients|Pregnancy Rate Between the Study and the Control Group","Benha University","Female","20 Years to 35 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Khalid 3","October 2013","February 2016","July 2016","August 11, 2016","March 14, 2017","March 14, 2017","Benha university hospitalا, Benha, Alqalubia, Egypt",,"https://ClinicalTrials.gov/show/NCT02863198"
404,"NCT02862730","Four Way Crossover Closed Loop With Exercise Detection",,"Completed","Has Results","Type 1 Diabetes","Device: Artificial Pancreas Controller in Dual Hormone Mode|Device: Subject's insulin pump|Device: Artificial Pancreas Controller in Single Hormone Mode|Device: Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode","Percent of Time With Sensed Glucose < 3.9 mmol/L|Percent of Time With Sensed Glucose Between 3.9-10 mmol/L|Mean Sensed Glucose|Number of Carbohydrate Treatments|Percent of Time With Sensed Glucose < 3.0 mmol/L|Percent of Time With Sensed Glucose > 10 mmol/L|Number of Events With Capillary Blood Glucose < 3.9 mmol/L|Number of Events With Capillary Blood Glucose < 3.0 mmol/L|Mean Amount of Insulin Delivered|Mean Amount of Glucagon Delivered","Oregon Health and Science University","All","21 Years to 45 Years   (Adult)","Not Applicable","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15590","October 2016","August 2017","January 31, 2018","August 11, 2016","May 17, 2018","September 14, 2018","Oregon Health and Science University, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02862730/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02862730"
405,"NCT02855541","Health Effects of Increasing Muscle Activation While Sitting in Office Workers",,"Completed","Has Results","Blood Pressure","Device: DeskCycle","Blood Glucose|Maximum Oxygen Consumption|Systolic Blood Pressure|HDL Cholesterol|LDL Cholesterol|Triglycerides|Lean Mass|Fat Mass","University of Colorado, Boulder","All","18 Years to 55 Years   (Adult)","Not Applicable","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UColoradoBoulder","August 2016","June 2017","June 2017","August 4, 2016","November 13, 2018","November 13, 2018","University of Colorado Boulder, Boulder, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02855541/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02855541"
406,"NCT02855411","A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)",,"Terminated","Has Results","Cognitive Impairment Associated With Schizophrenia (CIAS)","Drug: PF-04958242|Drug: placebo","Change From Baseline in the MCCB (MATRICS Consensus Cognitive Battery) Working Memory Domain to Week 12|Change From Baseline in the UPSA‑VIM (University of California, San Diego [UCSD] Performance Based Skills Assessment - Validation of Intermediate Measures) to Week 12|Scale for the Assessment and Rating of Ataxia (SARA)|Number of Participants With Categorical Results on the Columbia-Suicide Severity Rating Scale (C-SSRS)|Change From Baseline in the MCCB Neurocognitive Composite (Excluding Social Cognition Domain) to Week 12|Change From Baseline in MCCB Overall Composite (Including All 7 Domains) to Week 12|Change From Baseline in Each of the 6 Individual MCCB Domain Scores (Excluding MCCB Working Memory) to Week 12|Change From Baseline in the SCI‑PANSS (Structured Clinical Interview Positive and Negative Symptoms Scale) Total to Week 12|Change From Baseline in the SCI‑PANSS Positive, Negative and General Psychopathology Subscales to Week 12|Change From Baseline in the CGI‑S (Clinical Global Impression-Severity) to Week 12|CGI-I (Clinical Global Impression-Improvement) at Week 12|Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Laboratory Test Abnormalities|Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings|Number of Participants With Potentially Clinically Significant Vital Signs Findings|Number of Participants With Abnormalities in Neurological Examination|Number of Participants With Abnormalities in Physical Examination","Biogen","All","18 Years to 50 Years   (Adult)","Phase 2","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","B1701019|POC","August 29, 2016","September 26, 2016","September 26, 2016","August 4, 2016","October 4, 2017","January 9, 2020","Collaborative Neuroscience Network, LLC (Investigator Site File Location), Garden Grove, California, United States|Collaborative Neuroscience Network, LLC, Garden Grove, California, United States|Excell Research, Inc, Oceanside, California, United States|NRC Research Institute, Orange, California, United States|California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC), San Diego, California, United States|Collaborative Neuroscience Network, LLC, Torrance, California, United States|Atlanta Center For Medical Research, Atlanta, Georgia, United States|Alexian Brothers Centers for Psychiatric Research, Hoffman Estates, Illinois, United States|Chinmay K. Patel, D.O., Hoffman Estates, Illinois, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|CBH Health, LLC, Gaithersburg, Maryland, United States|Hassman Research Institute, Berlin, New Jersey, United States|CRI Worldwide, LLC, Marlton, New Jersey, United States|Research Strategies of Memphis, LLC, Memphis, Tennessee, United States|Pillar Clinical Research, LLC, Dallas, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02855411"
407,"NCT02854527","Transporter Cocktail Mutual Interaction",,"Completed","Has Results","Healthy","Drug: Digoxin|Drug: Furosemide|Drug: Metformin|Drug: Rosuvastatin|Drug: Metformin hydrochloride","Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz)|Maximum Concentration of Digoxin (Cmax)|Area Under the Curve of Furosemide From 0 to Last Quantifiable Data Point (AUC 0-tz)|Maximum Concentration of Furosemide (Cmax)|Area Under the Curve of Metformin From 0 to Last Quantifiable Data Point (AUC 0-tz)|Maximum Concentration of Metformin (Cmax)|Area Under the Curve of Rosuvastatin From 0 to Last Quantifiable Data Point (AUC 0-tz)|Maximum Concentration of Rosuvastatin (Cmax)|Area Under the Curve of Digoxin From 0 Extrapolated to Infinity (AUC 0-∞)|Area Under the Curve of Furosemide From 0 Extrapolated to Infinity (AUC 0-∞)|Area Under the Curve of Metformin From 0 Extrapolated to Infinity (AUC 0-∞)|Area Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC 0-∞)","Boehringer Ingelheim","Male","18 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","352.2096|2016-001893-14","August 22, 2016","November 11, 2016","November 19, 2016","August 3, 2016","August 6, 2018","August 6, 2018","Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany",,"https://ClinicalTrials.gov/show/NCT02854527"
408,"NCT02853435","To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.",,"Completed","Has Results","Infections, Bacterial","Drug: Gepotidacin RC Tablet|Drug: Gepotidacin HSWG Tablet|Drug: Gepotidacin Capsule","Area Under the Concentration-time Curve From Time 0 (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of Plasma Gepotidacin for Part 1a|Area Under the Concentration-time Curve (AUC) From Time 0 (Pre-dose) to Time of the Last Quantifiable Concentration (AUC [0-t]) of Plasma Gepotidacin for Part 1a|Relative Bioavailability of Drug (Frel) of Plasma Gepotidacin for Part 1a|Maximum Observed Concentration (Cmax) Determined Directly From the Concentration Time Data of Plasma Gepotidacin for Part 1a|Time to First Occurrence of Cmax (Tmax) of Plasma Gepotidacin for Part 1a|Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) of Plasma Gepotidacin for Part 1a|Terminal Phase Half-life (t1/2) of Plasma Gepotidacin for Part 1a|Total Unchanged Drug (Total Amount of Drug Excreted in Urine [Ae Total]) for Part 1a|Percentage of the Given Dose of Drug Excreted in Urine (fe%) of Plasma Gepotidacin for Part 1a|Renal Clearance of Drug in Urine (CLr) for Part 1a|Amount of Drug Excreted in Urine in a Time Intervals for Pre-dose, 0 to 2 Hours, 2 to 4 Hours, 4 to 6 Hours, 6 to 8 Hours, 8 to 12 Hours, 12 to 24 Hours, 24 to 36 Hours, and 36 to 48 Hours (Ae [t1-t2]) for Part 1a|Area Under the Urine Concentration-time Curve Over Time 0 (Pre-dose) to 12 Hours (AUC [0-12]) for Part 1a|Area Under the Urine Concentration-time Curve Over Time 0 (Pre-dose) to 24 Hours (AUC [0-24]) After Dosing for Part 1a|Area Under the Urine Concentration-time Curve Over Time 0 (Pre-dose) to 48 Hours (AUC [0-48]) After Dosing for Part 1a|AUC (0-infinity) of Plasma Gepotidacin for Part 1b|AUC (0-t) of Plasma Gepotidacin for Part 1b|Cmax of Plasma Gepotidacin for Part 1b|Tmax of Plasma Gepotidacin for Part 1b|Tlag of Plasma Gepotidacin for Part 1b|t1/2 of Plasma Gepotidacin for Part 1b|AUC (0-infinity) of Plasma Gepotidacin for Part 2|AUC (0-t) of Plasma Gepotidacin for Part 2|Cmax of Plasma Gepotidacin for Part 2|Tlag of Plasma Gepotidacin for Part 2|Tmax of Plasma Gepotidacin for Part 2|t1/2 of Plasma Gepotidacin for Part 2|Total Unchanged Drug (Ae Total) for Part 2|Ae (t1-t2) for Part 2|AUC (0-12) for Part 2|AUC (0-24) for Part 2|AUC (0-48) for Part 2|fe% for Part 2|CLr for Part 2|AUC (0-infinity) of Plasma Gepotidacin for Part 3|AUC (0-t) of Plasma Gepotidacin for Part 3|Cmax of Plasma Gepotidacin for Part 3|Tmax of Plasma Gepotidacin for Part 3|Tlag of Plasma Gepotidacin for Part 3|t1/2 of Plasma Gepotidacin for Part 3|Total Unchanged Drug (Ae Total) for Part 3|Urine Ae (t1-t2) for Part 3|Urine AUC (0-12) for Part 3|Urine AUC (0-24) for Part 3|Urine AUC (0-48) for Part 3|fe% for Part 3|CLr for Part 3|Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) for Part 1a|Change From Baseline in Clinical Chemistry Parameters Serum Glucose, Serum Calcium, Serum Carbon Dioxide, Serum Chloride, Serum Potassium, Serum Sodium and Serum Urea Nitrogen for Part 1a|Change From Baseline in Clinical Chemistry Parameters Serum Alanine Aminotransferase (ALT), Serum Alkaline Phosphatase (AP), Serum Aspartate Aminotransferase (AST) and Serum Creatinine Kinase (CK) for Part 1a|Change From Baseline in Clinical Chemistry Parameters Serum Albumin and Serum Protein for Part 1a|Change From Baseline in Clinical Chemistry Parameters Serum Bilirubin, Serum Creatinine and Serum Direct Bilirubin for Part 1a|Change From Baseline in Hematology Parameters Blood Basophils, Blood Eosinophils, Blood Leukocytes, Blood Lymphocytes, Blood Monocytes, Blood Neutrophils and Blood Platelets for Part 1a|Change From Baseline in Hematology Parameters Blood Erythrocyte (Ery.) Mean Corpuscular Hemoglobin Concentration (MCHC) and Blood Hemoglobin for Part 1a|Change From Baseline in Hematology Parameter Blood Ery. Mean Corpuscular Hemoglobin (MCH) for Part 1a|Change From Baseline in Hematology Parameter Blood Ery. Mean Corpuscular Volume (MCV) for Part 1a|Change From Baseline in Hematology Parameter Blood Ery. for Part 1a|Change From Baseline in Hematology Parameter Blood Hematocrit for Part 1a|Change From Baseline in Vital Sign Parameters Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) for Part 1a|Change From Baseline in Vital Sign Parameter Heart Rate for Part 1a|Change From Baseline in Electrocardiogram (ECG) Parameter Heart Rate for Part 1a|Change From Baseline in ECG Parameters PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and Corrected QT Interval Using Fridericia's Formula (QTcF) for Part 1a|Number of Participants With Abnormal Values on Urinalysis by Dipstick Analysis Part 1a|Number of Participants With AEs and SAEs for Part 1b|Change From Baseline in Clinical Chemistry Parameters Serum Glucose, Serum Calcium, Serum Carbon Dioxide, Serum Chloride, Serum Potassium, Serum Sodium and Serum Urea Nitrogen for Part 1b|Change From Baseline in Clinical Chemistry Parameters Serum ALT, Serum AP, Serum AST and Serum CK for Part 1b|Change From Baseline in Clinical Chemistry Parameters Serum Albumin and Serum Protein for Part 1b|Change From Baseline in Clinical Chemistry Parameters Serum Bilirubin, Serum Creatinine and Serum Direct Bilirubin in Part 1b|Change From Baseline in Hematology Parameters Blood Basophils, Blood Eosinophils, Blood Leukocytes, Blood Lymphocytes, Blood Monocytes, Blood Neutrophils and Blood Platelets for Part 1b|Change From Baseline in Hematology Parameters Blood Ery. MCHC and Blood Hemoglobin for Part 1b|Change From Baseline in Hematology Parameter Blood Ery. MCH for Part 1b|Change From Baseline in Hematology Parameter Blood Ery. MCV for Part 1b|Change From Baseline in Hematology Parameter Blood Ery. for Part 1b|Change From Baseline in Hematology Parameter Blood Hematocrit for Part 1b|Change From Baseline in Vital Sign Parameters SBP and DBP for Part 1b|Change From Baseline in Vital Sign Parameter Heart Rate for Part 1b|Change From Baseline in ECG Parameter Heart Rate for Part 1b|Change From Baseline in ECG Parameters PR Interval, QRS Duration, QT Interval, QTcB and QTcF for Part 1b|Number of Participants With Abnormal Values on Urinalysis by Dipstick Analysis Part 1b|Number of Participants With Non-serious AEs and SAEs for Part 2|Change From Baseline in Clinical Chemistry Parameters Serum Glucose, Serum Calcium, Serum Carbon Dioxide, Serum Chloride, Serum Potassium, Serum Sodium and Serum Urea Nitrogen in Part 2|Change From Baseline in Clinical Chemistry Parameters Serum ALT, Serum AP, Serum AST and Serum CK in Part 2|Change From Baseline in Clinical Chemistry Parameters Serum Albumin and Serum Protein for Part 2|Change From Baseline in Clinical Chemistry Parameters Serum Bilirubin, Serum Creatinine and Serum Direct Bilirubin for Part 2|Change From Baseline in Clinical Chemistry Parameter Serum Estradiol for Part 2|Change From Baseline in Hematology Parameters Blood Basophils, Blood Eosinophils, Blood Leukocytes, Blood Lymphocytes, Blood Monocytes, Blood Neutrophils and Blood Platelets for Part 2|Change From Baseline in Hematology Parameters Ery. MCHC and Blood Hemoglobin for Part 2|Change From Baseline in Hematology Parameter Blood Ery. MCH for Part 2|Change From Baseline in Hematology Parameter Blood Ery. MCV for Part 2|Change From Baseline in Hematology Parameter Blood Ery. for Part 2|Change From Baseline in Hematology Parameter Blood Hematocrit for Part 2|Change From Baseline in Vital Sign Parameters SBP and DBP for Part 2|Change From Baseline in Vital Sign Parameter Heart Rate for Part 2|Change From Baseline in ECG Parameter Heart Rate for Part 2|Change From Baseline in ECG Parameters PR Interval, QRS Duration, QT Interval, QTcB and QTcF for Part 2|Number of Participants With Abnormal Values on Urinalysis by Dipstick Analysis Part 2|Number of Participants With Non-serious AEs and SAEs for Part 3|Change From Baseline in Clinical Chemistry Parameters Serum Glucose, Serum Calcium, Serum Carbon Dioxide, Serum Chloride, Serum Potassium, Serum Sodium and Serum Urea Nitrogen for Part 3|Change From Baseline in Clinical Chemistry Parameters Serum ALT, Serum AP, Serum AST and Serum CK for Part 3|Change From Baseline in Clinical Chemistry Parameters Serum Albumin and Serum Protein for Part 3|Change From Baseline in Clinical Chemistry Parameters Serum Bilirubin and Serum Creatinine for Part 3|Change From Baseline in Hematology Parameters Blood Basophils, Blood Eosinophils, Blood Leukocytes, Blood Lymphocytes, Blood Monocytes, Blood Neutrophils and Blood Platelets for Part 3|Change From Baseline in Hematology Parameters Blood Ery. MCHC and Blood Hemoglobin for Part 3|Change From Baseline in Hematology Parameter Blood Ery. MCH for Part 3|Change From Baseline in Hematology Parameter Blood Ery. Mean Corpuscular Volume (MCV) for Part 3|Change From Baseline in Hematology Parameter Blood Ery. for Part 3|Change From Baseline in Hematology Parameter Blood Hematocrit for Part 3|Change From Baseline in Vital Sign Parameters SBP and DBP for Part 3|Change From Baseline in Vital Sign Parameter Heart Rate for Part 3|Change From Baseline in ECG Parameter Heart Rate for Part 3|Change From Baseline in ECG Parameters PR Interval, QRS Duration, QT Interval, QTcB and QTcF for Part 3|Number of Participants With Abnormal Values on Urinalysis by Dipstick Analysis Part 3","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","117351","August 4, 2016","October 17, 2017","October 17, 2017","August 3, 2016","November 14, 2018","November 14, 2018","GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Austin, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02853435/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02853435/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02853435"
409,"NCT02847169","Clinical Performance of Toric Hydrogel Contact Lenses Following One Week of Daily Wear",,"Completed","Has Results","Astigmatism","Device: filcon IV1 toric lens|Device: ocufilcon D toric lens","Overall Fit Acceptance|Lens Centration|Post-blink Movement|Overall Stability|Corneal Coverage|Lens Orientation in Primary Position of Gaze|Rotational Recovery in Degrees After 60 Seconds","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EX-MKTG-66","September 2016","November 2016","December 2016","July 28, 2016","May 8, 2017","May 8, 2017","Optometry Clinic, National Autonomous University, Mexico D.F., Mexico",,"https://ClinicalTrials.gov/show/NCT02847169"
410,"NCT02845700","Perceptual Retraining to Reduce Suicide Risk","PRS","Completed","Has Results","Perceptual Olfactory Bias","Behavioral: Perceptual Retraining Treatment|Behavioral: Sham Neutral training","Percent Change in Olfactory Perceptual Bias|Change From Baseline in Mean Clinician Administered PTSD Scale for DSM-5 (CAPS-5) at 1 Month|Change in Suicidal Ideation Assessed Using the Depressive Symptom Inventory - Suicidality Subscale|Change in Beck Suicide Scale Scores From Baseline to 1 Month|Change in the Beck Anxiety Inventory-II From Baseline to 1 Month","Florida State University|United States Department of Defense|Southeast Louisiana Veterans Health Care System","All","18 Years to 60 Years   (Adult)","Not Applicable","13","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","A-16054.13a","September 2015","September 2016","September 2016","July 27, 2016","January 14, 2019","January 14, 2019","Florida State University, Tallahassee, Florida, United States|Southeast Louisiana Veterans Health Care System, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT02845700"
411,"NCT02844998","The Impact and Benefit of Physical Activity on Premature Ejaculation","PE","Completed","Has Results","Premature Ejaculation","Behavioral: physical activity|Drug: dapoxetine 30 mg on demand","Premature Ejaculation Diagnostic Tool (Total Score)|Intravaginal Ejaculatory Latency Time","Ankara Training and Research Hospital","Male","18 Years to 40 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","5191","January 2015","May 2016","July 2016","July 26, 2016","September 29, 2017","September 29, 2017",,,"https://ClinicalTrials.gov/show/NCT02844998"
412,"NCT02844543","EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 1","ETA-TV","Completed","Has Results","Eye-tracking","Device: EYE-SYNC eye-tracking device|Other: SCAT-3|Device: Desktop Eye-Tracker","Changes in the Eye-tracking Score Before and After Practice or Game: Phase Error|Changes in the Eye-tracking Score Before and After Practice or Game: Tangential and Radial Error|Changes in the Eye-tracking Score Before and After Practice or Game: Vertical and Horizontal Gain|Changes in Sport Concussion Assessment Tool (SCAT-3) Standardized Assessment of Concussion (SAC) Score","Stanford University|Brain Trauma Foundation|United States Department of Defense|Food and Drug Administration (FDA)|U.S. Army Medical Research and Development Command|Department of Health and Human Services","All","18 Years to 25 Years   (Adult)","Not Applicable","155","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","34662","January 2016","December 2016","December 2016","July 26, 2016","April 30, 2018","May 30, 2018","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT02844543"
413,"NCT02842736","A CLinical Study to Evaluate the Safety And Effectiveness of the CeRene DevIce to Treat HeavY Menstrual Bleeding","CLARITY","Active, not recruiting","Has Results","Menorrhagia","Device: Cerene(R) Cryotherapy Device","Primary Safety Endpoint: Number of Serious Adverse Events and Serious Device-related Adverse Events|Primary Effectiveness Endpoint: Number of Subjects With Reduction in Menstrual Bleeding to PBLAC Score of ≤75","Channel Medsystems","Female","25 Years to 50 Years   (Adult)","Not Applicable","242","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIP-0101","April 2016","April 2018","March 2020","July 25, 2016","June 6, 2019","June 6, 2019","WomanCare PC, Arlington Heights, Illinois, United States|The Advance Gynecologic Surgery Institute, Naperville, Illinois, United States|Women's Health Advantage, Fort Wayne, Indiana, United States|Basinski LLC, Newburgh, Indiana, United States|Asheville Women's Medical Center, Asheville, North Carolina, United States|Seven Hills Women's Health, Cincinnati, Ohio, United States|Amy Brenner MD and Associates, LLC, Mason, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Premier Clinical Research, Spokane, Washington, United States|Allan Centre, Calgary, Alberta, Canada|LaSalle Hospital, Lasalle, Quebec, Canada|Hospital Universitario de la Universidad Autónoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02842736/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02842736/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02842736"
414,"NCT02842073","An Open Label Trial of Bupropion and Naltrexone for Binge Drinking",,"Completed","Has Results","Binge Drinking","Drug: Naltrexone|Drug: Bupropion","Number of Participants With Treatment-Associated Adverse Events|Number of Participants Discontinuing Subsequent to Defined Intolerance|Number of Binge Drinking Days During Treatment|Final Penn Alcohol Craving Scale (PACS) Score|Mean Number of Drinks/Binge Drinking Day During Treatment","University of North Carolina, Chapel Hill|North Carolina Translational and Clinical Sciences Institute","All","21 Years to 34 Years   (Adult)","Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-1370|TTSA018P1","November 1, 2016","December 13, 2017","December 13, 2017","July 22, 2016","December 26, 2018","December 26, 2018","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02842073/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02842073"
415,"NCT02842060","Development of a Tailored HIV Prevention Intervention for Young Men","myDEx","Completed","Has Results","HIV Infections","Behavioral: myDEx|Behavioral: NTHP","Number of Participants With Change in Number of Risky Sexual Partnerships|Number of Participants With Change in HIV Testing Behavior|Change in Self-efficacy Motivations to Engage in HIV Prevention Behaviors|Changes in Psychological Well-being","University of Pennsylvania|University of Michigan","Male","18 Years to 24 Years   (Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","R34MH101997","November 2016","May 2017","May 2017","July 22, 2016","July 16, 2019","July 16, 2019","University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02842060/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02842060/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02842060"
416,"NCT02840916","Laser Acupuncture for Postpartum Weight Retention",,"Completed","Has Results","Postpartum Weight Retention","Procedure: laser acupuncture|Procedure: sham laser acupuncture","Body Mass Index (BMI)|Waist-to-buttock Ratio (WBR)|Body Fat Percentage (BFP)","Chang Gung Memorial Hospital","Female","20 Years to 50 Years   (Adult)","Phase 3","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CMRPG8C0691","January 2014","December 2015","December 2015","July 21, 2016","January 16, 2017","January 16, 2017","Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT02840916"
417,"NCT02837952","A Study of Ibuprofen (IBU) 250mg/APAP 500mg In The Treatment Of Post-Surgical Dental Pain",,"Completed","Has Results","Pain","Drug: FDC IBU/APAP 250 mg/500 mg|Drug: Placebo","Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 0 to 24 Hours Post-dose (SPID11 [0-24])|Time-weighted Sum of Pain Intensity Difference Score on 11-Point Numerical Scale (SPID11) From 0 to 8, 6 to 8, 0 to 16, 8 to 16 and 0 to 48 Hours Post-dose|Duration of Relief After First Dose|Time to Onset of ""Meaningful"" Pain Relief After First Dose","Pfizer","All","18 Years to 40 Years   (Adult)","Phase 3","123","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","B5061004|GEMINI MDDP|MDDP","August 31, 2016","February 1, 2017","February 1, 2017","July 20, 2016","March 5, 2018","March 5, 2018","Pharmaceutical Research Associates, Inc., Salt Lake City, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02837952/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02837952/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02837952"
418,"NCT02829983","Clarithromycin as Adjuvant to Periodontal Debridement",,"Completed","Has Results","Aggressive Periodontitis","Drug: Clarithromycin|Drug: Placebo|Other: One-stage full-mouth ultrasonic debridement (FMUD)","Clinical Attachment Level|Probing Depth","Universidade Estadual Paulista Júlio de Mesquita Filho|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.","All","18 Years to 35 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NMRBA","March 2014","August 2015","November 2015","July 12, 2016","October 17, 2017","November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT02829983"
419,"NCT02829138","Personalized Nutrition in Young Adults: The Ability of Genetic Information to Motivate Changes in Omega-3 Consumption",,"Completed","Has Results","Health Behaviour|Nutrition Intervention|Impaired Health","Genetic: Genetic information and Omega-3 fat intake|Behavioral: General Nutrition related to Omega-3 fats","Omega-3 Dietary Intake|Change in Blood Triglycerides (Physiological Parameter)|Change in Omega-3 Index in Blood (Physiological Parameter)","University of Guelph","All","18 Years to 25 Years   (Adult)","Not Applicable","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Personalized Nutrition","August 2015","March 2016","March 2016","July 12, 2016","January 9, 2018","February 5, 2018",,,"https://ClinicalTrials.gov/show/NCT02829138"
420,"NCT02828241","A Study to Assess the Efficacy, Safety and Tolerability of DFD-04",,"Completed","Has Results","Rosacea","Drug: DFD-04 Ointment|Other: Placebo Ointment","Change in Inflammatory Lesion Counts|Number of Subjects With Investigator's Global Assessment (IGA) Success|Number of Subjects With Treatment Success by Clinician's Erythema Assessment (CEA) Scale","Dr. Reddy's Laboratories Limited","All","18 Years to 64 Years   (Adult)","Phase 2","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DFD04-CD-002","July 2016","January 2017","November 2017","July 11, 2016","January 23, 2019","January 23, 2019","Site 201, Berlin, Germany|Site 208, Berlin, Germany|Site 202, Bochum, Germany|Site 205, Hamburg, Germany|Site 203, Mahlow, Germany|Site 204, Munster, Germany|Site 207, Potsdam, Germany|Site 206, Wiesbaden, Germany",,"https://ClinicalTrials.gov/show/NCT02828241"
421,"NCT02823431","Effect of Urethral Analgesia on Voiding",,"Completed","Has Results","Urethral Analgesia","Drug: lidocaine gel|Other: Plain aqueous gel","Voiding Efficiency|Detrusor Pressure at Maximum Flow|Number of Participants With Interrupted Urinary Flow Pattern During Micturition|Visual Analog Scale Scores (Measure of Discomfort) After Catheterization","Duke University","Female","18 Years to 60 Years   (Adult)","Not Applicable","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Pro00071589","July 2016","December 2016","December 2016","July 6, 2016","July 27, 2018","July 27, 2018","Duke University Campus, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02823431"
422,"NCT02823080","Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome",,"Unknown status","Has Results","Infertility","Drug: Cetrorelix","Daily Serum E2 Levels|Daily Maximal Ovarian Diameter|Daily Numerical Pain Visual Analogue Scale Score|Daily Hematocrits Value|Ultrasound Detected Severity Grades of Ascites From Days 0-8|Daily Total Leucocytic Count","Benha University","Female","20 Years to 35 Years   (Adult)","Phase 2|Phase 3","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Benha U|kmsalama","October 2014","April 2017","May 2017","July 6, 2016","January 31, 2017","March 30, 2017","Benha university hospitalا, Benha, El qalubia, Egypt",,"https://ClinicalTrials.gov/show/NCT02823080"
423,"NCT02821819","Random-start Ovarian Stimulation in Egg-donors (ROSE)","ROSE","Terminated","Has Results","Infertility","Other: Random start ovarian stimulation|Drug: Gonadotrophins|Drug: GnRH antagonist|Drug: GnRH agonist","Percentage of Mature Eggs|Fertilization Rate","Instituto Bernabeu","Female","18 Years to 35 Years   (Adult)","Phase 4","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IB012016","January 10, 2017","January 12, 2018","January 12, 2018","July 4, 2016","August 19, 2019","August 19, 2019","Instituto Bernabeu, Alicante, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT02821819/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02821819"
424,"NCT02821403","Effects of Blue-light Blocking Lens on Visual Functions",,"Completed","Has Results","Effects of Blue-light Blocking Lens on Visual Functions","Device: clear lens with regular coating|Device: regular coating lens with yellow tint|Device: clear lens with blue-light blocking coating","Contrast Sensitivity as Assessed by Mars Contrast Sensitivity Chart|Color Vision as Assessed by the Farnsworth Munsell 100 Hue Test|Self-assessment of Lens Performance Through Questionnaire","The Hong Kong Polytechnic University","All","18 Years to 55 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","HSEARS20140512001-03","July 2014","May 2015","May 2015","July 1, 2016","April 7, 2017","April 7, 2017",,,"https://ClinicalTrials.gov/show/NCT02821403"
425,"NCT02818569","Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic",,"Completed","Has Results","Sleep|Insomnia","Drug: Dexmedetomidine|Other: Saline Placebo","Hemodynamic Stability (Phase I)|Polysomnography Sleep Quality (Phase II).|Performance on the Psychomotor Vigilance Task (Phase II)|Performance on the Motor Sequence Task (Phase II)|Subjective Sleep Quality (Phase II)","Massachusetts General Hospital","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2016P000269","October 2016","June 2018","June 2018","June 29, 2016","October 2, 2019","October 2, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02818569/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02818569"
426,"NCT02818036","An fMRI Study of Opioid-related Changes in Neural Activity",,"Completed","Has Results","Social Acceptance","Drug: Naltrexone|Drug: Placebo","Bold Oxygen-level Dependent (BOLD) Activations in Prespecified ROIs|Self-reported Feelings of Connection in Response to the Scanner Tasks","Tristen Inagaki|University of Pittsburgh","All","18 Years to 35 Years   (Adult)","Not Applicable","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","PRO15010292","August 2016","June 21, 2018","June 21, 2018","June 29, 2016","July 23, 2019","July 23, 2019","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02818036/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02818036"
427,"NCT02817828","E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study",,"Completed","Has Results","Contraception","Drug: 15 mg E4/3 mg DRSP","The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening|The Number of On-treatment Pregnancies (With 2-day Window) as Assessed by the Method Failure Pearl Index in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening|The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in the Overall Study Population (18-50 Years)|The Number of On-Treatment Pregnancies as Assessed by the Method Failure Pearl Index in the Overall Study Population (18-50 Years)|Number of Subjects With Unscheduled Bleeding/Spotting|Number of Unscheduled Bleeding Days Per Cycle|Number of Unscheduled Spotting Days Per Cycle|Number of Subjects With Absence of Scheduled Bleeding and/or Spotting|Number of Scheduled Bleeding and/or Spotting Days Per Cycle|Number of Subjects With Abnormal Vital Signs|Number of Subjects With Abnormal Laboratory Assessment Results|Number of Subjects With Abnormal Physical Examination Results|Number of Subjects With Abnormal Gynecological Examination Results|Endometrial Biopsy Histology at Screening and End of Treatment|Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Percentage Maximum (Sum of First 14 Items)|Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Satisfaction With Medicine and Overall Life Satisfaction Over the Past Week|Change From Baseline to End of Treatment in the Score of the Menstrual Distress Questionnaire (MDQ)","Estetra|PRA Health Sciences","Female","18 Years to 50 Years   (Adult)","Phase 3","1577","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MIT-Es0001-C301","June 2016","April 26, 2018","April 26, 2018","June 29, 2016","October 4, 2019","October 4, 2019","Hopital Saint-Pierre, Bruxelles, Belgium","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02817828/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02817828/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02817828"
428,"NCT02817516","A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants",,"Terminated","Has Results","Healthy Volunteers","Drug: TAK-828|Drug: Placebo","Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)|Percentage of Participants Who Discontinued the Treatment Due to an Adverse Event (AE)|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post-dose|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) at Least Once Post-dose|Cmax: Maximum Observed Plasma Concentration for Free Base of TAK-828 (TAK-828F)|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-828F|AUCtau: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-828F","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","TAK-828-1002|U1111-1177-8105","June 30, 2016","August 22, 2016","August 22, 2016","June 29, 2016","July 17, 2019","July 17, 2019","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02817516"
429,"NCT02816346","Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain",,"Completed","Has Results","Healthy","Biological: Shigella sonnei 53G","Number of Participants With Shigellosis|Geometric Mean Titer (GMT) of Immunoglobulin A (IgA) Antibodies in Stool: Lipopolysaccharide (LPS) Antigen|Geometric Mean Titer (GMT) of Immunoglobulin A (IgA) Antibodies in Stool: Invaplex Antigen|Geometric Mean Titer (GMT) of Immunoglobulin G (IgG) Antibodies in Serum: Lipopolysaccharide (LPS) Antigen|Geometric Mean Titer (GMT) of Immunoglobulin A (IgA) Antibodies in Serum: Lipopolysaccharide (LPS) Antigen|Geometric Mean Titer (GMT) of Immunoglobulin G (IgG) Antibodies in Serum: Invaplex Antigen|Geometric Mean Titer (GMT) of Immunoglobulin A (IgA) Antibodies in Serum: Invaplex Antigen","PATH|United States Department of Defense|Children's Hospital Medical Center, Cincinnati","All","18 Years to 49 Years   (Adult)","Phase 1","56","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","VAC-048","September 12, 2016","December 31, 2017","December 31, 2017","June 28, 2016","June 3, 2019","June 3, 2019","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02816346/Prot_ICF_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02816346/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02816346"
430,"NCT02815735","Multi-Centre Clinical Evaluation of Two Reusable Soft Contact Lenses",,"Completed","Has Results","Myopia","Device: comfilcon A|Device: lotrafilcon B","Comfort|Comfort During the Day","Coopervision, Inc.","All","18 Years to 34 Years   (Adult)","Not Applicable","85","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EX-MKTG-68 (VISA-407)","August 2016","January 2017","February 2017","June 28, 2016","May 8, 2017","May 8, 2017","Eyesite, Reading, Berkshire, United Kingdom|Brock and Houlford, Chew Magna, Bristol, United Kingdom|Tempany's Boutique Opticians, Broadstone, Dorset, United Kingdom|Chalmers Opticians, Cardiff, Glamorgan, United Kingdom|Leightons, St Albans, Hertfordshire, United Kingdom|David Gould Opticians, Rawtenstall, Lancashire, United Kingdom|Harrold Opticians, Uxbridge, Middlesex, United Kingdom|Boots Opticians Ltd, Birmingham, Warwickshire, United Kingdom|Visioncare Research Ltd., Farnham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02815735"
431,"NCT02815644","Empa/Lina FDC Food Effect Study (Japan)",,"Completed","Has Results","Healthy","Drug: empagliflozin/linagliptin FDC","Cmax for Linagliptin|Cmax for Empagliflozin|AUC 0-tz for Linagliptin|AUC 0-tz for Empagliflozin|AUC0-infinity for Linagliptin|AUC0-infinity for Empagliflozin|AUC0-72 for Linagliptin","Boehringer Ingelheim","Male","20 Years to 45 Years   (Adult)","Phase 1","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1275.17","July 15, 2016","October 5, 2016","October 5, 2016","June 28, 2016","August 16, 2018","August 16, 2018","SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan",,"https://ClinicalTrials.gov/show/NCT02815644"
432,"NCT02814656","Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: AZD8871|Drug: Placebo","Number of Participants With ≥1 Treatment Emergent Adverse Event in Any Category.|Number of Participants With Clinically Relevant Abnormalities in Recording of Physical Examination.|Number of Participants With Clinically Relevant Abnormalities in Vital Signs (Pulse, Blood Pressure and Body Temperature).|Number of Participants With Clinically Relevant New Findings or Worsening of Pre-existing Findings as Assessed by Haematology.|Number of Participants With Clinically Relevant Abnormalities in 12-lead Safety ECG.|Number of Participants With Clinically Relevant Abnormalities in Telemetry ECG.|Number of Participants With Clinically Relevant New Findings or Worsening of a Pre-existing Findings as Assessed by Clinical Chemistry.|Number of Participants With Clinically Relevant New Findings or Worsening of Pre-existing Findings as Assessed by Urinalysis Report.|Number of Participants With Clinically Relevant Abnormalities in 12-lead dECG (Including High Precision QTc Analysis) Findings.|Observed Maximum Concentration (Cmax) of AZD8871 and Its Metabolites (Single Dose).|Observed Maximum Concentration (Cmax) of AZD8871 and Its Metabolites (Day 16).|Time to Reach Maximum Concentration (Tmax) of AZD8871 and Its Metabolites (Single Dose).|Time to Reach Maximum Concentration (Tmax) of AZD8871 and Its Metabolites (Day 16).|Terminal Half-life (t½λz) of AZD8871 and Its Metabolites (Single Dose).|Terminal Half-life (t½λz) of AZD8871 and Its Metabolites (Day 16).|AUC(0-24) of AZD8871 and Its Metabolites (Single Dose).|AUC(0-24) of AZD8871 and Its Metabolites (Day 16).|AUC of AZD8871 and Its Metabolites (Single Dose).|Apparent Clearance for Parent Drug (CL/F) (Single Dose).|Apparent Clearance for Parent Drug (CL/F) (Day 16).|Apparent Volume of Distribution for Parent Drug at Terminal Phase (Vz/F) (Single Dose).|Accumulation Ratio for Cmax (Rac[Cmax]) for AZD8871 and Its Metabolites (Day 16).|Accumulation Ratio for AUC0-24 (Rac[AUC0-24]) for AZD8871 and Its Metabolites (Day 16).","AstraZeneca|Parexel","Male","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","D6640C00003","June 22, 2016","November 28, 2016","November 28, 2016","June 28, 2016","February 15, 2019","February 15, 2019","Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02814656"
433,"NCT02814565","Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin",,"Completed","Has Results","Neck Pain|Back Pain|Spasm","Drug: Cyclobenzaprine HCl|Drug: Placebo","Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Day 3 of Treatment|Percentage of Participants With Subject's Rating of Medication Helpfulness Impression on Days 7 and 14 of Treatment|Percentage of Participants With Physician's Clinical Global Assessment on Day 3 of Treatment|Percentage of Participants With Physician's Clinical Global Assessment on Days 7 and 15 of Treatment|Percentage of Participants With Subject-Rated Global Impression on Days 3, 7, and 14 of Treatment|Percentage of Responders on Days 3, 7, and 14 of Treatment|Percentage of Participants With Physician Rated Assessment of Presence of Muscle Spasm on Days 3, 7, and 15 of Treatment|Percentage of Participants With Physician Rated Assessment of Presence of Local Pain on Days 3, 7, and 15 of Treatment|Percentage of Participants With Physician Rated Assessment of Limitation of Range of Motion on Days 3, 7, and 15 of Treatment|Percentage of Participants With Physician Rated Assessment of Limitation of Activities of Daily Living on Days 3, 7, and 15 of Treatment","Takeda","All","18 Years to 50 Years   (Adult)","Phase 3","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CYC-RR-001|U1111-1162-4846","October 12, 2016","February 10, 2017","March 14, 2017","June 27, 2016","April 8, 2019","April 8, 2019","Lipetsk, Lipetsk Region, Russian Federation|Saransk, Republic Of Mordovia, Russian Federation|Kazan, Republic Of Tatarstan, Russian Federation|Ekaterinburg, Sverdlovsk Region, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Saint-Petersburg, Russian Federation|Tver, Russian Federation|Yaroslavl, Russian Federation","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02814565/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02814565/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02814565"
434,"NCT02813681","Ultrasound-Guided Landmark and Epidural Site Pain",,"Completed","Has Results","Back Pain|Epidural Analgesia, Obstetric","Procedure: US-epidural SVD|Procedure: US sham- epidural SVD|Procedure: Spontaneous vaginal delivery without an Epidural","Epidural Pressure Sensitivity at Level of Epidural Insertion|Induction Medication|Opioid Use During Labor|Short-term Back Pain|Number of Needle Repositions|Number of Needle Insertions","The University of Texas Medical Branch, Galveston","Female","18 Years to 35 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","14-0110","May 2014","May 2016","May 2016","June 27, 2016","October 3, 2019","October 3, 2019",,,"https://ClinicalTrials.gov/show/NCT02813681"
435,"NCT02812238","Study to Evaluate the Effect of Nicotinamide Riboside on Immunity",,"Completed","Has Results","Atherosclerosis|Diabetes|Coronary Artery Disease","Dietary Supplement: Nicotinamide riboside (NR)|Drug: Placebo","Mean IL-1 Beta Release From Peripheral Blood Mononuclear Cells During Refeeding After 24 Hour Fast","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 39 Years   (Adult)","Not Applicable","38","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","160129|16-H-0129","June 23, 2016","August 28, 2018","August 28, 2018","June 24, 2016","September 17, 2019","September 17, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02812238/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02812238"
436,"NCT02811159","An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids",,"Terminated","Has Results","Uterine Fibroids","Drug: Telapristone acetate","Percentage of Participants in Amenorrhea|Percentage Change From Baseline in Total Uterine Fibroid System Quality of Life Survey System Severity (UFS-SSS) Score|Percentage Change From Baseline in the Individual UFS-SSS Subscale Score Question 1|Percentage Change From Baseline in the Individual UFS-SSS Subscale Score Question 2|Percentage Change From Baseline in the Individual UFS-SSS Subscale Score Question 3|Percentage Change From Baseline in the Individual UFS-SSS Subscale Score Question 4|Percentage Change From Baseline in the Individual UFS-SSS Subscale Score Question 5|Percentage Change From Baseline in the Individual UFS-SSS Subscale Score Question 6|Percentage Change From Baseline in the Individual UFS-SSS Subscale Score Question 7|Percentage Change From Baseline in the Individual UFS-SSS Subscale Score Question 8|Change From Baseline in Pictorial Blood Loss Assessment Chart (PBAC) Score|Percentage Change From Baseline in Total Uterine Fibroid Volume","Repros Therapeutics Inc.","Female","18 Years to 47 Years   (Adult)","Phase 2","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZPU-203EXT","July 26, 2016","May 4, 2017","May 4, 2017","June 23, 2016","June 19, 2019","June 27, 2019","KO Clinical Research, LLC, Fort Lauderdale, Florida, United States|Atlanta Women's Research Institute, Inc., Atlanta, Georgia, United States|WR-Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States|Southern Clinical Research Associates, LLC, Metairie, Louisiana, United States|The Jackson Clinic, PA, Jackson, Tennessee, United States|Advances in Health, Houston, Texas, United States|The Women's Hospital of Texas Clinical Research Center, Houston, Texas, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02811159/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02811159"
437,"NCT02806869","Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment",,"Completed","Has Results","Human Gastrointestinal Physiology Data","Drug: Single dose of ibuprofen (800 mg tablet)|Dietary Supplement: Pulmocare, two 8.0 oz (236.6 mL) cans","Average Duodenal Fluid pH in Fasted Compared to Fed Participants Administered a Single Dose of Ibuprofen|Maximum Duodenal Fluid Concentration of Ibuprofen in Fasted Compared to Fed Participants Administered a Single Dose of Ibuprofen|Average Area Under the Plasma Concentration-time Curve (AUC) in Fasted Compared to Fed Participants Administered a Single Dose of Ibuprofen","University of Michigan|Food and Drug Administration (FDA)","All","18 Years to 55 Years   (Adult)","Not Applicable","48","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","FDA_13-RFQ-1116088|HHSF223201310144C","January 2015","November 2016","July 2017","June 21, 2016","December 8, 2017","December 8, 2017","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02806869"
438,"NCT02806024","Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study","TAPPAS","Completed","Has Results","Placenta Accreta|Postpartum Hemorrhage|Cesarean Section|Tranexamic Acid","Drug: Tranexamic Acid|Drug: Placebo Drug","Estimated Blood Loss (EBL)|Blood Transfusion (Number of Units Transfused) Intraoperatively","University of California, San Francisco|Central California Faculty Medical Group|University of California, San Francisco Fresno","Female","18 Years to 60 Years   (Adult)","Phase 4","14","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","2016036","November 2016","July 2018","August 2018","June 20, 2016","December 3, 2019","December 3, 2019","Community Regional Medical Center, Fresno, California, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02806024/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02806024/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02806024"
439,"NCT02804399","A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: PF-06463922|Drug: rifampin","Plasma AUCinf for PF-06463922 Given Alone and With Rifampin|Plasma Cmax for PF-06463922 Given Alone and With Rifampin|Plasma AUClast for PF-06463922 Given Alone and With Rifampin|Plasma Tmax for PF-06463922 Given Alone and With Rifampin|Plasma t1/2 for PF-06463922 Given Alone and With Rifampin|Plasma CL/F for PF-06463922 Given Alone and With Rifampin|Plasma Vz/F for PF-06463922 Given Alone and With Rifampin|Plasma AUClast for PF-06895751 When PF-06463922 Given Alone and With Rifampin|Plasma AUCinf for PF-06895751 When PF-06463922 Given Alone and With Rifampin|Plasma Tmax for PF-06895751 When PF-06463922 Given Alone and With Rifampin.|Plasma t1/2 for PF-06895751 When PF-06463922 Given Alone and With Rifampin|Plasma Cmax for PF-06895751 When PF-06463922 Given Alone and With Rifampin|Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for Cmax (MRCmax) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin|Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUClast (MRAUClast) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin|Plasma Molecular Weight Adjusted Metabolite to Parent (M/P) Ratio for AUCinf (MRAUCinf) of PF-06463922 and Its Metabolite: When PF-06463922 Given Alone and With Rifampin","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","B7461011|RIFAMPIN DDI STUDY","July 2016","October 2016","October 2016","June 17, 2016","January 25, 2019","January 25, 2019","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02804399"
440,"NCT02802865","Combined Letrozole and Clomid in Women With Infertility and PCOS",,"Completed","Has Results","Polycystic Ovary Syndrome|Infertility","Drug: Clomiphene|Drug: Letrozole","Number of Participants Achieving Ovulation Measured by Mid-luteal Progesterone Level|Number of Developing Follicles|Size of Largest Developing Follicle|Endometrial Thickness|Conception|Clinical Pregnancy|Multiple Gestation|Live Birth|Pregnancy Loss","Rachel Mejia|University of Iowa","Female","18 Years to 40 Years   (Adult)","Phase 4","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201606806","August 2016","May 2018","February 2019","June 16, 2016","September 27, 2019","September 27, 2019","University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02802865/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02802865"
441,"NCT02802592","EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)","EPORT","Terminated","Has Results","Cardiac Surgery-CABG|Cardiac Valve Replacement","Drug: Epogen|Drug: Normal Saline","Total Number of Packed Red Blood Cells Transfused During the Intraoperative and Immediate Postoperative Period|Length of Stay (# of Total Days Hospitalized)|Overall Hospitalization Cost|Change in Quality of Life as Assessed by Short Form-36 Quality of Life Survey","Johns Hopkins University","All","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00050961","May 2015","June 15, 2016","February 27, 2017","June 16, 2016","September 14, 2017","February 26, 2019","Suburban Hospital, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02802592"
442,"NCT02801942","Immune Profile in Subjects With New Onset Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Procedure: Inguinal lymph node fine needle aspirate biopsy|Procedure: Inguinal lymph node core biopsy|Procedure: Peripheral blood collection|Other: Pre- and post-biopsy questionnaire","Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in Blood|Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in iLN|Percentage of Leukocyte Subsets Including B-cells, Clusters of Differentiation 56 Positive (CD56+) CD16+ , CD56bright Natural Killer (NK) Cells, CD56lo CD16+, CD56lo CD16 Negative (CD56lo CD16-), Dendritic Cells, NK Cells in Blood|Percentage of Leukocyte Subsets Including B-cells, CD56+ CD16+, CD56bright NK Cells, CD56lo CD16+, CD56lo CD16-, Dendritic Cells, NK Cells in iLN|Percentage of Leukocyte Subsets Including CD56+CD16+, CD56bright NK Cells, CD56lo CD16+ and CD56lo CD16- in Blood|Percentage of Leukocyte Subsets Including CD56+CD16+, CD56bright NK Cells CD56lo CD16+ and CD56lo CD16- in iLN|Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in Blood|Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in iLN|Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes, and CD16+ Monocytes in Blood|Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes and CD16+ Monocytes in iLN|Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 Cells in Blood|Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 Cells in iLN|Percentage of Leukocyte Subsets Including Programmed Death 1 (PD-1)+ Inducible Costimulator (ICOS)+ Follicular Helper T (TFH) Cell-like Regulatory (Reg) T Cells in Blood|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cell-like Reg T Cells in iLN|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in Blood|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in iLN|Percentage of Leukocyte Subsets Including Central Memory Conventional (Conv) T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in Blood|Percentage of Leukocyte Subsets Including Central Memory Conv T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in iLN|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, Type 17 T Helper (TH17) Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in Blood|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, Type 17 T Helper (TH17) Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in iLN|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in Blood|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in iLN|Percentage of Leukocyte Subsets Including Reg T Cells in Blood|Percentage of Leukocyte Subsets Including Reg T Cells in iLN|Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in Blood|Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in iLN|Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in Blood|Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in iLN|Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in Blood|Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in iLN|Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in Blood|Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in iLN|Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including B-cells, CD56+ CD16+, CD56bright NK Cells, CD56lo CD16+, CD56lo CD16, Dendritic Cells, NK Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD56+CD16+, CD56br NK Cells CD56lo CD16+ and CD56lo CD16- in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes and CD16+ Monocytes in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cell-like Reg T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including Central Memory Conv T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH17 Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including Reg T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in iLN Core Biopsies and iLN FNA|Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in iLN Core Biopsies and iLN FNA|Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs|Number of Participants Undergoing Procedure Under Local Anesthetics|Number of Participants Undergoing iLN Biopsy Under Local Anesthetics|Number of Participants With Different Reasons for Participating in the Study|Number of Participants With Extreme Anxiety Towards the Lymph Node Biopsy|Number of Participants Looking Forward to Undergo the Procedure|Number of Participants With Aspects Better Explained About the Lymph Node Biopsy Procedure|Number of Participants Who Considered to Undergo Lymph Node Biopsy Procedure Another Time|Number of Participants Who Were Encouraged to be Included in Study for iLN Biopsy|Number of Participants Who Appreciated Receiving Study Feedback","GlaxoSmithKline","All","18 Years to 40 Years   (Adult)","Not Applicable","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","203158","July 25, 2016","December 21, 2017","December 21, 2017","June 16, 2016","February 27, 2019","February 27, 2019","GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Cardiff, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02801942/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02801942/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02801942"
443,"NCT02801396","Clinical Evaluation of Investigational Contact Lenses",,"Completed","Has Results","Visual Acuity","Device: Etafilcon A Design 1 (Test 1)|Device: Etafilcon A Design 2 (Test 2)|Device: Etafilcon A (Control)","CLUE Handling|Visual Performance (LogMar)|Percentage of Eyes With Acceptable Mechanical Lens Fit|Percentage of Eyes With Acceptable Cosmetic Lens Fit","Johnson & Johnson Vision Care, Inc.","All","18 Years to 55 Years   (Adult)","Not Applicable","116","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-5759","April 24, 2016","May 22, 2016","May 22, 2016","June 15, 2016","June 9, 2017","July 11, 2017","Hong Kong Polytechnic University, Hong Hom, Kowloon, Hong Kong",,"https://ClinicalTrials.gov/show/NCT02801396"
444,"NCT02801006","The Clinical Study of Silicone Hydrogel Daily Disposable Stenfilcon A Toric Lens",,"Completed","Has Results","Astigmatism","Device: stenfilcon A|Device: etafilcon A","Comfort|Dryness|Clarity of Vision|Stability of Vision|Lens Handling|Overall Satisfaction","Coopervision, Inc.","All","18 Years to 42 Years   (Adult)","Not Applicable","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JP-MKTG-201603","April 2016","June 2016","October 31, 2016","June 15, 2016","December 12, 2017","January 9, 2018","Kodama Eye Clinic, Terada, Kyoto, Japan|Dougenzaka Ioti Eye Clinic, Shibuya, Tokyo-to, Japan",,"https://ClinicalTrials.gov/show/NCT02801006"
445,"NCT02800928","Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?",,"Completed","Has Results","Smoking","Drug: CERC-501|Drug: Placebo","Latency|Number of Cigarettes Smoked","Yale University|National Institute on Drug Abuse (NIDA)|Office of Research on Women's Health (ORWH)|Janssen Pharmaceuticals","All","21 Years to 60 Years   (Adult)","Phase 2","17","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1602017291|P50DA033945","June 30, 2016","January 2, 2018","January 2, 2018","June 15, 2016","August 13, 2019","August 13, 2019","Yale University School of Medicine, New Haven, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02800928/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02800928"
446,"NCT02798978","A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects",,"Completed","Has Results","Cancer|Neoplasms","Drug: GSK1795091|Drug: Placebo","Number of Participants With Non-serious Adverse Events (AE) and Serious Adverse Events (SAE)|Change From Baseline in Body Temperature Part 1|Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) Part 1|Change From Baseline in Pulse Rate Part 1|Change From Baseline in Respiratory Rate Part 1|Number of Participants With Hematology Parameters Outside Reference Range Part 1|Number of Participants With Clinical Chemistry Parameters Outside Reference Range|Casts, Round Epithelial Cells (REC), Squamous Epithelial Cells (SEC), Urine Erythrocytes and Urine Leukocytes at Indicated Time Points|Ketones and Urine Glucose at Indicated Time Points|Occult Blood at Indicated Time Points|Urine Protein at Indicated Time Points|Specific Gravity at Indicated Time Points|Urine Potential of Hydrogen (pH) at Indicated Time Points|Number of Participants With Abnormal Electrocardiograms (ECG) Findings Worst Case Post-Baseline|Maximum Observed Drug Concentration (Cmax) of GSK1795091 for Part 1|Time of Occurrence of Cmax (Tmax) and Terminal Half Life (t1/2) of GSK1795091 for Part 1|Partial Area Under the Concentration-time Curve to Time t (AUC[0-t]), Area Under the Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK1795091 for Part 1|Clearance (CL) of GSK1795091 for Part 1|Volume of Distribution of GSK1795091 for Part 1|Percentage Fold Change of Concentration of Interleukin 6 (IL-6) From Baseline for Part 1|Percentage Fold Change of Concentration of Tumor Necrosis Factor (TNF)-Alpha From Baseline for Part 1|Percentage Fold Change of Concentration of Interferon (IFN)-Gamma From Baseline for Part 1|Percentage Fold Change of Concentration of Inducible Protein (IP)-10 From Baseline for Part 1|Percentage Fold Change of Concentration of Monocyte Chemotactic Protein 1 (MCP-1) From Baseline for Part 1|Percentage Fold Change of Colony Stimulating Factor 2 (GCSF) From Baseline for Part 1|Percentage Fold Change of Interleukin 1 Receptor Antagonist (IL-1Ra) From Baseline for Part 1|Percentage Fold Change of Interleukin 10 (IL-10) From Baseline for Part 1|Change From Baseline in WBC Differential for Part 1|Change From Baseline in CRP for Part 1|Maximum Observed Drug Concentration (Cmax) of GSK1795091 for Part 2|Time of Occurrence of Cmax (Tmax) and Terminal Half Life (t1/2) of GSK1795091 for Part 2|Partial Area Under the Concentration-time Curve to Time = t (AUC[0-t]), Area Under the Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK1795091 for Part 2|Area Under the Concentration-time Curve (AUC) Time Curve for a Dosing Interval (AUC[0-tau]), AUC (0-last) of GSK1795091 for Part 2|Clearance (CL) of GSK1795091 for Part 2|Volume of Distribution of GSK1795091 for Part 2|Accumulation Ratio of GSK1795091 for Part 2|Time Invariance of GSK1795091 for Part 2|Percentage Fold Change of Concentration of Interleukin 6 (IL-6) From Baseline for Part 2|Percentage Fold Change of Concentration of TNF-alpha From Baseline for Part 2|Percentage Fold Change of Concentration of IFN-gamma From Baseline for Part 2|Percentage Fold Change of Concentration of IP-10 From Baseline for Part 2|Percentage Fold Change of Concentration of MCP-1 From Baseline for Part 2|Percentage Fold Change of Concentration of GCSF From Baseline for Part 2|Percentage Fold Change of Concentration of IL-1Ra From Baseline for Part 2|Percentage Fold Change of Concentration of IL-10 From Baseline for Part 2|Change From Baseline in WBC Differential for Part 2|Number of Participants With Urinalysis Parameters Outside Reference Range for Part 2|Number of Participants With Hematology Parameters Outside Reference Range in Part 2|Number of Participants With Clinical Chemistry Parameters Outside Reference Range in Part 2|Change From Baseline in CRP for Part 2|Change From Baseline in Body Temperature for Part 2|Change From Baseline in SBP and DBP for Part 2|Change From Baseline in Respiratory Rate for Part 2|Change From Baseline in Pulse Rate for Part 2","GlaxoSmithKline","All","18 Years to 50 Years   (Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","204685|2016-000759-28","January 10, 2017","October 13, 2017","October 13, 2017","June 14, 2016","June 10, 2019","June 10, 2019","GSK Investigational Site, Berlin, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02798978/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02798978/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02798978"
447,"NCT02797678","Feasibility, Effectiveness and Efficacy of the PowerSleep Device",,"Completed","Has Results","Sleep|Sleep Disorders Not Due to A Substance or Known Physiological Condition","Device: Powersleep|Device: Sham Powersleep","Amount of Slow Wave Activity Detected by the Powersleep Device With and Without Stimulation|Amount of Cumulative Slow Wave Activity Detected by the Powersleep Device With and Without Stimulation|Changes in Vigilance Scores as Measured by the Psychomotor Vigilance Task (PVT)|Changes in Memory Scores as Measured by the Paired-Associate-Learning (PAL)","Philips Respironics","All","21 Years to 50 Years   (Adult)","Not Applicable","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CAI-16025-PSPIL-LO","June 2016","December 2016","January 2017","June 13, 2016","January 11, 2019","January 11, 2019","NeuroTrials Research Inc, Atlanta, Georgia, United States|St. Lukes Hospital, Chesterfield, Missouri, United States|Clayton Sleep Institute, Saint Louis, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02797678"
448,"NCT02793154","An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects",,"Terminated","Has Results","Diabetes Mellitus, Type 2","Drug: Exenatide|Drug: Albiglutide","Part A: Distribution of Average Power by Frequency Region|Part A: Ratios of Average Power Post- WLT/Pre-WLT by Frequency Region|Part A: Percentage of Time With the Dominant EGG Frequencies in the Four Frequency Ranges of Bradygastria, Normal, Tachygastria and Duodenal|Part A: Number of Par. With Shifts in Gastric Rhythm Status|Part A: Number Par. by Gastric Rhythm Status|Part A: Average Dominant Frequency|Part A: Assessment of Nausea by Visual Analogue Scale (VAS) Score|Part A: Time to Half-gastric Emptying|Part A: Rate of [13]C Dose Excreted in Breath|Part A: Gastroparesis Cardinal Symptom Index -Daily Diary (GCSI-DD) Score|Part A: The Volume of Water Ingested During EGG|Part A: Assessment of Stomach Fullness, Hunger, Bloating and Abdominal Pain by VAS Score|Part A: Assessment of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) as a Measure of Safety|Part A: Assessment of Heart Rate (HR) as a Measure of Safety|Part A: Basophils, Eosinophil, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils, White Blood Cell (WBC) Level at Indicated Time Points|Part A: Red Blood Cell (RBC) Count at Indicated Time Points|Part A: Hemoglobin Level at Indicated Time Points|Part A: Hematocrit Level at Indicated Time Points|Part A: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT) Levels at Indicated Time Points|Part A: Glucose, Calcium, Magnesium, Potassium, Sodium, Phosphorus Inorganic, Chloride, Urea/Blood Urea Nitrogen (BUN) Levels|Part A: Creatinine, Direct Bilirubin, Total Bilirubin, Indirect Bilirubin Levels at Indicated Time Points|Part A: Estimated Glomerular Filtration Rate at Indicated Time Points|Part A: Total Protein, Albumin Levels at Indicated Time Points|Part A: Albumin Level in Urine at Indicated Time Points|Part A: Concentration of Creatinine in Urine at Indicated Time Points|Part A: Number of Par. With Presence of Ketones, Occult Blood, Glucose, Nitrates and Leukocyte Esterase in Urine at Indicated Time Points|Part A: Presence RBC and WBC in Urine Assessed by Microscopy|Part A: Specific Gravity of Urine at Indicated Time Points|Part A: Potential of Hydrogen (pH) of Urine at Indicated Time Points|Part A: Number of Par. With Adverse Events (AEs) and Serious AEs (SAEs)|Part A: Number of Par. With Nausea AEs Presenting Outside the Timing of the WLT and GCSI-DD|Part B: Distribution of Average Power by Frequency Region|Part B: Ratios of Average Power Post- WLT/Pre-WLT by Frequency Region|Part B: Percentage of Time With the Dominant EGG Frequencies in the Four Frequency Ranges of Bradygastria, Normal, Tachygastria and Duodenal|Part B: Assessment of Nausea by VAS Score|Part B: Time to Half-gastric Emptying|Part B: Rate of [13]C Dose Excreted in Breath|Part B: The Volume of Water Ingested During EGG|Part B: Assessment of Stomach Fullness, Hunger, Bloating and Abdominal Pain by VAS Score|Part B: Number of Par. With Abnormal Values for Vital Signs|Part B: Number of Par. With Abnormal Values for Hematology Parameters|Part B: Number of Par. With Abnormal Values for Clinical Chemistry Parameters|Part B: Number of Par. With Abnormal Values for Urinalysis|Part B: Number of Par. With AEs and SAEs|Part B: Assessment of GCSI-DD Score|Part B: Number of Par. With Nausea AEs Presenting Outside the Timing of the WLT and GCSI-DD","GlaxoSmithKline|Wake Forrest Baptist Health","All","18 Years to 60 Years   (Adult)","Phase 4","4","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","204879","September 26, 2016","March 16, 2017","March 16, 2017","June 8, 2016","May 23, 2018","September 14, 2018","GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Dallas, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02793154/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02793154/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02793154"
449,"NCT02792829","Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers",,"Completed","Has Results","Healthy Volunteers","Drug: Lenvatinib","Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC(0-t))|Area Under the Plasma Concentration-Time Curve From Zero to Infinity (AUC(0-inf))|Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC(0-24))|Area Under the Plasma Concentration-Time Curve From Zero to 72 Hours (AUC(0-72))|Apparent Clearance (CL/F)|Apparent Volume of Distribution (Vz/F)|Maximum Concentration (Cmax) of Lenvatinib in Plasma|Time Prior to the First Measureable Concentration of Lenvatinib (Tlag)|Time to Maximum Plasma Concentration (Tmax)|Terminal Elimination Phase Half-life (t1/2)|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib|Summary Scores for Palatability of Lenvatinib","Eisai Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E7080-A001-009","August 2014","August 2014","August 2014","June 8, 2016","March 14, 2019","March 14, 2019","Las Vegas, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT02792829"
450,"NCT02792517","Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females",,"Completed","Has Results","Headache, Migraine","Drug: Erenumab|Drug: Ethynil Estradiol/Norgestimate Oral Contraceptive","Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol|Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours Postdose (AUCtau) for Ethinyl Estradiol|Maximum Observed Plasma Concentration (Cmax) of Norgestrel|Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours Postdose (AUCtau) for Norgestrel|Maximum Observed Plasma Concentration (Cmax) of Norelgestromin|Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours Postdose (AUCtau) for Norelgestromin|Time to Reach the Maximum Concentration (Tmax) of Ethinyl Estradiol|Time to Reach the Maximum Concentration (Tmax) of Norgestrel|Time to Reach the Maximum Concentration (Tmax) of Norelgestromin|Number of Participants With Treatment-emergent Adverse Events|Number of Participants Who Developed Anti-erenumab Binding Antibodies","Amgen","Female","18 Years to 45 Years   (Adult)","Phase 1","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20150334","February 12, 2016","September 9, 2016","September 9, 2016","June 7, 2016","December 20, 2018","December 20, 2018","Research Site, Anaheim, California, United States|Research Site, Cypress, California, United States|Research Site, Dallas, Texas, United States|Research Site, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02792517"
451,"NCT02792062","A Food Effect Study of TAK-385 Final Formulation",,"Completed","Has Results","Japanese Premenopausal Healthy Adult Women","Drug: TAK-385 40 mg","Cmax: Maximum Observed Plasma Concentration for TAK-385|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385|AUC(0-120): Area Under the Plasma Concentration-time Curve From Time 0 to 120 Hours Postdose for TAK-385|AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-385|Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) or Serious TEAEs.|Number of Participants With TEAEs Related to Vital Signs (Presyncope)|Number of Participants With TEAEs Related to Body Weight|Number of Participants With TEAEs Related to Electrocardiograms (ECG)|Number of Participants With TEAEs Related to Clinical Laboratory Tests","Takeda","Female","20 Years to 45 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-385-1011|JapicCTI-163273|U1111-1183-0020","July 4, 2016","August 31, 2016","August 31, 2016","June 7, 2016","November 17, 2017","December 18, 2017","Fukuoka-shi, Fukuoka, Japan",,"https://ClinicalTrials.gov/show/NCT02792062"
452,"NCT02790736","Brief Intervention to Reduce Fear of Public Speaking",,"Active, not recruiting","Has Results","Social Anxiety Disorder","Drug: propranolol|Drug: Placebo","Personal Report of Confidence as a Speaker|Behavioral Avoidance Task","New York State Psychiatric Institute","All","18 Years to 60 Years   (Adult)","Phase 4","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","7293 (SAD)","June 2016","May 2017","September 2020","June 6, 2016","September 5, 2018","November 1, 2019","New York State Psychiatric Institute, 1051 Riverside Drive, New York, New York, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02790736/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02790736"
453,"NCT02788188","Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults",,"Completed","Has Results","Middle East Respiratory Syndrome Coronavirus","Biological: SAB-301|Other: Normal (9%) Saline","Number of Participants Having Adverse Events","National Institute of Allergy and Infectious Diseases (NIAID)|Naval Medical Research Center|SAB Biotherapeutics Inc.|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","Phase 1","38","NIH|U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","160119|16-I-0119","May 28, 2016","April 10, 2018","April 30, 2018","June 2, 2016","June 12, 2018","June 12, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02788188/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02788188"
454,"NCT02788097","Comparison of Day 19 and Day 20 Artificial FET",,"Terminated","Has Results","Progesterone Induced Endometrial Receptivity","Procedure: Progesterone supplementation","Biochemical Pregnancy","Antalya IVF","Female","19 Years to 42 Years   (Adult)","Not Applicable","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)","AntalyaIVF","May 2016","October 2016","October 2016","June 2, 2016","December 8, 2016","February 3, 2017","Antalya IVF, Antalya, Turkey",,"https://ClinicalTrials.gov/show/NCT02788097"
455,"NCT02785770","A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects",,"Completed","Has Results","Healthy","Drug: PF-04447943|Drug: Placebo|Drug: Moxifloxacin","Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 0.5 Hour Post-Dose|Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 1 Hour Post-Dose|Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 2 Hours Post-Dose|Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 3 Hours Post-Dose|Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 4 Hours Post-Dose|Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 8 Hours Post-Dose|Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 12 Hours Post-Dose|Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 24 Hours Post-Dose|Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for Moxifloxacin and Placebo|Time-Matched Mean Difference in Heart Rate for PF-04447943 and Placebo|Time-Matched Mean Difference in PR Interval for PF-04447943 and Placebo|Time-Matched Mean Difference in QRS Interval for PF-04447943 and Placebo|Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Physical Examination Abnormalities|Number of Participants With Electrocardiogram (ECG) Abnormalities|Number of Participants With Vital Sign Abnormalities|Number of Participants With Laboratory Test Abnormalities|Maximum Plasma Concentration (Cmax) of PF-04447943|Time of Observed Maximum Plasma Concentration (Tmax) of PF-04447943|Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of PF-04447943","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","B0401018","June 29, 2016","October 20, 2016","October 20, 2016","May 30, 2016","December 28, 2018","December 28, 2018","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02785770"
456,"NCT02785406","Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use",,"Completed","Has Results","Cocaine Use Disorder|Anxiety","Drug: suvorexant|Drug: Placebo (for suvorexant)","Cue Reactivity as Assessed by the Attention Bias (AB) Task|Total Sleep as Assessed by the Misfit Shine Device|Stress as Assessed by the DASS21 Self-report Questionnaire Stress Subscale|Anxiety as Assessed by the DASS21 Self-report Questionnaire Anxiety Subscale.|Anxiety as Assessed by the DASS21 Self-report Questionnaire Anxiety Subscale|Anxiety as Assessed by the DASS21 Self-report Questionnaire|Cue Reactivity as Assessed by the Cocaine Craving Questionnaire (CCQ) Brief|Sleep Quality as by the Pittsburg Sleep Quality Index (PSQI)|Stress/Anxiety as Assessed by Blood Pressure During the Cold Pressor Test (CPT) - Systolic Blood Pressure|Stress/Anxiety as Assessed by Blood Pressure During the Cold Pressor Test (CPT) - Diastolic Blood Pressure|Stress/Anxiety as Assessed by Cortisol Level During the Cold Pressor Test (CPT)|Stress as Assessed by a Visual Analog Scale (VAS) for Stress|Percent Medication Compliance as Assessed by the Medical Event Monitoring System (MEMS, Aprex Corporation) Bottles|Percent Medication Compliance as Assessed by Pill Counts|Percent Medication Compliance as Assessed by Analysis of Riboflavin Markers in Urine Samples|Percent Medication Compliance as Assessed by Text Reminders and Replies","The University of Texas Health Science Center, Houston|Peter F. McManus Charitable Trust","All","19 Years to 55 Years   (Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-16-0120","May 2016","November 15, 2018","November 15, 2018","May 27, 2016","December 11, 2019","December 11, 2019","The University of Texas Health Science Center at Houston, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02785406/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02785406"
457,"NCT02783170","Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women","Tdap/IIV","Completed","Has Results","Pregnancy","Biological: Tetanus, Diphtheria, and Pertussis Vaccine|Biological: 2016-2017 Quadrivalent Inactivated Influenza Vaccine|Biological: 2017-2018 Quadrivalent Inactivated Influenza Vaccine","Percentage of Participants With Injection-site Reactions Post Tdap and IIV4 Administration|Percentage of Participants With Systemic Reactions Post Tdap and IIV4 Administration - Visit 1|Percentage of Participants With Systemic Reactions Post Tdap and IIV4 Administration - Visit 4|Pertussis Serum Antibody Levels, as Measured by Geometric Mean Titers|Percentage of Subjects With Seroprotection as Determined by Diphtheria Serum Antibody Levels (Defined as ≥ 0.1 IU/mL)|Percentage of Subjects With Seroprotection as Determined by Tetanus Serum Antibody Levels (Defined as ≥ 0.1 IU/mL)|Percentage of Subjects With Seroprotection as Determined by Influenza Serum Antibody Levels (≥1:40) (Pre- and Post-immunization) and Seroconversion (4-fold Rise From Baseline or a Change From <1:10 to ≥1:40) )|Percentage of Subjects Recruited Enrollment Period|Feasibility as Measured by Participant Retention (Percentage of Participants Who Complete All Visits)|Feasibility Reported as Percentage of Reactogenicity Data Collected|Feasibility Reported as Percentage of Adequate Biospecimens Collected|Feasibility Reported as Percentage of Timely Collected Biospecimens|Number of Participants With Adverse Maternal Outcomes|Number of Participants With Adverse Infant Outcomes Based on Medical Record Review|Percentage of Participants With Clinical Chorioamnionitis|Percentage of Participants With Histologic Chorioamnionitis on Surgical Pathology Examination of Placental Tissue|Feasibility as Measured by Percentage of Blood Samples in Testable Condition|Feasibility as Measured by Percentage of Blood Samples in With Sufficient Volume for Testing|Feasibility as Measured by Percentage of Testable Blood Samples Completed","Duke University|Children's Hospital Medical Center, Cincinnati|Centers for Disease Control and Prevention","Female","18 Years to 45 Years   (Adult)","Phase 4","81","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro00071192","September 2016","April 3, 2018","May 10, 2018","May 26, 2016","May 21, 2019","June 11, 2019","Centers for Disease Control and Prevention, Atlanta, Georgia, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT02783170/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02783170"
458,"NCT02781311","A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males",,"Completed","Has Results","Alopecia","Drug: Setipiprant|Drug: Placebo|Drug: Finasteride","Change From Baseline in Target Area Hair Count (TAHC) at Week 24|Subject Self-Assessment (SSA) Score in Hair Growth at Week 24","Allergan","Male","18 Years to 49 Years   (Adult)","Phase 2","169","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1922-201-002","July 14, 2016","March 15, 2018","May 22, 2018","May 24, 2016","April 5, 2019","April 5, 2019","Burke Pharmaceutical Research, Hot Springs, Arkansas, United States|Petrus Center for Aesthetic Surgery & Hair Transplantation, Little Rock, Arkansas, United States|Therapeutics Clinical Research, San Diego, California, United States|Radiant Research, Inc., Santa Rosa, California, United States|DeNova Research, Chicago, Illinois, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Michigan Center for Skin Care Research, Clinton Township, Michigan, United States|Minnesota Clinical Study Center, Fridley, Minnesota, United States|University of Minnesota Department of Dermatology Division of Clinical research, Minneapolis, Minnesota, United States|Wake Forest University Health Sciences Department of Dermatology Medical Center Boulevard, Winston-Salem, North Carolina, United States|Cleveland Clinic, Dept of Dermatology, Cleveland, Ohio, United States|NW Dermatology and Research Center, Portland, Oregon, United States|Oregon Medical Research Center, Portland, Oregon, United States|Penn State Hershey Medical Center Dermatology Research Office, Hershey, Pennsylvania, United States|Radiant Research, Inc., Greer, South Carolina, United States|DermResearch, Inc, Austin, Texas, United States|Suzzane Bruce and Associates P.A., The Center for Skin Research, Katy, Texas, United States|The Education & Research Foundation, Inc, Lynchburg, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02781311/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02781311/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02781311"
459,"NCT02778113","A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults",,"Completed","Has Results","Healthy","Drug: Nasal Glucagon|Drug: Glucagon","Number of Participants With One or More Serious Adverse Event(s) (SAEs)|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to T (AUC[0-tlast]) of Baseline Adjusted Glucagon|PK: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of Baseline Adjusted Glucagon|PK: Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon|PK: Maximum Change From Baseline Concentration (Cmax) of Glucagon|Pharmacodynamics (PD): Area Under the Effect Concentration Time Curve (AUEC₀₋₄) of Glucose|PD: Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose|PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax)","Eli Lilly and Company|Locemia Solutions ULC","All","18 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","16424|I8R-MC-IGBD|AMG 101|GUO-P1-557","October 2011","October 2011","November 2011","May 19, 2016","September 19, 2019","September 19, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount-Royal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02778113"
460,"NCT02778100","A Study of Nasal Glucagon in Participants With a Common Cold",,"Completed","Has Results","Common Cold","Drug: Nasal Glucagon|Drug: Oxymetazoline","Number of Participants With One or More Serious Adverse Event(s) (SAEs)|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to T (AUC[0-tlast]) of Baseline Adjusted Glucagon|PK: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of Baseline Adjusted Glucagon|PK: Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon|PK: Maximum Change From Baseline Concentration (Cmax) of Glucagon|Pharmacodynamics (PD): Area Under the Effect Concentration Time Curve (AUEC0-3) of Baseline-Adjusted Glucose From Time Zero up to 3 Hours|PD: Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose|PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax) of Baseline-Adjusted Glucose","Eli Lilly and Company|Locemia Solutions ULC","All","18 Years to 50 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16425|GUO-P2-628|AMG 104|I8R-MC-IGBE","March 2013","April 2013","April 2013","May 19, 2016","September 18, 2019","September 18, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount-Royal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02778100"
461,"NCT02777268","Comparison of Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone",,"Completed","Has Results","Healthy Subjects","Drug: Infacort|Drug: Hydrocortisone","Maximum Plasma Concentration (Cmax) of Infacort vs Hydrocortisone|Time to Reach the Maximum Plasma Concentration (Tmax) of Infacort vs Hydrocortisone|Area Under the Curve (AUC0-t) of Infacort vs Hydrocortisone|Maximum Plasma Concentration (Cmax) of Infacort at Doses of 0.5, 2, 5 and 10 mg|Time to Maximum Plasma Concentration (Tmax) of Infacort at Doses of 0.5, 2, 5 and 10 mg|Area Under the Curve (AUC0-t) of Infacort at Doses of 0.5, 2, 5 and 10 mg|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) as Assessed by Medical Dictionary for Regulatory Activities (MedDRA) Dictionary, Version 16.0.","Diurnal Limited|Simbec Research","Male","18 Years to 60 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Infacort 001","July 2013","September 2013","September 2013","May 19, 2016","August 10, 2017","December 2, 2017",,,"https://ClinicalTrials.gov/show/NCT02777268"
462,"NCT02775240","Study of SHP620 (Maribavir) in Healthy Adults",,"Completed","Has Results","Cytomegalovirus (CMV)","Drug: Digoxin|Drug: Maribavir|Drug: Dextromethorphan","Maximum Observed Plasma Concentration (Cmax) of Digoxin|Maximum Observed Plasma Concentration (Cmax) of Dextromethorphan|Maximum Observed Plasma Concentration (Cmax) of Dextrorphan|Maximum Observed Plasma Concentration (Cmax) of Maribavir|Time to Reach Maximum Plasma Concentration (Tmax) of Digoxin|Time to Reach Maximum Plasma Concentration (Tmax) of Dextromethorphan|Time to Reach Maximum Plasma Concentration (Tmax) of Dextrorphan|Time to Reach Maximum Plasma Concentration (Tmax) of Maribavir|Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Digoxin|Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Dextromethorphan|Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Dextrorphan|Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Digoxin|Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextromethorphan|Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Dextrorphan|Parent/Metabolite Ratio of Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) for Dextromethorphan Over AUClast for Dextrorphan (AUClast Parent/Metabolite Ratio)|Parent/Metabolite Ratio of Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) for Dextromethorphan Over AUC0-infinity for Dextrorphan (AUC0-infinity Parent/Metabolite Ratio)|Area Under the Plasma Concentration Versus Time Curve From Time Zero to the End of the Dosing Interval at Steady-State (AUCtau) of Maribavir|First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Digoxin|First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Dextromethorphan|First-order Rate Constant (Lambda z) Associated With the Terminal (Log-linear) Portion of the Curve of Dextrorphan|Terminal Half-life (t1/2) of Digoxin|Terminal Half-life (t1/2) of Dextromethorphan|Terminal Half-life (t1/2) of Dextrorphan|Terminal Half-life (t1/2) of Maribavir|Apparent Oral Clearance (CL/F) of Digoxin|Apparent Oral Clearance (CL/F) of Dextromethorphan|Apparent Oral Clearance (CL/F) of Maribavir|Concentration at the End of Dosing Interval (Ctau) of Maribavir|Volume of Distribution Divided by the Fraction of Dose Absorbed (Vz/F) of Digoxin|Volume of Distribution Divided by the Fraction of Dose Absorbed (Vz/F) of Dextromethorphan|Pre-dose Concentration (C0) of Maribavir|Number of Participants With Study-related Adverse Events (AEs), Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Clinically Significant Changes Reported as TEAE in Physical Examination, Vital Signs, 12-lead ECGs, Hematology, Blood Chemistry and Urinalysis","Shire","All","18 Years to 50 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SHP620-115|2015-004725-13","July 21, 2016","September 12, 2016","September 12, 2016","May 17, 2016","January 16, 2019","May 10, 2019","Clinical Pharmacology of Miami, Inc., Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02775240"
463,"NCT02774343","PPARγ Agonist Treatment for Cocaine Dependence",,"Completed","Has Results","Cocaine Use Disorder|Alcohol Use Disorder","Drug: Pioglitazone|Drug: Placebo|Behavioral: Therapy|Behavioral: Contingency Management","Craving as Assessed by the Brief Substance Craving Scale (BSCS)|Craving as Assessed by the Obsessive Compulsive Drug Use Scale (OCDUS)|Cue Reactivity as Assessed by a Visual Analogue Scale (VAS) of Cocaine Craving|Brain White Matter (WM) Integrity as Assessed by Diffusion Tensor Imaging (DTI) Fractional Anisotropy (FA) Value (Region - Posterior Thalamic Radiation)|Brain White Matter (WM) Integrity as Assessed by Diffusion Tensor Imaging (DTI) Fractional Anisotropy (FA) Value (Region - Anterior Thalamic Radiation)|Brain White Matter (WM) Integrity as Assessed by Diffusion Tensor Imaging (DTI) Fractional Anisotropy (FA) Value (Region - Splenium of Corpus Callosum)|Brain White Matter (WM) Integrity as Assessed by Diffusion Tensor Imaging (DTI) Fractional Anisotropy (FA) Value (Region - Genu of Corpus Callosum)|Brain White Matter (WM) Integrity as Assessed by Diffusion Tensor Imaging (DTI) Fractional Anisotropy (FA) Value (Region - External Capsule)|Brain White Matter (WM) Integrity as Assessed by Diffusion Tensor Imaging (DTI) Fractional Anisotropy (FA) Value (Region - Cingulum)|Feasibility - Subject Retention as Assessed by Number of Participants Who Completed All 12 Weeks of the Study|Feasibility - Medication Compliance as Assessed by Percentage of Urine Samples That Were Riboflavin-Positive|Feasibility - Medication Compliance as Assessed by Percentage of Self-reports That Indicate Capsules Were Taken|Feasibility - Tolerability as Assessed by Number of Participants Reporting Side Effects|Feasibility - Tolerability as Assessed by Number of Participants With Serious Adverse Events|Cocaine Use as Assessed by Percentage of Urine Samples That Were Cocaine-positive|Cocaine Use as Assessed by Percentage of Self-reports That Indicate Cocaine Use","The University of Texas Health Science Center, Houston|National Institute on Drug Abuse (NIDA)","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-12-0421|P50DA009262","August 2012","June 2015","June 2015","May 17, 2016","April 26, 2018","April 26, 2018","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02774343"
464,"NCT02773446","Human Challenge Model Refinement With Enterotoxigenic Escherichia Coli Strain B7A",,"Completed","Has Results","Healthy Volunteer","Biological: ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer","Number of Participants With Safety- Solicited Symptoms Related to Challenge Administration|Moderate-severe Diarrhea|Moderate-severe Diarrhea in Subjects Receiving Homologous Rechallenge|Number of Participants With Safety -Solicited Symptoms Unrelated to Challenge Administration|Immune Response to Challenge (Serology)|Immune Response to Challenge","Johns Hopkins Bloomberg School of Public Health|United States Department of Defense|PATH|Naval Medical Research Center","All","18 Years to 50 Years   (Adult)","Not Applicable","47","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","CIR303 B7A","April 2016","December 2016","December 2016","May 16, 2016","July 6, 2018","July 6, 2018","Johns Hopkins Center for Immunization Research, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02773446"
465,"NCT02772666","Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect",,"Completed","Has Results","Multiple Sclerosis|Glaucoma","Device: O-Glass|Other: Swinging Flashlight Test","Number of Participants With Detected Relative Afferent Pupillary Defect (RAPD)","Mashhad University of Medical Sciences","All","20 Years to 55 Years   (Adult)","Not Applicable","44","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","IR.MUMS.REC.1395.15","December 2015","May 2016","June 2016","May 13, 2016","November 1, 2016","December 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02772666"
466,"NCT02762799","Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® Compared to Neupogen®",,"Completed","Has Results","Leucocytosis","Biological: Leucostim®|Biological: Neupogen®","AUC (0-48 Hours)|Cmax After Subcutaneous Injection|Cmax After Intravenous Injection|Tmax After Injection|Т½|Kel|Clearance|ANC-AUEC (0-336 Hours)|ANC-Emax|CD34-AUEC (0-336 Hours)|CD34-Emax|Overall Frequency of Serious Adverse Events (SAE)|Overall Frequency of Adverse Events (AE)|Frequency of Local Reactions|Frequency of AE/SAE 3-4 Grade CTCAE 4.03|Frequency of Preliminary Withdrawal Due to AE/SAE|Proportion of Patients With Binding or Neutralizing Antibodies to Filgrastim","Biocad","Male","18 Years to 45 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","BCD-002-1","July 18, 2016","November 11, 2016","November 11, 2016","May 5, 2016","December 19, 2018","December 19, 2018",,,"https://ClinicalTrials.gov/show/NCT02762799"
467,"NCT02761980","A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers",,"Completed","Has Results","Fever","Drug: Ibuprofen 250 mg / Acetaminophen 500 mg|Drug: Ibuprofen 250 mg|Drug: Acetaminophen 500 mg|Drug: Placebo","Time Weighted Sum of Temperature Difference (WSTD) From 0 to 8 Hours|Time Weighted Sum of Temperature Differences (WSTD) From Baseline Through Hours 2, 4 and 6|Time to Return to Normal Body Temperature|Time to Rescue Medication|Time Weighted Sum of Temperature Difference From 6 to 8 Hours","Pfizer","Male","18 Years to 55 Years   (Adult)","Phase 3","290","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B5061002|GEMINI IF","December 6, 2016","December 6, 2017","December 6, 2017","May 4, 2016","December 7, 2018","December 7, 2018","New Orleans Center for Clinical Research, Knoxville, Tennessee, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02761980/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02761980/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02761980"
468,"NCT02760810","Clinical Evaluation of An Approved Contact Lens",,"Completed","Has Results","Tear Film Characteristics","Device: Marketed Contact Lens","Tear Film Osmolarity|Tear Film PH","Johnson & Johnson Vision Care, Inc.","All","18 Years to 45 Years   (Adult)","Not Applicable","31","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-5815","April 12, 2016","April 26, 2016","April 26, 2016","May 4, 2016","July 11, 2017","July 11, 2017","Aston University, Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02760810"
469,"NCT02760056","Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study","MST3K","Completed","Has Results","Multiple Sclerosis","Drug: Liothyronine sodium|Drug: Placebo","Determine the Maximum Tolerated Dose (MTD) of Oral L-T3 in Subjects With MS|Reliability of Visual Evoked Potential (VEP) Testing (ICC)","Oregon Health and Science University","All","18 Years to 50 Years   (Adult)","Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB 15101","June 6, 2016","January 10, 2017","January 10, 2017","May 3, 2016","November 19, 2018","November 19, 2018","Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02760056"
470,"NCT02759692","Clinical Evaluation of Two Approved Contact Lenses",,"Completed","Has Results","Visual Acuity","Device: TEST Contact Lens|Device: CONTROL Contact Lens","Overall Comfort|Overall Quality of Vision|Individual Patient Reported Outcomes (Items 1-5)|Individual Patient Reported Outcomes (Items 6-10)|Individual Patient Reported Outcomes (Items 11-14)|Individual Patient Reported Outcomes (Items 15-17)","Johnson & Johnson Vision Care, Inc.","All","18 Years to 39 Years   (Adult)","Not Applicable","283","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-5829","April 1, 2016","June 1, 2016","June 1, 2016","May 3, 2016","August 18, 2017","August 18, 2017","Becky Bizzle, OD, Montgomery, Alabama, United States|Complete Family Eye Care of Fruit Cove, Jacksonville, Florida, United States|Golden Family Eyecare, Sarasota, Florida, United States|St. Lucy's Vision Center, Tampa, Florida, United States|Eye Associates of Winter Park, Winter Park, Florida, United States|VisualEyes, Inc., Roswell, Georgia, United States|Advantage Eyecare Associates, LLC, Neodesha, Kansas, United States|Sacco Eye Group, Vestal, New York, United States|Advanced Family Eye Care, Denver, North Carolina, United States|Total Eye Care PA, Memphis, Tennessee, United States|Brian Frazier, OD, Jacksonville, Texas, United States|Timothy R. Poling, OD, Salem, Virginia, United States|Ziegler Leffingwell Eyecare, West Allis, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02759692"
471,"NCT02759471","One Month Dispensing Study Comparing the Clinical Performance of the Comfilcon A Sphere Lenses Compared to Comfilcon A Asphere Lenses.",,"Completed","Has Results","Myopia","Device: comfilcon A sphere lens (control)|Device: comfilcon A asphere lens (test)","Lens Fit - Centration|Lens Fit - Corneal Coverage|Lens Fit - Post-blink Movement|Lens Preference/Acceptability","Coopervision, Inc.","All","18 Years to 34 Years   (Adult)","Not Applicable","54","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)","EX-MKTG-63","April 2016","June 2016","August 2016","May 3, 2016","February 23, 2017","February 23, 2017","Golden Optometric Group, Whittier, California, United States|Complete Eye Care of Medina, Medina, Minnesota, United States|Sacco Eye Group, Vestal, New York, United States|Drs. Quinn, Foster, & Associates, Athens, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02759471"
472,"NCT02758613","A Study of Baricitinib (LY3009104) in Healthy Chinese Participants",,"Completed","Has Results","Healthy","Drug: Baricitinib|Drug: Placebo","Number of Participants With One or More Clinically Significant Event(s)|Pharmacokinetics(PK): Maximum Concentration (Cmax) of Baricitinib|Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Baricitinib","Eli Lilly and Company","All","18 Years to 60 Years   (Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","14778|I4V-GH-JAGR","May 2016","July 2016","July 2016","May 2, 2016","December 7, 2017","December 7, 2017","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Beijing, China",,"https://ClinicalTrials.gov/show/NCT02758613"
473,"NCT02758171","Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects",,"Completed","Has Results","Healthy","Drug: Empagliflozin|Drug: Linagliptin","AUC0-tz (Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)|AUC0-72 (Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours)|Cmax (Maximum Measured Concentration of Empagliflozin Analyte in Plasma)|Cmax (Maximum Measured Concentration of Linagliptin Analyte in Plasma)|AUC0-infinity (Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)|AUC0-infinity (Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)","Boehringer Ingelheim|Eli Lilly and Company","All","18 Years to 55 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1275.21|2015-004234-98","May 17, 2016","July 29, 2016","August 3, 2016","May 2, 2016","November 22, 2017","November 22, 2017","Humanpharmakologisches Zentrum Biberach, Biberach, Germany",,"https://ClinicalTrials.gov/show/NCT02758171"
474,"NCT02756078","Clinical Performance Evaluation of Two Silicone Hydrogel Lenses",,"Completed","Has Results","Visual Acuity","Device: TEST Contact Lens|Device: CONTROL Contact Lens","Overall CLUE Comfort|Overall CLUE Handling|Time to Haze|Average Wear Time|Average Comfortable Wear Time|Difference in Total Device Use Time and Comfortable Wear Time During Device Use|Comfort at the End of the Day","Johnson & Johnson Vision Care, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-5816","April 8, 2016","October 2, 2017","October 2, 2017","April 29, 2016","October 25, 2018","November 14, 2018","Centre for Contact Lens Research, University of Waterloo, Waterloo, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02756078/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02756078/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02756078"
475,"NCT02754674","Comparison of Femoral Tunnel and Clinical Outcome Using Two Anterior Cruciate Ligament Reconstruction Techniques",,"Completed","Has Results","Rupture of Anterior Cruciate Ligament","Procedure: type of anterior cruciate ligament reconstruction","Vascularity of Graft Tendon|Arthroscopy Grading|Clinical Knee Scoring|Instability|Graft Maturity (SNQ)","Samsung Medical Center","All","20 Years to 60 Years   (Adult)","Not Applicable","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SMC2013-07-097-001","May 2014","May 2014","December 2017","April 28, 2016","December 20, 2019","December 20, 2019","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02754674"
476,"NCT02753413","Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women",,"Completed","Has Results","Respiratory Syncytial Virus Infections","Biological: RSV vaccine GSK3003891A|Biological: Boostrix","Number of Subjects With Abnormal Biochemical Laboratory Values.|Number of Subjects With Abnormal Haematological Laboratory Values.|Number of Subjects With Abnormal Biochemical Laboratory Parameter Values by Maximum Grading|Number of Subjects With Abnormal Haematological Laboratory Parameter Values by Maximum Grading|Number of Subjects With Haematology Change From Baseline by Maximum Grade|Number of Subjects With Solicited Local Symptoms|Number of Subjects With Solicited General Symptoms|Number of Subjects With Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs)","GlaxoSmithKline","Female","18 Years to 45 Years   (Adult)","Phase 2","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","204813|2015-005742-58","April 1, 2016","June 28, 2016","June 28, 2016","April 27, 2016","July 11, 2017","June 26, 2018","GSK Investigational Site, Wilrijk, Belgium",,"https://ClinicalTrials.gov/show/NCT02753413"
477,"NCT02753075","A Study in Dentinal Hypersensitivity (DH) Participants to Assess the Efficacy of an Occluding Dentifrice.",,"Completed","Has Results","Dentin Sensitivity","Device: Experimental Oral Rinse 1|Device: Experimental Oral Rinse 2|Other: Placebo Oral Rinse|Drug: Fluoride toothpaste","Change From Baseline in Schiff Sensitivity Score of Experimental Oral Rinses 1 and 2 Against a Placebo Oral Rinse at Week 8|Change From Baseline in Schiff Sensitivity Score of Two Experimental Oral Rinses 1 and 2 at Week 8|Change From Baseline in Schiff Sensitivity Score of Two Experimental Oral Rinses 1 and 2 and a Placebo Oral Rinse at Week 4|Change From Baseline in Tactile Threshold (Gram [g]) of Two Experimental Oral Rinses 1, 2 and a Placebo Oral Rinse at Week 4|Change From Baseline in Tactile Threshold (g) of Two Experimental Oral Rinses 1, 2 and a Placebo Oral Rinse at Week 8|Change From Baseline in Visual Rating Scale (VRS) of Two Experimental Oral Rinses 1, 2 and a Placebo Oral Rinse at Week 4|Change From Baseline in VRS of Two Experimental Oral Rinses 1 and 2 and a Placebo Oral Rinse) at Week 8","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Not Applicable","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","204773","September 8, 2015","December 1, 2015","December 18, 2015","April 27, 2016","March 6, 2017","August 27, 2018","GSK Investigational Site, Fort Wayne, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02753075"
478,"NCT02752958","Impact of Long Term Management of Dentine Hypersensitivity (DH) With a Daily Use Anti-sensitivity Toothpaste on the Quality of Life Related to Oral Health",,"Completed","Has Results","Dentin Sensitivity","Drug: stannous fluoride","Change From Baseline in Mean Total Score (34 Item Total From Section 2) of Dentine Hyersensitivity Experience Questionnaire (DHEQ) at Week 4|Change From Baseline in Mean Total Score (34 Item Total From Section 2) of Dentine Hyersensitivity Experience Questionnaire (DHEQ) at Week 8|Change From Baseline in Mean Total Score (34 Item Total From Section 2) of Dentine Hyersensitivity Experience Questionnaire (DHEQ) at Week 12|Change From Baseline in Mean Total Score (34 Item Total From Section 2) of Dentine Hyersensitivity Experience Questionnaire (DHEQ) at Week 16|Change From Baseline in Mean Total Score (34 Item Total From Section 2) of Dentine Hyersensitivity Experience Questionnaire (DHEQ) at Week 20|Change From Baseline in Mean Total Score (34 Item Total From Section 2) of Dentine Hyersensitivity Experience Questionnaire (DHEQ) at Week 24|Change From Baseline in Mean DHEQ Score of Domain - Restrictions (4 Item Total From Section 2 Questions 1 to 4) at Week 4|Change From Baseline in Mean DHEQ Score of Domain - Restrictions (4 Item Total From Section 2 Questions 1 to 4) at Week 8|Change From Baseline in Mean DHEQ Score of Domain - Restrictions (4 Item Total From Section 2 Questions 1 to 4) at Week 12|Change From Baseline in Mean DHEQ Score of Domain - Restrictions (4 Item Total From Section 2 Questions 1 to 4) at Week 16|Change From Baseline in Mean DHEQ Score of Domain - Restrictions (4 Item Total From Section 2 Questions 1 to 4) at Week 20|Change From Baseline in Mean DHEQ Score of Domain - Restrictions (4 Item Total From Section 2 Questions 1 to 4) at Week 24|Change From Baseline in Mean DHEQ Score of Domain - Adaptation (12 Item Total From Section 2 Questions 5 to 16) at Week 4|Change From Baseline in Mean DHEQ Score of Domain - Adaptation (12 Item Total From Section 2 Questions 5 to 16) at Week 8|Change From Baseline in Mean DHEQ Score of Domain - Adaptation (12 Item Total From Section 2 Questions 5 to 16) at Week 12|Change From Baseline in Mean DHEQ Score of Domain - Adaptation (12 Item Total From Section 2 Questions 5 to 16) at Week 16|Change From Baseline in Mean DHEQ Score of Domain - Adaptation (12 Item Total From Section 2 Questions 5 to 16) at Week 20|Change From Baseline in Mean DHEQ Score of Domain - Adaptation (12 Item Total From Section 2 Questions 5 to 16) at Week 24|Change From Baseline in Mean DHEQ Score of Domain - Social Impact (5 Item Total From Section 2 Questions 17 to 21) at Week 4|Change From Baseline in Mean DHEQ Score of Domain - Social Impact (5 Item Total From Section 2 Questions 17 to 21) at Week 8|Change From Baseline in Mean DHEQ Score of Domain - Social Impact (5 Item Total From Section 2 Questions 17 to 21) at Week 12|Change From Baseline in Mean DHEQ Score of Domain - Social Impact (5 Item Total From Section 2 Questions 17 to 21) at Week 16|Change From Baseline in Mean DHEQ Score of Domain - Social Impact (5 Item Total From Section 2 Questions 17 to 21) at Week 20|Change From Baseline in Mean DHEQ Score of Domain - Social Impact (5 Item Total From Section 2 Questions 17 to 21) at Week 24|Change From Baseline in Mean DHEQ Score of Domain - Emotional Impact (8 Item Total From Section 2 Questions 22 to 29) at Week 4|Change From Baseline in Mean DHEQ Score of Domain - Emotional Impact (8 Item Total From Section 2 Questions 22 to 29) at Week 8|Change From Baseline in Mean DHEQ Score of Domain - Emotional Impact (8 Item Total From Section 2 Questions 22 to 29) at Week 12|Change From Baseline in Mean DHEQ Score of Domain - Emotional Impact (8 Item Total From Section 2 Questions 22 to 29) at Week 16|Change From Baseline in Mean DHEQ Score of Domain - Emotional Impact (8 Item Total From Section 2 Questions 22 to 29) at Week 20|Change From Baseline in Mean DHEQ Score of Domain - Emotional Impact (8 Item Total From Section 2 Questions 22 to 29) at Week 24|Change From Baseline in Mean DHEQ Score of Domain - Identity (5 Item Total From Section 2 Questions 30 to 34) at Week 4|Change From Baseline in Mean DHEQ Score of Domain - Identity (5 Item Total From Section 2 Questions 30 to 34) at Week 8|Change From Baseline in Mean DHEQ Score of Domain - Identity (5 Item Total From Section 2 Questions 30 to 34) at Week 12|Change From Baseline in Mean DHEQ Score of Domain - Identity (5 Item Total From Section 2 Questi 30 to 34) at Week 16|Change From Baseline in Mean DHEQ Score of Domain - Identity (5 Item Total From Section 2 Questions 30 to 34) at Week 20|Change From Baseline in Mean DHEQ Score of Domain - Identity (5 Item Total From Section 2 Questions 30 to 34) at Week 24|Change From Baseline in Mean DHEQ Score of Domain - Global Oral Health Rating (Response to Section 2 Question 35) at Week 4|Change From Baseline in Mean DHEQ Score of Domain - Global Oral Health Rating (Response to Section 2 Question 35) at Week 8|Change From Baseline in Mean DHEQ Score of Domain - Global Oral Health Rating (Response to Section 2 Question 35) at Week 12|Change From Baseline in Mean DHEQ Score of Domain - Global Oral Health Rating (Response to Section 2 Question 35) at Week 16|Change From Baseline in Mean DHEQ Score of Domain - Global Oral Health Rating (Response to Section 2 Question 35) at Week 20|Change From Baseline in Mean DHEQ Score of Domain - Global Oral Health Rating (Response to Section 2 Question 35) at Week 24|Change From Baseline in Mean DHEQ Score of Domain - Effect on Life Overall (4 Item Total From Section 2 Questions 36 to 39) at Week 4|Change From Baseline in Mean DHEQ Score of Domain - Effect on Life Overall (4 Item Total From Section 2 Questions 36 to 39) at Week 8|Change From Baseline in Mean DHEQ Score of Domain - Effect on Life Overall (4 Item Total From Section 2 Questions 36 to 39) at Week 12|Change From Baseline in Mean DHEQ Score of Domain - Effect on Life Overall (4 Item Total From Section 2 Questions 36 to 39) at Week 16|Change From Baseline in Mean DHEQ Score of Domain - Effect on Life Overall (4 Item Total From Section 2 Questions 36 to 39) at Week 20|Change From Baseline in Mean DHEQ Score of Domain - Effect on Life Overall (4 Item Total From Section 2 Questions 36 to 39) at Week 24|Change From Baseline in Mean Score of Dentine Hyersensitivity Experience Questionnaire (DHEQ) Section1 - Question (Q) No. 7 At Week 4|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 7 At Week 8|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 7 At Week 12|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 7 At Week 16|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 7 At Week 20|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 7 At Week 24|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 8 At Week 4|Change From Baseline in Mean Score DHEQ Section1 - Question (Q) No. 8 At Week 8|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 8 At Week 12|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 8 At Week 16|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 8 At Week20|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 8 At Week 24|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 9 At Week 4|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 9 at Week 8|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 9 At Week 12|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 9 At Week 16|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 9 At Week 20|Change From Baseline in Mean Score of DHEQ Section1 - Question (Q) No. 9 At Week 24","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Not Applicable","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Other","204930","May 23, 2016","February 1, 2017","February 3, 2017","April 27, 2016","August 27, 2018","August 27, 2018","GSK Investigational Site, Ellesmere Port, Cheshire, United Kingdom|GSK Investigational Site, Widnes, Cheshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02752958/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02752958/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02752958"
479,"NCT02752490","The Comparative Effectiveness of Liberal Versus Restricted Maternal Administration of Oxygen During Labor",,"Completed","Has Results","Maternal Oxygen Use in Labor","Drug: Liberal use of maternal oxygen|Drug: Indicated use of maternal oxygen","Number of Participants Who Delivered by Cesarean|Number of Participants With Umbilical Artery pH (Potential Hydrogen) < 7.10 at Birth|Number of Participants Who Delivered by Cesarean for Non-reassuring Fetal Status|Number of Participants Whose Infants Had an Apgar Score < 7 at 5 Minutes|Number of Participants Whose Infants Were Admitted to the Neonatal Intensive Care Unit (NICU)|Total Duration of Maternal Oxygen Use|Number of Participants Who Received Intrauterine Resuscitation Other Than Administration of Maternal Oxygen|Number of Participants With Clinical Chorioamnionitis","The University of Texas Health Science Center, Houston","Female","18 Years to 45 Years   (Adult)","Not Applicable","844","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-16-0142","April 2016","July 31, 2016","July 31, 2016","April 27, 2016","March 2, 2018","March 2, 2018","Children's Memorial Hermann Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02752490"
480,"NCT02751424","A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830",,"Terminated","Has Results","Infections, Bacterial","Drug: GSK3342830|Drug: Placebo","Part 1: Number of Participants With Adverse Event (AE) and Serious Adverse Event (SAE)|Part 2: Number of Participants With AE and SAE|Part 1: Number of Participants With Abnormal Hematology Parameters as a Measure of Safety-Grade 3 or Higher|Part 2: Number of Participants With Abnormal Hematology Parameters as a Measure of Safety-Grade 3 or Higher|Part 1: Number of Participants With Abnormal Clinical Chemistry Parameters as a Measure of Safety-Grade 3 or Higher|Part 2: Number of Participants With Abnormal Clinical Chemistry Parameters as a Measure of Safety-Grade 3 or Higher|Part 1: Number of Participants Having Abnormal Urine Parameters (Using Dipstick Test) as a Measure of Safety|Part 2: Number of Participants Having Abnormal Urine Parameters (Using Dipstick Test) as a Measure of Safety|Part 1: Number of Participants With Electrocardiogram (ECG) Parameters of Potential Clinical Importance (PCI)|Part 2: Number of Participants With ECG Parameters of PCI|Part 1: Number of Participants With Vital Signs of Potential Clinical Importance (PCI)|Part 2: Number of Participants With Vital Signs of PCI|Part 1-Area Under the Plasma Concentration (AUC) From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Across All Treatments AUC(0-t) for GSK3342830|Part 1-AUC Pre Dose to Infinite (Inf) Time (AUC [0-inf]) of GSK3342830|Part 1-Maximum Plasma Concentration (Cmax) of GSK3342830|Part 1-Time to Maximum Plasma Concentration (Tmax) of GSK3342830|Part 1-Terminal Elimination Half-life (t1/2) of GSK3342830 in Plasma|Part 1-Total Systemic Clearance (CL) of GSK3342830 in Plasma|Part 1-Steady-state Volume (Vss) of Distribution of GSK3342830 in Plasma|Part 1-Urinary Excretion Ratio Relative to Dose (Feu [t1-t2]) of GSK3342830|Part 1-Renal Clearance (CLr) of GSK3342830 in Urine|Part 1-Amount Excreted in Urine (Ae) of GSK3342830 in Urine|Part 1:Dose Proportionality: AUC (0-t)|Part 1:Dose Proportionality: AUC (0-inf)|Part 1:Dose Proportionality: Cmax|Part 2-AUC (0-inf) of GSK3342830|Part 2-Cmax of GSK3342830|Part 2-Tmax of GSK3342830|Part 2-Terminal t1/2 of GSK3342830 in Plasma|Part 2-Total CL of GSK3342830 in Plasma|Part 2- Vss of Distribution of GSK3342830 in Plasma|Part 2-Urinary Excretion Ratio Relative to Dose Feu (t1-t2) of GSK3342830|Part 2- Trough Concentration (Ctau)|Part 2-CLr of GSK3342830 in Urine|Part 2- Ae of GSK3342830 in Urine|Part 2: AUC From Time Zero to Last Measurable Concentration AUC (0- Tau)|Part 2: Dose Proportionality: AUC (0-tau)|Part 2: Observed Accumulation Ratio (Ro) Based on AUC and Cmax of GSK3342830 After Administration of Repeat IV Doses, as Data Permit|Part 2: Steady-state Ratio (Rss) of GSK3342830 to Assess Time Invariance, as Data Permit|Part 2: Trough Plasma Concentrations at the End of the Dosing Interval (Ctau) to Assess the Achievement of Steady-state of GSK3342830 After Administration of Repeat IV Doses, as Data Permit","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","204847","June 13, 2016","February 2, 2017","February 2, 2017","April 26, 2016","September 12, 2018","September 12, 2018","GSK Investigational Site, Adelaide, South Australia, Australia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02751424/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02751424/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02751424"
481,"NCT02750709","Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin",,"Completed","Has Results","Hereditary Tyrosinemia, Type I","Drug: Nitisinone|Drug: Nitisinone 10 mg Tablet High Compritol|Drug: Orfadin","Maximum Observed Plasma Concentration (Cmax)|Area Under the Plasma Concentration Versus Time Curve, From Time Zero to 120 Hours Post-dose (AUC(0-120))|Area Under the Plasma Concentration Versus Time Curve, From Time Zero to 72 Hours Post-dose (AUC(0-72))|Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞)|Time to Maximum Observed Plasma Concentration (Tmax)|Terminal Elimination Rate Constant (λz)|Apparent Terminal Half-life (t1/2)","Cycle Pharmaceuticals Ltd.|Parexel","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CT-001|PXL225418","October 2015","December 2015","January 2016","April 25, 2016","December 13, 2016","March 15, 2017","Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, Free State, South Africa",,"https://ClinicalTrials.gov/show/NCT02750709"
482,"NCT02750345","Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)",,"Completed","Has Results","Hereditary Tyrosinemia, Type I","Drug: Nitisinone|Drug: Nitisinone Baked Tablet|Drug: Orfadin","Maximum Observed Plasma Concentration (Cmax)|Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))|Area Under the Plasma Concentration Versus Time Curve (AUC(0-72))|Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞))|Time to Maximum Observed Plasma Concentration (Tmax)|Terminal Elimination Rate Constant (λz)|Apparent Terminal Elimination Half-life (t1/2)","Cycle Pharmaceuticals Ltd.|Parexel","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CT-003|PXL227430","March 2016","May 2016","May 2016","April 25, 2016","October 17, 2016","June 14, 2017","Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, Free State, South Africa",,"https://ClinicalTrials.gov/show/NCT02750345"
483,"NCT02750332","Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)",,"Completed","Has Results","Hereditary Tyrosinemia, Type I","Drug: Nitisinone","Maximum Observed Plasma Concentration (Cmax)|Area Under the Plasma Concentration Versus Time Curve (AUC(0-120))|Area Under the Plasma Concentration Versus Time Curve (AUC(0-72))|Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC(0-∞))|Time to Maximum Observed Plasma Concentration (Tmax)|Terminal Elimination Rate Constant (λz)|Apparent Terminal Elimination Half-life (t1/2)","Cycle Pharmaceuticals Ltd.|Parexel","All","18 Years to 55 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CT-002|PXL225421","November 2015","December 2015","January 2016","April 25, 2016","December 13, 2016","March 15, 2017","Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, Free State, South Africa",,"https://ClinicalTrials.gov/show/NCT02750332"
484,"NCT02748928","UltraShape Power for Abdominal Fat and Circumference Reduction",,"Completed","Has Results","Excess Abdominal Fat","Device: UltraShape Power","Change in Abdominal Fat Thickness Compared to Baseline as Measured by Ultrasound|Change in Abdominal Circumference Compared to Baseline|Number of Investigators Reporting Satisfaction With Participants' Treatment Outcome|Number of Participants Reporting Satisfaction With Treatment Outcome|Pain Scale for Rating Discomfort Associated With Treatment","Syneron Medical","All","18 Years to 60 Years   (Adult)","Not Applicable","62","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DHF21621","June 8, 2016","February 15, 2017","April 23, 2018","April 22, 2016","March 7, 2019","March 19, 2019","Laser Skin Surgery Center of Northern California, Sacramento, California, United States|Prana Medical Aesthetics, Jacksonville Beach, Florida, United States|Baumann Cosmetic and Research Institute, Inc, Miami, Florida, United States|DuPage Medical Group, Naperville, Illinois, United States|A Womans Touch Plastic Surgery, Louisville, Kentucky, United States|Syneron Candela Institute for Education Clinic, Wayland, Massachusetts, United States|Union Square Laser Dermatology, New York, New York, United States|Jewell Plastic Surgery, Eugene, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02748928/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02748928"
485,"NCT02747186","Clinical Outcomes Maxilla: Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine",,"Completed","Has Results","Anesthesia","Drug: Lidocaine","Mean Time to Pulpal Response After Maxillary Molar Anesthesia|Mean Time to Pulpal Response After Maxillary Canine Anesthesia","University of North Carolina, Chapel Hill","All","18 Years to 30 Years   (Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","16-0068b","May 2016","December 31, 2017","December 31, 2017","April 21, 2016","December 19, 2018","December 19, 2018","University of North Carolina School of Dentistry, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02747186/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02747186"
486,"NCT02746679","Impact of Mindfulness Based Stress Reduction on Anxiety, Depression and QOL in Women With Intrauterine Adhesion.","IMBSRADQWIUA","Completed","Has Results","Asherman Syndrome","Other: Mindfulness Based Stress Reduction","The Zung Self-Rating Anxiety Scale Scores Before and After the Intervention|Endometrial Thickness Were Measured by Ultrasound in the Middle of Menstruation in All Patients.|Menstruation Was Evaluated With Visual Analogue Scale (VAS) in Which the Menstruation Was Assessed by the Patients Themselves With 0 as Amenorrhea and 100 as Normal Menstruation|Numbers of Participants With Reformation of Intrauterine Adhesions Were Counted by the Follow-up Hysteroscopy Was Performed in the Third Month After the Surgery|The Zung Self-Rating Depression Scale Scores Before and After the Intervention|The Scores of Physical Function Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)|The Scores of Role-physical Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)|The Scores of Role-emotional Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)|The Scores of Vitality Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)|The Scores of Mental Health Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)|The Scores of Social Functioning Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)|The Scores of Bodily Pain Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)|The Scores of General Health Before and After the Intervention(One Dimensions of the 36-item Short-form Health Survey)","Yuqing Chen|First Affiliated Hospital, Sun Yat-Sen University","Female","20 Years to 46 Years   (Adult)","Not Applicable","226","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MBSR-5","January 2015","November 2015","January 2016","April 21, 2016","August 26, 2016","August 26, 2016",,,"https://ClinicalTrials.gov/show/NCT02746679"
487,"NCT02743117","Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season","FluMist","Completed","Has Results","Influenza|Healthy","Biological: Monovalent Influenza Vaccine|Other: Placebo","Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F)|Percentage of Participants With Solicited Symptoms|Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) and New Onset Chronic Diseases (NOCDs)|Percentage of Participants Who Require Antipyretic and/or Analgesic Medication","MedImmune LLC|AstraZeneca","All","18 Years to 49 Years   (Adult)","Phase 4","301","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D2560C00012","May 2, 2016","November 30, 2016","November 30, 2016","April 19, 2016","October 4, 2017","October 4, 2017","Research Site, South Miami, Florida, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02743117"
488,"NCT02741310","Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan",,"Completed","Has Results","Healthy Subjects","Drug: Placebo|Drug: Sumatriptan|Drug: Erenumab","Time-weighted Averages of Mean Arterial Pressure|Number of Participants With Adverse Events|Area Under the Concentration-time Curve From Time 0 to 6 Hours for Sumatriptan|Area Under the Concentration-time Curve From Time 0 to Infinity for Sumatriptan|Maximum Observed Plasma Concentration (Cmax) of Sumatriptan|Number of Participants Who Developed Anti-erenumab Antibodies","Amgen","All","18 Years to 55 Years   (Adult)","Phase 1","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20140255|2015-004537-28","February 22, 2016","August 11, 2016","August 11, 2016","April 18, 2016","March 5, 2019","April 2, 2019","Research Site, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT02741310"
489,"NCT02737852","A Single-Center, Clinical Study to Evaluate the Safety of a New Personal Lubricant in Healthy Female Subjects",,"Completed","Has Results","Erythema|Edema","Device: Trojan ""Chameleon"" Personal Lubricant","Number of Subjects With Observed Local Erythema Based on the 5 Point Scoring Scale|Number of Subjects With Observed Edema Based on the 5 Point Scoring Scale","Church & Dwight Company, Inc.","Female","18 Years to 60 Years   (Adult)","Not Applicable","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ST-7609","March 2016","May 2016","May 2016","April 14, 2016","August 2, 2017","September 1, 2017","Clinical Research Laboratories, LLC, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02737852"
490,"NCT02737592","A Clinical Study to Evaluate the Safety of a Personal Lubricant in Healthy Female Subjects",,"Completed","Has Results","Erythema|Edema","Device: Trojan ""Simply Pleasure"" Personal Lubricant","Number of Subjects With Observed Local Erythema Based on 5 Point Scale|Number of Subjects With Observed Edema Based on the 5 Point Scoring Scale","Church & Dwight Company, Inc.","Female","18 Years to 60 Years   (Adult)","Not Applicable","34","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","ST-7610","March 2016","April 2016","April 2016","April 14, 2016","March 20, 2017","April 17, 2017","Clinical Research Laboratories, LLC, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02737592"
491,"NCT02734238","Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery","OPS","Completed","Has Results","Caloric Restriction|Exercise","Drug: Sesame Oil|Drug: testosterone enanthate","Body Composition at the End of Each Study Phase","Pennington Biomedical Research Center|United States Army Research Institute of Environmental Medicine|MyoSyntax|Defence Research and Development Canada|United States Department of Defense","Male","18 Years to 39 Years   (Adult)","Phase 4","53","Other|U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PBRC 2015-063","April 2016","December 2017","December 2017","April 12, 2016","January 2, 2019","January 16, 2019","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02734238/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02734238"
492,"NCT02734056","Music During Labor Epidural Placement and Patient Satisfaction",,"Completed","Has Results","Satisfaction","Other: Music|Other: Control","Anxiety","Brigham and Women's Hospital","Female","18 Years to 45 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015P001230","October 2015","January 2016","January 2016","April 12, 2016","March 30, 2017","March 30, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02734056"
493,"NCT02732587","Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers",,"Completed","Has Results","Alcohol Drinking","Drug: Saracatinib","Safety/Tolerability of Study Medication.","Yale University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","21 Years to 50 Years   (Adult)","Phase 1","5","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0602001068-2|P50AA012870","November 2015","March 15, 2016","March 23, 2016","April 8, 2016","January 14, 2020","January 14, 2020","CMHC, Substance Abuse Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02732587"
494,"NCT02732561","The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety Among Homeless Adults",,"Completed","Has Results","Depression|Anxiety","Device: Alpha Stim device|Device: Sham device","Depressive Symptoms|Anxiety","Wake Forest University Health Sciences","All","18 Years to 64 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB00036461","March 2016","June 2016","June 2016","April 8, 2016","May 1, 2017","October 16, 2018","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02732561"
495,"NCT02731469","Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers",,"Completed","Has Results","Reticulocyte Count","Biological: BCD-131|Biological: Mircera®|Biological: Aranesp®","AUC (0-1176 Hours)|Cmax|Tmax|T1/2|Kel|Clearance of BCD-131|AUEC (0-1176 Hours) - Reticulocytes|AUEC (0-1176 Hours) - Hemoglobin|AC-Emax - Reticulocytes|AC-Emax - Hemoglobin|Intensity of Pain After Subcutaneous Injection According to Visual Analog Scale|Number of Participants With Adverse Events and Serious Adverse Events|Number of Participants With Local Reactions|Number of Participants With AE/SAE 3-4 Grade CTCAE|Number of Participants With Early Withdrawal Due to AE|Number of Participants With Binding Antibodies to BCD-131","Biocad","Male","18 Years to 45 Years   (Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","BCD-131-1","June 15, 2016","March 2017","March 2017","April 7, 2016","July 1, 2019","July 1, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02731469/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02731469/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02731469"
496,"NCT02729545","The Efficacy and Safety Study of Tung's Acupuncture for Polycystic Ovarian Syndrome",,"Completed","Has Results","Polycystic Ovarian Syndrome","Other: Tung's acupuncture|Drug: Cyproterone acetate/ethinylestradiol (CPA/EE)","Change in LH/FSH Ratio From Baseline to the End of Treatment|Change in LH/FSH Ratio From Baseline to the 24th Week|Changes in LH From Baseline to the End of Treatment|Changes in FSH From Baseline to the End of Treatment|Changes in Body Mass Index (BMI) From Baseline to the End of Treatment|Changes in Total Testosterone (TT) From Baseline to the End of Treatment|Changes in Ovarian Volume From Baseline to the End of Treatment|Changes in Polycystic Ovary Number From Baseline to the End of Treatment|Changes in the Number of Bleeding Events From Baseline to the End of Treatment","Beijing Hospital of Integrated Traditional Chinese and Western Medicine","Female","18 Years to 45 Years   (Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JJ2015-42","April 2016","March 2018","May 2018","April 6, 2016","September 24, 2019","October 8, 2019","Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, Beijing, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02729545/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02729545"
497,"NCT02728895","Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT",,"Completed","Has Results","Allogeneic Hematopoietic Stem Cell Transplantation","Drug: Vedolizumab","Number of Participants With Dose-Limiting Toxicities (DLTs)|Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Mean Serum Concentrations of Vedolizumab That Helped the Likelihood of Alpha4Beta7 Target Saturation on Day 100 Following Allo-HSCT|Time to Neutrophil Engraftment|Percentage of Participants With Overall Grade 2 to 4 Acute Graft-Versus-Host Disease (GvHD)|Percentage of Participants With Maximum Severity of Acute GvHD Based on Modified Glucksberg Criteria|Percentage of Participants With Maximum Severity of Acute GvHD Based on Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Modified International Bone Marrow Transplant Registry Database (IBMTR) Index|Ctrough: Serum Concentration Before Dosing for Vedolizumab","Takeda","All","18 Years to 60 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Vedolizumab-1015|U1111-1184-1822","June 15, 2016","July 10, 2018","July 10, 2018","April 5, 2016","August 26, 2019","August 26, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|OSU - James Comprehensive Cancer Center, Columbus, Ohio, United States|Medical College of Wisconsin, Inc., Milwaukee, Wisconsin, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02728895/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02728895/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02728895"
498,"NCT02727816","Non-dispensing Fitting Study Comparing the Clinical Performance Hydrogel Sphere Design Contact Lenses.",,"Completed","Has Results","Myopia","Device: filcon IV I (BC 8.6)|Device: filcon IV I (BC 8.7)|Device: ocufilcon D|Device: methafilcon A (BC 8.6)|Device: methafilcon A (BC 8.7)|Device: somofilcon A","Centration - Pair One|Centration - Pair Two|Centration - Pair Three|Centration - Pair Four|Post-blink Movement - Pair One|Post-blink Movement - Pair Two|Post-blink Movement - Pair Three|Post-blink Movement - Pair Four|Lens Tightness - Pair One|Lens Tightness - Pair Two|Lens Tightness - Pair Three|Lens Tightness - Pair Four|Overall Fit Preference - Pair One|Overall Fit Acceptance - Pair Two|Overall Fit Acceptance - Pair Three|Overall Fit Acceptance - Pair Four","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","EX-MKTG-65","April 2016","May 2016","August 2016","April 5, 2016","February 6, 2018","February 6, 2018","Optometry Clinic, National Autonomous University, Mexico D.F., Mexico",,"https://ClinicalTrials.gov/show/NCT02727816"
499,"NCT02726971","Comparison of Different Doses of Oestrogen Therapy for Preventing Intrauterine Adhesion",,"Completed","Has Results","Asherman Syndrome","Drug: Femoston","the AFS Score at Second-look Hysteroscopy|the AFS Score at Third-look Hysteroscopy|Participants With Improvement of Menstrual Pattern at Third-look Hysteroscopy","Fu Xing Hospital, Capital Medical University","Female","25 Years to 45 Years   (Adult)","Phase 1|Phase 2","141","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","LYuhuan","April 2016","August 2016","August 2016","April 4, 2016","April 10, 2017","April 10, 2017","Fu Xing Hospital,Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02726971"
500,"NCT02726789","Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B",,"Completed","Has Results","Hepatitis B, Chronic","Drug: REP 2139-Ca|Drug: pegylated interferon|Drug: entecavir","Number of Patients Experiencing Treatment Emergent Laboratory Test Abnormalities or Adverse Events.|Number of Patients Experiencing Reductions in Serum HBsAg|Number of Patients Experiencing Reductions in Serum HBV DNA|Number of Patients Experiencing Serum Anti-HBs > 10 mIU / ml","Replicor Inc.","All","18 Years to 55 Years   (Adult)","Phase 2","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REP 201","October 2012","September 2016","December 2016","April 4, 2016","May 8, 2019","May 8, 2019",,,"https://ClinicalTrials.gov/show/NCT02726789"
501,"NCT02723630","Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers",,"Completed","Has Results","Healthy Volunteers","Drug: Lenvatinib 10 mg","Area Under the Plasma Concentration-Time Curve From Zero Time (Predose) to Time of Last Quantifiable Concentration (AUC(0-t))|Area Under the Concentration-Time Curve From Zero Time (Predose) Extrapolated to Infinite Time (AUC(0-inf))|Area Under the Concentration-Time Curve From Zero Time (Predose) to 24 Hours (AUC(0-24))|Area Under the Concentration-Time Curve From Zero Time (Predose) to 72 Hours (AUC(0-72))|Maximum Observed Concentration (Cmax) of Lenvatinib in Plasma|Time to Cmax (Tmax) for Lenvatinib|Terminal Elimination Phase Half-life (t1/2)|Number of Participants With Non-Serious Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events as a Measure of Safety and Tolerability of Lenvatinib","Eisai Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E7080-A001-008","July 2013","August 2013","August 2013","March 30, 2016","March 14, 2019","March 14, 2019","Las Vegas, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT02723630"
502,"NCT02723201","TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants",,"Completed","Has Results","Healthy","Drug: TAK-020 Captisol Oral Solution|Drug: TAK-020 CCT|Drug: TAK-020 SDT|Drug: TAK-020 IRT|Drug: TAK-020 Solid Formulation","Cmax: Maximum Observed Plasma Concentration for TAK-020|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-020|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-020|Terminal Disposition Phase Half-life (T1/2z) in Plasma for TAK-020|Number of Participants Who Experience at Least One or More Treatment-emergent Adverse Event (TEAE)|Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Post Dose|Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose|Number of Participants Who Meet the Takeda Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-020-1002|U1111-1171-4650|2015-002635-18|16/WA/0012","April 28, 2016","August 5, 2016","August 24, 2016","March 30, 2016","April 13, 2018","April 13, 2018","Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02723201"
503,"NCT02723188","Modulation of Fear Extinction Processes Using Transcranial Electrical Stimulation",,"Completed","Has Results","Stress Related Disorder|Anxiety","Device: Sham stimulation (1.5 milliampere,30 seconds)|Device: DC stimulation (1.5 milliampere, 20 minutes)|Device: AC stimulation (1.5 milliampere,1.5 Hertz frequency)","Galvanic Skin Response (GSR)|Self-reported Fear Rankings","Tel Aviv University","All","18 Years to 50 Years   (Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","TASMC-13-TH-334","September 2014","April 2015","April 2015","March 30, 2016","June 14, 2017","June 14, 2017",,,"https://ClinicalTrials.gov/show/NCT02723188"
504,"NCT02722239","An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Xigduo XR|Drug: Metformin ER (Glucophage® long)|Drug: Dapagliflozin (Forxiga)","Maximum Concentration (Cmax).|Area Under the ""Concentration - Time"" Curve (AUC0-t)|Area Under the ""Concentration - Time"" Curve (AUC0-∞)|Bioequivalence Consideration: 90% Confidence Intervals for the Test:Reference Geometric Least Squares Mean Ratios|Adverse Events","AstraZeneca|Biocard","All","18 Years to 45 Years   (Adult)","Phase 1","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1691C00012","March 30, 2016","May 5, 2016","May 5, 2016","March 29, 2016","February 19, 2018","February 19, 2018","Research Site, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02722239"
505,"NCT02718118","Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines",,"Completed","Has Results","Glabellar Lines|Wrinkles","Device: Dysport reconstituted at 1.5 mL (0.05 mL/injection)|Device: Dysport reconstituted at 2.5 mL (0.08 mL/injection)","Proportion of Composite Responders Who Achieve at Least a 1-point Reduction From Baseline in Glabellar Line Severity Score (GLSS) at Maximum Frown.|Proportion of Responders, at Maximum Frown (Subject)|Proportion of Responders, at Maximum Frown (Blinded Evaluator)|Proportion of Responders, at Maximum Frown (Treating Investigator)|Proportion of Combination Responders, at Maximum Frown (Blinded Evaluator and Subject)|Proportion of Responders, at Rest (Subject)|Proportion of Responders, at Rest (Blinded Evaluator)|Proportion of Responders, at Rest (Treating Investigator)|Proportion of Combination Responders, at Rest (Blinded Evaluator and Subject)|Proportion of Subjects Who Achieved an Onset of Effect on the Appearance of the Subject's Glabellar Lines.|Subject Satisfaction With the Treatment of Glabellar Lines - I am Satisfied With How I Look.|Investigator Satisfaction With Treatment Outcome - Satisfied With the Study Product Results|Subject Psychological Well-being - Mean Change at Day 120 Compared to Baseline|Subject Age Appraisal Using the FACE-Q-Age Appraisal Visual Analog Scale (VAS) - Mean Change at Day 120 Compared to Baseline|Subject Appraisal of Lines Between the Eyebrows (FACE-Q) - Mean Change at Day 120 Compared to Baseline","Galderma Laboratories, L.P.","All","18 Years to 64 Years   (Adult)","Phase 4","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","GLI.04.SPR.US10348","April 2016","October 2016","October 2016","March 24, 2016","September 25, 2018","October 23, 2018","AboutSkin Dermatology and DermSurgery, Greenwood Village, Colorado, United States|Skin Research Institute, Coral Gables, Florida, United States|Marina Peredo, MD, PC, Smithtown, New York, United States",,"https://ClinicalTrials.gov/show/NCT02718118"
506,"NCT02717754","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants",,"Completed","Has Results","Healthy Volunteer","Drug: Oseltamivir|Drug: Placebo","Area Under the Plasma Concentration-Time Curve From Time 0 to 12 Hour (AUC0-12h) of Oseltamivir and RO0640802 at Steady State|Maximum Plasma Concentration (Cmax) of Oseltamivir and RO0640802 at Steady State|Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Oseltamivir and RO0640802|Area Under the Plasma Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUC0-last) of Oseltamivir and RO0640802|Cmax of Oseltamivir and RO0640802|Time to Reach Maximum Plasma Concentration (Tmax) of Oseltamivir and RO0640802|Half-Life (t1/2) of Oseltamivir and RO0640802|Volume of Distribution (Vd) of Oseltamivir and RO0640802|Clearance (CL) of Oseltamivir and RO0640802|Minimum Plasma Concentration (Cmin) of RO0640802","Hoffmann-La Roche","All","18 Years to 45 Years   (Adult)","Phase 1","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","NP25140","December 2009","May 2010","May 2010","March 24, 2016","June 27, 2016","June 27, 2016","Little Rock, Arkansas, United States|Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02717754"
507,"NCT02712554","A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route",,"Completed","Has Results","Pain|Nausea|Vomiting","Drug: CL-108|Drug: M366|Drug: Placebo","Subjective Effects: Maximum Effect (Emax) and Minimum Effect (Emin) of High Visual Analog Scale (VAS) in Dose Selection Phase|Subjective Effects: Emax of Any Effects VAS in Dose Selection Phase|Emax of Drug Liking VAS in Treatment Phase|Number of Adverse Events in Dose Selection Phase|Balance of Effects: Emin of Drug Liking VAS in Treatment Phase|Balance of Effects: Time-averaged Area Under the Effect Curve (TA_AUE) of Drug Liking VAS in Treatment Phase|Balance of Effects: Emax and Emin of Overall Drug Liking VAS in Treatment Phase|Balance of Effects: Emax and Emin of Take Drug Again VAS in Treatment Phase|Positive Effects: Emax of High VAS in Treatment Phase|Positive Effects: TA_AUE of High VAS in Treatment Phase|Positive Effects: Emax of Good Effects VAS in Treatment Phase|Positive Effects: TA_AUE of Good Effects VAS in Treatment Phase|Negative Effects: Emax of Bad Effects VAS in Treatment Phase|Negative Effects: TA_AUE of Bad Effects VAS in Treatment Phase|Sedative and Other Effects: Emin of Alertness/Drowsiness VAS in Treatment Phase|Sedative and Other Effects: TA_AUE of Alertness/Drowsiness VAS in Treatment Phase|Sedative and Other Effects: Emax of Any Effects VAS in Treatment Phase|Sedative and Other Effects: TA_AUE of Any Effects VAS in Treatment Phase|Objective Measures: Change From Baseline in Choice Reaction Time (CRT) in Treatment Phase|Change From Baseline in Number of Errors (Any Errors) in CRT Test in Treatment Phase|Pupillometry: Maximum Pupil Constriction (MPC)|Pupillometry: TA_AUE of MPC in Treatment Phase","Charleston Laboratories, Inc","All","18 Years to 55 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","CLCT-007","June 2015","September 2015","September 2015","March 18, 2016","October 14, 2019","October 14, 2019",,,"https://ClinicalTrials.gov/show/NCT02712554"
508,"NCT02712333","Health Effects of Indoor Air Filtration in Healthy Chinese Adults",,"Completed","Has Results","Blood Pressure","Behavioral: Air Purifiers|Behavioral: Sham Air Purifiers","Changes of Serum Cortisol Levels|Changes of Serum Cortisone Concentration|Changes of Serum Epinephrine Concentrations|Changes of Serum Norepinephrine Concentration|Systolic Blood Pressure|Diastolic Blood Pressure|Pulse Pressure","Fudan University","All","18 Years to 30 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","FDEH-AF2015","November 2015","December 2015","June 2016","March 18, 2016","October 2, 2017","October 2, 2017","Department of Environmental Health, School of Public Health, Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02712333"
509,"NCT02711306","Effects of Konjac Glucomannan Noodle Intervention in Subjects With Metabolic Syndrome",,"Completed","Has Results","Metabolic Syndrome","Dietary Supplement: Glucomannan noodle|Dietary Supplement: Placebo noodle","Body Weight|Waist Circumference|Glycemic Index|Lipid Index","Taipei Medical University","All","20 Years to 64 Years   (Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","201209019","May 2013","January 2014","March 2014","March 17, 2016","October 29, 2019","October 29, 2019",,,"https://ClinicalTrials.gov/show/NCT02711306"
510,"NCT02710630","Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects",,"Completed","Has Results","Healthy","Drug: Dabigatran etexilate tablet E1|Drug: Dabigatran etexilate tablet D1|Drug: Dabigatran etexilate tablet C1|Drug: Dabigatran etexilate tablet B1|Drug: Dabigatran etexilate tablet A1|Drug: Dabigatran etexilate capsule","AUC0-tz (Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)|Cmax (Maximum Concentration of Free Dabigatran)|AUC0-infinity (Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity) (if Applicable)|AUC0-tz (Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)|Cmax (Maximum Plasma Concentration of Total Dabigatran)|AUC0-infinity (Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity) (if Applicable)","Boehringer Ingelheim","Male","20 Years to 35 Years   (Adult)","Phase 1","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1160.246","March 22, 2016","May 11, 2016","June 10, 2016","March 17, 2016","September 29, 2017","November 6, 2017","SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan",,"https://ClinicalTrials.gov/show/NCT02710630"
511,"NCT02709577","A Study of the GI Sleeve for the Treatment of Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes","Device: EndoBarrier Gastrointestinal Liner|Other: Sham: endoscopy and standard of care","Change in HbA1c Values From Baseline Measurement|Absolute Weight Change","GI Dynamics|Hospital Dipreca","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","36","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","06-5","January 2007","January 2009","January 2009","March 16, 2016","December 28, 2016","December 28, 2016",,,"https://ClinicalTrials.gov/show/NCT02709577"
512,"NCT02709096","BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes",,"Completed","Has Results","Acne Vulgaris","Drug: BPX-01, 1% Topical Gel|Drug: BPX-01 Vehicle Gel","Logarithmic Change in Colony Counts of Facial Propionibacterium Acnes","BioPharmX, Inc.","All","18 Years to 40 Years   (Adult)","Phase 2","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BPX-01-C02","April 2016","June 2016","June 2016","March 15, 2016","September 14, 2017","September 14, 2017","KGL Skin Study Center, Broomall, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02709096"
513,"NCT02709005","Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis",,"Completed","Has Results","Bacterial Vaginosis","Drug: 5% Monolaurin Vaginal Gel|Other: Placebo","Number of Participants With Clinical Cure in Each Study Arm|Number of Participants Reporting Solicited Urogenital Adverse Events (AEs) Following the First Dose of the Study Product|Number of Participants Reporting Serious Adverse Events (SAEs) Considered Product-related|Number of Participants With Therapeutic Cure in Each Study Arm|Number of Participants With Nugent Score of 3 or Less (Negative for BV) in Each Study Arm|Number of Participants With Nugent Score of 4-6 (Intermediate BV) in Each Study Arm|Number of Participants Experiencing Non-laboratory Non-solicited AEs Following the First Dose of the Study Product|Number of Participants Experiencing Laboratory AEs Following the First Dose of the Study Product","National Institute of Allergy and Infectious Diseases (NIAID)","Female","18 Years to 50 Years   (Adult)","Phase 2","109","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12-0021|HHSN272201300017I","April 14, 2016","December 11, 2017","December 11, 2017","March 15, 2016","December 28, 2018","December 28, 2018","University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa, United States|Duke Human Vaccine Institute - Duke Clinical Vaccine Unit, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02709005/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02709005/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02709005"
514,"NCT02708524","Clinical Study of Approved and Investigational Contact Lenses",,"Completed","Has Results","Visual Acuity","Device: Senofilcon C Contact Lens|Device: Comfilcon A Contact Lens|Device: Lotrafilcon B Contact Lens|Device: Samfilcon A Contact Lens","Subjective Overall Comfort Composite Score|Overall Comfort Individual Item|Comfort at the End of the Day Individual Item|Comfort Each and Everyday Individual Item|Frequency of Lens Awareness Individual Item|Frequency of Experiencing Dryness Individual Item|Making Your Eyes Feel Moist Throughout the Day Individual Item|Subjective Overall Quality of Vision Composite Score|Overall Quality of Vision Individual Item|Overall Opinion Individual Item","Johnson & Johnson Vision Care, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","554","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR-5808","January 2016","March 2016","March 2016","March 15, 2016","November 9, 2016","November 9, 2016","Montgomery, Alabama, United States|Fruit Cove, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Longwood, Florida, United States|Tallahassee, Florida, United States|Tampa, Florida, United States|Roswell, Georgia, United States|Bloomington, Illinois, United States|East Lansing, Michigan, United States|Medina, Minnesota, United States|Closter, New Jersey, United States|Vestal, New York, United States|Granville, Ohio, United States|Jacksonville, Texas, United States|Salt Lake City, Utah, United States|Roanoke, Virginia, United States|West Allis, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02708524"
515,"NCT02708433","Clinical Outcomes of Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine",,"Completed","Has Results","Anesthesia","Drug: Lidocaine","Mean Time to Pulpal Response After Mandibular Molar Anesthesia|Mean Time to Pulpal Response After Mandibular Canine Anesthesia","University of North Carolina, Chapel Hill","All","18 Years to 30 Years   (Adult)","Not Applicable","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","16-0068a","March 2016","August 2017","September 2017","March 15, 2016","September 4, 2018","September 4, 2018","UNC School of Dentistry, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02708433/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02708433"
516,"NCT02706925","To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male Volunteers",,"Completed","Has Results","Healthy","Drug: BI 443651|Drug: Placebo","Percentage of Subjects With Drug-related Adverse Events (AEs)|AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)|Cmax (Maximum Measured Concentration of the Analyte in Plasma)","Boehringer Ingelheim","Male","18 Years to 50 Years   (Adult)","Phase 1","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","1363.1|2015-004395-30","March 22, 2016","June 12, 2016","June 13, 2016","March 11, 2016","January 2, 2020","January 2, 2020","Humanpharmakologisches Zentrum Biberach, Biberach, Germany",,"https://ClinicalTrials.gov/show/NCT02706925"
517,"NCT02706834","Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants",,"Completed","Has Results","Dose Finding Study","Drug: TAK-828|Drug: Placebo","Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event (TEAE)|Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event (AE)|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post-dose|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Measurements at Least Once Post-dose|Cmax: Maximum Observed Plasma Concentration for TAK-828F (Free Base of TAK-828)|Tmax: Time of First Occurrence of Cmax for TAK-828F (Free Base of TAK-828)|t1/2z: Terminal Disposition Phase Half-Life for TAK-828F (Free Base of TAK-828)|AUC∞: Area Under the Concentration-Time Curve From Time 0 to Infinity Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-828F (Free Base of TAK-828)","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","TAK-828-1001|U1111-1177-8044","March 1, 2016","June 17, 2016","June 17, 2016","March 11, 2016","October 19, 2018","October 19, 2018","Baltimore, Maryland, United States|Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02706834"
518,"NCT02706327","Comparison of Two Different Insole Types in Painful Flexible Flatfoot",,"Completed","Has Results","Flatfoot","Device: CAD/CAM Insole|Device: Semi-custom Insole|Other: Control","Change in Pain Intensity Measured by 100 mm Visual Analog Scale|Change in Quality of Life Assessed With Short Form-36 Scale","Eastern Mediterranean University|Hacettepe University","All","18 Years to 45 Years   (Adult)","Not Applicable","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","GO 14/18-31","January 2014","January 2016","February 2016","March 11, 2016","July 14, 2017","November 1, 2017",,,"https://ClinicalTrials.gov/show/NCT02706327"
519,"NCT02704702","A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects",,"Completed","Has Results","Hypertension","Drug: Fimasartan|Drug: Rosuvastatin|Drug: Fimasartan + Rosuvastatin","Area Under the Concentration-time Curve|Maximum Observed Concentration|Time to Reach Maximum Observed Plasma Concentration","Boryung Pharmaceutical Co., Ltd","Male","19 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","BR-FRC-CT-102|CA16652","March 2016","June 2016","June 2016","March 10, 2016","November 2, 2018","November 2, 2018",,,"https://ClinicalTrials.gov/show/NCT02704702"
520,"NCT02696434","Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL",,"Completed","Has Results","Opioid Use Disorder","Drug: Naltrexone|Drug: Placebo|Drug: Buprenorphine","Proportion of Subjects Who Receive and Tolerate a VIVITROL Injection on Day 8|Proportion of Days With COWS Peak Score </=12 During the Treatment Period Prior to the VIVITROL Injection|Proportion of Post-VIVITROL Days (Days 9-11) in Which Subjects in Each Group Demonstrate Mild Opioid Withdrawal|Mean Peak COWS Scores During the Treatment Period (Days 1/1a-7)|Area Under the Curve (AUC) for COWS Scores During the Treatment Period and VIVITROL Induction and Post-VIVITROL Observation Period|Mean Score for ""Desire for Opioids"" Visual Analog Scale (VAS) During the Treatment Period and VIVITROL Induction and Post-VIVITROL Observation Period|Incidence of Adverse Events (AEs)","Alkermes, Inc.","All","18 Years to 60 Years   (Adult)","Phase 3","101","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALK6428-A302","April 2016","November 2017","November 30, 2017","March 2, 2016","February 12, 2019","February 12, 2019","Segal Institute for Clinical Research, Lauderhill, Florida, United States|Research Centers of America, LLC, Oakland Park, Florida, United States|Neuroscience Research Institute, Inc., Winfield, Illinois, United States|John Hopkins School of Medicine, Baltimore, Maryland, United States|Hassman Research Institute, Berlin, New Jersey, United States|New York State Psychiatric Institute, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania Treatment Research Center, Philadelphia, Pennsylvania, United States|Western Psychiatric Institute and Clinic of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02696434/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02696434/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02696434"
521,"NCT02696291","Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects",,"Terminated","Has Results","Viral Infection","Drug: UV-4B 30 mg oral solution|Drug: UV-4B 75 mg oral solution|Drug: UV-4B 150 mg oral solution|Drug: UV-4B X mg (dose to be determined) oral solution|Drug: UV-4B Y mg (dose to be determined) oral solution|Drug: Placebo","Number of Subjects Reporting Treatment-emergent Adverse Events (TEAEs) by Group|Number of Subjects Reporting Serious Adverse Events (SAEs) by Group|Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group|Number of Subjects With Outlying Vital Sign Results by Group|Number of Subjects With 12-lead Electrocardiogram (ECG) Abnormalities Postdose by Group|Maximum Plasma Concentration (Cmax)|Time of Maximum Plasma Concentration (Tmax)|Area Under the Concentration-time Curve From Time Zero (Predose) to Time of the Last Quantifiable Concentration After the Last Dose [AUC(0-last)]|Total Daily Exposure at Steady State: Area Under the Concentration-time Curve From Time Zero (Predose) Until 24 Hours After the Last Dose [AUC(0-24)]|Area Under the Concentration-time Curve From Time Zero (Predose) Until 8 Hours After the Final Dose [AUC(0-8)]|Apparent Systemic Clearance (CL/F) at Steady State|Apparent Volume of Distribution of UV-4 During the Terminal Phase (Vz/F) After Multiple Doses|Apparent Terminal Half Life (t1/2)|Accumulation Ratio (AR)","Emergent BioSolutions|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 45 Years   (Adult)","Phase 1","7","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DMID 15-0062|HHSN272201100030C|8311-270","May 27, 2016","March 2, 2017","March 2, 2017","March 2, 2016","March 16, 2018","April 18, 2018","Clinical Research Unit, Dallas, Texas, United States|Clinical Research Unit, Madison, Wisconsin, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02696291/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02696291/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02696291"
522,"NCT02695524","Exercise Application in the Treatment of Patients With Subacromial Pain Syndrome",,"Completed","Has Results","Shoulder Impingement Syndrome","Other: Scapula-focused exercises|Other: Motor control exercises","Change in Functionality Evaluated With Specific Questionnaire|Change in Intensity of Pain Evaluated by a Scale|Change in Strength Evaluated by Hand Held Dynamometer and the Measures Provided in Kilogram-force (KgF)|Perceived Change Evaluated by Numerical Scale|Change in Kinesiophobia Evaluated With Specific Questionnaire|Range of Motion Evaluated by Digital Inclinometer and the Measures Provided in Degrees|Satisfaction With Treatment Evaluated With Specific Questionnaire|Scapula Position Evaluated by Digital Inclinometer and the Measures Provided in Degrees","University of Sao Paulo","All","18 Years to 60 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","U1111-1179-1921","March 2016","July 2017","August 2017","March 1, 2016","August 19, 2019","August 19, 2019","University of São Paulo, Ribeirão Preto Medical School, Ribeirão Preto, São Paulo, Brazil","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02695524/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02695524/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02695524"
523,"NCT02693132","Comparison of Supervised and Unsupervised Physical Activity Programs During a Weight Loss Intervention for Adults","REACH","Completed","Has Results","Obesity","Behavioral: Supervised (SUP-PA)|Behavioral: Unsupervised (UNSUP-PA)|Behavioral: Step-based (STEP)","Change in Moderate-to-Vigorous Physical Activity (Accumulated in Bouts of at Least 10 Minutes)|Change in Cardiorespiratory Fitness|Change in Body Weight|Change in Fat Mass|Change in Energy Intake","University of Pittsburgh","All","18 Years to 55 Years   (Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PRO15110570","February 2016","August 2016","August 2016","February 26, 2016","November 29, 2018","November 29, 2018","Physical Activity and Weight Management Research Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02693132"
524,"NCT02693002","Estrogen Diastolic Heart Failure",,"Terminated","Has Results","Menopause","Drug: Estradiol/Norethindrone acetate|Drug: Placebo","Diastolic Function Assessed by Echocardiography|Activity Level Assessed by Duke Activity Status Index (DASI)|Quality of Life Score Assessed by Utian Quality of Life Scale (UQoLS)|B-type Natriuretic Peptide (BNP) Levels","Gretchen Wells|University of Kentucky","Female","45 Years to 55 Years   (Adult)","Phase 4","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","15-0798-F6A","February 2016","November 2016","November 2016","February 26, 2016","July 11, 2018","August 8, 2018","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02693002"
525,"NCT02691572","Transversus Abdominis Plane Block Versus Wound Infiltration for Postcesarean Analgesia",,"Completed","Has Results","Postcesarean Analgesia","Procedure: Spinal anesthesia|Drug: Intrathecal bupivacaine|Drug: Intrathecal fentanyl|Procedure: Cesarean delivery|Procedure: Wound infiltration|Procedure: Sham procedure|Procedure: Transversus abdominis plane block|Drug: Ketorolac|Drug: Paracetamol|Procedure: Fentanyl patient-controlled analgesia","Cumulative Fentanyl Dose|Time to the First Postoperative Fentanyl Administration|Pain Scores at Rest and Movement|Number of Patients With Nausea and/or Vomiting|Level of Sedation|Number of Patients With Pruritis|Level of Patient Satisfaction","Mansoura University","Female","19 Years to 40 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","R/16.01.17","February 2016","May 2016","May 2016","February 25, 2016","October 31, 2018","October 31, 2018","Department of Anesthesia, Mansoura University Hospitals, Mansoura, Dakahlia, Egypt",,"https://ClinicalTrials.gov/show/NCT02691572"
526,"NCT02690727","To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: RP6530","Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC))|Number of Participants Who Were Evaluated for Adverse Events|Pharmacokinetic Parameters","Rhizen Pharmaceuticals SA","Male","18 Years to 45 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RP6530-1501|ISI-P5-416","February 2016","March 2016","March 2016","February 24, 2016","June 16, 2017","November 28, 2017","Algorithme Pharma Inc, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02690727"
527,"NCT02690181","Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.",,"Completed","Has Results","Bacterial Infection Due to Streptococcus, Group B","Biological: GBS Trivalent Vaccine","Percentage of Subjects With ELISA Antibody Concentrations of GBS Serotype Ia Above Pre-specified Thresholds - Day 61|Percentage of Subjects With Antibody Concentrations of GBS Serotype Ib Above Pre-specified Thresholds - Day 61|Percentage of All Subjects With Antibody Concentrations of GBS Serotype III Above Pre-specified Thresholds - Day 61|Numbers of Subjects With Solicited Local and Systemic Adverse Events (AEs)|Number of Subjects With Any Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs), Medically Attended AEs, and AEs Leading to Study Withdrawal|Percentage of Subjects With ELISA Antibody Concentrations of GBS Serotype Ia Above Pre-specified Thresholds - Day 31|Percentage of Subjects With Antibody Concentrations of GBS Serotype Ib Above Pre-specified Thresholds - Day 31|Percentage of Subjects With Antibody Concentrations of GBS Serotype III Above Pre-specified Thresholds - Day 31|Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia|Geometric Mean Antibody Concentrations of GBS Serotype Ib|Geometric Mean Antibody Concentrations of GBS Serotype III|Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in Subjects With Prevaccination Serotype-specific GBS Antibody Less Than the Lower Limit of Quantitation (LLQ)|Geometric Mean Antibody Concentrations of GBS Serotype Ib in Subjects With Prevaccination Serotype-specific GBS Antibody Less Than LLQ|Geometric Mean Antibody Concentrations of GBS Serotype III in Subjects With Prevaccination Serotype-specific GBS Antibody Less Than LLQ|Geometric Mean ELISA Antibody Concentrations of GBS Serotype Ia in Subjects With Prevaccination Serotype-specific GBS Antibody Equal or Greater Than LLQ|Geometric Mean Antibody Concentrations of GBS Serotype Ib in Subjects With Prevaccination Serotype-specific GBS Antibody Equal or Greater Than LLQ|Geometric Mean Antibody Concentrations of GBS Serotype III in Subjects With Prevaccination Serotype-specific GBS Antibody Equal or Greater Than LLQ|Geometric Mean ELISA Anti-Diphtheria Antibody Concentrations in All Subjects","GlaxoSmithKline","Female","22 Years to 46 Years   (Adult)","Phase 2","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","205421|2015-003094-15|V98_06E1","March 29, 2016","November 2, 2016","November 2, 2016","February 24, 2016","July 16, 2018","June 20, 2019","GSK Investigational Site, Ghent, Belgium","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT02690181/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02690181"
528,"NCT02689804","EC PK in Women With Normal and Obese BMI",,"Completed","Has Results","Contraception","Drug: LNG-EC|Drug: UPA-EC","Area Under the Curve From Time 0 to 24 Hours of Serum LNG Concentration|Area Under the Curve From Time 0 to 24 Hours of Serum UPA Concentration|Elimination Half-life of Serum LNG|Elimination Half-life of Serum UPA|Clearance of Serum LNG|Clearance of Serum UPA|Maximum Concentration of Serum LNG|Maximum Concentration of Serum UPA|Time to Maximum Concentration of Serum LNG|Time to Maximum Concentration of Serum UPA","Columbia University","Female","18 Years to 45 Years   (Adult)","Phase 4","34","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","AAAP1857","July 10, 2015","December 29, 2015","February 3, 2017","February 24, 2016","July 7, 2017","July 7, 2017","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02689804"
529,"NCT02688387","A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects",,"Completed","Has Results","Hypertension, Pulmonary","Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose|Drug: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)","Maximum Observed Concentration (Cmax) of Ambrisentan and Tadalafil in FDC (Ambrisentan 10 mg + Tadalafil 40 mg) and Montherapies (Ambrisentan 10 mg & Tadalafil 40 mg) - Part 1|Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to Infinite (Inf) Time, AUC (0-inf) of Ambrisentan and Tadalafil in FDC (Ambrisentan 10 mg + Tadalafil 40 mg) and Montherapies (Ambrisentan 10 mg & Tadalafil 40 mg) - Part 1|AUC From Time of Dose to Last Measurable Concentration (AUC [0-t]), in FDC, (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg & Tadalafil 40 mg), Under Fasting- Part 1|Cmax of Ambrisentan and Tadalafil in FDC (Ambrisentan 10 mg + Tadalafil 40 mg) and Montherapies (Ambrisentan 10 mg & Tadalafil 40 mg) - Part 2|AUC (0 - Inf) for FDC, (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg & Tadalafil 40 mg), Under Fasting- Part 2|AUC (0-t) for FDC, (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg & Tadalafil 40 mg), Under Fasting- Part 2|Cmax for Ambrisentan and Tadalafil, Following Candidate FDC (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg & Tadalafil 40 mg), Under Fed and Fasted Conditions-Part 3A|AUC (0-inf) for Ambrisentan and Tadalafil, Following Candidate FDC (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg & Tadalafil 40 mg), Under Fed and Fasted Conditions-3A|AUC (0-t) for Ambrisentan and Tadalafil, Following Candidate FDC (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg & Tadalafil 40 mg), Under Fed and Fasted Conditions-Part 3A|Cmax for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg & Tadalafil 40 mg) Under Fasted Conditions-3B|AUC (0-inf) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg & Tadalafil 40 mg) Under Fasted Conditions-3B|AUC (0-t) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg & Tadalafil 40 mg) Under Fasted Conditions-3B|Cmax for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 20 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg & Tadalafil 20 mg) Under Fasted Conditions-3B|AUC (0-inf) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 20 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg & Tadalafil 20 mg) Under Fasted Conditions-3B|AUC (0-t) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 20 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg & Tadalafil 20 mg) Under Fasted Conditions- Part 3B|Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 1|Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 2|Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 3A|Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 3B|Plasma Half Life (t1/2) for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part1|Plasma t1/2 for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part 2|Plasma t1/2 for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part 3A|Plasma t1/2 for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part 3B|Change From Baseline in Vital- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), Part 1|Change From Baseline in Vital Signs-Heart Rate, Part 1|Change From Baseline in Vital- Temperature, Part 1|Change From Baseline in Vital Signs-Respiratory Rate, Part 1|Change From Baseline in Vital- SBP and DBP, Part 2|Change From Baseline in Vital Signs-Heart Rate, Part 2|Change From Baseline in Vital- Temperature, Part 2|Change From Baseline in Vital Signs-Respiratory Rate, Part 2|Change From Baseline in Vital- SBP and DBP, Part 3A|Change From Baseline in Vital Signs-Heart Rate, Part 3A|Change From Baseline in Vital- Temperature, Part 3A|Change From Baseline in Vital Signs-Respiratory Rate, Part 3A|Change From Baseline in Vital- SBP and DBP, Part 3B|Change From Baseline in Vital Signs-Heart Rate, Part 3B|Change From Baseline in Vital- Temperature, Part 3B|Change From Baseline in Vital Signs-Respiratory Rate, Part 3-B|Number of Participants With Abnormal Electrocardiogram (ECG) Findings, -Part 1|Number of Participants With Abnormal ECG Findings, -Part 2|Number of Participants With Abnormal ECG Findings, -Part 3A|Number of Participants With Abnormal ECG Findings, -Part 3B|Number of Participants With Hematology Values of Potential Clinical Importance (PCI)- Part1|Number of Participants With Hematology Values of PCI - Part 2|Number of Participants With Hematology Values of PCI - Part 3A|Number of Participants With Hematology Values of PCI - Part 3B|Number of Participants With Clinical Chemistry Values of PCI- Part1|Number of Participants With Clinical Chemistry Values of PCI- Part 2|Number of Participants With Clinical Chemistry Values of PCI- Part 3A|Number of Participants With Clinical Chemistry Values of PCI- Part 3B|Number of Participants With Abnormal Urinalysis Results by Dipstick Method-Part 1|Number of Participants With Urinalysis Results by Dipstick Analysis-Part 2|Number of Participants With Urinalysis Results by Dipstick Analysis-Part 3A|Number of Participants With Urinalysis Results by Dipstick Analysis-Part 3B|Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs)-Part 1|Number of Participants With SAEs and AEs-Part 2|Number of Participants With SAEs and AEs-Part 3A|Number of Participants With SAEs and AEs-Part 3B","GlaxoSmithKline|Covance Harrogate|Hammersmith Medicines Research","All","18 Years to 60 Years   (Adult)","Phase 1","112","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201964","March 18, 2016","August 4, 2017","August 4, 2017","February 23, 2016","January 22, 2019","January 22, 2019","GSK Investigational Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02688387/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02688387/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02688387"
530,"NCT02688218","Exercise Detection Study",,"Completed","Has Results","Type 1 Diabetes","Behavioral: Aerobic Exercise|Behavioral: Resistance Exercise","Mean Change in Sensor Glucose in Subjects With Type 1 Diabetes","Oregon Health and Science University","All","21 Years to 45 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15452","February 2016","February 2, 2018","February 2, 2018","February 23, 2016","July 29, 2019","July 29, 2019","Oregon Health and Science University, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02688218/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02688218"
531,"NCT02687919","Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis",,"Completed","Has Results","Multiple Sclerosis, Relapsing-remitting","Other: Modified Paleo diet","Change in Fatigue Severity Scale (FSS)-9 Score|Change in Paced Auditory Serial Addition Test (PASAT) Score|Change in 6-minute Walk (6-MW) Distance|Change in (25-FW) 25-ft Walk Time|Quality of Life (MSQOL-54)|Quality of Life (Vitamin B-1 Blood Serum Measures)|Quality of Life (Vitamin B-9 Blood Serum Measures)|Quality of Life (Vitamins B-12 and K Blood Serum Measures)|Quality of Life (Homocysteine Blood Serum Measures)|Quality of Life (C-reactive Protein Blood Serum Measures)|Quality of Life (9-HPT)|Quality of Life (VSAQ)","Amanda Irish|University of Iowa","All","18 Years to 45 Years   (Adult)","Not Applicable","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201208703","October 2012","September 2014","October 2014","February 22, 2016","August 12, 2019","August 12, 2019","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT02687919"
532,"NCT02685488","Investigating Transcranial Ultrasound as a Potential Intervention for Depression",,"Completed","Has Results","Depression|Anxiety Disorders","Device: Transcranial Ultrasound Power|Device: Transcranial Ultrasound Sham","Depressive Symptoms Assessed With the Beck Depression Inventory-II|Rumination Symptoms Assessed With the Ruminative Responses Scale|Worry Symptoms Assessed With the Penn State Worry Questionnaire|Anxiety Symptoms Assessed With the Overall Anxiety Severity and Impairment Scale","University of Arizona","All","18 Years to 35 Years   (Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RSRCH--‐703FY'15","October 2015","April 2016","May 2016","February 18, 2016","January 8, 2018","January 8, 2018",,,"https://ClinicalTrials.gov/show/NCT02685488"
533,"NCT02685202","Temporomandibular Disorder (TMD) Pain in Response to Jaw Advancement in People With TMD and Obstructive Sleep Apnea",,"Terminated","Has Results","Myalgia|Apnea, Obstructive Sleep","Device: Mandibular advancement splint","Change in the Weekly Mean Pain Index Score|Change in the Apnea Hypopnea Index (AHI)|Change in the Epworth Sleepiness Scale (ESS) Score","University of North Carolina, Chapel Hill","All","30 Years to 64 Years   (Adult)","Not Applicable","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-4598","March 2016","March 2017","March 2017","February 18, 2016","November 14, 2017","November 14, 2017",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02685202/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02685202"
534,"NCT02685072","Progesterone Augmentation of Nicotine Replacement Therapy Study","PANS","Completed","Has Results","Smoking Cessation","Drug: Progesterone (200 mgs BID)|Drug: Placebo","7-day Point Prevalence of Smoking Abstinence|Carbon Monoxide <10 Ppm|Change in Stroop Measure of Inhibitory Function|Change in Go/No Go Task Measure of Inhibitory Function|Change in Digit Symbol Task Measure of Inhibitory Function|Positive and Negative Affect Schedule (PANAS) Total Score|Prolonged Abstinence Post Trial|Prolonged Abstinence Follow up","Yale University|National Cancer Institute (NCI)","Female","18 Years to 45 Years   (Adult)","Phase 4","64","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1504015618|R21CA198187","April 7, 2016","December 18, 2017","March 12, 2018","February 18, 2016","July 23, 2019","July 23, 2019","Yale School of Medicine, Department of Psychiatry, New Haven, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT02685072/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02685072"
535,"NCT02684396","Phase 1, TAK-648, Single-Rising Dose Study",,"Completed","Has Results","Healthy Volunteers","Drug: TAK-648|Drug: TAK-648 Placebo","Percentage of Participants Who Have at Least One Treatment-Emergent Adverse Event (TEAE)|Percentage of Participants Who Meet the Markedly Abnormal Criteria, for Safety Laboratory Tests at Least Once Post-dose|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Signs Measurements at Least Once Post-dose|Percentage of Participants With at Least One Occurrence of Severe Hypoglycemia Post-dose|Cmax: Maximum Observed Plasma Concentration for TAK-648|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-648|AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-648|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-648","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-648_101|U1111-1154-2329","August 2014","April 2015","July 2015","February 18, 2016","July 13, 2016","July 13, 2016",,,"https://ClinicalTrials.gov/show/NCT02684396"
536,"NCT02679729","To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration",,"Completed","Has Results","Cystic Fibrosis","Drug: AZD5634 for inhalation|Drug: AZD5634 for infusion|Other: Placebo","Safety and Tolerability of AZD5634 Following Inhaled Administration of Single-ascending Doses (SAD) (Part A) and Following Administration of Single Inhaled and IV Doses (Part B).|Observed Maximum Plasma Concentration, Taken Directly From the Individual Concentration-time Curve (Cmax)- For Part A and Part B|Area Under Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) for Part A and Part B|Area Under the Plasma Concentration-curve From Time Zero to Time of Last Quantifiable Concentration [AUC(0-t)] for Part A and Part B|Absolute Systemic Bioavailability After Inhalation (Part B Only) (Finhalation,Total)|Renal Clearance (CLR), Estimated by Dividing Ae(0-last) by AUC0-t - For Part A and Part B|Cmax, Divided by the Dose Aministered (Cmax/Dose) - For Part A and Part B|Terminal Half-life (t1/2λz), Estimated as (ln2)/λz - For Part A and Part B|AUC0-t, Divided by the Dose Administered (AUC0-t/Dose) - For Part A and Part B|AUC, Divided by the Dose Administered (AUC/Dose) - For Part A and Part B|Systemic Clearance for AZD5634 Estimated as Dose Divided by AUC (Part B IV Dosing Only) (CL)|Apparent Clearance for AZD5634 Estimated as Dose Divided by AUC (Part A and Part B Inhaled Dosing Only) (CL/F)|Mean Residence Time (MRT) - For Part A and Part B|Mean Absorption Time, Calculated as MRTinhaled - MRTIV (Part B Only) (MAT)|Volume of Distribution for AZD5634 at Steady State (IV Administration), Estimated by Dividing the MRT by the Systemic CL (Part B IV Dosing Only) (Vss)|Volume of Distribution for AZD5634 at Terminal Phase (IV Administration), Estimated by Dividing the Systemic CL by λz (Part B IV Dosing Only) (Vz)|Apparent Volume of Distribution for AZD5634 at Terminal Phase (Inhaled Administration), Estimated by Dividing the CL/F by λz (Part A and Part B Inhaled Dosing Only) (Vz/F)","AstraZeneca","All","18 Years to 50 Years   (Adult)","Phase 1","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","D6600C00001","February 11, 2016","October 24, 2016","October 24, 2016","February 10, 2016","November 5, 2018","November 5, 2018","Research Site, Glendale, California, United States|Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02679729"
537,"NCT02679469","A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects",,"Completed","Has Results","Alcohol Dependence","Drug: nalmefene hydrochloride 10 mg","Measure the Maximum (Peak) Plasma Concentration of the Drug (Cmax)|Measure the Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at Time t(AUCt)|Measure the Terminal-phase Elimination Half-life (T1/2)","Otsuka Pharmaceutical Co., Ltd.|H. Lundbeck A/S","Male","20 Years to 45 Years   (Adult)","Phase 1","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","339-102-00003","February 2016","March 2016","March 2016","February 10, 2016","April 18, 2017","April 18, 2017","Kyusyu, Region, Japan",,"https://ClinicalTrials.gov/show/NCT02679469"
538,"NCT02678416","Reduction in Pain Intensity Following IV or Oral Pain-relieving Products",,"Completed","Has Results","Pain","Drug: IV Acetaminophen (Treatment A)|Drug: Oral Acetaminophen (Treatment B)|Drug: Placebo (Treatment C)|Other: Morphine (Treatment D)","Part 1: Change From Baseline in Pain Intensity at Hour 6 Using the Thermal Suprathreshold Pain in the Ultraviolet-B (UVB) Burn Pain Model|Part 2: Observed Thermal Suprathreshold Pain Intensity in the UVB Burn Area","Mallinckrodt","Male","18 Years to 55 Years   (Adult)","Phase 4","79","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","MNK14504055","December 7, 2015","June 13, 2016","June 13, 2016","February 9, 2016","December 20, 2019","December 20, 2019","Pharmaceuticals Research Associates, Inc. (PRA), Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02678416"
539,"NCT02677740","Mechanisms of Non-Invasive Neuromodulation Interventions: Influence on Human Neurochemistry and Functional Connectivity",,"Completed","Has Results","Non-invasive Neuromodulation in Healthy Subjects","Device: Inhibitory rTMS (1 Hz)|Device: Excitatory rTMS (5 Hz)","Percent Change of GABA Concentration in a Voxel Encompassing the Left Motor Cortex, Measured at 30 Min After rTMS|Percent Change of GABA Concentration in a Voxel Encompassing the Right Motor Cortex, Measured at 60 Min After rTMS|Percent Change of Functional Connectivity in Left Motor Cortex, Where Functional Connectivity is Measured as a Dimensionless Fractional Amplitude of Low-frequency Fluctuations (fALFF), at 80 Min After rTMS|Percent Change of Functional Connectivity in Right Motor Cortex, Where Functional Connectivity is Measured as a Dimensionless Fractional Amplitude of Low-frequency Fluctuations (fALFF), at 80 Min After rTMS","University of Minnesota","Male","21 Years to 40 Years   (Adult)","Not Applicable","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","1601M83405","August 29, 2016","March 19, 2017","March 19, 2017","February 9, 2016","August 6, 2019","November 18, 2019","Center for Magnetic Resonance Research, Dept. of Radiology, University of Minnesota, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02677740/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02677740"
540,"NCT02676895","A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults",,"Completed","Has Results","Shigella Sonnei Infection","Biological: GVGH S. sonnei (1790GAHB) vaccine 25 μg|Biological: GVGH S. sonnei (1790GAHB) vaccine 100 μg|Biological: Menveo|Biological: Boostrix","Number of Subjects With Solicited Local and Systemic Adverse Reactions After Each Vaccination|Number of Subjects With Any Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs)|Number of Subjects With Deviations From Normal Ranges of Safety Laboratory Data at Day 8 by Baseline Ranges|Number of Subjects With Deviations From Normal Ranges of Safety Laboratory Data at Day 29 by Baseline Ranges|Number of Subjects With Deviations From Normal Ranges of Safety Laboratory Data at Day 36 by Baseline Ranges|Number of Subjects With Deviations From Normal Ranges of Safety Laboratory Data at Day 57 by Baseline Ranges|Number of Subjects With Reported Reactive Arthritis or Neutropenia (AESIs)|Anti-LPS S.Sonnei IgG ELISA Geometric Mean Concentrations (GMCs), by Baseline Titer|Anti-LPS S. Sonnei Geometric Mean Ratios (GMRs) Between Post- and Pre-vaccination Samples|Number of Subjects With Seroresponse to Anti-LPS S. Sonnei IgG ELISA, by Baseline Titer|Number of Subjects With Titers Post Vaccination Concentration for Anti-LPS S. Sonnei ≥ 121 U/mL","GlaxoSmithKline","All","18 Years to 45 Years   (Adult)","Phase 2","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","205494|H03_04TP","August 8, 2016","March 10, 2017","March 10, 2017","February 8, 2016","February 18, 2019","February 18, 2019","GSK Investigational Site, Kilifi, Kenya","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02676895/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02676895/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02676895"
541,"NCT02673138","Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion",,"Completed","Has Results","Type 1 Diabetes","Drug: canagliflozin|Other: basal interruption without canagliflozin","Differences in Plasma Glucose Levels Following the Interruption of Basal Subcutaneous Infusion of Insulin|Differences in BHB (Beta-hydroxybutyrate) Levels Following Interruption of Basal|Differences in Free Fatty Acid Levels Following Interruption of Basal Subcutaneous Insulin Infusion|Differences in Glucagon Levels Following the Interruption of the Basal Subcutaneous Insulin Infusion","Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 45 Years   (Adult)","Not Applicable","10","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1508016333|1K12DK094714-01","January 2016","January 2017","July 2017","February 3, 2016","November 29, 2018","November 29, 2018","Yale University School of Medicine, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02673138"
542,"NCT02671760","Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia",,"Completed","Has Results","Short-term Insomnia","Drug: SM-1|Drug: Comparator|Drug: Placebo","Total Sleep Time|Latency to Persistent Sleep|Awakenings|Latency to REM Sleep Onset|Adverse Events|Safety and Tolerability in Terms of Residual Sleepiness","Sequential Medicine Ltd|Clinilabs, Inc.","All","25 Years to 64 Years   (Adult)","Phase 2","39","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SM-A-02","February 2016","June 2016","June 2016","February 2, 2016","March 6, 2018","March 6, 2018",,,"https://ClinicalTrials.gov/show/NCT02671760"
543,"NCT02670811","Antihypertensive Effect of Fermented Milk With Lactococcus Lactis on Prehypertensive Subjects",,"Completed","Has Results","Hypertension","Dietary Supplement: Fermented milk|Dietary Supplement: Acidified milk","Systolic Blood Pressure Measurements|Diastolic Blood Pressure Measurements|Total Cholesterol Measurements|Low Density Lipoproteins Measurements|High Density Lipoproteins|Triglycerides Measurements","Centro de Investigación en Alimentación y Desarrollo A.C.","All","25 Years to 55 Years   (Adult)","Phase 1","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VAGB 001","August 2013","December 2013","December 2013","February 2, 2016","October 11, 2016","October 18, 2019",,,"https://ClinicalTrials.gov/show/NCT02670811"
544,"NCT02670473","Clinical Performance of Existing Wearers of Enfilcon A Following a Refit With Fanfilcon A Lenses for 4 Weeks",,"Completed","Has Results","Myopia","Device: fanfilcon A (test)","Lens Fit - Centration|Lens Fit - Post-blink Movement|Lens Tightness on Push-up|Overall Fit Acceptance|Overall Comfort|Dryness Overall|Handling|Overall Vision Satisfaction|Overall Satisfaction|Lens Preference Overall|Wearing Times|Conjunctival Staining|Corneal Staining","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","EX-MKTG-55 (CV-15-09)","January 2016","March 2016","May 2016","February 1, 2016","March 21, 2017","February 5, 2018","Optometry Research Group (GIO) Optics Department, University of Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02670473"
545,"NCT02669667","Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects",,"Completed","Has Results","Safety|Healthy Subjects","Drug: MEDI9314|Drug: placebo","Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)|Number of Participants With Electrocardiogram Abnormalities Reported as TEAEs|Number of Participants With Vital Signs Abnormalities Reported as TEAEs|Number of Participants With Physical Examination Abnormalities Reported as TEAEs|Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs|Number of Participants With TEAEs Related to Injection Site Reactions|Area Under the Serum Drug Concentration Versus Time Curves From Zero to Infinity (AUC 0-inf) of MEDI9314|Area Under the Serum Drug Concentration Versus Time Curve, to Last Quantifiable Time Point (AUClast)|Maximum Observed Serum Drug Concentration (Cmax) of MEDI9314|Time to Maximum Observed Serum Drug Concentration (Tmax) of MEDI9314|Terminal Phase Elimination Half-life (t1/2) of MEDI9314|Serum Concentrations of MEDI9314|Number of Participants Positive for Anti-Drug Antibodies to MEDI9314","MedImmune LLC","All","18 Years to 50 Years   (Adult)","Phase 1","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","D4361C00002","February 18, 2016","November 17, 2016","June 12, 2017","February 1, 2016","May 15, 2019","June 4, 2019","Research Site, Glendale, California, United States|Research Site, Harrow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02669667"
546,"NCT02669095","Clinical Evaluation of Approved and Investigational Contact Lenses",,"Completed","Has Results","Visual Disorder","Device: Investigational Contact Lenses (Test)|Device: Marketed Contact Lenses (Control)","Acceptable Lens Fitting|Overall Comfort","Johnson & Johnson Vision Care, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR-5796","January 2016","March 2016","March 2016","January 29, 2016","June 9, 2017","June 9, 2017","Golden Family Eyecare, Sarasota, Florida, United States|Eye Associates of Winter Park, Winter Park, Florida, United States|Pickens Family Eye Care, Pickens, South Carolina, United States|Total Eye Care PA, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02669095"
547,"NCT02669082","The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy",,"Completed","Has Results","Insomnia|Major Depressive Disorder","Drug: Ramelteon","Change From Baseline in Actigraphy-Measured Sleep Latency at the End of the Treatment Period|Change From Baseline in Diary-Measured Sleep Latency at the End of the Treatment Period|Change From Baseline in Actigraphy-Measured Total Nocturnal Sleep Time at the End of the Treatment Period|Change From Baseline in Actigraphy-Measured Nocturnal Wake Time at the End of the Treatment Period|Change From Baseline in Actigraphy-Measured Number of Nocturnal Awakenings at the End of the Treatment Period|Change From Baseline in Actigraphy-Measured Sleep Efficiency at the End of the Treatment Period|Change From Baseline in Diary-Measured Total Nocturnal Sleep Time at the End of the Treatment Period|Change From Baseline in Diary-Measured Number of Nocturnal Awakenings at the End of the Treatment Period|Change From Baseline in Actigraphy-Measured Daytime Activity Level, as Evaluated by the Number of Footsteps, at the End of the Treatment Period","Takeda","All","20 Years to 64 Years   (Adult)","Phase 4","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ramelteon-4002|JapicCTI-163143|U1111-1177-4116","May 9, 2017","January 31, 2018","January 31, 2018","January 29, 2016","July 22, 2019","July 22, 2019","You Ariyoshi Sleep Clinic, Kitakyushu, Fukuoka, Japan|Ishikawa Mental Clinic, Sapporo, Hokkaido, Japan|Minami 1jo Mental Clinic, Sapporo, Hokkaido, Japan|Senzoku Psychosomatic Clinic, Meguro, Tokyo, Japan|Sangenjaya Neurology and Psychosomatic Clinic, Setagaya, Tokyo, Japan|Himorogi Kokorono Clinic, Shinjuku, Tokyo, Japan|Seiwa Hospital, Shinjuku, Tokyo, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02669082/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02669082/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02669082"
548,"NCT02669043","Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects",,"Terminated","Has Results","Depression","Drug: Ketamine","Hamilton Depression Rating Scale (HDRS, HAM-D)","Massachusetts General Hospital|National Institute of Mental Health (NIMH)","All","18 Years to 64 Years   (Adult)","Not Applicable","8","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2015P002397|K23MH107776","July 2016","February 2017","February 2017","January 29, 2016","February 28, 2017","April 23, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02669043/Prot_SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02669043/ICF_003.pdf","https://ClinicalTrials.gov/show/NCT02669043"
549,"NCT02667704","Influence of Bosentan on the Pharmacokinetics of Nintedanib",,"Completed","Has Results","Healthy","Drug: Bosentan|Drug: Nintedanib","Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Concentration (AUC0-tz)|Maximum Measured Concentration of Nintedanib in Plasma (Cmax)|Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity)","Boehringer Ingelheim","Male","18 Years to 55 Years   (Adult)","Phase 1","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1199.239|2015-003819-38","February 2016","March 2016","March 2016","January 29, 2016","April 13, 2017","April 13, 2017","Boehringer Ingelheim Investigational Site, Biberach, Germany",,"https://ClinicalTrials.gov/show/NCT02667704"
550,"NCT02667639","Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects",,"Completed","Has Results","Healthy","Biological: RPH-104|Other: Sodium chloride Sterile Injection 0.9% w/v","Adverse Events|Serious Adverse Events|Respiratory Rate|Blood Pressure|Oxygen Saturation|Body Temperature|Clinical Laboratory Tests|RPH-104 - Area Under the Curve (AUC)|RPH-104 - Time to Maximum Concentration (Tmax)|RPH-104 - Elimination Half-life (t1/2)|RPH-104 - Maximum Plasma Concentration (Cmax)","TRPHARM|MonitorCRO","All","18 Years to 35 Years   (Adult)","Phase 1","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","RPH104FIH01","January 2016","June 2017","June 2017","January 29, 2016","October 4, 2019","October 4, 2019","ARGEFAR, Izmir, Turkey","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02667639/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02667639"
551,"NCT02664415","Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection",,"Completed","Has Results","HIV Infections","Biological: VRC01|Biological: Placebo for VRC01","Number of Participants With Serious Adverse Event|Number of Participants With Sustained Virologic Suppression|Time to Viral Rebound After Cessation of ART|Level of Rebound Viremia After Cessation of ART|Time to ART Resumption for Any Reason After Cessation of ART|Number of Participants With Detectable HIV-1 RNA Via Single Copy Assay|Change in CD4+ T Cell Count From ATI to ART Resumption|Total HIV DNA in the Peripheral Compartment|Number of Participants Hospitalized.|Number of Participants With Acute Retroviral Syndrome (ARS)|Neuropsychological Battery Performance|Computed Score on the Control and Attention Task (i.e., Flanker Task)","National Institute of Allergy and Infectious Diseases (NIAID)","All","20 Years to 50 Years   (Adult)","Phase 2","23","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RV 397|12001","August 2016","August 4, 2017","August 4, 2017","January 27, 2016","October 17, 2018","October 30, 2019","SEARCH Thai Red Cross AIDS Research Centre Non-Network CRS, Bangkok, Thailand","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02664415/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02664415/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02664415"
552,"NCT02663687","Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects",,"Completed","Has Results","Hereditary Angioedema (HAE)","Drug: Recombinant human C1 esterase inhibitor|Drug: Placebo|Drug: SHP623","Number of Participants With Treatment-emergent Adverse Events (TEAEs ) Including Serious Adverse Events (SAEs)|Maximum Observed Plasma Concentration (Cmax) of SHP623 Occurring at Time of Maximum Observed Concentration During a Dosing Interval (Tmax)|Time of Maximum Plasma Concentration (Tmax) of SHP623 Sampled During a Dosing Interval|Terminal Half-life (t1/2) of SHP623|Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC 0-inf) of SHP623|Area Under the Plasma Concentration Curve From Time Zero to 168 Hours Postdose (AUC 0-168) of SHP623|Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of SHP623|Total Body Clearance (CL) for Intravascular (IV) Administration of SHP623|Volume of Distribution Associated With the Terminal Slope (Vz) Following Intravenous (IV) Administration of SHP623|Total Body Clearance for Extravascular Administration (CL/F) of SHP623 for Subcutaneous (SC) Administration|Volume of Distribution Influenced by Fraction of Dose Absorbed (Vz/F) Following Extravascular Administration of SHP623","Shire","All","18 Years to 50 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SHP623-100","February 19, 2016","December 5, 2016","December 5, 2016","January 26, 2016","September 6, 2018","September 6, 2018","Clinical Pharmacology of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02663687"
553,"NCT02661594","Thorough QT Study of Intravenous Amisulpride",,"Completed","Has Results","Healthy","Drug: APD421 5 mg|Drug: APD421 40 mg|Drug: Moxifloxacin|Drug: Placebo","Maximal Mean ΔΔQTcF","Acacia Pharma Ltd","All","20 Years to 45 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","DP10013","November 2013","March 2014","March 2014","January 22, 2016","November 30, 2017","November 29, 2018",,,"https://ClinicalTrials.gov/show/NCT02661594"
554,"NCT02660918","Decreasing Postoperative Pain Following Endometrial Ablation",,"Completed","Has Results","Postoperative Pain","Drug: Bupivacaine|Other: Normal Saline","Postoperative Pain Score|Intraoperative Total Blood Loss|Remaining Tylenol Tablets With Codeine Not Taken at the End of Day 1 Following Discharge|Occurrence of Intraoperative Complication|Postoperative Complication|Postoperative Opioid Administered Following the Procedure But Prior to Discharge.|Postoperative Toradol|Postoperative Anti-emetic|Time Between Recovery Initiation and Discharge","Christiana Care Health Services","Female","30 Years to 55 Years   (Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","35179","April 2016","March 2017","March 2017","January 21, 2016","August 28, 2019","August 28, 2019","Christiana Care Health System, Newark, Delaware, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02660918/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02660918/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02660918"
555,"NCT02660801","Spinal Manipulation and Spinal Mobilization Effects in Participants With and Without Back Pain",,"Terminated","Has Results","Back Pain","Procedure: Spinal manipulation|Procedure: Spinal mobilization","Global Spinal Stiffness|Terminal Spinal Stiffness|Pressure Provoked Pain|Muscular Response, Superior Level Ratio|Muscular Response, Inferior Level Ratio, Normalized RMS","Université du Québec à Trois-Rivières|Canadian Institutes of Health Research (CIHR)|Fonds de la Recherche en Santé du Québec|Unité de recherche en santé musculosqulettique","All","18 Years to 60 Years   (Adult)","Not Applicable","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UQTR-2016-STIF","March 2016","April 2017","November 2017","January 21, 2016","June 21, 2019","June 26, 2019","Université du Québec à Trois-Rivières, Trois-Rivieres, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02660801/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02660801"
556,"NCT02660242","The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: G-Pen Mini™ (glucagon injection)|Other: Glucose Tabs|Other: Basal Insulin Reduction","Glycemic Response During Exercise and Early Recovery|Number of Participants With Hypoglycemia (<70 mg/dL) During Exercise and Early Recovery|Number of Participants With Hyperglycemia (≥250 mg/dL) During Exercise and Early Recovery|Continuous Glucose Monitor (CGM) Metrics During Late Recovery - Nadir Glucose|CGM Metrics During Late Recovery - Peak Glucose|CGM Metrics During Late Recovery - Mean Glucose|CGM Metrics During Late Recovery - Coefficient of Variation|CGM Metrics During Late Recovery - Time < 54 mg/dL|CGM Metrics During Late Recovery - Time < 70 mg/dL|CGM Metrics During Late Recovery - Time in Range (70-180 mg/dL)|CGM Metrics During Late Recovery - Time > 180 mg/dL|CGM Metrics During Late Recovery - Time > 250 mg/dL","Jaeb Center for Health Research|Xeris Pharmaceuticals","All","18 Years to 64 Years   (Adult)","Phase 2","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","T1DX Mini-dose Exercise","January 2016","February 15, 2017","February 15, 2017","January 21, 2016","August 7, 2018","August 7, 2018","Joslin Diabetes Center, Boston, Massachusetts, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02660242/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02660242/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02660242"
557,"NCT02659787","Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology","BED","Completed","Has Results","Depression","Drug: 0.2mg Buprenorphine|Drug: Placebo","Subjective Effects as Assessed by Score on ""Feel Drug"", ""Feel High"", ""Like Drug"", and ""Want More"" Subscales of the Drug Effects Questionnaire Subjective Response With and Without Buprenorphine","University of Chicago","All","18 Years to 35 Years   (Adult)","Not Applicable","38","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","14-0170","June 2016","April 2017","April 2017","January 20, 2016","May 29, 2019","May 29, 2019","University of Chicago, Chicago, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02659787/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02659787"
558,"NCT02656485","A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris",,"Completed","Has Results","Acne Vulgaris","Drug: B244|Drug: Placebo","Safety (Number of Participants With Treatment Related Adverse Events)|Efficacy","AOBiome LLC","All","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AVB244-001","August 5, 2015","March 1, 2016","July 15, 2016","January 15, 2016","April 5, 2017","April 5, 2017","Stephens Associates, Richardson, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02656485"
559,"NCT02653872","A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects",,"Completed","Has Results","Healthy Subjects","Drug: AZD7986|Drug: Verapamil|Drug: Itraconazole|Drug: Diltiazem","Effect of Verapamil and the Effect of Itraconazole on the PK of AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax).|Effect of Verapamil and the Effect of Itraconazole on the PK of AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC).|Pharmacokinetics (PK) of AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC [0-t]).|Pharmacokinetics (PK) of AZD7986 by Assessment of Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz).|Pharmacokinetics (PK) of AZD7986 by Assessment of the Time to Reach Maximum Plasma Concentration (Tmax)|Pharmacokinetics (PK) of AZD7986 by Assessment of the Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC (CL/F).|Pharmacokinetics (PK) of AZD7986 by Assessment of the Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F).|Assessment of the Area Under the Plasma Concentration-curve Over the Dosing Interval (AUC [0 - τ]) of Verapamil, Itraconazole and OH-itraconazole Following Co-administration of AZD7986 With Verapamil or Itraconazole.|Assessment of the Tmax of Verapamil, Itraconazole and OH-itraconazole Following Co-administration of AZD7986 With Verapamil or Itraconazole.","AstraZeneca","All","18 Years to 55 Years   (Adult)","Phase 1","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D6190C00003","January 22, 2016","April 13, 2016","April 13, 2016","January 12, 2016","February 23, 2018","February 23, 2018","Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02653872"
560,"NCT02652416","Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers",,"Completed","Has Results","Healthy","Drug: BI 1026706|Drug: Placebo","Percentage of Subjects With Drug-related Adverse Events (AEs)|Cmax|Tmax|AUC0-12|AUC0-infinity|t1/2|Cmax,ss|Tmax,ss|AUC Tau,ss","Boehringer Ingelheim","Male","20 Years to 45 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1320.23","September 16, 2016","December 9, 2016","December 9, 2016","January 11, 2016","July 11, 2019","July 11, 2019","Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan",,"https://ClinicalTrials.gov/show/NCT02652416"
561,"NCT02651688","A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene",,"Completed","Has Results","Acquired Hypogonadotropic Hypogonadism|Obesity","Drug: Placebo|Drug: Enclomiphene","Change From Baseline in Lean Body Mass (LBM) at Week 48|Change From Baseline in Body Strength (Chest Press Weight) at Week 48|Change From Baseline in Body Strength (Leg Press Weight) at Week 48|Change From Baseline in Blood Luteinizing Hormone (LH) Level at Week 48|Change From Baseline in Blood Testosterone (T) Level at Week 48|Change From Baseline in Blood Dihydrotestosterone (DHT) Level at Week 48|Change From Baseline in Blood Estradiol (E2) Level at Week 48|Change From Baseline in Ratio of Testosterone: Estradiol (T:E2) at Week 48|Change From Baseline in Ratio of Dihydrotestosterone: Testosterone (DHT:T) at Week 48|Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 48|Change From Baseline in Blood Glucose Level at Week 48|Change From Baseline in Blood C-reactive Protein (CRP) Level at Week 48|Change From Baseline in Blood Interleukin-6 (IL-6) Level at Week 48|Change From Baseline in Blood Tumor Necrosis Factor Alpha (TNF-α) Level at Week 48|Change From Baseline in Blood Leptin Level at Week 48|Change From Baseline in Homeostatic Model of Assessment - Insulin Resistance (HOMA-IR) at Week 48|Change From Baseline in Blood Quantose-Insulin Resistance (IR) Score at Week 48|Change From Baseline in Body Mass Index (BMI) at Week 48|Change From Baseline in Waist Circumference at Week 48|Change From Baseline in Weight at Week 48","Repros Therapeutics Inc.","Male","18 Years to 60 Years   (Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ZA-205","January 11, 2016","May 2, 2017","May 2, 2017","January 11, 2016","June 14, 2019","June 27, 2019","Albany, New York, United States|Garden City, New York, United States|Providence, Rhode Island, United States|Riverton, Utah, United States|Norfolk, Virginia, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02651688/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02651688/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02651688"
562,"NCT02648438","A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects",,"Completed","Has Results","Asthma|Chronic Obstructive Pulmonary Disease (COPD)","Drug: AZD7594 Solution for infusion (150 μg intravenous formulation)|Drug: AZD7594 Oral suspension (1200 μg oral formulation)|Drug: AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)|Drug: AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)|Drug: AZD7594 Pressurized inhalation suspension (400 μg) by pMDI","Pharmacokinetics (PK) of AZD7594 Delivered by Monodose Inhaler and Multiple-dose DPI or pMDI in Terms of Pulmonary Bioavailability After Inhalation (Fpulmonary)|PK of AZD7594 Following Oral Administration by Assessment of the Absolute Systemic Bioavailability After Oral Administration (Fpo)|Observed Maximum Plasma Concentration (Cmax)|Area Under the Plasma Concentration-curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t)|Absolute Systemic Bioavailability After Inhalation (F Inhalation, Total)|Oral Bioavailability After Inhaled Treatment (F Oral)|Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC)","AstraZeneca","Male","18 Years to 45 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D3741C00004","January 12, 2016","June 1, 2016","June 1, 2016","January 7, 2016","June 15, 2017","June 15, 2017","Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02648438"
563,"NCT02647281","First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects",,"Completed","Has Results","Hepatitis B","Drug: GSK3389404|Drug: Matching Placebo","Number of Participants With Any Non-serious Adverse Event (AE); Any Serious AE (SAE); Any AEs Leading to Discontinuation of Study Treatment (AELD) in Part 1|Number of Participants With Any Non-serious AE; Any SAE; Any AELD in Part 2|Number of Participants With Laboratory Values of Potential Clinical Importance in Part 1|Number of Participants With Laboratory Values of Potential Clinical Importance in Part 2|Change From Baseline in Complement Factor Component 3 (C3) and C4 Levels in Part 1|Change From Baseline in Complement Split Product C5a Levels in Part 1|Change From Baseline in Complement Split Product Bb Levels in Part 1|Change From Baseline in Complement Factor C3 and C4 Levels in Part 2|Change From Baseline in Complement Factor C5a Levels in Part 2|Change From Baseline in Complement Factor Bb Levels in Part 2|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 1|Change From Baseline in Pulse Rate (PR) at the Indicated Time Points in Part 1|Change From Baseline in Respiratory Rate (RR) at the Indicated Time Points in Part 1|Change From Baseline in Body Temperature at the Indicated Time Points in Part 1|Change From Baseline in SBP and DBP at the Indicated Time Points in Part 2|Change From Baseline in PR at the Indicated Time Points in Part 2|Change From Baseline in RR at the Indicated Time Points in Part 2|Change From Baseline in Body Temperature at the Indicated Time Points in Part 2|Number of Participants With 12-lead Electrocardiogram (ECG) Findings in Part 1|Area Under the Plasma Concentration Curve (AUC) From Time Zero to Infinity [AUC (0-inf)], AUC From Time Zero to the Time of Last Quantifiable Concentration [AUC(0-t)], AUC From Time Zero to 24 Hours [AUC(0-24)] of GSK3389404 After Single Dose in Part 1|Maximum Observed Concentration (Cmax), Observed Concentration at 24 Hours (C24) and at 168 Hours (C168) of GSK3389404 Following Single Dose in Part 1|Time to Maximum Observed Concentration (Tmax), Terminal Half-life (T1/2) and Lag Time (Tlag) of GSK3389404 Following Single Dose in Part 1|Apparent SC Plasma Clearance (CL/F) of GSK3389404 Following Single Dose in Part 1|AUC (0-t), AUC(0-24), AUC From Time Zero to 168 Hours Post-dose [AUC(0-168)] and AUC (0-inf) of GSK3389404 Following Single Dose on Day 1 of Part 2|Cmax, C24 and C168 of GSK3389404 Following Single Dose on Day 1 of Part 2|Tmax, T1/2 and Tlag of GSK3389404 Following Single Dose on Day 1 of Part 2|CL/F of GSK3389404 Following Single Dose on Day 1 of Part 2|AUC(0-24) and AUC From Time Zero to the End of the Dosing Interval [AUC(0-tau)] of GSK3389404 Following Dosing on Day 22 of Part 2|Observed Concentration at the End of the Dosing Interval (Ctau), C24 and Cmax of GSK3389404 Following Dosing on Day 22 of Part 2|Tmax, T1/2 and Tlag of GSK3389404 Following Dosing on Day 22 of Part 2|Cl/F of GSK3389404 Following Dosing on Day 22 of Part 2|Dose Proportionality of GSK202007 for Dose Range 10 mg - 120 mg After Single Dose Administrations|Dose Proportionality of GSK202007 for Dose Range 30 mg - 120 mg After Multiple Dose Administrations|Accumulation Ratio by AUC (RAUC), by Cmax (RCmax), by C24 (RC24) and by Ctau (RCtau) of GSK3389404 in Part 2|Time Invariance (LI) of GSK3389404 in Part 2|Trough Plasma Concentrations of GSK3389404 in Part 2|AUC (0-inf), AUC(0-t), AUC(0-24) of the Metabolite of GSK3389404 After Single Dose in Part 1|Cmax, C24 and C168 of the Metabolite of GSK3389404 Following Single Dose in Part 1|Tmax, T1/2 and Tlag of the Metabolite of GSK3389404 Following Single Dose in Part 1|AUC (0-t), AUC(0-24), AUC(0-168) and AUC (0-inf) of the Metabolite of GSK3389404 Following Single Dose on Day 1 of Part 2|Cmax, C24 and C168 of the Metabolite of GSK3389404 Following Single Dose on Day 1 of Part 2|Tmax, T1/2 and Tlag of the Metabolite of GSK3389404 Following Single Dose on Day 1 of Part 2|AUC(0-24) and AUC(0-tau) of the Metabolite of GSK3389404 Following Dosing of GSK3389404 on Day 22 of Part 2|Ctau, C24 and Cmax of the Metabolite of GSK3389404 Following Dosing of GSK3389404 on Day 22 of Part 2|Tmax, T1/2 and Tlag of the Metabolite of GSK3389404 Following Dosing on Day 22 of Part 2","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","202007|2015-003781-84","December 17, 2015","January 3, 2017","January 3, 2017","January 6, 2016","August 1, 2018","July 16, 2019","GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02647281"
564,"NCT02646449","Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial","YAAD-P","Completed","Has Results","Major Depressive Disorder|Alcohol Use Disorder","Drug: Mirtazapine|Drug: Placebo","Drinks Per Drinking Day|Level of Depressive Symptoms","University of Pittsburgh","All","18 Years to 30 Years   (Adult)","Phase 2","11","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1R21AA022863-01A1","June 2015","December 2016","December 2016","January 5, 2016","April 27, 2017","April 27, 2017","Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02646449"
565,"NCT02645760","Effectiveness of Core Stabilization Exercise in Patients With Subacute Non-Specific Low Back Pain","CSENSLBP","Completed","Has Results","Low Back Pain","Other: Core stabilization exercise|Other: Conventional treatment","Change From Baseline in Pain on 11- Point Numerical Rating Scale at Week 7|Change From Baseline in Functional Disability on Roland-Morris Disability Questionnaire at Week 7|Change From Baseline in Back Range of Motion (Flexion) on Modified-modified Schober's Test at Week 7|Change From Baseline in Repositioning Error on Repositioning Test at Week 7","Khon Kaen University","All","18 Years to 60 Years   (Adult)","Not Applicable","38","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","KKU-571H106","October 2015","June 2016","June 2016","January 5, 2016","October 6, 2016","October 6, 2016","Faculty of Associated Medical Sciences, Khon Kaen University, Muang Khon Kaen, Khon Kaen, Thailand",,"https://ClinicalTrials.gov/show/NCT02645760"
566,"NCT02645253","A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men",,"Completed","Has Results","Asthma|Chronic Obstructive Pulmonary Disease COPD","Drug: AZD7594 inhalation powder (200 μg)|Drug: AZD7594 inhalation powder (400 μg)|Drug: AZD7594 pressurized inhalation suspension (200 μg)|Drug: AZD7594 placebo inhalation powder|Drug: AZD7594 placebo pressurized inhalation suspension","Safety and Tolerability of AZD7594 by Assessment of the Number of Participants With Adverse Events|Rate and Extent of Absorption of AZD7594 (Inhalation/ Administration Via DPI) by Assessment of the Observed Maximum Plasma Concentration (Cmax)|Rate and Extent of Absorption of AZD7594 (Inhalation/ Administration Via DPI) by Assessment of the Time to Reach Maximum Plasma Concentration (Tmax)|Rate and Extent of Absorption of AZD7594 (Inhalation/ Administration Via DPI) by Assessment of the Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of Last Quantifiable Analyte Concentration (AUC [0-last])|Rate and Extent of Absorption of AZD7594 (Inhalation/ Administration Via DPI) by Assessment of the AUC From Time Zero to 24 Hours After Dosing (AUC [0-24]).|Rate and Extent of Absorption of AZD7594 (Inhalation/ Administration Via DPI) by Assessment of the AUC From Time Zero Extrapolated to Infinity (AUC).|Rate and Extent of Absorption of AZD7594 by Assessment of the Terminal Elimination Rate Constant, Estimated by Log-linear Least Squares Regression of the Terminal Part of the Concentration-time Curve(Lamda z or λz).|Rate and Extent of Absorption of AZD7594 (Inhalation/ Administration Via DPI) by Assessment of the Half-life Associated With the Terminal Slope of a Semi-logarithmic Concentration-time Curve (t1/2λz).|Rate and Extent of Absorption of AZD7594 (Inhalation/ Administration Via DPI) by Assessment of the Mean Residence Time From Time Zero Extrapolated to Infinity (MRT).|Rate and Extent of Absorption of AZD7594 by Assessment of the Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC (AZD7594) (CL/F).|Rate and Extent of Absorption of AZD7594 by Assessment of the Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration, Estimated by Dividing CL/F by Lamda z (Vz/F)|Rate and Extent of Absorption of AZD7594 by Assessment of the Cmax Divided by the Dose Administered (Cmax/D).|Rate and Extent of Absorption of AZD7594 by Assessment of the AUC Divided by the Dose Administered (AUC/D).|Rate and Extent of Absorption of AZD7594 by Assessment of the AUC(0-24) Divided by the Dose Administered (AUC(0-24)/D)|Rate and Extent of Absorption of AZD7594 by Assessment of the Observed Minimum Plasma Concentration (Cmin)|Rate and Extent of Absorption of AZD7594 (Inhalation/ Administration Via DPI) by Assessment of the Cmax at Steady State (Css,Max).|Rate and Extent of Absorption of AZD7594 (Inhalation/ Administration Via DPI) by Assessment of the Cmin at Steady State (Cmin, ss)|Rate and Extent of Absorption of AZD7594 (Inhalation/ Administration Via DPI) by Assessment of the Average Concentration Over One Dosing Interval (Cav)|Rate and Extent of Absorption of AZD7594 (Inhalation/ Administration Via DPI) by Assessment of the Tmax at Steady State (Tss,Max).|Rate and Extent of Absorption of AZD7594 by Assessment of the AUC(0-last)|Rate and Extent of Absorption of AZD7594 by Assessment of AUC(0-24)|Rate and Extent of Absorption of AZD7594 by Assessment of the Css,Max Divided by the Dose Administered (Css,Max/D).|Rate and Extent of Absorption of AZD7594 by Assessment AUC(0-24)/D.|Rate and Extent of Absorption of AZD7594 by Assessment of Lamda z (λz)|Rate and Extent of Absorption of AZD7594 by Assessment of t1/2λz.|Rate and Extent of Absorption of AZD7594 by Assessment of the Peak Trough Fluctuation (%Fluctuation).|Rate and Extent of Absorption of AZD7594 by Assessment of the Accumulation Ratio Calculated as AUC(0-24) on Day 16/AUC (0-24) on Day 1 (RAC).|Rate and Extent of Absorption of AZD7594 by Assessment of the Temporal Change Parameter (TCP)|Rate and Extent of Absorption of AZD7594 by Assessment of the Amount of AZD7594 Excreted Into the Urine From Time t1 to t2 (Ae [t1-t2])|Rate and Extent of Absorption of AZD7594 by Assessment of the Cumulative Amount of AZD7594 Excreted From Time Zero to the Last Sampling Interval (Ae [0-last])|Rate and Extent of Absorption of AZD7594 by Assessment of the Percentage of Dose Excreted Unchanged Into the Urine From Time Zero to the Last Measured Time Point for an AZD7594, Estimated by Dividing Ae(0-last) by Dose (fe(0-last)%)|Rate and Extent of Absorption of AZD7594 by Assessment of the Renal Clearance, Estimated by Dividing Ae(0-96) by AUC(0-96) (CLR)|Pharmacodynamic Analysis of AZD7594 by Assessment of the Area Under the Effect Curve for Plasma Cortisol From Time Zero to 24 Hours After Dosing (AUEC [0-24]).|Pharmacodynamic Analysis of AZD7594 by Assessment of Plasma Concentration of Dehydroepiandrosterone Sulphate (DHEAS)|Pharmacodynamic Analysis of AZD7594 by Assessment of Plasma Concentration of Osteocalcin","AstraZeneca","Male","20 Years to 45 Years   (Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","D3741C00005","January 12, 2016","April 17, 2016","April 17, 2016","January 1, 2016","February 19, 2018","February 19, 2018","Research Site, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT02645253"
567,"NCT02642237","The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response","LPS-Fluenz","Completed","Has Results","Innate Immune Response|Immune Tolerance","Biological: Fluenz|Other: placebo|Other: LPS","Peak Levels of Interferon Gamma-induced Protein 10 (IP-10) in Nasal Wash Fluid","Radboud University","Male","18 Years to 35 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","LPS-Fluenz","December 2015","January 2017","February 2018","December 30, 2015","April 19, 2019","May 14, 2019",,,"https://ClinicalTrials.gov/show/NCT02642237"
568,"NCT02641522","Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes",,"Completed","Has Results","Type 1 Diabetes","Drug: Siltuximab","Percent Change From Baseline in IL-6 Stimulated Intracellular p-STAT3 at Week 12","Carla Greenbaum, MD|Janssen Research & Development, LLC|Benaroya Research Institute","All","18 Years to 45 Years   (Adult)","Early Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","EMU-002","March 8, 2016","March 16, 2017","March 16, 2017","December 29, 2015","October 9, 2018","November 2, 2018","Benaroya Research Institute, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02641522/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02641522"
569,"NCT02639637","Effect of DPP4 Inhibition on Vasoconstriction",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Sitagliptin|Drug: Placebo|Drug: Neuropeptide Y|Drug: Enalaprilat|Drug: Valsartan 160mg","Forearm Blood Flow|Arterial Norepinephrine|Venous Norepinephrine|NPY Metabolites|Insulin|GLP-1|Glucose|ACE Activity|DPP4 Activity|Low Frequency Variability of Blood Pressure Activity|Arterial tPA|Venous tPA|Mean Arterial Pressure|Heart Rate","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years to 55 Years   (Adult)","Phase 4","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","151133","December 2015","June 2017","September 2017","December 24, 2015","August 27, 2018","August 27, 2018","Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02639637/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02639637"
570,"NCT02639351","Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine",,"Completed","Has Results","Infections, Meningococcal","Biological: Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R|Biological: Investigational MenC-CRM adjuavnted with 25 ug of LHD153R|Biological: Investigational MenC-CRM adjuavnted with 50 ug of LHD153R|Biological: Investigational MenC-CRM adjuavnted with 100 ug of LHD153R|Biological: Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)","Number of Subjects With Any Solicited Local and Systemic Adverse Events (AEs)|Number of Subjects With Any Solicited Local and Systemic AEs|Number of Subjects With Any Unsolicited AEs|Number of Subjects With Any Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Study Withdrawal, New Onset of Chronic Disease (NOCDs) and Adverse Events of Special Interest (AESIs).|Number of Subjects With Any SAEs, MAAEs, AEs Leading to Study Withdrawal, NOCDs and AESIs.|Absolute Values for Clinical Serum Chemistry Parameters- Sodium (Na), Potassium (K), Chlorine (Cl), Blood Urea Nitrogen (BUN) and Bicarbonate.|Changes in Clinical Serum Chemistry Parameters|Absolute Values for Clinical Serum Chemistry Parameters-Creatinine|Absolute Values for Clinical Serum Chemistry Parameters- Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Absolute Values for Clinical Serum Chemistry Parameters- C-reactive Protein (CRP)|Absolute Values for Hematology Parameters- Basophils, Eosniophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Plateletes.|Changes in Hematology Parameters|Absolute Values for Hematology Parameters- Red Blood Cells (RBC)|Absolute Values for Hematology Parameters- Hematocrit|Absolute Values for Hematology Parameters- Hemoglobin (HGB)|Absolute Values for Urinalysis Parameters- Urine Erythrocytes (Urine RBC)|Changes in Urinalysis Parameters|Absolute Values for Urinalysis Parameters- Urine Glucose|Absolute Values for Urinalysis Parameters- Urine Protein|Number of Subjects With Abnormal Laboratory Parameter Values|Human Complement Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup C (MenC)|hSBA GMTs Against N. Meningitidis Serogroup C (MenC)|Geometric Mean Ratio (GMR) of the Titers of Antibodies Measured by hSBA Against MenC Serogroup|GMR of the GMTs of Antibodies Measured by hSBA Against MenC Serogroup|Percentage of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroup C (MenC).|Concentrations of Antibodies Against MenC Serogroup Measured by Enzyme Linked Immunosorbent Assay (ELISA)|Percentage of Subjects With at Least a 4-fold Increase in Antibody Concentrations to MenC as Measured by ELISA","GlaxoSmithKline","All","18 Years to 45 Years   (Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","205496|V132_01EXP|2014-002430-31","March 1, 2016","August 31, 2017","August 31, 2017","December 24, 2015","June 7, 2019","June 28, 2019","GSK Investigational Site, Berlin, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02639351/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02639351/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02639351"
571,"NCT02639052","Itch Relieving Effect of Botox: a Study in Healthy Subjects",,"Completed","Has Results","Pruritus","Drug: Botox|Drug: Saline","Itch by VAS Itch Intensity at Baseline (Visit 1)|Itch by VAS Itch Intensity at 1 Week (Visit 2)|Itch by VAS Itch Intensity at 1 Month (Visit 3)|Itch by VAS Itch Intensity at 3 Months (Visit 4)|Change in Heat Pain Relief by VAS Pain Intensity Reporting After 1 Week, 1 Month, and 3 Months After Treatment","Temple University|Allergan","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","35","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","23230|126938","February 2016","July 2016","January 2017","December 24, 2015","April 27, 2017","April 27, 2017",,,"https://ClinicalTrials.gov/show/NCT02639052"
572,"NCT02638597","Gemfibrozil for Nicotine Smoking Cessation","GEMNIC","Completed","Has Results","Smoking Cessation","Drug: Gemfibrozil|Behavioral: smoking cessation counseling","Exhaled Carbon Monoxide (CO)|Heaviness of Smoking Index","University of Texas Southwestern Medical Center","All","18 Years to 64 Years   (Adult)","Phase 2","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU 072014-088","February 2015","December 23, 2016","December 23, 2016","December 23, 2015","February 1, 2019","February 1, 2019","Parkland Memorial Hospital, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02638597"
573,"NCT02637804","Daily Disposable Silicone Hydrogel Contact Lens, Stenfilcon A, Clinical Study",,"Completed","Has Results","Myopia","Device: stenfilcon A|Device: narafilcon A|Device: delefilcon A","Pain and Foreign Body Sensation|Itching Sensation on Removal|Red Eye Sensation|Dryness|Comfort|Vision|Handling|Lens Preference - Stenfilcon A/Narafilcon A (Group 1)|Lens Preference - Stenfilcon A/Delefilcon A (Group 2)|Lens Fit - Horizontal Centration|Lens Fit - Vertical Centration|Lens Fit - Post-blink Movement|Lens Fit Overall|Conjunctival Redness|Limbal Redness|Corneal Staining|Corneal Neovascularization|Conjunctival Staining|Corneal Oedema|Papillary Conjunctivitis","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","106","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","JP-MKTG-201512","January 2016","March 2016","August 2016","December 22, 2015","October 23, 2017","October 23, 2017",,,"https://ClinicalTrials.gov/show/NCT02637804"
574,"NCT02637037","A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects",,"Completed","Has Results","Bioequivalence|Fixed Dose Combination Tablets|Healthy Male and Female Subjects","Drug: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)|Drug: dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)|Drug: dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)|Drug: dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)","Area Under Plasma Concentration-time Curve [AUC] Under Fasted or Fed State|AUC From Time Zero to Time of Last Quantifiable Concentration [AUC (0-t)] Under Fasted or Fed State.|Observed Maximum Plasma Concentration [Cmax] Under Fasted or Fed State|Time to Reach Maximum Plasma Concentration (t Max)|Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve [t½λz]|Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC [CL/F]|Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration [Vz/F]","AstraZeneca","All","18 Years to 55 Years   (Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D1691C00008","December 21, 2015","April 7, 2016","April 7, 2016","December 22, 2015","March 13, 2018","March 13, 2018","Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02637037"
575,"NCT02635646","Interdisciplinary and Family Intervention to Prevent Type 2 Diabetes","CARE-in-DEEP","Completed","Has Results","Prediabetes","Other: Family and interdisciplinary approach|Other: individual approach","Individual Insulin Resistance and Insulin Secretion|Family Insulin Resistance and Insulin Secretion (Matsuda Index Measured in the Relatives of the Patients)|Weight|2h OGTT Glucose","Universidad de Guanajuato|University of Texas|National Council of Science and Technology, Mexico","All","18 Years to 60 Years   (Adult)","Not Applicable","122","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","UG 1/2014","October 2015","December 2016","February 2017","December 21, 2015","August 8, 2018","July 29, 2019","Universidad de Guanajuato, León, Guanajuato, Mexico",,"https://ClinicalTrials.gov/show/NCT02635646"
576,"NCT02635425","Aspiration of Limited Number of Follicles to Prevent Severe Ovarian Hyperstimulation Syndrome",,"Completed","Has Results","Infertility","Procedure: 7 eggs collection|Procedure: Full eggs collection","Number of Participants of Severe Ovarian Hyperstimulation Syndrome","Ahmad Hussieny Salama|Ain Shams Maternity Hospital","Female","18 Years to 35 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","LFOHSS","November 2015","March 2016","March 2016","December 18, 2015","April 19, 2016","May 19, 2016","Ain Shams University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02635425"
577,"NCT02632838","Improve Hypertension Monitoring and Self-management by Using mHealth",,"Completed","Has Results","Hypertension","Device: iHealth BP7-Wireless Blood Pressure Wrist Monitor,","Blood Pressure (BP) Change|Blood Pressure Monitoring Adherence","Rutgers, The State University of New Jersey","All","18 Years to 64 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pro20150001419","January 2016","September 2017","November 2017","December 17, 2015","June 19, 2018","June 19, 2018","Peijia Zha, Newark, New Jersey, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02632838/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02632838/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02632838"
578,"NCT02632526","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects",,"Completed","Has Results","Healthy Male Subjects|Cardiovascular Disease","Drug: AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)|Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)|Drug: AZD5718 placebo oral suspension|Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)","Safety and Tolerability of AZD5718 by Assessment of the Number of Participants With Adverse Events Following Oral Administration of SAD (Part A) and MAD (Part B).|Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve From Time Zero Extrapolated to Infinity (AUC) for Part A - Amorphous and Crystalline Suspension|Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) for Part B - Amorphous Suspension|Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-last)) for Part A - Amorphous and Crystalline Suspension|Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve Over the Dosing Interval (AUC(0-τ)) for Part B - Amorphous Suspension|Rate and Extent of Absorption of AZD5718 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part A - Amorphous and Crystalline Suspension|Rate and Extent of Absorption of AZD5718 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part B - Amorphous Suspension|Rate and Extent of Absorption of AZD5718 by Assessment of the Time to Reach the Observed Maximum Plasma Concentration (Tmax) for Part A - Amorphous and Crystalline Suspension|Rate and Extent of Absorption of AZD5718 by Assessment of the Time to Reach the Observed Maximum Plasma Concentration (Tmax) for Part B - Amorphous Suspension|Rate and Extent of Absorption of AZD5718 by Assessment of the Half-life Associated With Terminal Slope of a Semi-logarithmic Plasma Concentration-time Curve (t½λz) for Part A - Amorphous and Crystalline Suspension|Rate and Extent of Absorption of AZD5718 by Assessment of the Half-life Associated With Terminal Slope of a Semi-logarithmic Plasma Concentration-time Curve (t½λz) for Part B - Amorphous Suspension|Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC (CL/F) for Part A - Amorphous and Crystalline Suspension|Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC (CL/F) for Part B - Amorphous Suspension|Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for Part A - Amorphous and Crystalline Suspension|To Evaluate the Relative Bioavailability Between the Amorphous and Crystalline Form of AZD5718 (Part A) by Assessment of AUC for Part A - Amorphous and Crystalline Suspension|To Evaluate the Relative Bioavailability Between the Amorphous and Crystalline Form of AZD5718 (Part A) by Assessment of Cmax for Part A - Amorphous and Crystalline Suspension|Rate and Extent of Absorption of AZD5718 by Assessment of the Accumulation Ratio for AUC(0-τ) (RAC AUC(0-τ)) for Part B - Amorphous Suspension|Rate and Extent of Absorption of AZD5718 by Assessment of the Accumulation Ratio for Cmax (RAC Cmax) for Part B (Amorphous Suspension) Under Fasted Condition|Rate and Extent of Absorption of AZD5718 by Assessment of the Temporal Change Parameter in Systemic Exposure (TCP) for Part B (Amorphous Suspension) Under Fasted Condition|Rate and Extent of Absorption of AZD5718 by Assessment of the Effect of Food Following Administration of 180 mg AZD5718 With Food (Part B Day 9) and Fasted (Part B Day 10)|Rate and Extent of Absorption of AZD5718 by Assessment of Cumulative Amount of Analyte Excreted at the Last Sampling Interval (CumAe0-24) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)|Rate and Extent of Absorption of AZD5718 by Assessment of Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)|Rate and Extent of Absorption of AZD5718 by Assessment of Renal Clearance (CLR) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)|Rate and Extent of Absorption of AZD5718 by Assessment of Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)|Rate and Extent of Absorption of AZD5718 by Assessment of Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)|Rate and Extent of Absorption of AZD5718 by Assessment of Renal Clearance (CLR) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)|Pharmacodynamic Analysis by ex Vivo Stimulation of Leukotriene B4 (LTB4) Production Using Calcium Ionophore for Part A -Amorphous and Crystalline Suspension|Pharmacodynamic Analysis by ex Vivo Stimulation of LTB4 Production Using Calcium Ionophore for Part B - Amorphous Suspension","AstraZeneca","Male","18 Years to 50 Years   (Adult)","Phase 1","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","D7550C00001","February 10, 2016","August 26, 2016","August 26, 2016","December 16, 2015","March 21, 2019","March 21, 2019","Research Site, Harrow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02632526"
579,"NCT02629354","To Determine Blood Concentrations of Ibuprofen and Caffeine in a Tablet Against Ibuprofen Alone From Another Tablet",,"Completed","Has Results","Healthy","Drug: Ibuprofen|Drug: Caffeine","Maximum Observed Plasma Concentration (Cmax) of S-ibuprofen|Cmax of R-ibuprofen|Cmax of Ibuprofen|Area Under the Plasma Concentration of S-ibuprofen Versus Time Curve, From Time Zero to t (AUC0-t)|AUC0-t of R-ibuprofen|AUC0-t of Ibuprofen|Area Under the Plasma Concentration of S-ibuprofen Versus Time Curve, With Extrapolation to Infinity (AUC0-INF)|AUC0-INF of R-ibuprofen|AUC0-INF of Ibuprofen","Boehringer Ingelheim","All","18 Years to 50 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1335.3","November 2015","January 2016","January 2016","December 14, 2015","March 16, 2017","May 5, 2017","Boehringer Ingelheim Investigational Site, Bloemfontein, South Africa",,"https://ClinicalTrials.gov/show/NCT02629354"
580,"NCT02628938","Effect of Miswak and Miswak Extract on Oral Malodor",,"Completed","Has Results","Oral Malodor|Halitosis","Other: Miswak extract mouth wash|Other: Miswak stick|Other: Chlorohexidine gluconate","Organoleptic Scores After the First Use of the Prescribed Method by 15 Minutes (Masking Effect), and After 7 Days of Use (Therapeutic Effect).|Volatile Sulfur Compound Scores After the First Use of the Prescribed Method by 15 Minutes (Masking Effect), and After 7 Days of Use (Therapeutic Effect)|Self-assessment of Mouth Odor After 7 Days of Use","Riyadh Colleges of Dentistry and Pharmacy","Female","18 Years to 35 Years   (Adult)","Phase 2","212","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","FUGRP/2013/114","March 2014","December 2014","December 2014","December 11, 2015","May 11, 2016","May 11, 2016","Riyadh colleges of dentistry and pharmacy, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT02628938"
581,"NCT02626780","Adipose-derived SVF for Treatment of Alopecia",,"Completed","Has Results","Androgenetic Alopecia","Device: GID SVF-2","Incidence of Treatment-emergent Adverse Events (Safety)|Growth of New Hair","The GID Group","All","18 Years to 60 Years   (Adult)","Not Applicable","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIDAA-01","July 20, 2016","January 22, 2017","January 22, 2017","December 10, 2015","March 21, 2019","March 21, 2019","Maxwell Aesthetics, Nashville, Tennessee, United States|Renew Associates, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02626780/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02626780"
582,"NCT02625259","A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants",,"Completed","Has Results","Neoplasm, Advanced or Metastatic","Drug: TAK-117|Drug: Lansoprazole","Cmax: Maximum Observed Plasma Concentration for TAK-117|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117|AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-117|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-117|Part 1: Renal Clearance (CLr) of TAK-117","Millennium Pharmaceuticals, Inc.|Takeda","All","18 Years to 45 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MLN1117-1002|U1111-1159-5909","January 8, 2016","May 16, 2016","July 22, 2016","December 9, 2015","January 8, 2018","January 8, 2018",,,"https://ClinicalTrials.gov/show/NCT02625259"
583,"NCT02625220","Dispensing Evaluation of Investigational Contact Lenses",,"Completed","Has Results","Myopia; Astigmatism","Device: Prototype toric lens senofilcon A","Proportion of Eyes With Monocular Visual Acuity Better Than 20/40|The Proportion of Eyes With Absolute Rotation Less Than or Equal to 10 Degrees|Proportion of Subjects Eyes With Lens Stability With Blink Within 5 Degrees|Proportion of Subject Eyes With Acceptable Lens Fit","Johnson & Johnson Vision Care, Inc.","All","18 Years to 39 Years   (Adult)","Not Applicable","177","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-5769","October 2015","November 2015","November 2015","December 9, 2015","June 7, 2017","June 7, 2017","Edward S. Wygonik, OD, Jacksonville, Florida, United States|The Eye Center, Pembroke Pines, Florida, United States|Eye Associates of Winter Park, Winter Park, Florida, United States|Eyecare Associates, Bloomington, Illinois, United States|Indiana University College of Optometry, Bloomington, Indiana, United States|Kannarr Eye Care, Pittsburg, Kansas, United States|ABQ Eyecare, Albuquerque, New Mexico, United States|Sacco Eye Group, Vestal, New York, United States|New Image Eye Center, Springfield, Ohio, United States|Professional Vision Care, Westerville, Ohio, United States|West Bay Eye Associates, Warwick, Rhode Island, United States|Total Eye Care PA, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02625220"
584,"NCT02625207","THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC",,"Completed","Has Results","Healthy Subjects","Drug: Maraviroc (Part 1)|Drug: Maraviroc (Part 2)|Drug: Darunavir/cobicistat (Part 2)","Part 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Maraviroc|Part 2: Area Under The Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24]) of Maraviroc|Part 1: Metabolite to Parent Ratio for Area Under the Concentration-Time Curve From Time 0 to 12 Hours for Maraviroc and Its Metabolites (MRAUC12)|Part 1: Average Plasma Concentration (Cavg) of Maraviroc|Part 2: Average Plasma Concentration (Cavg) of Maraviroc|Part 1: Maximum Observed Plasma Concentration (Cmax) of Maraviroc|Part 2: Maximum Observed Plasma Concentration (Cmax) of Maraviroc|Part 1: Plasma Concentration of Maraviroc at 12 Hours Post-dose|Part 2: Plasma Concentration of Maraviroc at 24 Hours Post-dose|Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc|Part 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc|Part 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Metabolites of Maraviroc|Part 1: Average Plasma Concentration (Cav) of Metabolites of Maraviroc|Part 1: Maximum Observed Plasma Concentration (Cmax) of Metabolites of Maraviroc|Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metabolites of Maraviroc|Part 1: Plasma Concentration of Metabolites of Maraviroc at 12 Hour Post-dose|Part 1: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part 2: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part 1: Number of Participants With Clinically Significant Vital Sign Abnormalities|Part 2: Number of Participants With Clinically Significant Vital Sign Abnormalities|Part 1: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities|Part 2: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities|Part 1: Number of Participants With Laboratory Abnormalities|Part 2: Number of Participants With Laboratory Abnormalities","ViiV Healthcare|Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","47","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A4001110","November 6, 2015","March 26, 2016","March 26, 2016","December 9, 2015","April 17, 2017","April 17, 2017","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02625207"
585,"NCT02624791","Evaluating and Improving Functional Driving Vision of Patients With Astigmatism",,"Completed","Has Results","Astigmatism","Device: 1-DAY ACUVUE® MOIST contact lenses|Device: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses|Other: No contact lenses","Tactical Composite Score|Operational Composite Score","University of Virginia|Johnson & Johnson Vision Care, Inc.","All","18 Years to 39 Years   (Adult)","Not Applicable","11","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15920","September 2012","January 2013","January 2013","December 8, 2015","May 23, 2017","May 23, 2017","University of Virginia Driving Safety Lab, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02624791"
586,"NCT02624284","tDCS Effects on Resisting Smoking: Dose Ranging Study","RDR","Completed","Has Results","Nicotine Addiction","Device: transcranial direct current stimulation (tDCS)","Resisting Smoking - Time to First Cigarette in the Resist Smoking Paradigm|Resisting Smoking - Number of Cigarettes Smoked in the Resist Smoking Paradigm|Urge to Smoke for Negative Affect Relief|Number of Days Abstinent From Cigarettes During Monitored Abstinence Period","University of Pennsylvania","All","18 Years to 60 Years   (Adult)","Not Applicable","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","823413","November 2015","March 31, 2018","March 31, 2018","December 8, 2015","March 19, 2019","March 19, 2019","University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02624284/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02624284"
587,"NCT02621060","Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance",,"Completed","Has Results","Impaired Glucose Tolerance","Drug: Placebo|Drug: Chlorogenic acid","Fasting Plasma Glucose (FPG)|2 Hours Plasma Glucose (2-h PG)|Glycated Hemoglobin A1c (A1C)|Total Insulin Secretion|First Phase of Insulin Secretion|Insulin Sensitivity|Area Under the Curve of Glucose|Area Under the Curve of Insulin|Body Weight|Body Mass Index|Waist Circumference (WC)|Systolic Blood Pressure (SBP)|Diastolic Blood Plessure (DBP)|Triglycerides (TG)|Total Cholesterol (TC)|High-density Lipoprotein Cholesterol (HDL-C)|Low-density Lipoprotein Cholesterol (LDL-C)|Very-low Density Lipoprotein (VLDL)|Glutamic Pyruvic Transaminase (GPT)|Glutamic Oxaloacetic Transaminase (GOT)|Creatinine|Uric Acid","University of Guadalajara","All","30 Years to 60 Years   (Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CT-ACG-271281-LYZ","September 2015","January 2016","February 2016","December 3, 2015","August 2, 2019","August 2, 2019","Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara, Guadalajara, Jalisco, Mexico",,"https://ClinicalTrials.gov/show/NCT02621060"
588,"NCT02621034","Comparative Evaluation of Post-endodontic Pain Using Two Rotary Instrumentation Systems",,"Completed","Has Results","Pain","Procedure: Control|Procedure: Reciproc|Procedure: One shape","Post-operative Pain on the Visual Anlogue Scale (VAS) at the 6-hour Post-operative Interval|Comparison of Post-operative Pain in the Reciproc and Oneshape Groups Through Out the Intervals|Comparison of Post-operative Pain Between the Three Groups at the 72-hour Interval","Zahedan University of Medical Sciences","All","20 Years to 50 Years   (Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SRH-1","December 2015","February 2016","March 2016","December 3, 2015","June 6, 2016","June 6, 2016","Zahedan Dental School, Zahedan, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02621034"
589,"NCT02620683","Clinical Outcomes of Buffered vs. Non-Buffered Lidocaine","BUFFL","Completed","Has Results","Blood Levels of Buffered vs Non-buffered Lidocaine|Anesthetics, Local","Drug: Lidocaine","Lidocaine Blood Levels 30 Minutes Post Injection|Pain Intensity Scores|Number of Minutes to Anesthesia Symptoms of Lower Lip|Topical Anesthesia Effect Contralateral Lower Lip","University of North Carolina, Chapel Hill|Dental Foundation of North Carolina, Inc.","All","18 Years to 30 Years   (Adult)","Not Applicable","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","15-1741|CHDEN 29920, D0117439000","December 2015","August 2017","September 2017","December 3, 2015","January 23, 2018","January 23, 2018","UNC School of Dentistry, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02620683/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02620683"
590,"NCT02619799","A Comparative Study of Intrathecal Magnesium Sulphate & Midazolam With Epidural Ropivacaine for Caesarean Patients",,"Completed","Has Results","Postoperative Pain","Drug: intrathecal magnesium sulphate,|Drug: Intrathecal midazolam","Duration of Postoperative Analgesia|Onset of Sensory Blockade|Duration of Sensory Blockade|Onset of Motor Blockade|Duration of Motor Blockade|Perioperative Side Effects","Rangaraya Medical College","Female","18 Years to 28 Years   (Adult)","Phase 2|Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Rangaraya medical college","January 2015","December 2015","December 2015","December 2, 2015","February 8, 2016","March 14, 2016",,,"https://ClinicalTrials.gov/show/NCT02619799"
591,"NCT02618642","The Use of i/t Curve in Assessment of Phototherapy Effects",,"Completed","Has Results","Nerve Disorders","Radiation: Irradiations of the biceps brachii muscle with PILER light. The participants were randomized into 4 groups: group v - no filter/ group x - red filter/ group y - blue filter/ group z - placebo.","Change in the Pressure Pain Threshold (PPT)|Calculation of Sensory i/t Curve Coefficient for Rectangle (■I/T Coeff)|Calculation of Sensory I/T Curve Coefficient for Triangular (▲I/T Coeff) Pulses|Calculation of Motor i/t Curve Coefficient for Rectangle (■I/T Coeff)|Calculation of Motor I/T Curve Coefficient for Triangular (▲I/T Coeff) Pulses","University of Rzeszow","All","21 Years to 23 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","jz.i/t","February 2016","July 2019","July 2019","December 1, 2015","January 13, 2020","January 13, 2020",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02618642/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02618642"
592,"NCT02614729","The Consumption of Beef on Appetite and Cognitive Function",,"Completed","Has Results","Obesity|Poor Glycemic Control|Dietary Interventions","Other: Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN)|Other: Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN)|Other: High Protein-Beef, Even Distribution (HP-BEEF-EVEN)|Other: High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)","Daily Energy Intake: Total Daily Intake|Perceived Fullness|Reaction Time as a Measure of Cognitive Performance Assessed Using the Stroop Test|Perceived Alertness|Perceived Hunger|Perceived Prospective Food Consumption|Perceived Desire to Eat","University of Missouri-Columbia|National Cattlemen's Beef Association","Female","18 Years to 52 Years   (Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","0039674","January 2014","May 2015","May 2015","November 25, 2015","July 8, 2019","July 8, 2019",,,"https://ClinicalTrials.gov/show/NCT02614729"
593,"NCT02614586","Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia",,"Terminated","Has Results","Schizophrenia","Drug: TAK-058|Drug: Ondansetron|Drug: TAK-058 Placebo|Drug: Ondansetron Placebo","Change From Baseline in P50 Ratio S2/S1 at Central (Cz) Electrode Following Administration of TAK-058|Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)","Takeda","All","18 Years to 60 Years   (Adult)","Phase 1","11","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","TAK-058-1003|U1111-1168-1522","December 2015","April 2016","April 2016","November 25, 2015","May 1, 2017","May 1, 2017","St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02614586"
594,"NCT02614274","Nutramax Joint Health Formulation Biochemical Response Study",,"Completed","Has Results","Osteoarthritis, Knee","Dietary Supplement: Nutraceutical joint health formulation","Serum Biomarkers|Urine Biomarkers|Patient Reported Quality of Life Via SF-36 (36-Item Short Form Health Survey) Improvement|Patient Reported Opinions (About Their Knee) Via KOOS (Knee Injury and Osteoarthritis Outcome Score)|Patient Reported Survey to Assess: Pain, Stiffness, and Physical Function in Patients With Hip and/or Knee Osteoarthritis (OA) Via WOMAC (Western Ontario and McMaster Universities Arthritis Index)|Patient Reported Survey to Assess Symptoms and Function in Daily Living Via IKDC (International Knee Documentation Committee) Subject Exam","University of Missouri-Columbia|Nutramax Laboratories, Inc.","All","40 Years to 64 Years   (Adult)","Not Applicable","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1213242","November 2014","November 2015","January 2016","November 25, 2015","November 5, 2018","November 5, 2018","University of Missouri, Missouri Orthopaedic Institute, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02614274"
595,"NCT02612909","A Safety and Immunogenicity Study of IVACFLU-A/H5N1",,"Completed","Has Results","Avian Influenza","Biological: IVACFLU-A/H5N1 vaccine|Biological: Placebo","Number and Percentage of Subjects Achieving a Hemagglutination Inhibition (HAI) Titer of ≥1:40|Phase 2: Number and Percentage of Subjects Achieving a Hemagglutination Inhibition (HAI) Titer of ≥1:40|Phase 2: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Hemagglutination Inhibition (HAI) Titer|Phase 3: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Hemagglutination Inhibition (HAI) Titer|Phase 2: Geometric Mean Hemagglutination Inhibition (HAI) Titer|Phase 3: Geometric Mean Hemagglutination Inhibition (HAI) Titer|Phase 2: Geometric Mean Hemagglutination Inhibition (HAI) Titer Ratio, With Respect to Day 1|Phase 3: Geometric Mean Hemagglutination Inhibition (HAI) Titer Ratio, With Respect to Day 1|Number and Percentage of Subjects Experiencing Reactogenicity|Number and Percentage of Subjects Experiencing Unsolicited Adverse Events (AE)|Number and Percentage of Subjects Experiencing Unsolicited Serious Adverse Events (SAE)|Phase 2: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Neutralizing Antibody Titer|Phase 3: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Neutralizing Antibody Titer|Phase 2: Geometric Mean Neutralizing Antibody Titer|Phase 3: Geometric Mean Neutralizing Antibody Titer|Phase 2: Geometric Mean Neutralizing Antibody Titer Ratio, With Respect to Day 1|Phase 3: Geometric Mean Neutralizing Antibody Titer Ratio, With Respect to Day 1","Institute of Vaccines and Medical Biologicals, Vietnam|National Institute of Hygiene and Epidemiology, Vietnam|World Health Organization|Department of Health and Human Services|PATH|FHI 360","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","930","Industry|Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IVACFLU-A/H5N1-0203","March 7, 2017","August 29, 2017","August 30, 2017","November 24, 2015","April 16, 2019","May 21, 2019","Phase 3: Hai Phong Provincial Preventive Medicine Center, Haiphong, Hai Phong, Vietnam|Phase 2 & 3: Khanh Hoa Provincial Health Department, Nha Trang, Khanh Hoa, Vietnam","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02612909/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02612909/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02612909"
596,"NCT02612428","Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD",,"Terminated","Has Results","Acute Alcoholic Hepatitis","Biological: ELAD System|Other: Standard of Care (Control)","Overall Survival|Number of Survivors at Study Day 91|Number of Subjects With Early Change in Bilirubin Levels at Study Day 7","Vital Therapies, Inc.","All","18 Years to 49 Years   (Adult)","Phase 3","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VTL-308","January 2016","March 2018","September 2018","November 23, 2015","January 25, 2019","January 25, 2019","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Sharp Coronado Hospital, Coronado, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Mercy Medical Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Missouri Hospital, Columbia, Missouri, United States|Rutgers University Hospital, Newark, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Pennsylvania State University and The Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University, Philadelphia, Pennsylvania, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medizinische Universität Graz, Graz, Styria, Austria|Medizinische Universität Klinik Für Innere Medizin III, Vienna, Austria|Klinikum Landshut gemeinnuetzige GmbH, Landshut, Bavaria, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsmedizin Mainz, Mainz, Germany|Universitätsklinikum Münster, Münster, Germany|Universitätsmedizin Rostock, Rostock, Germany|St. Vincent's University Hospital, Dublin, Ireland|Hospital Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Aintree University Hospital, Liverpool, England, United Kingdom|Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom|Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom|Belfast Health and Social Care Trust, Belfast, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Doncaster Royal Infirmary, Doncaster, United Kingdom|Royal London Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Nottingham University Hospital, Nottingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02612428/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02612428/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02612428"
597,"NCT02612064","The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity",,"Completed","Has Results","Dentin Sensitivity","Device: Stannous Fluoride dentifice|Other: Sodium Monofluorophosphate dentifrice","Change From Baseline in Schiff Sensitivity Score on Day 3|Change From Baseline in Schiff Sensitivity Score Post First Treatment by Direct Application|Change From Baseline in Tactile Threshold Post First Treatment by Direct Application and on Day 3","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Not Applicable","488","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","205072","November 1, 2015","June 3, 2016","June 3, 2016","November 23, 2015","March 23, 2017","May 17, 2017","GSK Investigational Site, Ellesmere Port, Cheshire, United Kingdom|GSK Investigational Site, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02612064"
598,"NCT02611752","A Multiple Dose Opioid Challenge Study",,"Completed","Has Results","Moderate or Severe Opioid Use Disorder","Drug: CAM2038","Treatment Phase Drug Liking Visual Analog Scale (VAS) Emax Scores for Baseline and Four Challenge Sessions Compared to Baseline (Completer Population) for CAM2038 q1w, 24 mg|Treatment Phase Drug Liking Visual Analog Scale (VAS) Maximum Effect (Emax) Scores for Baseline and Four Challenge Sessions Compared to Baseline (Completer Population) for CAM2038 q1w, 32 mg|Inferential Analysis Results Drug Liking Visual Analog Scale (VAS) for Maximum Effect (Emax) Scores for Qualification/Baseline and Four Challenge Sessions (Completer Population) for CAM2038 q1w, 24 mg|Inferential Analysis Results Drug Liking Visual Analog Scale (VAS) Maximum Effect (Emax) Scores for Qualification/Baseline and Four Challenge Sessions (Completer Population) for CAM2038 q1w, 32 mg|Inferential Analysis Results for Unipolar High Visual Analog Scale (VAS) for Maximum Effect (Emax) (Completer Population)|Inferential Analysis Results for Unipolar Good Drug Effects Visual Analog Scale (VAS) for Maximum Effect (Emax) (Completer Population)|Analysis of Treatment Phase Unipolar Bad Drug Effects Visual Analog Scale (VAS) for Maximum Effect (Emax) in 24 mg CAM2038 q1w Group (Completer Population)|Analysis of Treatment Phase Unipolar Bad Drug Effects Visual Analog Scale (VAS) for Maximum Effect (Emax) in 32 mg CAM2038 q1w Group (Completer Population)|Analysis Results for Unipolar Desire to Use Visual Analog Scale (VAS) for Maximum Effect (Emax) (Completer Population)|Analysis Results for Bipolar Alertness/Drowsiness Visual Analog Scale (VAS) for Maximum Effect (Emax) (Completer Population)|Analysis Results for Unipolar Any Drug Effects Visual Analog Scale (VAS) for Maximum Effect (Emax) (Completer Population)","Braeburn Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 2","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HS-13-478","October 2015","April 2016","April 2016","November 23, 2015","November 14, 2019","November 14, 2019","Vince and Associates Clinical Research, Overland Park, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|New York Psychiatric Institute, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02611752/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02611752/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02611752"
599,"NCT02611154","Intranasal Delivery of Testosterone and Its Effect on Doping Markers","Intranasal","Completed","Has Results","Abuse of Anabolic Steroids","Drug: Testosterone","Steroid Levels in Urine Steroid Profile|Number of Participants With Suspicious Steroid Profile in Urine Samples at Baseline|Testosterone Level in Blood as Measured for Safety","University of Utah|Sports Medicine Research and Testing Laboratory|Partnership for Clean Competition","Male","18 Years to 35 Years   (Adult)","Phase 4","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","84225","November 18, 2015","January 19, 2016","January 19, 2016","November 20, 2015","March 10, 2017","March 10, 2017","University of Utah Orthopaedic Center, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02611154"
600,"NCT02609308","Lateral Ankle Sprain and Platelet Rich Plasma",,"Completed","Has Results","Ankle Injuries","Other: Short leg cast|Procedure: Platelet-rich plasma","American Orthopedic Foot and Ankle Society Ankle-Hindfoot Scale (AOFAS)|Visual Analogue Scale|Foot and Ankle Disability Index (FADI)","Universidad Autonoma de Nuevo Leon","All","18 Years to 60 Years   (Adult)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OR15-008","September 2015","December 2016","February 2017","November 20, 2015","October 23, 2019","October 23, 2019","Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT02609308"
601,"NCT02606500","Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success",,"Completed","Has Results","Obesity","Drug: Elonva","Number of Oocytes Retrieved Per Patient|Number of Mature Oocytes|Number of Fertilized Oocytes|Number of Frozen Embryos|Biochemical Pregnancy Rate|Real-time PCR Analysis of Genes That Were Proposed as Biomarkers of Oocyte Quality to Determine Effect of Corifollitropin Alpha on Oocyte Quality on Molecular Level","University Medical Centre Ljubljana|Merck Sharp & Dohme Corp.","Female","18 Years to 38 Years   (Adult)","Phase 4","70","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Merck-01","March 2016","January 2017","March 2017","November 17, 2015","November 26, 2018","November 26, 2018","Division of gynecology, Department of human reproduction, Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT02606500"
602,"NCT02606279","Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients","RAS-HIV","Terminated","Has Results","HIV|Aging|Sarcopenia|Angiotensin Receptor Antagonists","Drug: valsartan|Other: Placebo","Change From Baseline in 400m Walk|Change From Baseline in Grip Strength|Change From Baseline in Quantity of AT1R and AT2R on Monocytes|Change From Baseline in Frailty Status","Wake Forest University Health Sciences|Johns Hopkins University","All","40 Years to 60 Years   (Adult)","Not Applicable","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","WFUHS-28769","July 2014","August 4, 2016","August 4, 2016","November 17, 2015","December 5, 2017","August 28, 2018","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02606279"
603,"NCT02605876","Vibratory Stimuli, A Novel Rehabilitation Method for Preventing Post - Traumatic Knee Osteoarthritis",,"Completed","Has Results","Knee Osteoarthritis","Device: Whole body vibration|Device: Local muscle vibration","Linear Ground Reaction Force Loading Rate|Quadriceps Strength|Knee Proprioception|Instantaneous Ground Reaction Force Loading Rate|Peak Internal Knee Extension Moment|Peak Internal Knee Valgus Moment","University of North Carolina, Chapel Hill|United States Department of Defense","All","18 Years to 35 Years   (Adult)","Not Applicable","75","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","15-0838","October 1, 2015","December 30, 2018","December 30, 2018","November 16, 2015","November 19, 2019","November 19, 2019","Neuromuscular Research Lab, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02605876/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02605876"
604,"NCT02605395","Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions",,"Completed","Has Results","Gastrointestinal Diseases","Drug: IDIAZOLE 20mg DR tabs|Drug: PARIET 20 mg DR tabs","Maximal Measured Plasma Concentration (Cmax) of Rabeprazole|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC [0-t]) of Rabeprazole|Mean Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC [0 to Infinity]) of Rabeprazole|Mean Time to the Maximum Plasma Concentration (Tmax) of Rabeprazole|Mean Apparent First-order Elimination or Terminal Rate Constant (Ke) of Rabeprazole|Mean Terminal Half Life (t1/2) of Rabeprazole","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 4","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","201528","March 22, 2014","March 30, 2014","March 30, 2014","November 16, 2015","October 1, 2018","October 1, 2018","GSK Investigational Site, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02605395"
605,"NCT02605187","Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management",,"Completed","Has Results","Postoperative Pain","Other: No choice given|Other: Choice given|Drug: Ibuprofen|Drug: Acetaminophen|Drug: Gabapentin|Drug: Morphine (low)|Drug: Morphine (med)|Drug: Morphine (high)","Opioid Consumption in the 0-48 Hour Study Periods.|Pain Scores|Count of Participants Who Need Opioid Use|Count of Participants With Presence of Pruritus|Pruritus Score at 24 and 48 After Delivery|Count of Participants Who Need Medical Treatment of Pruritus|Counts of Participants With Presence of Nausea|Nausea Score Score at 24 and 48 After Delivery|Counts of Participants Who Need Medical Treatment for Nausea|Average Number of Vomiting Episodes After Delivery|Time to Discharge|Patient Overall Satisfaction With Postoperative Analgesia","Stanford University","Female","18 Years to 50 Years   (Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","34740","November 2015","May 22, 2017","May 22, 2017","November 16, 2015","June 11, 2018","October 16, 2018","Lucille Packard Children's Hospital, Palo Alto, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02605187/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02605187"
606,"NCT02604407","Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)",,"Completed","Has Results","Attention Deficit Hyperactivity Disorder (ADHD)","Drug: SHP465 12.5mg capsules (one capsule daily)|Other: Placebo|Drug: SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)","Change From Baseline in the Adult Attention-deficit/Hyperactivity Disorder Rating Scale-4 (ADHD-RS) With Prompts Total Score at Visit 6 (Week 4)|Clinical Global Impression of Improvement (CGI-I) Score at Visit 6 (Week 4)","Shire","All","18 Years to 55 Years   (Adult)","Phase 3","275","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SHP465-306","November 2015","March 2016","March 2016","November 13, 2015","June 14, 2017","June 14, 2017","Pharmacology Research Institute, Encino, California, United States|Pharmacology Research Institute (Pri), Los Alamitos, California, United States|Pharmacology Research Institute (Pri), Newport Beach, California, United States|Nrc Research Institute, Orange, California, United States|Elite Clinical Trials, Wildomar, California, United States|McB Clinical Research, Colorado Springs, Colorado, United States|Florida Clinical Research Center Llc, Bradenton, Florida, United States|Gulfcoast Clinical Research Center, Fort Myers, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Clinical Neuroscience Solutions, Inc, Jacksonville, Florida, United States|Florida Clinical Research Center, Llc, Maitland, Florida, United States|Qps Mra, Llc, Miami, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Capstone Clinical, Libertyville, Illinois, United States|Baber Research Group, Inc, Naperville, Illinois, United States|Psychiatric Associates, Overland Park, Kansas, United States|Louisiana Research Associates, Inc., New Orleans, Louisiana, United States|Rochester Center For Behavioral Medicine, Rochester Hills, Michigan, United States|Clinical Neurophysiology Services, Sterling Heights, Michigan, United States|Psychiatric Care and Research Center, O'Fallon, Missouri, United States|Midwest Research Group, Saint Charles, Missouri, United States|Premier Psychiatric Research Institutute, Lincoln, Nebraska, United States|Center For Psychiatry and Behavioral Medicine, Inc, Las Vegas, Nevada, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Bioscience Research Llc, Mount Kisco, New York, United States|Nyu Langone Medical Center, New York, New York, United States|Richard H Weisler, Md, Pa & Associates, Raleigh, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Ips Research Company, Oklahoma City, Oklahoma, United States|Oregon Center For Clinical Investigations, Inc, Portland, Oregon, United States|Oregon Center For Clinical Investigations, Salem, Oregon, United States|Omega Medical Research, Warwick, Rhode Island, United States|Rainbow Research, Inc., Barnwell, South Carolina, United States|Coastal Carolina Research, Mount Pleasant, South Carolina, United States|Clinical Neuroscience Solutions, Memphis, Tennessee, United States|Futuresearch Trials of Dallas, Lp, Dallas, Texas, United States|Bayou City Research, Ltd, Houston, Texas, United States|Red Oak Psychiatry Associates, Houston, Texas, United States|Houston Clinical Trials, Llc, Houston, Texas, United States|Research Across America, Plano, Texas, United States|Neuroscience, Inc, Herndon, Virginia, United States|Eastside Therapeutic Resource, Kirkland, Washington, United States|Summit Research Network (Seattle) Llc, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02604407"
607,"NCT02601976","Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population","EUROP","Completed","Has Results","Hepatitis C","Drug: Peginterferon alfa-2a|Drug: Ribavirin","Number of Participants With Sustained Virological Response (SVR)|Number of Participants With End Treatment Response|Number of Participants Who Reported Adverse Events","Getz Pharma|Dimension Research","All","18 Years to 55 Years   (Adult)","Phase 4","64","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GETZ-UNIP- 4010810","August 2010","September 2012","September 2014","November 11, 2015","September 27, 2018","September 27, 2018",,,"https://ClinicalTrials.gov/show/NCT02601976"
608,"NCT02601625","A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects",,"Completed","Has Results","Safety|Pharmacokinetics|Healthy Subjects","Drug: Anifrolumab SC injection (300mg)|Drug: Anifrolumab IV infusion (300mg)|Drug: Anifrolumab SC infusion (600mg)|Drug: Anifrolumab placebo SC injection (300mg)|Drug: Anifrolumab placebo IV infusion (300mg)|Drug: Anifrolumab placebo SC infusion (600mg)","Pharmacokinetics: Observed Maximum Serum Concentration (Cmax) Following Single Dose of Anifrolumab.|Pharmacokinetics: Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Following Single Dose of Anifrolumab|Pharmacokinetics: Area Under Serum Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) Following Single Dose of Anifrolumab|Safety: Number of Participants With Adverse Events (AEs)|Safety: Summary of Local Injection Site Pain (SC Cohorts) Assessed in Participants|Safety: Summary of Local Injection Site Pruritus (SC Cohorts) Assessed in Participants|Safety: Summary of Erythema Injection Site Reaction (SC Cohorts) Assessed in Participants|Safety: Summary of the Induration Injection Site Reaction (SC Cohorts) Assessed in Participants|Evaluation of Immunogenicity of Anifrolumab IV Infusions and SC Injections by the Measurement of Anti-drug Antibody (ADA).","AstraZeneca","All","18 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","D3461C00006","November 16, 2015","May 25, 2016","May 25, 2016","November 10, 2015","February 26, 2019","February 26, 2019","Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02601625"
609,"NCT02598089","Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)","IVACFLU-S","Completed","Has Results","Influenza, Human","Biological: Trivalent Seasonal Influenza Vaccine|Other: Placebo","Number of Participants With Immediate Adverse Events|Number and Percentage of Participants Reporting Solicited Local Reactogenicity|Number and Percentage of Participants Reporting Solicited Systemic Reactogenicity|Number and Percentage of Participants With Unsolicited Adverse Events|Number and Percentage of Participants With Serious Adverse Events (SAEs)|Number and Percentage of Subjects With Seroconversion Against Each of the 3 Antigens|Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine|Geometric Mean Titers (GMTs) of Serum Hemaggluntination Inhibition (HAI) Antibodies for Each Antigen|Geometric Mean Fold Rises (GMFRs) of Serum Hemaggluntination Inhibition (HAI) Antibodies|Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 1) and Post-Vaccination (Day 22) for Each of the 3 Antigens|Geometric Fold Rises (GMFRs) of Neutralizing Antibodies (MNT) Post-vaccination/Pre-vaccination for Each of the 3 Antigens","Institute of Vaccines and Medical Biologicals, Vietnam|National Institute of Hygiene and Epidemiology, Vietnam|World Health Organization|Department of Health and Human Services|PATH|Quintiles, Inc.","All","18 Years to 45 Years   (Adult)","Phase 1","60","Industry|Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IVACFLU-S-01","November 2015","February 2016","February 2016","November 5, 2015","January 28, 2019","February 15, 2019","Hung Ha District Health Center, Thai Binh, Thai Binh Province, Vietnam",,"https://ClinicalTrials.gov/show/NCT02598089"
610,"NCT02596750","The Effect of Microneedle Pretreatment on Topical Anesthesia",,"Completed","Has Results","Pain","Device: Microneedle Roller|Device: Sham microneedle Roller","Visual Analog Scale Pain","University of California, Davis","Male","18 Years to 60 Years   (Adult)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","252160","January 2014","June 2015","June 2015","November 4, 2015","November 27, 2018","November 27, 2018","University of California Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT02596750"
611,"NCT02596022","The Effect of Glutamatergic Modulation on Cocaine Self-administration",,"Completed","Has Results","Cocaine Dependence","Drug: CI-581a|Drug: CI-581b","Number of Choices to Self-administer Cocaine (Out of 5 Choices)","New York State Psychiatric Institute","All","21 Years to 55 Years   (Adult)","Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6716","June 2013","June 2015","July 2015","November 4, 2015","October 17, 2017","June 15, 2018",,,"https://ClinicalTrials.gov/show/NCT02596022"
612,"NCT02595723","Phenytoin for Memory Impairment Secondary to Megestrol",,"Completed","Has Results","Cognitive Impairment","Drug: Phenytoin 200 mg capsule|Drug: Megestrol 800 mg liquid|Drug: Phenytoin-matched Placebo capsule|Drug: Megestrol-matched liquid Placebo","Rey Auditory Verbal Learning Test (RAVLT)","University of Texas Southwestern Medical Center|The Rogosin Institute","All","18 Years to 50 Years   (Adult)","Phase 4","21","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","032015-004","July 2015","November 2016","December 2016","November 3, 2015","September 9, 2019","September 9, 2019","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02595723"
613,"NCT02595502","Clinical Evaluation of Two Silicone Hydrogel Daily Disposable Contact Lenses",,"Completed","Has Results","Vision Disorders","Device: JJVC Marketed Contact Lens (Test)|Device: Competitor Marketed Contact Lens (Control)","Overall Comfort","Johnson & Johnson Vision Care, Inc.","All","18 Years to 39 Years   (Adult)","Not Applicable","286","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-5743","September 1, 2015","November 1, 2015","November 1, 2015","November 3, 2015","July 20, 2016","July 5, 2017","Becky Bizzle, OD, Montgomery, Alabama, United States|Complete Family Eye Care of Fruit Cove, Fruit Cove, Florida, United States|Golden Family Eyecare, Sarasota, Florida, United States|St. Lucy's Vision Center, Tampa, Florida, United States|Eye Associates of Winter Park, Winter Park, Florida, United States|VisualEyes, Inc., Roswell, Georgia, United States|Advantage Eyecare Associates, LLC, Neodesha, Kansas, United States|Sacco Eye Group, Vestal, New York, United States|Advanced Family Eye Care, Denver, North Carolina, United States|total Eye Care PA, Memphis, Tennessee, United States|Brian Frazier, OD, Jacksonville, Texas, United States|Timothy R. Poling, OD, Roanoke, Virginia, United States|Ziegler Leffingwell Eyecare, West Allis, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02595502"
614,"NCT02592655","A Transparent Elasticized Adhesive Occlusive Compression Bandage for Use as an Arterial Tourniquet",,"Completed","Has Results","Hemorrhage|Vascular Injury","Device: Pneumatic Tourniquet|Device: One Windlass Tourniquet|Device: Two Windlass Tourniquets|Device: Tourniquet Tape 5 cm|Device: Tourniquet Tape 10 cm","Radiologist Limb Occlusion Assessment|Investigator Limb Occlusion Assessment","Marcus Migura|Mercy Health|Migura, Marcus","All","18 Years to 55 Years   (Adult)","Not Applicable","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HCT001","December 2015","December 2015","December 2015","October 30, 2015","August 24, 2017","August 24, 2017","Vascular Medicine & Surgical Associates, Youngstown, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02592655"
615,"NCT02591290","Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects",,"Completed","Has Results","Meningitis|Meningococcal Meningitis|Meningococcal Infections","Biological: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate","Number of Participants With Meningococcal Serogroups A, C, Y, and W-135 Antibody Titers >=1:128","Sanofi Pasteur, a Sanofi Company|Sanofi","All","20 Years to 55 Years   (Adult)","Phase 4","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","EFC14375/MTA89|U1111-1174-4291","October 20, 2015","March 16, 2016","March 16, 2016","October 29, 2015","November 6, 2017","November 6, 2017","Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT02591290"
616,"NCT02591238","Melatonin in Smoke-induced Vascular Injury",,"Completed","Has Results","Smoking|Vascular System Injuries","Other: non-smoker oral placebo|Drug: non-smoker oral melatonin|Other: smoker oral placebo|Drug: smoker oral melatonin","Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of Fbg.|Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of Glu.|Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of FFA.|Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of TC.|Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of TG.|Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of LDL-C.","Peking Union Medical College Hospital","All","25 Years to 39 Years   (Adult)","Phase 4","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","81470585","June 2015","July 2015","October 2015","October 29, 2015","March 3, 2016","March 3, 2016","PekingUMCH, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02591238"
617,"NCT02590354","Analytical Treatment Interruption in HIV Positive Patients","ISALA","Completed","Has Results","HIV-1 Infection","Other: ART interruption","Assessment of the Number of Participants With a HIV Plasma Viral Load Below the Lower Limit of Detection 48 Weeks Following Interruption of Antiretroviral Treatment|Number of Patients With and the Severity of Adverse Events That Are Related to the Study Intervention, Graded According to NCI CTCAE Version 4.0|Evaluation of the Reservoir Replenishment Upon Interruption of Antiretroviral Treatment (TI) by Quantifying the Viral Reservoir at Baseline (i.e. Just Before TI) and at Viral Rebound (Total HIV DNA).|Evaluation of the Reservoir Replenishment Upon Interruption of Antiretroviral Treatment (TI) by Quantifying the Viral Reservoir at Baseline (i.e. Just Before TI) and at Viral Rebound (Unspliced RNA).|Assessment of the Kinetics of HIV Viral Load Rebound After Treatment Interruption Based on the Repetitive Plasma Viral Load Measurements.","Institute of Tropical Medicine, Belgium|University Hospital, Ghent|Universitair Ziekenhuis Brussel|Saint-Pierre University Hospital|Agentschap voor Innovatie door Wetenschap en Technologie","All","18 Years to 64 Years   (Adult)","Not Applicable","114","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ITM0714","January 25, 2016","June 22, 2018","June 22, 2018","October 29, 2015","September 24, 2019","September 24, 2019","Institute of Tropical Medicine, Antwerp, Belgium|Saint-Pierre University Hospital, Brussels, Belgium|Brussels University Hospital, Brussels, Belgium|Ghent University Hospital, Ghent, Belgium","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02590354/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02590354/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02590354"
618,"NCT02590068","Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination",,"Terminated","Has Results","Hepatitis C","Drug: Zoster vaccine live","Serum Zoster Antibody Level|Interferon Stimulated Gene (ISG) Expression|Serum Biomarkers of Immune Activation(Expressed in%)|Responder Cell Frequency|Interferon-gamma Response","Rockefeller University|National Institute of Allergy and Infectious Diseases (NIAID)","All","50 Years to 60 Years   (Adult)","Not Applicable","14","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","OJE-0890|5U19AI111825-02","December 2015","September 8, 2017","September 8, 2017","October 28, 2015","December 18, 2019","December 18, 2019","Rockefeller University Hospital, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02590068/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02590068"
619,"NCT02585999","The Pharmacokinetics of 12 Week Continuous Patch Use",,"Completed","Has Results","Pharmacokinetics","Device: Xulane Contraceptive Patch","Change in Serum EE2 Levels Over 12 Weeks of Continuous Contraceptive Patch Use|NGMN Levels Over 12 Weeks of Continuous Patch Use","Boston Medical Center","Female","18 Years to 39 Years   (Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","H-34252","October 2015","May 2016","June 2016","October 26, 2015","May 30, 2017","May 30, 2017","Boston Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02585999"
620,"NCT02585700","A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine",,"Completed","Has Results","Influenza, Human","Biological: Influenza vaccine, split inactivated|Other: Placebo","Number of Subjects With Immediate Adverse Events|Number and Percentage of Subjects With Solicited Local Reactogenicity|Number and Percentage of Subjects With Solicited Systemic Reactogenicity|Number and Percentage of Subjects With Occurrence of Unsolicited Adverse Events|Number and Percentage of Subjects With Occurrence of Serious Adverse Events (SAE)|Number and Percentage of Seroconverted Subjects Against 3 Strains of Influenza Vaccine.|Number and Percentage of Seroprotected Subjects Against 3 Strains of Influenza Vaccine|Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies Pre- (Day 0) and Post-vaccination (Day 21) for Each of the 3 Antigens|Geometric Mean Fold Rises (GMFRs) of Serum (HAI) Antibodies (Post-vaccination / Pre-vaccination) for Each of the 3 Antigens.|Geometric Mean Neutralization Titers of Neutralizing Antibodies (MNT) Pre- (Day 0) and Post-vaccination (Day 21) for Each of the 3 Antigens.|Geometric Mean Fold Rises (GMFRs) of MNT (Post-vaccination / Pre-vaccination) for Each of the 3 Antigens.","Institute of Virology, Vaccines and Sera, Torlak|Department of Health and Human Services|World Health Organization|PATH|Comac Medical","All","18 Years to 45 Years   (Adult)","Phase 1","60","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TORLAK-100","November 2015","March 2016","March 2016","October 23, 2015","January 15, 2019","January 15, 2019","Clinical Center of Serbia, Belgrade, Serbia",,"https://ClinicalTrials.gov/show/NCT02585700"
621,"NCT02579421","Hormones and Reduction in Co-users of Marijuana and Nicotine",,"Completed","Has Results","Marijuana Dependence","Drug: Progesterone|Drug: placebo","Change in Marijuana Use as Defined by the TLFB","University of Minnesota","All","18 Years to 60 Years   (Adult)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1509M78103","November 2015","July 27, 2017","July 27, 2017","October 19, 2015","July 10, 2019","July 10, 2019","Delaware Clinical Research Unit, University of Minnesota, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02579421/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02579421"
622,"NCT02578186","Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness",,"Completed","Has Results","Occasional Sleeplessness","Drug: Diphenhydramine Hydrochloride|Drug: Placebo","Mean Latency to Persistent Sleep","Procter and Gamble","All","18 Years to 55 Years   (Adult)","Phase 4","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2013063","November 2013","December 2014","December 2014","October 16, 2015","March 15, 2017","March 15, 2017",,,"https://ClinicalTrials.gov/show/NCT02578186"
623,"NCT02577601","Impact of Combined Hormonal Contraceptives on UPA",,"Completed","Has Results","Contraception","Drug: Ulipristal Acetate|Drug: Levonorgestrel (LNG)/Ethinyl estradiol birth control pill","Number of Participants With Follicle Rupture","Oregon Health and Science University|Society of Family Planning","Female","18 Years to 35 Years   (Adult)","Phase 4","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","OHSU IRB 11784","September 8, 2015","June 17, 2017","June 17, 2017","October 16, 2015","December 31, 2018","November 8, 2019","Oregon Health & Science University, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02577601/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02577601"
624,"NCT02577510","Comparing Ways to Freeze the Nerve That Provides Thigh Sensation",,"Completed","Has Results","Meralgia Paresthetica","Drug: Nerve Injection- Nerve Stimulator|Drug: Nerve Injection - Ultrasound","Anesthesia Related Time|Success Rate|Needle Pass|Pain With Procedure","Canadian Forces Health Services Centre Ottawa","All","18 Years to 60 Years   (Adult)","Phase 3","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","#2014-005-","November 2015","February 2016","June 2016","October 16, 2015","September 15, 2017","September 15, 2017",,,"https://ClinicalTrials.gov/show/NCT02577510"
625,"NCT02577315","Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions",,"Completed","Has Results","Healthy","Drug: Empagliflozin|Drug: Metformin","Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)|Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)|Maximum Measured Concentration of the Empagliflozin in Plasma (Cmax)|Maximum Measured Concentration of the Metformin in Plasma (Cmax)|Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)|Area Under the Concentration-time Curve of the Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)","Boehringer Ingelheim","All","18 Years to 45 Years   (Adult)","Phase 1","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1276.27","September 2015","October 2015","October 2015","October 16, 2015","November 30, 2016","November 30, 2016","1276.27.001 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02577315"
626,"NCT02576041","Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria","F1","Completed","Has Results","Allergic Rhinitis|Urticaria","Drug: Bilastine|Drug: Placebo","Standard Deviation Lateral Position (SDLP) Evaluated During the F1 Simulator Test|Maintenance of Constant Speed Evaluated During the F1 Simulator|Time to Reaction Evaluated During the F1 Simulator","Menarini International Operations Luxembourg SA","All","21 Years to 55 Years   (Adult)","Phase 4","19","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MEIN/14/Bil-ARU/001|2015-001313-26","October 2015","December 2015","December 2015","October 15, 2015","January 16, 2017","April 18, 2017","Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy",,"https://ClinicalTrials.gov/show/NCT02576041"
627,"NCT02575950","Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne",,"Completed","Has Results","Acne Vulgaris","Drug: LEO43204|Drug: Placebo","Total Lesion Count (Inflammatory and Non-inflammatory)|Inflammatory Lesion Count|Non-inflammatory Lesion Count|Number of Participants Stratified by Investigator's Global Assessment (IGA) of the Treatment Area|Composite Local Skin Response (LSR) Score at All Visits|Participant's Component LSR Score: Erosion/Ulceration|Participant's Component LSR Score: Crusting|Participant's Component LSR Score: Erythema|Participant's Component LSR Score: Flaking/Scaling|Participant's Component LSR Score: Swelling|Participant's Component LSR Score: Vesiculation/Pustulation|Number of Participants With Occurrence of Unacceptable LSR Scores or Unacceptable Safety and Tolerability Events at All Visits","LEO Pharma","All","18 Years to 35 Years   (Adult)","Phase 2","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EXP-1223","June 2016","April 2017","April 2017","October 15, 2015","February 28, 2019","February 28, 2019","Torrance Clinical Research Institute Inc., Lomita, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02575950/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02575950/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02575950"
628,"NCT02574845","DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)",,"Completed","Has Results","Healthy","Drug: Rosuvastatin|Drug: Metformin HCl|Drug: Furosemide","Area Under the Curve of Rosuvastatin From 0 to the Last Quantifiable Data Point (AUC0-tz)|Maximum Concentration of Rosuvastatin (Cmax)|Area Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC0-∞)","Boehringer Ingelheim","Male","18 Years to 55 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","352.2094|2015-003052-46","October 2015","December 2015","December 2015","October 14, 2015","February 13, 2017","February 13, 2017","Boehringer Ingelheim Investigational Site, Biberach, Germany",,"https://ClinicalTrials.gov/show/NCT02574845"
629,"NCT02572752","Relative Bioavailability of 2 Oral Formulations of Nintedanib",,"Completed","Has Results","Healthy","Drug: Nintedanib","AUC0-tz|Cmax|AUC0-inf","Boehringer Ingelheim","Male","18 Years to 50 Years   (Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1199.237|2015-001348-12","August 2015","November 2015","November 2015","October 9, 2015","January 5, 2017","January 5, 2017","Boehringer Ingelheim Investigational Site, Biberach, Germany",,"https://ClinicalTrials.gov/show/NCT02572752"
630,"NCT02572609","Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride",,"Completed","Has Results","Healthy","Drug: Ambroxol hydrochloride soft pastille|Drug: Mucosolvan ® adult syrup","Cmax|AUC0-t","Boehringer Ingelheim",,"18 Years to 50 Years   (Adult)","Phase 1",,"Industry","Interventional","Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18.509","November 2011","December 2011","December 2011","October 9, 2015","December 31, 2015","December 31, 2015",,,"https://ClinicalTrials.gov/show/NCT02572609"
631,"NCT02572401","Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men","STAND","Completed","Has Results","Human Immunodeficiency Virus (HIV)|Sexually Transmitted Disease (STD)","Behavioral: STAND HIV Risk Reduction Intervention|Behavioral: Text Messaging Intervention","Consistent (100%) Condom Use|Unprotected Intercourse|Multiple Partners|Insertive Anal Intercourse|Proportion Condom-protected Intercourse","University of Pennsylvania|National Institute on Minority Health and Health Disparities (NIMHD)","Male","18 Years to 45 Years   (Adult)","Not Applicable","391","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","810971|R01MD004075","October 2011","June 2013","June 2015","October 8, 2015","October 15, 2019","October 15, 2019","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02572401"
632,"NCT02572388","A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1",,"Completed","Has Results","Malaria","Biological: R21|Biological: Matrix-M1","Safety and Tolerability of Administration of R21 With and Without the Adjuvant Matrix-M1 Assessed by the Occurrence of Solicited Local and Systemic Adverse Events.|Safety and Tolerability of R21 With and Without the Adjuvant Matrix-M1 Assessed by the Occurrence of Unsolicited Adverse Events.|Safety and Tolerability of R21 With and Without the Adjuvant Matrix-M1 Assessed by the Occurrence of Serious Adverse Events.|Safety and Tolerability of R21 With and Without the Adjuvant Matrix-M1 Assessed by the Occurrence of Laboratory Adverse Events.","University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","VAC053","October 15, 2015","August 29, 2017","August 29, 2017","October 8, 2015","November 12, 2019","November 12, 2019","Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, Oxfordshire, United Kingdom|NIHR Wellcome Trust Clinical Research Facility, Hammersmith Hospital, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02572388/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02572388"
633,"NCT02571439","Comparative Study of Two Different Techniques to Perform TAP-blocks","Surgical-TAP","Completed","Has Results","POSTOPERATIVE PAIN","Procedure: Surgical TAP block|Procedure: Conventional TAP block|Drug: 0.5% ropivacaine","Time Taken to Perform the Block|Time From Delivery of Neonate to Ready to Exit Operating Room|Severity of Postoperative Pain at Rest","Maimonides Medical Center","Female","18 Years to 40 Years   (Adult)","Phase 4","41","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB 2014-08-05","October 2014","August 2015","August 2015","October 8, 2015","August 3, 2018","August 3, 2018","Maimonides Medical Center, Brooklyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT02571439"
634,"NCT02571153","Low Doses of Ketamine and Postoperative Quality of Recovery",,"Completed","Has Results","Postoperative Pain|Postoperative Nausea and Vomiting","Drug: Ketamine 0.4 mg/kg|Drug: Normal saline|Drug: Ketamine 0.2 mg/kg","Quality of Postoperative Recovery Assessed by QoR-40 Questionnaire 24 Hours After Surgery|Length of PACU Stay|Occurrence of Postoperative, Nausea and Vomiting|Occurrence of Pain at PACU Using a 0-10 Numeric Pain Rating Scale|Morphine Consumption (mg) at PACU|The Severity of Postoperative Pain|Percentage of Participants With Tramadol Consumption","Pontificia Universidade Catolica de Sao Paulo","All","18 Years to 60 Years   (Adult)","Phase 4","135","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PUCSP 057539/2015","September 2015","March 2016","May 2016","October 8, 2015","March 6, 2017","March 6, 2017","Santa Lucinda Hospital, Sorocaba, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT02571153"
635,"NCT02570295","Swiss Army Physical Fitness Training","SAFT","Completed","Has Results","Wounds and Injuries|Physical Activity|Mood (Psychological Function)|Motivation|Motor Activity","Other: Swiss Army Physical Fitness Training","Number of Participants With Injuries|Physical Fitness Measured With the Swiss Physical Fitness Test Battery (SPFTB)|Psychological Questionnaires|Military Performance According to Military Marks|Questionnaire About Health and Physical Activities|Attrition Rate","Swiss Federal Institute of Sport Magglingen|Swiss Armed Forces","All","18 Years to 25 Years   (Adult)","Not Applicable","722","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","SAFT_82/15","July 2015","August 2016","August 2016","October 7, 2015","March 21, 2017","March 21, 2017","Casern of the Swiss Army rescue training school 75, Wangen an der Aare, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT02570295"
636,"NCT02570074","PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults","PROOF","Completed","Has Results","Healthy Subjects","Drug: Fosfomycin","Number (%) of Grade 2 or Higher AEs Regardless of Relationship to Study Drug|Day 1: Plasma PK Concentrations [mg/L]|Day 5: Plasma PK Concentrations [mg/L]|Maximum Plasma Concentration (Cmax)|Day 1: Area Under the Concentration Time Curve (AUC 0-infinity)|Day 5: Area Under the Concentration Time Curve (AUC Tau-infinity)|Number of Subjects Who Prematurely Discontinue Study Drug|Total Body Clearance (CL)|Apparent Volume of Distribution (Vss)|Elimination Rate Constant (z)|Elimination Half-life (t½)|Renal Clearance (CLR)|Amount Excreted in the Urine (Ae)|Urinary Bactericidal (UBT) Titers for E. Coli ATCC 25922|Urinary Bactericidal Kinetics (UBK)|Urine Fosfomycin Concentrations [mg/L]|UBT-time Curve (AUBT24)|Urinary Bactericidal (UBT) Titers for E. Coli ATCC BAA-2323|Urinary Bactericidal (UBT) Titers for K. Pneumoniae ATCC 33495|Urinary Bactericidal (UBT) Titers for K. Pneumoniae ATCC 700603|Urinary Bactericidal (UBT) Titers for P. Mirabilis ATCC 35659|Urinary Inhibitory (UIT) Titers for E. Coli ATCC 25922|Urinary Inhibitory (UIT) Titers for E. Coli ATCC BAA-2323|Urinary Inhibitory (UIT) Titers for K. Pneumoniae ATCC 33495|Urinary Inhibitory (UIT) Titers for K. Pneumoniae ATCC 700603|Urinary Inhibitory (UIT) Titers for P. Mirabilis ATCC 35659","Vance Fowler, M.D.|National Institute of Allergy and Infectious Diseases (NIAID)|Duke University","All","18 Years to 55 Years   (Adult)","Phase 1","19","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pro00066102|1UM1AI104681-01","January 2016","September 2016","November 2016","October 7, 2015","July 30, 2019","July 30, 2019","University of Illinois at Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02570074"
637,"NCT02569112","Evaluation of CoolSculpt Combining Venus Legacy Technology for Enhanced Results in Fat Reduction & Laxity of the Flanks",,"Completed","Has Results","Adipose Tissue","Device: multipolar RF, varipulse|Device: cryolipolysis","General Improvement in Skin Laxity of the Flank Area","Venus Concept","All","21 Years to 50 Years   (Adult)","Not Applicable","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CS0915","August 2015","June 2016","October 2016","October 6, 2015","June 18, 2018","June 18, 2018","Few Institute, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02569112"
638,"NCT02568397","A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants",,"Completed","Has Results","Healthy","Drug: Lanabecestat|Drug: Dabigatran etexilate","Pharmacokinetics (PK) : Maximum Concentration (Cmax) of Dabigatran|Pharmacokinetics: Area Under The Dabigatran Pharmacokinetic (PK) Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity)|Pharmacokinetics: Maximum Concentration (Cmax) of Lanabecestat|Pharmacokinetics: Area Under the Lanabecestat Pharmacokinetic (PK) Concentration Versus Time Curve During One Dosing Interval (24 Hours) (AUCtau)|Pharmacodynamics: Area Under the Effect Versus Time Curve (AUEC) of Thrombin Time|Pharmacodynamics: Ratio of Maximum Effect to Baseline Effect (ERmax) of Thrombin Time","AstraZeneca|Eli Lilly and Company","All","18 Years to 50 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","15997|I8D-MC-AZEE","October 31, 2015","January 31, 2016","January 31, 2016","October 5, 2015","April 5, 2019","November 1, 2019","Covance, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02568397"
639,"NCT02568345","Sugammadex ED90 Dose in the Obese Patients",,"Completed","Has Results","Incomplete Reversal of Neuromuscular Block","Drug: sugammadex ED90","Sugammadex ED90","Faculdade de Ciências Médicas da Santa Casa de São Paulo","All","18 Years to 60 Years   (Adult)","Phase 4","31","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","191.837","January 2013","October 2013","January 2014","October 5, 2015","February 22, 2016","February 22, 2016",,,"https://ClinicalTrials.gov/show/NCT02568345"
640,"NCT02568254","Evaluation of Three Daily Disposable Contact Lenses",,"Completed","Has Results","Visual Acuity","Device: Lens 1 (etafilcon A)|Device: Lens 2 (nelfilcon A)|Device: Lens 3 (nesofilcon A)","Overall Comfort","Johnson & Johnson Vision Care, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","CR-5735","September 3, 2015","January 18, 2016","January 18, 2016","October 5, 2015","July 17, 2017","July 17, 2017","Centre for Contact Lens Research, Waterloo, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02568254"
641,"NCT02567968","A Study to Determine if Caffeine Accelerates Emergence From Anesthesia",,"Completed","Has Results","Anesthesia","Drug: Caffeine|Drug: Placebo Control","Waking Time - Re-establishment of the Gag Reflex.|Cognitive Test1 - Visual Analog Scale --- Feel Good|Cognitive Test1 - Visual Analog Scale --- Feel Bad|Cognitive Test2 - Sternberg Test of Memory|Cognitive Test3 - Divided Attention Task|Bispectral Index|Minute Ventilation|Mean Arterial Blood Pressure|Heart Rate","University of Chicago|National Institutes of Health (NIH)|National Institute of General Medical Sciences (NIGMS)","Male","25 Years to 40 Years   (Adult)","Phase 4","8","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB15-0897|1R01GM116119-01","August 2016","May 1, 2017","May 1, 2017","October 5, 2015","July 18, 2018","August 16, 2018","The University of Chicago, Chicago, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02567968/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02567968"
642,"NCT02567552","Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone Versus Intramuscular Progesterone",,"Completed","Has Results","Reproductive Techniques, Assisted","Drug: Subcutaneous progesterone|Drug: Intramuscular progesterone","Predecidual Transformation|Decidualization of Stromal Cell|Endometrial Maturation Using Noyes' Criteria|Endometrial Gene Expression|Endometrial Gene Expression Difference|Endometrial Thickness|Blood Estradiol Level|Blood Progesterone Level|Blood LH Level|Number of Participants With Side Effects During the Study","IVI Barcelona","Female","18 Years to 34 Years   (Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1412-BCN-087-AB|2015-000290-12","May 2015","December 2015","January 2016","October 5, 2015","March 19, 2018","December 16, 2019","IVI Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02567552"
643,"NCT02566759","A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants",,"Terminated","Has Results","Schizophrenia, Cerebellar Ataxia","Drug: TAK-831 Oral Suspension|Drug: TAK-831 Placebo|Drug: TAK-831 Tablet","Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose|Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post Dose|Part 1, 2 and 4: Cmax: Maximum Observed Plasma Concentration for TAK-831|Part 2 and 3: Cmax, ss: Maximum Observed Plasma Concentration at Steady State for TAK-831|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-831|Part 1, 2 and 4: AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-831|Part 1, 2 and 4: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831|Part 2 and 3: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-831","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","TAK-831-1001|2015-002295-24|U1111-1168-6568|15/SC/0412","September 23, 2015","June 9, 2016","July 12, 2016","October 2, 2015","February 6, 2018","February 6, 2018","London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02566759"
644,"NCT02566135","I-gel Versus Classic-Laryngeal Mask Airway (C-LMA) as a Conduit for Tracheal Intubation Using Ventilating Bougie",,"Completed","Has Results","Intubation; Difficult","Device: Tracheal Intubation using I-gel and ventilating bougie|Device: Tracheal Intubation using C-LMA and ventilating bougie","Number of Attempts for I-gel or Classic-LMA Insertions|Number of Attempts for Ventilating Bougie Insertions Through I-gel or C-LMA|Number of Attempts for Railroading of Endotracheal Tube Over Ventilating Bougie|Time of Insertion|Total Intubation Time|Heart Rate|Systolic Blood Pressure|Diastolic Blood Pressure","Medical College Baroda","All","18 Years to 60 Years   (Adult)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECR/85/Inst/GJ/2013","March 2014","January 2015","February 2015","October 2, 2015","July 27, 2018","July 27, 2018",,,"https://ClinicalTrials.gov/show/NCT02566135"
645,"NCT02566005","A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor",,"Completed","Has Results","Pregnancy","Device: misoprostol|Device: Foley bulb","The Time Interval From Induction to Delivery: All Participants|Time (Hours) From Induction to Delivery: Nulliparous|Time (Hours) From Induction to Delivery: Multiparous|Time From Induction to Delivery: VD|Time From Induction to Delivery: CD|Per Treatment Protocol: Time (Hours) From Induction to Delivery|The Time From Induction Until to Active Phase Labor|The Time From Active Phase to Delivery|Incidence of Chorioamnionitis|Incidence of Uterine Tachysystole|Incidence of Patient Discomfort|Estimated Blood Loss","St. Luke's-Roosevelt Hospital Center","Female","18 Years to 60 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","15-0032","September 2015","July 2016","July 2016","October 1, 2015","March 27, 2018","March 27, 2018","Mount Sinai Roosevelt, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02566005"
646,"NCT02565810","An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis",,"Completed","Has Results","Rheumatoid Arthritis","Drug: Adalimumab PFS and Pen","The Change in Injection Site Pain Score Using an 11-point Visual Numeric Scale|Overall Impression of SC Delivery Administration of SB5 Using Questionnaire|Subject Preference of SC Delivery Administration of SB5 Using Questionnaire","Samsung Bioepis Co., Ltd.","All","18 Years to 55 Years   (Adult)","Phase 2","49","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","SB5-G21-RA","September 2015","March 2016","March 2016","October 1, 2015","April 1, 2019","April 1, 2019","Medica Pro Familia Sp. z o.o. S.K.A. Oddzial Gdynia, Gdynia, Poland|Medica pro Familia Sp z o.o. S.K.A Oddzial Warszawa, Warszawa, Poland",,"https://ClinicalTrials.gov/show/NCT02565810"
647,"NCT02565784","Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population",,"Completed","Has Results","Healthy Volunteers","Device: Restylane|Device: Perlane","Percentage of Participants Improved in ""Global Facial Aesthetic Appearance"" - Judged by Participant|Percentage of Participants Improved in Nasolabial Fold Severity (Merz Aesthetic Scale) - Judged by Investigator|Percentage of Participants Improved in Upper Cheek Fullness - Judged by Investigator","Q-Med AB","Female","25 Years to 50 Years   (Adult)","Not Applicable","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05DF1315","December 2015","December 29, 2016","September 28, 2018","October 1, 2015","October 3, 2019","October 3, 2019","Galderma Research Site, Kaohsiung, Taiwan|Galderma Research Site, Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT02565784"
648,"NCT02565485","Pulse Pressure and Post-epidural Fetal Heart Rate Changes",,"Completed","Has Results","Fetus or Neonate Affected by Maternal Epidural Anesthesia During Labor and Delivery","Drug: Lactated Ringer's","Incidence of New-onset Category II or III Fetal Heart Rate Tracings|New Onset Hypotension (>20% Decrease in Systolic and/or Diastolic Blood Pressure)|Interventions to Correct Maternal Hypotension or Fetal Heart Rate Abnormalities (Position Change, Supplemental Oxygen, Vasopressor Support, Emergent Operative Delivery)|Adverse Events (Pulmonary Edema)","MetroHealth Medical Center","Female","18 Years to 50 Years   (Adult)","Not Applicable","276","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","IRB15-00366","September 1, 2015","November 1, 2016","November 1, 2016","October 1, 2015","June 8, 2018","July 9, 2018","MetroHealth Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02565485"
649,"NCT02564497","A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C",,"Completed","Has Results","Renal Transplantation","Biological: Process E Belatacept|Biological: Process C Belatacept","Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (INF) of Belatacept.|Maximum Observed Serum Concentration (Cmax) of Belatacept|Time of Maximum Observed Serum Concentration (Tmax)|Area Under the Serum Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC 0-T)|Total Body Clearance (CLT)|Volume of Distribution at Steady State (Vss)|Half Life (T-HALF)","Bristol-Myers Squibb","All","18 Years to 55 Years   (Adult)","Phase 1","491","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IM103-349","October 2, 2015","January 27, 2017","January 27, 2017","September 30, 2015","April 17, 2019","April 17, 2019","PPD Development, Austin, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02564497/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02564497/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02564497"
650,"NCT02564029","PF-06372865 in Subjects With Photosensitive Epilepsy",,"Completed","Has Results","Reflex Epilepsy, Photosensitive","Drug: PF-06372865|Drug: Placebo|Drug: Lorazepam","The Standardized Photosensitivity Range (SPR) in the Subject's Most Sensitive Eye Condition|The SPR in the Eye Closure, Eyes Closed, and Eyes Open Condition|The Percentage of Participants With Complete Suppression, Partial Response, and no Response to Intermittent Photic Stimulation (IPS)|Maximum Plasma Concentration (Cmax) of PF-06372865|Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06372865|Time for Cmax (Tmax) of PF-06372865|Plasma Concentration of Lorazepam|Number of Participants With Clinically Significant Laboratory Test Abnormalities|Number of Participants With Clinically Significant Change From Baseline in Blood Pressure and Pulse Rate|Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings|Number of Participants With Treatment-emergent Adverse Events (AEs)","Pfizer","All","18 Years to 60 Years   (Adult)","Phase 2","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","B7431005","December 16, 2015","January 10, 2017","February 7, 2017","September 30, 2015","March 14, 2018","March 14, 2018","Consultants in Epilepsy & Neurology, PLLC, Boise, Idaho, United States|Johns Hopkins University Department of Neurology, Baltimore, Maryland, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Center for Advanced Medicine, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|New York University Comprehensive Epilepsy Center, New York, New York, United States|Clinical and Translational Research Center, Philadelphia, Pennsylvania, United States|Hospital of the Univ of PA Pharmacy Service, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Comprehensive Epilepsy Center, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital EEG lab, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Investigational Drug Service, Philadelphia, Pennsylvania, United States|General Clinical Research Center (GCRC), Nashville, Tennessee, United States|Vanderbilt University Epilepsy Clinic, Nashville, Tennessee, United States|Vanderbilt University Hospital Pharmacy, Nashville, Tennessee, United States|VU Department of Neurology, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02564029"
651,"NCT02563834","A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: thiapalmitate tracer|Drug: Saline|Drug: Insulin","Myocardial Fatty Acid Uptake Rate|Myocardial Oxidation Rate|Myocardial Perfusion Rate","Indiana University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 45 Years   (Adult)","Not Applicable","18","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","10100002643|R21DK071142","January 2007","June 2009","June 2009","September 30, 2015","August 31, 2016","August 31, 2016","Indiana University Hospital GCRC, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02563834"
652,"NCT02562482","Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults",,"Completed","Has Results","Chikungunya Virus Infection","Biological: VRC-CHKVLP059-00-VP|Other: VRC-PBSPLA043-00-VP","Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Any Injection|Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 7 Days of Any Injection|Number of Subjects With an Abnormal Laboratory Result|Number of Subjects Reporting Unsolicited Adverse Events (AEs)|Number of Subjects Reporting Serious Adverse Events (SAEs)|Number of Subjects With Confirmed Chikungunya Virus (CHIKV) Infection Events|Chikungunya Antigen-specific Neutralizing Antibody Geometric Mean Titer (GMT) - Per Protocol Population|Chikungunya Antigen-specific Neutralizing Antibody Geometric Mean Titer (GMT) - Intent-to-Treat Population|Chikungunya Antigen-specific Neutralizing Antibody Geometric Mean Titer (GMT) - Modified Intent-to-Treat","National Institute of Allergy and Infectious Diseases (NIAID)|The Emmes Company, LLC|Leidos|FHI 360","All","18 Years to 60 Years   (Adult)","Phase 2","400","NIH|Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","VRC 704","November 18, 2015","March 6, 2018","March 6, 2018","September 29, 2015","May 14, 2019","May 14, 2019","Instituto Dermatológico y Cirugía de Piel, Santo Domingo, Dominican Republic|University Hospital of Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe|Centres GHESKIO, Port Au Prince, Haiti|Centre Hospitalier Universitaire (CHU), Martinique, Fort-de-France, Martinique|San Juan Hospital, Research Unit, Rio Piedras, Puerto Rico|Puerto Rico Clinical and Translational Research Consortium, San Juan, Puerto Rico","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02562482/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02562482"
653,"NCT02561156","TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants",,"Completed","Has Results","Depressive Disorder","Drug: TAK-653 Placebo|Drug: TAK-653","Part 1: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)|Part 2: Percentage of Participants Who Experience at Least One TEAE|Part 1: Percentage of Participants Who Discontinued the Treatment Due to an Adverse Event (AE)|Part 2: Percentage of Participants Who Discontinued the Treatment Due to an AE|Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose|Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Postdose|Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose|Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Postdose|Part 1: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) at Least Once Postdose|Part 2: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety ECG at Least Once Postdose|Part 1: Percentage of Participants Who Experience Clinically Significant Abnormal Changes in Safety Electroencephalogram (EEG) Measurements at Least Once Postdose|Part 2: Percentage of Participants Who Experience Clinically Significant Abnormal Changes in Safety EEG Measurements at Least Once Postdose|Part 1: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)|Part 2: Number of Participants With Treatment-emergent Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS|Cmax: Maximum Observed Plasma Concentration for TAK-653 on Day 1|Part 2: Cmax: Maximum Observed Plasma Concentration for TAK-653 on Day 6|Part 2: Cmax,ss: Maximum Observed Plasma Concentration at Steady State for TAK-653|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-653 on Day 1|Part 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-653 on Day 18|AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-653|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-653|Part 2: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-653","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","TAK-653-1001|2015-002268-17|U1111-1170-0519|15/SS/0117","August 26, 2015","September 11, 2017","September 23, 2017","September 25, 2015","February 8, 2019","February 8, 2019","Hammersmith Medicines Research, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02561156/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02561156/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02561156"
654,"NCT02560389","Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)",,"Completed","Has Results","Stress Disorder, Post Traumatic","Drug: Placebo|Drug: Levodopa","Galvanic Skin Response|Percentage Change in Functional Activation of Amygdala|Functional Activation of Anterior Cingulate Cortex","University of Wisconsin, Madison","Female","25 Years to 50 Years   (Adult)","Phase 4","103","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","204583","March 2016","May 1, 2018","May 1, 2018","September 25, 2015","June 25, 2019","June 25, 2019","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02560389/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02560389"
655,"NCT02558790","L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD",,"Completed","Has Results","Attention Deficit/Hyperactivity Disorder|ADHD","Drug: L-Threonic Acid Magnesium Salt (L-TAMS)","Change in Adult ADHD Investigator Symptom Rating Scale (AISRS) Score","Massachusetts General Hospital|Neurocentria, Inc.","All","18 Years to 55 Years   (Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-P-000528","March 2016","October 2017","October 2017","September 24, 2015","May 14, 2018","May 14, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02558790/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02558790"
656,"NCT02555618","Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants",,"Completed","Has Results","Influenza Infection","Biological: TAK-850|Biological: Influenza HA vaccine","Seroconversion Rate of Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen)|Geometric Mean Titer (GMT) of HI Antibody Titer (Egg-Derived Antigen)|Seroprotection Rate of HI Antibody Titer (Egg-Derived Antigen)|Geometric Mean Fold Increase in HI Antibody Titer (Egg-Derived Antigen)|Seroconversion Rate of Single Radial Hemolysis (SRH) Antibody Titer (Egg-Derived Antigen)|GMT of SRH Antibody Titer (Egg-Derived Antigen)|Seroprotection Rate of SRH Antibody Titer (Egg-Derived Antigen)|Geometric Mean Fold Increase in SRH Antibody Titer (Egg-Derived Antigen)|Seroconversion Rate of HI Antibody Titer (Vero-Derived Antigen)|GMT of HI Antibody Titer (Vero-Derived Antigen)|Seroprotection Rate of HI Antibody Titer (Vero-Derived Antigen)|Geometric Mean Fold Increase in HI Antibody Titer (Vero-Derived Antigen)|Seroconversion Rate of SRH Antibody Titer (Vero-Derived Antigen)|GMT of SRH Antibody Titer (Vero-Derived Antigen)|Seroprotection Rate of SRH Antibody Titer (Vero-Derived Antigen)|Geometric Mean Fold Increase in SRH Antibody Titer (Vero-Derived Antigen)|Percentage of Participants With Solicited Local and Systemic Adverse Events (AEs)|Percentage of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)|Percentage of Participants With Abnormal Safety Laboratory Tests at Least Once Post Dose Reported as AEs","Takeda","All","20 Years to 49 Years   (Adult)","Phase 2","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TAK-850/CPH-003|U1111-1174-1290|JapicCTI-153019","September 2015","December 2015","December 2015","September 21, 2015","December 29, 2016","December 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02555618"
657,"NCT02554981","Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®","EMPOWER","Completed","Has Results","Dry Eye Syndromes","Drug: Cyclosporine 0.05% Ophthalmic Emulsion","Change From Baseline in the Total Corneal Staining Score With Fluorescein in the Worse Eye|Change From Baseline in the Total Conjunctival Staining Score With Fluorescein in the Worse Eye|Change From Baseline in the Central Region Staining Score With Fluorescein in the Worse Eye|Change From Baseline in the Total Corneal Staining Score With Lissamine Green in the Worse Eye|Change From Baseline in the Total Conjunctival Staining Score With Lissamine Green in the Worse Eye|Change From Baseline in the Central Region Staining Score With Lissamine Green in the Worse Eye|Change From Baseline in Font Size|Change From Baseline in Words Read Incorrectly|Change From Baseline in Time to Read Passage|Change From Baseline in Reading Rate|Change From Baseline in Tear Film Break Up Time (TFBUT) in the Worse Eye|Change From Baseline in Ocular Protection Index (OPI) 2.0 in the Worse Eye|Change From Baseline in Interblink Interval (IBI) in the Worst Eye|Change From Baseline in OSDI© Total Score|Change From Baseline in Driving at Night on the OSDI©|Change From Baseline in Working With a Computer or Bank Machine on the OSDI©|Change From Baseline in Watching Television (TV) on the OSDI©|Change From Baseline in Blurred Vision on the OSDI©|Change From Baseline in Poor Vision on the OSDI©|Change From Baseline in Reading on the OSDI©|Change From Baseline in the Ocular Discomfort Scale Post Wilkins Test in the Worst Eye","Allergan","All","18 Years to 55 Years   (Adult)","Phase 4","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MA-RES-015-001","July 21, 2015","March 24, 2016","March 24, 2016","September 21, 2015","June 1, 2017","June 1, 2017","Andover Eye Associates, Inc, Andover, Massachusetts, United States|Total Eye Care, PA, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02554981"
658,"NCT02554799","A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers",,"Completed","Has Results","Malaria","Drug: MMV390048 formulation A|Drug: MMV390048 formulation B","Cmax: Peak Plasma Concentration|Tmax: Time to Reach Peak Plasma Concentration|AUC: Area Under the Plasma Concentration-time Curve From Zero to Infinity|Terminal Elimination Half-life (t1/2)|Terminal Elimination Rate Constant (Lambda z)|Oral Plasma Clearance (CL/F)|Apparent Volume of Distribution (Vz/F)","Medicines for Malaria Venture|Richmond Pharmacology Limited","All","18 Years to 55 Years   (Adult)","Phase 1","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","MMV_MMV390048_15_01","September 17, 2015","October 28, 2015","October 28, 2015","September 18, 2015","August 28, 2019","September 10, 2019","Richmond Pharmacology Ltd., Croydon, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02554799"
659,"NCT02554279","MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population","MEGASET HR","Completed","Has Results","Infertility","Drug: menotropin|Drug: recombinant FSH","Ongoing Pregnancy Rate|Positive β-human Chorionic Gonadotropin (hCG) Rate|Clinical Pregnancy Rate|Early Pregnancy Loss|Follicular Development as Assessed by TVUS|Number of Oocytes Retrieved|Number of Metaphase II Oocytes|Fertilization Rate|Quality of Embryos|Quality of Blastocysts","Ferring Pharmaceuticals","Female","21 Years to 35 Years   (Adult)","Phase 4","620","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","000205","August 31, 2015","January 26, 2017","February 2, 2017","September 18, 2015","March 2, 2018","March 20, 2019","Bloom Reproductive Institute, Scottsdale, Arizona, United States|Fertility Treatment Center, Tempe, Arizona, United States|HRC Fertility, Encino, California, United States|California Fertility Partners, Los Angeles, California, United States|Colorado Center for Reproductive Medicine (CCRM), Lone Tree, Colorado, United States|Reproductive Associates of Delaware, Newark, Delaware, United States|Women's Medical Research Group, Clearwater, Florida, United States|Fertility and IVF Center of Miami, Miami, Florida, United States|Center for Reproductive Medicine, Orlando, Florida, United States|The Reproductive Medicine Group, Tampa, Florida, United States|Georgia Reproductive Specialists, Sandy Springs, Georgia, United States|Fertility Institute of Hawaii, Honolulu, Hawaii, United States|Idaho Center for Reproductive Medicine, Boise, Idaho, United States|Fertility Centers of Illinois, Chicago, Illinois, United States|InVia Fertility Specialists, SC, Hoffman Estates, Illinois, United States|The Advanced IVF Institute, Naperville, Illinois, United States|Shady Grove Fertility Centers, Rockville, Maryland, United States|Shady Grove Fertility, Towson, Maryland, United States|IVF New England, Lexington, Massachusetts, United States|Boston IVF, Waltham, Massachusetts, United States|Fertility Center of Las Vegas, Las Vegas, Nevada, United States|Reproductive Medicine Associates of New Jersey, Basking Ridge, New Jersey, United States|Reach, Charlotte, North Carolina, United States|Carolina Conceptions, Raleigh, North Carolina, United States|Abington Hospital, Jefferson Health, Abington, Pennsylvania, United States|Main Line Fertility Center, Bryn Mawr, Pennsylvania, United States|Coastal Fertility Specialists, Mount Pleasant, South Carolina, United States|Center for Assisted Reproduction, Bedford, Texas, United States|Houston Fertility Institute, Houston, Texas, United States|Center of Reproductive Medicine, Webster, Texas, United States|Utah Fertility Center, Pleasant Grove, Utah, United States|Reproductive Care Center, Sandy, Utah, United States|The Jones Institute for Reproductive Medicine, Norfolk, Virginia, United States|Virginia Center for Reproductive Medicine, Reston, Virginia, United States|Seattle Reproductive Medicine, Seattle, Washington, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02554279/SAP_000.pdf|""Study Protocol: Clinical Trial Protocol (including amendments 1-4)"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02554279/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02554279"
660,"NCT02552147","Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism",,"Completed","Has Results","Autism Spectrum Disorder|Aggression|Irritability","Drug: Transdermal nicotine|Other: Transdermal placebo","Change From Baseline in Aberrant Behavior Checklist Irritability Subscale (ABC-I)|Change in Social Responsiveness Scale-Adults (SRS-A)|Change in Qualitative Description of Irritability and Aggression Symptoms|Change in Frustration and Irritability Ratings During Frustration-induction Go-NoGo Task|Change in State/Trait Anxiety Inventory (STAI) Score|Nightly Sleep Quality","Yale University|Autism Speaks","All","18 Years to 60 Years   (Adult)","Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1502015384","September 2015","November 17, 2017","November 17, 2017","September 16, 2015","March 14, 2019","March 14, 2019","Yale University, New Haven, Connecticut, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02552147/ICF_001.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02552147/Prot_SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02552147"
661,"NCT02550197","Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years",,"Completed","Has Results","Influenza","Biological: Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016|Biological: Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation","Geometric Mean Titers of Influenza Antibodies Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route|Percentage of Participants Achieving Seroprotection Against Influenza Antigens Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route|Percentage of Participants With Influenza Antibodies Titers < 10 (1/Dil) Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route|Percentage of Participants Achieving Seroconversion or Significant Increase Against Influenza Antigens After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route|Geometric Mean Titer Ratios of Influenza Virus Antibodies After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route|Percentage of Participants Reporting Solicited Reactions Listed in The Former Committee for Medicinal Products for Human Use Note for Guidance Within 3 Days After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route|Percentage of Participants Reporting Solicited Injection-Site or Systemic Reaction After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route","Sanofi Pasteur, a Sanofi Company|Sanofi","All","18 Years to 60 Years   (Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","GQM07|U1111-1143-9015","September 2015","April 2016","July 2016","September 15, 2015","November 4, 2016","November 4, 2016","Ansan-si, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02550197"
662,"NCT02550132","The Role of the Rate of Force Application in Responses to Spinal Manipulation Therapy",,"Completed","Has Results","Spinal Manipulation","Procedure: Spinal manipulation|Device: Apparatus used to deliver spinal manipulations","Left T6 Normalized Root Mean Square (RMS) Value|Left T8 Normalized Root Mean Square (RMS) Value|Right T6 Normalized Root Mean Square (RMS) Value|Right T8 Normalized Root Mean Square (RMS) Value|Vertebral Displacement of the Sixth Thoracic Vertebra|Vertebral Displacement of the Seventh Thoracic Vertebra|Vertebral Displacement of the Eighth Thoracic Vertebra","Université du Québec à Trois-Rivières|Fondation Chiropratique du Québec","All","18 Years to 50 Years   (Adult)","Not Applicable","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UQTR-2013-SMTrate","June 2013","June 2014","June 2014","September 15, 2015","February 5, 2016","February 5, 2016",,,"https://ClinicalTrials.gov/show/NCT02550132"
663,"NCT02549040","Bioavailability of MK-1439 Experimental Nano Formulations in Healthy Adults (MK-1439-046)",,"Completed","Has Results","Human Immunodeficiency Virus-1 (HIV-1)","Drug: Treatment A: MK-1439 100 mg film coated tablet|Drug: Treatment B: MK-1439 150 mg tablet (40% drug loaded granule)|Drug: Treatment C: MK-1439 150 mg tablet (30% drug loaded granule)|Drug: Treatment D: MK-1439 150 mg tablet (50% drug loaded granule)|Drug: Treatment E: MK-1439 100 mg tablet (30% drug loaded granule)","Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1439 Following a Single Administration of MK-1439|Area Under the Plasma Concentration-time Curve From Time 0 to Last Time (AUC0-last) With Quantifiable MK-1439 Following a Single Administration of MK-1439|Maximum Plasma Concentration (Cmax) of MK-1439 Following a Single Administration of MK-1439|Plasma Concentration of MK-1439 at 24 Hours Post-dose (C24hr) Following a Single Administration of MK-1439|Number of Participants Who Experienced at Least One Adverse Event|Number of Participants Who Discontinued Study Treatment Due to an Adverse Event|Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours (AUC0-48 hr) Post-dose of MK-1439 Following a Single Administration of MK-1439","Merck Sharp & Dohme Corp.","All","18 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1439-046|2015-002702-36|MK-1439-046","September 21, 2015","December 24, 2015","December 24, 2015","September 14, 2015","February 22, 2019","February 22, 2019",,,"https://ClinicalTrials.gov/show/NCT02549040"
664,"NCT02549027","A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)",,"Completed","Has Results","Polysomnography","Drug: MK-1064|Drug: MK-6096|Drug: Placebo","Latency to Persistent Sleep (LPS) Following Single Doses of MK-1064 and Placebo|LPS Following Single Doses of MK-6096 and Placebo|Number of Participants With Adverse Events (AEs)|Number of Participants Who Discontinued Study Due to an AE|Wake Time After Sleep Onset (WASO) Following Single Doses of MK-1064 and Placebo|WASO Following Single Doses of MK-6096 and Placebo|Change From Baseline in Choice Reaction Time (CRT) Following Single Doses of MK-1064 and Placebo|Change From Baseline in CRT Following Single Doses of MK-6096 and Placebo","Merck Sharp & Dohme Corp.","Male","18 Years to 45 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1064-003","November 6, 2009","April 6, 2010","April 6, 2010","September 14, 2015","December 10, 2015","October 23, 2018",,,"https://ClinicalTrials.gov/show/NCT02549027"
665,"NCT02549014","A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)",,"Completed","Has Results","Pharmacokinetics","Drug: MK-1064|Drug: Placebo","Number of Participants Who Experienced One or More Adverse Events (AEs)|Number of Participants Who Discontinued Study Due to an AE|Average Plasma Concentration From Time Zero to 4 Hours (Area Under the Plasma Drug Concentration-time Curve From Time Zero to 4 Hours [AUC0-4hr]) Following Single Doses of MK-1064|Area Under the Plasma Drug Concentration-time Curve From Time Zero to Last Measurable Concentration (AUC0-last) Following Single Doses of MK-1064|Maximum Observed Plasma Concentration (Cmax) Following Single Doses of MK-1064|Time to Cmax (Tmax) Following Single Doses of MK-1064|Apparent Terminal Half-life (t1/2) Following Single Doses of MK-1064","Merck Sharp & Dohme Corp.","Male","18 Years to 45 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1064-001","July 6, 2009","September 29, 2009","September 29, 2009","September 14, 2015","January 21, 2016","October 23, 2018",,,"https://ClinicalTrials.gov/show/NCT02549014"
666,"NCT02548728","Oxytocin Treatment of Opioid Dependence",,"Completed","Has Results","Opioid Dependence|Opioid Withdrawal","Drug: Intranasal Oxytocin Spray|Drug: Placebo","Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive|AUC in Subjective Opiate Withdrawal Scale (SOWS) Total Score on Days 1 to 5 Inclusive|AUC in Visual Analog Scale (VAS) Score for Craving on Days 1 to 5 Inclusive|Speilberger State and Trait Anxiety Inventory","University of North Carolina, Chapel Hill","All","21 Years to 45 Years   (Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","14-3041","February 2016","December 2016","December 2016","September 14, 2015","August 7, 2019","August 7, 2019","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02548728"
667,"NCT02545868","A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis",,"Active, not recruiting","Has Results","Multiple Sclerosis, Relapsing-Remitting","Biological: 23-PPV|Biological: 13-PCV Booster|Biological: Influenza Vaccine|Biological: KLH|Drug: OCR|Biological: TT Vaccine","Percentage of Participants With Positive Response to TT Vaccine Measured 8 Weeks After TT Vaccine|Percentage of Participants With Positive Response to TT Vaccine Measured 4 Weeks After TT Vaccine|Percentage of Participants With Tetanus Antibody Titer >/=0.2 IU/mL or 2-Fold Increase in Tetanus Antibody Titers|Mean Levels of Anti-Tetanus Antibody|Mean Levels of Anti-KLH Antibody: Immunoglobulin (Ig) G|Mean Levels of Anti-KLH Antibody: Ig M|Percentage of Participants With Positive Response Against Individual Pneumococcal Serotypes in 23-PPV|Percentage of Participants With Positive Response Against >/=2 Pneumococcal Serotypes|Percentage of Participants With Positive Response Against >/=12 Pneumococcal Serotypes|Mean Levels of Anti-Pneumococcal Antibody|Percentage of Participants With Positive Response Against Individual Pneumococcal Serotypes in 13-PCV|Mean Level of Anti-Pneumococcal Antibody|Percentage of Participants With Seroprotection|Percentage of Participants With 2-Fold Increase in Strain-Specific HI Titers|Percentage of Participants With 4-Fold Increase in Strain-Specific HI Titers|Percentage of Participants With Seroconversion|Strain-Specific Geometric Mean Titer Levels|Ratio of Strain-Specific Geometric Mean Titer Levels Postvaccination to Prevaccination|Magnetic Resonance Imaging (MRI) Parameters: Volume of T2 Lesions|MRI Parameters: Number of T2 Lesions|MRI Parameters: Categorical Number of T2 Lesions|MRI Parameters: Number of Gadolinium (Gd)-Enhancing T1 Lesions|MRI Parameters: Categorical Number of Gd-enhancing T1 Lesions|MRI Parameters: Normalized Brain Volume|MRI Parameters: Volume of T2 Lesions: White Matter Volume|MRI Parameters: Cortical Grey Matter Volume|MRI Parameters: T1 Unenhancing Lesion Volume|MRI Parameters: Total Number of Lesions|Cellular Immune Response Assessed by Flow Cytometry|Total Immunoglobulin|Percentage of Participants With Anti-Drug Antibody Formation|Percentage of Participants With Adverse Events (AEs), Serious AEs, or AEs Leading to Study Discontinuation","Hoffmann-La Roche","All","18 Years to 55 Years   (Adult)","Phase 3","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","BN29739|2015-001357-32","October 27, 2015","February 14, 2017","December 13, 2022","September 10, 2015","June 6, 2018","November 7, 2019","North Central Neurology Associates, Cullman, Alabama, United States|Territory Neurology and Research Institute, Tucson, Arizona, United States|Fullerton Neurology and Headache Center, Fullerton, California, United States|Scripps Clinic, La Jolla, California, United States|Neurology Associates PA, Maitland, Florida, United States|University of Miami School of Medicine; Dept. of Neurology Movement Disorder Center, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, United States|The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States|Mercy Hospital St. Louis / Mercy Clinic Neurology, Chesterfield, Missouri, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, United States|University of New Mexico, Albuquerque, New Mexico, United States|Staten Island Univ Hospital, Staten Island, New York, United States|Ohio Health Research Institute Grant Medical Center, Columbus, Ohio, United States|MDH Research LLC, Westerville, Ohio, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Neurology Clinic PC, Cordova, Tennessee, United States|Central Texas Neurology Consultants, Round Rock, Texas, United States|Rocky Mountain MS Clinic, Salt Lake City, Utah, United States|Swedish Medical Center, Seattle, Washington, United States|University of Calgary, Calgary, Alberta, Canada|University of British Columbia Hospital; Division of Neurology, Vancouver, British Columbia, Canada","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02545868/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02545868/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02545868"
668,"NCT02544607","Ketamine for Depression: An MRI Study",,"Completed","Has Results","Depression|Anxious Depression|Major Depressive Disorder","Drug: Ketamine|Other: Magnetic Resonance Imaging (MRI)","Change in Hamilton Depression Rating Scale (HDRS) From Baseline/Minute 0 to 4 Hours Post-infusion.|Percent Change in Tissue Fractional Anisotropy Quantification (Left Inferior Longitudinal Fasciculus)|Percent Change in Tissue Fractional Anisotropy Quantification (Right Inferior Longitudinal Fasciculus)|Percent Change in Tissue Fractional Anisotropy Quantification (Left Superior Longitudinal Fasciculus)|Percent Change in Tissue Fractional Anisotropy Quantification (Right Uncinate Fasciculus)","Massachusetts General Hospital|Brain & Behavior Research Foundation|National Institutes of Health (NIH)","All","18 Years to 64 Years   (Adult)","Phase 4","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2015P001912|24032","March 2016","December 29, 2017","December 29, 2017","September 9, 2015","April 4, 2019","April 16, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02544607/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02544607"
669,"NCT02543528","A Clinical Trial to Evaluate Investigational Silicone Hydrogel Contact Lenses Worn Continuously for One Week",,"Completed","Has Results","Visual Disorder","Device: Investigational Lens 1|Device: Investigational Lens 2|Device: Investigational Lens 3|Device: etafilcon A (Reusable)|Device: etafilcon A (1-Day)","Number of First Occurred Serious and Significant Lens-related Corneal Infiltrative Event (CIE)|Overall Comfort Score|Overall Vision Score","Johnson & Johnson Vision Care, Inc.","All","18 Years to 39 Years   (Adult)","Not Applicable","171","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR-5201","June 1, 2015","November 8, 2016","November 8, 2016","September 7, 2015","March 29, 2018","October 1, 2019","Medical Research Foundation, Sankara Nethralaya, Chennai, India",,"https://ClinicalTrials.gov/show/NCT02543528"
670,"NCT02542943","Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity",,"Completed","Has Results","Dentin Sensitivity","Device: Experimental Oral Rinse 1|Device: Experimental Oral Rinse 2|Other: Placebo Oral Rinse|Drug: Standard fluoride toothpaste","Change From Baseline in Schiff Sensitivity Score of Experimental Oral Rinses 1 and 2 Against a Placebo Oral Rinse at Week 8|Change From Baseline in Schiff Sensitivity Score of Two Experimental Oral Rinses 1 and 2 at Week 8|Change From Baseline in Schiff Sensitivity Score of Two Experimental Oral Rinses 1 and 2 and a Placebo Oral Rinse at Week 4|Change From Baseline in Tactile Threshold (Gram [g]) of Two Experimental Oral Rinses 1 and 2 and a Placebo Oral Rinse at Week 4|Change From Baseline in Tactile Threshold (g) of Two Experimental Oral Rinses 1 and 2 and a Placebo Oral Rinse at Week 8|Change From Baseline in Visual Rating Scale (VRS) of Two Experimental Oral Rinses 1 and 2 and a Placebo Oral Rinse) at Week 4|Change From Baseline in VRS of Two Experimental Oral Rinses 1 and 2 and a Placebo Oral Rinse) at Week 8","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Not Applicable","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","204762","September 2015","December 2015","December 2015","September 7, 2015","March 6, 2017","March 6, 2017","GSK Investigational Site, Las Vegas, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT02542943"
671,"NCT02542605","To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients",,"Completed","Has Results","Migraine","Drug: Erenumab|Drug: Placebo|Drug: PACAP-38 Challenge Agent","Number of Participants With a MLA Within 24 Hours of Challenge Agent Infusion|Number of Participants With a Headache Within 24 Hours of Challenge Agent Infusion|Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Day 1, Day 8 and EOS|Mean Change From Baseline in Heart Rate at Day 1, Day 8 and EOS|Mean Change From Baseline in Respiratory Rate at Day 1, Day 8 and EOS|Mean Change From Baseline in Temperature at Day 1, Day 8 and EOS|Mean Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) at Day 8, Day 9 and EOS|Mean Change From Baseline in Total Bilirubin at Day 8, Day 9 and EOS|Mean Change From Baseline in Blood Urea at Day 8, Day 9 and EOS|Mean Change From Baseline in Creatine Kinase at Day 8, Day 9 and EOS|Mean Change From Baseline in Creatinine at Day 8, Day 9 and EOS|Mean Change From Baseline in Direct Bilirubin at Day 8, Day 9 and EOS|Mean Change From Baseline in Eosinophil Count at Day 8, Day 9 and EOS|Mean Change From Baseline in Blood Glucose at Day 8, Day 9 and EOS|Mean Change From Baseline in Hemoglobin A1C (Fraction of 1) at Day 8, Day 9 and EOS|Pharmacokinetics (PK): Mean Erenumab Serum Concentration at 1 Hour (C1h)|PK: Mean Area Under the Concentration-time Curve From Time 0 to 84 Days Post-dose (AUC84d)|Number of Participants With Anti-Erenumab Antibodies|Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters|Number of Participants With Clinically Significant Changes in Physical Parameters|Number of Participants With Clinically Significant Changes in Neurological Assessments","Amgen","All","18 Years to 45 Years   (Adult)","Phase 1","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","20140207","November 11, 2015","September 28, 2017","November 8, 2017","September 7, 2015","June 3, 2019","June 3, 2019","Research Site, Anaheim, California, United States|Research Site, Leuven, Belgium|Research Site, Leiden, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02542605/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02542605/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02542605"
672,"NCT02542280","Does Endometrial Injury Improve Intrauterine Insemination Outcome?",,"Completed","Has Results","Infertility","Procedure: endometrial injury.|Procedure: intrauterine insemination|Drug: ovarian stimulation","Chemical Pregnancy Rate|Clinical Pregnancy Rate","Ain Shams Maternity Hospital","Female","18 Years to 38 Years   (Adult)","Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","abahaa050301","July 2013","July 2015","September 2015","September 7, 2015","January 8, 2016","January 8, 2016",,,"https://ClinicalTrials.gov/show/NCT02542280"
673,"NCT02542072","Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses",,"Completed","Has Results","Myopia","Device: comfilcon A|Device: samfilcon A","Comfort|Comfortable Wearing Time Via SMS (Short Message Service)|Wearing Times|Deterioration in Comfort|Vision Quality|Overall Lens Handling|Biomicroscopy Scores|Lens Surface Wetting|Film Deposits|White Spot Deposits|Visual Acuity (VA)|Lens Centration|Corneal Coverage|Post-Blink Movement|Primary Gaze Lag|Lens Tightness Push-up|Overall Fit Acceptance|Dryness","Coopervision, Inc.","All","18 Years to 50 Years   (Adult)","Not Applicable","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","EX-MKTG-59 (VISA-406)","August 2015","February 2016","March 2016","September 4, 2015","March 21, 2017","October 24, 2017","Golden Optometric Group, Whittier, California, United States|Complete Eye Care of Medina, Medina, Minnesota, United States|Brock & Houlford, Chew Magna, Bristol, United Kingdom|Tempany's Boutique Opticians, Broadstone, Dorset, United Kingdom|David Gould Opticians, Rawtenstall, Lancashire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02542072"
674,"NCT02540538","Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders",,"Completed","Has Results","Hepatitis B","Biological: HBVaxPro|Biological: HBAI20","Subjects With Local and/or General Adverse Events Irrespective of Severity|Subjects With Local and/or General SEVERE Adverse Events|Number of Participants With Seroprotection","Maastricht University Medical Center|CyTuVax","All","18 Years to 59 Years   (Adult)","Phase 1","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HBnr01|2014-000913-30","September 2015","July 2016","July 2016","September 4, 2015","November 29, 2018","December 19, 2018","Maastricht UMC, Maastricht, Netherlands",,"https://ClinicalTrials.gov/show/NCT02540538"
675,"NCT02540447","Purge Vs no Purge in Living Donor Liver Transplantation Recipients","PNP","Completed","Has Results","Ischemia Reperfusion Injury","Procedure: Purge","Lowest 5 Minutes Post-reperfusion Mean Arterial Blood Pressure|Biliary Complications (Participants)|Ischemia Reperfusion Injury|Post-operative Infectious Complications|3 Months Mortality","Mansoura University","All","18 Years to 60 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Purge_LTX","January 2013","May 2014","May 2015","September 4, 2015","October 20, 2015","April 26, 2017","Liver transplantation project - Gastroenterology surgical center - Mansoura university, Mansoura, Dakahlia, Egypt",,"https://ClinicalTrials.gov/show/NCT02540447"
676,"NCT02539797","Improving Cognition in Schizophrenia Using tDCS","ICDC","Completed","Has Results","Schizophrenia","Device: tDCS","Change From Baseline in Cognition on MCCB|Change From Baseline in Managing Emotions on MSCEIT","University of California, Los Angeles","All","18 Years to 55 Years   (Adult)","Not Applicable","37","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","22017","October 2014","October 2016","October 2016","September 3, 2015","March 7, 2018","March 7, 2018","UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02539797"
677,"NCT02539563","Do Peanut Shaped Birthing Balls Reduce the Length of Labor in Patients With Epidural Analgesia?",,"Terminated","Has Results","Labor","Other: peanut shaped birthing ball","Length of Labor|Maternal Satisfaction|Participant Cesarean Delivery Incidence-Mode of Deliveries|Number of Participants With Post-delivery Complications","Wake Forest University Health Sciences","Female","18 Years to 50 Years   (Adult)","Not Applicable","101","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB00033103","June 4, 2015","December 26, 2017","December 26, 2017","September 3, 2015","April 29, 2019","April 29, 2019","Novant Health-Forsyth Medical Center, Winston-Salem, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02539563/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02539563"
678,"NCT02539134","TAK-935 Multiple Rising Dose Study in Healthy Participants",,"Completed","Has Results","Epilepsy","Drug: TAK-935|Drug: Placebo","Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE)|Percentage of Participants Who Meet the Takeda Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose|Percentage of Participants Who Meet the Takeda Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose|Percentage of Participants Who Meet the Takeda Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose|Cmax: Maximum Observed Plasma Concentration for TAK-935|AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-935|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-935|AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Over the Dosing Interval for TAK-935","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","TAK-935-1002|U1111-1168-6634","September 2015","April 2016","April 2016","September 2, 2015","July 12, 2017","July 12, 2017","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02539134"
679,"NCT02537574","Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)",,"Completed","Has Results","Opioid Use Disorder","Drug: NTX/BUP|Drug: NTX/PBO-B|Drug: PBO-N/PBO-B","Proportion of Subjects Who Receive and Tolerate a VIVITROL Injection|Proportion of Days With COWS Peak Score of Less Than or Equal to 12 During the Treatment Period Prior to the VIVITROL Injection|Mean Peak COWS Score During Treatment Period Prior to VIVITROL Injection|Area Under the Curve (AUC) COWS Score During the Treatment Period Prior to VIVITROL Injection|Mean Score for Desire of Opioids During Treatment Period Prior to VIVITROL Injection|Incidence of Adverse Effects|Area Under the Curve SOWS Score During the Treatment Period Prior to the VIVITROL Injection","Alkermes, Inc.","All","18 Years to 60 Years   (Adult)","Phase 3","380","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALK6428-A301","August 2015","October 27, 2016","January 9, 2017","September 1, 2015","January 9, 2019","March 6, 2019","North Country Clinical Research, Oceanside, California, United States|NRC Research Institute, Orange, California, United States|Atlantic Shores Hospital, Lauderhill, Florida, United States|TRY Research, Maitland, Florida, United States|Research Centers of America, Oakland Park, Florida, United States|CNS Healthcare, Orlando, Florida, United States|Neuroscience Research Institute, Winfield, Illinois, United States|John Hopkins University School of Medicine, Baltimore, Maryland, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|PRA Health Sciences, Marlton, New Jersey, United States|New York State Psychiatric Institute/ Columbia University, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|Midwest Clinical Research Center, LLC, Dayton, Ohio, United States|University Of Pennsylvania - Treatment Research Center, Philadelphia, Pennsylvania, United States|Western Psychiatric Institute and Clinic of UPMC, Pittsburgh, Pennsylvania, United States|Community Clinical Research, Inc., Austin, Texas, United States|Insite Clinical Research, DeSoto, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Pharmaceutical Research Associates Inc., Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02537574"
680,"NCT02537522","Evaluation of 8.5 vs 9.0 Base Curve for 1-DAY ACUVUE(r) TruEye(r) Brand Contact Lenses",,"Completed","Has Results","Contact Lens Base Curve (BC) Fit and Comfort","Device: Contact Lenses with 8.5 BC|Device: Contact Lenses with 9.0 BC","Correlation Between Subjective CLUE Comfort and Keratometry|Correlation Between Subjective CLUE Comfort and Corneal Diameter","Johnson & Johnson Vision Care, Inc.","All","18 Years to 45 Years   (Adult)","Phase 4","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","CR-5730","July 1, 2015","July 1, 2015","July 1, 2015","September 1, 2015","January 10, 2017","July 11, 2017","Jacksonville, Florida, United States|Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02537522"
681,"NCT02536781","Efficacy of Anthocyanin Mouthrinse for Oral Anti-inflammation From Orthodontic Treatment",,"Completed","Has Results","Inflammation of Mouth|Acute Mucous Inflammation","Drug: Anthocyanin|Drug: Placebo","Wound Size (mm^2) Reduction|VAS Scores Range From 0 (no Pain) to 10 (Severe Pain)","Khon Kaen University","All","18 Years to 25 Years   (Adult)","Phase 2|Phase 3","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HE582088","August 2015","January 2016","January 2016","September 1, 2015","August 2, 2017","August 2, 2017","Khon Kaen University, Maung, Khon Kaen, Thailand",,"https://ClinicalTrials.gov/show/NCT02536781"
682,"NCT02535416","A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers",,"Completed","Has Results","Healthy","Drug: ARC-520|Drug: cetirizine|Drug: diphenhydramine","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24) of the Analytes of ARC-520|Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Plasma Concentration (AUClast) of the Analytes of ARC-520|Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Zero Extrapolated to Infinity (AUCinf) of the Analytes of ARC-520|Pharmacokinetics: Maximum Plasma Concentration (Cmax) of the Analytes of ARC-520|Pharmacokinetics: Clearance (CL) of the Analytes of ARC-520|Pharmacokinetics: Apparent Volume of Distribution (V) of the Analytes of ARC-520|Pharmacokinetics: Terminal Elimination Rate Constant (Lambda z) of the Analytes of ARC-520|Pharmacokinetics: Half-Life (t1/2) of the Analytes of ARC-520","Arrowhead Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Heparc-1002","September 2015","August 2016","August 2016","August 28, 2015","February 26, 2018","February 26, 2018","QPharm, Pty Limited, Royal Brisbane Hospital, Herston, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT02535416"
683,"NCT02533167","Impact of Skin to Skin Contact on Maternal Satisfaction, Pain Scores, and Narcotic Usage After Cesarean Delivery",,"Completed","Has Results","Skin to Skin Contact in Cesarean Deliveries","Other: skin to skin","Maternal Evoked Pain Scores","Wake Forest University Health Sciences","Female","18 Years to 50 Years   (Adult)","Not Applicable","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB00033101","July 2015","December 2015","December 2015","August 26, 2015","August 6, 2018","September 5, 2018","Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02533167"
684,"NCT02532998","A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects",,"Completed","Has Results","Pharmacodynamics|Healthy Subjects","Drug: AZD9977 oral suspension|Drug: AZD9977 placebo oral suspension|Drug: Fludrocortisone, tablets|Drug: Eplerenone, tablets","Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977.|Observed Maximum Concentration (Cmax) of AZD9977|Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of AZD9977.|Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC[0-t]) of AZD9977.|Time to Reach Maximum Concentration (Tmax) of AZD9977.|Terminal Half-life (t½λz) of AZD9977.|Apparent Clearance (CL/F) of AZD9977.|Apparent Volume of Distribution at Terminal Phase (Vz/F) of AZD9977.|Apparent Volume of Distribution at Terminal Phase (Vz/F) of Eplerenone.|Apparent Clearance (CL/F) of Eplerenone.|Terminal Half-life (t½λz) of Eplerenone.|Time to Reach Maximum Concentration (Tmax) of Eplerenone.|Observed Maximum Concentration (Cmax) of Eplerenone.|Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC(0-t)) of Eplerenone.|Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of Eplerenone.|Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in AZD9977 Treatment With Placebo Versus Treatment With AZD9977.|Number of Participants With Clinically Significant Blood Pressure Values.|Number of Participants With Clinically Significant Pulse Rate.|Number of Participants With Clinically Significant Electrocardiogram.|Number of Participants With Clinically Significant Physical Examination Values.|Number of Participants With Clinically Significant Safety Laboratory Tests Values.|Pharmacodynamics of AZD9977 Assessed by Estimating the Fractional Sodium Excretion in Urine for Each Urine Collection Time Interval.|Pharmacodynamics of AZD9977 Assessed Per Total Sodium Excreted Cumulatively and During Each of the Urine Collection Intervals.|Pharmacodynamics of AZD9977 Assessed Per Fractional Potassium Excretion in Urine for Each Urine Collection Time Interval.|Pharmacodynamics of AZD9977 by Assessment of Total Potassium Excreted Cumulatively and During Each of the Urine Collection Intervals|Pharmacodynamics of AZD9977 Assessed Per Urine Production for Each Urine Collection Time Interval.|Pharmacodynamics of AZD9977 by Assessment of Total Urine Volume Excreted Cumulatively and During Each of the Urine Collection Intervals","AstraZeneca","Male","18 Years to 50 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","D6400C00004|2015-002224-11","September 2015","December 2015","December 2015","August 26, 2015","March 29, 2017","March 29, 2017","Research Site, Harrow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02532998"
685,"NCT02532764","Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients",,"Completed","Has Results","Cystic Fibrosis","Drug: QR-010|Drug: Placebo","Incidence of Subjects Experiencing Treatment Emergent Adverse Events From Baseline Through End of Study|Severity of Treatment Emergent Adverse Events From Baseline Through End of Study|Incidence of Subjects Experiencing Dose-Limiting Toxicities (DLT) in Each Dose Cohort From Baseline Through End of Study Visit.|Number of Subjects With Abnormalities Reported Regarding Laboratory Parameters, Vital Signs, ECG, Spirometry, and Physical Findings.|Maximum Serum Concentration|Time to Maximum Serum Concentration|Terminal Half-life (T1/2)|Area Under the Curve to Final Sample [AUC(0-last)]|Area Under the Curve to Infinity [AUC(0-∞)]|Serum Clearance (CL)","ProQR Therapeutics|European Commission","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","70","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PQ-010-001","June 2015","September 14, 2017","September 14, 2017","August 26, 2015","February 6, 2019","February 6, 2019","University of Southern California USC - Keck School of Medicine, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Washington Medical Center, Seattle, Washington, United States|Universitair Ziekenhuis Brussel, Brussels, Belgium|University of Leuven, Leuven, Belgium|University of Calgary (Health Sciences Centre), Calgary, Alberta, Canada|Motol University Hospital, Prague, Czechia|Cystic Fibrosis Center Rigshospitalet, Copenhagen, Denmark|HGRL Chu Nantes, Nantes, France|Hopital Necker- Enfants Malades, Paris, France|Charité Universitätsmedizin Berlin, Berlin, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Munich U. Hospital, Cystic Fibrosis Center for Adults, Munich, Germany|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|Hospital Vall D'Hebron, Barcelona, Spain|Celerion, Belfast, Northern Ireland, United Kingdom|Royal Brompton Hospital, London, United Kingdom|Southampton General Hospital, Southampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02532764/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02532764/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02532764"
686,"NCT02532179","Subcutaneous Immunotherapy for Mouse in Adults","SCITMO","Completed","Has Results","Asthma|Perennial Allergic Rhinitis","Biological: Mouse Allergenic Extract","Number of Reported Adverse Events (AEs)|Number of Reported Serious Adverse Events (SAEs)|Change in Mouse-Specific IgE Antibodies|Change in Mouse-Specific IgG Antibodies|Change in Mouse-Specific IgG4 Antibodies|Change in In-vitro Mouse Antigen Binding to B-cells","National Institute of Allergy and Infectious Diseases (NIAID)|Inner-City Asthma Consortium","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","12","NIH|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAIT ICAC-26","October 2015","October 2016","October 2016","August 25, 2015","November 28, 2017","March 7, 2018","Children's National Health System, Washington, District of Columbia, United States|Ann and Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Johns Hopkins Children's Center: Department of Allergy & Immunology, Baltimore, Maryland, United States|Henry Ford Health System: Division of Allergy and Immunology, Detroit, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02532179/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02532179"
687,"NCT02531321","Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics",,"Terminated","Has Results","Contraception|HIV","Drug: Levonorgestrel and Ethinyl Estradiol","Levonorgestrel Area Under the Curve|Ethinyl Estradiol Area Under the Curve|Serum Progesterone Level >3ng/dL Reflecting Ovulation","University of Southern California","Female","18 Years to 45 Years   (Adult)","Phase 4","17","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS-15-00112","August 2015","November 2016","November 1, 2016","August 24, 2015","May 31, 2019","May 31, 2019","University of Southern California, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02531321"
688,"NCT02530385","Fecal Microbiota Transplant for Improvement of Metabolism","FMT-TRIM","Completed","Has Results","Obesity","Other: Placebo Capsules|Biological: FMT Capsules","Percent Change From Baseline in Insulin Resistance Based on Insulin-Stimulated Glucose Uptake (M) During Hyperinsulinemic Euglycemic Clamp|Change in Insulin Resistance Based on Homeostasic Model Assessment of Insulin Resistance (HOMA-IR)|Body Weight (Metabolic Scale)|Lean Mass|Fat Mass","Massachusetts General Hospital","All","25 Years to 60 Years   (Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2015-P001632","June 2016","June 27, 2018","June 27, 2018","August 21, 2015","July 25, 2019","July 25, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02530385/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02530385"
689,"NCT02528305","The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis",,"Completed","Has Results","Non-alcoholic Steatohepatitis|Non-alcoholic Fatty Liver Disease","Other: High-intensity Interval Training","Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)|Oral Glucose Tolerance Test|AST: ALT Ratio|FIB-4|Body Fat Mass Estimated Via Bioimpedance|Blood Pressure|General Well-being as Assessed by SF-36 Questionnaire|Short-term Memory Recall|Estimated VO2 Max|Physical Function-""Get up and go"" Test|Ankle Brachial Pressure Index (ABPI)|Long-term Memory Recall|Executive Function (Verbal Fluency Test)","University of Bath|Abertay University","All","20 Years to 59 Years   (Adult)","Not Applicable","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015CM","October 2015","June 2016","June 2016","August 19, 2015","May 4, 2018","May 4, 2018","Abertay University, Dundee, United Kingdom|Ninewells Hospital, Dundee, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02528305"
690,"NCT02524561","KEEPS Mammographic Density And Breast Health Ancillary Study","KEEPS MDBHAS","Completed","Has Results","Mammographic Density|Abnormal Mammogram","Drug: CEE pill|Drug: Estradiol patch|Drug: Active Progesterone|Other: Placebo tablet|Other: Placebo patch|Other: Placebo progesterone","BIRADS Breast Density|Abnormal Mammogram/Biopsy","Brigham and Women's Hospital|National Cancer Institute (NCI)|Kronos Longevity Research Institute|Albert Einstein College of Medicine|Columbia University|Mayo Clinic|University of California, San Francisco|University of Utah|University of Washington|Yale University","Female","42 Years to 58 Years   (Adult)","Not Applicable","517","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","2009P002326|R01CA136918","September 2005","December 2013","December 2013","August 17, 2015","March 8, 2017","March 8, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02524561"
691,"NCT02522624","Supporting Decisions About Health Insurance to Improve Care for the Uninsured",,"Completed","Has Results","Health Literacy|Health Insurance|Health Services Accessibility|Informed Decision Making","Behavioral: Decision Aid (DA)","Knowledge Score (% Correct)|Decision Self-efficacy|Confidence in Choice|Improvements in HILM 1 (Health Insurance Literacy Measure)|Improvements in HILM 2 (Health Insurance Literacy Measure)|Intended Choice Metal Level","Washington University School of Medicine|National Institutes of Health (NIH)|National Institute on Minority Health and Health Disparities (NIMHD)","All","18 Years to 64 Years   (Adult)","Not Applicable","328","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","201407058|5R01MD008808-02","September 2015","February 2016","February 2016","August 13, 2015","January 11, 2017","February 28, 2018","The Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02522624"
692,"NCT02522325","Reinforcing Effects of Cocaine During Phendimetrazine Maintenance","BED IN 31","Completed","Has Results","Cocaine Use Disorder","Drug: Phendimetrazine|Drug: Cocaine|Drug: Placebo","Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative","William Stoops|National Institute on Drug Abuse (NIDA)|University of Kentucky","All","18 Years to 55 Years   (Adult)","Phase 1","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","15-0553|R01DA036553","August 2015","December 2018","December 2018","August 13, 2015","July 2, 2019","July 2, 2019","University of Kentucky Department of Behavioral Science, Lexington, Kentucky, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02522325/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02522325"
693,"NCT02518685","ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss",,"Completed","Has Results","Obesity","Device: TransPyloric Shuttle|Device: Sham procedure|Behavioral: Lifestyle Counseling","Mean Percent Total Body Weight Loss (% TBL) Between the TPS and the Control Group|Proportion of TPS-treated Subjects With Weight Loss ≥ 5% TBL","BaroNova, Inc.","All","22 Years to 60 Years   (Adult)","Not Applicable","302","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","DTC006","September 2015","December 2017","March 2018","August 10, 2015","July 17, 2019","July 17, 2019","HonorHealth Bariatric Center, Scottsdale, Arizona, United States|University of California San Diego, San Diego, California, United States|University of Miami, Miami, Florida, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Stony Brook Medicine, Stony Brook, New York, United States|MidSouth Bariatrics, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02518685/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02518685"
694,"NCT02516306","A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia",,"Completed","Has Results","Presbyopia","Drug: EV06 Ophthalmic Solution|Drug: Placebo Ophthalmic Solution","Ocular Comfort Assessment Following Instillation at Baseline and the Day Prior to Each Study Visit","Encore Vision, Inc.","All","45 Years to 55 Years   (Adult)","Phase 1|Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EV-C-002","September 16, 2015","March 10, 2016","March 10, 2016","August 5, 2015","April 21, 2017","July 2, 2018","Sall Research Medical Center, Inc., Artesia, California, United States|North Valley Eye Medical Group, Mission Hills, California, United States|Comprehensive Eye Care, Ltd., Washington, Missouri, United States|Total Eye Care, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02516306"
695,"NCT02516098","Determine the Bioequivalence of Two Formulations of Hyoscine Butylbromide.",,"Completed","Has Results","Healthy","Drug: hyoscine butylbromide","Maximum Observed Plasma Concentration of Hyoscine Butylbromide (Cmax)|AUC Time Zero to Times of Last Quantifiable Concentration (AUC 0-t)|Area Under the Plasma Concentration Versus Time Curve, With Extrapolation to Infinity (AUC0-∞).|Area Under the Curve, for the Test Product, to the Time of the Maximum Concentration of the Reference Product and the Test Product (AUCReftmax)","Boehringer Ingelheim","All","18 Years to 50 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","202.850","October 2015","December 2015","December 2015","August 5, 2015","February 13, 2017","April 5, 2017","Boehringer Ingelheim Investigational Site, Bloemfontein, Canada",,"https://ClinicalTrials.gov/show/NCT02516098"
696,"NCT02515656","Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis","PRISM","Completed","Has Results","Vaginitis","Drug: POLYGYNAX®|Drug: GYNODAKTARIN®|Drug: Placebo","Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment Visit|Change in Vaginal Discharge and in Each Associated Vaginal Clinical Symptoms Reported by the Patient in the Diary|Number of Patients With Change in Vaginal Discharge Assessed by the Investigator|Clinical Treatment Efficacy (Success/Failure) Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Study Visit|Investigator's Global Satisfaction|Patient's Global Satisfaction","Laboratoire Innotech International|International Clinical Trials Association|Venn Life Sciences","Female","18 Years to 64 Years   (Adult)","Phase 3","661","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PGX 401-11|2014-001759-22","September 2015","August 2016","August 2016","August 5, 2015","January 22, 2019","January 22, 2019","TURKOVA, Praha, Czechia|PERCEVAL, Lyon, France|MARICIC, Belgrade, Serbia|GATOVA, Martin, Slovakia",,"https://ClinicalTrials.gov/show/NCT02515656"
697,"NCT02515253","A Breast Support Intervention for Women With Breast Pain",,"Completed","Has Results","Mastodynia","Other: Bra prescription|Other: Standard Care","Patient Global Impression of Change (PGIC)","University of Portsmouth|Portsmouth Hospitals NHS Trust","Female","18 Years to 55 Years   (Adult)","Not Applicable","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","BP-01","October 2015","June 2016","June 2016","August 4, 2015","August 7, 2019","September 9, 2019","Department of Sport and Exercise Science, University of Portsmouth, Portsmouth, United Kingdom|Breast Care Services, Queen Alexandra Hospital, Portsmouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02515253"
698,"NCT02514122","Subcutaneous Ketamine for Postoperative Pain Relief in Rwanda",,"Completed","Has Results","Post Operative Pain|Pain","Drug: Ketamine|Drug: Saline","Postoperative Pain as Measured on a 11-point Numerical Rating Scale|Hallucination","University of Saskatchewan|National University, Rwanda","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","61","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bio# 14-193","June 2015","July 2015","July 2015","August 3, 2015","November 9, 2018","November 9, 2018","University of Rwanda, Kigali, Rwanda",,"https://ClinicalTrials.gov/show/NCT02514122"
699,"NCT02513446","Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects",,"Completed","Has Results","Healthy","Drug: BI 1026706|Drug: Itraconazole","Area Under the Curve of BI 1026706 From 0 to the Last Quantifiable Data Point (AUC0-tz)|Maximum Concentration of BI 1026706 (Cmax)|Area Under the Curve of BI 1026706 From 0 Extrapolated to Infinity (AUC0-inf)","Boehringer Ingelheim","Male","18 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1320.20|2015-002140-14","September 29, 2015","November 14, 2015","November 20, 2015","July 31, 2015","March 29, 2019","March 29, 2019","1320.20.1 Boehringer Ingelheim Investigational Site, Biberach, Germany",,"https://ClinicalTrials.gov/show/NCT02513446"
700,"NCT02513095","Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)",,"Completed","Has Results","Heat Stroke","Drug: Dantrolene sodium for injectable suspension","Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13|Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13 Over the Course of the Study","Eagle Pharmaceuticals, Inc.|Quintiles, Inc.","All","18 Years to 45 Years   (Adult)","Phase 2","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EGL-4104-C-1502","September 2015","September 2015","October 2015","July 31, 2015","May 9, 2017","May 9, 2017","Mecca, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT02513095"
701,"NCT02512575","A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.",,"Completed","Has Results","Safety|Tolerability|Pharmacokinetics|Pharmacodynamics|Healthy Subjects|Rheumatoid Arthritis","Drug: AZD9567 Monohydrat|Drug: Placebo oral suspension/ Placebo capsule|Drug: Prednisolone","Safety and Tolerability of AZD9567 by Assessing the Number of Participants With Adverse Events|Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Observed Maximum Plasma Concentration (Cmax)|Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Time to Reach Maximum Plasma Concentration(Tmax)|Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Terminal Half-life (t½λz)|Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Area Under the Plasma Concentration-curve From Time Zero to the Time of Last Quantifiable Analyte Concentration (AUC(0-last))|Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Area Under the Plasma Concentration-curve From Time Zero Extrapolated to Infinity (AUC)|Secondary Outcome: Relative Change From Baseline of AUC0-4h for Plasma Glucose to Assess the Effects on Glucose Homeostasis (Oral Glucose Tolerance Test [OGTT])|Relative Change From Baseline of AUC0-4h for Serum Insulin to Assess the Effects on Glucose Homeostasis (Oral Glucose Tolerance Test [OGTT])|Relative Change From Baseline of AUC0-4h for Serum C-peptide to Assess the Effects on Glucose Homeostasis (Oral Glucose Tolerance Test [OGTT])","AstraZeneca","Male","18 Years to 55 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","D6470C00001|2015-002002-37","November 18, 2015","September 26, 2016","September 26, 2016","July 31, 2015","October 4, 2018","October 4, 2018","Research Site, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02512575"
702,"NCT02511587","Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun®",,"Completed","Has Results","Vaccine Efficacy","Biological: FSME-Immune vaccination","Humoral Immunity to TBE (Tick-borne Encephalitis) Vaccine|Cellular Immune Responses - Cytokines|TBE Titer Profile","Medical University of Vienna","All","18 Years to 60 Years   (Adult)","Phase 4","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","RV_FSME_1.2","October 2012","June 2015","June 2015","July 30, 2015","May 18, 2018","May 18, 2018",,,"https://ClinicalTrials.gov/show/NCT02511587"
703,"NCT02511535","TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients",,"Completed","Has Results","Vaccine Responsiveness in Allergy|Vaccine Responsiveness During Allergy De-sensitization Treatment","Biological: TBE booster vaccination","Humoral TBE Immunity|Cellular Immune Response - Cytokine Production|Cellular Immune Response - Lymphocyte Subpopulations|TBE Titer Course","Medical University of Vienna","All","18 Years to 60 Years   (Adult)","Phase 4","119","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TBE_1.1","September 2013","February 2016","September 2016","July 30, 2015","October 25, 2019","October 25, 2019","Medical University Vienna, Institute of Specific Prophylaxis and Tropical Medicine, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT02511535"
704,"NCT02508701","A Pilot Study Comparing the Effectiveness of Campus Intervention to Increase HPV Vaccine Rate Among College Aged Men",,"Terminated","Has Results","Human Papilloma Virus, Male","Behavioral: Message X Onsite/Offsite Vaccination","Number of Participants With 1st Uptake Shots|Number of Participants With 1st Uptake Shot|Number of Participants With Second Uptake Shot|Number of Participants With 3rd Uptake Shots","Purdue University|Merck Sharp & Dohme Corp.","Male","18 Years to 21 Years   (Adult)","Not Applicable","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1506016224","August 2015","May 2016","May 2016","July 27, 2015","September 20, 2018","September 20, 2018",,,"https://ClinicalTrials.gov/show/NCT02508701"
705,"NCT02508103","Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study",,"Completed","Has Results","Premenstrual Dysphoric Disorder","Drug: Oxytocin|Drug: Placebo","Change in Premenstrual Symptom Severity|Amygdala Response to Cognitive-emotional Processing Task During Functional Magnetic Resonance Imaging (fMRI)","University of North Carolina, Chapel Hill","Female","18 Years to 52 Years   (Adult)","Phase 2|Phase 3","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","14-1153","July 2015","June 2016","July 2016","July 24, 2015","June 27, 2017","June 27, 2017","University of North Carolina, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02508103"
706,"NCT02507219","Study of Ibuprofen Effects on Brain Function",,"Completed","Has Results","Major Depressive Disorder","Drug: Ibuprofen","Dose-dependent Differences in the BOLD Response to fMRI Tasks in the Amygdala","Laureate Institute for Brain Research, Inc.|University of Oklahoma","All","18 Years to 55 Years   (Adult)","Phase 2|Phase 3","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2015-007-00","July 2015","October 2015","October 2015","July 23, 2015","February 23, 2018","February 23, 2018","Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT02507219"
707,"NCT02506881","Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: Darbepoetin alfa","AUC|Cmax|AUEC|AC-Emax|T1/2|Tmax|Cl","Biocad","Male","18 Years to 45 Years   (Adult)","Phase 1","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BCD-066-1","March 2013","July 2014","July 2014","July 23, 2015","May 2, 2016","June 14, 2016","City Mariin Hospital, St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02506881"
708,"NCT02506257","Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects",,"Completed","Has Results","Acanthamoeba Keratitis","Drug: 0.04% PHMB|Drug: 0.06% PHMB|Drug: 0.08% PHMB|Drug: PHMB Vehicle","Number of Subjects With Dose-limiting Adverse Events|Plasma Concentration of PHMB","SIFI SpA","All","18 Years to 55 Years   (Adult)","Phase 1","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","042SI","November 2015","April 2016","April 2016","July 23, 2015","November 23, 2016","February 10, 2017",,,"https://ClinicalTrials.gov/show/NCT02506257"
709,"NCT02504775","Bioequivalence Study for Mejoral 500 Product",,"Completed","Has Results","Pain","Drug: Mejoral® 500 Tablets|Drug: Tylenol® Caplets","Area Under the Curve From Time Zero to Last Sampling Time [AUC(0-t)]|Area Under the Curve From Time Zero Extrapolated to Infinity [AUC(0-inf)]|Maximum Plasma Concentration (Cmax)|Time to Reach Maximum Plasma Concentration (Tmax)","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Not Applicable","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","204779","August 1, 2015","August 1, 2015","August 19, 2015","July 22, 2015","May 27, 2016","July 19, 2018","GSK Investigational Site, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT02504775"
710,"NCT02504320","Phase 1, Febuxostat XR Relative Bioavailability Study",,"Completed","Has Results","Healthy Volunteers","Drug: Febuxostat XR 80 mg Capsule F1|Drug: Febuxostat XR 80 mg Capsule F2|Drug: Febuxostat XR 80 mg Capsule F3|Drug: Febuxostat XR 80 mg Capsule F4","Mean Cmax: Maximum Observed Plasma Concentration for Febuxostat|Mean AUCt: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Febuxostat|Mean AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Febuxostat XR-1011|U1111-1168-1117","August 2015","September 2015","October 2015","July 21, 2015","January 19, 2017","January 19, 2017","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02504320"
711,"NCT02503085","Ibuprofen Suspension Bioequivalence Study",,"Completed","Has Results","Healthy Volunteer Study","Drug: Nurofen for Children®|Drug: Algifor Dolo Junior®","Maximum Plasma Concentration (Cmax)|Area Under the Plasma Concentration-time Curve From Administration to the Last Quantifiable Concentration at Time t (AUC0-t)|Elimination Rate Constant (Kel)|AUC From Administration to Infinity (AUC0-inf)|Ratio of AUC0-t/AUC0-inf (AUCR)|Time to Cmax (Tmax)|Plasma Concentration Half-life (T1/2)|Plasma Concentration at Each Planned Nominal Time-point (Cn)|Number of Subjects With Adverse Events (AEs).","Reckitt Benckiser Healthcare (UK) Limited","All","18 Years to 50 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","NL1304|2013-003366-14","June 2, 2015","August 25, 2015","August 25, 2015","July 20, 2015","April 13, 2018","April 13, 2018","Reckit Benckiser, Hull, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02503085"
712,"NCT02502071","Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes","Alk-UA","Completed","Has Results","Type 1 Diabetes|Diabetic Nephropathy|Diabetic Kidney Disease","Drug: sodium bicarbonate","Change in Urine Uric Acid Concentration (Increased Solubility) by Assay|Change in Number of Participants With Urine Uric Acid Precipitation by Polarized Microscopy","University of Colorado Denver School of Medicine Barbara Davis Center","All","18 Years to 45 Years   (Adult)","Phase 4","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-0541","January 2017","July 2017","August 2017","July 20, 2015","November 20, 2018","November 20, 2018","Barbara Davis Center for Diabetes, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02502071/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02502071"
713,"NCT02498522","Effect of Metformin on Early Pregnancy Loss in Pregnant Women With Polycystic Ovarian Syndrome","MIP","Completed","Has Results","Polycystic Ovary Syndrome","Drug: Metformin","Miscarriage Rate","Ain Shams University","Female","25 Years to 35 Years   (Adult)","Early Phase 1","166","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Metformin in pregnancy","August 2015","February 2016","March 2016","July 15, 2015","May 19, 2016","May 19, 2016","Faculty of Medicine, Ain Shams University, Cairo, Al Qahirah, Egypt",,"https://ClinicalTrials.gov/show/NCT02498522"
714,"NCT02497235","A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935",,"Completed","Has Results","Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents","Drug: TAK-935|Drug: [18F]MNI-792 (tracer)","Cholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 45 Minutes Post-TAK-935 Dose|CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose|CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 10 Hours Post-TAK-935 Dose|CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose|Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods|Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC)","Takeda","All","19 Years to 55 Years   (Adult)","Phase 1","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-935_1003|U1111-1170-0452","July 2015","December 2015","January 2016","July 14, 2015","April 11, 2017","April 11, 2017","New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02497235"
715,"NCT02495831","Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: Diclofenac sodium|Drug: Diclofenac sodium and safinamide","To Evaluate Plasma Diclofenamic Acid Extent of Exposure Reported as Plasma AUC After Single Administration of 50 mg Diclofenac Sodium, With and Without Co-administration of a Single 200 mg Dose of Safinamide.|Evaluate Diclofenac Rate of Absorption Reported as Plasma Cmax After Single Administration of 50 mg Diclofenac With and Without 200 mg of Safinamide.|Tmax and T1/2|Lamda z|Relative Bioavailability (Frel)","Zambon SpA|Cross Research S.A.","All","22 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","Z7219J01","May 2015","May 2015","May 2015","July 13, 2015","April 15, 2016","April 15, 2016","Cross Research SA, Phase I Unit, Arzo, Ticino, Switzerland",,"https://ClinicalTrials.gov/show/NCT02495831"
716,"NCT02495038","Optimal Dose of Combination of Rocuronium and Cisatracurium","CRC","Completed","Has Results","Chronic Otitis Media|Anesthesia","Drug: 10% reduction of combination of Esmeron® and Nimbex®|Drug: 20% reduction of combination of Esmeron® and Nimbex®","Onset of Neuromuscular Blocking Agents(NMBAs)|Duration 25% of Neuromuscular Blocking Agents(NMBAs)|Recovery Index of Neuromuscular Blocking Agents(NMBAs)|Operation Time|Anesthetic Time|Additional Rescue Doses Per Hour Ratio.","Yonsei University","All","20 Years to 60 Years   (Adult)","Not Applicable","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","combination P-1","March 2014","February 2015","February 2015","July 13, 2015","December 20, 2017","March 2, 2018",,,"https://ClinicalTrials.gov/show/NCT02495038"
717,"NCT02494180","A Non-inferiority Trial on Pain Relief During Oocyte Retrieval",,"Completed","Has Results","Infertility","Drug: fentanyl|Drug: pethidine|Drug: Diazepam|Drug: Midazolam","Pain Level During Oocyte Retrieval|Pain Level After Oocyte Retrieval|Percentage of Participants With Side Effects by Type|Patient's Satisfaction on Oocyte Retrieval|Clinical Pregnancy Rate|Ongoing Pregnancy Rate|Patient's Satisfaction on Pain Relief|Sedation Level","Kwong Wah Hospital|The University of Hong Kong|Queen Mary Hospital, Hong Kong","Female","18 Years to 40 Years   (Adult)","Phase 4","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","KW/FR-15-021(83-22)","March 2016","February 2018","February 2018","July 10, 2015","March 5, 2019","March 5, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02494180/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02494180"
718,"NCT02493868","A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","SUSTAIN-1","Completed","Has Results","Depressive Disorder, Treatment-Resistant","Drug: Esketamine|Drug: Placebo|Drug: Duloxetine (Oral Antidepressant)|Drug: Escitalopram (Oral antidepressant)|Drug: Sertraline (Oral Antidepressant)|Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)","Time to Relapse in Participants With Stable Remission (Maintenance Phase)|Time to Relapse in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)|Change From Baseline in MADRS Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)|Change From Baseline in MADRS Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)|Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)|Change From Baseline in PHQ-9 Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)|Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Endpoint in Participants With Stable Remission (Maintenance Phase)|Change From Baseline in Clinical Global Impression-Severity Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)|Change From Baseline in Generalized Anxiety Disorder-7 Items (GAD-7) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)|Change From Baseline in Generalized Anxiety Disorder-7 Items Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)|Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Sum Score at Endpoint in Participants With Stable Remission (Maintenance Phase)|Change From Baseline in EQ Visual Analogue Scale Score at Endpoint in Participants With Stable Remission (Maintenance Phase)|Change From Baseline in EQ-5D-5L Health Status Index at Endpoint in Participants With Stable Remission (Maintenance Phase)|Change From Baseline in EuroQol-5 Dimension-5 Level Sum Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)|Change From Baseline in EQ-5D-5L EQ Visual Analogue Scale Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)|Change From Baseline in EQ-5D-5L Health Status Index at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)|Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)|Change From Baseline in Sheehan Disability Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 3","719","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR107128|ESKETINTRD3003|2014-004586-24","October 1, 2015","February 15, 2018","February 16, 2018","July 10, 2015","May 21, 2019","May 21, 2019","Birmingham, Alabama, United States|Little Rock, Arkansas, United States|Anaheim, California, United States|Garden Grove, California, United States|Glendale, California, United States|Oakland, California, United States|Orange, California, United States|San Diego, California, United States|San Marcos, California, United States|San Rafael, California, United States|Hartford, Connecticut, United States|Bradenton, Florida, United States|Gainesville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Hoffman Estates, Illinois, United States|Joliet, Illinois, United States|Maywood, Illinois, United States|Schaumburg, Illinois, United States|Skokie, Illinois, United States|Prairie Village, Kansas, United States|Wichita, Kansas, United States|Lake Charles, Louisiana, United States|Baltimore, Maryland, United States|Gaithersburg, Maryland, United States|Boston, Massachusetts, United States|New Bedford, Massachusetts, United States|Quincy, Massachusetts, United States|Watertown, Massachusetts, United States|Worcester, Massachusetts, United States|Rochester Hills, Michigan, United States|Minneapolis, Minnesota, United States|O'Fallon, Missouri, United States|Saint Charles, Missouri, United States|Omaha, Nebraska, United States|New York, New York, United States|Durham, North Carolina, United States|Hickory, North Carolina, United States|Oklahoma City, Oklahoma, United States|Media, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Scranton, Pennsylvania, United States|Lincoln, Rhode Island, United States|Providence, Rhode Island, United States|Arlington, Texas, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Charlottesville, Virginia, United States|Waukesha, Wisconsin, United States|Aalst, Belgium|Brugge, Belgium|Brussel, Belgium|Heusden-Zolder, Belgium|Liège, Belgium|Yvoir, Belgium|Belo Horizonte, Brazil|Curitiba, Brazil|Fortaleza, Brazil|Goiania, Brazil|Itapira, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Rio de Janeiro, Brazil|Santo André, Brazil|São José do Rio Preto, Brazil|São Paulo, Brazil|Vancouver, British Columbia, Canada|Kingston, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Calgary, Canada|Brno, Czechia|Hostivice, Czechia|Klecany, Czechia|Kutna Hora, Czechia|Litomerice, Czechia|Plzen, Czechia|Prague, Czechia|Praha 10, Czechia|Praha 1, Czechia|Praha 2, Czechia|Praha 6, Czechia|Strakonice 1, Czechia|Parnu, Estonia|Tallinn, Estonia|Tartu, Estonia|Clermont Ferrand, France|Douai, France|Nantes, France|Nimes Cedex 9, France|Paris, France|Poitiers, France|Toulon, France|Berlin, Germany|Cham, Germany|Gelsenkirchen, Germany|Halle (Saale), Germany|Mainz, Germany|Mittweida, Germany|Pfaffenhofen, Germany|Prien, Germany|Balassagyarmat, Hungary|Budapest, Hungary|Debrecen, Hungary|Győr, Hungary|Pécs, Hungary|Sopron, Hungary|Szeged, Hungary|Szekszárd, Hungary|Vác, Hungary|Guadalajara, Mexico|Leon, Mexico|Mexico City, Mexico|Monterrey, Mexico|San Luis Potosi, Mexico|San Luis Potosí, Mexico|Belchatow, Poland|Bialystok, Poland|Bydgoszcz, Poland|Gdansk, Poland|Gdańsk, Poland|Leszno, Poland|Lodz, Poland|Lublin, Poland|Pruszkow, Poland|Torun, Poland|Tuszyn, Poland|Warszawa, Poland|Bratislava, Slovakia|Liptovsky Mikulas, Slovakia|Rimavska Sobota, Slovakia|Roznava, Slovakia|Svidnik, Slovakia|Alcorcón, Spain|Barcelona, Spain|Palma, Spain|Pamplona, Spain|Ponferrada, Spain|Sabadell, Spain|Salamanca, Spain|Vitoria-Gasteiz, Spain|Lund, Sweden|Skövde, Sweden|Solna, Sweden|Stockholm, Sweden|Adana, Turkey|Ankara, Turkey|Bursa, Turkey|Denizli, Turkey|Istanbul, Turkey|İzmir, Turkey|Manisa, Turkey|Sakarya, Turkey|Samsun, Turkey|Çanakkale, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02493868/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02493868/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02493868"
719,"NCT02493062","Evaluation of Hysterotomy Site After Open Fetal Surgery","Hysterotomy","Terminated","Has Results","Myelomeningocele|Pregnancy","Device: Sonohysterogram","Cesarean Hysterotomy Myometrial Thickness|Cesarean Hysterotomy Site Myometrial Percentage of Thinning at the Niche|Fetal Myelomeningocele Hysterotomy Site Myometrial Thickness|Fetal Myelomeningocele Hysterotomy Site Myometrial Percentage of Thinning at the Niche|Percent of Participants With/Without Dehiscence (>80% Thinning of the Myometrium) at the Niche","St. Louis University|SSM St. Mary’s Health Center Foundation.","Female","18 Years to 50 Years   (Adult)","Not Applicable","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FCI-22581","June 2013","December 20, 2017","December 20, 2017","July 9, 2015","February 5, 2019","February 5, 2019","SSM Cardinal Glennon Fetal Care Institute, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT02493062/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02493062"
720,"NCT02492451","Endometrial Injury Versus Luteal Phase Support in Intrauterine Insemination Cycles",,"Terminated","Has Results","Pregnancy","Other: Endometrial Injury|Drug: progesterone (Crinone® %8 vaginal progesterone gel)","Pregnancy Rate","Zeynep Kamil Maternity and Pediatric Research and Training Hospital","Female","18 Years to 40 Years   (Adult)","Not Applicable","118","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","zeynepkamil","June 2015","December 2015","December 2015","July 8, 2015","October 20, 2016","October 20, 2016","Selcuk Selcuk, İstanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT02492451"
721,"NCT02491463","A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults",,"Completed","Has Results","Respiratory Synctial Virus Infections","Biological: GSK3389245A_LD GROUP|Biological: GSK3389245A_HD GROUP|Biological: Bexsero|Drug: Placebo","Number of Subjects With Solicited Local Symptoms|Number of Subjects With Solicited General Symptoms|Number of Subjects With Haematological and Biochemical Laboratory Abnormalities|Number of Subjects With Haematological and Biochemical Results by Maximum Grade|Number of Subjects With Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs)|Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers|Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value|Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells|Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC)","GlaxoSmithKline","All","18 Years to 45 Years   (Adult)","Phase 1","73","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","201974","July 23, 2015","April 8, 2016","January 26, 2017","July 8, 2015","August 20, 2018","August 20, 2018","GSK Investigational Site, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02491463"
722,"NCT02491437","A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)","LOTUS II","Completed","Has Results","Female Infertility","Drug: Dydrogesterone 30 mg|Drug: intravaginal progesterone gel 90 mg","Percentage of Participants With Presence of Fetal Heart Beats at 12 Week's Gestation Determined by Transvaginal Ultrasound|Positive Pregnancy Test Rate (Percentage of Participants With a Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer)|Rate of Successful Completion of Pregnancy (Percentage of Participants With a Live Birth)|Physical Examination Newborn (Number of Delivered Newborns That Are Male or Female)","Abbott|PRA Health Sciences|Datamap","Female","19 Years to 41 Years   (Adult)","Phase 3","1034","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-625|2012-002993-29","July 2015","May 2017","May 2017","July 8, 2015","October 1, 2019","October 1, 2019","Melbourne IVF, East Melbourne, Australia|IVF Australia - St George Private HospitalIVF Australia - St George Private Hospital, Kogarah, Australia|Univerité Catholique de Louvain, Cliniques universitaires Saint-Luc, Brussels, Belgium|Algemeen Ziekenhuis Jan Palfijn Gent, Gent, Belgium|UZ Gent, Gent, Belgium|Universitair Ziekenhuis Brussel, Jette, Belgium|Peking University People's Hospital, Beijing, China|Reproductive & Genetic Hospital of Citic -Xiangya, Changsha, China|West China Second University Hospital, Chengdu, China|Sun Yat-Sen Memorial Hsopiatl, Sun Yat-Sen University, Guangzhou, China|The Sixth Hospital of Sun Yat-Sen University, Guangzhou, China|The First Affiliate Hospital of Anhui Medical University, Hefei, China|The First Affiliated Hospital of Nanjing Medical University, Nanjing, China|Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China|First Affiliated Hospital of Zhengzhou University, Zhengzhou, China|Fertility Center Berlin, Berlin, Germany|Bielefeld Fertility Center, Bielefeld, Germany|Kinderwunschzentrum Dortmund, Dortmund, Germany|Universitäres Kinderwunschzentrum Lübeck, Lübeck, Germany|Queen Mary Hospital, Hong Kong, Hong Kong|United CIIGMA Hospital, Aurangabad, India|MILANN (Bangalore Assisted Conception Center), Bangalore, India|Apollo Hospitals - Bangalore, Bangalore, India|All India Institute of Medical Sciences, Delhi, India|Max Hospital, Delhi, India|Institute of Reproductive Medicine, Kolkata, India|Ajanta Research Center, Ajanta Hospital and IVF center, Lucknow, India|Inamdar Multispecialty Hospital, Pune, India|Shree Hospital and Diagnostic Centre, Pune, India|CJSC ""Center of Family Medicine"", Ekaterinburg, Russian Federation|Scientific Research Center of Obstetrics, Gynecology and Perinatology n. a. Ac. V. I. Kulakova, Moscow, Russian Federation|CJSC ""Nasledniki"", Moscow, Russian Federation|Saint-Petersburg State Budgetary Healtcare Institution ""Maternity Hospital # 17"", Saint-Petersburg, Russian Federation|Singapore General Hospital, Singapore, Singapore|Songklanagarind Hospital, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|Medical Centre of Infertility Treatment ""Clinic of Professor Yuzko"", Chernivtsi, Ukraine|""NADIYA"" Clinic, Kiev, Ukraine|The Institute for Reproductive Medicine in Ukraine, Kiev, Ukraine|""Mother and Child"" clinic, Kiev, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02491437/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02491437/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02491437"
723,"NCT02490670","A Study of Cephalexin Liquid in Healthy Participants",,"Completed","Has Results","Healthy","Drug: Cephalexin","Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Cephalexin Following a Single Dose|Pharmacokinetics: Maximum Concentration (Cmax) of Cephalexin Following a Single Dose","Eli Lilly and Company|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.","All","18 Years to 50 Years   (Adult)","Phase 1","28","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16062|A3Q-ME-AFBS","July 2015","July 2015","July 2015","July 7, 2015","October 26, 2016","October 26, 2016","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT02490670"
724,"NCT02489279","Training Attentional Awareness and Control in ADHD","SAC-I","Completed","Has Results","Attention Deficit Hyperactivity Disorder","Behavioral: Sustained Attention Control (SAC) Method|Behavioral: Scrabble","Change From Baseline in Conners Continuous Performance Test (CPT) RT Variability Scaled Score|Change From Baseline in Nelson-Denny Reading Test - Comprehension Score|Change From Baseline in Adult Attention-Deficit Hyperactivity Disorder Self-Report Scale (ASRS) - Inattentive Subscale|Change From Baseline in Adult Attention-Deficit Hyperactivity Disorder Self-Report Scale (ASRS) - Hyperactive Subscale","Think Now Incorporated|National Institute of Mental Health (NIMH)","All","18 Years to 40 Years   (Adult)","Not Applicable","107","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","TNI-SAC-I|R43MH101924","June 2015","December 2016","April 2017","July 3, 2015","July 10, 2019","July 10, 2019","UCLA Semel Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02489279"
725,"NCT02488980","An Evaluation of Weekly Tafenoquine",,"Completed","Has Results","Falciparum Parasitaemia","Drug: Tafenoquine|Drug: Mefloquine|Drug: Placebo","Prophylactic Outcome Defined by the Subject Having no Positive Smears|Protective Efficacy Based on Two Consecutive Positive Smears|Time to a Single Positive Smear","U.S. Army Medical Research and Development Command|SmithKline Beecham","All","18 Years to 55 Years   (Adult)","Phase 2","306","U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","A-9467","May 2000","October 2000","March 2003","July 2, 2015","February 24, 2017","May 30, 2017",,,"https://ClinicalTrials.gov/show/NCT02488980"
726,"NCT02488018","Investigation of the Glycemic Index of Ethiopian Honey",,"Completed","Has Results","Hyperglycemia, Postprandial","Biological: Provision of experimental honey","Examine Effect of Monofloral Honey Types on Glycemic Index of Health Human Subjects","Addis Ababa University","All","20 Years to 24 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Honey-1","June 2015","November 2015","February 2016","July 2, 2015","December 28, 2016","December 28, 2016",,,"https://ClinicalTrials.gov/show/NCT02488018"
727,"NCT02486016","Transdermal Patch CVD 2000: The Effect of Heat on Fentanyl Release From Fentanyl TDSs in Healthy Adults",,"Completed","Has Results","Peer Review, Research","Drug: Duragesic reference fentanyl TDS|Drug: Apotex generic fentanyl TDS|Drug: Mylan generic fentanyl TDS","Partial Area Under the Curve (AUC) Attained With Early and Late Heat in Each of the Three Fentanyl TDSs (Reference and Generic)","University of Maryland, Baltimore|Food and Drug Administration (FDA)","All","18 Years to 45 Years   (Adult)","Phase 4","10","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","HP-00059884","June 2015","August 8, 2017","March 31, 2018","June 30, 2015","September 10, 2019","September 10, 2019","University of Maryland, Baltimore Center for Vaccine Development, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan: Stat Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02486016/Prot_SAP_000.pdf|""Statistical Analysis Plan: Stat Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02486016/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02486016"
728,"NCT02485912","Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination",,"Completed","Has Results","Ebola Virus Disease","Biological: ChAd3-EBO Z|Biological: MVA-EBO Z","Safety and Tolerability of Administration of ChAd3-EBO Z and MVA-EBO Z 7 Days Later. This Will be Done by Recording the Number of Participants Who Experience Adverse Events and the Severity of Any Adverse Events.|To Assess the Immunogenicity Generated by Heterologous Prime-boost Immunisation With Monovalent ChAd3-EBO Z (2.5 x 1010 vp - 3.7 x 1010vp) and MVA-EBO Z (1.0 x 108 Pfu) in Healthy Senegalese Volunteers Aged 18-50 Years","University of Oxford|Centre Hospitalier Universitaire le Dantec (CHUD), Dakar, Senegal","All","18 Years to 50 Years   (Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","EBL06","July 2015","January 2016","January 2016","June 30, 2015","February 6, 2019","February 6, 2019","Centre Hospitalier Universitaire le Dantec, Dakar, Senegal",,"https://ClinicalTrials.gov/show/NCT02485912"
729,"NCT02485158","Individual Differences in the Response to Drugs","TDS","Completed","Has Results","Healthy","Drug: THC|Drug: AMP|Drug: ALC|Drug: Placebo capsules|Drug: Placebo beverage","Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration|Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Drink Administration|Change in General Drug Effects (Drug Effects Questionnaire) at 90 Minutes After Drink Administration|Change in General Drug Effects (Drug Effects Questionnaire) at 120 Minutes After Drink Administraion|Change in General Drug Effects (Drug Effects Questionnaire) at 150 Minutes After Drink Administration|Change in General Drug Effects (Drug Effects Questionnaire) at 180 Minutes After Drink Administration|Change in General Drug Effects (Drug Effects Questionnaire) at 210 Minutes After Drink Administration|Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Capsule Administration|Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Drink Administration|Change in Specific Drug Effects (Addiction Research Center Inventory) at 90 Minutes After Drink Administration|Change in Specific Drug Effects (Addiction Research Center Inventory) at 120 Minutes After Drink Administration|Change in Specific Drug Effects (Addiction Research Center Inventory) at 150 Minutes After Drink Administration|Change in Specific Drug Effects (Addiction Research Center Inventory) at 180 Minutes After Drink Administration|Change in Specific Drug Effects (Addiction Research Center Inventory) at 210 Minutes After Drink Administration","University of Chicago","All","21 Years to 35 Years   (Adult)","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB13-0534","July 2013","December 2013","December 2013","June 30, 2015","November 29, 2016","November 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02485158"
730,"NCT02484729","A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males",,"Completed","Has Results","Safety|Tolerability|Pharmacokinetics|Healthy Subjects","Drug: AZD9977, oral suspension|Drug: Placebo, oral suspension|Drug: AZD9977, oral solution","Safety and Tolerability of AZD9977 by Assessing the Percentage of Participants With Adverse Events|Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Pulse Rate|Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Trends in 12-lead Electrocardiograms|Safety and Tolerability of AZD9977 by Number of Participants With Clinically Significant Trends in Cardiac Telemetry|Safety and Tolerability of AZD9977 by Assessing the Number of Subjects With Adverse Events|Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Blood Pressure|Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Hematology|Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Clinical Chemistry|Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Urinalysis|Area Under the Plasma Concentration Versus Time Curve (AUC) From Zero Extrapolated to Infinity.|Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte concentrationAUC(0-t)|Observed Maximum Concentration (Cmax)|Time to Maximum Observed Plasma Concentration (t Max)|Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t1/2λz)|Apparent Clearance (CL/F)|Apparent Volume of Distribution (Vz/F)|Cumulative Amount of Unchanged Drug Excreted Into Urine [Ae (0-48)]|Fraction Excreted Unchanged in Urine[Fe (0-48)]|Renal Clearance of Drug From Plasma [CLR (0-48)]","AstraZeneca","Male","18 Years to 50 Years   (Adult)","Phase 1","196","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","D6400C00001|2015-000877-11","July 2015","November 2015","November 2015","June 30, 2015","March 24, 2017","April 28, 2017","Research Site, Harrow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02484729"
731,"NCT02483611","Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block",,"Completed","Has Results","Neuromuscular Block","Drug: Magnesium Sulfate|Drug: Lidocaine|Drug: Isotonic Solution|Drug: Cisatracurium","Latency|Clinical Duration|Recovery Index|Final Recovery Index|Total Duration (Dur95%)|Spontaneous Recovery (T4/T1=90%)|MAP - M1 (Mean Arterial Pressure in the Moment 1)|MAP - M2 (Mean Arterial Pressure in the Moment 2)|MAP - M3 (Mean Arterial Pressure in the Moment 3)|MAP - M4 (Mean Arterial Pressure in the Moment 4)|MAP - M5 (Mean Arterial Pressure in the Moment 5)|MAP - M6 (Mean Arterial Pressure in the Moment 6)|HR - M1 (Heart Rate in the Moment 1)|HR - M2 (Heart Rate in the Moment 2)|HR - M3 (Heart Rate in the Moment 3)|HR - M4 (Heart Rate in the Moment 4)|HR - M5 (Heart Rate in the Moment 5)|HR - M6 (Heart Rate in the Moment 6)|MAP - M7a (Mean Arterial Pressure in the Moment 7a)|MAP - M7b (Mean Arterial Pressure in the Moment 7b)|MAP - M7c (Mean Arterial Pressure in the Moment 7c)|MAP - M7d (Mean Arterial Pressure in the Moment 7d)|MAP - M7e (Mean Arterial Pressure in the Moment 7e)|MAP - M7f (Mean Arterial Pressure in the Moment 7f)|HR - M7a (Heart Rate in the Moment 7a)|HR - M7b (Heart Rate in the Moment 7b)|HR - M7c (Heart Rate in the Moment 7c)|HR - M7d (Heart Rate in the Moment 7d)|HR - M7e (Heart Rate in the Moment 7e)|HR - M7f (Heart Rate in the Moment 7f)","University of Sao Paulo","All","18 Years to 60 Years   (Adult)","Phase 4","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","5362/2013|15541213.3.0000.5440","July 2015","August 2015","September 2015","June 29, 2015","January 15, 2016","January 15, 2016",,,"https://ClinicalTrials.gov/show/NCT02483611"
732,"NCT02482870","Efficiency of the King Vision Video Laryngoscope",,"Completed","Has Results","Respiratory Failure|Intubation","Device: Macintosh laryngoscope|Device: King Vision video laryngoscope","Intubation Success Rate|Intubation Time|Glottic View Time|Cormack-Lehane Score|Airway Complications","Rize Üniversitesi","All","18 Years to 60 Years   (Adult)","Not Applicable","388","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other","2014/109","January 2014","July 2014","November 2014","June 26, 2015","February 22, 2018","February 22, 2018","Recep Tayyip Erdogan University, Rize, Turkey",,"https://ClinicalTrials.gov/show/NCT02482870"
733,"NCT02482675","Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk",,"Completed","Has Results","Prediabetes","Other: Glucose|Other: Glucose with Non-fat Milk|Other: Glucose with Whey Protein Isolate|Other: Glucose with Sodium Caseinate","Vascular Endothelial Function|Nitrite/Nitrate (NOx)|Plasma Glucose|Malondialdehyde (MDA)|Arginine (ARG)|Asymmetric Dimethylarginine/Arginine (ADMA/ARG)|Symmetric Dimethylarginine/Arginine (SDMA/ARG)|Tetrahydrobiopterin/Dihydrobiopterin (BH4/BH2)|Insulin|Cholecystokinin (CCK)|8-isoprostaglandin-F2a|8-isoprostaglandin-F2a/Arachidonic Acid|Arachidonic Acid","Ohio State University","All","18 Years to 50 Years   (Adult)","Not Applicable","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2015H0088","June 2015","July 2016","February 2018","June 26, 2015","May 3, 2019","May 14, 2019","The Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02482675"
734,"NCT02482610","Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Fat",,"Completed","Has Results","Prediabetes","Other: Glucose|Other: Glucose with Whole Fat Milk|Other: Glucose with Non-fat Milk","Vascular Endothelial Function|Biomarker of Nitric Oxide Homeostasis (NOx)|Glucose|Oxidative Stress Biomarker (Malondialdehyde; MDA)","Ohio State University","All","18 Years to 50 Years   (Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2015H0088B","June 2016","April 2017","March 2018","June 26, 2015","April 29, 2019","April 29, 2019","The Ohio State University, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02482610/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02482610"
735,"NCT02482571","Metabolic Changes in the Activated Human Visual Cortex During Mild Hypoxia",,"Completed","Has Results","Brain Hypoxia","Device: Mild Hypoxia","Change in Glutamate Concentration During a Visual Stimulus Measured by fMRS at Normoxia|Change in Glutamate Concentration During a Visual Stimulus Measured by Functional MRS at Hypoxia|Brain Activity Measured by Blood Oxygenation Level Dependent (BOLD) Signal at Normoxia|Brain Activity Measured by Blood Oxygenation Level Dependent (BOLD) Signal at Hypoxia","University of Minnesota","Male","18 Years to 40 Years   (Adult)","Not Applicable","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","201503M65382","August 13, 2015","September 26, 2016","September 26, 2016","June 26, 2015","May 24, 2018","March 19, 2019","Center for Magnetic Resoance Research, University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02482571"
736,"NCT02482428","Efficacy and Tolerability of Topical LFX453 for External Genital Warts",,"Completed","Has Results","External Genital Warts","Drug: Investigational Treatment|Drug: Aldara","Complete Clearance of Disease at Week 14|Number of Adverse Events (AE)/Serious Adverse Events (SAE) as a Measure of Safety and Tolerability up to 30 Weeks|Number of Participants That Had Partial Clearance Rate of at Least 75 Percent Reduction in External Genital Wart (EGW)s Count at End of Treatment (EOT) Week 12 or 16","Novartis Pharmaceuticals|Novartis","Male","18 Years to 60 Years   (Adult)","Phase 2","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLFX453X2202","May 12, 2015","May 31, 2016","May 31, 2016","June 26, 2015","June 23, 2017","April 10, 2019","Novartis Investigative Site, Arlington Heights, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02482428"
737,"NCT02482298","A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease","Hestia2","Completed","Has Results","Sickle Cell Disease","Drug: Ticagrelor|Drug: Placebo","Change in Proportion of Days With Pain Due to Sickle Cell Disease as Measured by an eDiary|Average of the Daily Worst Pain Values Reported Via eDiary|Change in Proportion of Days With Analgesic Use Measured by an eDiary","AstraZeneca","All","18 Years to 30 Years   (Adult)","Phase 2","87","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","D5136C00008","July 9, 2015","November 16, 2016","November 16, 2016","June 26, 2015","December 14, 2017","December 19, 2018","Research Site, Miami, Florida, United States|Research Site, Bethesda, Maryland, United States|Research Site, Charleston, South Carolina, United States|Research Site, Alexandria, Egypt|Research Site, Cairo, Egypt|Research Site, Cairo, Egypt|Research Site, Bordeaux Cedex, France|Research Site, Strasbourg, France|Research Site, Verona, Italy|Research Site, Kikuyu, Kenya|Research Site, Kisian, Kenya|Research Site, Nairobi, Kenya|Research Site, Beirut, Lebanon|Research Site, Beirut, Lebanon|Research Site, Adana, Turkey|Research Site, Mersin, Turkey|Research Site, Van, Turkey|Research Site, Harrow, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02482298"
738,"NCT02481375","Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?",,"Completed","Has Results","Anemia|Iron Deficiency|Hemoglobin Disorder|Infection|Inflammation","Dietary Supplement: Multiple micronutrients|Dietary Supplement: Iron|Dietary Supplement: Placebo","Hemoglobin Levels at 12-weeks. Marginal Means (95% CI).","University of British Columbia|Micronutrient Initiative|DSM Nutritional Products, Inc.|International Development Research Centre, Canada|Canadian Institutes of Health Research (CIHR)|Helen Keller International","Female","18 Years to 45 Years   (Adult)","Not Applicable","809","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","H15-00933","July 2015","January 2016","January 2016","June 25, 2015","October 24, 2018","May 14, 2019","Kampong Chhnang province, Kampong Chhnang, Kampong Chhnang Province, Cambodia",,"https://ClinicalTrials.gov/show/NCT02481375"
739,"NCT02480998","Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults",,"Completed","Has Results","Influenza, Human","Biological: IL-YANG Flu Vaccine QIV 0.5mL|Biological: IL-YANG Flu Vaccine TIV 0.5mL","Seroconversion Rate|Seroprotection Rate|GMT|GMR|Percentage of Subjects With a Pre-vaccination (Day 0) HI Antibody Titer < 1:40","Il-Yang Pharm. Co., Ltd.","All","19 Years to 64 Years   (Adult)","Phase 1|Phase 2","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IY_IFEZ_Q120","February 2015","April 2015","April 2015","June 25, 2015","September 28, 2018","September 28, 2018",,,"https://ClinicalTrials.gov/show/NCT02480998"
740,"NCT02480582","The Impact of Snacks Which Vary Nutritionally in Their Satiating Potential on Measures of Appetite Control",,"Completed","Has Results","Lack of Satiety|Hyperphagia","Other: Almonds|Other: Cheese Savouries","Test Meal Energy Intake|Food Preference|Appetite Sensations (Hunger)|24 Hour Energy Intake","University of Leeds|Almond Board of California","Female","18 Years to 55 Years   (Adult)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","LDS-2015-ABC|RG.PSYC.102933","June 2015","November 2015","December 2015","June 24, 2015","March 15, 2017","March 15, 2017",,,"https://ClinicalTrials.gov/show/NCT02480582"
741,"NCT02480439","A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants",,"Completed","Has Results","Healthy Volunteers","Drug: TAK-648 Tablet|Drug: TAK-648 Oral Solution","Cmax: Maximum Observed Plasma Concentration for TAK-648|AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-648|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-648|Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)|Percentage of Participants With Markedly Abnormal Laboratory Values at Least Once Post-dose|Percentage of Participants With Markedly Abnormal Vital Sign Values at Least Once Post-dose","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-648-1003|U1111-1170-0503","June 2015","August 2015","September 2015","June 24, 2015","August 31, 2016","August 31, 2016","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02480439"
742,"NCT02475564","Resveratrol for Pain Due to Endometriosis","ResvEndo","Completed","Has Results","Endometriosis","Drug: Placebo|Drug: Resveratrol","Pain Scores Measured by VAS (Visual Analog Scale) at Day 42.|Serum CA125 Levels at 42 Days|Serum Prolactin Levels at 42 Days","Hospital de Clinicas de Porto Alegre","Female","20 Years to 50 Years   (Adult)","Phase 4","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","140626","June 2015","November 2015","November 2015","June 18, 2015","August 5, 2016","October 14, 2016","HCPA, Porto Alegre, RS, Brazil",,"https://ClinicalTrials.gov/show/NCT02475564"
743,"NCT02475395","Study of the Consumer Use of a New Home Test to Measure Sperm Concentration",,"Completed","Has Results","Fertility, Male|Sub-Fertility, Male","Device: TRAK device","Number of Untrained Lay Users That Obtained Accurate and Inaccurate Subfertility Results From the TRAK Device When Compared to Results Obtained From the Gold Standard|Number of Accurate and Inaccurate Subfertility Results as Obtained by Healthcare Professionals Observing Assays Result Performed by Untrained Lay Users.|Number of Accurate and Inaccurate Results Obtained by Healthcare Professionals Performing Trak Assays on Subjects' Samples.","Sandstone Diagnostics","All","20 Years to 50 Years   (Adult)","Not Applicable","272","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SD001","September 2, 2015","November 2015","November 2015","June 18, 2015","July 21, 2017","October 18, 2017","California Reproductive Services: Huntington Reproductive Center, Encino, California, United States|San Fernando Valley Urological Associates Medical Group, Tarzana, California, United States|Men's Fertility Laboratory, Great Neck, New York, United States",,"https://ClinicalTrials.gov/show/NCT02475395"
744,"NCT02475278","Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine",,"Completed","Has Results","Norovirus|Healthy Participants","Biological: NoV GI.1/GII.4 Bivalent VLP Vaccine","Number of Participants With Serum Samples Obtained on Day 8 for Assessment of Seropositivity for Both Anti-NoV GI.1 VLP and GII.4 VLP Antibodies|Number of Participants With Serum Samples Obtained on Day 15 for Assessment of Seropositivity for Both Anti-NoV GI.1 VLP and GII.4 VLP Antibodies|Number of Participants With Serum Samples Obtained on Day 29 for Assessment of Seropositivity for Both Anti-NoV GI.1 VLP and GII.4 VLP Antibodies|Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Maximum Severity|Percentage of Participants With Solicited Systemic Adverse Events (AEs) by Maximum Severity|Percentage of Participants With Elevated Daily Oral Temperature|Percentage of Participants With Unsolicited Adverse Events (AEs) by Maximum Severity|Percentage of Participants Experiencing Serious Adverse Events","Takeda","All","18 Years to 49 Years   (Adult)","Phase 2","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NOR-210|U1111-1165-3548","February 26, 2015","April 7, 2015","September 9, 2015","June 18, 2015","October 28, 2016","February 22, 2018","Benchmark Research Austin, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02475278"
745,"NCT02475265","Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa","1180","Completed","Has Results","Anorexia Nervosa|Osteoporosis","Drug: estradiol 0.045 mg/levonorgestrel 0.015mg","Percent Change in Bone Mineral Density (BMD) of Lumbar Spine by Dual Energy X-ray Absorptiometry (DXA)","Massachusetts General Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Female","25 Years to 50 Years   (Adult)","Phase 2","11","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015P000463|R03DK106410","July 2015","June 27, 2018","July 30, 2018","June 18, 2015","July 22, 2019","July 22, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02475265/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02475265"
746,"NCT02473510","Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season","FluMist","Completed","Has Results","Influenza|Healthy","Biological: Trivalent Influenza Vaccine|Other: Placebo","Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F)|Percentage of Participants With Solicited Symptoms|Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs) and New Onset Chronic Disease (NOCDs)|Percentage of Participants Who Require Antipyretic and/or Analgesic Medication","MedImmune LLC|AstraZeneca","All","18 Years to 49 Years   (Adult)","Phase 4","301","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D2560C00009","June 2015","January 2016","January 2016","June 16, 2015","November 28, 2016","November 28, 2016","Research Site, South Miami, Florida, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02473510"
747,"NCT02473289","An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder",,"Completed","Has Results","Depressive Disorder, Major","Drug: Sirukumab 50 mg|Drug: Placebo","Change From Baseline in Hamilton Depression Rating Scale (HDRS-17) Total Score at Week 12|Change From Baseline in HDRS-17 Total Score at Weeks 1, 4 and 8|Percentage of Participants With Remission as Assessed by HDRS-17 Total Score at Week 12|Percentage of Participants With Response as Assessed by HDRS-17 Total Score at Week 12|Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Score at Weeks 1, 4, 8, 12, 16, and 22|Change From Baseline in Patient Health Questionnaire (PHQ-9) Total Score at Weeks 1, 4, 8, 12, 16, and 22|Change From Baseline in Snaith Hamilton Pleasure Scale (SHAPS) Total Score (Definition 1) at Weeks 1, 4, 8, 12, 16, and 22|Change From Baseline in Snaith Hamilton Pleasure Scale (SHAPS) Total Score (Definition 2) at Weeks 1, 4, 8, 12, 16, and 22|Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score at Weeks 1, 4, 8, 12, 16, and 22","Janssen Research & Development, LLC","All","21 Years to 64 Years   (Adult)","Phase 2","193","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR107171|CNTO136MDD2001|2014-005206-37","July 23, 2015","May 22, 2018","May 22, 2018","June 16, 2015","June 11, 2019","June 11, 2019","Birmingham, Alabama, United States|Little Rock, Arkansas, United States|Bellflower, California, United States|Glendale, California, United States|Lemon Grove, California, United States|Orange, California, United States|Santa Ana, California, United States|Torrance, California, United States|Wildomar, California, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Edgewood, Kentucky, United States|Baltimore, Maryland, United States|Grand Rapids, Michigan, United States|Lebanon, New Hampshire, United States|Brooklyn, New York, United States|New York, New York, United States|Staten Island, New York, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Houston, Texas, United States|Plano, Texas, United States|Salt Lake City, Utah, United States|Edmonton, Alberta, Canada|Chatham, Ontario, Canada|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Belchatow, Poland|Bydgoszcz, Poland|Chelmno, Poland|Gorlice, Poland|Lublin, Poland|Karelia, Russian Federation|Moscow, Russian Federation|Nizny Novgorod, Russian Federation|Rostov-on-Don, Russian Federation|Saratov Region, Russian Federation|Saratov, Russian Federation|St-Petersburg, Russian Federation|Tomsk, Russian Federation|Yaroslavl, Russian Federation|Edinburgh, United Kingdom|Glasgow, United Kingdom|Oxford, United Kingdom|Redruth, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02473289/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02473289/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02473289"
748,"NCT02472847","Cannabinoid Control of Fear Extinction Neural Circuits in Humans",,"Completed","Has Results","Healthy Participants","Drug: Dronabinol|Drug: Placebo","BOLD Signal Measured by Functional Magnetic Resonance Imaging (fMRI)","University of Illinois at Chicago|National Institute of Mental Health (NIMH)|National Institutes of Health (NIH)","All","21 Years to 45 Years   (Adult)","Phase 4","85","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","2012-0242|R21MH093917","May 2012","July 2014","July 2014","June 16, 2015","August 25, 2015","August 25, 2015",,,"https://ClinicalTrials.gov/show/NCT02472847"
749,"NCT02472652","Aripiprazole, Abilify Maintena Collaborative Clinical Protocol","KISS","Terminated","Has Results","Sexual Dysfunction","Drug: Abilify Maintena","Change in Arizona Sexual Experiences Scale (ASEX) Score|Prolactin Concentrations ng/ml (Normal Range 4.0 - 15.2ng/ml)","Gazda, Thomas D., M.D., PC|Otsuka America Pharmaceutical","All","18 Years to 40 Years   (Adult)","Phase 4","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COL.AOM.2013-007","June 2015","December 31, 2016","March 1, 2017","June 16, 2015","April 11, 2019","April 11, 2019","Mohammed Ramadan MD Private Practice, Bullhead City, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02472652"
750,"NCT02472522","Comparative Study of Ropivacaine and Ropivacaine With Dexmeditomedine in TAP Blocks",,"Completed","Has Results","Pregnancy","Drug: Ropivacaine + Dexmedetomidine|Other: Ropivacaine","The Time After the TAP Block When Rescue Analgesia Was First Sought|Total Dose of Required Morphine in 24 Hours Postoperatively|Adverse Effects Like Pruritus, Nausea and Vomiting","Tata Main Hospital","Female","18 Years to 40 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","SR9851450","May 2015","November 2015","November 2015","June 16, 2015","July 6, 2016","July 6, 2016","Tata Main Hospital, Jamshedpur, Jharkhand, India",,"https://ClinicalTrials.gov/show/NCT02472522"
751,"NCT02471755","Electro-acupuncture for Menopausal Transition Symptoms",,"Completed","Has Results","Menopause","Device: Eelectro-acupuncture|Device: Sham Eelectro-acupuncture","Change of Average 24 h Hot Flash Score From Baseline|Change of MRS (Menopause Rating Scale) From Baseline|Change of FSH From Baseline|Change of LH From Baseline|Change of FSH/LH From Baseline|Change of E2 From Baseline","Guang'anmen Hospital of China Academy of Chinese Medical Sciences","Female","40 Years to 55 Years   (Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2012BAI24B01-012","April 2013","December 2014","December 2014","June 15, 2015","November 23, 2015","November 23, 2015","Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02471755"
752,"NCT02470949","Influence of a Monopoly Game on Subtle Behaviors",,"Completed","Has Results","Obesity|Eating Behavior","Behavioral: Low Social Status|Behavioral: High Social Status","Calories Consumed Following the Experimental Manipulation|The Macronutrient Composition of Foods Consumed|Percent of Calories Consumed Following the Experimental Manipulation","University of Colorado, Denver|University of Alabama at Birmingham|Brown University","All","19 Years to 25 Years   (Adult)","Not Applicable","9","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)","14-0719","September 2014","December 2015","December 2015","June 12, 2015","August 16, 2016","September 22, 2016","University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02470949"
753,"NCT02469298","Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza",,"Completed","Has Results","Virus Diseases","Drug: GSK1325756 (Danirixin)|Drug: Placebo To Match GSK1325756|Drug: Oseltamivir Phosphate|Drug: Placebo To Match Oseltamivir Phosphate","Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)|Change From Baseline in Hematology Parameters-Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Total Absolute Neutrophil Count [Total ANC]), Platelet Count and White Blood Cell (WBC) Count|Change From Baseline in Hematology Parameters- Hemoglobin|Change From Baseline in Hematology Parameters- Hematocrit|Change From Baseline in Hematology Parameters- Mean Corpuscle Hemoglobin (MCH)|Change From Baseline in Hematology Parameters- Mean Corpuscle Volume (MCV)|Change From Baseline in Hematology Parameters- Red Blood Cell (RBC) Count and Reticulocytes Count|Change From Baseline in Clinical Chemistry Parameters- Albumin and Total Protein|Change From Baseline in Clinical Chemistry- Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST) and Gamma Glutamyl Transferase (GGT)|Change From Baseline in Clinical Chemistry Parameters- Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid|Change From Baseline in Clinical Chemistry Parameters- Calcium, Carbon Dioxide (CO2) Content/ Bicarbonate, Glucose, Potassium, Sodium and Urea/Blood Urea Nitrogen (BUN)|Change From Baseline in Urinalysis Parameters- Urine pH|Change From Baseline in Urinalysis Parameters- Urine Specific Gravity|Number of Participants With Maximum Post-baseline Urine Dipstick Abnormalities- Urine Occult Blood (Dipstick)|Number of Participants With Maximum Post-baseline Urine Dipstick Abnormalities- Urine Glucose (Dipstick)|Number of Participants With Maximum Post-baseline Urine Dipstick Abnormalities- Urine Protein (Dipstick)|Change From Baseline in Vital Signs- Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)|Change From Baseline in Vital Signs- Heart Rate (HR)|Change From Baseline in Vital Signs- Respiration Rate (RR)|Change From Baseline in Vital Signs- Temperature|Change From Baseline in Vital Signs- Percent Oxygen in Blood (POB)|Change From Baseline in Electrocardiogram (ECG) Parameters|Number of Participants With Disease Related Events (DREs) of Interest|Number of Participants With DRE of Interest-associated Antibiotic Use|Time to Resolution of Fever Over Time Post Initiation of Treatment|Number of Afebrile Participants Over Time Post Initiation of Treatment|Number of Participants Who Used Relief Medication|Number of Hospital Admissions Due to Influenza Infection|Change From Baseline in Influenza Viral Load as Measured by Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR) From Nasopharyngeal Swabs on Day 3, Day 5, Day 8 and Day 14|Number of Participants With no Detectable Influenza Viral RNA by qRT-PCR From Nasopharyngeal Swabs on Baseline (Day 1), Day 3, Day 5, Day 8 and Day 14|Total Dose of Relief Medication|Change From Baseline in Influenza Viral Load as Measured by Quantitative Virus Culture From Nasopharyngeal Swabs on Day 3, Day 5, Day 8 and Day 14|Number of Participants With no Detectable Influenza Viral RNA by Quantitative Virus Culture From Nasopharyngeal Swabs on Baseline (Day 1), Day 3, Day 5, Day 8 and Day 14","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201682","June 1, 2015","April 25, 2016","April 25, 2016","June 11, 2015","August 24, 2017","July 23, 2019","GSK Investigational Site, Palmetto Bay, Florida, United States|GSK Investigational Site, Blackfoot, Idaho, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Marshfield, Wisconsin, United States|GSK Investigational Site, Baulkham Hills, New South Wales, Australia|GSK Investigational Site, Brookvale, New South Wales, Australia|GSK Investigational Site, Hinchinbrook, New South Wales, Australia|GSK Investigational Site, Liverpool, New South Wales, Australia|GSK Investigational Site, Browns Plains, Queensland, Australia|GSK Investigational Site, Everton Plaza, Queensland, Australia|GSK Investigational Site, Kedron, Queensland, Australia|GSK Investigational Site, Springfield, Queensland, Australia|GSK Investigational Site, Glenelg East, South Australia, Australia|GSK Investigational Site, Happy Valley, South Australia, Australia|GSK Investigational Site, Berwick, Victoria, Australia|GSK Investigational Site, Lynbrook, Victoria, Australia|GSK Investigational Site, Noble Park, Victoria, Australia|GSK Investigational Site, Pakenham, Victoria, Australia|GSK Investigational Site, Tarneit, Victoria, Australia|GSK Investigational Site, Applecross, Western Australia, Australia|GSK Investigational Site, Baldivis, Western Australia, Australia|GSK Investigational Site, Claremont, Western Australia, Australia|GSK Investigational Site, Morley, Western Australia, Australia|GSK Investigational Site, Yokine, Western Australia, Australia|GSK Investigational Site, Port Elizabeth, Eastern Cape, South Africa|GSK Investigational Site, Johannesburg, Gauteng, South Africa|GSK Investigational Site, Johannesburg, Gauteng, South Africa|GSK Investigational Site, Moloto South, Gauteng, South Africa|GSK Investigational Site, Pretoria, Gauteng, South Africa|GSK Investigational Site, Middelburg, Mpumalanga, South Africa|GSK Investigational Site, Western Cape, Western Province, South Africa|GSK Investigational Site, Reiger Park, South Africa",,"https://ClinicalTrials.gov/show/NCT02469298"
754,"NCT02468583","Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee",,"Terminated","Has Results","Post-traumatic Osteoarthritis of the Knee","Drug: FX006 32 mg|Drug: TCA IR 40 mg","Average Change From Baseline in the Weekly Mean of the Average Daily (24-hour) Pain Intensity Scores Over Weeks 5 to 10|Weekly Mean of the Average Daily (24-hr) Pain Intensity Scores, Change From Baseline to Each Week and Average Change From Baseline Over Weeks 1 to 12 and Weeks 4 to 12|Proportion of Patients Experiencing a >20% Decrease in Pain From Baseline in Weekly Mean of the Average Daily (24-hr) Pain Intensity Scores at Each Week|Proportion of Patients Experiencing a >50% or >30% Decrease in Pain From Baseline in Weekly Mean of Average Daily 24-hr Pain Intensity Scores at Each Week|Proportion of Patients Experiencing Each of >50% or >30% Decrease in Pain From Baseline in Weekly Mean of the Average Daily (24-hr) Pain Intensity Scores at Each Week|WOMAC A (Pain Subscale)|WOMAC A1 (Pain on Walking Question)|WOMAC B (Stiffness)|WOMAC C (Function)|WOMAC (Total):|Knee Injury and Osteoarthritis Score (KOOS)|Patient Global Impression of Change (PGIC) at Weeks 4, 8 and 12|Clinical Global Impression of Change (CGIC) at Weeks 4, 8 and 12|Percent of Responders (Defined as Patients With High Improvement in Pain or Function) According to OMERACT-OARSI Criteria at Weeks 4, 8 and 12|Time to Onset of Pain Relief|Average Weekly and Total Consumption of Rescue Medication","Flexion Therapeutics, Inc.","All","20 Years to 50 Years   (Adult)","Phase 2","6","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FX006-2014-007","February 2015","July 2016","July 2016","June 11, 2015","December 21, 2017","August 29, 2018","San Antonio Military Medical Center, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02468583"
755,"NCT02466555","Music Therapy in Sickle Cell Transition Study",,"Completed","Has Results","Sickle Cell Disease","Behavioral: Music Therapy","Change (T1 - T5) From Baseline in Scores on the Sickle Cell Self-Efficacy Scale (SCSES)|Change (T1-T5) From Baseline in Scores on the Wake Forest Trust in the Medical Profession Scale|Change (T1-T5) From Baseline in Scores on the Seidman Sickle Cell Knowledge Quiz|Change From Baseline in Percentage of Attended Clinic Appointments During the One-year Study Period.","University Hospitals Cleveland Medical Center|Kulas Foundation","All","18 Years to 23 Years   (Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","03-15-30","June 2015","August 2016","August 2016","June 9, 2015","September 13, 2019","September 13, 2019","University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02466555"
756,"NCT02465489","Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: Deferiprone extended release|Drug: Deferiprone immediate release","Cmax for Serum Deferiprone|Tmax for Serum Deferiprone|AUC0-∞for Serum Deferiprone|Number of Subjects With Adverse Events (AEs)","ApoPharma","All","18 Years to 49 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","LA51-0115","June 2015","August 2015","August 2015","June 8, 2015","January 26, 2016","February 26, 2016","Algorithme Pharma Inc., Mount-Royal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02465489"
757,"NCT02465216","Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion",,"Completed","Has Results","Pulmonary Tuberculosis","Other: Placebo|Biological: ID93 + GLA-SE","Number of Adverse Events|Immunogenicity Responder Rate","IDRI|Wellcome Trust|South African Tuberculosis Vaccine Initiative","All","18 Years to 60 Years   (Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IDRI-TBVPX-203","June 2015","January 2017","January 2017","June 8, 2015","November 9, 2018","March 12, 2019","TASK Applied Sciences, Cape Town, South Africa|Desmond Tutu HIV Centre (DTHC), Cape Town, South Africa|South African Tuberculosis Vaccine Initiative (SATVI), Worcester, South Africa",,"https://ClinicalTrials.gov/show/NCT02465216"
758,"NCT02463981","Anterior Insula Regulation and Pain Empathy",,"Completed","Has Results","Anterior Insula Activity During Regulation|Empathic Responses After Anterior Insula Regulation","Device: real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)","Neural Activity of Anterior Insula During Neorofeedback Training|Pain Empathy Rating Scores","University of Electronic Science and Technology of China","All","18 Years to 30 Years   (Adult)","Not Applicable","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","UESTC-SCAN-02","June 2015","July 2015","July 2015","June 8, 2015","January 4, 2018","January 29, 2018",,,"https://ClinicalTrials.gov/show/NCT02463981"
759,"NCT02461758","Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients",,"Completed","Has Results","Inflammatory Bowel Disease (IBD)","Biological: Standard dose Influenza vaccine (SDIV)|Biological: High dose influenza vaccine (HDIV)","Measure Antibody Concentrations in Immunosuppressed IBD Patients Who Receive High Dose and Standard of Care Dose Influenza Vaccine|Response Rate Against Influenza Vaccine in Patients With Inflammatory Bowel Disease: Number of Participants Positive for Seroconversion|Seroprotection: Number of Participants With Antibody Concentration at Least 1:40 at Week 4 Postimmunization|Seroprotection: Number of Participants With Antibody Titer of 160 at Week 4 Post-immunization","University of Wisconsin, Madison","All","18 Years to 64 Years   (Adult)","Phase 4","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2015-0813|Influenza in IBD","October 2016","June 2018","July 2018","June 3, 2015","September 13, 2019","October 2, 2019","University of Wisconsin Hospital & Clinics, Madison, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02461758/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02461758/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02461758"
760,"NCT02460562","Caries Prevention Effect of S-PRG Filler Incorporated in Denture Base Resins on Edentulous Elderly People",,"Completed","Has Results","Dental Caries","Device: S-PRG filler|Device: PMMA resin","Saliva Fluoride Concentration (Part Per Million,Ppm)|Assessment of Enamel Caries","Kritirat Kiatsirirote|University of Washington|Thammasat University","All","35 Years to 60 Years   (Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","67-4326","June 2015","August 30, 2016","January 20, 2017","June 2, 2015","June 3, 2019","June 3, 2019","Health Promotion Center 1, Bang Khen, Bangkok, Thailand|Thammasat Hospital, Khlong Luang, Pathum Thani, Thailand|Krathumbaen Hospital, Samut Sakhon, Samutsakorn, Thailand",,"https://ClinicalTrials.gov/show/NCT02460562"
761,"NCT02460380","The Effects of Vitamin D on Angiogenic Factors in Women With Polycystic Ovary Syndrome",,"Completed","Has Results","Polycystic Ovary Syndrome|Vitamin D Deficiency","Drug: Vitamin D3|Other: Placebo","Effect of Vitamin D on Angiogenic Factors|The Effects of Vitamin D3 on Clinical Disease Parameters in Women With PCOS","Maimonides Medical Center","Female","18 Years to 38 Years   (Adult)","Phase 4","93","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2013-06-03","October 2013","March 2015","March 2015","June 2, 2015","September 14, 2018","October 12, 2018",,,"https://ClinicalTrials.gov/show/NCT02460380"
762,"NCT02459665","Rwanda Vaginal Microbiota Restoration Study","VMB","Completed","Has Results","Bacterial Vaginosis","Biological: Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence|Drug: Prophylactic use of metronidazole pills (500 mg)|Biological: Vaginal Lcr35-containing probiotic for prevention of BV recurrence","Bacterial Vaginosis (BV) Incidence by Modified Amsel Criteria|Bacterial Vaginosis (BV) Incidence by Nugent Scoring (Nugent 7-10)|Trichomonas Vaginalis (TV) Incidence by Culture|Vaginal Candidiasis Incidence by Wet Mount Microscopy|Vaginal Microbiota Composition by Illumina HiSeq Sequencing: Lactobacillus Genus Concentration","Janneke van de Wijgert|Rinda Ubuzima, Rwanda|University of Liverpool","Female","18 Years to 45 Years   (Adult)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","RETH000828","June 5, 2015","February 23, 2016","August 6, 2018","June 2, 2015","July 16, 2019","July 16, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02459665/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02459665/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02459665"
763,"NCT02459418","Comparative Pharmacokinetics of AFOLIA and US Gonal-f® RFF Redi-ject After Single Subcutaneous Application",,"Completed","Has Results","Healthy Volunteers","Drug: Afolia|Drug: US Gonal-f®","Baseline Corrected FSH Area Under the Serum Concentration-time Curve From Zero to the Last Quantifiable Measurement [AUC(0-last)]|Baseline Corrected FSH Maximum Serum Concentration (Cmax)|Baseline Corrected FSH Area Under the Serum Concentration-time Curve Extrapolated to Infinity [AUC(0-∞)]|Baseline Corrected Time to Reach Maximum FSH Serum Concentration (Tmax)|Baseline Corrected FSH Apparent Terminal Half-life|Baseline Corrected 17ß-Estrodiol (E2) Serum Exposure AUC(0-last)|Baseline Corrected E2 Cmax|Baseline Corrected E2 Tmax","Fertility Biotech AG","Female","18 Years to 42 Years   (Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","FIN1002","May 7, 2015","May 19, 2016","May 19, 2016","June 2, 2015","May 29, 2018","June 29, 2018","Quintiles Drug Research Unit at Guy's Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02459418"
764,"NCT02459093","Subcuticular Suture for Cesarean Skin Incision Closure",,"Completed","Has Results","Complications; Cesarean Section|Surgical Wound Infection","Device: poliglecaprone 25 suture|Device: polyglactin 910 suture","Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc)","Montefiore Medical Center","Female","18 Years to 45 Years   (Adult)","Phase 4","550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2015-4655","May 2015","July 2016","July 2016","June 1, 2015","June 1, 2018","June 1, 2018","Montefiore Medical Center Weiler Division, Bronx, New York, United States|Montefiore Medical Center Wakefield Division, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT02459093"
765,"NCT02458768","Multicenter, Randomized, Open Label, Parallel Study to Evaluate the Efficacy & Safety of IVF-M HP Inj. vs. Menopur® Inj.",,"Completed","Has Results","Infertility, Female","Drug: IVF-M HP Inj.|Drug: Menopur® Inj.","Number of Retrieved Oocytes","LG Life Sciences","Female","20 Years to 39 Years   (Adult)","Phase 4","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LG-IMHCL001","July 2013","November 2014",,"June 1, 2015","February 3, 2016","February 3, 2016",,,"https://ClinicalTrials.gov/show/NCT02458768"
766,"NCT02456896","Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder",,"Completed","Has Results","Bipolar Disorder","Drug: Oxcarbazepine","Change in Serum Brain Derived Neurotrophic Factor (BDNF)|Correlation Between Young Mania Rating Scale (YMRS) and Serum Brain Derived Neurotrophic Factor (BDNF)","All India Institute of Medical Sciences, Bhubaneswar","All","18 Years to 45 Years   (Adult)","Phase 4","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T/IM-NF/Pharm/14/19","June 2015","December 2015","December 2015","May 29, 2015","April 16, 2019","May 7, 2019","All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India",,"https://ClinicalTrials.gov/show/NCT02456896"
767,"NCT02454296","Paracervical Block for Pain Associated With Laminaria Insertion",,"Completed","Has Results","Pain","Drug: Paracervical Block with lidocaine|Drug: Sham paracervical block","Pain After Placement of Laminaria (100 mm Visual Analog Scale)|Satisfaction With Overall Pain Control (100 mm Visual Analog Scale)|Paracervical or Sham Block Pain","University of Hawaii","Female","18 Years to 49 Years   (Adult)","Not Applicable","41","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","22702","May 2015","December 2015","December 2015","May 27, 2015","April 14, 2017","April 14, 2017","University Women's Health Specialists, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT02454296"
768,"NCT02453672","Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects",,"Completed","Has Results","Healthy","Biological: SB8|Biological: EU sourced Avastin®|Biological: US Sourced Avastin®","Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)|Maximum Serum Concentration (Cmax)|Time to Reach Cmax (Tmax)","Samsung Bioepis Co., Ltd.","Male","18 Years to 55 Years   (Adult)","Phase 1","119","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SB8-G11-NHV|2015-001026-41","April 2015","September 2015","September 2015","May 25, 2015","June 3, 2019","June 3, 2019","Samsung Investigational Site, Antwerp, Belgium",,"https://ClinicalTrials.gov/show/NCT02453672"
769,"NCT02453581","Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers",,"Completed","Has Results","Malaria","Drug: OZ439","Individual Parasite Reduction Ratio (PRR)|500mg Cohort Mean Parasite Reduction Ratio (PRR)|OZ439 Cmax|OZ439 AUC(0-144)","Medicines for Malaria Venture|Queensland Institute of Medical Research","All","18 Years to 45 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QP12C10","September 2012","March 2013","March 2013","May 25, 2015","July 13, 2015","August 17, 2015","Q-Pharm, Herston, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT02453581"
770,"NCT02453048","Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine",,"Completed","Has Results","Pertussis|Whooping Cough","Biological: BPZE1|Other: Placebo","The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28|Proportion of Subjects With BPZE1 Colonization|The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination","Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years to 32 Years   (Adult)","Phase 1","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C14-80|2015-001287-20","September 2015","March 2017","December 2017","May 25, 2015","January 2, 2020","January 2, 2020","Karolinska University Hospital, Huddinge, Stockholm, Sweden","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02453048/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02453048"
771,"NCT02451202","Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures",,"Completed","Has Results","Laryngoscopic Surgical Procedures","Procedure: Deep Neuromuscular Blockade|Procedure: Moderate Neuromuscular Blockade|Drug: Sugammadex|Drug: Rocuronium","Proportion of Patients Who Have a Clinically Acceptable Surgical Conditions|Time to Modified Aldrete's Score ≥ 9","Chulalongkorn University|Merck Sharp & Dohme Corp.","All","18 Years to 60 Years   (Adult)","Phase 4","102","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","51815","June 2016","March 2018","March 2018","May 21, 2015","January 7, 2020","January 7, 2020",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02451202/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02451202"
772,"NCT02449889","A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation","FASHION","Completed","Has Results","Infertility","Drug: highly purified human chorionic gonadotropin|Drug: recombinant human chorionic gonadotropin","Number of Oocytes Retrieved|Number of Metaphase II (MII) Oocytes|Number of Fertilized (2 Pronuclei (2PN)) Oocytes|Positive β Unit of Human Chorionic Gonadotropin (βhCG) Rate|Clinical Pregnancy Rate|Frequency of Adverse Events (AEs)|Intensity of AEs","Ferring Pharmaceuticals","Female","18 Years to 39 Years   (Adult)","Phase 3","176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","000191","April 2016","July 9, 2017","March 1, 2018","May 20, 2015","June 10, 2019","June 26, 2019","Instituto Ideia Fértil de Saúde Reproductive (there may be other sites in this country), São Paulo, Brazil","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02449889/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02449889/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02449889"
773,"NCT02448719","Single-Dose Phase 1 Study of TAK-792",,"Completed","Has Results","Healthy Male Adults Participants","Drug: TAK-792 30 mg|Drug: TAK-792 30 mg placebo|Drug: TAK-792 100 mg|Drug: TAK-792 100 mg placebo|Drug: TAK-792 250 mg|Drug: TAK-792 250 mg placebo|Drug: TAK-792 500 mg|Drug: TAK-792 500 mg placebo|Drug: TAK-792 750 mg|Drug: TAK-792 750 mg placebo|Drug: TAK-792 1250 mg|Drug: TAK-792 1250 mg placebo","Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)|Number of Participants With TEAE Related to Vital Signs|Number of Participants With TEAE Related to Body Weight|Number of Participants With TEAE Related to Electrocardiograms (ECG)|Number of Participants With TEAEs Related to Laboratory Tests|Number of Participants With TEAE Related to Gastrointestinal Symptom Rating Scale (GSRS)|AUC(0-96): Area Under the Plasma Concentration-time Curve From Time 0 to 96 Hours Postdose for TAK-792F and Its Metabolites M-I and M-II|AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for TAK-792F and Its Metabolites M-I and M-II|Cmax: Maximum Observed Plasma Concentration for TAK-792F and Its Metabolites M-I and M-II|Tmax: Time to Reach the Cmax for TAK-792F and Its Metabolites M-I and M-II|Urinary Excretion Ratio of TAK-792F and Its Metabolites M-I and M-II as Percentage of TAK-792 Dose From 0 to 96 Hours Postdose|AUC(0-2.5): Area Under the Plasma Concentration-time Curve From Time 0 to 2.5 Hours Postdose for Total Branched Chain Amino Acids (BCAA) Parameter in Cohorts 4a-2, 4b-2, 5a-2 and 5b-2|Cmax: Maximum Observed Plasma Concentration for Total BCAA Parameter in Cohorts 4a-2, 4b-2, 5a-2 and 5b-2|Tmax: Time to Reach the Cmax for Total BCAA Parameter in Cohorts 4a-2, 4b-2, 5a-2 and 5b-2","Takeda","Male","20 Years to 45 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-792-1001|U1111-1170-1571|JapicCTI-152897","May 27, 2015","January 28, 2016","January 28, 2016","May 19, 2015","February 15, 2019","March 19, 2019","Kagoshima, Japan",,"https://ClinicalTrials.gov/show/NCT02448719"
774,"NCT02447458","MLN3126 Single Rising Dose Study",,"Terminated","Has Results","Healthy Volunteers","Drug: MLN3126|Drug: MLN3126 Placebo","Number of Participants That Experience At Least One Treatment-Emergent Adverse Event (TEAE) Post-Dose|Percentage of Participants With Markedly Abnormal Clinical Laboratory Results Post-Dose|Percentage of Participants With Markedly Abnormal Vital Signs Post-Dose|Percentage of Participants With Markedly Abnormal Electrocardiogram (ECG) Findings Post-Dose|Cmax: Maximum Plasma Concentration of MLN3126 and Metabolite M-I|Tmax: Time to Maximum Plasma Concentration of MLN3126 and Metabolite M-I|AUC(0-tlqc): Area Under the Plasma Concentration Time Curve of MLN3126 and Metabolite M-I From Time 0 to the Last Quantifiable Concentration|AUC(0-inf): Area Under the Plasma Concentration Time Curve of MLN3126 and Metabolite M-I From Time 0 to Infinity|CL/F: Oral Clearance of MLN3126|T ½: Half-life of MLN3126 and Metabolite M-I|Ae (0-96): Total Amount of MLN3126 and Metabolite M-I Excreted in the Urine|Fe: Fraction of MLN3126 Excreted in the Urine|Renal Clearance (CLr) of MLN3126 and Metabolite M-I","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MLN3126_102|U1111-1163-1717","September 2013","January 2014","February 2014","May 18, 2015","August 5, 2015","August 5, 2015","Eatontown, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02447458"
775,"NCT02446496","A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects",,"Completed","Has Results","Infections, Urinary Tract","Drug: Cefadroxil tablets manufactured by GSK|Drug: Cefadroxil tablets manufactured by NP","Maximal Measured Plasma Concentration (Cmax) After a Single Dose|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) and Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-infinity)|Time of the Maximum Plasma Concentration (T-max) and Terminal Half- Life (T-half)|Apparent First-order Elimination or Terminal Rate Constant (Ke)","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 4","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","201529","March 31, 2014","April 8, 2014","April 8, 2014","May 18, 2015","April 25, 2017","September 21, 2017","GSK Investigational Site, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02446496"
776,"NCT02446483","A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults",,"Completed","Has Results","Gastrointestinal Diseases","Drug: Idiazole 20mg DR tabs|Drug: PARIET 20 mg DR tabs","Mean Maximal Measured Plasma Concentration (Cmax) After a Single Dose|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) and Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-infinity)|Time of the Maximum Plasma Concentration (T-max) and Terminal Half-life (T-half)|Apparent First-order Elimination or Terminal Rate Constant","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 4","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","201527","March 19, 2014","March 26, 2014","March 26, 2014","May 18, 2015","June 14, 2017","November 17, 2017","GSK Investigational Site, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02446483"
777,"NCT02446171","A Bioavailability Study With Alternate Methods of Administration of Naloxegol Tablets, and Solution",,"Completed","Has Results","Bioavailability|Healthy Subjects","Drug: Naloxegol 25 mg tablet, crushed, suspended in water, given orally|Drug: Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube|Drug: Naloxegol 25 mg (10 mL oral solution)|Drug: Naloxegol 25 mg tablet, given orally","Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-infinity).|Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC 0-t).|Observed Maximum Plasma Concentration (Cmax).|Time to Reach Maximum Plasma Concentration (Tmax).|Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz).|Mean Dissolution Time (MDT).|Mean Residence Time (MRT).|Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC (CL/F).|Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F).|Percentage of Participants With Adverse Events (AE).|Mean Change From Baseline for Vital Signs of Supine Systolic and Diastolic Blood Pressure.|Mean Change From Baseline for Vital Signs in Supine Pulse Rate.|Participants With Significant Findings in Physical Examination.|Participants With Significant Findings in Columbia-Suicide Severity Rating Scale (C-SSRS).|Participants With Significant Findings in 12-Lead Electrocardiography (ECG).|Participants With Significant Findings in Hematology, Clinical Chemistry and Urinalysis.|Taste Test Assessment.","AstraZeneca","All","18 Years to 55 Years   (Adult)","Phase 1","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D3820C00035","May 2015","July 2015","July 2015","May 18, 2015","June 9, 2016","March 10, 2017","Research Site, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02446171"
778,"NCT02443740","Safety, Tolerability and Pharmacokinetics of PF-05251749",,"Completed","Has Results","Healthy","Drug: PF-05251749","Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|Number of Participants With Laboratory Abnormalities|Number of Participants With Clinically Significant Change From Baseline in Vital Signs|Number of Participants With Abnormal 12-Lead Electrocardiogram (ECG) Findings|Change From Baseline in Bond and Lader Visual Analogue Scale (BL-VAS) at 2 Hours Post Dose in Cohorts 1 and 2|Change From Baseline in Bond and Lader Visual Analogue Scale (BL-VAS) at 6 Hours Post Dose in Cohorts 1 and 2|Change From Baseline in Bond and Lader Visual Analogue Scale (BL-VAS) at 48 Hours Post Dose in Cohorts 1 and 2|Change From Baseline in Extrapyramidal Symptom Rating Scale (ESRS) at 2 Hours Post Dose in Cohorts 1 and 2|Change From Baseline in Extrapyramidal Symptom Rating Scale (ESRS) at 48 Hours Post Dose in Cohorts 1 and 2|Maximum Observed Plasma Concentration (Cmax) of PF-05251749|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-05251749|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-05251749|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-05251749|Plasma Decay Half-Life (t1/2) of PF-05251749|Apparent Oral Clearance (CL/F) of PF-05251749|Apparent Volume of Distribution (Vz/F) of PF-05251749|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Milled and Unmilled PF-05251749: Cohort 4|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Milled and Unmilled PF-05251749: Cohort 4|Maximum Observed Plasma Concentration (Cmax) of Milled and Unmilled PF-05251749: Cohort 4|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Milled and Unmilled PF-05251749: Cohort 4|Area Under the Curve From Time Zero to Last Quantifiable Cerebrospinal Fluid (CSF) Concentration (AUClast) of PF-05251749|Area Under the Curve From Time Zero to Extrapolated Cerebrospinal Fluid (CSF) Infinite Time [AUC (0 - ∞)] of PF-05251749|Maximum Observed Cerebrospinal Fluid (CSF) Concentration (Cmax) of PF-05251749|Time to Reach Maximum Observed Cerebrospinal Fluid (CSF) Concentration (Tmax) of PF-05251749","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","B8001001|SAD","May 2015","October 2015","October 2015","May 14, 2015","May 17, 2018","May 17, 2018","New Haven Clinical Research Unit, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02443740"
779,"NCT02443688","EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients",,"Completed","Has Results","Cystic Fibrosis","Drug: CTX-4430|Drug: Placebo","Difference From Placebo in Absolute Change From Baseline in Forced Expiratory Volume in 1 Second Percent Predicted (ppFEV1)|Number of Pulmonary Exacerbations Through 48 Weeks|Hazard Ratio Pulmonary Exacerbation While in the Study|Subjects Without a Pulmonary Exacerbation While in the Study|Relative Change (Percent Change) From Baseline in ppFEV1|Change From Baseline at 48 Weeks for Forced Vital Capacity Percent Predicted (FVC) and FEF25-75% (Forced Expiratory Flow During the Middle Half of the Forced Vital Capacity) Percent Predicted|Change From Baseline for Specified Biomarkers|Change From Baseline for C-reactive Protein (Hs-CRP)","Celtaxsys, Inc.","All","18 Years to 30 Years   (Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CTX-4430-CF-201","October 30, 2015","April 20, 2018","May 16, 2018","May 14, 2015","July 25, 2019","September 4, 2019","University of Alabama, Birmingham, Alabama, United States|Providence Health and Services, Anchorage, Alaska, United States|Banner University of Arizona Medical Center, Tucson, Arizona, United States|Childrens Hospital Los Angeles, Los Angeles, California, United States|Pediatric Pulmonary and Cystic Fibrosis Clinic, Stanford University, Palo Alto, California, United States|University of California Davis Medical Center, Sacramento, California, United States|National Jewish Health, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Central Florida Pulmonary Group, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|St. Francis Medical Center, Peoria, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Harper University Hospital, Detroit, Michigan, United States|Spectrum Health Butterworth Campus, Grand Rapids, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of New Mexico, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|Columbia University Medical Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Wake Forest Hospital, Winston-Salem, North Carolina, United States|UC Cincinnati Children's Hospital, Cincinnati, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oregon Health & Sciences University, Portland, Oregon, United States|Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University, Philadelphia, Pennsylvania, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Sanford Clinical Research, Sioux Falls, South Dakota, United States|Universiy of Tennessee Medical Center UHS, Knoxville, Tennessee, United States|Dell Children's Medical Center, Austin, Texas, United States|Cook Children's Hospital, Fort Worth, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Hôpital Erasme, Brussels, Belgium|UZ Leuven, Leuven, Belgium|University of Calgary, Calgary, Alberta, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Centre hospitalier de Dunkerque, Dunkerque, France|Hôpital Albert Michallon, Grenoble, France|Hopital Arnaud de Villeneuve, Montpellier, France|Hôpital Cochin, Paris, France|CH Lyon Sud, Pierre Benite, France|Charite' University, Berlin, Germany|Krankenhaus Donaustauf, Donaustauf, Germany|Carl-Gustav-Klinikum Dresden, Mukoviszidose Centrum ""Christiane Herzog"", Dresden, Germany|Ruhrlandklinik Essen, Essen, Germany|Institut für klinische Forschung Pneumologie, Frankfurt, Germany|Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena CF Centre, Jena, Germany|Lungenärztliche Praxis München-Pasing, München-Pasing, Germany|Klinikum Stuttgart CF Ambulanz, Stuttgart, Germany|Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Ospedaliero Universitaria, Catania, Italy|Azienda Ospedaliera A Meyer, Florence, Italy|IRCCS Ospedale Pediatrico Bambino, Rome, Italy|Ospedale Civile Maggiore, Verona, Italy|Belfast City Hospital, Belfast, United Kingdom|Bristol Royal Infirmary, Bristol, United Kingdom|Llandough Hospital, Cardiff, United Kingdom|St James's University Hospital, Leeds, United Kingdom|Liverpool Heart and Chest Hospital, Liverpool, United Kingdom|King's College Hospital, London, United Kingdom|Royal Brompton Hospital, London, United Kingdom|University Hospital of South Manchester, Manchester, United Kingdom|Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom|University Hospital Southampton, Southampton, United Kingdom|Royal Stoke University Hospital, Stoke on Trent, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02443688/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02443688/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02443688"
780,"NCT02442310","Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: Deferiprone delayed release tablet formulation|Drug: Deferiprone oral solution","Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide|Tmax for Serum Deferiprone and Deferiprone 3-O-glucuronide|AUC0-∞for Serum Deferiprone and Deferiprone 3-O-glucuronide|Number of Subjects With Adverse Events (AEs)","ApoPharma|Algorithme Pharma Inc","All","18 Years to 49 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","LA46-0114","May 2015","July 2015","July 2015","May 13, 2015","May 13, 2016","May 13, 2016","Algorithme Pharma Inc., Mount-Royal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02442310"
781,"NCT02441114","Pharmacokinetics of Co-administration of Seretide 250 Diskus (HCP0910) and Spiriva Capsule for Inhalation (HGP1011)",,"Completed","Has Results","Pulmonary Disease, Chronic Obstructive","Drug: HCP0910 and HGP1011","Area Under the Concentration Versus Time Curve (AUClast)|Time to Maximum Concentration (Tmax)|Maximum Observed Concentration (Cmax)","Seoul National University Hospital","Male","19 Years to 45 Years   (Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","HM_COPD_PILOT","July 2015","October 2015","October 2015","May 12, 2015","July 11, 2016","January 11, 2017","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02441114"
782,"NCT02440633","A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects",,"Completed","Has Results","Bacterial Enteritis","Drug: 14C-OPS-2071","The Amounts of Radioactivity Excreted in Urine and Faeces|Area Under Curve (AUC) of Total Radioactivity in Plasma and Whole Blood|AUC of OPS-2071 in Plasma","Otsuka Pharmaceutical Co., Ltd.","Male","35 Years to 55 Years   (Adult)","Phase 1","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","341-14-001","May 2015","August 2015","August 2015","May 12, 2015","August 24, 2016","October 21, 2016","Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02440633"
783,"NCT02440204","Optimal Sevoflurane Concentration for Intubation in Combination of Clincal Remifentanil Doses",,"Completed","Has Results","Postoperative Pain","Procedure: Intubation|Drug: Remifentanil|Drug: Sevoflurane","EC50 for Successful Intubation in Each Groups|EC95 for Successful Intubation","Severance Hospital|Armed Forces Capital Hospital, Republic of Korea","Male","19 Years to 30 Years   (Adult)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","AFMC-15036","May 2015","April 2016","April 2016","May 12, 2015","January 17, 2019","January 17, 2019","Armed Forces Capital Hospital, Republic of Korea, Seongnam-si, Kyung-ki Do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02440204"
784,"NCT02439164","Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma",,"Completed","Has Results","Glioma","Drug: Midazolam","Task Completing Time Change Between Sedation and Baseline Measured by 9-hole Peg Test|Number of Participants With OAA/S=4 After Sedation|Mean Arterial Blood Pressure (MAP) as a Measure of Physiological Change|Heart Rate as a Measure of Physiological Change|Brain Glioma Pathological Diagnose as a Measure of Tumor Type","Beijing Tiantan Hospital","All","18 Years to 60 Years   (Adult)","Not Applicable","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","2014MP06","May 26, 2015","March 21, 2017","March 21, 2017","May 8, 2015","August 25, 2017","August 25, 2017","Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02439164/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02439164/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02439164"
785,"NCT02438423","Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle",,"Completed","Has Results","Influenza","Biological: Inactivated influenza vaccine|Other: Placebo","Occurrence of Solicited Injection Site and Systemic Reactogenicity on the Day of Study Product Administration Through 7 Days After Administration.|Occurrence of Study Product-related Serious Adverse Events From D0 Until D180 (+/- 14 Days) After Study Product Administration.|Occurrence of Grade 3 Solicited or Unsolicited Adverse Events From D0 Until D28 (+/- 2 Days) After Study Product Administration.|Geometric Mean Titer (GMT) of HAI Antibody Approximately 28 Days Following Receipt of IIV Delivered by Microneedle Patch or by Hypodermic Needle (Both Vaccines Administered by Study Staff).|Percentage of Subjects Achieving Seroprotection (Defined as a HAI Antibody Titer of 1:40 or Greater) Approximately 28 Days Following Receipt of IIV Delivered by Microneedle Patch or by Hypodermic Needle (Both Vaccines Administered by Study Staff).|Percentage of Subjects Achieving Seroconversion Approximately 28 Days Following Receipt of IIV Delivered by Microneedle Patch or by Hypodermic Needle (Both Vaccines Administered by Study Staff).","Mark Prausnitz|Emory University|Georgia Institute of Technology","All","18 Years to 49 Years   (Adult)","Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","2015 TIV-MNP","June 2015","March 23, 2016","March 23, 2016","May 8, 2015","July 5, 2019","July 5, 2019","The Hope Clinic, Decatur, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02438423"
786,"NCT02437890","A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus",,"Completed","Has Results","Lupus Erythematosus, Systemic","Biological: ALX-0061|Biological: Placebo","Number and Percentage of Subjects Who Achieved a Response at Week 24 According to the Modified British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (mBICLA) Score|Number and Percentage of Subjects With mBICLA Response at Week 24 and Week 48|Number and Percentage of Subjects With Modified Systemic Lupus Erythematosus Responder Index (mSRI-4) Response at Week 24 and Week 48|Number and Percentage of Subjects With mSRI-5 Response at Week 24 and Week 48|Number and Percentage of Subjects With mSRI-6 Response at Week 24 and Week 48|Number and Percentage of Subjects With mSRI-7 Response at Week 24 and Week 48|Number and Percentage of Subjects With mSRI-8 Response at Week 24 and Week 48.|Change From Baseline in Modified Systemic Lupus Erythematosus Disease Activity Index 2000 (mSLEDAI-2K) Score at Week 24 and Week 48|Number and Percentage of Subjects With BILAG-2004 Normal Improvement at Week 24 and Week 48|Number and Percentage of Subjects With BILAG-2004 Enhanced Improvement at Week 24 and Week 48|BILAG-2004 Total Score at Baseline, Week 24 and Week 48|Number and Percentage of Subjects With BILAG-2004 Normal Improvement in Mucocutaneous System at Week 24 and Week 48|Number and Percentage of Subjects With BILAG-2004 Normal Improvement in Musculoskeletal System at Week 24 and Week 48|Number and Percentage of Subjects With Persistent Minimal or no Activity in 9 Organ Systems According to BILAG-2004 Systems Tally at Week 24 and Week 48|Change From Baseline in Physician's Global Assessment (PGA) at Week 24 and Week 48|Change From Baseline in Patient's Global Assessment at Week 24 and Week 48|Change From Baseline in Proteinuria at Week 24 and Week 48|Number of Subjects Who Were Treatment-emergent Urine Sediment Positive at Week 24 and Week 48|Change From Baseline in Serum Creatinine at Week 24 and Week 48|Change From Baseline in Creatinine Clearance Estimation (eGFR) at Week 24 and Week 48|Number of and Percentage Treatment Failures From Baseline to Week 24 and Week 48|Number and Percentage of Subjects Experiencing Severe Flares According to BILAG-2004 Flare Index From Baseline to Week 24 and Week 48|Number and Percentage of Subjects Experiencing Severe Flares According to mSLEDAI-2K Flare Index (mSFI) From Baseline to Week 24 and Week 48|Percent Change From Baseline in Daily Dose of Steroids at Week 24 and Week 48|Number and Percentage of Subjects Whose Daily Dose of Steroids Was Reduced Without Severe Flares During Weeks 40-48|Number and Percentage of Subjects Who Discontinued Prednisone (or Equivalent) by Week 48 Without Experiencing a Severe Flare|Change From Baseline in Physical Component Scores of Short Form (36) Health Survey (SF-36) at Week 24 and Week 48|Change From Baseline in Mental Component Scores of SF-36 at Week 24 and Week 48|Change From Baseline in 28 Joint Count Swollenness (SJC28) Score at Week 24 and Week 48|Change From Baseline in 28 Joint Count Tenderness (TJC28) Score at Week 24 and Week 48|Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12, Week 24 and Week 48|Change From Baseline in CLASI Damage Score at Week 12, Week 24 and Week 48|ALX-0061 Serum Concentrations at Week 24 and Week 48|Actual Values of Soluble Interleukin 6 Receptor (sIL-6R) Concentrations at Baseline, Week 24, and Week 48|Actual Values of C-reactive Protein (CRP) Concentrations at Baseline, Week 24, and Week 48|Actual Values of Fibrinogen Concentrations at Baseline, Week 24, and Week 48|Actual Values of Anti-double-stranded (ds) DNA Concentrations at Baseline, Week 24, and Week 48|Actual Values of Complement C3 Concentrations at Baseline, Week 24, and Week 48|Actual Values of Complement C4 Concentrations at Baseline, Week 24, and Week 48|Actual Values for Hemolytic Complement Component 50 (CH50) at Baseline, Week 24, and Week 48|Number and Percentage of Subjects Who Were Treatment-emergent (TE) Anti-drug Antibody (ADA) Positive","Ablynx","All","18 Years to 64 Years   (Adult)","Phase 2","312","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALX0061-C204|2015-000372-95","July 2015","January 2018","January 2018","May 8, 2015","February 6, 2019","February 26, 2019","Investigator Site, Birmingham, Alabama, United States|Investigator Site, Glendale, Arizona, United States|Investigator Site, Phoenix, Arizona, United States|Investigator Site, Tucson, Arizona, United States|Investigator Site, Artesia, California, United States|Investigator Site, La Jolla, California, United States|Investigator Site, La Palma, California, United States|Investigator Site, Los Angeles, California, United States|Investigator Site, Upland, California, United States|Investigator Site, Aventura, Florida, United States|Investigator Site, Clearwater, Florida, United States|Investigator Site, Orlando, Florida, United States|Investigator Site, Pinellas Park, Florida, United States|Investigator Site, Atlanta, Georgia, United States|Investigator Site, Stockbridge, Georgia, United States|Investigator Site, Louisville, Kentucky, United States|Investigator Site, Cumberland, Maryland, United States|Investigator Site, Lansing, Michigan, United States|Investigator Site, New York, New York, United States|Investigator Site, New York, New York, United States|Investigator Site, Smithtown, New York, United States|Investigator Site, Syracuse, New York, United States|Investigator Site, Charlotte, North Carolina, United States|Investigator Site, Raleigh, North Carolina, United States|Investigator Site, Pittsburgh, Pennsylvania, United States|Investigator Site, Jackson, Tennessee, United States|Investigator Site, Austin, Texas, United States|Investigator Site, Houston, Texas, United States|Investigator Site, Caba, Buenos Aires, Argentina|Investigator Site, Caba, Argentina|Investigator Site, Ciudad Autónoma de Buenos Aire, Argentina|Investigator Site, Córdoba, Argentina|Investigator Site, San Juan, Argentina|Investigator Site, Tucuman, Argentina|Investigator Site 1, Santiago, Chile|Investigator Site 2, Santiago, Chile|Investigator Site, Prague, Czechia|Investigator Site, Berlin, Germany|Investigator Site, Dresden, Germany|Investigator Site, Mainz, Germany|Investigator Site, Mannheim, Germany|Investigator Site 1, Budapest, Hungary|Investigator Site 2, Budapest, Hungary|Investigator Site, Debrecen, Hungary|Investigator Site, Gyula, Hungary|Investigator Site, Zalaegerszeg, Hungary|Investigator Site, Daegu, Korea, Republic of|Investigator Site, Gwangju, Korea, Republic of|Investigator Site 1, Seoul, Korea, Republic of|Investigator Site 2, Seoul, Korea, Republic of|Investigator Site 1, Guadalajara, Mexico|Investigator Site 2, Guadalajara, Mexico|Investigator Site 3, Guadalajara, Mexico|Investigator Site, Merida, Mexico|Investigator Site, Mexicali, Mexico|Investigator Site, Mexico City, Mexico|Investigator Site, San Luis Potosi, Mexico|Investigator Site 1, Lima, Peru|Investigator Site 2, Lima, Peru|Investigator Site 3, Lima, Peru|Investigator Site 4, Lima, Peru|Investigator Site 1, Cebu City, Philippines|Investigator Site 2, Cebu City, Philippines|Investigator Site, Lipa City, Philippines|Investigator Site, Makati City, Philippines|Investigator Site, Manila, Philippines|Investigator Site, Quezon City, Philippines|Investigator Site, Bydgoszcz, Poland|Investigator Site, Katowice, Poland|Investigator Site 1, Poznan, Poland|Investigator Site 2, Poznan, Poland|Investigator Site, Szczecin, Poland|Investigator Site 1, Łódź, Poland|Investigator Site 2, Łódź, Poland|Investigator Site, Almada, Portugal|Investigator Site, Amadora, Portugal|Investigator Site, Lisboa, Portugal|Investigator Site, Ponte de Lima, Portugal|Investigator Site, Porto, Portugal|Investigator Site, Kazan, Russian Federation|Investigator Site, Kemerovo, Russian Federation|Investigator Site, Orenburg, Russian Federation|Investigator Site, Ryazan, Russian Federation|Investigator Site 1, Saint-Petersburg, Russian Federation|Investigator Site 2, Saint-Petersburg, Russian Federation|Investigator Site, Smolensk, Russian Federation|Investigator Site, Vladimir, Russian Federation|Investigator Site, Voronezh, Russian Federation|Investigator Site 1, Belgrade, Serbia|Investigator Site 2, Belgrade, Serbia|Investigator Site 3, Belgrade, Serbia|Investigator Site 4, Belgrade, Serbia|Investigator Site 5, Belgrade, Serbia|Investigator Site, Niska Banja, Serbia|Investigator Site, A Coruna, Spain|Investigator Site 1, Barcelona, Spain|Investigator Site 2, Barcelona, Spain|Investigator Site 3, Barcelona, Spain|Investigator Site, Bilbao, Spain|Investigator Site 1, Madrid, Spain|Investigator Site 2, Madrid, Spain|Investigator Site, Sant Joan Despi, Spain|Investigator Site, Kaohsiung, Taiwan|Investigator Site 1, Taichung, Taiwan|Investigator Site 2, Taichung, Taiwan|Investigator Site, Taipei, Taiwan|Investigator Site, Taoyuan, Taiwan|Investigator Site, Ivano-Frankivs'k, Ukraine|Investigator Site, Kharkiv, Ukraine|Investigator Site, Kryvyi Rih, Ukraine|Investigator Site 1, Kyiv, Ukraine|Investigator Site 2, Kyiv, Ukraine|Investigator Site 3, Kyiv, Ukraine|Investigator Site, Lviv, Ukraine|Investigator Site 1, Poltava, Ukraine|Investigator Site 2, Poltava, Ukraine|Investigator Site 1, Vinnytsia, Ukraine|Investigator Site 2, Vinnytsia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02437890/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02437890/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT02437890"
787,"NCT02437344","Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence",,"Completed","Has Results","Opioid Dependence","Drug: CI-581aa|Drug: Naltrexone titration and XR-NTX initiation","Successful Naltrexone Initiation|Withdrawal: Subjective Opioid Withdrawal Scale (SOWS) Scores at Baseline and Administered Subsequently","New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)","All","21 Years to 60 Years   (Adult)","Phase 2","16","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#7057","January 2015","December 2016","December 2016","May 7, 2015","September 6, 2017","April 8, 2019","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02437344"
788,"NCT02436577","Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects",,"Completed","Has Results","Bioequivalence|Healthy Japanese Subjects|Pharmacokinetics","Drug: Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water|Drug: Ticagrelor OD tablet (90 mg single dose) administered without water|Drug: Ticagrelor IR tablet (90 mg) administered with 150 mL of water","Maximum Observed Plasma Concentration (Cmax) of Ticagrelor and Its Active Metabolite AR-C124910XX.|Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte Concentration AUC (0-t) of Ticagrelor and Its Active Metabolite AR-C124910XX.|Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC) of Ticagrelor and Its Active Metabolite AR-C124910XX.|Time to Reach Maximum Observed Concentration (Tmax) of Ticagrelor and Its Active Metabolite AR-C124910XX.|Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) of Ticagrelor and Its Active Metabolite AR-C124910XX.|Terminal Elimination Rate Constant (λz) of Ticagrelor and Its Active Metabolite, AR-C124910XX.|Mean Residence Time (MRT) of Ticagrelor and Its Active Metabolite AR-C124910XX|MRCmax (Ratio of Metabolite Cmax to Parent Cmax, Adjusted for Differences in Molecular Weights) of Active Metabolite AR-C124910XX|Ratio of Metabolite AUC(0-t) to Parent AUC(0-t), Adjusted for Differences in Molecular Weights (MRAUC [0-t]) of Active Metabolite AR-C124910XX|Ratio of Metabolite AUC to Parent AUC, Adjusted for Differences in Molecular Weights (MRAUC) of Active Metabolite AR-C124910XX|Number of Participants With Adverse Events (AEs)|Elimination Rate Constant (Kel) of Ticagrelor and Its Active Metabolite AR-C124910XX|Mean Change From Baseline for Vital Signs of Supine Blood Pressure (SBP) and Diastolic BP (DBP)|Mean Change From Baseline for Vital Signs in Supine Pulse Rate.|Participants With Significant Findings in 12-Lead Electrocardiography (ECG).|Participants With Clinically Significant Findings in Hematology, Clinical Chemistry and Urinalysis.","AstraZeneca","All","20 Years to 45 Years   (Adult)","Phase 1","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D5139C00004","June 2015","August 2015","August 2015","May 7, 2015","January 11, 2017","January 11, 2017","Research Site, Harrow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02436577"
789,"NCT02435966","Dry Needling in Patients With Chronic Neck Pain",,"Completed","Has Results","Neck Pain","Device: Dry needling|Device: Sham Dry needling|Other: Manual therapy","Change in Pain Scores on the Visual Analog Scale (VAS: 0-10) After 30 Days|Change in the Pressure Pain Threshold Measured by Algometer|Change in the Cervical Range of Motion Measured by Goniometer|Change in the Neck Disability Index Questionnaire","European University of Madrid","All","18 Years to 55 Years   (Adult)","Not Applicable","131","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","University European of Madrid","May 2013","June 2014","March 2015","May 6, 2015","September 7, 2015","September 7, 2015",,,"https://ClinicalTrials.gov/show/NCT02435966"
790,"NCT02434523","Trial of the Treatment of Chronic Laryngitis With Amitryptiline",,"Terminated","Has Results","Laryngeal Diseases|Chronic Laryngeal Neuropathy","Drug: Amitriptyline|Other: Placebo","Reflux Symptom Index|Voice Handicap Index|Side Effects|Lost to Follow up","Boston Medical Center|American Laryngological Association","All","18 Years to 64 Years   (Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H-29925","September 2013","January 2015","January 2015","May 5, 2015","November 30, 2016","November 30, 2016","Boston Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02434523"
791,"NCT02431273","Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women",,"Completed","Has Results","Human Immunodeficiency Virus (HIV) Prophylaxis","Drug: TDF IVR|Drug: TDF-FTC IVR|Drug: TDF-FTC-MVC IVR","Number of Participants With Specific Graded Adverse Events in Single, Dual, and Triple Antiretroviral (ARV) Intravaginal Rings (IVRs)|Pharmacokinetics of the Single, Dual and Triple ARV IVRs: Cervicovaginal Fluid (CVF)|Pharmacokinetics of the Single, Dual and Triple ARV IVRs: Cervicovaginal Lavage (CVL)|Pharmacokinetics of the Single, Dual and Triple ARV IVRs: Vaginal Tissue|Pharmacokinetics of the Single, Dual and Triple ARV IVRs: Plasma|Pharmacokinetics of the Single, Dual and Triple ARV IVRs: Terminal Half-life|Acceptability of the IVRs","Auritec Pharmaceuticals|The University of Texas Medical Branch, Galveston|Oak Crest Institute of Science|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","18 Years to 45 Years   (Adult)","Early Phase 1","10","Industry|Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ARV-IVR 01|2R44HD075636-02","June 2015","December 2016","December 2016","May 1, 2015","July 2, 2019","July 2, 2019","University of Texas Medical Branch, Galveston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02431273"
792,"NCT02430532","BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis","INSPIRE","Terminated","Has Results","Multiple Sclerosis, Secondary Progressive","Drug: dimethyl fumarate|Other: Placebo","Time to Disability Progression Independent of Relapse|Change From Baseline to 2 Years on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12)|Change From Baseline to Week 108 in ABILHAND Questionnaire Score|Percentage Change From Baseline to Week 108 in Whole Brain Volume|Change From Baseline to Week 108 in Cognitive Function as Measured by the Symbol Digit Modalities Test (SDMT)","Biogen","All","18 Years to 58 Years   (Adult)","Phase 3","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","109MS308|2014-003021-18","May 2015","January 2016","January 2016","April 30, 2015","March 27, 2017","April 26, 2017","Research Site, Long Beach, California, United States|Research Site, San Francisco, California, United States|Research Site, Tampa, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Willow Grove, Pennsylvania, United States|Research Site, Round Rock, Texas, United States|Research Site, Bruxelles, Belgium|Research Site, Brno, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Sittard-Geleen, Netherlands|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Plewiska, Poland|Research Site, Poznan, Poland|Research Site, Banska Bystrica, Slovakia",,"https://ClinicalTrials.gov/show/NCT02430532"
793,"NCT02430090","Comparison of Intratechal Levobupivacaine and Adding With Sufetanil and Fentanyl in Ceserean Section",,"Completed","Has Results","Anesthesia","Drug: Levobupivacaine|Drug: Fentanyl|Drug: Sufentanil","Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Number of Participants With Pain Scores on the Visual Analog Scale","Ankara City Hospital Bilkent","Female","18 Years to 45 Years   (Adult)","Phase 2","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2006-099","November 2006","March 2007","March 2007","April 30, 2015","June 10, 2015","June 10, 2015",,,"https://ClinicalTrials.gov/show/NCT02430090"
794,"NCT02428699","Study Comparing Blood Levels of Fatty Acids After Consuming Two Forms of Cod Liver Oil",,"Completed","Has Results","Growth and Development","Other: Emulsified cod liver oil product|Other: Non-emulsified cod liver oil product","Incremental Area Under the Curve to 24 Hours (h) (iAUC0-24h) of the Sum of Plasma Total and Free n-3 Fatty Acids (Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)|iAUC0-24h of Sum of Total and Free DHA|iAUC0-24h of Sum of Total and Free EPA|iAUC0-10h of Sum of Total and Free DHA|iAUC0-10h of Sum of Total and Free EPA|iAUC0-10h of Sum of Total and Free DHA and EPA|Maximum Concentration (Cmax) of Sum of Total and Free DHA and EPA|Cmax of Sum of Total and Free DHA|Cmax of Sum of Total and Free EPA|Time to Maximum Concentration (Tmax) of Sum of Total and Free DHA and EPA|Tmax of Sum of Total and Free DHA|Tmax of Sum of Total and Free EPA","GlaxoSmithKline|Hammersmith Medicines Research","All","18 Years to 45 Years   (Adult)","Not Applicable","50","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","202359","May 20, 2015","July 15, 2015","July 15, 2015","April 29, 2015","August 28, 2018","August 28, 2018","GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02428699"
795,"NCT02428478","Effect of Desipramine on Genioglossus Muscle Activity in Healthy Adults Study A","DESOSA","Completed","Has Results","Sleep Apnea, Obstructive","Drug: Desipramine|Drug: Placebo","Genioglossus Activity During Non-rapid Eye Movement (NREM) Sleep Measured as Percent of Wakefulness Activity|Change in Pharyngeal Critical Collapsing Pressure (Pcrit) as a Measure of Upper Airway Collapsibility","Brigham and Women's Hospital","All","18 Years to 60 Years   (Adult)","Phase 2","17","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BWH-2014P001033A","March 2015","November 2015","March 2016","April 28, 2015","March 30, 2017","March 30, 2017","Sleep Disorders Research Program Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02428478"
796,"NCT02428309","Autologous Polyclonal Tregs for Lupus",,"Terminated","Has Results","Lupus Erythematosus, Cutaneous|Lupus Erythematosus, Discoid|Lupus Erythematosus, Systemic","Biological: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells","Number of Significant Adverse Events (AEs) Through Week 48|Number of Significant Adverse Events (AEs) Through Week 152|Number of Grade 3 or Higher Adverse Events (AEs) Through Week 152|Number of Infection-Related Adverse Events (AEs) Through Week 152|Number of Lupus Flares Through Week 152 by Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Criteria|Number Infusion-Related Adverse Events (AEs) Within 24 Hours of Infusion|Change From Baseline: Alkaline Phosphatase (ALK), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST)|Change From Baseline in g/dL: Albumin, Hemoglobin|Change From Baseline in mg/dL: Total Bilirubin, Creatinine|Change From Baseline in mmol/L: Potassium, Sodium, Chloride|Change From Baseline in Cell Counts: White Blood Cells (WBC), Total Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Platelets|Change From Baseline Red Blood Cell Count|Change From Baseline in mm/hr: Sedimentation Rate (ESR)|Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score|Change From Baseline in SELENA-SLEDAI Total Score|Change From Baseline in Patient's Global Assessment (PGA)|Change From Baseline in Physician's Global Assessment (PhGA)|Change From Baseline in Anti-dsDNA Antibody Titers|Change From Baseline in Serum C3 Complement Levels|Change From Baseline in Serum C4 Complement Levels","National Institute of Allergy and Infectious Diseases (NIAID)|Autoimmunity Centers of Excellence","All","18 Years to 60 Years   (Adult)","Phase 1","1","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAIT ALE08","August 27, 2015","September 2, 2016","October 3, 2018","April 28, 2015","November 12, 2019","November 12, 2019","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02428309"
797,"NCT02427477","A Comparison of Two Daily Disposable Soft Contact Lenses",,"Completed","Has Results","Visual Acuity","Device: senofilcon A|Device: delefilcon A","Subjective Overall Comfort|Subjective Overall Vision","Johnson & Johnson Vision Care, Inc.","All","18 Years to 39 Years   (Adult)","Not Applicable","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-5698","March 2015","April 2015","April 2015","April 28, 2015","June 13, 2016","June 19, 2018","Montgomery, Alabama, United States|Jacksonville Beach, Florida, United States|Longwood, Florida, United States|Winter Park, Florida, United States|Westerville, Ohio, United States|Salem, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02427477"
798,"NCT02427399","Conducting Outreach to Improve Cervical Cancer Screening Rates Among Underscreened Patients",,"Completed","Has Results","Uterine Cervical Neoplasms","Other: Letter and informational sheet|Other: Email|Other: Phone|Other: Multimodal","Proportion of Patients Who Receive a Pap Test at End of Follow up|Proportion Receiving Pap Test at 6 Months|Proportion Receiving Pap Test at 12 Months","Fenway Community Health","Female","21 Years to 64 Years   (Adult)","Not Applicable","1100","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Cervical Cancer Screening","January 2013","December 2014","January 2017","April 28, 2015","June 22, 2017","June 22, 2017",,,"https://ClinicalTrials.gov/show/NCT02427399"
799,"NCT02425098","Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore",,"Completed","Has Results","Dengue Fever","Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|Biological: Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)","Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 15|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 30|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 90|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 180|Geometric Mean Neutralizing Antibody Titer (GMT) for Each of the Four Dengue Serotypes at Day 365|Seropositivity Rate for Each of the Four Dengue Serotypes at Day 15|Seropositivity Rate for Each of the Four Dengue Serotypes at Day 30|Seropositivity Rate for Each of the Four Dengue Serotypes at Day 90|Seropositivity Rate for Each of the Four Dengue Serotypes at Day 180|Seropositivity Rate for Each of the Four Dengue Serotypes at Day 365|Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary Recorded) Following Vaccination by Severity|Number of Participants With Solicited Systemic Adverse Events (AEs) (Diary Recorded) Following Vaccination by Severity|Number of Participants With at Least One Unsolicited Adverse Events (AEs) Following Vaccination|Number of Participants With Serious Adverse Events (SAEs)|Geometric Mean Neutralizing Antibody Titers (GMT) for Each of the Four Dengue Serotypes Assessed by Dengue Baseline Seropositivity (MNT) Status|Seropositivity Rate for Each of the Four Dengue Serotypes Assessed by Dengue Baseline Seropositivity (MNT) Status|Percentage of Participants Positive for Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination|Duration of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination|Level of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination","Takeda","All","21 Years to 45 Years   (Adult)","Phase 2","351","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DEN-205|U1111-1166-8884","June 3, 2015","September 18, 2017","September 18, 2017","April 23, 2015","August 28, 2019","August 28, 2019","Singapore General Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Changi General Hospital, Singapore, Singapore","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02425098/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02425098/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02425098"
800,"NCT02423577","Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain",,"Completed","Has Results","Influenza","Drug: FF-3 dry powder|Drug: Placebo","Frequencies of Viral Shedding","Autoimmune Technologies, LLC|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 50 Years   (Adult)","Phase 2","79","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AIT02-2001|2015-001103-31|HHSN272201400003C|DMID 14-0052","September 2015","June 2016","June 2016","April 22, 2015","August 14, 2017","August 14, 2017","Quintiles Drug Research Unit, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02423577"
801,"NCT02421146","The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study",,"Completed","Has Results","Chronic Schizophrenia","Device: Transcranial direct current stimulation|Device: Transcranial direct current stimulation - Sham","Cognition on the RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) Scale|Cognition on the RBANS ( Repeatable Battery for the Assessment of Neuropsychological Status) Scale. Change Between 26th Day and Baseline.","Northwell Health","All","18 Years to 60 Years   (Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","14-623","April 2015","September 12, 2016","September 12, 2016","April 20, 2015","April 30, 2018","April 30, 2018","Zucker Hillside Hospital, Glen Oaks, New York, United States",,"https://ClinicalTrials.gov/show/NCT02421146"
802,"NCT02420353","Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears",,"Completed","Has Results","Rupture of Anterior Cruciate Ligament","Drug: Somatropin|Drug: Placebo","Normative Isokinetic Knee Extension Strength, Measured in Newton Meters (Nm) at 26 Weeks Post-op|Normative Isokinetic Extension (Nm) at Pre-op (Baseline)|Normative Isokinetic Flexion (Nm) at Pre-op (Baseline)|Normative Isokinetic Flexion (Nm) at 26 Weeks Post-op|Normative Isometric Extension (Nm) at Pre-op (Baseline)|Normative Isometric Extension (Nm) at 26 Weeks Post-op|Normative Isometric Flexion (Nm) at Pre-op (Baseline)|Normative Isometric Flexion (Nm) at 26 Weeks Post-op|Absolute Isokinetic Extension (Nm) at Pre-op (Baseline)|Absolute Isokinetic Extension (Nm) at 26 wk Post-op|Absolute Isokinetic Flexion (Nm) at Pre-op (Baseline)|Absolute Isokinetic Flexion (Nm) at 26 Weeks Post-op|Absolute Isometric Extension (Nm) at Pre-op (Baseline)|Absolute Isometric Extension (Nm) at 26 Weeks Post-op|Absolute Isometric Flexion (Nm) at Pre-op (Baseline)|Absolute Isometric Flexion (Nm) at 26 Weeks Post-op|VR12 Health Survey: Physical Health Summary Measure Score at Pre-op (Baseline)|VR12 Health Survey: Physical Health Summary Measure Score at 26 Weeks Post-op|VR12 Health Survey: Mental Health Summary Measure Score at Pre-op (Baseline)|VR12 Health Survey: Mental Health Summary Measure Score at 26 Weeks Post-op|International Knee Document Committee (IKDC) at Pre-op (Baseline)|International Knee Documentation Committee (IKDC) up to 26 wk Post-op|The Knee Injury and Osteoarthritis Outcome Score (KOOS): Patient Reported Outcome Measure: ADL at 26 Weeks Post-op|KOOS Patient Reported Outcome Measure: ADL at Pre-op (Baseline)|KOOS Patient Reported Outcome Measure: Pain at 26 Weeks Post-op|KOOS Patient Reported Outcome Measure: Pain at Pre-op (Baseline)|KOOS Patient Reported Outcome Measure: Quality of Life at 26 Weeks Post-op|KOOS Patient Reported Outcome Measure: Quality of Life at Pre-op (Baseline)|KOOS Patient Reported Outcome Measure: Sport and Recreation at 26 Weeks Post-op|KOOS Patient Reported Outcome Measure: Sports and Recreation at Pre-op (Baseline)|KOOS Patient Reported Outcome Measure: Symptoms at 26 Weeks Post-op|KOOS Patient Reported Outcome Measure: Symptoms at Pre-op (Baseline)|Absolute Quadriceps Volume (L) at Pre-op (Baseline)|Absolute Quadricep Volume (L) at 26 Week Post-op|Absolute Hamstring Volume (L) at Pre-op (Baseline)|Absolute Hamstring Volume (L) at 26 Weeks Post-op|Normalized Quadriceps Volume (L) at Pre-op (Baseline)|Normalized Quadriceps Volume (L) at 26 Weeks Post-op|Normalized Hamstring Volume (L) at Pre-op (Baseline)|Normalized Hamstring Volume (L) at 26 Weeks Post-op|Insulin Like Growth Factor (IGF1) at -1 and 5 Weeks Post-op|Myostatin at -1 and 5 Weeks Post-op|MMP3 at -1 and 5 Weeks Post-op|Hyaluronic Acid at -1 and 5 Weeks Post-op","University of Michigan|Hospital for Special Surgery, New York","Male","18 Years to 35 Years   (Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HUM00087702|IND Exemption 123189","May 2015","October 2018","October 2018","April 17, 2015","January 6, 2020","January 6, 2020","University of Michigan, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02420353/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02420353"
803,"NCT02420327","Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine","GalaNic","Completed","Has Results","Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor","Drug: Placebo patch & placebo capsule|Drug: Placebo patch & galantamine capsule|Drug: Nicotine patch & placebo capsule|Drug: Nicotine patch and galantamine capsule","Spatial Attentional Resource Allocation Task Predictive Trials Reaction Time|Rapid Visual Information Processing Task Hit Rate|Change Detection Task Accuracy|Spatial Attentional Resource Allocation Task (SARAT) Non-predictive Trial Reaction Time|Rapid Visual Information Processing Task Reaction Time|Change Detection Task Reaction Time|Profile of Mood Scale - Total Mood Disturbance","University of Maryland, Baltimore","All","21 Years to 55 Years   (Adult)","Not Applicable","43","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","HP-00057097","September 2014","March 2017","March 2017","April 17, 2015","August 17, 2018","November 4, 2019","University of Maryland School of Medicine, Maryland Psychiatric Research Center, Catonsville, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02420327/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02420327"
804,"NCT02418819","A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia",,"Completed","Has Results","Schizophrenia","Drug: PF-06412562 3mg BID|Drug: PF-06412562 9mg BID|Drug: PF-06412562 45mg BID|Other: Placebo","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Supine and Standing Vital Signs Meeting Categorical Summarization Criteria|Number of Participants With Electrocardiogram (ECG) (Standard 12‑Lead) Data Meeting Categorical Summarization Criteria|Number of Participants With Blood and Urine Safety Laboratory Test Abnormalities|Number of Participants With New Onset and Worsening of Post Baseline Suicidality in Columbia Suicide Severity Rating Scale (C‑SSRS) on Day 1, Day 7 and Follow-up.|Change From Baseline to Day 13 of Wechsler Memory Scale (WMS III) Spatial Span + Letter Number Span Composite Score (Working Memory Domain)|Change From Baseline in Blood Oxygen Level Dependent (BOLD) fMRI Activation Parameter Estimates (Z-scores) in Anterior Ventral Striatum Region of Interest (ROI) for the Contrast of Cue Gain > Cue No Gain in Monetary Incentive Delay (MID) Task on Day 15|Plasma Concentrations of PF-06412562 for Each Dose.|Plasma Concentrations of PF-06663872 at for Each Dose.","Pfizer","All","18 Years to 45 Years   (Adult)","Phase 1","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","B7441007","April 2015","October 2016","October 2016","April 16, 2015","February 4, 2019","February 4, 2019","Arcadia MRI & Imaging Center, Arcadia, California, United States|California Clinical Trials Medical Group, Glendale, California, United States|Glendale Adventist Medical Center, Glendale, California, United States|Maryland Psychiatric Research Center (MPRC) of the University of Maryland, Baltimore, Maryland, United States|CBH Health, LLC, Gaithersburg, Maryland, United States|Foers Long Term Care Pharmacy LLC, Rockville, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02418819"
805,"NCT02418585","A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","TRANSFORM-2","Completed","Has Results","Treatment-resistant Depression","Drug: Esketamine|Drug: Placebo|Drug: Duloxetine (Oral Antidepressant)|Drug: Escitalopram (Oral antidepressant)|Drug: Sertraline (Oral Antidepressant)|Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)","Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis|Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Analysis of Covariance (ANCOVA) Analysis|Percentage of Participants With Onset of Clinical Response on Day 2 and Day 8|Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis|Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis|Change From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis|Change From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis|Percentage of Participants Who Achieved >=50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28])|Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])|Percentage of Participants in Response (SDS Total Score <=12 and Individual Item Scores Each <=4) at the End of 4-Week Double-blind Induction Phase (Day 28)|Percentage of Participants in Remission (SDS Total Score <=6 and Individual Item Scores Each <=2) at the End of 4-Week Double-blind Induction Phase (Day 28)|Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])|Change From Baseline in Generalized Anxiety Disorder (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])|Change From Baseline in EQ 5D-5L-Health Status Index to End of Double-blind Induction Phase (Day 28)|Change From Baseline in EQ 5D-5L- European Quality of Life - Visual Analogue Scale (EQ-VAS) to End of Double-blind Induction Phase (Day 28)|Change From Baseline in EQ 5D-5L- Sum Score to End of Double-blind Induction Phase (Day 28)","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 3","236","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR107147|ESKETINTRD3002|2014-004585-22","August 7, 2015","June 1, 2017","November 6, 2017","April 16, 2015","April 19, 2019","April 29, 2019","Birmingham, Alabama, United States|Orange, California, United States|San Rafael, California, United States|Maitland, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Gaithersburg, Maryland, United States|Boston, Massachusetts, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Klecany, Czechia|Litomerice, Czechia|Plzen, Czechia|Prague, Czechia|Praha 10, Czechia|Praha 6, Czechia|Prerov, Czechia|Berlin, Germany|Cham, Germany|Dresden, Germany|Gelsenkirchen, Germany|Halle (Saale), Germany|Leipzig, Germany|Mainz, Germany|Mannheim, Germany|Mittweida, Germany|Pfaffenhofen, Germany|Prien, Germany|Tübingen, Germany|Bialystok, Poland|Bydgoszcz, Poland|Gdańsk, Poland|Krakow, Poland|Myslowice, Poland|Pruszkow, Poland|Torun, Poland|Tuszyn, Poland|Warszawa, Poland|Alcorcón, Spain|Barcelona, Spain|Córdoba, Spain|Mostoles, Spain|Murcia, Spain|Málaga, Spain|Palma, Spain|Pamplona, Spain|Sabadell, Spain|Salamanca, Spain|Santa Coloma De Gramanet, Spain|Vitoria-Gasteiz, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02418585/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02418585/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02418585"
806,"NCT02417441","TiLE (Time Lapse Eeva) Clinical Trial","TiLE","Completed","Has Results","Fertility","Device: Eeva","Implantation Rate|Clinical Pregnancy Rate|Number of Subjects With Ongoing Pregnancy Status|Multiple Pregnancy Rate|Utilization Rate|Spontaneous Miscarriage Rate","Merck KGaA, Darmstadt, Germany","Female","18 Years to 40 Years   (Adult)","Phase 4","976","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","EMR700623_545","June 29, 2015","February 9, 2017","February 9, 2017","April 15, 2015","April 29, 2019","April 29, 2019","Please contact the Communication Center, Darmstadt, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02417441/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02417441/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02417441"
807,"NCT02417064","A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","TRANSFORM-1","Completed","Has Results","Treatment-resistant Depression","Drug: Esketamine|Drug: Placebo|Drug: Duloxetine (Oral Antidepressant)|Drug: Escitalopram (Oral antidepressant)|Drug: Sertraline (Oral Antidepressant)|Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)","Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis|Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis|Percentage of Participants With Onset of Clinical Response by Day 2 and Day 8|Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis|Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis|Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis|Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis|Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at Day 28 of Double-blind Induction Phase (Observed Data)|Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)|Percentage of Participants in Remission (MADRS<=12) at Day 28 of Double-blind Induction Phase (Observed Data)|Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis (LOCF Data)|Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score up to Endpoint (Double-blind Induction Phase [Day 28])|Change From Baseline in Generalized Anxiety Disorder-7 Item (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])|Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Health Status Index|Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): EQ-VAS|Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Sum Score","Janssen Research & Development, LLC","All","18 Years to 64 Years   (Adult)","Phase 3","346","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR107146|ESKETINTRD3001|2014-004584-20","August 10, 2015","February 20, 2018","February 20, 2018","April 15, 2015","April 18, 2019","April 18, 2019","Birmingham, Alabama, United States|Little Rock, Arkansas, United States|Garden Grove, California, United States|Orange, California, United States|San Diego, California, United States|San Marcos, California, United States|San Rafael, California, United States|Bradenton, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Chicago, Illinois, United States|Hoffman Estates, Illinois, United States|Maywood, Illinois, United States|Schaumburg, Illinois, United States|Wichita, Kansas, United States|Gaithersburg, Maryland, United States|Boston, Massachusetts, United States|Quincy, Massachusetts, United States|Watertown, Massachusetts, United States|Worcester, Massachusetts, United States|Minneapolis, Minnesota, United States|O'Fallon, Missouri, United States|Saint Charles, Missouri, United States|Omaha, Nebraska, United States|New York, New York, United States|Durham, North Carolina, United States|Dayton, Ohio, United States|Oklahoma City, Oklahoma, United States|Media, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Lincoln, Rhode Island, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Woodstock, Vermont, United States|Bothell, Washington, United States|Middleton, Wisconsin, United States|Aalst, Belgium|Brugge, Belgium|Brussel, Belgium|Gent, Belgium|Hasselt, Belgium|Heusden-Zolder, Belgium|Liège, Belgium|Spa, Belgium|Yvoir, Belgium|Belo Horizonte, Brazil|Curitiba, Brazil|Fortaleza, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Rio de Janeiro, Brazil|Santo André, Brazil|Vancouver, British Columbia, Canada|Kingston, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Calgary, Canada|Parnu, Estonia|Tallinn, Estonia|Tartu, Estonia|BESANCON Cedex, France|Clermont Ferrand, France|Douai, France|Issy-les-Moulineaux, France|La Tronche, France|Lille, France|Limoges, France|Montpellier Cedex 5, France|Nantes, France|Neuilly sur Marne, France|Nimes Cedex 9, France|Paris, France|Poitiers, France|Toulon, France|TOURS cedex 9, France|Budapest, Hungary|Vác, Hungary|Guadalajara, Mexico|Leon, Mexico|Mazatlan, Mexico|Mexico City, Mexico|Monterrey, Mexico|San Luis Potosi, Mexico|San Luis Potosí, Mexico|Bratislava, Slovakia|Liptovsky Mikulas, Slovakia|Rimavska Sobota, Slovakia|Roznava, Slovakia|Svidnik, Slovakia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02417064/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02417064/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02417064"
808,"NCT02415166","Influenza Challenge in Mood Disorders",,"Terminated","Has Results","MAJOR DEPRESSIVE DISORDER","Biological: INFLUENZA VACCINE|Other: NaCl-saline placebo","THE TITER OF INFLUENZA ANTIBODIES|THE INFLUENZA VIRUS-INDUCED PROLIFERATION OF CD4+ MEMORY T-CELLS","Laureate Institute for Brain Research, Inc.","Female","18 Years to 55 Years   (Adult)","Not Applicable","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","LIBR # 2015-001-00","July 2015","March 2016","March 2016","April 14, 2015","December 26, 2017","January 23, 2018","Laureate Institute for Brian Research, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT02415166"
809,"NCT02414828","A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB","C-010-402","Completed","Has Results","Tuberculosis","Biological: Placebo|Biological: AERAS-402 3 x 10^8 vp|Biological: AERAS-402 3 x 10^9 vp|Biological: AERAS-402 3 x 10^10 vp","Number of Participants With Solicited and Unsolicited AEs|Forced Expiratory Volume in One Second (FEV1)|Forced Vital Capacity (FVC)|Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)|Immunogenicity of AERAS-402 Based on the Percentage of CD4 Cells of Participants in the ""on TB Treatment"" Stratum|Immunogenicity of AERAS-402 Based on the Percentage of CD8 Cells of Participants in the ""on TB Treatment"" Stratum|Immunogenicity of AERAS-402 Based on the Percentage of CD4 Cells of Participants in the ""Post TB Treatment"" Stratum|Immunogenicity of AERAS-402 Based on the Percentage of CD8 Cells of Participants in the ""Post TB Treatment"" Stratum","Aeras|Crucell Holland BV","All","18 Years to 45 Years   (Adult)","Phase 2","72","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C-010-402","October 2008","July 2010","November 2010","April 13, 2015","May 4, 2016","May 4, 2016","University of Cape Town Lung Institute Pty (Ltd), Cape Town, Mowbray, South Africa",,"https://ClinicalTrials.gov/show/NCT02414828"
810,"NCT02413255","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers",,"Completed","Has Results","Healthy Volunteers","Drug: TAK-020|Drug: TAK-020 Placebo","Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) in Part 1 Single-rising Dose (SRD)|Percentage of Participants With Markedly Abnormal Values (MAV) for Safety Laboratory Findings at Least Once Post-dose in Part 1 (SRD)|Percentage of Participants With MAV for Vital Sign Measurements at Least Once Post-dose in Part 1 (SRD)|Percentage of Participants With MAV for Safety Electrocardiogram (ECG) Parameters at Least Once Post-dose in Part 1 (SRD)|Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) in Part 2 Multiple-rising Dose (MRD)|Percentage of Participants With MAV for Safety Laboratory Findings at Least Once Post-dose in Part 2 (MRD)|Percentage of Participants With MAV for Vital Sign Measurements at Least Once Post-dose in Part 2 (MRD)|Percentage of Participants With MAV for Safety ECG Parameters at Least Once Post-dose in Part 2 (MRD)|Cmax: Maximum Observed Plasma Concentration for TAK-020 in Part 1 (SRD)|Cmax: Maximum Observed Plasma Concentration for TAK-020 in Part 2 (MRD)|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-020 in Part 1 (SRD)|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-020 in Part 2 (MRD)|AUC24: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for TAK-020 in Part 1 (SRD)|AUC24: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for TAK-020 in Part 2 (MRD)|AUC24/D: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours Divided by TAK-020 Dose for TAK-020 in Part 1 (SRD)|AUC24/D: Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours Divided by TAK-020 Dose for TAK-020 in Part 2 (MRD)|AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for TAK-020 (SRD)|AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for TAK-020 in Part 2 (MRD)|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 1 (SRD)|AUC∞:Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 2 (MRD)|Rac(AUC): Accumulation Ratio Based on AUC Calculated as AUC24 at Steady State/AUC24 After a Single Dose for TAK-020 (MRD)|Rac(Cmax): Accumulation Ratio Based on Cmax Calculated as Cmax at Steady State/Cmax After a Single Dose for TAK-020 (MRD)|Cmax/D: Maximum Observed Plasma Concentration Divided by TAK-020 Dose for TAK-020 (SRD)|Cmax/D: Maximum Observed Plasma Concentration Divided by TAK-020 Dose for TAK-020 (MRD)|Terminal Disposition Phase Half-life for TAK-020 in Part 1 (SRD)|T1/2z : Terminal Disposition Phase Half-life (T1/2z) for TAK-020 in Part 2 (MRD)|Lambda z (Λz): Terminal Disposition Phase Rate Constant for TAK-020 (SRD)|Lamda z (Λz):Terminal Disposition Phase Rate Constant for TAK-020 (MRD)|Tlag: Lag Time to First Quantifiable Concentration for TAK-020 (SRD)|Tlag: Lag Time to First Quantifiable Concentration for TAK-020 (MRD)|CL/F: Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration of TAK-020 in Part 1 (SRD)|CL/F: Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration of TAK-020 in Part 2 (MRD)|Apparent Volume of Distribution (Vz/F) During the Terminal Disposition Phase After Extravascular Administration Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 1 (SRD)|Apparent Volume of Distribution (Vz/F) During the Terminal Disposition Phase After Extravascular Administration Calculated Using the Observed Value for the Last Quantifiable Concentration for TAK-020 in Part 2 (MRD)|Ae(0-24) : Amount of Drug Excreted in Urine During a 24-hour Dosing Interval for TAK-020 in Part 1 (SRD)|Ae(0-24): Amount of Drug Excreted in Urine During a 24-hour Dosing Interval for TAK-020 in Part 2 (MRD)|Ae(0-96): Amount of Drug Excreted in Urine From Time 0 to Time 96 Hours for TAK-020 in Part 1 (SRD)|Fe(0-24): Fraction of Drug Excreted in Urine for TAK-020 in Part 1 (SRD)|Fe(0-24): Fraction of Drug Excreted in Urine for TAK-020 in Part 2 (MRD)|Fe(0-96): Fraction of Drug Excreted in Urine for TAK-020 in Part 1 (SRD)|Renal Clearance (CLr) for TAK-020 in Part 1 (SRD)|Renal Clearance (CLr) for TAK-020 in Part 2 (MRD)|R: Linearity Index Calculated as AUC24 at Steady State/AUC∞ After a Single Dose for TAK-020 in Part 2 (MRD)","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-020-1001|U1111-1163-9637","March 18, 2015","May 4, 2017","May 4, 2017","April 9, 2015","January 7, 2019","January 7, 2019","Glendale, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02413255/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02413255/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02413255"
811,"NCT02413203","Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B",,"Completed","Has Results","Healthy","Drug: Celecoxib|Drug: Placebo","Quantification of Plasma Lipids in the Whole Blood: Prostaglandin E2 (PGE2)|Quantification of Plasma Lipids in the Whole Blood: Prostaglandin F2a (PGF2a)|Quantification of Plasma Lipids in the Whole Blood: Thromboxane B2 (TxB2)|Quantification of Plasma Lipids in the Whole Blood: 15-Hydroxyeicosatetraenoic Acid (15-HETE)|Urinary Lipid Metabolites: PGE2 Metabolite (PGE-M)|Celecoxib Plasma Concentration|Urinary Lipid Metabolites: PGI2 Metabolite (PGI-M)|Urinary Lipid Metabolites: TxB2 Metabolite (Tx-M)","University of Pennsylvania|Eli Lilly and Company","All","18 Years to 50 Years   (Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Screening","818658-Part B","March 2015","November 2015","November 2015","April 9, 2015","May 30, 2017","May 30, 2017","The Clinical Translational Research Center (CTRC) at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02413203"
812,"NCT02412436","PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB","PRIDE-HT","Completed","Has Results","HIV-1 Infection|Tuberculosis","Drug: Depot medroxyprogesterone acetate","Percent of Participants With DMPA Concentrations Below 0.1 ng/mL at Week 12|Percent of Participants With Progesterone Levels Above 1 ng/mL at Week 12|Percent of Participants With DMPA Concentrations Below 0.1 ng/mL at Weeks 2, 4, 6, 8, and 10|Cumulative Percentage of Participants With DMPA < 0.1 ng/mL|DMPA AUC|DMPA Cmin|DMPA Cmax|DMPA CL/F|Percent of Participants Who Experienced a Grade 3 or Higher Sign/Symptom or Laboratory Abnormality|DMPA Half-life|Time at Which Participant-specific Estimated Elimination Slopes for DMPA Level Cross the Threshold of 0.1 ng/mL","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)","Female","18 Years to 46 Years   (Adult)","Phase 2","62","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5338|UM1AI068636","November 3, 2015","June 15, 2017","June 15, 2017","April 9, 2015","September 25, 2018","July 1, 2019","Gaborone Prevention/Treatment Trials CRS (12701), Gaborone, Botswana|Kenya Medical Research Institute/Center for Disease Control (KEMRI/CDC) CRS (31460), Kisumu, Kenya|Durban Adult HIV CRS (11201), Durban, South Africa|Univ. of Witwatersrand CRS (11101), Johannesburg, South Africa|UZ-Parirenyatwa CRS (30313), Harare, Zimbabwe","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02412436/Prot_ICF_000.pdf|""Statistical Analysis Plan: Primary Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02412436/SAP_001.pdf|""Statistical Analysis Plan: PK Modeling Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02412436/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02412436"
813,"NCT02411578","Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: G-Pen Mini™ (glucagon injection)|Other: Glucose Tablets","Number of Hypoglycemic Events ≥50 mg/dl 15 Minutes AND ≥ 70 mg/dl 30 Minutes After Initial Treatment|Continuous Glucose Monitor (CGM) Minimum Glucose, Event Level|CGM Maximum Glucose, Event Level|CGM Mean Glucose, Event Level|CGM Time in Range, Event Level|CGM Time Below 70 mg/dL, Event Level|CGM Minimum Glucose, Event Level|CGM Time Below 70 mg/dL|CGM Mean Glucose|CGM Time in Range|CGM Time Below 70|CGM Coefficient of Variation","Jaeb Center for Health Research|Xeris Pharmaceuticals","All","18 Years to 64 Years   (Adult)","Phase 2","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T1DX Mini-dose Non-Severe","September 2015","April 2016","May 2016","April 8, 2015","October 23, 2017","November 27, 2017","University of Colorado/Barbara Davis Center for Diabetes, Aurora, Colorado, United States|Yale University of Medicine, New Haven, Connecticut, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02411578"
814,"NCT02410018","Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata",,"Completed","Has Results","Leiomyomata","Device: OCL 503 (uterine artery embolization)","Number of Participants With Serious Adverse Events|Change in Fibroid Perfusion From Baseline at 7 Days Post Treatment|Change in Fibroid Perfusion From Baseline at 28 Days Post Treatment of Women With Leiomyomata by UAE|Tissue Necrosis Assessed by Histology Graded Scale at 7 Days Post Treatment of Women With Leiomyomata by UAE|Inflammatory Response Assessed by Histology at 7 Days Post Treatment of Women With Leiomyomata by UAE|Tissue Necrosis Assessed by Histology Graded Scale at 28 Days Post Treatment of Women With Leiomyomata by UAE|Inflammatory Response Assessed by Histology at 28 Days Post Treatment of Women With Leiomyomata by UAE","IMBiotechnologies Ltd.","Female","30 Years to 55 Years   (Adult)","Not Applicable","3","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OCL503-P1-UFE-01","April 2015","June 2016","June 2016","April 7, 2015","September 7, 2018","December 5, 2018","Albany Medical Center, Albany, New York, United States",,"https://ClinicalTrials.gov/show/NCT02410018"
815,"NCT02408692","Emergency Contraception and Body Weight: Pilot Study",,"Completed","Has Results","Contraception|Body Weight","Drug: ECx1|Drug: ECx2","Maximum Serum Concentration Between Normal and Obese BMI Women Ingesting 1.5mg Levonorgestrel|Maximum Serum Concentration Between Obese BMI Women Ingesting 1.5mg of Levonorgestrel and Then the Same Obese BMI Women Ingesting 3mg Levonorgestrel","Oregon Health and Science University|Medical Research Foundation, Oregon","Female","18 Years to 35 Years   (Adult)","Phase 4","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","OHSU IRB 11419","February 2015","July 2015","August 2015","April 3, 2015","June 2, 2017","October 25, 2017","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02408692"
816,"NCT02408068","Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only",,"Completed","Has Results","Healthy","Drug: Dexamethasone|Drug: Chronocort: fasted|Drug: Immediate release hydrocortisone: fasted|Drug: Chronocort: fed","Chronocort Cmax|Comparison of Fed and Fasted Chronocort AUC0-t|Comparison of Fed and Fasted Chronocort Tmax|Bioavailability of Chronocort® vs Hydrocortisone Tablets - Cmax|Bioavailability of Chronocort® vs Hydrocortisone Tablets - Fasted Using AUC0-t|Bioavailability of Chronocort® vs Hydrocortisone Tablets - Fasted Using Tmax.","Diurnal Limited|Simbec Research","Male","18 Years to 60 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","DIUR-004","January 2015","March 2015","March 2015","April 3, 2015","December 15, 2017","December 15, 2017",,,"https://ClinicalTrials.gov/show/NCT02408068"
817,"NCT02407223","An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis",,"Terminated","Has Results","Nonradiographic Axial Spondylitis, Ankylosing","Drug: Group 1: Placebo|Drug: Group 2: Ustekinumab 45 mg|Drug: Group 3: Ustekinumab 90 mg","Percentage of Participants Who Achieved Assessment of SpondyloArthritis International Society (ASAS) 20 Response at Week 24|Percentage of Participants Who Achieved an ASAS 40 Response at Week 24|Percentage of Participants Who Achieved at Least a 50% Improvement From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Percentage of Participants Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive Protein (CRP) Inactive Disease (<1.3) at Week 24|Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) Levels Through Week 24|Percentage of Participants With ASAS 20 Components at Week 24|Percentage of Participants Who Achieved ASAS 40 Response at Week 4, 8, 12, 16 and 20|Percentage of Participants Who Achieved ASAS 20 Response at Week 4, 8, 12, 16 and 20|Percentage of Participants Who Achieved at Least a 50% Improvement From Baseline in BASDAI at Week 4, 8, 12, 16 and 20|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 4, 8, 12, 16 and 20|Percentage of Participants With ASDAS (CRP) Inactive Disease (<1.3) at Week 4, 8, 12, 16, and 20","Janssen Research & Development, LLC","All","18 Years to 50 Years   (Adult)","Phase 3","356","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR106995|CNTO1275AKS3003|2015-000289-67","July 13, 2015","September 26, 2017","September 26, 2017","April 2, 2015","March 13, 2019","March 13, 2019","Buenos Aires, Argentina|Ciudad De Buenos Aires, Argentina|Ciudad De La Plata, Argentina|Ciudad De San Miguel De Tucuman, Argentina|Cordoba, Argentina|Geelong, Australia|Hobart, Australia|Kogarah, Australia|Queensland, Australia|Woodville South, Australia|Woolloongabba, Australia|Genk, Belgium|Gent, Belgium|Leuven, Belgium|Liège, Belgium|Merksem, Belgium|Brno, Czechia|Bruntal, Czechia|Kladno, Czechia|Ostrava, Czechia|Pardubice, Czechia|Prague 5, Czechia|Praha 2, Czechia|Praha 4, Czechia|Uherske Hradiste, Czechia|Zlin, Czechia|Boulogne-Billancourt, France|Chambray Les Tours, France|Echirolles, France|Montpellier, Herault, France|Paris, France|Toulouse, France|Bad Nauheim, Germany|Berlin, Germany|Hamburg, Germany|Hannover, Germany|Herne, Germany|Köln, Germany|Olsberg, Germany|Budapest, Hungary|Debrecen, Hungary|Esztergom, Hungary|Kistarcsa, Hungary|Nyíregyháza, Hungary|Szolnok, Hungary|Székesfehérvár, Hungary|Veszprem, Hungary|Gwangju, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Chihuahua, Mexico|Culiacan, Mexico|Guadalajara, Mexico|Mexico, Mexico|Bydgoszcz, Poland|Szczecin, Poland|Torun, Poland|Warszawa, Poland|Wrocław, Poland|Chelyabinsk, Russian Federation|Chita, Russian Federation|Kemerovo, Russian Federation|Kirov, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Orenburg, Russian Federation|Petrozavodsk, Russian Federation|Sankt-Petersburg., Russian Federation|Saratov, Russian Federation|St.Petersburg, Russian Federation|Stavropol, Russian Federation|Ulyanovsk, Russian Federation|Zelenograd, Russian Federation|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Ternopil, Ukraine|Vinnytsya, Ukraine|Zaporizhzhya, Ukraine|Bath, United Kingdom|Leeds, United Kingdom|Leytonstone, United Kingdom|London, United Kingdom|Norwich, United Kingdom|Staffordshire, United Kingdom|Torquay, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02407223/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02407223/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02407223"
818,"NCT02406495","Clinical Performance of Habitual Wearers of Bioclear 1-day Lenses When Refitted With Biomedics 1-day Extra for 1 Week",,"Completed","Has Results","Myopia|Hyperopia","Device: filcon IV 1|Device: ocufilcon D","Lens Fit, Centration - Filcon IV 1 and Ocufilcon D|Lens Fit, Post-blink Movement - Filcon IV 1 and Ocufilcon D|Lens Fit, Lens Tightness - Filcon IV 1 and Ocufilcon D|Lens Fit, Overall Fit Acceptance - Filcon IV 1 and Ocufilcon D|Visual Acuity - Filcon IV 1 and Ocufilcon D|Comfort (Subjective Ratings) - Filcon IV 1 and Ocufilcon D|Dryness (Subjective Ratings) - Filcon IV 1 and Ocufilcon D|Handling (Subjective Ratings) - Filcon IV 1 and Ocufilcon D|Vision Satisfaction (Subjective Ratings) - Filcon IV 1 and Ocufilcon D|Lens Preference (Subjective Ratings) - Filcon IV 1 and Ocufilcon D|Lens Satisfaction, Comfort - Filcon IV 1 and Ocufilcon D|Lens Satisfaction, Dryness - Filcon IV 1 and Ocufilcon D|Lens Satisfaction, Handling - Filcon IV 1 and Ocufilcon D|Lens Satisfaction, Vision - Filcon IV 1 and Ocufilcon D|Lens Satisfaction, Overall - Filcon IV 1 and Ocufilcon D","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","EX-MKTG-58","April 2015","April 2015","May 2015","April 2, 2015","May 3, 2016","May 3, 2016","Optometry Research Group (GIO) Optics Department, University of Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02406495"
819,"NCT02403986","An Efficacy and Safety Study Evaluating Treatment Sessions of Restylane Skinboosters Vital Lidocaine in the Face",,"Completed","Has Results","Aged Skin","Device: Restylane Vital Skinboosters Lidocaine","Percentage of Improved Participants on the Global Aesthetic Improvement Scale (GAIS)-Subject|Percentage of Improved Participants on the Global Aesthetic Improvement Scale (GAIS)-Investigator","Q-Med AB","Female","35 Years to 45 Years   (Adult)","Phase 4","53","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTN 05DF1404","April 2015","March 30, 2017","March 30, 2017","March 31, 2015","September 6, 2019","September 6, 2019","Rosenpark Research, Darmstadt, Germany","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02403986/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02403986"
820,"NCT02403635","Drug-Drug Interaction Study: ASP2151 and Midazolam",,"Completed","Has Results","Healthy","Drug: Midazolam|Drug: ASP2151","Peak Plasma Concentration (Cmax) of Midazolam|Time of Peak Concentration (Tmax) of Midazolam|Area Under Concentration-Time Curve Extrapolated to Infinite Time (AUC0-∞) of Midazolam|Half-life (t1/2) of Midazolam|Number of Participants With Serious and Non-Serious Adverse Events","Maruho Europe Limited","Male","18 Years to 45 Years   (Adult)","Phase 1","27","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","M522101-EU24","April 2015","May 2015","May 2015","March 31, 2015","January 14, 2019","February 21, 2019","Hammersmith Medicines Research Ltd, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02403635"
821,"NCT02402322","Internet-based Self-help Treatment for Panic Disorder: Two Ways of Complementary Psychological Support",,"Completed","Has Results","Panic Disorder","Behavioral: Scheduled support|Behavioral: Non-scheduled support","Change From Baseline Score in the Panic Disorder Severity Scale at 8 Weeks and 6 Months.|Change From Baseline Score in the Anxiety Sensitivity Index-3 at 8 Weeks and 6 Months.|Change From Baseline Score in the Beck Anxiety Inventory at 8 Weeks and 6 Months.|Change From Baseline Score in the Beck Depression Inventory at 8 Weeks and 6 Months.|Change From Baseline Score in the Sheehan Disability Inventory (Work Subscale) at 8 Weeks and 6 Months.|Change From Baseline Score in the Sheehan Disability Inventory (Social Life Subscale) at 8 Weeks and 6 Months.|Change From Baseline Score in the Sheehan Disability Inventory (Family Subscale) at 8 Weeks and 6 Months.|Change From Baseline Score in the Sheehan Disability Inventory (Stress Subscale) at 8 Weeks and 6 Months.|Change From Baseline Score in the Sheehan Disability Inventory (Social Support Subscale) at 8 Weeks and 6 Months.","Universitat Autonoma de Barcelona","All","18 Years to 60 Years   (Adult)","Not Applicable","77","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","PTCCAP","August 2013","November 2014","November 2014","March 30, 2015","December 7, 2015","December 7, 2015",,,"https://ClinicalTrials.gov/show/NCT02402322"
822,"NCT02402296","Host Modulatory Effects of β-glucan on Localized Aggressive Periodontitis",,"Completed","Has Results","Localized Aggressive Periodontitis","Drug: β-1,3/1,6-D-glucan|Other: Placebo","Assessment of Change in Clinical Attachment Level (CAL)|Pocket Depth (PD)|Gingival Index (GI)|Matrix Metallo-proteinase (MMP-1&9)","Al-Azhar University","All","20 Years to 27 Years   (Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Al-Azhar 1-2013","January 2013","June 2014","August 2014","March 30, 2015","June 9, 2015","June 9, 2015",,,"https://ClinicalTrials.gov/show/NCT02402296"
823,"NCT02401464","A Bioequivalence Study of TAK-536 Pediatric Formulation",,"Completed","Has Results","Japanese Healthy Adult Males","Drug: TAK-536 Tablet|Drug: TAK-536 Dry Syrup Formulation|Drug: TAK-536 Ganule Formulation","AUC(0-48): Area Under the Plasma Concentration-Time Curve From Time 0 to 48 Hours Postdose for TAK-536 in Dry Syrup Cohort|Cmax: Maximum Observed Plasma Concentration for TAK-536 in Dry Syrup Cohort|AUC(0-48): Area Under the Plasma Concentration-Time Curve From Time 0 to 48 Hours Postdose for TAK-536 in Granule Cohort|Cmax: Maximum Observed Plasma Concentration for TAK-536 in Granule Cohort|Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)|Number of Participants With TEAEs Related to Vital Signs|Number of Participants With TEAEs Related to Body Weight|Number of Participants Who Had Clinically Meaningful Changes From Baseline in 12-lead Electrocardiograms (ECG)|Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Laboratory Values","Takeda","Male","20 Years to 35 Years   (Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-536/CPH-101|U1111-1168-3113|JapicCTI-152853","March 2015","May 2015","May 2015","March 27, 2015","July 6, 2016","July 6, 2016","Kagoshima, Japan",,"https://ClinicalTrials.gov/show/NCT02401464"
824,"NCT02401256","CYP2B6 Genetics and Drug Interactions in Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: Efavirenz|Drug: Bupropion|Drug: Rosuvastatin|Drug: Montelukast","Efavirenz AUC0-inf (Single Dose) and AUC0-24(Multiple Dose)","Indiana University|National Institute of General Medical Sciences (NIGMS)","All","18 Years to 49 Years   (Adult)","Phase 4","70","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1205008739|5R01GM078501","July 2013","May 2016","May 31, 2016","March 27, 2015","October 11, 2017","October 11, 2017","Indiana University School of Medicine, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02401256"
825,"NCT02401230","PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV",,"Completed","Has Results","HIV","Drug: Truvada|Device: Gel lubricant","Median Percentage of CD4 Positive T-Cells|Median Cumulative Amount of p24|Median Plasma Emtricitabine (FTC) Concentration|Median Plasma Tenofovir (TDF) Concentration|Median Rectal Secretion Emtricitabine (FTC) Concentration|Median Rectal Secretion Tenofovir (TDF) Concentration|Median Peripheral Blood Mononuclear Cell (PBMC) Emtricitabine (FTC) Concentration|Median Peripheral Blood Mononuclear Cell (PBMC) Tenofovir (TDF) Concentration|Median Rectal Tissue Emtricitabine (FTC) Concentration|Median Rectal Tissue Tenofovir (TDF) Concentration|Median Rectal Tissue Deoxyadenosine Triphosphate (dATP) Concentration|Median Rectal Tissue Deoxycytidine Triphosphate (dCTP) Concentration|Median Peripheral Blood Mononuclear Cell (PBMC) Deoxyadenosine Triphosphate (dATP) Concentration","Emory University|Centers for Disease Control and Prevention","Male","18 Years to 49 Years   (Adult)","Phase 4","86","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00077593","March 2015","January 25, 2017","January 25, 2017","March 27, 2015","February 19, 2018","February 19, 2018","The Hope Clinic of of Emory University, Decatur, Georgia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02401230/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02401230/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02401230"
826,"NCT02400333","Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet",,"Completed","Has Results","Bioavailability|Healthy Subjects","Drug: Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water|Drug: Ticagrelor OD tablet (90 mg single dose) administered without water|Drug: Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube|Drug: Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water","Maximum Observed Plasma Concentration (Cmax) of Ticagrelor and Its Active Metabolite AR-C124910XX.|Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte Concentration (AUC[0-t]) of Ticagrelor and Its Active Metabolite AR-C124910XX.|Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC [0-∞]).|Time to Reach Maximum Observed Concentration (Tmax) of Ticagrelor and Its Active Metabolite AR-C124910XX.|Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) of Ticagrelor and Its Active Metabolite AR-C124910XX.|Ratio of Metabolite Cmax to Parent Cmax, Adjusted for Differences in Molecular Weights (MRCmax) of Metabolite AR-C124910XX.|Ratio of Metabolite AUC(0-t) to Parent AUC(0-t), Adjusted for Differences in Molecular Weights (MRAUC[0-t]) of Metabolite AR-C124910XX.|Ratio of Metabolite AUC [0-∞] to Parent AUC [0-∞], Adjusted for Differences in Molecular Weights (MRAUC [0-∞]) of Metabolite AR-C124910XX.|Percentage of Participants With Adverse Events (AEs).|Mean Change From Baseline for Vital Signs of Supine Blood Pressure (SBP) and Diastolic BP (DBP).|Mean Change From Baseline for Vital Signs in Supine Pulse Rate.|Participants With Significant Findings in 12-Lead Electrocardiography (ECG).|Participants With Clinically Significant Findings in Hematology, Clinical Chemistry and Urinalysis.","AstraZeneca","All","18 Years to 55 Years   (Adult)","Phase 1","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D5139C00003","June 2015","July 2015","July 2015","March 27, 2015","August 3, 2016","September 29, 2016","Research Site, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02400333"
827,"NCT02396147","Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants",,"Completed","Has Results","Healthy Volunteers","Drug: TAK-385 T2 Formulation|Drug: TAK-385 T4 Formulation B|Drug: TAK-385 T4 Formulation C","Cmax: Maximum Observed Plasma Concentration for TAK-385|AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose for TAK-385|AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385|Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant|Percentage of Participants With Electrocardiogram (ECG) Parameters Abnormal and Clinically Significant|Percentage of Participants With Markedly Abnormal Vital Sign Measurements|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-385|Terminal Phase Elimination Half-Life (T1/2) for TAK-385|Oral Clearance (CL/F) for TAK-385","Takeda","Male","18 Years to 55 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-385-1010|U1111-1165-3720","March 2015","April 2015","June 2015","March 24, 2015","July 25, 2016","July 25, 2016","Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02396147"
828,"NCT02395055","Comparative Clinical Trial to Evaluate Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: Adalimumab (BCD-057)|Drug: Adalimumab (Humira)","Maximum Concentration of Adalimumab After Single SC Injection of BCD-057/Humira|Area Under the Plasma Concentration-time Curve From Zero (0) to Time Infinity|Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours of Adalimumab After Single SC Injection of BCD-057/Humira.","Biocad","Male","18 Years to 45 Years   (Adult)","Phase 1","94","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","BCD-057-1","June 2015","October 2015","October 2015","March 20, 2015","May 23, 2016","October 18, 2016","LLC BioEk, Saint-Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02395055"
829,"NCT02394808","2-week Evaluation of Marketed Silicone Hydrogel Contact Lenses in Indian Population",,"Completed","Has Results","Visual Acuity","Device: senofilcon A|Device: lotrafilcon B","Subjective Overall Comfort|Subjective Overall Quality of Vision","Johnson & Johnson Vision Care, Inc.","All","18 Years to 39 Years   (Adult)","Not Applicable","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-5625","January 1, 2015","September 1, 2015","September 1, 2015","March 20, 2015","June 19, 2017","June 19, 2018","Chennai, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT02394808"
830,"NCT02394756","Investigation of Ocular Signs & Symptoms in Wearers Fitted With Contact Lenses Following Digital Device Use",,"Completed","Has Results","Visual Performance","Device: Marketed Soft Contact lens|Device: AIR OPTIX® AQUA|Device: Biofinity®","Subjective Overall Comfort|Subjective Overall Quality of Vision","Johnson & Johnson Vision Care, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-5615","February 2015","September 2015","September 2015","March 20, 2015","April 25, 2017","June 19, 2018","Waterloo, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02394756"
831,"NCT02393950","Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers","FIMPAM","Completed","Has Results","Healthy Volunteer Study","Drug: ODM-106|Drug: Placebo","Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability.|Peak Plasma Concentration (cMax) of ODM-106|Area Under the Plasma Concentration Versus Time Curve (AUC) of ODM-106|Time to Peak Plasma Concentration (Tmax) of ODM-106|Elimination Half-life of ODM-106|Metabolite Screening in Plasma and Urine|Effect of ODM-106 on Growth Hormone Levels|Sedation Scores on a Visual Analogue Scale (VAS)|Dexterity and Reaction Times|Quantitative EEG","Orion Corporation, Orion Pharma","Male","18 Years to 45 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","3117001|2014-001317-33","March 2015","October 2015","March 2016","March 20, 2015","December 23, 2016","December 23, 2016","Parexel International GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02393950"
832,"NCT02393677","Supraclavicular Brachial Plexus Block Using Ropivacaine Alone and With Dexmedetomidine",,"Completed","Has Results","Brachial Plexus Anesthesia","Drug: Ropivacaine|Drug: Ropivacaine with Dexmedetomidine","Duration of Analgesia|Onset of Sensory Block|Onset of Motor Block|Duration of Motor Block","Government Medical College, Haldwani","All","18 Years to 60 Years   (Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","DN57/FM","July 2011","July 2012","July 2012","March 19, 2015","November 6, 2015","November 6, 2015",,,"https://ClinicalTrials.gov/show/NCT02393677"
833,"NCT02390557","Persons With Disabilities Generating Quality Metrics",,"Completed","Has Results","Physical Disability|Chronic Mental Disorder","Other: Survey|Other: YESHealth","Improved Quality of Care","Massachusetts General Hospital|Patient-Centered Outcomes Research Institute","All","21 Years to 64 Years   (Adult)","Not Applicable","451","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Health Services Research","2014000899","July 1, 2015","October 7, 2016","October 7, 2016","March 17, 2015","November 21, 2018","November 21, 2018",,,"https://ClinicalTrials.gov/show/NCT02390557"
834,"NCT02390076","Behavioral Study of Effects of Low-Level Light Therapy on Mood and Reaction Time",,"Completed","Has Results","Depression","Device: Left Low Level Light Therapy|Other: Attention bias modification|Device: Right Low Level Light Therapy|Device: Sham Low Level Light Therapy","Presence and Severity of Depressive Symptoms Assessed by Center for Epidemiologic Studies - Depression Scale (CES-D)|Biased Attention for Emotional Stimuli Measured by the Dot Probe Task","Seth Disner|University of Texas at Austin","All","18 Years to 35 Years   (Adult)","Not Applicable","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IMHR-0001","January 2013","January 2015","January 2015","March 17, 2015","May 8, 2019","May 8, 2019",,,"https://ClinicalTrials.gov/show/NCT02390076"
835,"NCT02389088","Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH.",,"Completed","Has Results","Polycystic Ovary Syndrome","Drug: Letrozole","Estradiol During Phase I and Phase II|Inhibin B During Phase I and Phase II|LH and FSH During Phase I and Phase II|Testosterone, Androstenedione and 17-OH Progesterone During Phase I and Phase II","University of California, San Diego","Female","18 Years to 40 Years   (Adult)","Not Applicable","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","UCSD-2016","April 2006","January 2013","January 2013","March 17, 2015","September 28, 2015","March 10, 2016",,,"https://ClinicalTrials.gov/show/NCT02389088"
836,"NCT02388997","Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus",,"Completed","Has Results","Asthma","Drug: omalizumab|Biological: Rhinovirus (strain 16)","Airway Symptom Scores Experienced by Participants During the First 4 Days of the Acute Infection.|Airway Symptom Scores Experienced by Participants During the First 7 Days of the Acute Infection.|Airway Symptom Scores Experienced by Participants During the 21 Days of Monitoring During the Infection.|Airway Symptom Scores Experienced by Participants During the First 4 Days of the Acute Infection With Cough.|Airway Symptom Scores Experienced by Participants During the First 4 Days of the Acute Infection (Upper Respiratory Tract Symptoms).|Number of Participants Whose FEV1 Dropped by More Than 20% During the Infection.","University of Virginia|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 40 Years   (Adult)","Phase 2","31","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","14427|U01AI100799","February 1, 2013","May 4, 2017","May 4, 2017","March 17, 2015","July 9, 2018","July 9, 2018","University of Virginia, Charlottesville, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02388997/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02388997"
837,"NCT02388347","A Study to Assess the Safety of MEDI7836 in Healthy Adults.",,"Completed","Has Results","Healthy Adults","Drug: Placebo SC|Biological: MEDI7836 Dose 1|Biological: MEDI7836 Dose 2|Biological: MEDI7836 Dose 3|Biological: MEDI7836 Dose 4","Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)|Number of Participants With Injection Site Reactions|Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events|Number of Participants With Vital Signs and Physical Examination Abnormalities Reported as Treatment-Emergent Adverse Events|Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events|Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) of MEDI7836|Area Under the Concentration-Time Curve From Zero to Last Observation (AUC [0-t]) of MEDI7836|Maximum Observed Serum Concentration (Cmax) of MEDI7836|Apparent Systemic Clearance (CL/F) of MEDI7836|Terminal Phase Elimination Half Life (T1/2) of MEDI7836|Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI7836|Apparent Terminal-Phase Volume of Distribution (Vz/F) of MEDI7836|Percentage of Participants Positive for Anti-Drug Antibodies to MEDI7836","MedImmune LLC","All","18 Years to 50 Years   (Adult)","Phase 1","79","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D5450C00001","March 2015","January 2016","April 2016","March 17, 2015","April 12, 2017","May 16, 2017","Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02388347"
838,"NCT02387749","Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .",,"Completed","Has Results","Diabetic Peripheral Neuropathy","Genetic: mesenchymal stem cells","Measurement of b-FGF, v-EGF MEASURED BY ELISA|Change of Nerve Conduction Velocities of Nerves Affected Measured by Nerve Conduction Study.|Change of Nerve Conduction Latency of Nerves Affected Measured by Nerve Conduction Study|Change of Nerve Conduction Amplitude of Nerves Affected Measured by Nerve Conduction Study.|Change of Levels of Fasting Blood Sugar and 2 Hours Post Prandial at Base Line ( Zero Day ) and After (90 Days) After Stem Cells Transfusion|Change of Levels of Glycated Haemoglobin( HA1C) After Stem Cells Transfusion Measured in Percent %","Cairo University","All","18 Years to 45 Years   (Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FACULTY OF MEDICINE,CAIRO U","May 2014","August 2016","December 2016","March 13, 2015","October 11, 2017","July 3, 2018",,,"https://ClinicalTrials.gov/show/NCT02387749"
839,"NCT02387580","Bioavailability Study of Oral OZ439 Prototype Granule Formulations Administered With Piperaquine Phosphate (PQP) Tablets",,"Completed","Has Results","Malaria","Drug: OZ439 + TPGS|Drug: OZ439 Prototype 1|Drug: OZ439 Prototype 3|Drug: PQP","OZ439 Cmax|OZ439 AUC(0-168 h)|Piperaquine Cmax|Piperaquine AUC(0-168 h)","Medicines for Malaria Venture|Quotient Clinical","All","18 Years to 55 Years   (Adult)","Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MMV_OZ439_15_001","April 2015","June 2015","June 2015","March 13, 2015","January 14, 2016","February 8, 2016","Quotient Clinical, Nottingham, Nottinghamshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02387580"
840,"NCT02387554","Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405",,"Completed","Has Results","Hypertension(HTN)","Drug: HGP0904|Drug: HGP0608|Drug: HGP1405","AUClast|Cmax|AUCinf|Tmax|T1/2|CL/F|Vz/F","Hanmi Pharmaceutical Company Limited|Seoul National University Bundang Hospital","Male","19 Years to 45 Years   (Adult)","Phase 1","33","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HM-ALCH-101","August 2014","October 2014","October 2014","March 13, 2015","June 12, 2015","June 12, 2015","Seoul National University Bundang Hospital, Bundang, Gyeonggi, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02387554"
841,"NCT02387502","Comparison of Three Laryngoscopes in Difficult Laryngoscopy",,"Completed","Has Results","Intubation; Difficult","Device: Intubation- Macintosh laryngoscope|Device: Intubation- MacCoy laryngoscope|Device: Intubation- Airtraq laryngoscope","Time of Intubation","Government Medical College, Haldwani","All","18 Years to 60 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","123-IEC/01/13","January 2014","December 2014","December 2014","March 13, 2015","May 4, 2015","May 4, 2015",,,"https://ClinicalTrials.gov/show/NCT02387502"
842,"NCT02383940","Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C",,"Completed","Has Results","Type 1 Diabetes Mellitus","Drug: Sotagliflozin|Drug: Placebo","Change From Baseline in Hemoglobin A1C (A1C) at Week 12|Change From Baseline in Total Daily Bolus Insulin Dose and Total Daily Basal Insulin Dose at Week 12|Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Standardized Mixed Meal at Week 12|Change From Baseline in Glycemic Instability by Hyperglycemia (Continuous Glucose Monitoring [CGM] Area Under the Curve [AUC] >150 mg/dL) and Hypoglycemia (CGM AUC <70 mg/dL) Over a 24-hour Period at Week 12|Change From Baseline in Number of Hypoglycemic Events/Day (<=70 mg/dL) by Self-Monitored Blood Glucose (SMBG) at Week 12","Sanofi|Juvenile Diabetes Research Foundation|Lexicon Pharmaceuticals","All","18 Years to 30 Years   (Adult)","Phase 2","87","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","LX4211.1-204-T1DM|LX4211.204","April 2015","September 2016","September 2016","March 10, 2015","October 30, 2019","October 30, 2019","Lexicon Investigational Site, Tustin, California, United States|Lexicon Investigational Site, Aurora, Colorado, United States|Lexicon Investigational Site, New Haven, Connecticut, United States|Lexicon Investigational Site, Tampa, Florida, United States|Lexicon Investigational Site, West Palm Beach, Florida, United States|Lexicon Investigational Site, Atlanta, Georgia, United States|Lexicon Investigational Site, Roswell, Georgia, United States|Lexicon Investigational Site, Indianapolis, Indiana, United States|Lexicon Investigational Site, New Orleans, Louisiana, United States|Lexicon Investigational Site, Auburn, Maine, United States|Lexicon Investigational Site, Boston, Massachusetts, United States|Lexicon Investigational Site, Buffalo, New York, United States|Lexicon Investigational Site, Wilmington, North Carolina, United States|Lexicon Investigational Site, Austin, Texas, United States|Lexicon Investigational Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02383940"
843,"NCT02383043","Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer",,"Completed","Has Results","Active Cocaine Users","Drug: Cocaine|Drug: Sustained Release d-Amphetamine","The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative","Joshua A. Lile, Ph.D.|University of Kentucky","All","21 Years to 45 Years   (Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","R01DA033364-02","February 1, 2015","April 5, 2018","April 5, 2018","March 9, 2015","April 11, 2019","April 11, 2019","Laboratory of Human Behavioral Pharmacology, Lexington, Kentucky, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02383043/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT02383043"
844,"NCT02382913","Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)",,"Completed","Has Results","Pertussis","Biological: aP booster|Biological: TdaP booster|Biological: Licensed TdaP booster (Boostrix®)","Geometric Mean Concentrations (GMCs) of Antibodies in aP1, aP2, aP4 Groups Against Pertussis Antigens at Day 1.|Geometric Mean Concentrations (GMCs) of Antibodies in T5D2aP1, T5D2aP2 and T5D2aP4 Groups Against Pertussis Antigens at Day 1.|Geometric Mean Concentrations (GMCs) of Antibodies in T5D4aP1, T5D4aP2 and T5D4aP4 Groups Against Pertussis Antigens at Day 1.|Geometric Mean Ratios Antibodies Concentrations in aP1, aP2, aP4 Groups as Measured at V113_01E1 Day 1 vs. All V113_01 Time Points.|Geometric Mean Ratios Antibodies Concentrations in T5D2aP1, T5D2aP2 and T5D2aP4 Groups as Measured at V113_01E1 Day 1 vs. All V113_01 Time Points.|Geometric Mean Ratios Antibodies Concentrations in T5D4aP1, T5D4aP2 and T5D4aP4 Groups as Measured at V113_01E1 Day 1 vs. All V113_01 Time Points.","Novartis","All","18 Years to 43 Years   (Adult)","Phase 1","315","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","V113_01E1|2014-003729-16","April 2015","June 2015","June 2015","March 9, 2015","February 12, 2016","March 24, 2016","Site 02, Center for Vaccinology (CEVAC), Ghent University Hospital, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT02382913"
845,"NCT02382848","Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD",,"Completed","Has Results","Stress Disorders, Post-Traumatic|Bulimia Nervosa","Drug: Prazosin|Drug: Placebo","Decrease in Frequency of Nightmares Using the Sleep-50 Questionnaire|Decrease in Rapid Eye Movement (REM) Density & Normalization of REM Disruptions|Decrease in Bulimia Symptoms|Decrease in Total CAPS Score (PTSD)|Decrease in Depressed Mood as Measured by the HDRS (Hamilton Depression Rating Scale) and Subject Interview|Decrease in Self Harm Thoughts as Measured by the HDRS and Subject Interview","Milton S. Hershey Medical Center","Female","18 Years to 45 Years   (Adult)","Not Applicable","9","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","00001746","July 2015","March 9, 2018","March 9, 2018","March 9, 2015","July 16, 2019","July 16, 2019","Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02382848/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02382848"
846,"NCT02382640","Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule",,"Completed","Has Results","Healthy Volunteers","Drug: Febuxostat XR|Drug: Maalox Advance Regular Strength liquid","Cmax: Maximum Observed Plasma Concentration for Febuxostat|AUC(0-tau): Area Under the Plasma Concentration-time Curve During the Dosing Interval for Febuxostat|AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat|Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Change From Baseline in Vital Signs|Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings|Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Evaluation|Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG)","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Febuxostat XR-1010|U1111-1163-1813","March 2015","May 2015","May 2015","March 9, 2015","April 29, 2016","April 29, 2016","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02382640"
847,"NCT02381015","Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a",,"Completed","Has Results","Prostate Cancer|Prostate Cancer, Familial|Hereditary Prostate Cancer","Genetic: Genetic Risk Score: Number Format|Genetic: Genetic Risk Score: Number + Pictograph|Behavioral: Family History: Number Format|Behavioral: Family History: Number + Pictograph","Number of Participants Who Had Prostate Specific Antigen (PSA) Discussion With Physician at 3 Months, Measured by Survey|Number of Participants Who Had PSA Testing at 3 Months, Measured by Survey|Number of Participants Who Had PSA Testing at 3 Years, Measured by Medical Records|Anxiety, Measured by State-trait Anxiety Inventory (STAI)|Accuracy of Immediate Recall of Risk Information Measured by Survey|Accuracy of Recall of Risk Information at 3 Months Measured by Survey","NorthShore University HealthSystem|Van Andel Research Institute|Spectrum Health Medical Group|National Cancer Institute (NCI)|Wake Forest University Health Sciences","Male","40 Years to 49 Years   (Adult)","Not Applicable","700","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","IRB00011784|1RC2CA148463-01","June 2011","June 2012","June 2012","March 6, 2015","November 22, 2019","November 22, 2019",,,"https://ClinicalTrials.gov/show/NCT02381015"
848,"NCT02380287","First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy Subjects",,"Completed","Has Results","Healthy","Drug: humanized monoclonal antibody against human IL-17","Area Under the Plasma Concentration of BCD-085-time Curve From Zero (0) Hours to 1320 Hours After the Single Subcutaneous Injection of BCD-085|Maximum Concentration of BCD-085 After Single Subcutaneous Injection","Biocad","Male","18 Years to 45 Years   (Adult)","Phase 1","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCD-085-1","March 2015","September 2015","October 2015","March 5, 2015","May 23, 2016","May 23, 2016",,,"https://ClinicalTrials.gov/show/NCT02380287"
849,"NCT02377921","Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)","GNEM","Completed","Has Results","Hereditary Inclusion Body Myopathy|Distal Myopathy With Rimmed Vacuoles|Distal Myopathy, Nonaka Type|GNE Myopathy","Drug: aceneuramic acid extended-release (Ace-ER)|Drug: Placebo","Change From Baseline in UEC Score (Total Force in kg) at Week 48|Change From Baseline in Muscle Strength in the Knee Extensors at Week 48|Change From Baseline in LEC Score (Total Force in kg) at Week 48|Change From Baseline in GNEM FAS Mobility Domain Score at Week 48|Change From Baseline in Number of Lifts in the 30 Second Weighted Arm Lift Test at Week 48|Change From Baseline in Number of Stands in the Sit to Stand Test at Week 48|Change From Baseline in Meters Walked in the 6MWT at Week 48|Change From Baseline in Percent Predicted Meters Walked in the 6MWT at Week 48|Change From Baseline in GNEM FAS Upper Extremity Domain Score at Week 48","Ultragenyx Pharmaceutical Inc","All","18 Years to 55 Years   (Adult)","Phase 3","89","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UX001-CL301","May 20, 2015","June 9, 2017","June 9, 2017","March 4, 2015","July 9, 2018","June 27, 2019","University of California, Irvine, Irvine, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|New York University School of Medicine, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|UMHAT ""Alexandrovska"", Sofia, Bulgaria|McMaster University, Hamilton, Ontario, Canada|CHU La Réunion - site GHSR, Saint-Pierre, Reunion, France|Institut de Myologie GH Pitié-Salpêtrière, Paris, France|Hadassah-Hebrew University Medical Center, Jerusalem, Israel|University of Messina, Messina, Italy|University of Milan, Milan, Italy|Università Cattolica, Rome, Italy|The Newcastle upon Tyne Hospitals, Newcastle Upon Tyne, Tyne And Wear, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02377921/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02377921/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02377921"
850,"NCT02377349","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women",,"Completed","Has Results","Diphtheria-Tetanus-acellular Pertussis Vaccines","Biological: Boostrix™|Drug: Saline placebo","Antibody Concentrations Against Pertussis Toxoid Antigen (Anti-PT), Filamentous Haemagglutinin Antigen (Anti-FHA) and Pertactin Antigen (Anti-PRN) in Cord Blood Samples|Percentage of Subjects by Pregnancy Outcomes|Percentage of Subjects With Listed Pregnancy/Neonate Related Adverse Events of Interest|Percentage of Seroprotected Subjects Against Diphteria Antigen (Anti-D), Tetanus Antigen (Anti-T) and of Seropositive Subjects Against Anti-PT, Anti-FHA and Anti-PRN|Anti-D, Anti-T, Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations|Percentage of Subjects With Vaccine Response to Anti-D and Anti-T|Percentage of Subjects With Vaccine Response to Anti-PT, Anti-FHA and Anti-PRN|Percentage of Seropositive Subjects Against Anti-PT, Anti-FHA and Anti-PRN in the Cord Blood Samples|Percentage of Subjects With Solicited Local Adverse Events (AEs)|Percentage of Subjects With Solicited General AEs|Percentage of Subjects With Unsolicited AEs|Percentage of Infants With Unsolicited AEs|Number of Subjects With Serious AEs (SAEs)|Percentage of Household Contacts of the Infants Born to Pregnant Women Vaccinated in Spain|Percentage of Household Contacts With SAEs","GlaxoSmithKline","Female","18 Years to 45 Years   (Adult)","Phase 4","688","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","116945|2014-001119-38","October 14, 2015","August 14, 2017","October 24, 2017","March 3, 2015","January 28, 2019","January 28, 2019","GSK Investigational Site, Carlton, Victoria, Australia|GSK Investigational Site, Fitzroy, Victoria, Australia|GSK Investigational Site, Parkville, Victoria, Australia|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Sudbury, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Mount Royal, Quebec, Canada|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Hradec Kralove, Czechia|GSK Investigational Site, Ostrava - Vitkovice, Czechia|GSK Investigational Site, Praha 4, Czechia|GSK Investigational Site, Praha, Czechia|GSK Investigational Site, Kokkola, Finland|GSK Investigational Site, Oulu, Finland|GSK Investigational Site, Seinajoki, Finland|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Turku, Finland|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Novara, Piemonte, Italy|GSK Investigational Site, Torino, Piemonte, Italy|GSK Investigational Site, Málaga, Andalucia, Spain|GSK Investigational Site, Antequera/Málaga, Spain|GSK Investigational Site, Aravaca, Spain|GSK Investigational Site, Boadilla del Monte, Spain|GSK Investigational Site, Burgos, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Móstoles, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Sevilla, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02377349/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02377349/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02377349"
851,"NCT02377063","The Effect of Fruit/Vegetable Drinks on the Human Intestine",,"Completed","Has Results","Intestinal Bacteria Flora Disturbance","Dietary Supplement: Pressed Juice","Change in Colonic Flora Composition","University of California, Los Angeles","All","18 Years to 50 Years   (Adult)","Not Applicable","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","15-000274","April 2015","August 2015","August 2015","March 3, 2015","September 9, 2019","September 9, 2019","UCLA Center for Human Nutrition, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02377063"
852,"NCT02375698","A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TB","C-037-456","Completed","Has Results","Tuberculosis","Biological: H56:IC31|Biological: Placebo","Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Mean Percent Change From Baseline of Participants' Responses to TB Antigens Ag85A and ESAT-6","Aeras|Statens Serum Institut","All","18 Years to 60 Years   (Adult)","Phase 1","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","C-037-456","November 21, 2014","June 24, 2016","October 24, 2016","March 3, 2015","November 18, 2019","November 18, 2019","Task Clinical Research Centre, Bellville 7530, Cape Town, South Africa|University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa|The Aurum Institue, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT02375698"
853,"NCT02374671","A Clinical Trial of The VisAbility Micro Insert System for Presbyopic Patients",,"Completed","Has Results","Presbyopia","Device: VisAbility Micro Insert","Number of Primary Eyes With Distance Corrected Near Visual Acuity (DCNVA) to 20/40 or Better and Gain of At Least 10 Letters.|Number of Primary Eyes With DCNVA 20/40 of Better and Gain of 10 Letters More at 6 Months for the Randomized Substudy","Refocus Group, Inc.","All","45 Years to 60 Years   (Adult)","Not Applicable","365","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VIS-2014","November 15, 2014","April 13, 2018","April 13, 2018","March 2, 2015","January 6, 2020","January 6, 2020","Coastal Vision, Orange, California, United States|Gordon Weiss Vision Institute, San Diego, California, United States|Aloha Laser Vision, Honolulu, Hawaii, United States|The Midwest Center for Sight, Des Plaines, Illinois, United States|Eye Surgeons Of Indiana PC, Indianapolis, Indiana, United States|Eye Care Institute, Louisville, Kentucky, United States|Chu Vision Institute, Bloomington, Minnesota, United States|South Shore Eye Care LLP, Wantagh, New York, United States|South Shore Eye Care, LLP, Wantagh, New York, United States|Physicians Protocol, Greensboro, North Carolina, United States|Comprehensive EyeCare of Central Ohio, Westerville, Ohio, United States|Bucci Laser Vision, Wilkes-Barre, Pennsylvania, United States|Key Whitman Eye Center, Dallas, Texas, United States|Braverman-Terry-Oei Eye Associates, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02374671/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02374671"
854,"NCT02374164","Food Effect Study of Febuxostat XR in Healthy Participants",,"Completed","Has Results","Gout","Drug: Febuxostat XR","Cmax: Maximum Observed Plasma Concentration for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States|Cmax: Maximum Observed Plasma Concentration for Febuxostat XR 40 mg (Regimen B) and Febuxostat XR 80 mg (Regimen C) in Fasted States|AUCt: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States|AUCt: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for Febuxostat XR 40 mg (Regimen B) and Febuxostat XR 80 mg (Regimen C) in Fasted States|AUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States|AUCinf: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Febuxostat XR 40 mg (Regimen B) and Febuxostate XR 80 mg (Regimen C) in Fasted States","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Febuxostat-XR-1009|U1111-1165-0441","February 2015","March 2015","April 2015","February 27, 2015","April 27, 2016","April 27, 2016","Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02374164"
855,"NCT02373124","Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial",,"Completed","Has Results","Cocaine Use Disorders","Drug: infusion of NMDA antagonist","Cocaine Use","New York State Psychiatric Institute","All","21 Years to 55 Years   (Adult)","Phase 1|Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7051","December 2014","October 2016","October 2016","February 26, 2015","April 24, 2019","April 24, 2019","New York State Psychiatric Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02373124"
856,"NCT02372344","A Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA of AZD0585 in Healthy Male Japanese Subjects",,"Completed","Has Results","Healthy","Drug: AZD0585","The Effect of Food Timing (Fasting, Before Meal, and After Meal) on Pharmacokinetics (PK; AUC) of AZD0585 in Healthy Male Japanese.|The Effect of Food Timing (Fasting, Before Meal, and After Meal) on PK (Cmax) of AZD0585 in Healthy Male Japanese.|The Effect of Food Timing (Fasting, Before Meal, and After Meal) on PK (AUC0-72) of AZD0585 in Healthy Male Japanese.","AstraZeneca","Male","20 Years to 45 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D5884C00004","March 2015","May 2015","May 2015","February 26, 2015","May 16, 2016","May 16, 2016","Research Site, Fukuoka-shi, Japan",,"https://ClinicalTrials.gov/show/NCT02372344"
857,"NCT02372253","Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes",,"Active, not recruiting","Has Results","Type 1 Diabetes Mellitus","Drug: Verapamil|Drug: Placebo","Functional Beta Cell Mass|Percent Change From Baseline in Exogenous Insulin Requirements|HbA1C|HbA1c|Hypoglycemic Events","University of Alabama at Birmingham|Juvenile Diabetes Research Foundation","All","18 Years to 45 Years   (Adult)","Phase 2","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","3-SRA-2014-302-M-R","February 2015","December 2017","December 2019","February 26, 2015","January 30, 2019","January 30, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02372253/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02372253"
858,"NCT02372097","A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets",,"Completed","Has Results","Healthy","Drug: SYR-472","AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for Unchanged SYR-472 (SYR-472Z)|Cmax: Maximum Observed Plasma Concentration for SYR-472Z|AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for SYR-472Z|Tmax: Time to Reach the Cmax for SYR-472Z|MRT: Mean Residence Time From Time Zero to Infinity for SYR-472Z|Apparent Terminal Elimination Rate Constant (λz) for SYR-472Z|Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With TEAEs Related to Vital Signs|Number of Participants With TEAEs Related to Body Weight|Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Laboratory Values|Number of Participants Who Had Abnormal and Clinically Significant 12-lead Electrocardiograms (ECG) Findings After Study Drug Administration","Takeda","Male","20 Years to 35 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SYR-472-1005|U1111-1167-0746|JapicCTI-152813|JapicCTI-R160849","March 2015","April 2015","April 2015","February 26, 2015","May 13, 2016","May 13, 2016","Fukuoka, Japan",,"https://ClinicalTrials.gov/show/NCT02372097"
859,"NCT02371850","Transdermal Patch CVD 1000: The Effect of Heat on Nicotine Release From Nicotine Patches in Adult Smokers",,"Completed","Has Results","Smoking","Drug: Nicoderm patch first, then Aveva patch","Measurement of Maximum Plasma Concentration (Cmax)|Area Under the Curve (AUC) Attained With and Without Heating in Each of the Two Nicotine Patches (Reference and Generic)","University of Maryland, Baltimore|Food and Drug Administration (FDA)","All","18 Years to 45 Years   (Adult)","Phase 4","10","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HP-00059146","October 2014","April 2015","June 2015","February 26, 2015","August 17, 2017","October 15, 2019","University of Maryland, Baltimore Center for Vaccine Development, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02371850"
860,"NCT02371616","Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersensitivity",,"Completed","Has Results","Dentine Sensitivity","Device: Calcium sodium phosphosilicate|Other: Sodium fluoride|Other: Sodium monofluorophosphate","Mean Change From Baseline in Evaporative Air Sensitivity as Measured by Visual Analogue Score (VAS) at Week 8|Mean Change From Baseline in Evaporative Air Sensitivity as Measured by Visual Analogue Score (VAS) at Week 4|Mean Change From Baseline in Evaporative Air Sensitivity as Measured by Schiff Sensitivity Score at Week 4 and Week 8|Change From Baseline in Tactile Threshold at Week 4 and Week 8","GlaxoSmithKline","All","18 Years to 60 Years   (Adult)","Not Applicable","304","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","202199","September 29, 2014","December 18, 2014","December 18, 2014","February 25, 2015","February 26, 2018","April 4, 2018","GSK Investigational Site, Ellesmere Port, Cheshire, United Kingdom|GSK Investigational Site, Maldon, Essex, United Kingdom|GSK Investigational Site, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02371616"
861,"NCT02371187","Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?",,"Completed","Has Results","Physical Activity","Drug: Dapagliflozin|Drug: Placebo","Change From Baseline of Maximal Oxygen Uptake at Week 12|Change From Baseline of Respiratory Exchange Ratio at Week 12|Change From Baseline of Maximal Aerobic Enzyme Activities in Skeletal Muscle at Week 12|Change From Baseline of Insulin Sensitivity at Week 12|Change From Baseline of Fat Free Mass at Week 12","Christopher Bell|AstraZeneca|Colorado State University","All","18 Years to 50 Years   (Adult)","Phase 2","37","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","14-5529H","June 2015","January 2018","January 2018","February 25, 2015","April 10, 2019","April 10, 2019","Colorado State University, Dept. of Health and Exercise Science, Fort Collins, Colorado, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02371187/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02371187"
862,"NCT02370641","Effects of Pomegranate Extract on Intestinal Flora","PomX","Completed","Has Results","Urolith","Dietary Supplement: PomX","Change in Percentage of Total Microflora Between Urolithin Excretors and Non-excretors","University of California, Los Angeles","All","20 Years to 50 Years   (Adult)","Not Applicable","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","12-000874","October 2012","July 2013","July 2013","February 25, 2015","September 19, 2019","October 2, 2019",,,"https://ClinicalTrials.gov/show/NCT02370641"
863,"NCT02370615","Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam",,"Completed","Has Results","Japanese Healthy Adult Males","Drug: TAK-272|Drug: Digoxin|Drug: Itraconazole|Drug: Midazolam","Cmax: Maximum Observed Plasma Concentration for TAK 272F and TAK 272-Metabolite (M-I) in Cohort 1|AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK 272F and TAK 272-M-I in Cohort 1|AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK 272F and TAK 272-M-I in Cohort 1|Cumulative Urinary Excretion Ratio of TAK 272F and TAK 272-M-I From 0 to 72 Hours Postdose in Cohort 1|Cmax: Maximum Observed Plasma Concentration for Digoxin in Cohort 2|AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Digoxin in Cohort 2|AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Digoxin in Cohort 2|Urinary Excretion Ratio of Digoxin From 0 to 48 Hours Postdose in Cohort 2|Cmax: Maximum Observed Plasma Concentration for Midazolam and 1'Hydroxymidazolam in Cohort 2|AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Midazolam and 1'Hydroxymidazolam in Cohort 2|AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Midazolam and 1'Hydroxymidazolam in Cohort 2|Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)|Number of Participants With TEAEs Related to Vital Signs|Number of Participants With TEAEs Related to Body Weight|Number of Participants Who Had Clinically Significant Changes From Baseline in 12-lead Electrocardiograms|Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis|Number of Participants With Clinically Significant Change From Baseline in Continuous Pulse Oximetry (SpO2) in Cohort 2","Takeda","Male","20 Years to 35 Years   (Adult)","Phase 1","34","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-272/CPH-011|U1111-1167-0017|JapicCTI-152810","February 2015","April 2015","April 2015","February 25, 2015","May 23, 2016","May 23, 2016","Osaka-shi, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT02370615"
864,"NCT02370602","An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodiesterase10A Occupancy by TAK-063",,"Completed","Has Results","Healthy Volunteers","Drug: TAK-063|Drug: [^11C]T-773","Phosphodiesterase 10A (PDE10A) Occupancy of Brain Regions With [^11C]T-773 at 3 Hours Following a Single Dose of TAK-063|Phosphodiesterase 10A (PDE10A) Occupancy of Brain Regions With [^11C]T-773 at 23 Hours Following a Single Dose of TAK-063|Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event|Percentage of Participants With Markedly Abnormal Safety Laboratory Findings|Percentage of Participants With Markedly Abnormal Vital Sign Measurements|Percentage of Participants With Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters|Cmax: Maximum Observed Plasma Concentration for TAK-063 and TAK-063 Metabolite M-I|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-063 and TAK-063 Metabolite M-I|AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-063 and TAK-063 Metabolite M-I|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-063 and TAK-063 Metabolite M-I|Average Plasma Concentration on Day 1 (Cavg) for TAK-063 and TAK-063 Metabolite M-I|CL/F: Oral Clearance of TAK-063|Ratio of TAK-063 Metabolite Cmax to TAK-063 Cmax|Ratio of TAK-063 Metabolite M-I AUC( 0-24) to TAK-063 AUC (0-24)|AUC During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 3 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I|Cavg During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 3 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I|AUC During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 23 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I|Cavg During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 23 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I","Takeda","Male","20 Years to 45 Years   (Adult)","Phase 1","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-063_103|U1111-1165-3362|2012-004576-18","October 2013","February 2014","March 2014","February 25, 2015","March 20, 2015","March 20, 2015",,,"https://ClinicalTrials.gov/show/NCT02370602"
865,"NCT02370121","Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin",,"Completed","Has Results","Metabolic Syndrome","Drug: Placebo|Drug: Gymnema Sylvestre","Waist Circumference (WC)|Triglycerides (TGs)|High-density Lipoprotein Cholesterol (HDL-C)|Fasting Plasma Glucose (FPG)|Systolic Blood Pressure (SBP)|Diastolic Blood Pressure (DBP)|Total Insulin Secretion|First Phase of Insulin Secretion|Insulin Sensitivity|Body Weight (BW)|Body Mass Index (BMI)|Total Cholesterol (TC)|Low-density Lipoprotein Cholesterol (LDL-C)|Very-low Density Lipoprotein (VLDL)|2-hour Postload Plasma Glucose (2-h PG)|Area Under the Curve of Glucose (AUCG)|Area Under the Curve of Insulin (AUCI)","University of Guadalajara","All","30 Years to 60 Years   (Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CT-271281-YZ","February 2013","December 2014","January 2015","February 24, 2015","June 3, 2016","June 18, 2019",,,"https://ClinicalTrials.gov/show/NCT02370121"
866,"NCT02369796","A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism",,"Terminated","Has Results","Hypogonadotropic Hypogonadism","Drug: TAK-448","Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Total Serum Testosterone for Once Weekly Dosing Groups|Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Total Serum Testosterone for Twice Weekly Dosing Groups|Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Free Serum Testosterone for Once Weekly Dosing Groups|Percent Change From Baseline in Mean Area Under the Effect Curve From Time 0 to 72 Hours (AUEC72) of Free Serum Testosterone for Twice Weekly Dosing Groups|Trough Serum Concentration (Ctrough) of Total Serum Testosterone for Once Weekly Dosing Groups|Trough Serum Concentration (Ctrough) of Total Serum Testosterone for Twice Weekly Dosing Group|Trough Serum Concentration (Ctrough) of Free Serum Testosterone for Once Weekly Dosing Groups|Trough Serum Concentration (Ctrough) of Free Serum Testosterone for Twice Weekly Dosing Groups|Cmax: Mean Maximum Observed Plasma Concentration for TAK-448 Free Base Form (TAK-448F)|AUC(0-∞): Mean Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-448F|AUC(0-tlqc): Mean Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-448F|Mean Terminal Phase Elimination Half-life (T1/2) for TAK-448F","Takeda","Male","18 Years to 60 Years   (Adult)","Phase 2","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-448-2001|U1111-1162-4892|2014-002155-25|14/LO/1950","February 2015","October 2015","November 2015","February 24, 2015","March 31, 2017","March 31, 2017","Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02369796"
867,"NCT02369510","Does the Addition of Epinephrine Prolong the Duration of Spinal Anesthesia for Repeat Cesarean Section?",,"Completed","Has Results","Spinal Anesthesia|Cesarean Section","Drug: Low-dose epinephrine|Drug: High-dose epinephrine|Drug: No epinephrine","Sensory Recovery|Motor Recovery|Block Onset|Number of Participants With Hypotension|Adequacy of Anesthesia|Patient Satisfaction|Incidence of Nausea and Vomiting|Incidence of Pruritus","Icahn School of Medicine at Mount Sinai","Female","18 Years to 50 Years   (Adult)","Phase 4","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","GCO 14-2058","February 2015","May 2016","May 2016","February 24, 2015","August 30, 2017","August 30, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02369510"
868,"NCT02369172","Drug-Drug Interaction Study: ASP2151 and Bupropion",,"Completed","Has Results","Healthy","Drug: Bupropion|Drug: ASP2151","Peak Plasma Concentration (Cmax) of Bupropion|Area Under the Concentration-time Curve Extrapolated to Infinite Time (AUC0-∞) of Bupropion|Number of Participants With Serious and Non-Serious Adverse Events","Maruho Europe Limited","Male","18 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","M522101-EU25","February 2015","April 2015","April 2015","February 23, 2015","January 15, 2019","February 21, 2019","Hammersmith Medicines Research Ltd, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02369172"
869,"NCT02367833","Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis",,"Completed","Has Results","Bone; Disorder, Development and Growth","Drug: Combined Oral Contraceptive|Drug: Transdermal Contraceptive|Drug: Contraceptive Vaginal Ring","Changes in Insulin-like Growth Factor-1 (IGF-1), IGF Binding Proteins (IGFBP-1, IGFBP-3), and Acid Labile Subunit (ALS)|Changes in Bone Turnover Markers|Changes in GH-stimulated IGF-1 Secretion","Penn State University|Massachusetts General Hospital|Purdue University","Female","18 Years to 30 Years   (Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STUDY00000053","January 2015","December 2017","December 2018","February 20, 2015","February 6, 2019","February 26, 2019","Women's Health and Exercise Laboratories, The Pennsylvania State University, University Park, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02367833/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02367833"
870,"NCT02365298","Clinical and Laboratory Study of Lysozyme Deposition on Daily Disposable Contact Lenses",,"Completed","Has Results","Visual Acuity","Device: etafilcon A|Device: nelfilcon A","Total Protein and Total Lysosome Deposits|Total Protein and Lysosome Deposits|Quantity of Cytokines and Albumin in Tear Fluid","Johnson & Johnson Vision Care, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","CR-5695","January 1, 2015","June 1, 2015","June 1, 2015","February 18, 2015","July 13, 2017","June 19, 2018","University of Waterloo, Waterloo, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02365298"
871,"NCT02365285","Racial Differences in Vagal Control of Glucose Homeostasis","RDVCGH","Completed","Has Results","Obesity","Drug: Galantamine|Drug: Placebo Oral Capsule|Drug: Intralipid|Drug: Heparin","Change in Oxidative Stress: Baseline to 2 Hours|Change in Oxidative Stress: Baseline to 4 Hours","Vanderbilt University Medical Center|Doris Duke Charitable Foundation","Female","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","141552","March 2015","October 5, 2017","October 5, 2017","February 18, 2015","March 19, 2019","March 19, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02365285/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02365285"
872,"NCT02364570","Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults",,"Completed","Has Results","Prediabetes|Cardiovascular Disease","Other: Glucose (100g)|Other: Glucose (75g)|Other: Whole Eggs|Other: Egg Whites|Other: Egg Yolks","Vascular Endothelial Function|Glucose|Oxidative Stress Biomarker (Malondialdehyde; MDA)|Insulin|Cholecystokinin (CCK)|Methylglyoxal (MGO)|8-isoprostaglandin-F2a|Arachidonic Acid (AA)|8-isoprostaglandin-F2a/Arachidonic Acid|Nitric Oxide Metabolites (Nitrites/Nitrates) (NOx)|Arginine (Arg)|Asymmetric Dimethylarginine/Arginine (ADMA/Arg)|Symmetric Dimethylarginine/Arginine (SDMA/Arg)|Angiotensin-II|Endothelin-I","Ohio State University","Male","18 Years to 50 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2014H0307","January 2015","August 2016","June 2017","February 18, 2015","April 29, 2019","May 3, 2019","The Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02364570"
873,"NCT02362412","Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes",,"Completed","Has Results","Bipolar Depression","Drug: FK949E","Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Hamilton Depression Scale (HAM-D17)|Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S): Overall Bipolar Illness|Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S):Depression|Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S): Mania|Clinical Global Impression-Bipolar-Change (CGI-BP-C):Overall Bipolar Illness|Clinical Global Impression-Bipolar-Change (CGI-BP-C):Depression|Clinical Global Impression-Bipolar-Change (CGI-BP-C):Mania|Number of Participants With Adverse Events","Astellas Pharma Inc","All","20 Years to 64 Years   (Adult)","Phase 3","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6949-CL-0023","February 18, 2015","February 6, 2016","February 6, 2016","February 12, 2015","March 17, 2017","February 8, 2019","Fukushima, Japan|Kanagawa, Japan|Kumamoto, Japan|Kyoto, Japan|Osaka, Japan|Tokushima, Japan|Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02362412"
874,"NCT02362373","Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users","WESAIL","Completed","Has Results","Epilepsy|Contraception","Drug: levonorgestrel IUS","Percent of Participants That Experienced Clinically Meaningful Change in Lamotrigine Level|Percent of Participants That Experienced Clinically Meaningful Change in Levetiracetam Level|Percent of Participants That Experienced Clinically Meaningful Change in Oxcarbazepine Level|Change in Seizure Frequency|Number of Participants Continuing With IUD","Columbia University|Bayer","Female","18 Years to 45 Years   (Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","AAAI0750","August 2011","January 2014","January 2014","February 12, 2015","January 18, 2016","January 18, 2016","Columbia University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02362373"
875,"NCT02360475","Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women",,"Completed","Has Results","Respiratory Syncytial Virus Infections","Biological: RSV vaccine GSK3003895A (formulation 1)|Biological: RSV vaccine GSK3003898A (formulation 2)|Biological: RSV vaccine GSK3003899A (formulation 3)|Biological: Boostrix","Number of Subjects With Solicited Local Symptoms|Number of Subjects With Solicited General Symptoms|Number of Subjects With Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs)|Titres of RSV-A Neutralizing Antibodies|Concentrations of Palivizumab Competing Antibodies (PCA)|Concentrations of PCA|Number of Subjects With SAEs","GlaxoSmithKline","Female","18 Years to 45 Years   (Adult)","Phase 2","507","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","201510|2014-002688-14","March 20, 2015","July 2, 2015","June 21, 2016","February 10, 2015","August 16, 2017","July 3, 2018","GSK Investigational Site, Mesa, Arizona, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Lenexa, Kansas, United States|GSK Investigational Site, Lexington, Kentucky, United States|GSK Investigational Site, Milford, Massachusetts, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Hradec Kralove, Czechia|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Dippoldiswalde, Sachsen, Germany|GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT02360475"
876,"NCT02360293","Stay Strong: A Physical Activity Program for Afghanistan and Iraq Veterans",,"Completed","Has Results","Exercise","Behavioral: Stay Strong w/coaching|Behavioral: Stay Strong","Change in Physical Activity (PA) as Measured by the Study-provided Monitoring Device|Change in Weight as Measured From VA Medical Record|Change in Depression Score as Assessed by the Personal Health Questionnaire Depression Scale (PHQ-8)|Change in Pain Measures as Assessed by the VA Pain Intensity","VA Office of Research and Development","All","18 Years to 64 Years   (Adult)","Not Applicable","465","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CRE 12-305","September 25, 2017","May 31, 2019","September 30, 2019","February 10, 2015","January 6, 2020","January 6, 2020","VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02360293/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02360293"
877,"NCT02359877","Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: BCD-054|Drug: Rebif|Drug: Avonex","AUC (0-168); AUC (0-336); AUC (0-672); AUC (0-∞ ) of Interferon (IFN) Beta-1a|AUC(0-last); AUC (0-∞ ) BCD-054 of Interferon (IFN) Beta-1a - 180 mcg - SC, BCD-054 - 180 mcg - IM|AUC (0-168); AUC (0-336); AUC (0-672);AUC (0-∞ ) of Neopterin|AUC(0-∞), AUC(0-last) of Neopterin|Adverse Event (AE) and Serious Adverse Event (SAE) Incidence|Adverse Event (AE) and Serious Adverse Event (SAE) Incidence BCD-054 - 180 mcg - SC/IM","Biocad","Male","18 Years to 45 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCD-054-1","July 2014","October 2015","December 2015","February 10, 2015","December 23, 2016","April 10, 2017","OOO ""BioEk"", Saint-Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02359877"
878,"NCT02359045","Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions",,"Completed","Has Results","Relative Bioavailability|AUC|Cmax|Pharmacokinetics","Drug: D1400147|Drug: D14000136|Drug: D14000137|Drug: Epanova®","Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC) Assessed for Eicosapentaenoic Acid (EPA) After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|AUC Assessed for Docosahexaenoic Acids (DHA) After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|AUC Assessed for Total (Combined) EPA + DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|Area Under the Plasma Concentration-time Curve From Time Zero to 72 Hours After Dosing {AUC(0-72)} Assessed for EPA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|AUC (0-72) Assessed for DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|AUC (0-72) Assessed for Total (Combined) EPA + DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|Maximum Observed Plasma Concentration (Cmax) Assessed for EPA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|Cmax Assessed for DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|Cmax Assessed for Total (Combined) EPA + DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte Concentration {AUC (Last)} Assessed for EPA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|AUC (Last) Assessed for DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|AUC (Last) Assessed for Total (Combined) EPA + DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|Baseline Concentration (C0) Assessed for EPA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|C0 Assessed for DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|C0 Assessed for Total (Combined) EPA + DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) Assessed for EPA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|t½λz Assessed for DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|t½λz Assessed for Total (Combined) EPA + DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|Time to Reach Maximum Observed Concentration (Tmax) Assessed for EPA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|Tmax Assessed for DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|Tmax Assessed for Total (Combined) EPA + DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|Terminal Elimination Rate Constant (λz ) Assessed for EPA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|λz Assessed for DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|λz Assessed for Total (Combined) EPA + DHA After Administration of Test Formulation 1, 2 and 3 and Reference Formulation.|Safety of Omega-3-carboxylic Acids by Assessing Summary of Adverse Events|Safety of Omega-3-carboxylic Acids by Assessing Number of Subjects Who Had at Least One Adverse Event|Safety of Omega-3-carboxylic Acids by Assessing Number of Subjects With Clinically Significant Blood Pressure|Safety of Omega-3-carboxylic Acids by Assessing Number of Subjects With Clinically Significant Pulse|Safety of Omega-3-carboxylic Acids by Assessing Number of Subjects With Clinically Significant 12-lead Electrocardiograms (ECGs)|Safety of Omega-3-carboxylic Acids by Assessing Number of Subjects With Clinically Significant Hematology Parameters|Safety of Omega-3-carboxylic Acids by Assessing Number of Subjects With Clinically Significant Clinical Chemistry Laboratory Results|Safety of Omega-3-carboxylic Acids by Assessing Number of Subjects With Clinically Significant Urinalysis","AstraZeneca","Male","18 Years to 55 Years   (Adult)","Phase 1","137","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D5884C00003","February 12, 2015","July 27, 2015","July 27, 2015","February 9, 2015","May 1, 2017","May 1, 2017","Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02359045"
879,"NCT02359006","The Effects of Minocycline in Opioid-maintained Patients",,"Completed","Has Results","Opioid Dependence|Pain","Drug: Minocycline|Drug: Placebo","Pain Threshold|Pain Tolerance|Brief Pain Inventory - Short Form: Pain Severity|Brief Pain Inventory - Short Form: Interference|Opioid Withdrawal Symptom Checklist (OWSC): Back Pain Item|Profile of Mood States (POMS) Depression Subscale|Profile of Mood States (POMS) - Total Mood Disturbance|Short-Form McGill Pain Questionnaire (SF-MPQ): Sensory Subscale|Short-Form McGill Pain Questionnaire (SF-MPQ): Affective Subscale|Interleukin-1 Beta (IL-1β)|Interleukin-6 (IL-6)|Tumor Necrosis Factor Alpha (TNF-α)|Ecological Momentary Assessments (EMA) - Pain|Ecological Momentary Assessments (EMA) - Craving|Ecological Momentary Assessments (EMA): SOWS|Digit Symbol Substitution Test|Sustained Attention to Response Test (SART): No-go Trials: Errors of Commission|Sustained Attention to Response Test (SART): Go Trials: Errors of Omission","Yale University","All","18 Years to 55 Years   (Adult)","Not Applicable","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","1412015119","March 12, 2015","April 19, 2017","April 19, 2017","February 9, 2015","January 9, 2019","June 27, 2019","VA Hospital, West Haven, Connecticut, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02359006/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02359006/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02359006"
880,"NCT02357394","Cervical Pessary to Prevent Preterm Birth in Singleton Pregnancies With a Sonographically Measured Short Cervix",,"Terminated","Has Results","Premature Birth","Device: Arabin Pessary","Preterm Birth Before 37 Weeks|Preterm Birth Before 34 Weeks|Neonatal Composite Morbidity|Neonatal Length of Stay|Admission to Neonatal Intensive Care Unit|Total Days in the Neonatal Intensive Care Unit|Duration of Ventilator Support|Retinopathy of Prematurity Requiring Treatment|Birthweight < 1500 Grams|Birthweight < 2500 Grams|Gestational Age at Delivery|Use of Tocolysis|Use of Antenatal Steroids|Chorioamnionitis|Vaginal Bleeding|Preterm Premature Rupture of Membranes|Cesarean Delivery","Gene Lee, MD|Medical University of South Carolina|University of Kansas Medical Center","Female","18 Years to 45 Years   (Adult)","Not Applicable","7","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KUOBGYN001","May 2015","June 6, 2017","April 1, 2019","February 6, 2015","October 31, 2019","October 31, 2019","University of Kansas Medical Center, Kansas City, Kansas, United States|Medical University of South Carolina, Charleston, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02357394/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02357394"
881,"NCT02356900","Hyperbaric VO2max Study",,"Terminated","Has Results","Exercise Training","Procedure: Hyperoxic hyperbaric interval exercise training|Procedure: Normoxic, normobaric, interval exercise training|Drug: Oxygen","Change in Maximum Aerobic Capacity (VO2max) From Baseline to Post-training (< 72 Hours )|Change in Ventilatory Threshold (VT) From Baseline to Post-training (<72 Hours)|Mitochondrial Mass Change|Tfam Muscle Protein Content Change|Pgc-1a Coactivator Muscle Protein Content Change|COX-I Gene Expression Change|Muscle Phenotype Change","Duke University","All","18 Years to 35 Years   (Adult)","Phase 2","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00060147","February 2015","May 2016","May 2016","February 5, 2015","April 12, 2017","May 17, 2017","Duke University Hospital, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02356900"
882,"NCT02356107","5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females",,"Completed","Has Results","Major Depressive Disorder","Drug: 5-hydroxytryptophan and Creatine monohydrate","Change From Baseline in Hamilton Depression Rating Scale","Perry Renshaw|University of Utah","Female","18 Years to 64 Years   (Adult)","Phase 4","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5HTP/Creatine","April 2015","August 2016","August 2016","February 5, 2015","January 4, 2018","January 29, 2018","University of Utah/The Brain Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02356107"
883,"NCT02354833","Phenylephrine vs. Norepinephrine Infusion After Spinal Anesthesia for Cesarean Delivery",,"Completed","Has Results","Effects of; Anesthesia, in Labor and Delivery","Drug: Phenylephrine|Drug: Norepinephrine","Number of Rescue Boluses to Maintain SBP|Median Total Rescue Bolus Dose of Ephedrine (mg) to Maintain SBP|Median Total Rescue Bolus Dose of Phenylephrine (mcg) to Maintain SBP|Percentage of Participants Experiencing Both Nausea and Emesis","West Virginia University","Female","18 Years to 45 Years   (Adult)","Phase 4","85","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1406316590","August 2014","August 2015","August 2015","February 3, 2015","January 4, 2017","January 4, 2017","West Virginia University Hospital, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02354833"
884,"NCT02354599","Single-Dose Study of MT203",,"Completed","Has Results","Healthy Volunteers","Drug: MT203 80 mg or matching Placebo|Drug: MT203 150mg or matching Placebo|Drug: MT203 300 mg or matching placebo","Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)|Number of Participants With TEAEs Related to Vital Signs|Number of Participants With TEAEs Related to Body Weight|Number of Participants With TEAEs Related to 12-lead Electrocardiograms (ECG)|Number of Participants With TEAEs Related to Lung Functioning Monitoring|Number of Participants With TEAEs Related to Hematology, Serum Chemistry and Urinalysis|Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC(0-inf)) of MT203|Area Under the Serum Concentration-Time Curve From Time 0 to Time 84 Days (AUC(0-84d)) of MT203|Maximum Observed Serum Concentrations (Cmax) of MT203|Terminal Elimination Half-Life (T1/2) of MT203|Plasma Total Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Concentration|Number of Participants With Positive Response for Anti MT203 Antibody","Takeda","Male","20 Years to 45 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MT203/CPH-001|U1111-1163-4003|JapicCTI-142699","November 2014","May 2015","May 2015","February 3, 2015","June 20, 2016","June 20, 2016","Kagoshima-shi, Kagoshima, Japan",,"https://ClinicalTrials.gov/show/NCT02354599"
885,"NCT02353806","Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation",,"Completed","Has Results","Chronic Hypertension in Pregnancy","Drug: Amlodipine besylate","Area Under the Curve for Amlodipine in the Maternal Serum|Time to Maximal Concentration in the Maternal Serum.|Maximal Amlodipine Maternal Serum Concentration|Half-life of Amlodipine in Maternal Plasma|Clearance Rate of Plasma Amlodipine|Drug Levels/Concentration in Cord Blood (Amlodipine Levels/Concentrations)|Amlodipine Concentration in Breastmilk|Drug Level/Concentration in Infant Blood (Amlodipine Level/Concentration)|Neonatal Birth Weight|Infant Gestational Age at Delivery.|Infant Length of Stay.|Major Infant Complications","University of Texas Southwestern Medical Center|National Center for Advancing Translational Science (NCATS)","Female","18 Years to 50 Years   (Adult)","Phase 4","16","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","042014-059|UL1TR001105","January 2015","July 2016","September 2016","February 3, 2015","February 6, 2019","February 6, 2019","Parkland Health and Hospital System, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02353806"
886,"NCT02353442","Changes in Subjects With Posterior Capsule Tightness",,"Completed","Has Results","Shoulder Pain","Other: Posterior shoulder mobilizations|Other: External rotators strengthening|Other: Placebo ultrasound|Other: Scapular squeezing|Other: Upper trapezius stretching|Other: Posterior Capsule Stretching","Scapular Kinematics at 4weeks (Pre and Post Treatment)|Humeral Translations at 4weeks (Pre and Post Treatment).|Strength of the Shoulder External Rotators at 4weeks (Pre and Post Treatment).|Pressure Pain Threshold at 4weeks (Pre and Post Treatment).|Pain and Function at 4weeks (Pre and Post Treatment)","Universidade Federal de Sao Carlos","All","18 Years to 60 Years   (Adult)","Not Applicable","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","860.648","March 2015","August 2016","August 2016","February 2, 2015","February 15, 2017","March 21, 2017","UFSCar, São Carlos, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02353442"
887,"NCT02353299","Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: Silenor 6 mg|Drug: zolpidem 10 mg|Drug: Placebo","Auditory Arousal Threshold (AAT) at T-max|Tandem Walk Step-Offs|Tandem Walk Duration Over Five Trials|Berg Balance Test|Immediate Free Recall Task|Delayed Free Recall Task|Number of Participants With Adverse Events","Currax Pharmaceuticals|Henry Ford Hospital","Male","21 Years to 50 Years   (Adult)","Phase 4","52","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","PT-D1402","January 2015","January 2016","March 2016","February 2, 2015","December 7, 2017","January 2, 2018","Henry Ford Hospital Sleep Disorders & Research Center, Novi, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02353299"
888,"NCT02349711","Probiotics and Health-related Quality of Life in Individuals With Seasonal Allergies","JEN","Completed","Has Results","Healthy","Dietary Supplement: Probiotic mixture|Dietary Supplement: Placebo","Change in Health-related Quality of Life Score From Baseline to the Peak Week of Allergy Season for Probiotic Versus Placebo, as Measured by MiniRQLQ|Serum Total Immunoglobulin E (IgE)|Constipation Symptom Score, Measured by Gastrointestinal Symptom Response Scale (GSRS) Questionnaire|Regulatory T Cells (Tregs)","University of Florida|Wakunaga Pharmaceutical Co., Ltd.","All","18 Years to 60 Years   (Adult)","Not Applicable","224","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB201400894|Project No. 00120905","January 2015","May 2015","May 2015","January 29, 2015","August 31, 2016","June 9, 2017","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02349711"
889,"NCT02349438","Assessment of Contact Lens Wettability Using Wavefront Aberrometry",,"Completed","Has Results","Visual Acuity","Device: senofilcon A|Device: lotrafilcon B","Higher Order Root Mean Square (HO RMS) - Near Target in Downgaze With Natural Blinking|Higher Order Root Mean Square (HO RMS) - Near Target in Downgaze With Controlled Blink|Higher Order Root Mean Square (HO RMS) - Distance Target in Primary Gaze With Controlled Blink","Johnson & Johnson Vision Care, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","CR-5685","December 2014","May 2015","May 2015","January 28, 2015","January 20, 2017","June 19, 2018","Kelvin Grove, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT02349438"
890,"NCT02349360","Safety, Tolerability and Host Response to Lactobacillus Johnsonii","LJ","Completed","Has Results","Healthy","Biological: L. johnsonii N6.2|Biological: Placebo","Number of Participants Reporting Adverse Events|Composite Measure of Blood Chemistry Profiles","University of Florida|Juvenile Diabetes Research Foundation","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","201400370","August 2015","December 2016","December 2016","January 28, 2015","May 18, 2018","June 14, 2018","University of Florida, Food Science and Human Nutrition Dept, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02349360"
891,"NCT02348658","A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet",,"Completed","Has Results","Hypertension","Drug: TAK-536TCH","Cmax: Maximum Plasma Concentration for TAK-536, Its Metabolites (M-I and M-II) and Hydrochlorothiazide (HCTZ)|Cmax: Maximum Plasma Concentration for Amlodipine Besilate (AML)|AUC(0-48): Area Under the Plasma Concentration-Time Curve From Time 0 to 48 Hours Postdose in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ|AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose in Each Period for AML|AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ|AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration in Each Period for AML|AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity in Each Period for TAK-536, Its Metabolites (M-I and M-II) and HCTZ|AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for AML|Urinary Excretion Ratio of TAK-536, Its Metabolites (M-I and M-II) and HCTZ|Urinary Excretion Ratio of AML|Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)|Number of Participants With TEAEs Related to Vital Signs|Number of Participants With TEAEs Related to Body Weight|Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Laboratory Values|Number of Participants With Clinical Significant Findings in Electrocardiograms After Study Drug Administration","Takeda","Male","20 Years to 35 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-536TCH/CPH-004|U1111-1165-5595|JapicCTI-152777","January 2015","March 2015","March 2015","January 28, 2015","April 26, 2016","April 26, 2016","Fukuoka-shi, Fukuoka, Japan",,"https://ClinicalTrials.gov/show/NCT02348658"
892,"NCT02347605","Medicinal Nicotine for Preventing Cue Induced Craving",,"Completed","Has Results","Tobacco Use Disorder","Drug: Nicotine lozenge 4 mg|Drug: Placebo lozenge","Craving Symptom Severity Score Assessed Via Questionnaire|Withdrawal Symptom Severity Score Assessed Via Questionnaire","University of Minnesota","All","18 Years to 64 Years   (Adult)","Not Applicable","56","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","WS2385492","September 2013","January 2015","January 2015","January 27, 2015","December 18, 2017","December 18, 2017","Clinical and Translational Sciences Institute, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02347605"
893,"NCT02347345","Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs",,"Completed","Has Results","Hepatitis C","Drug: Harvoni (Fixed dose combination ledipasvir/sofosbuvir)","sCD14 (ng/mL)|Virologic Response to Therapy as Measured by HCV RNA|Gene Expression Profiles","Rockefeller University|National Institute on Drug Abuse (NIDA)","All","18 Years to 55 Years   (Adult)","Phase 4","34","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MMA-0874|5R01DA033777","November 15, 2016","November 15, 2016","November 15, 2016","January 27, 2015","August 13, 2019","August 13, 2019","Rockefeller University Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02347345"
894,"NCT02346461","An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy",,"Completed","Has Results","GNE Myopathy","Drug: ManNAc","Mean Area Under the Curve (AUClast) of Plasma ManNAc (Baseline-adjusted)|Maximum Observed Plasma Concentration (Cmax) of ManNAc (Baseline-adjusted)|The Time to Cmax (Tmax) for ManNAc|Half-life (t ½) for ManNAc|Mean Area Under the Curve (AUClast) of Plasma Neu5Ac (Baseline-adjusted)|Maximum Observed Plasma Concentration (Cmax) of Neu5Ac (Baseline-adjusted)|The Time to Cmax (Tmax) for Neu5Ac","National Human Genome Research Institute (NHGRI)|National Center for Advancing Translational Science (NCATS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","Phase 2","12","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","150068|15-HG-0068","February 5, 2015","December 30, 2017","November 15, 2018","January 27, 2015","April 16, 2019","April 16, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02346461/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02346461"
895,"NCT02343380","Timing of Caloric Intake, Diet-induced Thermogenesis and Hormonal Pattern",,"Completed","Has Results","Diet-induced Thermogenesis","Other: calorimetric exam after a standard meal","Intra-individual Variation in Morning Diet-induced Thermogenesis (DIT) Evaluated by Calorimetric Exam After the Consumption of a Meal at 8:00 am Compared With Evening DIT Evaluated by Calorimetric Exam After the Consumption of the Same Meal at 8:00 pm|Variation in Morning Glucose and Insulin Area-Under the Curve (AUC)s After the Consumption of a Meal at 8:00 am Compared With Evening Glucose and Insulin AUCs After the Consumption of the Same Meal at 8:00 pm|Variation in Morning Triglyceride and Free Fatty Acid (FFA) Area-Under the Curve (AUC)s After the Consumption of a Meal at 8:00 am Compared With Evening Glucose and Insulin AUCs After the Consumption of the Same Meal at 8:00 pm|Intra-individual Variations in the Values of Adrenalin and Noradrenalin, After the Morning and Evening Meal Consumption|Intra-individual Variations in the Values of Acylated Ghrelin After the Morning and Evening Meal Consumption|Intra-individual Variations in the Values of Glucagon-like Peptide-1 After the Morning and Evening Meal Consumption","University of Turin, Italy","All","20 Years to 35 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","DIT-01","May 2014","July 2014","December 2014","January 22, 2015","December 31, 2015","January 24, 2018",,,"https://ClinicalTrials.gov/show/NCT02343380"
896,"NCT02342704","Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants","REVEAL","Terminated","Has Results","Relapsing-Remitting Multiple Sclerosis","Drug: natalizumab|Drug: fingolimod","Cumulative Number of ≥ 6-Month Confirmed T1-Hypointense Lesions Arising From New On-Treatment T1-Gadolinium-Enhancing (Gd+) Lesions|Cumulative Number of New T1-Gd+ Lesions|Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 24|Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 52|Cumulative Number of New or Enlarging T2 Lesions|Proportion of Participants With No Evidence of Disease Activity (NEDA)|Time to First Relapse|Cumulative Risk of Relapse|Time to Complete Recovery From First Relapse|Change From Baseline in Symbol Digit Modalities Test (SDMT) at Week 24|Change From Baseline in SDMT at Week 52","Biogen","All","18 Years to 60 Years   (Adult)","Phase 4","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","101MS408|2013-004622-29","November 30, 2014","May 18, 2016","May 18, 2016","January 21, 2015","June 9, 2017","June 9, 2017","Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Des Moines, Iowa, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Round Rock, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jihlava, Czechia|Research Site, Ostrava - Poruba, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 5, Czechia|Research Site, Teplice, Czechia|Research Site, Nimes, Gard, France|Research Site, Libourne Cedex, Gironde, France|Research Site, Toulouse cedex 9, Haute Garonne, France|Research Site, Freiburg, Baden Wuerttemberg, Germany|Research Site, Erbach, Hessen, Germany|Research Site, Gianicolense, Roma, Italy|Research Site, Roma, Italy|Research Site, El Palmar, Murcia, Spain|Research Site, Malaga, Málaga, Spain|Research Site, Vigo, Pontevedra, Spain|Research Site, Santa Cruz de Tenerife, Tenerife, Spain|Research Site, Barcelona, Spain|Research Site, Girona, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Göteborg, Sweden|Research Site, Stockholm, Sweden|Research Site, London, Greater London, United Kingdom|Research Site, Glasgow, Strathclyde, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02342704"
897,"NCT02342418","Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults",,"Completed","Has Results","Obesity","Drug: Tedizolid phosphate","This Outcome Measure is the Tedizolid Area Under the Concentration Time-curve From Time 0 to 72 Hours in Morbidly Obese Subjects and Matched Non-obese Subjects.|This Outcome Measure is the Maximum Plasma Concentration of Tedizolid in Morbidly Obese Subjects Compared to Nonobese Subjects","Amit.Pai|Merck Sharp & Dohme Corp.|Albany College of Pharmacy and Health Sciences","All","18 Years to 50 Years   (Adult)","Phase 4","19","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","14-019","March 2015","September 2015","December 2015","January 21, 2015","March 15, 2017","March 15, 2017",,,"https://ClinicalTrials.gov/show/NCT02342418"
898,"NCT02342197","Comparative Study Between Minidose Long Protocol and Microdose Flare Protocol in Controlled Ovarian Hyperstimulation",,"Completed","Has Results","Infertility","Drug: Decapeptyl","Number of Oocytes Retrieved","Kasr El Aini Hospital","Female","35 Years to 42 Years   (Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","610012011","January 2011","December 2011","December 2011","January 19, 2015","January 28, 2015","January 28, 2015",,,"https://ClinicalTrials.gov/show/NCT02342197"
899,"NCT02341859","Lens Fitting Evaluation of CooperVision MyDay™ Compared With 1-DAY ACUVUE® TruEye® and DAILIES TOTAL1®",,"Completed","Has Results","Myopia","Device: stenfilcon A|Device: delefilcon A|Device: narafilcon A","Conjunctival Staining - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Conjunctival Indentation - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Limbal Redness - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Corneal Staining Type - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Corneal Staining Extent - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Corneal Staining Depth - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Corneal Shape Change - Tangential Radius - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Corneal Shape Change - Wavefront Error - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Lens Fit - Corneal Coverage - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Lens Fit - Horizontal Centration - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Lens Fit - Vertical Centration - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Lens Fit - Post-blink Movement - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Lens Fit - Tightness on up Gaze Blink Lag - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Lens Fit Overall - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Pain and Foreign Body Sensation (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Itching Sensation on Insertion (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Itching Sensation on Removal (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Red Eye (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Dryness (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Comfort (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Handling (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Vision (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Overall Wearing Satisfaction (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A|Lens Preferences (Subjective Rating) - Stenfilcon A/Delefilcon A and Stenfilcon A/Narafilcon A","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","JP-MKTG-201501","January 2015","June 2015","July 2015","January 19, 2015","May 26, 2016","March 10, 2017","Clinical Research Center, University of California, Berkeley, Berkeley, California, United States",,"https://ClinicalTrials.gov/show/NCT02341859"
900,"NCT02341482","A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects",,"Completed","Has Results","Healthy","Drug: PF-04958242|Drug: Itraconazole","Area Under the Concentration-Time Profile From Time 0 to Time Tau, the Dosing Interval, Where Tau = 12 Hours (AUCtau) of PF-04958242|Maximum Observed Plasma Concentration (Cmax) of PF-04958242|Time for Cmax (Tmax) of PF-04958242|Lowest Concentration Observed During the Dosing Interval (Cmin) of PF-04958242|Predose Concentration (Ctrough) of PF-04958242|Apparent Oral Clearance (CL/F) of PF-04958242|Number of Participants With Abnormal Clinical Laboratory Measurements|Number of Participants With Vital Signs Data Meeting Criteria of Potential Clinical Concern|Number of Participants With Electrocardiogram Data Meeting Criteria of Potential Clinical Concern|Number of Participants With Significant Change in Neurological Examination From Previous Examination|Number of Participants With Significant Change in Physical Examination From Previous Examination|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Positive Response to Columbia-Suicide Severity Rating Scale (C-SSRS)","Biogen","All","18 Years to 55 Years   (Adult)","Phase 1","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1701021|DDI","February 5, 2015","March 31, 2015","March 31, 2015","January 19, 2015","June 30, 2016","January 9, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02341482"
901,"NCT02340338","rTSST-1 Variant Vaccine Phase 1 First-in-man Trail","rTSST-1","Completed","Has Results","Toxic Shock Syndrome|Vaccination; Sepsis","Biological: rTSST-1 Variant Candidate Vaccine","Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Number of Participants With Seroconversion","Biomedizinische Forschungs gmbH|Medical University of Vienna","All","18 Years to 64 Years   (Adult)","Phase 1","46","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BioMed0713","July 2014","June 2015","July 2015","January 16, 2015","January 31, 2017","January 31, 2017","Medical University of Vienna Department of Clinical Pharmacology, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT02340338"
902,"NCT02340091","A Clinical Study to Evaluate the Efficacy and Safety of YVOIRE Classic Plus Versus YVOIRE Classic in Nasolabial Fold Injection",,"Completed","Has Results","Wrinkles","Device: HA IDF plus|Device: HA IDF","Proportion of the Subjects With at Least 10mm Difference in VAS Pain Scale Scores Within the Subject (VAS of the Control Medical Device - VAS of the Test Medical Device) Immediately After Treatment With the Investigational Medical Devices","LG Life Sciences","Female","30 Years to 60 Years   (Adult)","Not Applicable","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","LG-HACL012","February 2014","June 2014","June 2015","January 16, 2015","January 23, 2019","January 23, 2019",,,"https://ClinicalTrials.gov/show/NCT02340091"
903,"NCT02340078","A Clinical Study to Evaluate the Efficacy and Safety of YVOIRE Volume Plus Versus YVOIRE Volume in Nasolabial Fold Injection",,"Completed","Has Results","Wrinkles","Device: HA IDF II plus|Device: HA IDF II","Proportion of the Subjects With at Least 10mm Difference in VAS Pain Scale Scores Within the Subject (VAS of the Control Device - VAS of the Test Device) Immediately After Treatment With the Investigational Devices","LG Life Sciences","Female","30 Years to 60 Years   (Adult)","Not Applicable","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LG-HACL011","November 2013","February 2015","February 2015","January 16, 2015","January 23, 2019","January 23, 2019",,,"https://ClinicalTrials.gov/show/NCT02340078"
904,"NCT02339506","Stress and the Nervous System",,"Active, not recruiting","Has Results","Autonomic Nervous System|Baroreflex|Stress, Physiological","Drug: Cosyntropin|Drug: Placebo","Cardiovagal Baroreflex Sensitivity (Modified Oxford Technique)","Brigham and Women's Hospital|Beth Israel Deaconess Medical Center","All","18 Years to 55 Years   (Adult)","Not Applicable","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","2014P002423","April 2015","October 2016","December 2019","January 15, 2015","November 30, 2017","May 29, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02339506"
905,"NCT02338193","Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women","DAPA-GDM","Completed","Has Results","Diabetes Prevention in Women After GDM Who Are at High-risk","Drug: DAPA/MET XR|Drug: DAPA|Drug: MET XR","Change in Body Weight|Change in Percent Body Weight|Body Mass Index (BMI)|Waist Circumference (WC)|Waist- to -Hip Ratio (WHR; Measure of Central Adiposity)|Waist-to-height Ratio (WHtR)|Diastolic Blood Pressure (DBP)|Systolic Blood Pressure (SBP)|Liver Enzymes|Total Cholesterol Levels (CHOL)|Triglyceride (TRG) Levels|Fasting Blood Glucose (FBG)|Mean Blood Glucose (MBG) During an OGTT|Fasting Insulin Sensitivity (HOMA-IR)|Matsuda Sensitivity Index (SI OGTT)|First Phase Insulin Secretion (IGI/HOMA-IR)","Woman's|AstraZeneca","Female","18 Years to 45 Years   (Adult)","Phase 3","69","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","RP-14-012","September 22, 2015","February 13, 2019","March 13, 2019","January 14, 2015","April 30, 2019","June 11, 2019","Woman's Hospital, Baton Rouge, Louisiana, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02338193/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02338193/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02338193"
906,"NCT02337361","Computerized Tool for Preventing Prenatal Drinking",,"Completed","Has Results","Foetal Exposure During Pregnancy","Behavioral: Electronic SBI","Number of Participants Reporting Risky Alcohol Use|Number of Participants Reporting Weekly Alcohol Use|Number of Participants Reporting Heavy Alcohol Use|Number of Participants Reporting Any Tobacco Use|Number of Participants Reporting Frequent Sugar Sweetened Beverage Use|Number of Participants Reporting Significant Depression|Number of Participants Reporting Any Drug Use","Public Health Institute, California|Sonoma County Department of Health Services|La Clínica de La Raza Inc.","Female","18 Years to 44 Years   (Adult)","Not Applicable","185","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","R34AA022697","February 22, 2016","August 31, 2017","August 31, 2018","January 13, 2015","January 23, 2019","January 25, 2019","La Clinica Women Infants and Children Program Site, Oakland, California, United States|Sonoma County Department of Health Services, Santa Rosa, California, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02337361/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02337361/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02337361"
907,"NCT02336074","Research In Viral Eradication of HIV Reservoirs","RIVER","Active, not recruiting","Has Results","HIV","Drug: Combination Antiretroviral Therapy (cART)|Drug: Raltegravir|Drug: Vorinostat|Biological: ChAdV63.HIVconsv (ChAd)|Biological: MVA.HIVconsv (MVA)","Total HIV DNA From CD4 T-cells|Clinical Adverse Events|Quantitative Viral Outgrowth|Percentage of CD4+ CD154+ IFNγ+ T Cells|CD8+ T-cell Responses|Viral Inhibition","Imperial College London|Medical Research Council|University of Oxford|University of Cambridge|Chelsea and Westminster NHS Foundation Trust|Royal Free Hospital NHS Foundation Trust|Brighton and Sussex University Hospitals NHS Trust|Guy's and St Thomas' NHS Foundation Trust|Central and North West London NHS Foundation Trust","All","18 Years to 60 Years   (Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCT-NAPN-24772|2014-001425-32","November 27, 2015","November 2017","November 2022","January 12, 2015","September 25, 2019","September 25, 2019","Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom|Central and North West London NHS Foundation Trust, London, United Kingdom|Chelsea and Westminster NHS Foundation Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|Royal Free Hospital NHS Foundation Trust, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02336074/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02336074/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02336074"
908,"NCT02334982","Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants",,"Completed","Has Results","Dose Finding Study","Drug: TAK-137|Drug: Placebo","Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event|Percentage of Participants With Abnormal Safety Laboratory Findings|Percentage of Participants With Markedly Abnormal Vital Sign Measurements|Cmax: Maximum Observed Plasma Concentration for TAK-137|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-137|AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-137|AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-137|Terminal Elimination Half-life (T1/2) for TAK-137_101|Apparent Clearance (CL/F) for TAK-137_101|Apparent Volume of Distribution (Vz/F) for TAK-137_101|Total Amount of Drug (TAK-137) Excreted in Urine From Time 0 to Time t (Ae[0-t])|Fraction of TAK-137 Excreted in Urine (Fe)|Renal Clearance (CLr) for TAK-137","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","TAK-137_101|U1111-1164-7376","June 2013","January 2014","January 2014","January 9, 2015","February 10, 2015","February 10, 2015",,,"https://ClinicalTrials.gov/show/NCT02334982"
909,"NCT02334787","A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects",,"Completed","Has Results","Atopic Dermatitis","Drug: 0.3% OPA-15406 Ointment|Drug: 1% OPA-15406 Ointment|Drug: 3% OPA-15406 Ointment|Drug: Placebo Ointment","Cmax of OPA-15406 in a Single Administration Period|Cmax of OPA-15406 in the Multiple Administration Period|AUC12h of OPA-15406 in a Single Administration Period|AUC12h of OPA-15406 in the Multiple Administration Period","Otsuka Pharmaceutical Co., Ltd.","Male","20 Years to 40 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","271-14-001","January 2015","February 2015","February 2015","January 8, 2015","October 3, 2016","October 3, 2016","Kanto Region, Japan",,"https://ClinicalTrials.gov/show/NCT02334787"
910,"NCT02333045","Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women","MIP","Terminated","Has Results","HIV","Drug: Truvada qd|Drug: Maraviroc 300 qd","Count of Total Cells Obtained From Cervicovaginal Lavage Samples|Steady-state Area Under the Plasma Concentration-time Curve of Study Drug|Steady-state Area Under the Female Genital Tract Concentration-time Curve of Study Drug","Emory University","Female","18 Years to 44 Years   (Adult)","Not Applicable","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00074767","January 2015","October 28, 2016","October 28, 2016","January 7, 2015","December 13, 2017","January 19, 2018","Grady Memorial Hospital, Atlanta, Georgia, United States|Grady Infectious Diseases Clinic (Ponce Clinic), Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02333045"
911,"NCT02332798","Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia","MAD","Completed","Has Results","Schizophrenia","Drug: PF-04958242|Drug: Placebo","Maximum Observed Plasma Concentration (Cmax) (Single Dose)|Cmax (Steady State)|Time for Cmax (Tmax) (Single Dose)|Tmax (Steady State)|Area Under the Concentration-Time Profile From Time 0 to Time Tau (τ), the Dosing Interval, Where τ = 12 Hours (AUCτ) (Single Dose)|AUCτ (Steady State)|Apparent Oral Clearance (CL/F) (Steady State)|Apparent Volume of Distribution (Vz/F) (Steady State)|Terminal Half-Life (t1/2) (Steady State)|Observed Accumulation Ratio (Rac) (Steady State)|Observed Accumulation Ratio for Cmax (Rac, Cmax) (Steady State)|Peak-to-Trough Ratio at Steady State (PTR)|Number of Participants With Abnormal Clinical Laboratory Measurements|Number of Participants With Vital Signs Data Meeting Criteria of Potential Clinical Concern|Number of Participants With Electrocardiogram Data Meeting Criteria of Potential Clinical Concern|Number of Participants With Abnormalities in Neurological Examination|Number of Participants With Abnormalities in Physical Examination|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Positive Response to Columbia-Suicide Severity Rating Scale (C-SSRS)","Biogen","All","18 Years to 55 Years   (Adult)","Phase 1","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B1701017|MAD","January 6, 2015","April 15, 2015","April 15, 2015","January 7, 2015","June 14, 2016","January 9, 2020","Collaborative Neuroscience Network, LLC., Long Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT02332798"
912,"NCT02330055","Determination of the Predictors of Nocturnal Desaturation in Postpartum Women",,"Completed","Has Results","Sleep Disordered Breathing|Nocturnal Oxygen Desaturation|Upper Airway Edema","Procedure: Forty-five degrees elevated upper body position|Procedure: non-elevated upper body position|Device: Noninvasive wrist pulse oximeter (WristOx Model 3150)|Other: Stop-Bang questionnaire|Other: Epworth Sleepiness Scale|Other: P-SAP Score|Other: self-reported pain","SpO2 < 90%|Oxygen Desaturation Index > 3|Minimal & Mean SpO2|P-SAP Score|STOP-BANG Score|Pain-score on a Verbal Numerical Rating Scale|Average Pulse Rate","Massachusetts General Hospital","Female","18 Years to 55 Years   (Adult)","Not Applicable","99","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011P001326B","May 2014","February 2017","December 2017","January 1, 2015","April 9, 2018","July 6, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02330055/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02330055/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02330055"
913,"NCT02328404","The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome (PCOS)",,"Completed","Has Results","Polycystic Ovary Syndrome|Hypovitaminosis D","Drug: 50,000 IU vitamin D3|Drug: Placebo","Ultrasound Examination of Number of Follicles and Ovarian Volume|Menstrual Regularity|Hirsutism Score|Serum Progesterone Level|Total Testosterone Level|Free Androgen Index|Sex Hormone Binding Globulin Concentration|Serum 25-Hydroxy Vitamin D3 Level|Serum Chromium Concentration|Serum Glucose Concentration in Oral Glucose Tolerance Test 1st hr After Treatment|Body Mass Index|Serum Parathyroid Hormone Concentration|Serum Calcium Concentration|Serum Phosphorous Concentration|Serum C-Reactive Protien Concentration","Hayat Pharmaceutical Co. PLC|Jordan University of Science and Technology","Female","18 Years to 49 Years   (Adult)","Phase 3","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VitD31.0|2013-003353-22","February 2014","September 2014","December 2014","December 31, 2014","April 17, 2015","August 4, 2016","King Abdullah University Hospital, Irbid, Jordan",,"https://ClinicalTrials.gov/show/NCT02328404"
914,"NCT02327013","Investigating the Effect of Vortioxetine in Adult ADHD Patients",,"Completed","Has Results","Attention Deficit Hyperactivity Disorder","Drug: vortioxetine 10 mg tablet|Drug: vortioxetine 20 mg tablet|Other: Placebo tablet","Change in ADHD Investigator Symptom Rating Scale (AISRS) Total Score|Inattention/Meta-cognition: Change in Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Using Metacognition Index|Cognitive Function/Global Executive Function: Change in BRIEF-A Using the Global Executive Composite Score|Overall Functioning: Change in Sheehan Disability Scale (SDS) Total Score|Productivity: Change in Work Limitations Questionnaire (WLQ) Productivity Loss Score|Change in AISRS Inattention Sub-score|Change AISRS Hyperactivity/Impulsivity Sub-score|Percentage of Patients Responding (Response Defined as 30% or Greater Reduction From Baseline in AISRS Total Score)|Change in Adult ADHD Self-Report Scale (ASRS) Total Score|Change in Clinical Global Impression - Severity of Illness (CGI-S) Score|Clinical Global Impression - Global Improvement (CGI-I) Score|Response (Defined as a CGI-I Score of 1 or 2), Stage 1|Change in BRIEF-A Using the Behavioural Regulation Index|Change in BRIEF-A Subscales - Inhibit|Change BRIEF-A Subscales - Initiate|Change in BRIEF-A Subscales - Organization of Materials|Change in BRIEF-A Subscales - Planning/Organize|Change in BRIEF-A Subscales - Shift|Change in BRIEF-A Subscales - Self Monitor|Change in BRIEF-A Subscales - Task Monitor|Change in BRIEF-A Subscales - Working Memory|Change in BRIEF-A Subscales - Emotional Control|Change in Perceived Deficits Questionnaire - Depression (PDQ-D) Total Score|Change in PDQ-D Subscales - Attention and Concentration Sub-score|Change in PDQ-D Sub-scales - Retrospective Memory Sub-score|Change in PDQ-D Sub-scales - Prospective Memory Sub-score|Change in PDQ-D Sub-scales - Planning and Organisation Sub-score|Change in SDS Item Scores - Family|Change in SDS Item Scores - Work|Change in SDS Item Scores - Social Life|Change in SDS Item Scores - Number of Days Lost|Change in SDS Item Scores - Number of Underproductive Days|Change in WLQ Using the Global Productivity Index|Change in WLQ Domain Scores - Limitations Handling Time|Change in WLQ Domain Scores - Mental-Interpersonal Work Demands|Change in WLQ Domain Scores - Physical Demands|Change in WLQ Domain Scores - Output Demands|Change in Adult ADHD Quality of Life Measure (AAQoL) Total Score|Change in AAQoL Subscales - Life Productivity Sub-score|Change in AAQoL Subscales - Psychological Health Sub-score|Change in AAQoL Subscales - Life Outlook Sub-score|Change in AAQoL Subscales - Relationships Sub-score","H. Lundbeck A/S","All","18 Years to 55 Years   (Adult)","Phase 2","227","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15996A","December 2014","September 2016","September 2016","December 30, 2014","January 31, 2018","March 7, 2018","US015, Beverly Hills, California, United States|US002, Garden Grove, California, United States|US004, National City, California, United States|US013, Bradenton, Florida, United States|US006, Gainesville, Florida, United States|US010, Alpharetta, Georgia, United States|US014, Libertyville, Illinois, United States|US011, Baltimore, Maryland, United States|US009, Boston, Massachusetts, United States|US016, Las Vegas, Nevada, United States|US005, New York, New York, United States|US008, New York, New York, United States|US001, Austin, Texas, United States|US007, Herndon, Virginia, United States|US003, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02327013"
915,"NCT02326233","Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects",,"Completed","Has Results","Healthy","Biological: Pen of SB5|Biological: PFS of SB5","Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)|Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)|Maximum Serum Concentration (Cmax)|Time to Reach Cmax (Tmax)","Samsung Bioepis Co., Ltd.","All","18 Years to 55 Years   (Adult)","Phase 1","190","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","SB5-G12-NHV|2014-005178-12","June 2015","September 2015","September 2015","December 29, 2014","March 18, 2019","March 18, 2019","Samsung Investigational Site, Antwerpen, Belgium|Samsung Investigational Site, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT02326233"
916,"NCT02325713","Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: Oral dispersible tablet of praziquantel (ODT-PZQ)|Drug: Cysticide|Drug: ODT-PZQ","Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-inf) Adjusted for the Actual Administered Dose (AUC0-inf, Adj) of L-Praziquantel (L-PZQ)|Maximum Observed Concentration in Plasma (Cmax) Adjusted for the Actual Administered Dose (Cmax, Adj) of L-PZQ, D-PZQ and Racemate PZQ|Time to Reach Maximum Plasma Concentration (Tmax) of L-PZQ, D-PZQ, and Racemate PZQ|Apparent Terminal Half-life (t1/2) of L-PZQ, D-PZQ, and Racemate PZQ|Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-PZQ, D-PZQ, and Racemate PZQ|AUC From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) Adjusted for the Actual Administered Dose (AUC0-t, Adj) of L-PZQ, D-PZQ, and Racemate PZQ|Extrapolated Area Under the Plasma Concentration Curve From Time Tlast to Infinity (AUCextra) of L-PZQ, D-PZQ, and Racemate PZQ|Apparent Terminal Elimination Rate Constant (λz) of L-PZQ, D-PZQ, and Racemate PZQ|Relative Bioavailability (Frel) of L-PZQ, D-PZQ, and Racemate PZQ|Apparent Total Body Clearance of Drug From Plasma (CL/f) of L-PZQ, D-PZQ, and Racemate PZQ|Apparent Volume of Distribution During the Terminal Phase (Vz/f) of L-PZQ, D-PZQ, and Racemate PZQ|Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Infinity (AUC0-inf) Adjusted for the Actual Administered Dose (AUC0-inf, Adj) of D-PZQ and Racemate PZQ|Number of Subjects With Treatment-emergent Adverse (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation|Palatability Assessment Based on Visual Analog Scale (VAS) Score|Number of Subjects With Clinically Significant Change From Baseline in Vital Signs, Physical Examinations, Electrocardiogram (ECG) and Laboratory Parameters","Merck KGaA, Darmstadt, Germany","Male","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200585-001","January 2015","January 2015","March 2015","December 25, 2014","February 23, 2017","February 23, 2017","Please contact the Merck KGaA Communication Center, Darmstadt, Germany",,"https://ClinicalTrials.gov/show/NCT02325713"
917,"NCT02323646","Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids",,"Completed","Has Results","Uterine Fibroids","Drug: Placebo|Drug: Telapristone Acetate","Percentage of Participants in Amenorrhea at the End of Treatment Course 1|Percentage of Participants in Amenorrhea at the End of Treatment Course 2|Percentage Change in PBAC Scores From Baseline to the End of Treatment Courses 1 and 2|Percentage Change in Transformed Total Uterine Fibroid System Quality of Life Survey System Severity (UFS-SSS) Score From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 1 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 2 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 3 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 4 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 5 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 6 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 7 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 8 From Baseline to the End of Treatment Courses 1 and 2 and the Course 2 Week 24 Follow-up Visit|Percentage Change in Total Uterine Fibroid Volume From Baseline to the End of Treatment Courses 1 and 2","Repros Therapeutics Inc.","Female","18 Years to 47 Years   (Adult)","Phase 2","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ZPV-201","February 12, 2015","April 6, 2017","April 6, 2017","December 23, 2014","June 14, 2019","June 25, 2019","Fort Lauderdale, Florida, United States|Sandy Springs, Georgia, United States|Metairie, Louisiana, United States|Saginaw, Michigan, United States|Raleigh, North Carolina, United States|Houston, Texas, United States|Houston, Texas, United States|Richmond, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02323646/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02323646/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02323646"
918,"NCT02323048","Acquisition of Responses to a Methamphetamine-associated Cue in Healthy Humans","CAM","Completed","Has Results","Substance Abuse","Drug: methamphetamine|Drug: placebo","Subjective Effects as Assessed by Score on ""Feel Drug"", ""Feel High"", ""Like Drug"", and ""Want More"" Subscales of the Drug Effects Questionnaire","University of Chicago","All","21 Years to 35 Years   (Adult)","Not Applicable","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","12-2047","July 2014","November 2014","December 2014","December 23, 2014","July 26, 2018","July 26, 2018",,,"https://ClinicalTrials.gov/show/NCT02323048"
919,"NCT02322879","Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing","APAPII","Completed","Has Results","Acetaminophen Toxicity","Drug: First Treatment Period|Other: Washout|Drug: Second Treatment Period","Rise in Plasma Transaminases: Proportion of Responders.","Beth Israel Deaconess Medical Center|Harvard University","All","20 Years to 40 Years   (Adult)","Phase 4","21","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2013P000070","May 2013","August 2016","December 2016","December 23, 2014","September 1, 2017","September 1, 2017","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02322879"
920,"NCT02322749","A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers",,"Completed","Has Results","Healthy Volunteers Bioequivalence or Bioavailability Study","Drug: selumetinib 75mg single dose","Bioequivalence of the Free Base Variant of Selumetinib (Treatment B) Compared to the Blue Reference Capsule (Treatment A) [Selumetinib Cmax]|Bioequivalence of the Free Base Variant of Selumetinib (Treatment B) Compared to the Blue Reference Capsule (Treatment A) [Selumetinib AUC]|Bioequivalence of the Free Base Variant of Selumetinib (Treatment B) Compared to the Blue Reference Capsule (Treatment A) [Selumetinib AUC(0-t)]|Relative Bioavailability of the TPGS Capsule Variant (Treatment C) Compared to the Blue Reference Capsule (Treatment A) [Selumetinib Cmax]|Relative Bioavailability of the TPGS Capsule Variant (Treatment C) Compared to the Blue Reference Capsule (Treatment A) [Selumetinib AUC]|Relative Bioavailability of the TPGS Capsule Variant (Treatment C) Compared to the Blue Reference Capsule (Treatment A) [Selumetinib AUC(0-t)]|The PK of the Metabolite N-desmethyl Selumetinib by Assessment of Cmax|The PK of N-desmethyl Selumetinib by Assessment of the AUC(0-t)","AstraZeneca","Male","18 Years to 45 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D1532C00078","February 2015","April 2015","April 2015","December 23, 2014","August 31, 2016","August 31, 2016","Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02322749"
921,"NCT02321748","Drug-Drug Interaction Study: ASP2151 and Montelukast",,"Completed","Has Results","Healthy","Drug: Montelukast|Drug: ASP2151","Peak Plasma Concentration (Cmax) of Montelukast|Time of Peak Concentration (Tmax) of Montelukast|Area Under the Curve (AUC) of Montelukast|Half-Life (t1/2) of Montelukast|Apparent Volume of Distribution (Vd/f) of Montelukast|Apparent Total Body Clearance (CL/f) of Montelukast|Number of Participants With Serious and Non-Serious Adverse Events","Maruho Europe Limited","Male","18 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","M522101-EU23","December 2014","April 2015","April 2015","December 22, 2014","January 14, 2019","February 27, 2019","Hammersmith Medicines Research Ltd, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02321748"
922,"NCT02320838","Unmodulated 5 Kilohertz Currents Versus TENS: Effect on Pain Thresholds, Tactile Threshold, and Nerve Conduction",,"Completed","Has Results","Pain","Device: 5 KHz|Device: TENS|Device: Sham stimulation","Mechanical Pain Threshold During Treatment|Thermal Pain Threshold During Treatment|Nerve Conduction Latency Immediately After Treatment|Tactile Threshold During Treatment|Habituation to Electrical Stimulation|Perception Current Comfortability|Change Current Density (mA/cm2)|Change From Baseline in Nerve Conduction Amplitude ( µV)|Baseline Mechanical Pain Threshold|Mechanical Pain Threshold Post-treatment 20 Min.|Mechanical Pain Threshold Post-treatment 40 Min.|Baseline Thermal Pain Threshold|Thermal Pain Threshold Post-treatment 20 Min.|Thermal Pain Threshold Post-treatment 40 Min.|Baseline Nerve Conduction Latency|Nerve Conduction Latency Post-treatment 20 Min.|Nerve Conduction Latency Post-treatment 40 Min.|Baseline Tactile Threshold|Tactile Threshold Post-treatment 20 Min.|Tactile Threshold Post-treatment 40 Min.","University of Castilla-La Mancha|Hospital Nacional de Parapléjicos de Toledo","All","18 Years to 30 Years   (Adult)","Not Applicable","38","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","javendano","November 2014","January 2015","February 2015","December 19, 2014","July 31, 2017","July 31, 2017",,,"https://ClinicalTrials.gov/show/NCT02320838"
923,"NCT02320227","A Single-Center, Clinical Study to Evaluate the Safety of a Non-Fragranced Personal Lubricant in Healthy Female Subjects",,"Completed","Has Results","Erythema|Edema","Device: Miami w/o frag Personal lubricant","Number of Participants With Observed Local Erythema|Number of Participants With Observed Local Edema","Church & Dwight Company, Inc.","Female","18 Years to 60 Years   (Adult)","Not Applicable","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ST-7557","December 2014","January 2015","January 2015","December 19, 2014","October 12, 2016","March 10, 2017","Clinical Research Laboratories, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02320227"
924,"NCT02320214","A Single-Center, Clinical Study to Evaluate the Safety of a Fragranced Personal Lubricant in Healthy Female Subjects",,"Completed","Has Results","Erythema|Edema","Device: Miami w/ frag Personal lubricant","Number of Participants With Observed Local Erythema|Number of Participants With Observed Local Edema","Church & Dwight Company, Inc.","Female","18 Years to 60 Years   (Adult)","Not Applicable","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","ST-7555","December 2014","January 2015","January 2015","December 19, 2014","September 20, 2016","December 6, 2016","Clinical Research Laboratories, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02320214"
925,"NCT02319668","Antimicrobial Agent for Reducing Bacteria in Aerosols and Oral Cavity",,"Completed","Has Results","Dental Prophylaxis and Implant Surgery","Drug: 0.2% w/v Chlorhexidine digluconate|Drug: Sodium fluoride toothpaste (Aquafresh Mild & Minty)","Total Number of Detectable Plaque Bacteria Sampled 3 Days Post Implant Surgery|Total Number of Detectable Plaque Bacteria Sampled at Implant Surgery (at Pre-rinse, Pre, Mid and Post Implant Surgery) and Post Implant Surgery (at Day 1 and 7)|Area Under the Curve (AUC) for the Total Number of Plaque Bacteria in the Mouth Post Implant Surgery|Total Number of Recoverable Viable Bacteria in the Aerosol Generated During Dental Prophylaxis","GlaxoSmithKline","All","18 Years to 64 Years   (Adult)","Phase 4","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","202200|2014-003222-40|RH02604","February 1, 2015","June 1, 2015","February 29, 2016","December 18, 2014","April 17, 2017","July 19, 2017","GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02319668"
926,"NCT02319148","A Study to Estimate the Effect of CYP3A4 Inhibitors (Itraconazole, Diltiazem or Verapamil) on the Pharmacokinetics of Single Dose PF- 00489791 in Healthy Volunteers",,"Completed","Has Results","Healthy Volunteers","Drug: itraconazole|Drug: diltiazem|Drug: SR verapamil|Drug: PF-00489791","Maximum Observed Plasma Concentration (Cmax) of PF-00489791|Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-00489791|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-00489791|Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-00489791|Apparent Volume of Distribution (Vz/F) of PF-00489791|Apparent Oral Clearance (CL/F) of PF-00489791|Terminal Elimination Half-Life (t1/2) of PF-00489791|Number of Participants With Laboratory Abnormalities Meeting the Criteria for Potential Clinical Concern|Number of Participants With Potentially Clinically Significant Vital Signs Findings|Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings|Number of Participants Who Used at Least 1 Concomitant Medication|Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","A7331022|2014-001979-31","July 2014","October 2014","October 2014","December 18, 2014","September 16, 2016","September 16, 2016","Pfizer Clinical Research Unit, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT02319148"
927,"NCT02318979","What is the Optimal Stiffness and Height of a Running-specific Prosthesis?",,"Completed","Has Results","Amputation, Traumatic|Traumatic Amputation of Lower Extremity|Wounds and Injuries","Device: Otto Bock prosthesis|Device: Ossur prosthesis|Device: Freedom Innovations prosthesis","Biomechanics|Metabolic Demand|Top Speed","VA Eastern Colorado Health Care System|United States Department of Defense","All","18 Years to 55 Years   (Adult)","Not Applicable","30","U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","W81XWH-11-2-0222","October 2013","January 2018","January 2018","December 17, 2014","July 16, 2019","July 30, 2019","University of Colorado Boulder, Boulder, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02318979/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02318979"
928,"NCT02317809","Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects",,"Completed","Has Results","Healthy","Drug: Liquid pergoveris|Drug: Freeze-dried pergoveris","Baseline Corrected Area Under the Concentration-Time Curve From Zero to Last Quantifiable Concentration (AUC 0-t,Adj) for Follicle-Stimulating Hormone (FSH)|Baseline Corrected Area Under the Concentration-Time Curve From Zero to Last Quantifiable Concentration (AUC0-t,Adj) for Luteinizing Hormone (LH)|Baseline Corrected Maximum Serum Concentration (Cmax,Adj) for Follicle-Stimulating Hormone (FSH)|Baseline Corrected Maximum Serum Concentration (Cmax,Adj) for Luteinizing Hormone (LH)|Baseline Corrected Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUC0-inf, Adj) for Follicle-stimulating Hormone (FSH) and Luteinizing Hormone (LH)|Baseline Corrected Area Under the Serum Concentration-time Curve From Time Tlast Extrapolated to Infinity (%AUCextra,Adj) for Follicle-stimulating Hormone (FSH) and Luteinizing Hormone (LH)|Apparent Terminal Elimination Rate Constant (Lambda[z]) for Follicle-stimulating Hormone (FSH) and Luteinizing Hormone (LH)|Time to Reach the Maximum Serum Concentration (Tmax) for Follicle-stimulating Hormone (FSH) and Luteinizing Hormone (LH)|Apparent Terminal Half-life (t1/2) for Follicle-stimulating Hormone (FSH) and Luteinizing Hormone (LH)|Apparent Serum Clearance (CL/F) for Follicle-stimulating Hormone (FSH) and Luteinizing Hormone (LH)|Apparent Volume of Distribution During Terminal Phase (Vz/F) for Follicle-stimulating Hormone (FSH) and Luteinizing Hormone (LH)|Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Related to Laboratory Assessments, Vital Signs or Electrocardiogram Findings|Number of Subjects With Follicle Size Greater Than (>)13 Millimeter|Serum Estradiol Levels|Number of Subjects With Local Tolerability/Injection Site Reactions (ISRs)|Pain Visual Analogue Scale (VAS) Score|Number of Subjects With Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) for Luteinizing Hormone (LH)|Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) Titers for Luteinizing Hormone (LH)|Number of Subjects With Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) for Follicle-stimulating Hormone (FSH)|Number of Subjects With Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) for Follicle-stimulating Hormone (FSH) at Follow-up Visit|Anti-Drug Antibodies (ADAs) Titers for Follicle-stimulating Hormone (FSH)|Anti-Drug Antibodies (ADAs) Titers for Follicle-stimulating Hormone (FSH) at Follow-up Visit|Neutralizing Antibodies (NAbs) Titers for Follicle-stimulating Hormone (FSH)","Merck KGaA, Darmstadt, Germany","Female","18 Years to 40 Years   (Adult)","Phase 1","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200061-006|2014-003506-32","January 31, 2015","October 31, 2015","October 31, 2015","December 16, 2014","December 13, 2016","July 16, 2018","Please contact the Merck KGaA Communication Center, Darmstadt, Germany",,"https://ClinicalTrials.gov/show/NCT02317809"
929,"NCT02314923","Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)",,"Completed","Has Results","Ebola Virus","Biological: V920 Vaccine|Other: Placebo","Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity|Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity|Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity|Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity|Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody|Optimum Dose for General Use Prophylaxis With V920|Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ)|Percentage of Participants With Seroconversion for ZEBOV-specific IgG|Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies","Merck Sharp & Dohme Corp.|BioProtection Systems Corporation|Department of Health and Human Services","All","18 Years to 60 Years   (Adult)","Phase 1","513","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","V920-004|NLG0507","December 5, 2014","June 23, 2016","June 23, 2016","December 11, 2014","January 2, 2020","January 2, 2020",,,"https://ClinicalTrials.gov/show/NCT02314923"
930,"NCT02314689","A Dose Escalation Study of Intravenous L-citrulline in Steady-state Sickle Cell Disease",,"Completed","Has Results","Sickle Cell Disease","Drug: Intravenous (IV) citrulline","Number of Participants With Grade 2 or Higher Adverse Event According to NCI Criteria","Suvankar Majumdar|University of Mississippi Medical Center","All","18 Years to 25 Years   (Adult)","Phase 1","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCD-124700.","January 2015","December 2015","December 2015","December 11, 2014","March 7, 2016","September 3, 2019","University of Mississippi Medical Center, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT02314689"
931,"NCT02313155","Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults",,"Completed","Has Results","Influenza Infection","Drug: Subcutaneous injection of TAK-850|Drug: Intramuscular injection of TAK-850","Number of Participants Reporting Solicited Local and Systemic Adverse Events (AEs)|Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)|Percentage of Participants With Seroprotection in Hemagglutination Inhibition (HI) Antibody Titer (Egg-derived Antigen) of >=40.|Percentage of Participants With Seroconversion in Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen)|Geometric Mean Fold Increase (GMFI) in HI Antibody Titer (Egg-derived Antigen) From Pre-vaccination to 21 Days After Vaccination|Number of Participants Reporting Clinically Significant Change From Baseline in Laboratory Values|Change From Baseline in Blood Pressure|Change From Baseline in Pulse|Change From Baseline in Body Temperature|Geometric Mean Titer (GMT) in HI Antibody Titer (Egg-derived Antigen)|Percentage of Participants With Seroprotection in SRH Antibody Titer (Egg-derived Antigen) of >=25 mm^2|Percentage of Participants With Seroconversion in SRH Antibody Titer (Egg-Derived Antigen)|GMFI in SRH Antibody Titer (Egg-derived Antigen) From Pre-vaccination to 21 Days After Vaccination|GMT in SRH Antibody Titer (Egg-derived Antigen)|Percentage of Participants With Seroprotection in HI Antibody Titer (Cell Derived Antigen) of >=40|Percentage of Participants With Seroconversion in HI Antibody Titer (Cell Derived Antigen)|GMFI in HI Antibody Titer (Cell Derived Antigen) From Pre-vaccination to 21 Days After Vaccination|GMT in HI Antibody Titer (Cell Derived Antigen)|Percentage of Participants With Seroprotection in SRH Antibody Titer (Cell Derived Antigen) of >=25 mm^2|Percentage of Participants With Seroconversion in SRH Antibody Titer (Cell Derived Antigen)|GMFI in SRH Antibody Titer (Cell Derived Antigen) From Pre-vaccination to 21 Days After Vaccination|GMT in SRH Antibody Titer (Cell Derived Antigen)","Takeda","All","20 Years to 49 Years   (Adult)","Phase 1|Phase 2","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TAK-850/CPH-002|U1111-1164-1969|JapicCTI-142724","December 2014","January 2015","January 2015","December 9, 2014","February 17, 2016","February 17, 2016",,,"https://ClinicalTrials.gov/show/NCT02313155"
932,"NCT02311478","Tracking IUD Bleeding Experiences: An Evaluation of Bleeding Profiles in New Intrauterine Device Users","TRIBE","Completed","Has Results","Intrauterine Devices, Copper|Metrorrhagia|Menstruation|Menstrual Cycle","Device: T380A Intrauterine Copper Contraceptive","Evaluate Changes in Bleeding Duration Among Women Initiating the Copper T380 IUD During the 90 Days Prior to Initiation Compared to Two 90 Periods After IUD Insertion.|Assess the Relationship of Menstrual Cycle Changes Among Women Initiating the Copper T380 IUD to Method Satisfaction and Continuation at 6 Months Post Insertion.","University of Utah","Female","18 Years to 40 Years   (Adult)","Not Applicable","79","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","75363","December 2014","August 2016","February 2017","December 8, 2014","July 30, 2019","July 30, 2019","University of Utah Health Sciences Center, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02311478"
933,"NCT02308748","Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block",,"Completed","Has Results","Drug-induced QT Prolongation|Pharmacokinetics|Pharmacodynamics","Drug: Dofetilide|Drug: Mexiletine|Drug: Lidocaine|Drug: Moxifloxacin|Drug: Diltiazem|Drug: Placebo","Change in Placebo Corrected Change From Baseline QTc and J-Tpeakc Intervals on the ECG Measured in Milliseconds When Dofetilide is Administered With Mexiletine or Lidocaine Compared to When Dofetilide is Administered Alone at Evening Dose on Treatment Day|Change in Placebo Corrected Change From Baseline QTc Interval on the ECG Measured in Milliseconds When Moxifloxacin is Administered With Diltiazem at the Evening Dose Compared to When Moxifloxacin is Administered Alone at Afternoon Dose on Treatment Day.","Food and Drug Administration (FDA)|Spaulding Clinical Research LLC","All","18 Years to 35 Years   (Adult)","Phase 1","22","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","14-022D|SCR-003","May 2014","June 2014","June 2014","December 4, 2014","June 8, 2016","June 8, 2016",,,"https://ClinicalTrials.gov/show/NCT02308748"
934,"NCT02308189","The Back Exercises to Neutralize Disability Study","BEND","Completed","Has Results","Low Back Pain","Behavioral: Exercise with blood flow restriction|Behavioral: Exercise","Trunk Extensor Muscle Cross Sectional Area % of Change|Muscle Strength % of Change|Muscle Endurance (Time to Task Failure) % of Change","Ohio University|National Institutes of Health (NIH)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","All","18 Years to 50 Years   (Adult)","Not Applicable","32","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","14F025|1R21AR063909","December 2014","November 24, 2016","May 24, 2017","December 4, 2014","June 19, 2018","June 19, 2018","Ohio Musculoskeletal and Neurological Institute (OMNI) at Ohio University, Athens, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02308189"
935,"NCT02305446","Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.",,"Completed","Has Results","Meningitis, Meningococcal, Serogroup B","Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine","Number of Subjects Reporting Unsolicited Adverse Events (AEs).","Novartis","All","18 Years to 50 Years   (Adult)","Phase 3","55","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","V72_74|2014-002972-95","December 2014","April 2015","April 2015","December 2, 2014","November 1, 2015","January 5, 2016","01, Novartis Investigational Site, Krakow, Poland",,"https://ClinicalTrials.gov/show/NCT02305446"
936,"NCT02305329","Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation",,"Completed","Has Results","Epilepsy","Drug: BIA 9-1067","Cmax - Maximum Observed Plasma Concentration of 9-1067|Tmax - Time of Occurrence of Cmax of 9-1067|AUC0-t - Area Under the Plasma Concentration-time Curve Calculated Between Time of Administration and Time t|AUC0-∞ - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity","Bial - Portela C S.A.","Male","18 Years to 45 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIA-91067-121","February 2014","April 2014","April 2014","December 2, 2014","August 21, 2015","August 21, 2015",,,"https://ClinicalTrials.gov/show/NCT02305329"
937,"NCT02305316","Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone",,"Completed","Has Results","Parkinson Disease","Drug: BIA 9-1067 non-micronized|Drug: BIA 9-1067 micronized","Cmax - Maximum Observed Plasma Concentration|AUC0-t - Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration|Tmax - Time of Occurrence of Cmax of BIA 9-1067|AUC0-inf - Area Under the Plasma Concentration-time Curve From Time 0 to the Infinity","Bial - Portela C S.A.","All","18 Years to 45 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIA-91067-120","February 2014","March 2014","March 2014","December 2, 2014","August 21, 2015","August 21, 2015",,,"https://ClinicalTrials.gov/show/NCT02305316"
938,"NCT02305017","Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers",,"Completed","Has Results","Parkinson's Disease","Drug: BIA 9-1067|Drug: Paracetamol","Cmax - Maximum Plasma Concentration|Tmax - Time of Occurrence of Cmax|AUC0-t - Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Sampling Time at Which the Drug Concentration Was at or Above the Lower Limit of Quantification|AUC0-∞ - Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity.","Bial - Portela C S.A.","All","18 Years to 45 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIA-91067-125","March 2014","April 2014","April 2014","December 2, 2014","November 18, 2015","November 18, 2015",,,"https://ClinicalTrials.gov/show/NCT02305017"
939,"NCT02304432","Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine","DCS","Completed","Has Results","Schizophrenia|Bipolar Disorder","Drug: D-cycloserine|Drug: DCS or placebo","Positive and Negative Symptom Scores|Brief Psychiatric Rating Scale (BPRS) Scores|Clinical Global Impression (CGI) Severity Scores|Mania Symptom Scores|Depression Symptom Scores|Neurocognitive Function|Brain Glycine/CR Ratio|Auditory Evoked Potentials in Latency (Msec)|Auditory Evoked Potentials in Amplitude (Degrees Measured in Microvolts)|Auditory Evoked Potentials in Gamma Oscillations (the Power Spectrum is Measured in Microvolts Squared)|Auditory Evoked Potentials - P50 Ratio (P50 S2/S1) (Amplitude)","Mclean Hospital|University of Minnesota","All","34 Years to 62 Years   (Adult)","Early Phase 1","2","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1R21MH105732","September 27, 2015","September 30, 2016","July 31, 2017","December 2, 2014","September 19, 2017","September 19, 2017",,"""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02304432/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02304432/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02304432/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02304432"
940,"NCT02303574","Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study",,"Completed","Has Results","Safety, Pharmacokinetics, Pharmacodynamics, Food Effect","Drug: AZD7986, oral solution, 1 to 50 mg/mL|Drug: Placebo, oral solution","Safety and Tolerability of AZD7986 by Assessment of the Number of Adverse Events (AEs) Following Administration of Oral Solution in Single Ascending Dose (SAD - Part 1a and 1b) and Multiple Ascending Doses (MAD -Part 2)|Rate and Extent of Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD|Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Analyte Concentration (AUC(0-last)) for Part 2 - MAD|Rate and Extent of Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD|Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 2 - MAD|Rate and Extent of Absorption of AZD7986 by Assessment of Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUCτ) for Part 2 - MAD|Rate and Extent of Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD|Rate and Extent of Absorption of AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 2 - MAD|Rate and Extent of Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD|Rate and Extent of Absorption of AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 2 - MAD|Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD|Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 2 - MAD|Rate and Extent of Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD|Rate and Extent of Absorption of AZD7986 by Assessment of Mean Residence Time (MRT) for Part 2 - MAD|Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD|Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 2 - MAD|Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD|Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 2 - MAD|Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for (Rac(AUC(0-τ)) for Part 2 - MAD|Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for Cmax (Rac(Cmax)) for Part 2 - MAD|Rate and Extent of Absorption of AZD7986 by Assessment of the Temporal Change Parameter (TCP) for Part 2 - MAD|Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD|Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD|Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Renal Clearance From 0 to 48 Hours (CLR0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD|Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24)) Parameters for Part 2 - MAD|Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24)) Parameter for Part 2 - MAD|Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 24 Hours (CLR0-24)) Parameter for Part 2 - MAD|Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Parameter for Part 2 - MAD|Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0 48)) Parameter for Part 2 - MAD|Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 48 Hours (CLR0-48)) Parameter for Part 2 - MAD|Effect of Food on Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD|Effect of Food on Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD|Effect of Food on Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD|Effect of Food on Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD|Effect of Food on Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD|Effect of Food on Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD|Effect of Food on Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD|Effect of Food on Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD|Assessment of Mean Normalized Relative Neutrophil Elastase (NE) Activity in All Cohorts of Part 2|Assessment of Absolute Neutrophil Count (ANC) in All Cohorts of Part 2","AstraZeneca","All","18 Years to 50 Years   (Adult)","Phase 1","89","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","D6190C00001|2014-004043-13","December 3, 2014","August 3, 2016","August 3, 2016","December 1, 2014","December 11, 2018","December 11, 2018","Research Site, Harrow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02303574"
941,"NCT02301897","A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids",,"Completed","Has Results","Uterine Fibroids","Drug: Telapristone Acetate|Drug: Placebo","Percentage of Participants in Amenorrhea at the End of Treatment Course 1|Percentage of Participants in Amenorrhea at the End of Treatment Course 2|Change in Pictorial Blood Loss Assessment Chart (PBAC) Score From Baseline to the End of Treatment Courses 1 and 2, ODI Course 1 and the Course 2 Week 28 Follow-up (FU) Visit|Percentage Change in PBAC Score From Baseline to the End of Treatment Courses 1 and 2, ODI Course 1 and the Course 2 Week 28 FU Visit|Percentage Change in Uterine Fibroid System Quality of Life Survey System Severity (UFS-SSS) Score From Baseline to the End of Treatment Courses 1 and 2, On-drug Course 2 and the Course 2 Week 24 FU Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 1 From Baseline to the End of Treatment Courses 1 and 2, On-drug Course 2 and the Course 2 Week 24 FU Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 2 From Baseline to the End of Treatment Courses 1 and 2, On-drug Course 2 and the Course 2 Week 24 FU Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 3 From Baseline to the End of Treatment Courses 1 and 2, On-drug Course 2 and the Course 2 Week 24 FU Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 4 From Baseline to the End of Treatment Courses 1 and 2, On-drug Course 2 and the Course 2 Week 24 FU Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 5 From Baseline to the End of Treatment Courses 1 and 2, On-drug Course 2 and the Course 2 Week 24 FU Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 6 From Baseline to the End of Treatment Courses 1 and 2, On-drug Course 2 and the Course 2 Week 24 FU Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 7 From Baseline to the End of Treatment Courses 1 and 2, On-drug Course 2 and the Course 2 Week 24 FU Visit|Percentage Change in the Individual UFS-SSS Subscale Score Question 8 From Baseline to the End of Treatment Courses 1 and 2, On-drug Course 2 and the Course 2 Week 24 FU Visit|Percentage Change in Total Uterine Fibroid Volume From Baseline to the End of Treatment Courses 1 and 2, On-drug Course 2 and the Course 2 Off-drug","Repros Therapeutics Inc.","Female","18 Years to 47 Years   (Adult)","Phase 2","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ZPU-203","March 16, 2015","June 2, 2017","June 2, 2017","November 26, 2014","June 19, 2019","June 19, 2019","Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States|Phoenix, Arizona, United States|MomDoc Women's Health Research, Scottsdale, Arizona, United States|KO Clinical Research, LLC, Fort Lauderdale, Florida, United States|South Florida Clinical Research Institute, Margate, Florida, United States|Atlanta Women's Research Institute, Inc., Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|WR-Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States|Southern Clinical Research Associates, LLC, Metairie, Louisiana, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|The Jackson Clinic, PA, Jackson, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|DCT-HCWC, LLC dba Discovery Clinical Trials, Dallas, Texas, United States|Advances in Health, Houston, Texas, United States|The Women's Hospital of Texas Clinical Research Center, Houston, Texas, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02301897/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02301897/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02301897"
942,"NCT02299869","Comparative Study to Evaluate the Cosmetic Appearance of Two Brands (Coopervision (CVI) vs. Competitor) of Color Soft Contact Lenses.",,"Completed","Has Results","Myopia","Device: Verde (Competitor-control)|Device: Green (CVI-test)|Device: Cinza (Competitor-control)|Device: Grey (CVI-test)|Device: Esmeralda (Competitor-control)|Device: Jade (CVI-test)|Device: Azul (Competitor-control)|Device: Blue (CVI-test)","Cosmetic Appearance Preference|Comfort|Comfort Preference","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","EX-MKTG-51","October 2014","October 2014","November 2014","November 24, 2014","August 24, 2016","March 10, 2017","Optometry Clinic, National Autonomous University, Mexico D.F., Mexico",,"https://ClinicalTrials.gov/show/NCT02299869"
943,"NCT02298179","A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults",,"Completed","Has Results","Respiratory Syncytial Virus (RSV)","Biological: RSV F subunit 45 μg No adjuvant|Biological: RSV F subunit 45 μg Aluminum hydroxide adjuvant|Biological: RSV F subunit 45 μg MF59 adjuvant|Biological: RSV F subunit 90 μg No adjuvant|Biological: RSV F subunit 90 μg Aluminum hydroxide adjuvant|Biological: RSV F subunit 90 μg MF59 adjuvant|Biological: RSV F subunit 135 μg No adjuvant|Biological: RSV F subunit 135 μg Aluminum hydroxide adjuvant|Biological: RSV F subunit 135 μg MF59 adjuvant|Drug: Placebo","Geometric Mean Titers (GMTs) of the Serum Anti-RSV Neutralizing Antibody (NAb) Titers|Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titers|Number of Subjects With Any Solicited Local Symptoms|Number of Subjects With Any Solicited Systemic Symptoms and Other Indicators of Reactogenicity|Number of Subjects With Unsolicited Adverse Events (AEs)|Number of Subjects With Serious Adverse Events (SAEs) and Other Significant AE(s)|Percentage of Subjects With a ≥ 4-fold Increase in Serum Anti-RSV NAb Titer|Percentage of Subjects With Serum Anti-RSV NAb Titers Greater Than the 3rd Quartile of Serum Anti-RSV NAb Titers at Day 1|Geometric Mean Titers (GMTs) of the Serum Total Binding Antibody to Each of the RSV Proteins F, G and N|Percentage of Subjects With a ≥ 4-fold Increase in Serum Total Binding Antibody to Each of the RSV Proteins F, G and N|Percentage of Subjects With Serum Total Binding Antibody Titers to Each of the RSV Proteins F, G, and N Greater Than the 3rd Quartile of Serum Total Binding Antibody Titers to RSV Protein F at Day 1|Ratio of RSV F Serum Nab Titers to Each of the RSV F Serum Total Binding Antibody Titers to RSV Proteins F, G and N","GlaxoSmithKline","All","18 Years to 45 Years   (Adult)","Phase 1","288","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","205219|2014-000145-69|V122_01","December 19, 2014","March 27, 2017","March 27, 2017","November 21, 2014","August 13, 2018","August 13, 2018","GSK Investigational Site, Ghent, Belgium","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02298179/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02298179/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02298179"
944,"NCT02297516","Safety and Efficacy of Azzalure/Dysport, Restylane/Emervel Filler and Restylane Skinbooster Treatment",,"Completed","Has Results","Aesthetics","Drug: Azzalure or Dysport|Device: Restylane or Emervel filler|Device: Restylane Skinbooster","Percentage of Subjects With Improvement in Global Facial Aesthetic Appearance|Number of Subjects Improved on the Global Aesthetic Improvement Scale (GAIS) as Assessed by Blinded Evaluator|Number of Participants Satisfied With Facial Appearance|Number of Participants for Which the Investigator is Satisfied With the Outcome|Percentage of Subjects Improved in Wrinkle Severity Score|Injected Volume of Study Products at Initial Single Treatment","Q-Med AB","All","35 Years to 50 Years   (Adult)","Phase 4","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05PDF1401","November 2014","March 2017","March 2017","November 21, 2014","September 30, 2019","September 30, 2019","Brazilian Center for Studies in Dermatology, Porto Alegre, Brazil|Mediti Center, Paris, Antibes, France|Centre Medical Saint-Jean, Arras, France|Akademikliniken, Stockholm, Sweden","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02297516/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02297516"
945,"NCT02297503","Safety and Efficacy of Treatment With Azzalure, Restylane/Emervel Filler and Restylane Skinbooster",,"Completed","Has Results","Facial Aesthetic Treatment","Drug: Azzalure|Device: Restylane/Emervel filler|Device: Restylane Skinbooster","Number of Subjects With Improvement in Global Facial Aesthetic Appearance at 7 Months (Review of Photographs)|Number of Subjects With Improvement in Global Facial Aesthetic Appearance at 1, 7 and 13 Months (Review of Photographs)|Number of Participants Improved on the Global Aesthetic Improvement Scale (GAIS) as Assessed by Blinded Evaluator|Number of Subjects Satisfied With Overall Facial Appearance (Questionnaire)|Number of Subjects for Which the Investigator is Satisfied With Overall Facial Aesthetic Outcome|Number of Participants Who Had Improvement in Wrinkle Severity Score of Treated Glabellar Lines (Validated Photo Scales)|Change in Perceived Age of Subjects|Injected Filler Volume|Adverse Event Reporting","Q-Med AB","All","35 Years to 50 Years   (Adult)","Phase 4","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05DF1211","November 2014","December 2016","December 2016","November 21, 2014","September 23, 2019","September 23, 2019","Mediti Center, Paris, Antibes, France|Centre Medical Saint-Jean, Arras, France|Akademikliniken, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT02297503"
946,"NCT02294773","Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit",,"Completed","Has Results","Infertility","Procedure: Intrauterine Insemination|Drug: Clomiphene|Drug: Letrozole","Number of Pregnancies Achieved Per Menstrual Cycle.","Midwest Fertility Specialists","Female","21 Years to 39 Years   (Adult)","Not Applicable","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","13-MIDW-101","October 2013","September 2015","September 2015","November 19, 2014","December 9, 2015","December 9, 2015","Midwest Fertility Specialists- Fort Wayne, Fort Wayne, Indiana, United States|Midwest Fertility Specialists, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02294773"
947,"NCT02292433","A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: PF-04937319 high dose|Drug: PF-04937319 low dose|Drug: Placebo","Number of Participants With Treatment Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|Number of Participants With Protocol Defined Hypoglycaemic Adverse Events (HAEs)|Maximum Observed Plasma Concentration (Cmax) on Day 1 for PF-04937319|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1 for PF-04937319|Area Under the Concentration-Time Curve (AUC24) From Time Zero to 24 Hour on Day 1 for PF-04937319|Maximum Observed Plasma Concentration (Cmax) on Day 7 for PF-04937319|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 7 for PF-04937319|Area Under the Concentration-Time Curve (AUC24) From Time Zero to 24 Hour on Day 7 for PF-04937319|Pre-dose Plasma Concentration (Ctrough) on Day 7 for PF-04937319|Average Plasma Concentration (Cav) on Day 7 for PF-04937319|Apparent Oral Clearance on Day 7 for PF-04937319|Terminal Half-Life (t1/2) on Day 7 for PF-04937319|Apparent Volume of Distribution on Day 7 for PF-04937319|Accumulation Ratio (Rac) on Day 7 for PF-04937319|Maximum Observed Plasma Concentration (Cmax) on Day 1 for PF-06455349|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1 for PF-06455349|Area Under the Concentration-Time Curve (AUC24) From Time Zero to 24 Hour on Day 1 for PF--06455349|Metabolite to Parent Ratio for AUC24 (MRAUC24) on Day 1|Maximum Observed Plasma Concentration (Cmax) on Day 7 for PF--06455349|Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 7 for PF-06455349|Area Under the Concentration-Time Curve (AUC24) From Time Zero to 24 Hour on Day 7 for PF--06455349|Pre-dose Plasma Concentration (Ctrough) on Day 7 for PF--06455349|Average Plasma Concentration (Cav) on Day 7 for PF--06455349|Terminal Half-Life (t1/2) on Day 7 for PF-06455349|Accumulation Ratio (Rac) on Day 7 for PF-06455349|Metabolite to Parent Ratio for AUC24 (MRAUC24) on Day 7|Change From Baseline in Weighted Mean Daily Glucose (WMDG) at Day 7|Change From Baseline in Fasting Plasma Glucose (FPG) at Last Day of Treatment|Change From Baseline in Pre-Meal Insulin at Day 7|Change From Baseline in Pre-Meal C-Peptide at Day 7","Pfizer","All","20 Years to 64 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","B1621018","January 2015","March 2015","March 2015","November 17, 2014","March 15, 2016","March 15, 2016","P-one Clinic, Keikokai Medical Corporation, Hachioji-shi, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02292433"
948,"NCT02290691","Inactivated Influenza Via Jet Injection","IIJI","Completed","Has Results","Influenza, Human","Biological: Influenza Vaccine","Anti Influenza Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT)|The Number of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titer.|Percentage of Subjects With Immediate Complaints|Percentage of Subjects With Solicited Local or Systemic Adverse Events|Percentage of Subjects With Spontaneously Reported Adverse Events","PharmaJet, Inc.","All","18 Years to 64 Years   (Adult)","Phase 4","985","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","PJ-501-14","November 2014","January 2015","January 2015","November 14, 2014","November 30, 2017","November 30, 2017","Optimal Research LLC, Huntsville, Alabama, United States|Optimal Research, LLC, San Diego, California, United States|Optimal Research, LLC, Melbourne, Florida, United States|Optimal Research, LLC, Peoria, Illinois, United States|Optimal Reserach, LLC, Mishawaka, Indiana, United States|Optimal Research, LLC, Rockville, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02290691"
949,"NCT02290509","Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age",,"Completed","Has Results","Influenza","Biological: Flublok Quadrivalent|Biological: Inactivated Influenza Vaccine (IIV4)","Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine|Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine|Number of Participants With Systemic and Injection Site Reactogenicity|Number of Participants With Serious Adverse Events (SAEs) and Medically-attended Adverse Events (MAEs)","Protein Sciences Corporation|Syneos Health|Department of Health and Human Services","All","18 Years to 49 Years   (Adult)","Phase 3","1350","Industry|Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PSC16","October 2014","May 2015","May 2015","November 14, 2014","September 22, 2016","October 27, 2016","Benchmark Research - Sacramento, Sacramento, California, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Meridian Clinical Research, Savannah, Georgia, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Benchmark Research, Metairie, Louisiana, United States|Meridian Research, Bellevue, Nebraska, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Meridian Research, Dakota Dunes, South Dakota, United States|Benchmark Reseach, Austin, Texas, United States|Benchmark Research - Fort Worth, Fort Worth, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02290509"
950,"NCT02288312","Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate",,"Completed","Has Results","Epilepsy","Drug: BIA 2-093","Cmax (BIA 2-005)|AUC0-t (BIA 2-005)|Tmax (BIA 2-005)|AUC0-∞ (BIA 2-005)","Bial - Portela C S.A.","All","18 Years to 55 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIA-2093-117","May 2007","July 2007","July 2007","November 11, 2014","January 8, 2015","January 8, 2015",,,"https://ClinicalTrials.gov/show/NCT02288312"
951,"NCT02287415","The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin",,"Completed","Has Results","Epilepsy","Drug: BIA 2-093|Drug: Warfarin","Cmax - Maximum Steady-state Plasma Concentration|Tmax - Time of Occurrence of Cmax|AUCτ - Steady-state Area Under the Plasma Concentration-time Profile Over 24 h, the Dosing Interval","Bial - Portela C S.A.","All","18 Years to 45 Years   (Adult)","Phase 1","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIA-2093-108","May 2002","July 2002","July 2002","November 10, 2014","December 1, 2014","December 1, 2014",,,"https://ClinicalTrials.gov/show/NCT02287415"
952,"NCT02287038","Atomoxetine in Veterans With Comorbid ADHD/PTSD",,"Completed","Has Results","Post Traumatic Stress Disorder|Attention Deficit Hyperactivity Disorder","Drug: Atomoxetine 80 MG","Conners' Adult ADHD Rating Scales-Self-Report: Short Version (CAARS-S:S, Conner et al, 1999)|The Adult ADHD Quality of Life-29 (AAQOL-29, Brod et al, 2006)","VA Office of Research and Development","All","20 Years to 60 Years   (Adult)","Phase 4","44","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1725-P|I01BX007080","October 15, 2014","March 2, 2017","April 14, 2017","November 10, 2014","April 3, 2019","April 3, 2019","Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02287038/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02287038"
953,"NCT02286518","TAK-114 Single- and Multiple-Dose Phase 1 Study",,"Completed","Has Results","Clinical Pharmacology","Drug: TAK-114 10 mg capsule|Drug: TAK-114 matched placebo","Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)|Number of Participants With TEAEs Related to Vital Signs|Number of Participants With TEAEs Related to Body Weight|Number of Participants With Clinically Meaningful Changes From Baseline in 12-lead Electrocardiograms (ECG)|Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis|Cmax - Maximum Observed Plasma Concentration for TAK-114|AUC (0-Infinity) - Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity for Unchanged TAK-114: Part 1 and Part 2|AUC (0-tau) - Area Under the Plasma Concentration-Time Curve From Time 0 to Time Tau for TAK-114: Part 3|Mean Terminal Phase Elimination Half-life (T1/2) for TAK-114|Mean R(Cmax): Mean Accumulation Coefficient of Observed Maximum Plasma Concentration for TAK-114: Part 3|Mean R(AUC): Mean of Accumulation Coefficient of Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-114: Part 3|Urinary Excretion Ratio of TAK-114 From 0 to 48 Hours Postdose: Part 1","Takeda","Male","20 Years to 45 Years   (Adult)","Phase 1","82","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-114/CPH-001|U1111-1162-6078|JapicCTI-142691","November 2014","April 2015","April 2015","November 7, 2014","July 25, 2016","July 25, 2016","Sumida-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02286518"
954,"NCT02285907","Protein Quality on Appetite Control, Reward-driven Eating, & Subsequent Food Intake",,"Completed","Has Results","Appetite and General Nutritional Disorders","Other: Macronutrient and Fiber Matched BEEF|Other: Macronutrient and Fiber Matched SOY|Other: Serving Size Matched BEEF|Other: Serving Size Matched SOY","Eating Initiation|Subsequent Food Intake|Net Incremental Area Under the Curve (niAUC) of Perceived Hunger and Fullness|Net Incremental Area Under the Curve (niAUC) of Plasma Total Glucagon-like Peptide (GLP-1) and Total Peptide YY (PYY)|Food Cue-stimulate fMRI Brain Scans|Plasma Amino Acids","University of Missouri-Columbia","All","18 Years to 30 Years   (Adult)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","UMissouri","May 2012","December 2013","March 2014","November 7, 2014","March 26, 2018","May 15, 2019","University of Missouri, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02285907"
955,"NCT02285270","Circadian Brown Adipose Tissue Metabolism",,"Completed","Has Results","Healthy","Device: FDG PET/CT","Change in Maximum Standardized Update Value (SUVmax) in Brown Adipose Tissue FDG Uptake in the Neck or Upper Chest on Evening and Imaging Compared to Morning Imaging|Correlation Between Cortisol Level and Brown Adipose Tissue FDG Uptake|Change in Total Brown Adipose Tissue FDG Uptake as Measured by Total Volume of Segmented Fat Times the Mean Standardized Uptake Value (SUVmean)","University of Pennsylvania","Male","18 Years to 45 Years   (Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","819607","March 2014","April 2015","April 2015","November 6, 2014","June 17, 2016","December 7, 2016","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02285270"
956,"NCT02284880","Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate",,"Completed","Has Results","Epilepsy","Drug: BIA 2-093","Cmax - Maximum Plasma Concentration|Tmax - Time of Occurrence of Cmax|AUC0-t - Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Sampling Time at Which Concentrations Were at or Above the Limit of Quantification","Bial - Portela C S.A.","All","18 Years to 55 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","BIA-2093-130","October 2010","November 2010","November 2010","November 6, 2014","January 12, 2015","January 12, 2015",,,"https://ClinicalTrials.gov/show/NCT02284880"
957,"NCT02284854","Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine",,"Completed","Has Results","Epilepsy","Drug: BIA 2-093|Drug: Carbamazepine","Cmax (BIA 2-093) - the Maximum Plasma Concentration|Cmax (CBZ) - the Maximum Plasma Concentration|Cmax (CBZE) - the Maximum Plasma Concentration|AUC0-t (BIA 2-093) - Area Under the Curve to Last Measurable Concentration for BIA 2-093|AUC0-t (CBZ) - Area Under the Curve to Last Measurable Concentration for CBZ|AUC0-t (CBZE) - Area Under the Curve to Last Measurable Concentration for CBZE","Bial - Portela C S.A.","All","18 Years to 45 Years   (Adult)","Phase 1","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIA-2093-129","July 2009","November 2009","November 2009","November 6, 2014","January 8, 2015","January 8, 2015",,,"https://ClinicalTrials.gov/show/NCT02284854"
958,"NCT02284828","Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function",,"Completed","Has Results","Epilepsy","Drug: BIA 2-093","Motor Reaction Time (MRT) (ms): Change From Baseline at Each Time Point During Acute Dosing Phase|Motor Reaction Time (MRT) (ms): Raw Values at Each Time Point During Acute Dosing Phase|Recognition Reaction Time (RRT) (ms): Change From Baseline at Each Time Point During Acute Dosing Phase|Recognition Reaction Time (RRT) (ms): Raw Values at Each Time Point During Acute Dosing Phase|Total Reaction Time (TRT) (ms): Raw Values at Each Time Point During Acute Dosing Phase|Total Reaction Time (TRT) (ms): Change From Baseline at Each Time Point During Acute Dosing Phase","Bial - Portela C S.A.","All","18 Years to 45 Years   (Adult)","Phase 1","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","BIA-2093-123","September 2007","November 2007","November 2007","November 6, 2014","December 10, 2014","December 10, 2014",,,"https://ClinicalTrials.gov/show/NCT02284828"
959,"NCT02284568","A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo","ARPEGGIO","Completed","Has Results","Primary Progressive Multiple Sclerosis","Drug: Placebo|Drug: Laquinimod","Percent Brain Volume Change (PBVC) From Baseline to Week 48 Using a Repeated Measures ANCOVA Model|Percent Brain Volume Change (PBVC) From Baseline to Weeks 24 and 48|Percentage of Participants With 12-Week Confirmed Disability Progression (CDP) As Measured by Expanded Disability Status Scale (EDSS) up to Week 48|Percentage of Participants With 12-Week Confirmed Disability Progression (CDP) As Measured by Expanded Disability Status Scale (EDSS) or the Timed 25-foot Walk (T25FW) Test up to Week 48|Change From Baseline for the Timed 25-foot Walk (T25FW) Score at Weeks 12, 24, 36 and 48|Number of New T2 Brain Lesions at Week 48|Participants With Treatment-Emergent Adverse Events (TEAEs)","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","All","25 Years to 55 Years   (Adult)","Phase 2","374","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TV5600-CNS-20006|2014-001579-30","January 12, 2015","May 4, 2017","October 1, 2017","November 6, 2014","November 2, 2018","November 2, 2018","Teva Investigational Site 12966, Phoenix, Arizona, United States|Teva Investigational Site 12967, Newport Beach, California, United States|Teva Investigational Site 12962, San Francisco, California, United States|Teva Investigational Site 12964, Aurora, Colorado, United States|Teva Investigational Site 12973, Northbrook, Illinois, United States|Teva Investigational Site 12975, Kansas City, Kansas, United States|Teva Investigational Site 12969, Lenexa, Kansas, United States|Teva Investigational Site 12977, Golden Valley, Minnesota, United States|Teva Investigational Site 13010, Golden Valley, Minnesota, United States|Teva Investigational Site 12965, Chesterfield, Missouri, United States|Teva Investigational Site 12968, Saint Louis, Missouri, United States|Teva Investigational Site 12963, New York, New York, United States|Teva Investigational Site 12971, Charlotte, North Carolina, United States|Teva Investigational Site 12976, Columbus, Ohio, United States|Teva Investigational Site 12970, Uniontown, Ohio, United States|Teva Investigational Site 11084, Halifax, Nova Scotia, Canada|Teva Investigational Site 11082, Montreal, Quebec, Canada|Teva Investigational Site 11089, Calgary, Canada|Teva Investigational Site 11081, Ottawa, Canada|Teva Investigational Site 11088, Quebec, Canada|Teva Investigational Site 11087, Toronto, Canada|Teva Investigational Site 32505, Bad Mergentheim, Germany|Teva Investigational Site 32512, Bamberg, Germany|Teva Investigational Site 32510, Berlin, Germany|Teva Investigational Site 32522, Bochum, Germany|Teva Investigational Site 32509, Dresden, Germany|Teva Investigational Site 32517, Dusseldorf, Germany|Teva Investigational Site 32543, Goettigen, Germany|Teva Investigational Site 32514, Hamburg, Germany|Teva Investigational Site 32507, Hannover, Germany|Teva Investigational Site 32513, Munchen, Germany|Teva Investigational Site 32504, Munchen, Germany|Teva Investigational Site 32516, Rostock, Germany|Teva Investigational Site 32523, Trier, Germany|Teva Investigational Site 32503, Ulm, Germany|Teva Investigational Site 32511, Wurzburg, Germany|Teva Investigational Site 30106, Cefalu, Italy|Teva Investigational Site 30110, Firenze, Italy|Teva Investigational Site 30105, Gallarate, Italy|Teva Investigational Site 30108, Genova, Italy|Teva Investigational Site 30102, Milano, Italy|Teva Investigational Site 30107, Orbassano, Italy|Teva Investigational Site 30103, Padova, Italy|Teva Investigational Site 30101, Rome, Italy|Teva Investigational Site 30104, Rome, Italy|Teva Investigational Site 38068, Amsterdam, Netherlands|Teva Investigational Site 38067, Nijmegen, Netherlands|Teva Investigational Site 38069, Sittard, Netherlands|Teva Investigational Site 53262, Bialystok, Poland|Teva Investigational Site 53250, Bydgoszcz, Poland|Teva Investigational Site 53253, Gdansk, Poland|Teva Investigational Site 53257, Katowice, Poland|Teva Investigational Site 53258, Katowice, Poland|Teva Investigational Site 53256, Katowice, Poland|Teva Investigational Site 53255, Kielce, Poland|Teva Investigational Site 53260, Lublin, Poland|Teva Investigational Site 53261, Olsztyn, Poland|Teva Investigational Site 53252, Warsaw, Poland|Teva Investigational Site 50285, Kaluga, Russian Federation|Teva Investigational Site 50288, Kazan, Russian Federation|Teva Investigational Site 50290, Kazan, Russian Federation|Teva Investigational Site 50294, Kirov, Russian Federation|Teva Investigational Site 50292, Krasnoyarsk, Russian Federation|Teva Investigational Site 50287, Moscow, Russian Federation|Teva Investigational Site 50291, Nizhny Novgorod, Russian Federation|Teva Investigational Site 50286, Novosibirsk, Russian Federation|Teva Investigational Site 50295, Perm, Russian Federation|Teva Investigational Site 50293, Saint Petersburg, Russian Federation|Teva Investigational Site 50289, St. Petersburg, Russian Federation|Teva Investigational Site 31108, Barcelona, Spain|Teva Investigational Site 31106, Barcelona, Spain|Teva Investigational Site 31105, El Palmar, Spain|Teva Investigational Site 31111, Lleida, Spain|Teva Investigational Site 31112, Madrid, Spain|Teva Investigational Site 31192, Madrid, Spain|Teva Investigational Site 31101, Malaga, Spain|Teva Investigational Site 31104, San Sebastian, Spain|Teva Investigational Site 31102, Sevilla, Spain|Teva Investigational Site 31100, Valencia, Spain|Teva Investigational Site 58158, Dnipropetrovsk, Ukraine|Teva Investigational Site 58159, Ivano-Frankivsk, Ukraine|Teva Investigational Site 58157, Kharkiv, Ukraine|Teva Investigational Site 58160, Kyiv, Ukraine|Teva Investigational Site 58152, Lutsk, Ukraine|Teva Investigational Site 58154, Lviv, Ukraine|Teva Investigational Site 58153, Lviv, Ukraine|Teva Investigational Site 58156, Zaporizhzhia, Ukraine|Teva Investigational Site 58150, Zaporizhzhya, Ukraine|Teva Investigational Site 58151, Zaporizhzhya, Ukraine|Teva Investigational Site 34190, Bristol, United Kingdom|Teva Investigational Site 34188, Edinburgh, United Kingdom|Teva Investigational Site 34189, Exeter, United Kingdom|Teva Investigational Site 34182, Liverpool, United Kingdom|Teva Investigational Site 34181, London, United Kingdom|Teva Investigational Site 34183, Nottingham, United Kingdom|Teva Investigational Site 34184, Oxford, United Kingdom|Teva Investigational Site 34186, Plymouth, United Kingdom|Teva Investigational Site 34185, Stoke-on-Trent, United Kingdom|Teva Investigational Site 34187, Swansea, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02284568/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02284568/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02284568"
960,"NCT02284009","Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus",,"Completed","Has Results","Diabetes Mellitus, Type 1","Biological: Albiglutide weekly injection|Biological: Placebo weekly injection|Biological: Insulin","Mean Change From Baseline in Time Normalized Stimulated (From Mixed Meal Tolerance Test [MMTT]) 2-hour Plasma C-peptide Area Under the Curve (AUC) at Week 52|Mean Change From Baseline in Time Normalized Stimulated (From MMTT) 2 Hour Plasma C-peptide AUC at Week 16, 28 and Week 64|Maximum Stimulated Plasma C-peptide (MMTT) at Baseline, Week 16, 28, 52 and 64|Mean Change From Baseline in Time Normalized Plasma Glucagon AUC (From MMTT) at Week 16, 28, 52 and 64|Percentage of Responders at Baseline, Weeks 4, 8, 16, 28, 40, 52 and 64|Percentage of Participants Achieving Partial Remission Status (Insulin Dose-adjusted Hemoglobin A1c (IDAA1C)<= 9.0) at Baseline, Week 4, 8, 16, 28, 40, 52 and 64|Change From Baseline in Percent HbA1c at Week 52|Percent HbA1c Over Time (at Weeks 4, 8, 16, 28, 40, 52 and 64)|Change From Baseline in Mean Daily Insulin Use at Week 4, 8, 16, 28, 40, 52 and 64|Number of Events of Participant-reported Significant Hypoglycemia, Occurring > Week 24 and <= Week 52|Time Spent With Plasma Glucose Level <= 3.9, > 3.9 to <= 10.0, and > 10.0 Measured by 72 Hour Continuous Glucose Monitoring (CGM) at Baseline, Week 28 and 52|Number of Hypoglycemic Excursions for Each Participant From 7-Point Glucose Profile at Baseline, Week 28 and 52|Greatest Magnitude of Hypoglycemic Excursions for Each Participant From 7-Point Glucose Profile at Baseline, Week 28 and 52|Number of Hyperglycemic Excursions for Each Participant From 7-Point Glucose Profile at Baseline, Week 28 and 52|Greatest Magnitude of Hyperglycemic Excursions for Each Participant From 7-Point Glucose Profile at Baseline, Week 28 and 52|Change From Baseline in Body Weight (Kilograms) at Week 52|Weight Over Time (at Weeks 2, 4, 6, 8, 16, 28, 40, 52 and 64)|Population Estimates of Pharmacokinetic (PK) Parameters: Apparent Clearance [CL/F]|Population Estimates of PK Parameters: Apparent Volume of Distribution [V/F]|Population Estimates of PK Parameters: First-order Absorption Rate Constant [Ka]","GlaxoSmithKline","All","18 Years to 30 Years   (Adult)","Phase 2","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","110933","October 10, 2014","October 18, 2017","October 18, 2017","November 5, 2014","March 25, 2019","March 25, 2019","GSK Investigational Site, Bois-Guillaume, France|GSK Investigational Site, Caen Cedex 9, France|GSK Investigational Site, Lille Cedex, France|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Latina, Lazio, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Roma, Italy|GSK Investigational Site, Alzira/Valencia, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Hospitalet de Llobregat, Spain|GSK Investigational Site, Lleida, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Málaga, Spain|GSK Investigational Site, Pama de Mallorca, Spain|GSK Investigational Site, San Juan (Alicante), Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Bristol, United Kingdom|GSK Investigational Site, Cardiff, United Kingdom|GSK Investigational Site, Darlington, United Kingdom|GSK Investigational Site, Dundee, United Kingdom|GSK Investigational Site, Durham, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Newcastle upon Tyne, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02284009/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02284009/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02284009"
961,"NCT02283840","Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation",,"Completed","Has Results","Epilepsy","Drug: BIA 2-093","Cmax BIA 2-005 - the Maximum Plasma Concentration of BIA 2-005|AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time|Tmax BIA 2-005 - Time of Maximum Plasma Concentration of BIA 2-005","Bial - Portela C S.A.","All","18 Years to 55 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","BIA-2093-122","May 2007","June 2007","June 2007","November 5, 2014","December 10, 2014","December 10, 2014",,,"https://ClinicalTrials.gov/show/NCT02283840"
962,"NCT02283827","Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.",,"Completed","Has Results","Epilepsy","Drug: BIA 2-093|Drug: Phenytoin","Cmax - the Maximum Plasma Concentration|AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time|Tmax - the Time of Occurrence of Cmax","Bial - Portela C S.A.","Male","18 Years to 45 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIA-2093-121","January 2007","March 2007","March 2007","November 5, 2014","December 18, 2014","December 18, 2014",,,"https://ClinicalTrials.gov/show/NCT02283827"
963,"NCT02283814","A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate",,"Completed","Has Results","Epilepsy","Drug: BIA 2-093|Drug: Topamax","Cmax - the Maximum Plasma Concentration|Tmax - the Time of Occurrence of Cmax|AUCτ - Cumulative Area Under the Plasma Concentration Time Curve Over the Dosing Interval at Steady State.","Bial - Portela C S.A.","Male","18 Years to 45 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIA-2093-120","January 2007","February 2007","February 2007","November 5, 2014","December 22, 2014","December 22, 2014",,,"https://ClinicalTrials.gov/show/NCT02283814"
964,"NCT02283788","Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization",,"Completed","Has Results","Epilepsy","Drug: BIA 2-093|Drug: Moxifloxacin|Drug: Placebo","QTcI - QT Interval Individually Corrected for Heart Rate - Day 5|QTcB - QT Interval Corrected for Heart Rate Using Bazett's Formula|QTcF - QT Interval Corrected Using Fridericia's Formula","Bial - Portela C S.A.","All","18 Years to 45 Years   (Adult)","Phase 1","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIA-2093-116","March 2007","June 2007","June 2007","November 5, 2014","December 22, 2014","December 22, 2014","Comprehensive Phase OneTM, Miramar, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02283788"
965,"NCT02281773","A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.",,"Completed","Has Results","Schizophrenia","Drug: BI 409306 100 mg QD|Drug: BI 498306 50 mg QD|Drug: Placebo|Drug: BI 498306 25 mg QD|Drug: BI 409306 10 mg QD","Change From Baseline in the Composite Score of Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) After 12 Weeks of Treatment|Occurrence of Serious Adverse Events (SAEs) (Including the Abnormalities of Physical Examination, Vital Signs, Electrocardiogram (ECG) Test and Laboratory Tests)|Occurrence of Protocol-specified Adverse Events of Special Interest (AESI)|Dramatic Worsening of Disease State as Assessed by Positive and Negative Syndrome Scale (PANSS)|Suicidality as Assessed by Columbia Suicidal Severity Rating Scale (C-SSRS)|Change From Baseline in Everyday Functional Capacity as Measured by Schizophrenia Cognition Rating Scale (SCoRS) Global Ratings After 12 Weeks of Treatment|Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Scale Score After 12 Weeks of Treatment|Patient Global Impressions-Improvement (PGI-I) Scale Score Measured After 12 Weeks of Treatment|Change From Baseline in PANSS Negative Symptom Factor Score After 12 Weeks of Treatment (for Subset of Patients Diagnosed With Negative Symptom)|Change in Psychopathology Symptoms as Assessed by Positive and Negative Syndrome Scale (PANSS)","Boehringer Ingelheim","All","18 Years to 55 Years   (Adult)","Phase 2","518","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1289.6|2013-005015-28","November 10, 2014","May 26, 2016","June 13, 2016","November 4, 2014","October 19, 2017","October 19, 2017","K and S Professional Research Services, LLC, Little Rock, Arkansas, United States|Comprehensive Clinical Development, Inc., Cerritos, California, United States|Collaborative Neuroscience Network, Garden Grove, California, United States|Pacific Institute of Medical Research, Los Angeles, California, United States|SRSD, Inc. dba Synergy San Diego, National City, California, United States|NRC Research Institute, Orange, California, United States|Artemis Institute for Clinical Research, LLC, San Diego, California, United States|Collaborative Neuroscience Network, Torrance, California, United States|Comprehensive Clinical Development, Washington, D.C., District of Columbia, United States|Innovative Clinical Research, Lauderhill, Florida, United States|Florida Clinical Research Center, Maitland, Florida, United States|Behavioral Clinical Research, Inc., North Miami, Florida, United States|Atlanta Center, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Uptown Research Institute, Chicago, Illinois, United States|Lake Charles Clinical Trials LLC, Lake Charles, Louisiana, United States|Mid-America Clinical Research, LLC, Saint Louis, Missouri, United States|St. Louis Clinical Trials, Saint Louis, Missouri, United States|Neurobehavioral Research, Inc., Cedarhurst, New York, United States|Finger Lakes Research, Rochester, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Community Clinical Research, Inc., Austin, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|Dr. Alexander McIntyre Inc., Penticton, British Columbia, Canada|Depression, Mood Disorders and Schizophrenia Treatment Centr, Burlington, Ontario, Canada|LVR-Klinikum Düsseldorf, Düsseldorf, Germany|Uniklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Köln (AöR), Köln, Germany|Fujita Health University Hospital, Aichi, Toyoake, Japan|Hokkaido University Hospital, Hokkaido, Sapporo, Japan|Kobe University Hospital, Hyogo, Kobe, Japan|Nara Medical University Hospital, Nara, Kashihara, Japan|Kansai Med. Univ. Med. Ctr., Osaka, Neuropsychiatry, Osaka, Moriguchi-city, Japan|Hizen Psychiatric Center, Saga, PSY, Saga, Kanzaki-gun, Japan|Iwaki Clinic, Tokushima, Psychosomatic Medicine, Tokushima, Anan, Japan|National Center Neurology and Psychiatry, Tokyo, Kodaira, Japan|Showa University Karasuyama Hospital, Tokyo, Setagaya, Japan|Showa University East Hospital, Tokyo, Shinagawa, Japan|Chang-Hua Christian Hospital, Changhua, Taiwan|Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan|NCKUH, Tainan, Taiwan|Taipei City Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02281773"
966,"NCT02281591","Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine",,"Completed","Has Results","Epilepsy","Drug: BIA 2-093|Drug: S-licarbazepine|Drug: R-licarbazepine","Cmax - the Maximum Plasma Concentration|Tmax - the Time of Occurrence of Cmax|AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity|AUC0-t - the Area Under the Plasma Concentration-time Curve to Last Measurable Time Point","Bial - Portela C S.A.","All","18 Years to 45 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIA-2093-115","June 2006","July 2006","July 2006","November 2, 2014","December 3, 2014","December 3, 2014","Scope International Life Sciences AG,, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT02281591"
967,"NCT02281448","Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.",,"Completed","Has Results","Epilepsy","Drug: BIA 2-093|Drug: Contraceptives, Oral, Combined","Cmax - Maximum Observed Plasma BIA 2-194 Concentration|Cmax|Tmax|AUC0-t","Bial - Portela C S.A.","All","18 Years to 40 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIA-2093-114","March 2005","May 2005","May 2005","November 2, 2014","December 3, 2014","December 3, 2014","BIAL - Portela & Cª, S.A., S. Mamede do Coronado, Portugal",,"https://ClinicalTrials.gov/show/NCT02281448"
968,"NCT02280421","Drug-Drug Interaction Study: ASP2151 and Ciclosporin",,"Completed","Has Results","Healthy","Drug: ASP2151 400mg + 100mg ciclosporin|Drug: ASP2151 1200mg + 100mg ciclosporin","Peak Plasma Concentration (Cmax) of ASP2151|Time of Peak Concentration (Tmax) of ASP2151|Area Under the Curve (AUC) of ASP2151|Half-Life (t1/2) of ASP2151|Apparent Total Body Clearance (CL/F) of ASP2151 From Plasma|Apparent Volume of Distribution (Vd/F) of ASP2151|Number of Participants With Serious and Non-Serious Adverse Events","Maruho Europe Limited","Male","18 Years to 45 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","M522101-EU21","October 2014","January 2015","January 2015","October 31, 2014","May 3, 2019","May 3, 2019","Hammersmith Medicines Research Ltd, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02280421"
969,"NCT02280096","Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis",,"Completed","Has Results","Multiple Sclerosis","Drug: 4-aminopyridine|Drug: Placebo","The Brief Repeatable Battery of Rao|Integrated Program of Neuropsychological Exploration Test Barcelona|Rey-Osterrieth Complex Figure Test (ROCF)|Five Digit Test (FDT). Processing Speed|Wisconsin Card Sorting Test (WCST)|Color Trails Test (CTT)|Tower Of London (TOL). Total Moves and Total Correct Moves|Tower Of London (TOL). Execution Time and Problem-solving Time|Improved Physical Capacity|Fatigue|Walk|Number of Participants With Abnormal Studies","Coordinación de Investigación en Salud, Mexico","All","18 Years to 60 Years   (Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012-785-091","October 2014","February 2016","February 2017","October 31, 2014","September 12, 2019","September 12, 2019","Hospital de Especialidades, CMN Siglo XXI, Mexico City, Distrito Federal, Mexico",,"https://ClinicalTrials.gov/show/NCT02280096"
970,"NCT02280044","Efficacy of Rifaximin in Preventing Campylobacteriosis",,"Completed","Has Results","Dysentery|Diarrhea|Enteric Campylobacteriosis","Biological: Rifaximin intervention|Biological: Placebo intervention","Campylobacteriosis","Johns Hopkins Bloomberg School of Public Health|Naval Medical Research Center|Uniformed Services University of the Health Sciences","All","18 Years to 50 Years   (Adult)","Phase 2|Phase 3","30","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CIR296","October 2014","August 9, 2016","August 9, 2016","October 31, 2014","November 20, 2018","November 20, 2018","Center for Immunization Research, Johns Hopkins Bloomberg School of Public Heatlh, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02280044"
971,"NCT02279667","Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093",,"Completed","Has Results","Epilepsy","Drug: BIA 2-093","Cmax - the Maximum Plasma Concentration|Tmax - the Time of Occurrence of Cmax|AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time|AUC0-∞ - the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity","Bial - Portela C S.A.","All","18 Years to 45 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIA-2093-109","February 2004","March 2004","March 2004","October 31, 2014","January 1, 2015","January 1, 2015","CEB - Centre for Bioavailability Studies, AIBILI, Azinhaga de Santa Comba - Celas, Coimbra, Portugal",,"https://ClinicalTrials.gov/show/NCT02279667"
972,"NCT02279420","ESSENTIAL Trial™ Sham Cross-over",,"Completed","Has Results","Obesity","Device: g-Cath EZ™ Suture Anchor Delivery Catheter","Mean Percent Total Body Weight Loss","USGI Medical","All","23 Years to 61 Years   (Adult)","Not Applicable","73","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TPR 50402","January 5, 2015","August 31, 2016","September 30, 2016","October 31, 2014","May 12, 2017","May 12, 2017","Shea Campus -Scottsdale Healthcare, Scottsdale, Arizona, United States|University of Miami Hospital, Miami, Florida, United States|Hamilton Medical Center, Dalton, Georgia, United States|Northshore/Evanston Hospital, Evanston, Illinois, United States|Crescent City Surgical, Metairie, Louisiana, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Fairview UMMC-University, Minneapolis, Minnesota, United States|Saint Luke's Hospital, Kansas City, Missouri, United States|WA University School of Medicine, St. Louis, Missouri, United States|Lexington Medical Center, West Columbia, South Carolina, United States|Baptist Memorial Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02279420"
973,"NCT02279043","Online Peer Influence on IUD Behaviors and Attitudes",,"Completed","Has Results","Contraception","Behavioral: Interaction with users of IUC and non-IUC users|Behavioral: Interaction with non-IUC users only","Number of Participants Reporting IUC Use|Mean Change in Attitude About Hormonal IUC as Method for Self Between Pre-survey and Post-survey|Mean Change in Attitude About Hormonal IUC as Method for Women in General Between Pre-survey and Post-survey|Mean Change in Attitude About Non-hormonal IUC as Method for Self Between Pre-survey and Post-survey|Mean Change in Attitude About Non-hormonal IUC as Method for Women in General Between Pre-survey and Post-survey|Number of Participants With Responses Indicating Knowledge of IUC Safety|Number of Participants With Responses Indicating Knowledge of IUC Effectiveness|Number of Participants With Responses Indicating Knowledge of IUC Being More Effective Than Birth Control Pill|Number of Participants Reporting Informational Support (Receiving New Information From Birth Control Connect)|Number of Participants Reporting Informational Support (Better Idea of What IUC Would be Like)|Number of Participants Reporting Information-seeking on Internet|Number of Participants Reporting Information-seeking From a Health Care Provider|Number of Participants Reporting Information-seeking From Peers","University of California, San Francisco|William and Flora Hewlett Foundation|University of Pennsylvania","Female","18 Years to 45 Years   (Adult)","Not Applicable","630","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","2014-9716|820383|14-14827","October 2015","July 2016","July 2016","October 30, 2014","March 11, 2019","March 19, 2019","University of Pennsylvania, Annenberg School of Communication, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02279043"
974,"NCT02278120","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","MONALEESA-7","Active, not recruiting","Has Results","Advanced Metastatic Breast Cancer","Drug: LEE011|Drug: Tamoxifen|Drug: Letrozole|Drug: Anastrozole|Drug: Goserelin|Drug: LEE011 Placebo","Progression Free Survival (PFS) Per Investigator's Assessment|Overall Survival (OS)|Overall Response Rate (ORR) Per Local Assessment|Clinical Benefit Rate (CBR)|Safety and Tolerability of LEE011|Time to Response (TTR) Per Local Investigator's Assessment|Duration of Response (DOR) Per Investigator's Assessment - Patients With Confirmed Complete Response (CR) or Partial Response (PR)|Time to Definitive Deterioration of the ECOG PS From Baseline|Time to 10% Deterioration in the Global Health Status/QOL Scale Score of the EORTC QLQ-C30|Change From Baseline in the Global Health Status/QOL Scale Score of the EORTC QLQ-C30","Novartis Pharmaceuticals|Novartis","Female","18 Years to 59 Years   (Adult)","Phase 3","672","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLEE011E2301|2014-001931-36","November 20, 2014","August 21, 2017","December 21, 2020","October 29, 2014","February 26, 2019","January 15, 2020","Comprehensive Blood and Cancer Center SC-2, Bakersfield, California, United States|City of Hope National Medical Center SC-5, Duarte, California, United States|University of California San Diego - Moores Cancer Center Onc Dep, La Jolla, California, United States|University of California at Los Angeles Dept of Onc, Los Angeles, California, United States|Stanford University Medical Center SC, Palo Alto, California, United States|Sansum Clinic SC, Santa Barbara, California, United States|Comprehensive Cancer Center at Saint Joseph Hospital SC, Denver, Colorado, United States|Danbury Hospital SC, Danbury, Connecticut, United States|Florida Cancer Specialists Onc Dept, Fort Myers, Florida, United States|Florida Cancer Specialists SC-2, Fort Myers, Florida, United States|Memorial Cancer Institute SC, Hollywood, Florida, United States|University of Miami Univ Miami 2, Miami, Florida, United States|Sacred Heart Medical Oncology SC, Pensacola, Florida, United States|NorthWest Georgia Oncology Centers NW Georgia Oncology, Marietta, Georgia, United States|Moanalua Medical Center. Attn: Oncology Dept SC, Honolulu, Hawaii, United States|University of Chicago SC-3, Chicago, Illinois, United States|University of Kansas Hospital and Medical Center Medical Pavilion, Kansas City, Kansas, United States|Norton Cancer Institute SC, Louisville, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Med Dept of Onc., Baltimore, Maryland, United States|Massachusetts General Hospital Onc Dept, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center Onc Dept, Ann Arbor, Michigan, United States|Washington University School of Medicine SC, Saint Louis, Missouri, United States|Meridian Health Systems SC, Neptune, New Jersey, United States|University of New Mexico Hospital SC-2, Albuquerque, New Mexico, United States|Clinical Research Alliance, Lake Success, New York, United States|Duke University Medical Center Duke (SC), Durham, North Carolina, United States|Penn State University Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Bon Secours Cancer Center SC, Greenville, South Carolina, United States|Erlanger Medical Center SC, Chattanooga, Tennessee, United States|Tennessee Oncology Tennessee Oncology (3), Nashville, Tennessee, United States|The Center for Cancer and Blood Disorders SC, Fort Worth, Texas, United States|Methodist Hospital / Methodist Cancer Center Dept of Oncology, Houston, Texas, United States|University of Texas MD Anderson Cancer Center SC-5, Houston, Texas, United States|Millennium Oncology SC, Houston, Texas, United States|Cancer Therapy and Research Center UT Health Science Center SC-4, San Antonio, Texas, United States|Brooke Army Medical Center SC, San Antonio, Texas, United States|Northern Utah Cancer Associates, Ogden, Utah, United States|Bon Secours Virginia Health System, Midlothian, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Kadlec Clinic Hematology and Oncology Kadlec Clinic Hematology & Onc, Kennewick, Washington, United States|Northwest Medical Specialties Dept of Onc, Tacoma, Washington, United States|University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 3, Madison, Wisconsin, United States|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Jujuy, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Waratah, New South Wales, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Murdoch, Western Australia, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Londrina, PR, Brazil|Novartis Investigative Site, Ljui, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Passo Fundo, RS, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montréal, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Strasbourg Cedex, Cedex, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Muehlhausen, Thueringen, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Esslingen, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Offenbach, Germany|Novartis Investigative Site, Ravensburg, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Heraklion Crete, Greece|Novartis Investigative Site, Patras, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Kolkatta, West Bengal, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, L'Aquila, AQ, Italy|Novartis Investigative Site, Benevento, BN, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Cremona, CR, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Lecce, LE, Italy|Novartis Investigative Site, Lucca, LU, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Macerata, MC, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Prato, PO, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Terni, TR, Italy|Novartis Investigative Site, Udine, UD, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, El Chouf, LBN, Lebanon|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Johor Bahru, Johor, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Torreón, Coahuila, Mexico|Novartis Investigative Site, Mexico D.F, D.f., Mexico|Novartis Investigative Site, Mexico D F, Distrito Federal, Mexico|Novartis Investigative Site, Metepec, Edo. De México, Mexico|Novartis Investigative Site, Leon, Guanajuato, Mexico|Novartis Investigative Site, Monterrey Nuevo Leon, Monterrey, Mexico|Novartis Investigative Site, Cancun, Quintana Roo, Mexico|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Konin, Poland|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Jeddah, Saudi Arabia|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Elche, Alicante, Spain|Novartis Investigative Site, Almeria, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Sant Joan Despi, Barcelona, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Manresa, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Alcorcon, Madrid, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Baracaldo, Vizcaya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Geneve, Switzerland|Novartis Investigative Site, New Taipei City, TWN, Taiwan|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Diyarbakir, Turkey|Novartis Investigative Site, Edirne, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Al Ain Abu Dhabi, United Arab Emirates","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02278120/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02278120/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02278120"
975,"NCT02276274","Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects",,"Completed","Has Results","Clinical Pharmacology","Drug: SYR-322-MET","AUC (0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Postdose for Unchanged SYR-322 (SYR-322Z)|AUC (0-tlqc): Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for SYR-322Z|Cmax: Maximum Observed Plasma Concentration for SYR-322Z|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for SYR-322Z|AUC (0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for SYR-322Z|Apparent Terminal Elimination Rate Constant (λz) for SYR-322Z|Terminal Phase Elimination Half-life (T1/2) for SYR-322Z|Apparent Clearance After Extra Vascular Administration (CL/F) for SYR-322Z|Mean Residence Time (MRT) for SYR-322Z|MRT (0-tlqc): Mean Residence Time From Time 0 to Time of the Last Quantifiable Concentration (Tlqc) for SYR-322Z|AUC (0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Post Dose for SYR-322 Metabolites M-I and M-II|AUC (0-tlqc): Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for SYR-322 Metabolites M-I and M-II|MRT (0-tlqc): Mean Residence Time From Time 0 to Time of the Last Quantifiable Concentration (Tlqc) for SYR-322 Metabolites M-I and M-II|Cmax: Maximum Observed Plasma Concentration for SYR-322 Metabolites M-I and M-II|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for SYR-322 Metabolites M-I and M-II|AUC (0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for SYR-322 Metabolites M-I and M-II|Apparent Terminal Elimination Rate Constant (λz) for SYR-322 Metabolites M-I and M-II|Terminal Phase Elimination Half-life (T1/2) for SYR-322 Metabolites M-I and M-II|Mean Residence Time (MRT) for SYR-322 Metabolites M-I and M-II|AUC (0-48): Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours Postdose for Metformin|AUC (0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Metformin|MRT (0-tlqc): Mean Residence Time From Time 0 to Time of the Last Quantifiable Concentration (Tlqc) for Metformin|Cmax: Maximum Observed Plasma Concentration for Metformin|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Metformin|AUC (0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Metformin|Apparent Terminal Elimination Rate Constant (λz) for Metformin|Terminal Phase Elimination Half-life (T1/2) for Metformin|Apparent Clearance After Extra Vascular Administration (CL/F) for Metformin|Mean Residence Time (MRT) for Metformin|Urinary Excretion Ratio of SYR-322Z From 0 to 12 Hours Postdose|Urinary Excretion Ratio of SYR-322Z From 0 to 24 Hours Postdose|Urinary Excretion Ratio of SYR-322Z From 0 to 48 Hours Postdose|Urinary Excretion Ratio of SYR-322Z From 0 to 72 Hours Postdose|Urinary Excretion Ratio of SYR-322 Metabolites M-I and M-II From 0 to 12 Hours Postdose|Urinary Excretion Ratio of SYR-322 Metabolites M-I and M-II From 0 to 24 Hours Postdose|Urinary Excretion Ratio of SYR-322 Metabolites M-I and M-II From 0 to 48 Hours Postdose|Urinary Excretion Ratio of SYR-322 Metabolites M-I and M-II From 0 to 72 Hours Postdose|Urinary Excretion Ratio of Metformin From Time 0 to 12 Hours Postdose|Urinary Excretion Ratio of Metformin From 0 to 24 Hours Postdose|Urinary Excretion Ratio of Metformin From 0 to 48 Hours Postdose|CLr: Renal Clearance of SYR-322Z|CLr: Renal Clearance of Metformin|Inhibition Rate of Dipeptidyl-peptidase-4 (DPP-4) Activity|DPP-4 Activity|AUC (0-24): Area Under the Inhibition Rate of Plasma DPP-4 Activity-time Curve From Time 0 to 24 Hours|Emax: Maximum Inhibition Rate of Plasma DPP-4 Activity|Tmax: Time to Reach Emax|Number of Participants Reporting 1 or More Treatment-emergent Adverse Events|Number of Participants With Clinically Significant Change From Baseline in Vital Signs|Number of Participants With Clinically Significant Change From Baseline in Body Weight|Number of Participants With Significant Change From Baseline in Electrocardiograms|Number of Participants With Laboratory-related Treatment Emergent Adverse Events (TEAEs)","Takeda","Male","20 Years to 35 Years   (Adult)","Phase 3","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SYR-322-MET/CPH-002|U1111-1157-8500|JapicCTI-142584","June 2014","June 2014","June 2014","October 28, 2014","June 29, 2015","June 29, 2015","Fukuoka-shi, Fukuoka, Japan",,"https://ClinicalTrials.gov/show/NCT02276274"
976,"NCT02275546","Performance and Safety of Vaginal Ring Applicator in Healthy Females (MK-8342A-063)",,"Completed","Has Results","Contraception: Optional Applicator for Insertion of Vaginal Ring","Drug: Placebo vaginal ring|Device: Single-use, non-sterile applicator","Percentage of Participants With Successful Ring Insertion|Percentage of Participants With Vaginal Ring Expulsion Within 48 Hours of Insertion","Merck Sharp & Dohme Corp.","Female","18 Years to 45 Years   (Adult)","Phase 3","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8342A-063","December 11, 2014","April 10, 2015","April 10, 2015","October 27, 2014","April 28, 2016","August 31, 2018",,,"https://ClinicalTrials.gov/show/NCT02275546"
977,"NCT02271984","Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers",,"Completed","Has Results","Healthy","Drug: MSC2499550A|Drug: Cysticide","Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-inf) Adj of L-Praziquantel (L-PZQ) After Dose Adjustment|Time to Reach the Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ)|Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ)|Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of L-Praziquantel (L-PZQ) After Dose Adjustment|Extrapolated Area Under the Concentration Time Curve (AUC) From Time Tlast to Infinity Given as Percentage From AUC0-inf (AUCextra) of L-Praziquantel (L-PZQ)|Maximum Observed Concentration in Plasma (Cmax) of L-Praziquantel (L-PZQ) After Dose Adjustment|Apparent Terminal Half-life (T1/2) of L-Praziquantel (L-PZQ)|Relative Bioavailability (Frel) of L-Praziquantel (L-PZQ)|Apparent Terminal Elimination Rate Constant (Lambda Z) of L-Praziquantel (L-PZQ)|Apparent Total Body Clearance of Drug From Plasma (CL/f) of L-Praziquantel (L-PZQ)|Apparent Volume of Distribution During the Terminal Phase (Vz/f) of L-Praziquantel (L-PZQ)|Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Discontinuation|Palatability Score|Number of Subjects With Clinical Significant Laboratory Abnormalities, Electrocardiogram (ECG), Physical Examination and Vital Signs Reported as Treatment Emergent Adverse Events","Merck KGaA, Darmstadt, Germany","Male","18 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200661-001","October 31, 2014","December 31, 2014","December 31, 2014","October 22, 2014","January 3, 2018","January 3, 2018","Please contact the Merck KGaA Communication Center, Darmstadt, Germany",,"https://ClinicalTrials.gov/show/NCT02271984"
978,"NCT02271854","A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness",,"Completed","Has Results","Muscle Soreness","Drug: Diclofenac sodium gel 1%|Drug: Placebo","Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW.|Sum of Pain Intensity Differences Over 48 Hours After Initiating Treatment (SPID 48), Derived From POW.","Novartis","All","18 Years to 35 Years   (Adult)","Phase 3","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","197-P-323","October 2014","December 2014","December 2014","October 22, 2014","April 5, 2016","April 5, 2016","Lotus Clinical Research, 100 W California Blvd,, Pasadena,, California, United States",,"https://ClinicalTrials.gov/show/NCT02271854"
979,"NCT02270944","Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine",,"Completed","Has Results","Infections, Streptococcal|Streptococcal Infections","Biological: GBS Vaccine","Concentration of Serotype Ia GBS IgG Levels in Healthy Non-pregnant Women|Concentration of Serotype III GBS IgG Levels in Healthy Non-pregnant Women|Concentration of Serotype Ib GBS IgG Levels in Healthy Non-pregnant Women|Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)|Number of Subjects Reporting Any Unsolicited AEs|Number of Subjects Reporting Any Serious Adverse Events (SAEs)","GlaxoSmithKline|Novartis Vaccines","Female","18 Years to 40 Years   (Adult)","Phase 2","1053","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","205220|V98_21|2013-003111-22","November 20, 2014","April 23, 2015","September 22, 2015","October 22, 2014","July 28, 2017","December 5, 2019","GSK Investigational Site, Redding, California, United States|GSK Investigational Site, Lenexa, Kansas, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Stevensville, Michigan, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Antwerp, Belgium|GSK Investigational Site, Ghent, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Hradec Kralove, Czechia",,"https://ClinicalTrials.gov/show/NCT02270944"
980,"NCT02269423","Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)",,"Completed","Has Results","Ebola Virus","Biological: V920|Other: Placebo","Number of Participants With One or More Solicited Local Treatment-Emergent Adverse Events (TEAE)|Number of Participants With One or More Solicited Local Treatment-Emergent Adverse Events (TEAE) by Severity|Number of Participants With One or More Solicited Systemic Treatment-Emergent Adverse Events (TEAE)|Number of Participants With One or More Solicited Systemic Treatment-Emergent Adverse Events (TEAE) by Severity|Number of Participants With One or More Unsolicited Treatment-Emergent Adverse Events (TEAE)|Number of Participants With One or More Vaccination-Related Unsolicited Treatment-Emergent Adverse Events (TEAE)|Number of Participants With One or More Vaccination-Related Unsolicited Treatment-Emergent Adverse Events (TEAE) by Severity|Number of Participants With Early Study Discontinuation Due to an Adverse Event|Number of Participants With One or More Serious Adverse Event|Geometric Mean Titers of ZEBOV Envelope Glycoprotein-specific Binding Antibodies|Geometric Mean Titers of ZEBOV-specific Neutralizing Antibodies|Number of Participants With Vaccine Viremia|Number of Participants With Vaccine Shedding/Excretion in Saliva or Urine|Mean Copy Number of Vector RNA (Vector Viremia)","Merck Sharp & Dohme Corp.|BioProtection Systems Corporation|United States Department of Defense","All","18 Years to 50 Years   (Adult)","Phase 1","39","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","V920-001|NLG0307 (WRAIR #2163)","October 13, 2014","August 25, 2015","August 25, 2015","October 21, 2014","October 23, 2019","October 23, 2019",,,"https://ClinicalTrials.gov/show/NCT02269423"
981,"NCT02268955","Analgesic Efficacy of Intravenous Ibuprofen in Biliary Colic",,"Completed","Has Results","Biliary Colic","Drug: IV Ibuprofen|Drug: Saline","Pain Score 120 Minutes After Study Medication Administration","Maricopa Integrated Health System","All","18 Years to 55 Years   (Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2014-067","September 9, 2014","June 21, 2017","June 28, 2017","October 20, 2014","May 14, 2019","May 14, 2019","Maricopa Integrated Health System, Phoenix, Arizona, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02268955/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02268955"
982,"NCT02268877","A Randomized Prospective Analysis of Time to Diagnosis and Length of Stay of Emergency Department Pelvic Ultrasonography",,"Completed","Has Results","Pregnancy","Other: Emergency Medicine Physician Ultrasound|Device: Ultrasound","Time to Definitive Diagnosis|Emergency Department Length-of-Stay","Denver Health and Hospital Authority|United States Naval Medical Center, Portsmouth|United States Naval Medical Center, San Diego|University of Colorado, Denver","Female","18 Years to 55 Years   (Adult)","Not Applicable","224","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","11-1444","March 2013","March 2016","March 2016","October 20, 2014","May 31, 2017","June 27, 2017",,,"https://ClinicalTrials.gov/show/NCT02268877"
983,"NCT02267629","Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder",,"Completed","Has Results","Obsessive-Compulsive Disorder (OCD)","Drug: Rapastinel (formerly GLYX-13)","Scores Change in Yale-Brown Obsessive Compulsive Challenge Scale (YBOCCS) Scores From Baseline to 230 Minutes Postinfusion.|Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale.","New York State Psychiatric Institute","All","18 Years to 55 Years   (Adult)","Phase 2","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#6986","October 2014","February 2016","February 2016","October 17, 2014","May 10, 2017","July 18, 2017","New York State Psychiatric Insitute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02267629"
984,"NCT02266472","Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female",,"Completed","Has Results","Healthy","Drug: metformin|Drug: empagliflozin/metformin|Drug: empagliflozin","AUC0-tz of Empagliflozin in Plasma|AUC0-tz of Metformin in Plasma|Cmax of Empagliflozin in Plasma|Cmax of Metformin in Plasma|AUC0-infinity of Empagliflozin in Plasma|AUC0-infinity of Metformin in Plasma","Boehringer Ingelheim|Eli Lilly and Company","All","18 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1276.28|2014-002360-32","November 2014","December 2014","December 2014","October 17, 2014","March 9, 2017","March 9, 2017","Boehringer Ingelheim Investigational Site, Ingelheim, Germany",,"https://ClinicalTrials.gov/show/NCT02266472"
985,"NCT02265783","Sensor Off Study Using a Nellcor USB Pulse Oximetry Monitor Interface Cable",,"Completed","Has Results","Healthy Volunteers","Device: Nellcor USB Pulse Oximeter Monitor Interface Cable","Report the Time Until the Device Posts ""Sensor Off"" After the Sensor is Removed","Medtronic - MITG","All","18 Years to 50 Years   (Adult)","Not Applicable","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","COVMOPR0461","September 2014","November 2014","November 2014","October 16, 2014","May 1, 2017","May 1, 2017","Boulder Clinical Laboratory, Boulder, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02265783"
986,"NCT02263547","Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride","TERCOL","Terminated","Has Results","Teriflunomide Elimination|Healthy Volunteers","Drug: teriflunomide|Drug: Colestipol","Primary Outcome Measures: Teriflunomide Concentrations at Day 28|Secondary Outcome Measure: Mean Percentage Change of Serum Teriflunomide Levels Percentage Change of Teriflunomide Concentrations at Day 8, Day 14, Day 26 ad Day 36 Following Administration of Colestipol Hydrochloride Tablets.","Derrick Scott Robertson|Genzyme, a Sanofi Company|University of South Florida","All","18 Years to 45 Years   (Adult)","Phase 1","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","GZ-2013-11023","March 2015","June 2016","June 2016","October 13, 2014","July 1, 2019","September 19, 2019","USF Carol and Frank Morsani Center for Advanced Healthcare, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02263547"
987,"NCT02263040","A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV",,"Completed","Has Results","Influenza","Biological: Fluzone High-Dose|Biological: Fluzone (standard dose)","Number of Participants With Seroconversion to A/California/07/2009 (H1N1)|Number of Participants With Seroconversion to A/Texas/50/2012 (H3N2)|Number of Participants With Seroconversion to Influenza B/Phuket/3073/2013|Number of Participants With Seroconversion to A/Switzerland/9715293/2013 (H3N2)|Number of Participants With Seroconversion to B/Massachusetts/02/2012|Geometric Mean Fold Ratio (GMFR) Against A/California/07/2009 (H1N1)|Geometric Mean Fold Ratio (GMFR): A/Switzerland/9715293/2013|Geometric Mean Fold Ratio (GMFR): A/Texas/50/2012|Geometric Mean Fold Ratio (GMFR): B/Phuket/3073/2013 Ether-treated|Geometric Mean Fold Ratio (GMFR): B/Massachusetts/02/2012 Ether-treated|Number of Participants Reporting Adverse Event: Injection Site|Number of Participants Reporting Adverse Event: Systemic","Mount Sinai Hospital, Canada","All","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","14-0909","October 2014","July 2016","December 31, 2016","October 13, 2014","January 28, 2019","January 28, 2019","Mount Sinai Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02263040"
988,"NCT02259608","γ-irradiated BCG to Train Innate Immunity",,"Completed","Has Results","Innate Immune Response","Biological: BCG vaccine SSI","Cytokine Production Measured by ELISA Compared to Baseline","Radboud University","All","18 Years to 55 Years   (Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","NL45427.091.13|2013/319","November 2013","March 2014","April 2014","October 8, 2014","June 29, 2016","June 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02259608"
989,"NCT02257918","Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea",,"Completed","Has Results","Gonorrhoea","Drug: AZD0914|Drug: Ceftriaxone","Number of Participants With Microbiological Cure at Urethral or Cervical Sites in Each Study Arm|Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) Considered Product-related.|Number of Participants With Microbiological Cure at Rectal Sites in Each Study Arm|Number of Participants With Microbiological Cure at Pharyngeal Sites in Each Study Arm|Number of Participants With Clinical Cure in Each Study Arm|Number of Participants With no Detectable N. Gonorrhoeae Nucleic Acid in Urethral/Cervical Specimens in Each Study Arm at Baseline.|Number of Participants With no Detectable N. Gonorrhoeae Nucleic Acid in Urethral/Cervical Specimens in Each Study Arm at Day 6.|Number of Participants With no Detectable N. Gonorrhoeae Nucleic Acid in Rectal Specimens in Each Study Arm|Number of Participants With no Detectable N. Gonorrhoeae Nucleic Acid in Pharyngeal Specimens in Each Study Arm|Median in Vitro Minimum Inhibitory Concentrations (MIC) Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Urethral/Cervical Sites at Baseline|Median in Vitro MIC Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Urethral/Cervical Sites at Day 6|Median in Vitro MIC Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Rectal Site at Baseline|Median in Vitro MIC Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Rectal Site at Day 6|Median in Vitro MIC Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Pharyngeal Site at Baseline|Median in Vitro MIC Against AZD0914/ETX0914 and Ceftriaxone of Gonococcal Isolates From Culture of Isolates From the Pharyngeal Site at Day 6","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 55 Years   (Adult)","Phase 2","180","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","14-0014|HHSN272201300012I","November 25, 2014","December 30, 2015","December 30, 2015","October 7, 2014","February 8, 2017","March 22, 2017","Jefferson County Department of Health - STD Clinic, Birmingham, Alabama, United States|Indiana University - Bell Flower Clinic, Indianapolis, Indiana, United States|CrescentCare Health and Wellness Center, New Orleans, Louisiana, United States|Durham County Health Department, Durham, North Carolina, United States|Public Health STD Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02257918"
990,"NCT02256488","Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects",,"Completed","Has Results","Prophylaxis: Influenza","Biological: TIVc_LOT A|Biological: TIVc_LOT B|Biological: TIVc_LOT C|Biological: TIVf","Immunologic Equivalence of 3 Consecutive Influenza Vaccine (TIVc) Production Lots.|Percentages of Subjects Who Achieved HI Seroconversion and HI Titer ≥1:40 Against Each of Three Strains After One Vaccination of TIVc and TIVf Vaccine.|Number of Subjects Who Reported Solicited Local and Systemic Adverse Events After One Vaccination of TIVc and TIVf|Number of Subjects With Unsolicited Adverse Events","Novartis Vaccines|Novartis","All","18 Years to 49 Years   (Adult)","Phase 3","1561","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","V58_23","September 2014","December 2014","December 2014","October 3, 2014","August 7, 2015","June 11, 2019","Anaheim Clincial Trials, Anaheim, California, United States|Northern California Clinical Research Center, Redding, California, United States|Southern California CRC, San Diego, California, United States|Broward Research Group, Hollywood, Florida, United States|Comprehensive Clinical Trials, LLC, West Palm Beach, Florida, United States|Palm Bech Research, West Palm Beach, Florida, United States|Meridian Clinical Research, Savannah, Georgia, United States|Johnson County Clin-Trials, LLC, Lenexa, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Milford Emergency Associate,Inc, Milford, Massachusetts, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Rochester Clinical Research, Inc, Rochester, New York, United States|PMG Research of Charlotte, Charlotte, North Carolina, United States|PMG Research of Hickory, Hickory, North Carolina, United States|PMG Research of Raleigh, Raleigh, North Carolina, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Columbia Research Group, Inc, Portland, Oregon, United States|Omega Medical Research, Warwick, Rhode Island, United States|Clinical Research Solutions, LLC, Franklin, Tennessee, United States|Clinical Research Associates, Inc, Nashville, Tennessee, United States|Foothill Family Clinc South, J. Lewis Research Inc., Salt Lake City, Utah, United States|Foothill Family Clinic, J. Lewis Research Inc., Salt Lake City, Utah, United States|Jordan River Family Medicine, J. Lewis Research, Inc., South Jordan, Utah, United States|Clinical Research Associates, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02256488"
991,"NCT02255760","Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults",,"Completed","Has Results","MEDI3902 for Prevention of P. Aeruginosa Pneumonia","Drug: MEDI3902 - Dose 1|Drug: MEDI3902 - Dose 2|Drug: MEDI3902 - Dose 3|Drug: MEDI3902 - Dose 4|Other: Placebo","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment Emergent Adverse Events of Special Interest (TEAESIs)|Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs)|Area Under the Serum Concentration-time Curve From Zero to Infinity (AUC [0-infinity])|Maximum Observed Serum Concentration (Cmax) for MEDI3902 After First Dose|Terminal Phase Elimination Half-life (t1/2)|Volume of Distribution at Steady State (Vss)|MEDI3902 Serum Clearance (CL) of MEDI3902|Number of Participants With Positive Anti-drug Antibody (ADA) to MEDI3902","MedImmune LLC","All","18 Years to 60 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D5470C00002","September 4, 2014","April 20, 2015","April 20, 2015","October 3, 2014","August 13, 2018","August 13, 2018","Research Site, South Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02255760"
992,"NCT02255357","Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients.",,"Completed","Has Results","Cocaine Dependence","Drug: Placebo|Drug: Intranasal Oxytocin","Number of Consecutive Weeks of Abstinence From Cocaine After Abstinence Induction","New York State Psychiatric Institute","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","#6933|DA035461-01A1","March 2015","February 14, 2018","February 14, 2018","October 2, 2014","November 29, 2019","November 29, 2019","Divison on Substance Abuse - Albert Einstein College of Medicine, Bronx, New York, United States|Substance Treatment and Research Service (STARS), Manhattan, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02255357/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02255357/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02255357"
993,"NCT02255175","Perimenopausal Effects of Estradiol on Reward Responsiveness","PEERS","Completed","Has Results","Perimenopausal Depression","Drug: Estradiol|Drug: Progesterone","Caudate Signal Intensity in Response to Reward During the MID fMRI Task at Pre-treatment|Nucleus Accumbens (NAcc) Signal Intensity in Response to Reward During the MID fMRI Task at Pre-treatment|Putamen Signal Intensity in Response to Reward During the MID fMRI Task at Pre-treatment|Caudate Signal Intensity in Response to Reward During the MID fMRI Task Following Estradiol Treatment.|Nucleus Accumbens (NAcc) Signal Intensity in Response to Reward During the MID fMRI Task Following Estradiol Treatment.|Putamen Signal Intensity in Response to Reward During the MID fMRI Task Following Estradiol Treatment.|Response Latency to Reward During the MID fMRI Task at Pre-treatment|Response Latency to Reward During the MID fMRI Task Following Estradiol Treatment|Change in Inventory of Depression and Anxiety Symptoms (IDAS) Dysphoria Scores","University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","Female","44 Years to 55 Years   (Adult)","Phase 4","64","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13-3572|K12HD001441-15|K23MH105569-01A1","October 1, 2015","October 17, 2018","October 17, 2018","October 2, 2014","November 12, 2019","November 12, 2019","University of North Carolina, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT02255175/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02255175"
994,"NCT02253160","An Evaluation of the Spectra Optia CMNC Collection Procedure","CMNC","Completed","Has Results","Healthy Apheresis Donors|Mononuclear (MNC) Cell Donors","Device: Spectra Optia CMNC|Device: COBE Spectra MNC|Drug: Granulocyte-colony stimulating factor (G-CSF)","CD34+ Collection Efficiency (CE1 %)|CD34+ Collection Efficiency (CE2 %)|MNC Collection Efficiency (CE1%)|CD34+ Per kg of Body Weight|MNC Product Contamination/Purity (%) - Hematocrit (%)|MNC Product Contamination/Purity (%) - Granulocyte Concentration (10^3/mL)|MNC Product Contamination/Purity (%) - Platelet Concentration (10^3/µL)|MNC Product Contamination/Purity (%) - Platelet Collection Efficiency (CE1 %)|MNC Blood Product Volume (mL)|Purity of Plasma Collected for Laboratory Processing of MNC Product - Platelet Concentration in Plasma (10^3/µL)|Procedure Time (Minutes)|MNC Collection Efficiency (CE2%)|MNC Product Contamination/Purity - RBC Concentration (10^6/µL)","Terumo BCT","All","18 Years to 50 Years   (Adult)","Not Applicable","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","CTS-5038","September 2014","January 2015","January 2015","October 1, 2014","September 24, 2015","September 24, 2015","Hoxworth Blood Center, Cincinnati, Ohio, United States|Key Biologics, LLC, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02253160"
995,"NCT02252354","TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study",,"Completed","Has Results","Healthy Volunteers","Drug: [14C]-TAK-385 Oral Solution|Drug: TAK-385 Tablets|Drug: [14C]-TAK-385 Solution for Intravenous Infusion","Part 1: Time to Reach the Maximum Plasma and Whole Blood Radioactivity Concentration (Cmax) for [14C]-TAK-385|Part 1: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-385|Part 1: Cmax: Maximum Observed Plasma and Whole Blood Radioactivity Concentration for [14C]-TAK-385|Part 1: Cmax: Maximum Observed Plasma Concentration for TAK-385|Part 1: AUC(0-inf): Area Under the Plasma and Whole Blood Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-385|Part 1: AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385|Part 1: AUC(0-168): Area Under the Plasma and Whole Blood Radioactivity Concentration-Time Curve From Time 0 to 168 Hours Postdose for [14C]-TAK-385|Part 1: AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for TAK-385|Part 1: Terminal Phase Elimination Half-Life (t1/2z) in Plasma and Whole Blood Radioactivity for [14C]-TAK-385|Part 1: Terminal Phase Elimination Half-Life (t1/2z) in Plasma for TAK-385|Part 1: Overall Cumulative Percent Recovery of Total Dosed Radioactivity in Urine and Feces|Part 2: Tmax : Time to Reach the Maximum Plasma Radioactivity Concentration (Cmax) for [14C]-TAK-385|Part 2: Tmax : Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-385|Part 2: Cmax: Maximum Observed Plasma Radioactivity Concentration for [14C]-TAK-385|Part 2: Cmax: Maximum Observed Plasma Radioactivity Concentration for TAK-385|Part 2: AUC(0-inf): Area Under the Plasma Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-385|Part 2: AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385|Part 2: AUC(0-168): Area Under the Plasma Radioactivity Concentration-Time Curve From Time 0 to 168 Hours Postdose for [14C]-TAK-385|Part 2: AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for TAK-385|Part 2: Terminal Phase Elimination Half-Life (t1/2z) in Plasma Radioactivity for [14C]-TAK-385|Part 2: Terminal Phase Elimination Half-Life (t1/2z) in Plasma for TAK-385|Part 2: Absolute Bioavailability for the Oral Tablet Formulation|Part 1: Excretion of TAK-385 and Its Metabolites in Human Feces as Percent Radioactivity|Part 1: Excretion of TAK-385 and Its Metabolites in Human Urine as Percent Radioactivity|Part 1: Excretion of TAK-385 and Its Metabolites in Human Feces as Percentage of Dose|Part 1: Excretion of TAK-385 and Its Metabolites in Human Urine as Percentage of Dose|Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 1 Post-dose|Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 2 Post-dose|Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 4 Post-dose|Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 8 Post-dose|Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 12 Post-dose|Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 24 Post-dose|Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 36 Post-dose|Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 48 Post-dose|Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 72 Post-dose|Part 1: Apparent Oral Clearance (CL/F) for TAK-385|Part 2: Apparent Oral Clearance (CL/F) for TAK-385|Part 1: Volume of Distribution (Vz/F) for TAK-385|Part 2: Volume of Distribution (Vz/F) for TAK-385|Part 2: Overall Cumulative Percent Recovery of Total Dosed Radioactivity in Urine and Feces|Part 2: Clearance (CL) for [14C]-TAK-385","Takeda","Male","18 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","TAK-385-1009|2014-001564-35|U1111-1159-5663|14/WA/1087","September 2014","October 2014","October 2014","September 30, 2014","December 1, 2015","October 27, 2016","Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02252354"
996,"NCT02251236","Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals",,"Completed","Has Results","HIV","Drug: Stribild|Drug: Genvoya","Concentration of Elvitegravir in Cerebrospinal Fluid at Baseline|Concentration of Elvitegravir in Cerebrospinal Fluid at Week 24|Concentration of Tenofovir in Cerebrospinal Fluid at Baseline|Concentration of Tenofovir in Cerebrospinal Fluid at Week 24","University of California, San Diego|Gilead Sciences|University at Buffalo","All","18 Years to 60 Years   (Adult)","Not Applicable","14","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IN-US-236-1266","January 2016","January 18, 2017","January 18, 2017","September 29, 2014","October 31, 2019","October 31, 2019","UC San Diego AntiViral Research Center, San Diego, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02251236/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02251236"
997,"NCT02248818","AZD8108 SAD/MAD in Healthy Volunteers","AZD8108","Completed","Has Results","Healthy Volunteers","Drug: AZD8108|Drug: Placebo","Safety Laboratory - Thyroid Stimulating Hormone Above Upper Limit of Normal|Pharmacokinetic :Area Under the Concentration Curve (0 to Infinity), AZD6765 After Single/1st Dose of AZD8108|Pharmacokinetic :Area Under the Concentration Curve (0 to 24 Hour), AZD6765 MAD Day 6 Dose of AZD8108|Pharmacokinetic :Area Under the Concentration Curve (0 to Infinity), AZD6765 MAD Day 12 Dose of AZD8108|Pharmacokinetic :Area Under the Concentration Curve (0 to 24 Hours), AZD6765 After DAY 12 Dose of AZD8108|Pharmacokinetic : Maximum Concentration of AZD6765 After Single/1st Dose of AZD8108|Pharmacokinetic : Maximum Concentration of AZD6765 After MAD Day 6 Dose of AZD8108|Pharmacokinetic : Maximum Concentration of AZD6765 After MAD Day 12 Dose of AZD8108|Pharmacokinetic: Time to Maximum Plasma Concentration of AZD6765 After Single (SAD)/ 1st (MAD) Dose of AZD8108|Pharmacokinetic: Fraction of Equivalent Dose of AZD6765 Excreted in Urine (SAD) After Single Dose of AZD8108|Pharmacokinetic: Fraction of Equivalent Dose of AZD6765 Excreted in Urine (MAD) After Day 12 Dose of AZD8108|Pharmacokinetic: Time to Maximum Plasma Concentration of AZD6765 After Day 12 (MAD) Dose of AZD8108|Pharmacokinetic: Accumulation Index for Area Under Concentration Curve (0 to 24 Hour) MAD","AstraZeneca","All","18 Years to 55 Years   (Adult)","Phase 1","258","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","D5800C00001","November 2014","September 2015","September 2015","September 25, 2014","January 27, 2017","April 7, 2017","Clinilabs, Inc., New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02248818"
998,"NCT02248766","Clinical Performance of Habitual Wearers of Avaira Toric When Refitted With Clariti Toric Lenses",,"Completed","Has Results","Astigmatism","Device: somofilcon A","Visual Acuity - Enfilcon A and Somofilcon A|Subjective Assessments- Enfilcon A and Somofilcon A","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)","EX-MKTG-53","September 2014","October 2014","October 2014","September 25, 2014","March 23, 2016","June 27, 2016","Optometry Research Group (GIO) - Optics Department, University of Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02248766"
999,"NCT02248727","Clinical Performance of Existing Wearers of Avaira Sphere Following a Refit With Clariti Elite Sphere",,"Completed","Has Results","Myopia","Device: somofilcon A","Visual Acuity - Enfilcon A and Somofilcon A|Subjective Assessments. - Enfilcon A and Somofilcon A","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","EX-MKTG-52","September 2014","October 2014","December 2014","September 25, 2014","March 23, 2016","May 17, 2016","Optometry Research Group (GIO) Optics Department, University of Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02248727"
1000,"NCT02248103","Comparison of Autogenous Periosteal Pedicle Graft and Collagen Membrane in Management of Periodontal Intrabony Defects",,"Completed","Has Results","Chronic Periodontitis","Procedure: Periosteal pedicle graft|Biological: Bioresorbable collagen membrane","Clinical Attachment Level|Pocket Depth|Bone Defect Area","Cairo University","All","35 Years to 50 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MPP graft_GTR","March 2013","April 2014","May 2014","September 25, 2014","October 9, 2015","April 24, 2017",,,"https://ClinicalTrials.gov/show/NCT02248103"
